US11708351B2 - Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders - Google Patents

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders Download PDF

Info

Publication number
US11708351B2
US11708351B2 US17/366,670 US202117366670A US11708351B2 US 11708351 B2 US11708351 B2 US 11708351B2 US 202117366670 A US202117366670 A US 202117366670A US 11708351 B2 US11708351 B2 US 11708351B2
Authority
US
United States
Prior art keywords
formula
alkyl
group
disorder
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US17/366,670
Other versions
US20220396563A1 (en
Inventor
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao Gadhachanda
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
Joel Charles Barrish
William Greenlee
Kyle J. Eastman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Achillion Pharmaceuticals Inc
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Priority to US17/366,670 priority Critical patent/US11708351B2/en
Assigned to ACHILLION PHARMACEUTICALS, INC. reassignment ACHILLION PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: WANG, XIANGZHU
Assigned to ACHILLION PHARMACEUTICALS, INC. reassignment ACHILLION PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AGARWAL, ATUL, CHEN, DAWEI, DESHPANDE, MILIND, EASTMAN, KYLE J., GADHACHANDA, Venkat Rao, GREENLEE, WILLIAM, HASHIMOTO, AKIHIRO, PAIS, GODWIN, PHADKE, AVINASH S., WANG, QIUPING, WILES, JASON ALLAN, BARRISH, JOEL CHARLES
Publication of US20220396563A1 publication Critical patent/US20220396563A1/en
Priority to US18/196,128 priority patent/US20230357199A1/en
Application granted granted Critical
Publication of US11708351B2 publication Critical patent/US11708351B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention provides aryl, heteroaryl and heterocyclic drugs to treat medical disorders, such as complement-mediated disorders.
  • the complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear pathogens.
  • This sophisticated regulatory pathway allows rapid reaction to pathogenic organisms while protecting host cells from destruction.
  • Over thirty proteins and protein fragments make up the complement system. These proteins act through opsonization (enhancing phagocytosis of antigens), chemotaxis (attracting macrophages and neutrophils), cell lysis (rupturing membranes of foreign cells), and agglutination (clustering and binding of pathogens together).
  • Complement Factor D plays an early and central role in activation of the alternative pathway of the complement cascade. Activation of the alternative complement pathway is initiated by spontaneous hydrolysis of a thioester bond within C3 to produce C3(H 2 O), which associates with Factor B to form the C3(H 2 O)B complex.
  • Complement Factor D acts to cleave Factor B within the C3(H 2 O)B complex to form Ba and Bb. The Bb fragment remains associated with C3(H 2 O) to form the alternative pathway C3 convertase C3(H 2 O)Bb.
  • C3b generated by any of the C3 convertases also associates with Factor B to form C3bB, which Factor D cleaves to generate the later stage alternative pathway C3 convertase C3bBb.
  • This latter form of the alternative pathway C3 convertase may provide important downstream amplification within all three of the defined complement pathways, leading ultimately to the recruitment and assembly of additional factors in the complement cascade pathway, including the cleavage of C5 to C5a and C5b.
  • C5b acts in the assembly of factors C6, C7, C8, and C9 into the membrane attack complex, which can destroy pathogenic cells by lysing the cell.
  • complement The dysfunction of or excessive activation of complement has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
  • activation of the alternative pathway of the complement cascade contributes to the production of C3a and C5a, both potent anaphylatoxins, which also have roles in a number of inflammatory disorders. Therefore, in some instances, it is desirable to decrease the response of the complement pathway, including the alternative complement pathway.
  • disorders mediated by the complement pathway include age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), multiple sclerosis, and rheumatoid arthritis.
  • AMD age-related macular degeneration
  • PNH paroxysmal nocturnal hemoglobinuria
  • multiple sclerosis multiple sclerosis
  • rheumatoid arthritis Some examples include age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), multiple sclerosis, and
  • ASD Age-related macular degeneration
  • Paroxysmal nocturnal hemoglobinuria is a non-malignant, hematological disorder characterized by the expansion of hematopoietic stem cells and progeny mature blood cells that are deficient in some surface proteins. PNH erythrocytes are not capable of modulating their surface complement activation, which leads to the typical hallmark of PNH—the chronic activation of complement mediated intravascular anemia.
  • the anti-C5 monoclonal antibody eculizumab has been approved in the U.S. for treatment of PNH.
  • many of the patients treated with eculizumab remain anemic, and many patients continue to require blood transfusions.
  • treatment with eculizumab requires life-long intravenous injections.
  • C3G is a recently defined entity comprised of dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) which encompasses a population of chronic kidney diseases wherein elevated activity of the alternative complement pathway and terminal complement pathway results in glomerular deposits made solely of complement C3 and no immunoglobulin (Ig).
  • DDD dense deposit disease
  • C3GN C3 glomerulonephritis
  • Immune-complex membranoproliferative glomerulonephritis is a renal disease which shares many clinical, pathologic, genetic and laboratory features with C3G, and therefore can be considered a sister disease of C3G.
  • an underlying disease or disorder most commonly infections, autoimmune diseases, or monoclonal gammopathies—are identified to which the renal disease is secondary.
  • Patients with idiopathic IC-MPGN can have low C3 and normal C4 levels, similar to those observed in C3G, as well as many of the same genetic or acquired factors that are associated with abnormal alternative pathway activity.
  • aHUS hemolytic uremic syndrome
  • HUS hemolytic uremic syndrome
  • NMO neuromyelitis optica
  • MG myasthenia gravis
  • MG myasthenia gravis
  • fatty liver nonalcoholic steatohepatitis
  • NASH nonalcoholic steatohepatitis
  • liver inflammation cirrhosis
  • liver failure dermatomyositis
  • amyotrophic lateral sclerosis amyotrophic lateral sclerosis
  • Factor D is an attractive target for inhibition or regulation of the complement cascade due to its early and essential role in the alternative complement pathway, and for its potential role in signal amplification within the classical and lectin complement pathways. Inhibition of Factor D effectively interrupts the pathway and attenuates the formation of the membrane attack complex.
  • Novartis PCT patent publication WO2012/093101 titled “Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration” describes certain Factor D inhibitors. Additional Factor D inhibitors are described in Novartis PCT patent publications WO2013/164802, WO2013/192345, WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054, WO2014/002057, WO2014/002058, WO2014/002059, WO2014/005150, WO2014/009833, WO2014/143638, WO2015/009616, WO2015/009977, and WO2015/066241.
  • PCT patent publication WO2017/098328 titled “Therapeutic Inhibitory Compounds” describes various Factor D inhibitors with variations in the central core ring heterocycle ring.
  • PCT patent publication WO/2018/015818 is also titled “Therapeutic Inhibitory Compounds” and describes Factor D inhibitors without cyclic central core.
  • Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled “Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases” discloses antibodies directed to C5 of the complement pathway for the treatment of glomerulonephritis and inflammatory conditions involving pathologic activation of the complement system.
  • Alexion Pharmaceutical's anti-C5 antibody eculizumab Soliris® is currently the only complement-specific antibody on the market, and is the first and only approved treatment for paroxysmal nocturnal hemoglobinuria (PNH).
  • This invention includes a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, wherein at least one of R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle substituent, which is R 32 .
  • the compound or its salt or composition, as described herein is used to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity including the alternative complement pathway, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
  • a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity including the alternative complement pathway, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
  • the compound presented herein has one or more of the following:
  • a method for the treatment of such a disorder includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as described in more detail below.
  • compounds are provided that have minimal effect on BSEP (bile salt export pump protein) (e.g., with an IC 50 of greater than about 20, 30, 40, 50, 60, 75 or 100 ⁇ M or greater), or with a therapeutic index of BSEP relative to complement D inhibition (e.g., IC 50 inhibition of BSEP/IC 50 inhibition of complement D inhibitor), of about at least 50, 100, 200, 300, 400, 500, 750 or 1000 or greater).
  • BSEP inhibition correlates with cholestatic drug-induced liver injury.
  • Certain compounds of the present invention with low BSEP inhibition have at least one R 201 .
  • the compounds of the present invention exhibit minimal hydrolysis of the amide bond between the C ring and the B ring in vivo, for example, by including a proline that has a cis-substituent relative to the proline-carbonyl bond directed toward the B-ring.
  • the cis-substituent is in the Q3 position or the Q2 position or is a group that bridges Q3 and Q2.
  • an R 301 acylated embodiment of an active compound of the invention that exhibits extended half-life or other advantageous pharmacokinetic properties, which may be achieved by albumin stabilization in vivo.
  • the acylated analogue can include several linking moieties in linear, branched or cyclic manner.
  • either one or a series of amino acids is used as a linker to a terminal fatty acid.
  • a non-natural amino acid such as one described below, for example 8-amino-3,6-dioxaoctanoic acid (one or several in sequence) is covalently bound to the selected complement D inhibitor of the present invention through a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group.
  • a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group.
  • the 8-amino-3,6-dioxaoctanoic acid or similar molecule is covalently linked to an aliphatic acid, including but not limited to a C 16 , C 18 , C 20 aliphatic acid, or a dicarboxylic acid, including but not limited to a C 8 , C 10 , C 12 , C 14 , C 16 , C 18 or C 20 diacid.
  • One or more amino acids can also be used in the selected configuration to add length or functionality.
  • nonlimiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another linking moiety, and which may be albumin stabilized in vivo.
  • a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another linking moiety, and which may be albumin stabilized in vivo.
  • 2, 3, 4 or 5 linking moieties are covalently bound in sequence, branched or cyclic fashion to the parent compound.
  • an R 301 acyl group is located in a position of the active compound that does not significantly adversely affect the complement D inhibition of the molecule, for example, as (i) a substituent on the R 32 group or (ii) a substituent on a C-ring, such as proline, or as a substituent on a substituent on the C-ring, such as on an R 1 , R 2 or R 3 substituent, including for example, on a bridged moiety such as a fused cyclopropyl on the proline ring.
  • the acyl group has an aliphatic or heteroaliphatic carbon range of C 12 , C 14 , C 16 , C 18 , C 20 , C 22 or C 24 .
  • the disorder is associated with the alternative complement cascade pathway. In yet another embodiment, the disorder is associated with the complement classical pathway. In a further embodiment, the disorder is associated with the complement lectin pathway.
  • the active compound or its salt or prodrug may act through a different mechanism of action than the complement cascade, or in particular as a complement factor D inhibitor, to treat the disorder described herein.
  • a method for the treatment of C3 glomerulonephritis includes the administration of an effective amount of a compound to a host of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
  • a method for the treatment of paroxysmal nocturnal hemoglobinuria includes the administration of an effective amount of a compound to a host of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
  • PNH paroxysmal nocturnal hemoglobinuria
  • a method for the treatment of wet or dry age-related macular degeneration (AMD) in a host includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
  • a method for the treatment of rheumatoid arthritis in a host includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
  • a method for the treatment of multiple sclerosis in a host includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
  • an active compound or its salt or prodrug as described herein can be used to treat fatty liver and conditions stemming from fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, and liver failure, dermatomyositis, or amyotrophic lateral sclerosis.
  • NASH nonalcoholic steatohepatitis
  • the active compound or its pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as disclosed herein is also useful for administration in combination (in the same or a different dosage form) or alternation with a second pharmaceutical agent for use in ameliorating or reducing a side effect of the second pharmaceutical agent.
  • the active compound may be used in combination with an adoptive cell transfer therapy to reduce an inflammatory response associated with such therapy, for example, a cytokine mediated response such as cytokine response syndrome.
  • the adoptive cell transfer therapy is a chimeric antigen receptor T-Cell (CAR T) or a dendritic cell used to treat a hematologic or solid tumor, for example, a B-cell related hematologic cancer.
  • the hematologic or solid tumor is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), pancreatic cancer, glioblastoma, or a cancer that expresses CD19.
  • the associated inflammatory response is a cytokine mediated response.
  • Another embodiment includes the administration of an effective amount of an active compound or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition to a host to treat an ocular, pulmonary, gastrointestinal, or other disorder that can benefit from topical or local delivery.
  • any of the compounds described herein can be administered to the eye in any desired form of administration, including via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, scleral, circumcorneal, and tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion.
  • intravitreal intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, scleral, circumcorneal, and tear duct injections, or through a mucus, mucin, or a mucosal barrier
  • the active compound includes a lipophilic group, such as a lipophilic acyl group, which is delivered to the eye in a polymeric drug delivery system such as polylactic acid, polylactide-co-glycolide, polyglycolide or other erodible polymer, or a combination thereof, or in another type of lipophilic material for ocular delivery.
  • a lipophilic active molecule is more soluble in the polymeric or other form of delivery system than in ocular fluid.
  • an active compound provided herein can be used to treat or prevent a disorder in a host mediated by complement factor D, or by an excessive or detrimental amount of the complement-C3 amplification loop of the complement pathway.
  • the invention includes methods to treat or prevent complement associated disorders that are induced by antibody-antigen interactions, a component of an immune or autoimmune disorder or by ischemic injury.
  • the invention also provides methods to decrease inflammation or an immune response, including an autoimmune response, where mediated or affected by factor D.
  • a method for treating a host, typically a human, with a disorder mediated by the complement system, that includes administration of a prophylactic antibiotic or vaccine to reduce the possibility of a bacterial infection during the treatment using one of the compounds described herein.
  • the host typically a human
  • the host is given a prophylactic vaccine prior to, during or after treatment with one of the compounds described herein.
  • the host typically a human
  • the infection is a meningococcal infection (e.g., septicemia and/or meningitis), an Aspergillus infection, or an infection due to an encapsulated organism, for example, Streptococcus pneumoniae or Haemophilus influenza type b (Hib), especially in children.
  • the vaccine or antibiotic is administered to the patient after contracting an infection due to, or concommitent with inhibition of the complement system.
  • A is selected from A1, A2, and A3;
  • B is selected from B1, B2, and B3;
  • C is selected from C1, C2, C3, and C4;
  • A is A3, B is B3, or C is C4;
  • Q 1 is N(R 1 ), C(R 1 R 1′ ), C(R 1 R 1′ )C(R 1 R 1′ ), C(R 1 R 1′ )C(R 1 R 1′ )C(R 1 R 1′ ), S or O;
  • Q 2 is C(R 2 R 2′ ), C(R 2 R 2′ )C(R 2 R 2′ ), C(R 2 R 2′ )C(R 2 R 2′ )C(R 2 R 2′ ), N(R 2 ), S, O, or C(R 2 R 2′ )O;
  • Q 3 is N(R 3 ), S, O, C(R 3 R 3′ ), C(R 3 R 3′ )C(R 3 R 3′ ), or C(R 3 R 3′ )C(R 3 R 3′ )C(R 3 R 3′ );
  • X 1 and X 2 are independently N, CH, or CZ;
  • Z is F, Cl, NH 2 , CH 3 , CH 2 D, CHD 2 , or CD 3 ;
  • R 1 , R 1′ , R 2 , R 2′ , R 3 , and R 3′ are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R 201 , R 301 , halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, alkoxy including C 1 -C 6 alkoxy, alkanoyl including C 2 -C 6 alkanoyl, thioalkyl including C 1 -C 6 alkylthio, hydroxyC 1 -C 6 alkyl, aminoC 1 -C 6 alkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)OR 9 , —OR′, —NR′R′′, —OC
  • R 1 and R 1′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • R 3 and R 3′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • R 2 and R 2′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring;
  • each of the above spiro rings may be optionally substituted with 1 or more substituents independently selected from R 201 , halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C 1 -C 4 alkyl (and in particular methyl), alkenyl including C 2 -C 4 alkenyl, alkynyl including C 2 -C 4 alkynyl, alkoxy including C 1 -C 6 alkoxy, alkanoyl, including C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-alkylamino)C 1 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O-alkyl(C 3 -C 7 cycloalkyl), haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 or more substitu
  • each of the above spiro rings may be optionally substituted with an aryl ring;
  • R 1 and R 2 are taken together to form a 3-membered carbocyclic ring, a 4- to 6-membered carbocyclic or aryl ring, or a 4- to 6-membered heterocyclic or heteroaryl ring containing 1 or 2 heteroatoms independently selected from N, O, and S;
  • R 2 and R 3 are taken together to form a 3- to 6-membered carbocyclic or aryl ring or a 3- to 6-membered heterocyclic or heteroaryl ring;
  • R 1 and R 2 or R 2 and R 3 rings are optionally substituted with 1 or more substituents independently selected from R 201 , halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C 1 -C 4 alkyl (and in particular methyl), alkenyl including C 2 -C 4 alkenyl, alkynyl including C 2 -C 4 alkynyl, alkoxy including C 1 -C 4 alkoxy, alkanoyl including C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-alkylamino)C 0 -C 4 alkyl, alkyl(C 3 -C 7 cycloalkyl) including —C 1 -C 4 alkyl(C 3 -C 7 cycloalkyl
  • R 1 and R 1′ are taken together to form a carbonyl group
  • R 2 and R 2′ are taken together to form a carbonyl group
  • R 3 and R 3′ are taken together to form a carbonyl group
  • R 1 and R 2 are taken together to form a carbon-carbon double bond
  • R 2 and R 3 are taken together to form a carbon-carbon double bond
  • R and R′ are independently selected from H, R 201 , alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
  • R, R′, and R′′ are independently selected from R 301 , heteroalkyl, H, R 201 , alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, and heteroaliphatic;
  • R 9 and R 10 are independently selected from hydrogen, alkyl including C 1 -C 6 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), and —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);
  • C2 is selected from:
  • q 0, 1, 2 or 3;
  • r is 1, 2 or 3;
  • R 44 , R 44′ , R 45 , R 45′ are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R 201 , halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, alkoxy including C 1 -C 6 alkoxy, alkanoyl including C 2 -C 6 alkanoyl, thioalkyl including —C 1 -C 6 alkylthio, hydroxyC 1 -C 6 alkyl, aminoC 1 -C 6 alkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)OR 9 , —OC(O)R 9 , —NR 9 C(O)R 10 , —C(O)
  • R 44 and R 44′ or R 45 and R 45′ , or two R 47 groups are taken together to form a carbonyl group
  • R 44 and R 44′ or R 45 and R 45′ substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • each of the above spiro rings may be optionally substituted with 1 or more substituents independently selected from R 201 , halogen (and in particular F), hydroxyl, cyano, —COOH; alkyl including C 1 -C 4 alkyl (and in particular methyl), alkenyl including C 2 -C 4 alkenyl, alkynyl including C 2 -C 4 alkynyl, alkoxy including C 1 -C 6 alkoxy, alkanoyl including C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-alkylamino)C 1 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O-alkyl(C 3 -C 7 cycloalkyl), haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 --C
  • R 44 and R 45 or R 44′ and R 45′ are taken together to form a 4- to 6-membered carbocyclic or aryl ring or a 4- to 6-membered heterocyclic or heteroaryl ring; each of which ring may be optionally substituted with 1 or more substituents;
  • each of which fused rings or generally R 44 , R 44′ , R 45 , or R 45′ are optionally substituted with 1 or more substituents independently selected from R 201 , halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C 1 -C 4 alkyl (and in particular methyl), alkenyl including C2-C 4 alkenyl, alkynyl including C 2 -C 4 alkynyl, alkoxy including C 1 -C 4 alkoxy, alkanoyl including C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-alkylamino)C 0 -C 4 alkyl, alkyl(C 3 -C 7 cycloalkyl) including —C 1 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—(C 3 -C 7 cycloalkyl), haloalkyl
  • C3 is selected from:
  • X 3 is C(R 1 R 1′ );
  • X 4 is N or CH
  • X 4a is N, CH or CZ
  • X 5 and X 6 are C(R 1 R 1′ );
  • X 4 and X 5 or X 5 and X 6 together are C ⁇ C;
  • X 7 is SO or SO 2 ;
  • X 8 is C(R 1 R 1′ ) or N(R 43 );
  • X 5a is independently selected from C(R 1 R 1′ ) and O;
  • Q 4 is N or CH
  • Q 5 is N(R 47 ) or C(R 46 R 46′ );
  • Q 5a is independently selected from C(R 47 R 47 ), N(R 47 ), O, S, SO, and SO 2 ;
  • Q 6 is N(R 47 ), C(R 46 R 46′ ), S, or O;
  • Q 7 is C(R 46 R 46′ ), S or N(R 47 );
  • Q 8 , Q 9 , Q 10 , Q 11 and Q 12 are each independently C(R 2 R 2′ ), S, SO, SO 2 , O, N(R 2 ), B(R 50 ), or Si(R 49 ) 2 ;
  • R 40 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
  • R 42 is halo, hydroxy, alkoxy including C 1 -C 6 alkoxy, haloalkoxy including C 1 -C 6 haloalkoxy, —SH, or —S(C 1 -C 6 alkyl);
  • R 43 is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
  • R 46 and R 46′ are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
  • R 46 and R 46′ are taken together to form an optionally substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • R 47 is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
  • R 49 is halo, hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted
  • R 50 is hydroxy or C 1 -C 6 alkoxy
  • C3 is a small mimetic of a beta-turn such as a benzodiazepine, a Friedinger lactam, a 2-oxo-1,3-oxazolidine-4-carboxylate or a ⁇ -D-glucose scaffold.
  • a beta-turn such as a benzodiazepine, a Friedinger lactam, a 2-oxo-1,3-oxazolidine-4-carboxylate or a ⁇ -D-glucose scaffold.
  • the central core moiety, C can comprise a reverse turn mimetic that can include, but is not limited to; a non-peptidic residue, a metal chelation based mimic, or a foldamer. See, Nair, R. V. et al., “Synthetic turn mimetics and hairpin nucleators: Quo Vadimus?”, Chem. Comm., 2014, 50, 13874-13884.
  • the central core moiety, C can comprise a conformationally constrained cyclic amino acid including but not limited to a (S)- or (R)- ⁇ -trifluoromethyl pyroglutamic acid derivative.
  • a conformationally constrained cyclic amino acid including but not limited to a (S)- or (R)- ⁇ -trifluoromethyl pyroglutamic acid derivative. See, Chaume, G. et al., “Concise access to enantiopure (S)- or (R)- ⁇ -trifluoromethyl pyroglutamic acids from ethyl trifluoropyruvate-base chiral CF3-oxazolidines (Fox)”, J. Fluor. Chem., 2008, 129, 1104-1109 and Andre, C.
  • the central core moiety, C can comprise a monomeric unit of a foldamer such as, but not limited to an oxazolidin-2-one. See, Tomasii, C., Angelicim G. and Castellucci, N., “Foldamers Based on Oxazolidin-2-ones”, Eur. J. Org. Chem., 2011, 3648-3669;
  • C4 is selected from:
  • C5 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • A2 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • X 51 , X 52 , and X 53 are independently selected from N, CR 31 , and CR 201 ;
  • X 51 , X 52 , and X 53 is selected from CR 201 ;
  • X 54 , X 55 , and X 56 are independently selected from N, CR 31 , and CR 201 ;
  • R 104 is selected from R 201 , C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 4 haloalkyl, deuterium, —CO 2 H, CO 2 R 9 , heteroaryl, F, Cl, Br, and cyano;
  • R 201 is selected from aminoalkyl-, alkylaminoalkyl-, heterocycloalkyl-, and hydroxyalkyl; -alkyl-O-alkyl including —CH 2 OCH 3 , -alkyl-S-alkyl, -alkyl-N(alkyl)-alkyl, -alkyl-NH-alkyl, -aliphatic-O-aliphatic, -aliphatic-S-aliphatic, -aliphatic-N(aliphatic)-aliphatic, -aliphatic-NH-aliphatic, -aliphatic-O-heterocycle, -aliphatic-S-heterocycle, -aliphatic-N(aliphatic)-heterocycle, -aliphatic-NH-heterocycle, -alkyl-NHC(O)haloalkyl, -alkyl-NR 9 C(O)haloalkyl, -alkyl-C(O)
  • R 201 is selected from R 301 , -alkyl-CN, -alkyl-NR 9 C(O)alkenyl, -alkyl-SO 2 -alkyl; and -alkyl-S(O)NR 9 -alkyl;
  • R 201 is substituted with an oxime, and —C(O)Oalkyl
  • R 202 is selected from aryl, heteroaryl, and heterocycle, wherein the aryl, heteroaryl, or heterocycle ring is substituted with R 201 ;
  • R 301 is selected from the following:
  • R 4 , R 5 , and R 6 are selected from hydrogen, -JCHO, -JC(O)NH 2 , -JC 2 -C 6 alkanoyl, -JC(O)NH(CH 3 ), -J-COOH, -JP(O)(OR 9 ) 2 , -JOC(O)R 9 , -JC(O)OR 9 , -JC(O)N(CH 2 CH 2 R 9 )(R 10 ), -JNR 9 C(O)R 10 , -JSO 2 NH 2 , -JS(O)NH 2 , -JC(CH 2 ) 2 F, -JCH(CF 3 )NH 2 , -JC(O)C 0 -C 2 alkyl(C 3 -C 7 cycloalkyl), -JNR 9 (C 2 -C 6 alkanoyl), -JNR 9 C(O)NR 9 R 10 , -JSO 2 (C 1 -C 6 al
  • J is independently selected from a covalent bond, alkylene including C 1 -C 4 alkylene, O-alkylene including —OC 1 -C 4 alkylene, alkenylene including C 2 -C 4 alkenylene, and alkynylene C 2 -C 4 alkynylene;
  • R 6′ is hydrogen, halogen, hydroxyl, C 1 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), or C 1 -C 4 alkoxy;
  • R 6 and R 6′ may be taken together to form an oxo, vinyl, or imino group
  • R 7 is hydrogen, alkyl including C 1 -C 6 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);
  • R 8 and R 8′ are selected from hydrogen, halogen, hydroxyl, alkyl including C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), alkoxy including C 1 -C 6 alkoxy, and (C 1 -C 4 alkylamino)C 0 -C 2 alkyl;
  • R 8 and R 8′ are taken together to form an oxo group
  • R 8 and R 8′ are taken together with the carbon that they are bonded to form a 3-membered carbocyclic ring;
  • R 16 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, —C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy,
  • R 19 is hydrogen, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, —SO 2 C 1 -C 6 alkyl, (mono- and di-C 1 -C 6 alkylamino)C 1 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(C 3 -C 7 heterocycloalkyl), —C 0 -C 4 alkyl(aryl), or C 0 -C 4 alkyl(heteroaryl), wherein each R 19 other than hydrogen is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, amino, —COOH, and —C(O)OC 1 -C 4 alkyl;
  • X 11 is N or CR 11 ;
  • X 12 is N or CR 12 ;
  • X 13 is N or CR 13 ;
  • X 14 is N or CR 14 ;
  • R 12 and R 13 are R 32 and the other is R 31 or R 32 ;
  • R 12 is R 32 ;
  • R 13 is R 32 ;
  • R 31 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, haloalkyl including C 1 -C 6 haloalkyl, haloalkoxy including C 1 -C 6 haloalkoxy, alkyl including C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, alkenyloxy including C 2 -C 6 alkenyloxy, —C(O)OR 9 , thioalkyl including C 1 -C 6 thioalkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)NR 9 R 10 , —SO 2 R 9 , —SO 2 NR 9 R 10
  • R 32 is selected from aryl, heteroaryl, and heterocycle wherein the aryl, heteroaryl, or heterocycle ring can be optionally substituted;
  • R 32 is substituted with R 301 , —CH 2 —R 301 , or R 201 ;
  • R 11 , R 14 , and R 15 are independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, —O(PO)(OR 9 ) 2 , —(PO)(OR 9 ) 2 , alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, C 2 -C 6 alkenyl(aryl), C 2 -C 6 alkenyl(cycloalkyl), C 2 -C 6 alkenyl(heterocycle), C 2 -C 6 alkenyl(heteroaryl), C 2 -C 6 alkynyl(aryl), C 2 -C 6 alkynyl(cycloalkyl), C 2 -C 6 alkynyl(heterocycle), C 2 -C 6 alkynyl(heteroaryl), alkanoyl including C 2 -C 6 alkano
  • X 15 is NH, O, or S
  • X 16 is CR 12 ;
  • X 17 is N or CR 13 ;
  • X 18 is CR 12 ;
  • X 19 is N or CR 13 ;
  • X 20 is NH or O
  • X 21 is N or CR 14 ;
  • X 22 is N or CR 13 ;
  • X 23 is CR 12 ;
  • X 24 is O or S
  • X 26 is N or CR 41 ;
  • X 27 is CR 12 , NH, or O
  • X 28 is N or CH
  • X 30 is N or CR 5 ;
  • X 31 is N, C(R 34 ) 2 , or CR 54 ;
  • X 32 is NH, C(R 54 ) 2 , or CR 54 ;
  • X 33 is —CO—, —SO—, or —SO 2 —;
  • X 34 is CHR 13 , NH, O, or S;
  • R 41 is hydrogen, alkyl including C 1 -C 6 alkyl, or —(C 0 -C 2 alkyl)(C 3 -C 5 cycloalkyl);
  • R 48 and R 48a is selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, alkyl including C 1 -C 6 alkyl, haloalkyl including C 1 -C 6 haloalkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, thioalkyl including C 1 -C 6 thioalkyl, alkoxy including C 1 -C 6 alkoxy, -JC 3 -C 7 cycloalkyl, —B(OH) 2 , -JC(O)NR 9 R 23 , -JOSO 2 OR 21 , —C(O)(CH 2 ) 1-4 S(O)R 21 , —O(CH 2 ) 1-4 S(O)NR 21 R 22 , -JOP(O)(OR 21 )(OR 22 ), -JP(O))(OR 21 )(OR 22 ), -J
  • R 103 is independently C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, fluorine, chlorine, or bromine;
  • R 54 is hydrogen, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, alkoxy including C 1 -C 6 alkoxy, C 2 -C 6 alkynyl, alkanoyl including C 2 -C 6 alkanoyl, thioalkyl including C 1 -C 6 thioalkyl, hydroxyC 1 -C 6 alkyl, aminoC 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), (phenyl)C 0 -C 4 alkyl-, (heterocycloalkyl)C 0 -C 4 alkyl or (heteroaryl)C 0 -C 4 alkyl- wherein each R 54 is optionally substituted;
  • s 1 or 2;
  • L is selected from L1 and L2;
  • R 17 is hydrogen, alkyl including C 1 -C 6 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);
  • R 18 and R 18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl;
  • n 0, 1, 2, or 3;
  • L2 is selected from:
  • L2 is selected from an optionally substituted monocyclic or bicyclic carbocyclic; an optionally substituted monocyclic or bicyclic carbocyclic-oxy group; an optionally substituted monocyclic or bicyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and from 4 to 7 ring atoms per ring, an optionally substituted —(C 0 -C 4 alkyl)(aryl); an optionally substituted —(C 0 -C 4 alkyl)(5-membered heteroaryl); an optionally substituted —(C 0 -C 4 alkyl)(6-membered heteroaryl); an optionally substituted —(C 0 -C 4 alkyl)(8-membered heteroaryl); an optionally substituted —(C 0 -C 4 alkyl)(9-membered heteroaryl); and —(C 0 -C 4 alkyl)(10-membered heteroaryl);
  • q 1, 2 or 3;
  • R 51 is CH 3 , CH 2 F, CHF 2 or CF 3 ;
  • R 53 is cyano, nitro, hydroxyl, or alkoxy including C 1 -C 6 alkoxy;
  • X 29 can be O or S
  • L3 is —C(O)—, —C(S)—, —P(O)OH—, —S(O)—, —S(O) 2 —, or —C(R 52 ) 2 —;
  • each R 52 is independently selected from halo, hydrogen, or optionally substituted alkyl including C 1 -C 6 alkyl;
  • R 52 groups are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • B1 is heteroaryl; aryl; biphenyl, a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including C 2 -C 6 alkenyl; or alkynyl including C 2 -C 6 alkynyl; each of which B1 is optionally substituted with one or more substituents independently selected from R 33 , R 34 , R 35 , and R 36 ;
  • R 33 is independently selected from halogen, hydroxyl, —COOH, cyano, alkyl including C 1 -C 6 alkyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, —C 0 -C 4 alkylNR 9 R 10 , —SO 2 R 9 , haloalkyl including C 1 -C 6 haloalkyl, S(O) ⁇ NHR 21 , SF 5 , and JC(R 9 ) ⁇ NR 21 , and haloalkoxy including C 1 -C 6 haloalkoxy;
  • R 34 is independently selected from nitro, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, thioalkyl including C 1 -C 6 thioalkyl, -JC 3 -C 7 cycloalkyl, -JB(OH) 2 , -JC(O)NR 9 R 23 , -JOSO 2 OR 21 , -JC(O)(CH 2 ) 1-4 S(O)R 21 , —O(CH 2 ) 1-4 S(O)NR 21 R 22 , -JOP(O)(OR 21 )(OR 22 ), -JP(O)(OR 21 )(OR 22 ), -JOP(O)(OR 21 )R 22 , -JP(O)(OR 21 )R 22 , -JOP(O)R 21 R 22 , -JP(O)R 21 R 22 , -JSP(O)(OR 21 )
  • R 35 is independently selected from naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl containing 1 or 2 heteroatoms selected from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and containing 4- to 8-ring atoms in each ring; each of which R 35 is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —SO 2 R 9 , haloalkyl including C 1
  • R 36 is independently selected from tetrazolyl, (phenyl)C 0 -C 2 alkyl, (phenyl)C 1 -C 6 alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, Boron, Si, and S, each of which R 36 is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, C 1 -C 6 alkylester, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —SO 2 R 9 , —OSi(CH 3 ) 2 C(CH 3 ) 3 , —Si(CH 3 ) 2
  • R 36 is a bicyclic heteroaryl such as a 9-membered heteroaryl
  • R 21 and R 22 are independently selected from hydrogen, hydroxyl, cyano, amino, C 1 -C 6 alkyl, haloalkyl including C 1 -C 6 haloalkyl, alkoxy including C 1 -C 6 alkoxy, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (phenyl)C 0 -C 4 alkyl, —C 1 -C 4 alkylOC(O)OC 1 -C 6 alkyl, —C 1 -C 4 alkylOC(O)C 1 -C 6 alkyl, —C 1 -C 4 alkylC(O)OC 1 -C 6 alkyl, (4- to 8-membered heterocycloalkyl)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl having 1, 2, or
  • R 21 and R 22 can be taken together to form a carbocyclic or heterocyclic ring
  • R 23 is independently selected at each occurrence from alkyl including C 1 -C 6 alkyl, haloalkyl including C 1 -C 6 haloalkyl, (aryl)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (phenyl)C 0 -C 4 alkyl, (4- to 8-membered heterocycle)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein each R 23 can be optionally substituted;
  • R 24 and R 30 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycle, or a 6- to 10-membered bicyclic heterocycle group having fused, spiro, or bridged rings, wherein each ring can be optionally substituted;
  • B2 is selected from:
  • B2 can be further substituted 1, 2, 3, or 4 times or more with the substituents independently selected from R 33 , R 34 , R 35 , R 36 , and R 48 ;
  • B3 is a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including C 2 -C 6 alkenyl; alkynyl including C 2 -C 6 alkynyl; —(C 0 -C 4 alkyl)(aryl); —(C 0 -C 4 alkyl)(heteroaryl); or —(C 0 -C 4 alkyl)(biphenyl), each of which B3 is substituted with at least one R 201 and optionally substituted with one or more substituents independently selected from R 33 , R 34 , R 35 , and R 36 ;
  • B4 is a six membered heteroaryl ring with at least two substituents selected from R 25 , R 26 , R 27 and R 28 ;
  • B4 is a six membered heteroaryl ring with at least three substituents selected from R 25 , R 26 , R 27 and R 28 ;
  • B4 is a pyridine with at least two substituents selected from R 25 , R 26 , R 27 and R 28 ;
  • R 25 , R 26 , R 27 , and R 28 are independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, thioalkyl including C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 25 , R 26 , R 27 , and R 28 other than hydrogen
  • R 25 , R 26 , R 27 , and R 28 are independently selected from tetrazole, halogen, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, thioalkyl including C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 25 , R 26 , R 27
  • any of these groups may be further optionally substituted as that term is defined in the Terminology Section below, if desired to achieve the target effect, results in a stable compound that makes chemical sense to the skilled artisan, and the group is not redundant (i.e., as known in the art, alkyl substituted with alkyl is redundant; however for examples, alkoxy substituted with alkoxy is not redundant); and
  • any of the structures illustrated herein e.g., A1, A2, A3, B1, B2, B3, B4, C1, C2, C3, C4, C5, L, L3, or any of the R moieties, can be optionally independently substituted with 0, 1, 2, 3, or 4, as appropriate, R 48 substituents.
  • the R 32 group on the A-ring is selected from
  • L3 is as defined above.
  • A4 is selected from:
  • compositions comprising a compound or salt of Formula I, Formula II, Formula III, Formula IV, or Formula V together with a pharmaceutically acceptable carrier are also disclosed.
  • the present invention thus includes at least the following features:
  • FIG. 1 is the six-step procedure to synthesize intermediate tert-butyl (1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.
  • FIG. 2 is the two-step synthesis of intermediate 2-bromo-3-fluoro-5-methylpyridine 1-oxide (Compound 3 in FIG. 2 ).
  • FIG. 3 is the three-step procedure to synthesize the intermediate tert-butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate.
  • FIG. 4 is a seven-step procedure to synthesize the intermediate 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid.
  • FIG. 5 is the two-step procedure to synthesize the intermediate tert-butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate.
  • FIG. 6 is the six-step procedure to synthesize intermediate (S)-3-fluoro-4-methylpent-3-en-2-amine hydrochloric acid salt.
  • FIG. 7 is the six-step procedure to synthesize intermediate (R)-1-((R)-2,2-dichlorocyclopropyl)ethan-1-amine hydrochloric acid salt.
  • FIG. 8 is the expanded eight-step synthesis of Compound 208 shown in Scheme 153.
  • FIG. 9 is the eight-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-(oxetan-3-yl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
  • FIG. 10 is a four-step procedure to synthesize (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(oxetan-3-yl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide.
  • FIG. 11 is a three-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N—((S)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
  • FIG. 12 is a seven-step procedure to synthesize Compound 100.
  • FIG. 13 is a three-step procedure for synthesizing Compound 50 and is an alternative to a synthesis shown in Scheme 45.
  • FIG. 14 is the expanded six-step synthesis of Compound 107 shown in Scheme 80.
  • FIG. 15 A is the eight-step procedure to synthesize intermediate 2-(3-acetyl-7-methyl-5-(2-(3-((trimethylsilyl)oxy)oxetan-3-yl)pyrimidin-5-yl)-1H-indazol-1-yl)acetic acid.
  • FIG. 15 B is the final two steps of a synthesis of (1R,3S,5R)-2-(2-(3-acetyl-5-(2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide from the intermediate shown in FIG. 18 A .
  • FIG. 16 is the eight-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-5-(2-(3-fluorooxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
  • FIG. 17 is a schematic showing the various potential attachment points for R 301 functionality on the A-ring, B-ring, C-ring, or heteroaryl-containing R 32 group.
  • X 9 as used in FIG. 17 is selected from —CH 2 —, —O—, —NH—, and —Nalkyl-.
  • FIGS. 18 A, 18 B, 18 C, 18 D, 18 E, 18 F, 18 G, 18 H, 18 I, 18 J, 18 K, 18 L, 18 M, 18 N, 18 O, 18 P, 18 Q, 18 R, 18 S, 18 T, 18 U , and 18 V are examples of compounds that exemplify Formula I, Formula II, or Formula III.
  • FIG. 19 depicts Formula I, Formula II, and Formula III.
  • the compounds in any of the Formulas described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context.
  • the present invention includes compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched.
  • Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.
  • isotopes examples include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 CI, 125 I respectively.
  • isotopically labelled compounds can be used in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
  • PET positron emission tomography
  • SPECT single-photon emission computed tomography
  • an 18 F labeled compound may be particularly desirable for PET or SPECT studies.
  • Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • isotopes of hydrogen for example, deuterium ( 2 H) and tritium ( 3 H) may optionally be used anywhere in described structures that achieves the desired result.
  • isotopes of carbon e.g., 13 C and 14 C, may be used.
  • the isotopic substitution is replacing hydrogen with a deuterium at one or more locations on the molecule to improve the performance of the drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax, Cmax, etc.
  • the deuterium can be bound to carbon in a location of bond breakage during metabolism (an ⁇ -deuterium kinetic isotope effect) or next to or near the site of bond breakage (a ⁇ -deuterium kinetic isotope effect).
  • Isotopic substitutions for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium.
  • the isotope is 80, 85, 90, 95 or 99% or more enriched in an isotope at any location of interest.
  • deuterium is 80, 85, 90, 95 or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance. And in an embodiment is enough to alter a detectable property of the drug in a human.
  • the substitution of a hydrogen atom for a deuterium atom can be provided in any of A1, A1′, A2, B1, B1′, B2, B3, B4, C1, C1′, C2, C3, C4, L1, L1′, L2, L2′, L4 or L5.
  • the substitution of a hydrogen atom for a deuterium atom occurs within any R group.
  • the R group is selected from any of R 1 , R 1′ , R 2 , R 2′ , R 3 , R 3′ , R 4 , R 4′ , R 5 , R 6 , R 6′ , R 7 , R 8 , R 8′ , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , R 17 , R 18 , R 18′ , R 19 , R 21 , R 22 , R 23 , R 25 , R 26 , R 27 , R 28 , R 30 , R 31 , R 32 , R 33 , R 34 , R 35 , R 36 , R 40 , R 41 , R 42 , R 43 , R 44 , R 44′ , R 45 , R 45′ , R 46 , R 46′ , R 47 , R 48 , R 48a , R 49 , R 50 , R 51 , R 52 , R 53 , R 49
  • the alkyl residue may be deuterated (in nonlimiting embodiments, CD 3 , CH 2 CD 3 , CD 2 CD 3 , CDH 2 , CD 2 H, CD 3 , CHDCH 2 D, CH 2 CD 3 , CHDCHD 2 , OCDH 2 , OCD 2 H, or OCD 3 etc.).
  • an R group has a “′” or an “a” designation, which in one embodiment can be deuterated.
  • the unsubstituted methylene carbon may be deuterated.
  • the compound of the present invention may form a solvate with solvents (including water). Therefore, in one embodiment, the invention includes a solvated form of the active compound.
  • solvate refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Nonlimiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents.
  • hydrate refers to a molecular complex comprising a compound of the invention and water.
  • Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
  • a solvate can be in a liquid or solid form.
  • a dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
  • —(C ⁇ O)NH 2 is attached through carbon of the keto (C ⁇ O) group.
  • substituted means that any one or more hydrogens on the designated atom or group is replaced with a moiety selected from the indicated group, provided that the designated atom's normal valence is not exceeded and the resulting compound is stable.
  • substituent is oxo (i.e., ⁇ O) then two hydrogens on the atom are replaced.
  • oxo i.e., ⁇ O
  • a pyridyl group substituted by oxo is a pyridone.
  • a stable active compound refers to a compound that can be isolated and can be formulated into a dosage form with a shelf life of at least one month.
  • a stable manufacturing intermediate or precursor to an active compound is stable if it does not degrade within the period needed for reaction or other use.
  • a stable moiety or substituent group is one that does not degrade, react or fall apart within the period necessary for use.
  • Nonlimiting examples of unstable moieties are those that combine heteroatoms in an unstable arrangement, as typically known and identifiable to those of skill in the art.
  • Any suitable group may be present on a “substituted” or “optionally substituted” position that forms a stable molecule and meets the desired purpose of the invention and includes, but is not limited to, e.g., halogen (which can independently be F, Cl, Br or I); cyano; hydroxyl; nitro; azido; alkanoyl (such as a C 2 -C 6 alkanoyl group); carboxamide; alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy such as phenoxy; thioalkyl including those having one or more thioether linkages; alkylsulfinyl; alkylsulfonyl groups including those having one or more sulfonyl linkages; aminoalkyl groups including groups having more than one N atoms; aryl (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted
  • “optionally substituted” includes one or more substituents independently selected from halogen, hydroxyl, amino, cyano, —CHO, —COOH, —CONH 2 , alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkynyl including C 2 -C 6 alkynyl, —C 1 -C 6 alkoxy, alkanoyl including C 2 -C 6 alkanoyl, C 1 -C 6 alkylester, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 2 alkyl, haloalkyl including C 1 -C 6 haloalkyl, hydroxyC 1 -C 6 alkyl, ester, carbamate, urea, sulfonamide, —C 1 -C 6 alkyl(heterocyclo),
  • Alkyl is a branched or straight chain saturated aliphatic hydrocarbon group. In one embodiment, the alkyl contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the alkyl contains from 1 to about 8 carbon atoms. In certain embodiments, the alkyl is C 1 -C 2 , C 1 -C 3 , C 1 -C 4 , C 1 -C 5 or C 1 -C 6 .
  • the specified ranges as used herein indicate an alkyl group having each member of the range described as an independent species.
  • C 1 -C 6 alkyl indicates a straight or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species.
  • C 1 -C 4 alkyl indicates a straight or branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species.
  • C 0 -C n alkyl is used herein in conjunction with another group, for example, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C 0 alkyl), or attached by an alkyl chain in this case 1, 2, 3, or 4 carbon atoms.
  • Alkyls can also be attached via other groups such as heteroatoms as in —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl).
  • alkyl examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, 2,3-dimethylbutane, and hexyl.
  • the alkyl group is optionally substituted as described above.
  • trimethylsilyl can be used instead of t-butyl.
  • “Aliphatic” refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon. “Aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions.
  • “aliphatic” is used to indicate those aliphatic groups having 1-20 carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, di-unsaturated, tri-unsaturated, polyunsaturated, or alkynyl.
  • Unsaturated aliphatic groups can be in a cis or trans configuration.
  • the aliphatic group contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms.
  • the aliphatic group contains from 1 to about 8 carbon atoms.
  • the aliphatic group is C 1 -C 2 , C 1 -C 3 , C 1 -C 4 , C 1 -C 5 or C 1 -C 6 .
  • the specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species.
  • C 1 -C 6 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species.
  • C 1 -C 4 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species.
  • the aliphatic group is substituted with one or more functional groups that results in the formation of a stable moiety.
  • heteroaliphatic refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom.
  • the only heteroatom is nitrogen.
  • the only heteroatom is oxygen.
  • the only heteroatom is sulfur.
  • Heteroaliphatic is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties.
  • heteroaliphatic is used to indicate a heteroaliphatic group (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-20 carbon atoms.
  • the heteroaliphatic group is optionally substituted in a manner that results in the formation of a stable moiety.
  • Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, —O-alkyl-O-alkyl, alkyl-O-haloalkyl, etc.
  • alk when a term is used that includes “alk” it should be understood that “cycloalkyl” or “carbocyclic” can be considered part of the definition, unless unambiguously excluded by the context.
  • alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkenyloxy, haloalkyl, aminoalkyl, alkylene, alkenylene, alkynylene, etc. can all be considered to include the cyclic forms of alkyl, unless unambiguously excluded by context.
  • Alkenyl is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon double bonds that may occur at a stable point along the chain. Nonlimiting examples are C 2 -C 8 alkenyl, C 2 -C 7 alkenyl, C 2 -C 6 alkenyl, C 2 -C 5 alkenyl and C 2 -C 4 alkenyl.
  • the specified ranges as used herein indicate an alkenyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. In one embodiment, the alkenyl group is optionally substituted as described above.
  • Alkynyl is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon triple bonds that may occur at any stable point along the chain, for example, C 2 -C 8 alkynyl or C 2 -C 6 alkynyl.
  • the specified ranges as used herein indicate an alkynyl group having each member of the range described as an independent species, as described above for the alkyl moiety.
  • alkynyl examples include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl.
  • the alkynyl group is optionally substituted as described above.
  • Alkylene is a bivalent saturated hydrocarbon. Alkylenes, for example, can be a 1, 2, 3, 4, 5, 6, 7 to 8 carbon moiety, 1 to 6 carbon moiety, or an indicated number of carbon atoms, for example C 1 -C 2 alkylene, C 1 -C 3 alkylene, C 1 -C 4 alkylene, C 1 -C 5 alkylene, or C 1 -C 6 alkylene.
  • Alkenylene is a bivalent hydrocarbon having at least one carbon-carbon double bond. Alkenylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C 2 -C 4 alkenylene.
  • Alkynylene is a bivalent hydrocarbon having at least one carbon-carbon triple bond.
  • Alkynylenes for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C 2 -C 4 alkynylene.
  • Alkoxy is an alkyl group as defined above covalently bound through an oxygen bridge (—O—).
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy.
  • an “alkylthio” or a “thioalkyl” group is an alkyl group as defined above with the indicated number of carbon atoms covalently bound through a sulfur bridge (—S—). In one embodiment, the alkoxy group is optionally substituted as described above.
  • Alkenyloxy is an alkenyl group as defined covalently bound to the group it substitutes by an oxygen bridge (—O—).
  • Alkanoyl is an alkyl group as defined above covalently bound through a carbonyl (C ⁇ O) bridge.
  • the carbonyl carbon is included in the number of carbons, that is C 2 alkanoyl is a CH 3 (C ⁇ O)— group.
  • the alkanoyl group is optionally substituted as described above.
  • Alkylester is an alkyl group as defined herein covalently bound through an ester linkage.
  • the ester linkage may be in either orientation, e.g., a group of the formula —O(C ⁇ O)alkyl or a group of the formula —(C ⁇ O)Oalkyl.
  • “Amide” or “carboxamide” is —C(O)NR a R b wherein R a and R b are each independently selected from hydrogen, alkyl, for example, alkyl including C 1 -C 6 alkyl, alkenyl, for example, C 2 -C 6 alkenyl, alkynyl, for example, C 2 -C 6 alkynyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —C 0 -C 4 alkyl(C 3 -C 7 heterocycloalkyl), —C 0 -C 4 alkyl(aryl), and —C 0 -C 4 alkyl(heteroaryl); or together with the nitrogen to which they are bonded, R a and R b can form a C 3 -C 7 heterocyclic ring.
  • the R a and R b groups are each independently be optionally substituted as described herein.
  • Carbocyclic group is a saturated or partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms.
  • a carbocyclic group typically contains 1 ring of 3 to 7 carbon atoms or 2 fused rings each containing 3 to 7 carbon atoms.
  • Cycloalkyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents can have a cycloalkyl group, which is attached as a spiro group.
  • carbocyclic rings examples include cyclohexenyl, cyclohexyl, cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl and cyclopropyl rings.
  • the carbocyclic ring is optionally substituted as described above.
  • the cycloalkyl is a partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms.
  • the cycloalkyl is a saturated group containing all carbon ring atoms.
  • Carbocyclic-oxy group is a monocyclic carbocyclic ring or a mono- or bi-cyclic carbocyclic group as defined above attached to the group it substitutes via an oxygen, —O—, linker.
  • Haloalkyl indicates both branched and straight-chain alkyl groups substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms.
  • Examples of haloalkyl include, but are not limited to, trifluoromethyl, monofluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
  • Haloalkoxy indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
  • Hydroalkyl is an alkyl group as previously described, substituted with at least one hydroxyl substituent.
  • aminoalkyl is an alkyl group as previously described, substituted with at least one amino substituent.
  • Halo or “halogen” indicates independently, any of fluoro, chloro, bromo or iodo.
  • Aryl indicates an aromatic group containing only carbon in the aromatic ring or rings.
  • the aryl group contains 1 to 3 separate or fused rings and is 6 to about 14 or 18 ring atoms, without heteroatoms as ring members.
  • such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Such substitution may include fusion to a 4 to 7 or a 5 to 7-membered saturated or partially unsaturated cyclic group that optionally contains 1, 2 or 3 heteroatoms independently selected from N, O, B, P, Si and/or S, to form, for example, a 3,4-methylenedioxyphenyl group.
  • Aryl groups include, for example, phenyl and naphthyl, including 1-naphthyl and 2-naphthyl.
  • aryl groups are pendant.
  • An example of a pendant ring is a phenyl group substituted with a phenyl group.
  • the aryl group is optionally substituted as described above.
  • heterocycle refers to a saturated or a partially unsaturated (i.e., having one or more double and/or triple bonds within the ring without aromaticity) carbocyclic moiety of 3 to about 12, and more typically 3, 4, 5, 6, 7, 8 to 10 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus sulfur, silicon and boron, the remaining ring atoms being C, where one or more ring atoms is optionally substituted independently with one or more substituents described above.
  • a heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, S, Si and B) or a bicycle having 6 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, S, Si and B), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system.
  • the only heteroatom is nitrogen.
  • the only heteroatom is oxygen.
  • the only heteroatom is sulfur, boron or silicon.
  • heterocyclic rings include, but are not limited to, pyrrolidinyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, piperidonyl, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, di
  • Spiro moieties are also included within the scope of this definition.
  • Examples of a heterocyclic group wherein 1 or 2 ring carbon atoms are substituted with oxo ( ⁇ O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl.
  • the heterocycle groups herein are optionally substituted independently with one or more substituents described herein, for example, 1, 2, or 3 substituents.
  • Heterocyclicoxy group is a monocyclic heterocyclic ring or a bicyclic heterocyclic group as described previously linked to the group it substitutes via an oxygen, —O—, linker.
  • Heteroaryl refers to a stable monocyclic, bicyclic, or multicyclic aromatic ring which contains from 1 to 3, or in some embodiments from 1, 2, or 3 heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5, 6, or 7 membered aromatic ring which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon.
  • the only heteroatom is nitrogen.
  • the only heteroatom is oxygen.
  • the only heteroatom is sulfur.
  • Monocyclic heteroaryl groups typically have from 5, 6, or 7 ring atoms.
  • bicyclic heteroaryl groups are 8- to 10-membered heteroaryl groups, that is, groups containing 8 or 10 ring atoms in which one 5, 6, or 7 member aromatic ring is fused to a second aromatic or non-aromatic ring.
  • the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another.
  • the total number of S and O atoms in the heteroaryl group is not more than 2.
  • the total number of S and O atoms in the aromatic heterocycle is not more than 1.
  • heteroaryl groups include, but are not limited to, pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazoly
  • Heterocycloalkyl is a fully saturated heterocycle as defined herein. It may have, for example, include 1, 2, 3, or 4 heteroatoms independently selected from N, S, O, Si and B with the remaining ring atoms being carbon. In a typical embodiment, nitrogen is the heteroatom. Monocyclic heterocycloalkyl groups typically have from 3 to about 8 ring atoms or from 4 to 6 ring atoms.
  • mono- and/or di-alkylamino indicate a secondary or tertiary alkylamino group, wherein the alkyl groups are independently selected as defined herein.
  • the point of attachment of the alkylamino group is on the nitrogen.
  • mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.
  • a “dosage form” means a unit of administration of an active agent.
  • dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, implants, particles, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gel, mucosal, and the like.
  • a “dosage form” can also include an implant, for example an optical implant.
  • “Pharmaceutical compositions” are compositions comprising at least one active agent, and at least one other substance, such as a carrier. “Pharmaceutical combinations” are combinations of at least two active agents which may be combined in a single dosage form or provided together in separate dosage forms with instructions that the active agents are to be used together to treat any disorder described herein.
  • a “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, pharmaceutically acceptable, acid or base addition salts thereof.
  • the salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
  • salts of the present compounds further include solvates of the compounds and of the compound salts.
  • Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include salts which are acceptable for human consumption and the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic acids.
  • salts examples include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH 2 ) n —COOH where n is 0-4, and the like, or using a different acid that produces the same counterion.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric
  • carrier applied to pharmaceutical compositions/combinations of the invention refers to a diluent, excipient, or vehicle with which an active compound is provided.
  • a “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, acceptable for human consumption, and neither biologically nor otherwise inappropriate for administration to a host, typically a human. In one embodiment, an excipient is used that is acceptable for veterinary use.
  • a “patient” or “host” or “subject” is a human or non-human animal in need of treatment or prevention of any of the disorders as specifically described herein, including but not limited to by modulation of the complement Factor D pathway or with a condition that is treatable with one of the compounds described herein.
  • the host is a human.
  • a “patient” or “host” or “subject” also refers to for example, a mammal, primate (e.g., human), cows, sheep, goat, horse, dog, cat, rabbit, rat, mice, bird and the like.
  • a “prodrug” as used herein means a compound which when administered to a host in vivo is converted into a parent drug.
  • the term “parent drug” means any of the presently described chemical compounds herein.
  • Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent, including to increase the half-life of the drug in vivo.
  • Prodrug strategies provide choices in modulating the conditions for in vivo generation of the parent drug.
  • prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to acylation, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation or anhydride, among others.
  • the prodrug renders the parent compound more lipophilic.
  • a prodrug can be provided that has several prodrug moieties in linear, branched or cyclic manner.
  • nonlimiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another prodrug moiety, and is typically biodegradable in vivo.
  • a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another prodrug moiety, and is typically biodegradable in vivo.
  • 2, 3, 4 or 5 prodrug biodegradable moieties are covalently bound in sequence, branched or cyclic fashion to the parent compound.
  • prodrugs according to the present invention are formed with:
  • a prodrug is provided by attaching a natural or non-natural amino acid to an appropriate functional moiety on the parent compound, for example, oxygen, nitrogen or sulfur, and typically oxygen or nitrogen, usually in a manner such that the amino acid can be cleaved in vivo to provide the parent drug.
  • the amino acid can be used alone or covalently linked (straight, branched or cyclic) to one or more other prodrug moieties to modify the parent drug to achieve the desired performance, such as increased half-life, lipophilicity, or other drug delivery or pharmacokinetic properties.
  • the amino acid can be any compound with an amino group and a carboxylic acid, which includes an aliphatic amino acid, alkyl amino acid, aromatic amino acid, heteroaliphatic amino acid, heteroalkyl amino acid, or heterocyclic amino acid or heteroaryl amino acid.
  • “Providing a compound with at least one additional active agent,” for example, in one embodiment can mean that the compound and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration.
  • the compound administrations are separated by some amount of time that is within the time in which both the compound and the at least one additional active agent are within the blood stream of a patient.
  • the compound and the additional active agent need not be prescribed for a patient by the same medical care worker.
  • the additional active agent or agents need not require a prescription.
  • Administration of the compound or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories, parenteral, sublingual, buccal, intravenous, intraaortal, transdermal, polymeric controlled delivery, non-polymeric controlled delivery, nano or microparticles, liposomes, and/or topical contact.
  • the instructions for administration in a form of combination therapy is provided in the drug labeling.
  • a “therapeutically effective amount” of a pharmaceutical composition/combination of this invention means an amount effective, when administered to a host, provides a therapeutic benefit such as an amelioration of symptoms or reduction or dimunition of the disease itself.
  • a therapeutically effective amount is an amount sufficient to prevent a significant increase or will significantly reduce the detectable level of complement Factor D in the patient's blood, serum, or tissues.
  • any of the active compounds can be provided in its N-oxide form to a patient in need thereof.
  • an N-oxide of an active compound or a precursor of the active compound is used in a manufacturing scheme.
  • the N-oxide is a metabolite of administration of one of the active compounds herein, and may have independent activity.
  • the N-oxide can be formed by treating the compound of interest with an oxidizing agent, for example a suitable peroxyacid or peroxide, to generate an N-oxide compound.
  • a heteroaryl group for example a pyridyl group
  • an oxidizing agent such as sodium percarbonate
  • a rhenium-based catalyst under mild reaction conditions to generate an N-oxide compound.
  • oxidizing agent such as sodium percarbonate
  • protecting groups may be necessary to carry out the chemistry. See, Jain, S. L. et al., “Rhenium-Catalyzed Highly Efficient Oxidations of Tertiary Nitrogen Compounds to N-Oxides Using Sodium Percarbonate as Oxygen Source, Synlett, 2261-2663, 2006.
  • the N-oxide is in the A-Ring. In one embodiment the N-oxide is in the B-Ring. In one embodiment the N-oxide is on the R 32 group.
  • any of the active compounds with a sulfur can be provided in its sulfoxide or sulfone form to a patient in need thereof.
  • a sulfoxide or sulfone of one of the active compounds or a precursor of the active compound is used in a manufacturing scheme.
  • a sulfur atom in a selected compound as described herein can be oxidized to form a sulfoxide
  • TAPC 1,3,5-triazo-2,4,6-triphosphorine-2,2,4,4,6,6-tetrachloride
  • TAPC 1,3,5-triazo-2,4,6-triphosphorine-2,2,4,4,6,6-tetrachloride
  • Oxidation of sulfides with 30% hydrogen peroxide catalyzed by tantalum carbide provides sulfoxides in high yields, see, Kirihara, A., et al., “Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones”, Synlett, 1557-1561 (2010).
  • Sulfides can be oxidized to sulfones using, for example, niobium carbide as the catalyst, see, Kirihara, A., et al., “Tantalum Cardide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones”, Synlett, 1557-1561 (2010).
  • Urea-hydrogen peroxide adduct is a stable inexpensive and easily handled reagent for the oxidation of sulfides to sulfones, see Varma, R. S. and Naicker, K.
  • alkyl is a C 1 -C 10 alkyl, C 1 -C 9 alkyl, C 1 -C 8 alkyl, C 1 -C 7 alkyl, C 1 -C 6 alkyl, C 1 -C 5 alkyl, C 1 -C 4 alkyl, C 1 -C 3 alkyl, or C 1 -C 2 alkyl.
  • alkyl has one carbon
  • alkyl has two carbons.
  • alkyl has three carbons.
  • alkyl has four carbons.
  • alkyl has five carbons.
  • alkyl has six carbons.
  • alkyl include: methyl, ethyl, propyl, butyl, pentyl, and hexyl.
  • alkyl examples include: isopropyl, isobutyl, isopentyl, and isohexyl.
  • alkyl examples include: sec-butyl, sec-pentyl, and sec-hexyl.
  • alkyl examples include: tert-butyl, tert-pentyl, and tert-hexyl.
  • alkyl include: neopentyl, 3-pentyl, and active pentyl.
  • alkyl is “substituted alkyl”
  • alkenyl is “substituted alkenyl”
  • alkynyl is “substituted alkynyl”
  • haloalkyl is a C 1 -C 10 haloalkyl, C 1 -C 9 haloalkyl, C 1 -C 8 haloalkyl, C 1 -C 7 haloalkyl, C 1 -C 6 haloalkyl, C 1 -C 5 haloalkyl, C 1 -C 4 haloalkyl, C 1 -C 3 haloalkyl, and C 1 -C 2 haloalkyl.
  • haloalkyl has one carbon
  • haloalkyl has one carbon and one halogen.
  • haloalkyl has one carbon and two halogens.
  • haloalkyl has one carbon and three halogens.
  • haloalkyl has two carbons.
  • haloalkyl has three carbons.
  • haloalkyl has four carbons.
  • haloalkyl has five carbons.
  • haloalkyl has six carbons.
  • haloalkyl include:
  • haloalkyl include:
  • haloalkyl include:
  • haloalkyl include:
  • aryl is a 6 carbon aromatic group (phenyl)
  • aryl is a 10 carbon aromatic group (napthyl)
  • aryl is “substituted aryl”.
  • heteroaryl is a 5 membered aromatic group containing 1, 2, or 3, nitrogen atoms.
  • Non-limiting examples of 5 membered “heteroaryl” groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.
  • heteroaryl is a 6 membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).
  • Non-limiting examples of 6 membered “heteroaryl” groups with 1 or 2 nitrogen atoms include:
  • heteroaryl is a 9 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
  • Non-limiting examples of“heteroaryl” groups that are bicyclic include indole, benzofuran, isoindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.
  • heteroaryl groups that are bicyclic include:
  • heteroaryl groups that are bicyclic include:
  • heteroaryl groups that are bicyclic include:
  • heteroaryl is a 10 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
  • heteroaryl groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.
  • heteroaryl groups that are bicyclic include:
  • heteroaryl is “substituted heteroaryl.”
  • heteroaryl is tetrazole.
  • cycloalkyl is a C 3 -C 8 cycloalkyl, C 3 -C 7 cycloalkyl, C 3 -C 6 cycloalkyl, C 3 -C 5 cycloalkyl, C 3 -C 4 cycloalkyl, C 4 -C 8 cycloalkyl, C 5 -C 8 cycloalkyl, or C 6 -C 8 cycloalkyl.
  • cycloalkyl has three carbons.
  • cycloalkyl has four carbons.
  • cycloalkyl has five carbons.
  • cycloalkyl has six carbons.
  • cycloalkyl has seven carbons.
  • cycloalkyl has eight carbons.
  • cycloalkyl has nine carbons.
  • cycloalkyl has ten carbons.
  • cycloalkyl include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclodecyl.
  • cycloalkyl is a “substituted cycloalkyl”
  • heterocycle refers to a cyclic ring with one nitrogen and 3, 4, 5, 6, 7, or 8 carbon atoms.
  • heterocycle refers to a cyclic ring with one nitrogen and one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
  • heterocycle refers to a cyclic ring with two nitrogens and 3, 4, 5, 6, 7, or 8 carbon atoms.
  • heterocycle refers to a cyclic ring with one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
  • heterocycle refers to a cyclic ring with one sulfur and 3, 4, 5, 6, 7, or 8 carbon atoms.
  • heterocycle examples include aziridine, oxirane, thiirane, azetidine, 1,3-diazetidine, oxetane, and thietane.
  • heterocycle examples include pyrrolidine, 3-pyrroline, 2-pyrroline, pyrazolidine, and imidazolidine.
  • heterocycle examples include tetrahydrofuran, 1,3-dioxolane, tetrahydrothiophene, 1,2-oxathiolane, and 1,3-oxathiolane.
  • heterocycle examples include piperidine, piperazine, tetrahydropyran, 1,4-dioxane, thiane, 1,3-dithiane, 1,4-dithiane, morpholine, and thiomorpholine.
  • heterocycle also include:
  • heterocycle includes:
  • heterocycle includes:
  • heterocycle also include:
  • heterocycle also include:
  • heterocycle includes:
  • heterocycle includes:
  • heterocycle is “substituted heterocycle”.
  • R 201 is selected from —(CH 2 ) m —O-heterocycle, —(CH 2 ) m —NH-heterocycle, or —(CH 2 ) m —NR 9 -heterocycle;
  • R 201 is selected from —(CH 2 ) m —NR 9 R 10 , —(CH 2 ) m —OR 9 , or —(CH 2 ) m -heterocycle;
  • R 201 is selected from —CH 2 —O-heterocycle, —CH 2 —NH-heterocycle, or —CH 2 —NR 9 -heterocycle;
  • R 201 is selected from —CH 2 —NR 9 R 10 , —CH 2 —OR 9 , or —CH 2 -heterocycle;
  • R 201 is selected from —(CH 2 ) m —NH 2 , —(CH 2 ) m —OH, or —(CH 2 ) m —OC 1 -C 6 alkyl;
  • m is 1, 2, or 3.
  • n 1
  • n is 2.
  • m is 3.
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • R 201 is selected from:
  • C5 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • C5 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • C5 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • C5 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • C1 is selected from:
  • C1 is selected from:
  • a methyl group in a structure illustrated above can be replaced with a different alkyl group, as defined herein.
  • the fluoro atoms in the structures illustrated above can be replaced with any other halogen. Any of the structures illustrated above or otherwise can be optionally substituted with 0, 1, 2, 3, or 4, as appropriate, and independently, with an R 48 substituent.
  • central core small mimetics of a beta-turn, beta turn inducers, reverse turn mimetics and foldamer monomers include:
  • R 101 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl
  • R 102 is C 1 -C 4 alkyl, fluorine, chlorine, or bromine.
  • C4 is selected from:
  • C4 is selected from:
  • C4 is selected from:
  • C4 is selected from:
  • R 1 is selected from F, Cl, Br, and C 1 -C 6 alkyl.
  • R 1 is selected from hydroxyl and C 1 -C 6 alkoxy.
  • R 1 is selected from C 2 -C 6 alkynyl, C 2 -C 6 alkanoyl, and C 1 -C 6 thioalkyl.
  • R 1 is selected from aminoC 1 -C 6 alkyl and —C 0 -C 4 alkylNR 9 R 10 .
  • C is selected from
  • Non-limiting examples of A1 include:
  • A1 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A3 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • A1 is selected from:
  • R 101 is C 1 -C 4 alkyl or C 3 -C 7 cycloalkyl.
  • A1 is selected from:
  • A4 is selected from:
  • A4 is
  • A4 is selected from:
  • A4 is selected from:
  • A4 is selected from:
  • A4 is
  • L1 is selected from:
  • L1 is selected from:
  • L1 is selected from:
  • L1 is selected from:
  • L1 is selected from:
  • methyl groups in the structures illustrated above can be replaced with another alkyl group, as defined herein.
  • L2 is selected from:
  • Non-limiting examples of L2 include:
  • Non-limiting examples of L2 include:
  • Non-limiting examples of L2 include:
  • Non-limiting examples of L2 include:
  • Non-limiting examples of L2 include:
  • the methyl groups in the structures illustrated above can be replaced with another alkyl or acyl, as defined herein.
  • the carbocyclic, heterocyclic, aryl or heteroaryl rings can be optionally substituted.
  • any of the structures illustrated above or below can be optionally substituted with 0, 1, 2, 3, or 4, as appropriate, and independently, of an R 48 substituent.
  • L2 is a bond. In certain embodiments, if L2 is heterocyclic or heteroaryl, then B can be hydrogen.
  • B1 is selected from:
  • R 36 is selected from:
  • B is selected from:
  • R 27 is hydrogen, methyl, or trifluoromethyl
  • R 28 is hydrogen or halogen
  • R 29 is hydrogen, methyl, trifluoromethyl, or —Si(CH 3 ) 2 C(CH 3 ) 3 .
  • B is selected from:
  • B moieties include, but are not limited to
  • B4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B4 is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • R 25 , R 26 , R 27 , and R 28 are independently selected from hydrogen, halogen, and C 1 -C 6 alkyl.
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is selected from:
  • B4 is -alkyl-Si(alkyl) 3 or -alkyl-SF 5 .
  • B4 is a B ring substituted with oxo.
  • the nitrogen may also be substituted as defined herein. For example:
  • B4 is selected from:
  • R 32 is a heteroaryl ring substituted with oxo as allowed by valence.
  • R 32 ring is a nitrogen containing heteroaryl group then the nitrogen may also be substituted as defined herein.
  • the nitrogen may also be substituted as defined herein.
  • R 32 is selected from:
  • B4 is an alkyl group.
  • B4 is an alkenyl group.
  • C4 is selected from:
  • L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula I is:
  • L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula II is:
  • L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula III is:
  • R 32 is selected from:
  • R 32 is selected from:
  • R 32 is selected from:
  • R 11 , R 12 , R 13 , R 14 , or R 15 is -alkyl-R 32 or —O-alkyl-R 32 .
  • R 11 , R 12 , R 13 , R 14 , or R 15 is
  • R 11 , R 12 , R 13 , R 14 , or R 15 is
  • X 31 is selected from N and CR 54 ;
  • X 31 is C(R 54 ) 2 ;
  • X 25 is O or S
  • R 4′ is selected from -JCHO, -JCONH 2 , -JCONR 9 R 10 , JC 2 -C 6 alkanoyl, -JSO 2 NH 2 , -JSO 2 NR 21 R 22 , -JC(CH 2 ) 2 F, -JCH(CF 3 )NH 2 , -J-haloalkyl-NH 2 , -J-haloalkyl-NR 9 R 10 , alkyl including C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), -JC(O)C 0 -C 2 alkyl(C 3 -C 7 cycloalkyl), -JNR 9 (C 2 -C 6 alkanoyl), -JNR 9 C(O)NR 9 R 10 ,
  • each of which R 4′ other than —CHO, is optionally substituted with one or more of amino, imino, halogen, hydroxyl, cyano, cyanoimino, alkyl including C 1 -C 6 alkyl, alkoxy including C 1 -C 6 alkoxy, —C 0 -C 2 alkyl(mono- and di-C 1 -C 6 alkylamino), haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 -C 6 haloalkoxy.
  • R 32 is
  • R 301 examples of R 301 are provided below.
  • R 301 is monovalently attached to the molecule.
  • the divalent species below are presented to illustrate that the R 301 can be linked at either point and the other is capped for example with H, alkyl, halogen, haloalkyl, aryl, heteroaryl, and heterocycle, each of which may be optionally substituted as described herein.
  • R 301 is selected from:
  • the moiety is shown as a divalent species, it can also be capped with hydrogen, methyl, alkyl, haloalkyl, aryl, heteroaryl, heterocyclic, other capping moiety of another bioactive moiety, or an additional prodrug moiety.
  • R 301 is selected from:
  • R 301 is
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected from: bond, polyethylene glycol, a natural amino acid, an unnatural amino acid,
  • R 309 is selected from: alkyl, hydrogen,
  • n2 is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20;
  • X 300 is selected from bond, —NH—, —N(alkyl)-, O, —CH 2 —O—, —CH 2 —NH—, and —CH 2 —N(alkyl).
  • R 302 , R 303 , R 30 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • none of R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • R 302 , R 303 , R 304 , R 305 , R 306 , R 307 , and R 308 are selected to be bond.
  • Non-limiting examples of compounds of the present invention with a R 301 group include:
  • Non-limiting examples of compounds of the present invention with a R 301 group include:
  • Non-limiting examples of compounds of the present invention with a R 301 group include:
  • Non-limiting examples of compounds of the present invention with a R 301 group include:
  • Non-limiting examples of compounds of the present invention with a R 301 group include:
  • R 32 is:
  • the disclosure includes compounds and salts of Formulas in Table 1 for any use and in any composition described in this application.
  • R 32 is illustrated as
  • R 103 is C 1 -C 4 alkyl, C 3 -C 6 cycloalkyl, fluorine, chlorine, or bromine.
  • Formula III-1 Formula III-2 Formula III-3 Formula III-4 Formula III-5 Formula III-6 Formula III-7 Formula III-8 Formula III-9 Formula III-10 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III-13 Formula III-14 Formula III-15 Formula III-16 Formula III-11 Formula III-12 Formula III
  • the invention includes a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, wherein at least one of R 12 or R 13 on the A group is an heteroaryl, or heterocycle for example, R 32 .
  • R 12 and R 13 is selected from R 31 and the other of R 12 and R 13 is selected from R 32 . In another embodiment, each of R 12 and R 13 can be independently selected from R 32 .
  • R 31 is selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, haloalkyl including C 1 -C 6 haloalkyl, haloalkoxy including C 1 -C 6 haloalkoxy, alkyl including C 1 -C 6 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, alkenyloxy including C 2 -C 6 alkenyloxy, —C(O)OR 9 , thioalkyl including C 1 -C 6 thioalkyl, —C 0 -C 4 alkylNR 9 R 10 , —C(O)NR 9 R 10 , —SO 2 R 9 , —SO 2 NR 9 R 10 ,
  • R 32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl, saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
  • R 12 is R 32 .
  • R 13 is R 32 .
  • R 12 is an optionally substituted heteroaryl.
  • R 13 is an optionally substituted heteroaryl.
  • R 12 is R 32 .
  • R 12 is R 32 , which is (4- to 7-membered heterocycloalkyl) having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
  • the disclosure provides compounds of Formula I, wherein;
  • R 12 and R 13 is H and the other of R 12 and R 13 is R 32 , where
  • R 32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
  • the disclosure provides compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V wherein;
  • R 1 , R 1′ , R 2 , and R 3′ are all hydrogen
  • R 2 is fluoro and R 3 is hydrogen, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), or —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);
  • R 5 is hydrogen, halogen, or C 1 -C 6 alkyl
  • R 11 , R 13 , R 14 , and R 15 if present, are independently selected at each occurrence from hydrogen, halogen, hydroxyl, amino, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, —C 0 -C 2 alkyl(mono- and di-C 1 -C 6 alkylamino), trifluoromethyl, and trifluoromethoxy;
  • X 12 is CR 12 ;
  • R 12 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
  • the disclosure provides compounds of Formula I, wherein;
  • n 0 or 1
  • R 2 is halogen
  • R 2′ is hydrogen or halogen
  • R 3 is hydrogen, halogen, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), or —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl);
  • R 6 is —C(O)C 1 -C 4 alkyl, —C(O)NH 2 , —C(O)CF 3 , —C(O)(C 3 -C 7 cycloalkyl), or -ethyl(cyanoimino);
  • R 12 and R 13 is selected from hydrogen, halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, trifluoromethyl, and trifluoromethoxy; the other of R 12 and R 13 is R 32 , where
  • R 32 is selected from aryl, heteroaryl; saturated or unsaturated heterocycle; wherein the aryl, heteroaryl, saturated or unsaturated heterocycle ring can be optionally substituted.
  • the disclosure provides compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V, wherein one of R 12 and R 13 is hydrogen, hydroxyl, halogen, methyl, or methoxy; and the other of R 12 and R 13 is R 32 , wherein one of R 12 and R 13 is hydrogen, hydroxyl, halogen, methyl, or methoxy; and the other of R 12 and R 13 is R 32 , wherein one of R 12 and R 13 is hydrogen, hydroxyl, halogen, methyl, or methoxy; and the other of R 12 and R 13 is R 32 , where
  • R 32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring, can be optionally substituted.
  • R 32 may be unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, oxo, —B(OH) 2 , —Si(CH 3 ) 3 , —COOH, —CONH 2 , —P(O)(OH) 2 , C 1 -C 6 alkyl, alkoxy including C 1 -C 6 alkoxy, —C 0 -C 2 alkyl(mono- and di-C 1 -C 4 alkylamino), C 1 -C 6 alkylester, C 1 -C 4 alkylamino, C 1 -C 4 hydroxylalkyl, haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 -C 6 haloalkoxy.
  • substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, oxo, —
  • R 31 is hydrogen and R 32 is pyrimidinyl.
  • R 31 is hydrogen and R 32 is pyrimidine substituted with a methyl group.
  • R 1 and R 1′ or R 3 and R 3′ may be taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
  • R 2 and R 2′ may be taken together to form a 3- to 6-membered carbocyclic spiro ring; or
  • R 2 and R 2′ may be taken together to form a 3- to 6-membered heterocyclic spiro ring; each of which ring may be unsubstituted or substituted with 1 or more substituents independently selected from halogen (and in particular F), hydroxyl, cyano, —COOH, C 1 -C 4 alkyl (including in particular methyl), C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, hydroxyC 1 -
  • R 1 and R 2 may be taken together to form a 3-membered carbocyclic ring;
  • R 1 and R 2 may be taken together to form a 4, 5 or 6-membered carbocyclic or an aryl ring or a 4, 5 to 6-membered heterocyclic or heteroaryl ring containing 1 or 2 heteroatoms independently selected from N, O, and S; or
  • R 2 and R 3 if bound to adjacent carbon atoms, may be taken together to form a 3- to 6-membered carbocyclic or aryl ring or a 3- to 6-membered heterocyclic or heteroaryl ring;
  • each of which ring may be unsubstituted or substituted with 1 or more substituents independently selected from halogen (and in particular F), hydroxyl, cyano, —COOH, C 1 -C 4 alkyl (including in particular methyl), C 2 -C 4 alkenyl, C 2 -C 4 alkynyl, C 1 -C 4 alkoxy, C 2 -C 4 alkanoyl, hydroxyC 1 -C 4 alkyl, (mono- and di-C 1 -C 4 alkylamino)C 0 -C 4 alkyl, —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl), haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 -C 6 haloalkoxy.
  • substituents independently selected from
  • the central core moiety is proline.
  • the central core moiety is 4-fluoroproline.
  • R 1 , R 1′ , R 2′ , R 3 , and R 3′ if present, are all hydrogen; and R 2 is fluoro.
  • R 1 , R 1′ , R 2′ , and R 3′ if present, are all hydrogen; and R 2 is fluoro and R 3 is —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl) or —O—C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl).
  • R 1 and R 2 are taken together to form a 3- to 6-membered cycloalkyl group, and R 1′ , R 2′ , R 3 , and R 3′ , where present, are all hydrogen.
  • the bicycle is fused in a cis fashion.
  • the bicyclic ring is fused in a trans fashion.
  • R 1 and R 2 are taken together to form a 3- to 6-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
  • R 1 and R 2 are taken together to form a 3- to 6-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
  • R 1 , R 1′ , R 3 , and R 3′ if present, are all hydrogen, and R 2 and R 2′ are taken together to form a 5- or 6-membered heterocycloalkyl group having 1 or 2 oxygen atoms.
  • R 1 is hydrogen and R 2 is fluoro.
  • R 1 and R 2 are joined to form a 3 membered ring.
  • R 1 and R 2 are taken together to form a 3-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
  • R 1 and R 2 are taken together to form a 3-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
  • R 2 and R 3 are taken together to form a 3- to 6-membered cycloalkyl group
  • R 1 , R 1′ , R 2′ and R 3′ where present, are selected from hydrogen, C 1 -C 3 alkyl or C 1 -C 3 alkoxy.
  • R 2 and R 3 are taken together to form a 3- to 6-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
  • R 2 and R 3 are taken together to form a 3- to 6-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
  • R 2 and R 3 are taken together to form a 3-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
  • R 2 and R 3 are taken together to form a 3-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
  • R 1 , R 1′ , R 3 , and R 3′ if present, are all hydrogen, and R 2 and R 2′ are taken together to form a 5- or 6-membered heterocycloalkyl group having 1 or 2 oxygen atoms.
  • R 1 is hydrogen and R 2 is fluoro.
  • R 1 and R 2 are joined to form a 3 membered ring.
  • L is a bond or is selected from the formulas:
  • R 17 is hydrogen, C 1 -C 6 alkyl, or —C 0 -C 4 alkyl(C 3 -C 7 cycloalkyl) and R 18 and R 18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0, 1, 2, or 3.
  • -L1-B1- is:
  • R 18 and R 18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0 or 1; and
  • R 26 , R 27 , and R 28 are independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, thioalkyl including C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 26 , R 27 , and R 28 other than hydrogen, halogen,
  • R 29 is hydrogen, alkyl including C 1 -C 6 alkyl, C 1 C 2 haloalkyl or —Si(CH 3 ) 2 C(CH 3 ) 3 .
  • -L-B1- moiety is selected:
  • -L1-B1- moiety is selected:
  • -L2-B1- moiety is selected:
  • -L2-B1- moiety is selected:
  • m is 0.
  • the disclosure further includes compounds and salts of Formula I in which B1 is 2-fluoro-3-chlorophenyl.
  • B1 is 2-fluoro-3-chlorophenyl.
  • another carbocyclic, aryl, heterocyclic, or heteroaryl group such as 2-bromo-pyridin-6-yl, 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl, 2,2-dichlorocyclopropylmethyl, or 2-fluoro-3-trimethylsilylphenyl is used.
  • B1 is phenyl, pyridyl, or indanyl each of which is unsubstituted or substituted with one or more substituents independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, alkoxy including C 1 -C 6 alkoxy, thioalkyl including C 1 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycycloalkyl)C 0 -C 4 alkyl, —C 0 -C 4 alkoxy(C 3 -C 7 cycycloalkyl), (phenyl)C 0 -C 2 alkyl, (pyridyl)C
  • B1 is phenyl or pyridyl substituted with 1, 2, or 3 substituents selected from chloro, bromo, hydroxyl, —SCF 3 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, trifluoromethyl, phenyl and trifluoromethoxy each of which substituents other than chloro, bromo, hydroxyl, —SCF 3 , can be optionally substituted.
  • B1 is a 2-fluoro-3-chlorophenyl or a 2-fluoro-3-trifluoromethoxyphenyl group.
  • B1 is pyridyl, optionally substituted with halogen, C 1 -C 6 alkoxy, and trifluoromethyl.
  • B1 is phenyl, substituted with 1, 2, or 3 substituents independently selected from halogen, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, trifluoromethyl, and optionally substituted phenyl.
  • R 23 is independently selected at each occurrence from (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (phenyl)C 0 -C 4 alkyl, (4- to 7-membered heterocycloalkyl)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C 0 -C 4 alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
  • L1-B3 is:
  • R 27′ , and R 28′ are independently selected from hydrogen, fluoro, bromo, iodo, hydroxyl, nitro, cyano, alkyl including C 1 -C 6 alkyl, alkenyl including C 2 -C 6 alkenyl, alkanoyl including C 2 -C 6 alkanoyl, C 2 -C 6 alkoxy, C 2 -C 6 thioalkyl, (mono- and di-C 1 -C 6 alkylamino)C 0 -C 4 alkyl, (C 3 -C 7 cycloalkyl)C 0 -C 4 alkyl, (aryl)C 0 -C 4 alkyl-, (heteroaryl)C 0 -C 4 alkyl-, and —C 0 -C 4 alkoxy(C 3 -C 7 cycloalkyl); each of which R 27′ , and R 28′ other than hydrogen, fluoro, bromo, i
  • R 5 and R 6 are independently selected from —CHO, —C(O)NH 2 , —C(O)NH(CH 3 ), C 2 -C 6 alkanoyl, and hydrogen.
  • each R 5 and R 6 other than hydrogen, hydroxyl, cyano, and —COOH is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, imino, cyano, cyanoimino, alkyl including C 1 -C 6 alkyl, C 1 -C 4 alkoxy, —C 0 -C 2 alkyl(mono- and di-C 1 -C 4 alkylamino), haloalkyl including C 1 -C 6 haloalkyl, and haloalkoxy including C 1 -C 6 haloalkoxy.
  • R 8 and R 8′ are independently hydrogen or methyl.
  • R 8 and R 8′ are hydrogen.
  • R 7 is hydrogen or methyl.
  • R 7 is hydrogen
  • Active compounds described herein can be administered to a host in need thereof as the neat chemical, but are more typically administered as a pharmaceutical composition that includes an effective amount for a host, typically a human, in need of such treatment of an active compound as described herein or its pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof.
  • the disclosure provides pharmaceutical compositions comprising an effective amount of compound or pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof together with at least one pharmaceutically acceptable carrier for any of the uses described herein.
  • the pharmaceutical composition may contain a compound or salt as the only active agent, or, in an alternative embodiment, the compound and at least one additional active agent.
  • an effective amount of an active compound as described herein, or the active compound described herein in combination or alternation with, or preceded by, concomitant with or followed by another active agent can be used in an amount sufficient to (a) inhibit the progression of a disorder mediated by the complement pathway, including an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (b) cause a regression of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (c) cause a cure of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; or inhibit or prevent the development of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder.
  • an effective amount of an active compound or its salt or composition described herein will provide a sufficient amount of the active agent when administered to a patient to provide a clinical benefit.
  • the exact amount of the active compound or pharmaceutical composition described herein to be delivered to the host, typically a human, in need thereof, will be determined by the health care provider to achieve the desired clinical benefit.
  • the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form.
  • Examples are dosage forms with at least about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1100, 1200, 1250, 1300, 1400, 1500, or 1600 mg of active compound, or its salt or prodrug.
  • the dosage form has at least about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, 500 mg, 600 mg, 1000 mg, 1200 mg, or 1600 mg of active compound, or its salt. The amount of active compound in the dosage form is calculated without reference to the salt.
  • the dosage form can be administered, for example, once a day (q.d.), twice a day (b.i.d.), three times a day (t.i.d.), four times a day (q.i.d.), once every other day (Q2d), once every third day (Q3d), as needed, or any dosage schedule that provides treatment of a disorder described herein.
  • the pharmaceutical composition may for example include a molar ratio of the active compound and an additional active agent that achieves the desired result.
  • the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an additional active agent in combination with the active compound (additional active agent: active compound), or its salt, described herein.
  • the additional active agent is an anti-inflammatory or immunosuppressing agent.
  • Compounds disclosed herein or used as described herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intravenous, intra-aortal, intracranial, subdermal, intraperitoneal, subcutaneous, transnasal, sublingual, intrathecal, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers.
  • the compound can be administered, as desired, for example, as a solution, suspension, or other formulation via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, subchoroidal, choroidal, conjunctival, subconjunctival, episcleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device, injection, or topically administered formulation, for example a solution or suspension provided as an eye drop.
  • the pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a gel cap, a pill, a microparticle, a nanoparticle, an injection or infusion solution, a capsule, a tablet, a syrup, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution or suspension.
  • Some dosage forms, such as tablets and capsules are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
  • compositions, and methods of manufacturing such compositions, suitable for administration as contemplated herein are known in the art.
  • known techniques include, for example, U.S. Pat. Nos. 4,983,593, 5,013,557, 5,456,923, 5,576,025, 5,723,269, 5,858,411, 6,254,889, 6,303,148, 6,395,302, 6,497,903, 7,060,296, 7,078,057, 7,404,828, 8,202,912, 8,257,741, 8,263,128, 8,337,899, 8,431,159, 9,028,870, 9,060,938, 9,211,261, 9,265,731, 9,358,478, and 9,387,252, incorporated by reference herein.
  • compositions contemplated here can optionally include a carrier.
  • Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated.
  • the carrier can be inert or it can possess pharmaceutical benefits of its own.
  • the amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.
  • Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, fillers, flavorants, glidents, lubricants, pH modifiers, preservatives, stabilizers, surfactants, solubilizers, tableting agents, and wetting agents.
  • Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others.
  • Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils.
  • examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch.
  • surface active agents include sodium lauryl sulfate and polysorbate 80.
  • Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins.
  • Examples of disintegrants include sodium starch glycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, colloidal silicon dioxide, and croscarmellose sodium.
  • Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth.
  • Examples of lubricants include magnesium stearate and calcium stearate.
  • pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids.
  • bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids.
  • buffers generally comprising mixtures of acids and the salts of said acids.
  • optionalal other active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
  • the pharmaceutical composition for administration further includes a compound or salt of Formula I, II, or III and optionally comprises one or more of a phosphoglyceride; phosphatidylcholine; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohol such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acid; fatty acid monoglyceride; fatty acid diglyceride; fatty acid amide; sorbitan trioleate (Span®
  • the pharmaceutical preparation may include polymers for controlled delivery of the described compounds, including, but not limited to pluronic polymers, polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, poly(1,3-dioxan-2one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates.
  • polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides. See, e.g., Papisov, 2001, ACS Symposium Series, 786:301, incorporated by reference herein.
  • the compounds of the present invention can be formulated as particles.
  • the particles are or include microparticles.
  • the particles are or include nanoparticles.
  • common techniques for preparing particles include, but are not limited to, solvent evaporation, solvent removal, spray drying, phase inversion, coacervation, and low temperature casting. Suitable methods of particle formulation are briefly described below.
  • Pharmaceutically acceptable excipients including pH modifying agents, disintegrants, preservatives, and antioxidants, can optionally be incorporated into the particles during particle formation.
  • the particles are derived through a solvent evaporation method.
  • a compound described herein or polymer matrix and one or more compounds described herein
  • a volatile organic solvent such as methylene chloride.
  • the organic solution containing a compound described herein is then suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol).
  • the resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid nanoparticles or microparticles.
  • the resulting nanoparticles or microparticles are washed with water and dried overnight in a lyophilizer. Nanoparticles with different sizes and morphologies can be obtained by this method.
  • compositions which contain labile polymers may degrade during the fabrication process due to the presence of water.
  • labile polymers such as certain polyanhydrides
  • methods which are performed in completely or substantially anhydrous organic solvents can be used to make the particles.
  • Solvent removal can also be used to prepare particles from a compound that is hydrolytically unstable.
  • the compound or polymer matrix and one or more compounds
  • a volatile organic solvent such as methylene chloride.
  • This mixture is then suspended by stirring in an organic oil (such as silicon oil) to form an emulsion.
  • Solid particles form from the emulsion, which can subsequently be isolated from the supernatant.
  • the external morphology of spheres produced with this technique is highly dependent on the identity of the drug.
  • an active compound as described herein is administered to a patient in need thereof as particles formed by solvent removal.
  • the present invention provides particles formed by solvent removal comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein.
  • the particles formed by solvent removal comprise a compound of the present invention and an additional therapeutic agent.
  • the particles formed by solvent removal comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients.
  • any of the described particles formed by solvent removal can be formulated into a tablet and then coated to form a coated tablet.
  • the particles formed by solvent removal are formulated into a tablet but the tablet is uncoated.
  • the particles are derived by spray drying.
  • a compound or polymer matrix and one or more compounds
  • an organic solvent such as methylene chloride.
  • the solution is pumped through a micronizing nozzle driven by a flow of compressed gas, and the resulting aerosol is suspended in a heated cyclone of air, allowing the solvent to evaporate from the micro droplets, forming particles.
  • Microparticles and nanoparticles can be obtained using this method.
  • an active compound as described herein is administered to a patient in need thereof as a spray dried dispersion (SDD).
  • the present invention provides a spray dried dispersion (SDD) comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein.
  • the SDD comprises a compound of the present invention and an additional therapeutic agent.
  • the SDD comprises a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients.
  • any of the described spray dried dispersions can be coated to form a coated tablet.
  • the spray dried dispersion is formulated into a tablet but is uncoated.
  • Particles can be formed from the active compound as described herein using a phase inversion method.
  • the compound or polymer matrix and one or more active compounds
  • the solution is poured into a strong non-solvent for the compound to spontaneously produce, under favorable conditions, microparticles or nanoparticles.
  • the method can be used to produce nanoparticles in a wide range of sizes, including, for example, from nanoparticles to microparticles, typically possessing a narrow particle size distribution.
  • an active compound as described herein is administered to a patient in need thereof as particles formed by phase inversion.
  • the present invention provides particles formed by phase inversion comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein.
  • the particles formed by phase inversion comprise a compound of the present invention and an additional therapeutic agent.
  • the particles formed by phase inversion comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients.
  • any of the described particles formed by phase inversion can be formulated into a tablet and then coated to form a coated tablet.
  • the particles formed by phase inversion are formulated into a tablet but the tablet is uncoated.
  • Coacervation involves the separation of a compound (or polymer matrix and one or more compounds) solution into two immiscible liquid phases.
  • One phase is a dense coacervate phase, which contains a high concentration of the compound, while the second phase contains a low concentration of the compound.
  • the compound forms nanoscale or microscale droplets, which harden into particles.
  • Coacervation may be induced by a temperature change, addition of a non-solvent or addition of a micro-salt (simple coacervation), or by the addition of another polymer thereby forming an interpolymer complex (complex coacervation).
  • an active compound as described herein is administered to a patient in need thereof as particles formed by coacervation.
  • the present invention provides particles formed by coacervation comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein.
  • the particles formed by coacervation comprise a compound of the present invention and an additional therapeutic agent.
  • the particles formed by coacervation comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients.
  • any of the described particles formed by coacervation can be formulated into a tablet and then coated to form a coated tablet.
  • the particles formed by coacervation are formulated into a tablet but the tablet is uncoated.
  • a compound of the present invention is administered to a patient in need thereof as particles formed by low temperature casting.
  • the present invention provides particles formed by low temperature casting comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein.
  • the particles formed by low temperature casting comprise a compound of the present invention and an additional therapeutic agent.
  • the particles formed by low temperature casting comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients.
  • any of the described particles formed by low temperature casting can be formulated into a tablet and then coated to form a coated tablet.
  • the particles formed by low temperature casting are formulated into a tablet but the tablet is uncoated.
  • an effective amount of an active compound as described herein is incorporated into a nanoparticle, e.g. for convenience of delivery and/or extended release delivery.
  • a nanoparticle e.g. for convenience of delivery and/or extended release delivery.
  • the use of materials in nanoscale provides one the ability to modify fundamental physical properties such as solubility, diffusivity, blood circulation half-life, drug release characteristics, and/or immunogenicity.
  • a number of nanoparticle-based therapeutic and diagnostic agents have been developed for the treatment of cancer, diabetes, pain, asthma, allergy, and infections. These nanoscale agents may provide more effective and/or more convenient routes of administration, lower therapeutic toxicity, extend the product life cycle, and ultimately reduce health-care costs. As therapeutic delivery systems, nanoparticles can allow targeted delivery and controlled release.
  • nanoparticle-based compound delivery can be used to release compounds at a sustained rate and thus lower the frequency of administration, deliver drugs in a targeted manner to minimize systemic side effects, or deliver two or more drugs simultaneously for combination therapy to generate a synergistic effect and suppress drug resistance.
  • a number of nanotechnology-based therapeutic products have been approved for clinical use. Among these products, liposomal drugs and polymer-based conjugates account for a large proportion of the products. See, Zhang, L., et al., Nanoparticles in Medicine: Therapeutic Applications and Developments, Clin. Pharm. and Ther., 83(5):761-769, 2008.
  • polyesters examples include poly(L-lactide-co-L-lysine) (Barrera et al., 1993, J. Am. Chem. Soc., 115:11010), poly(serine ester)(Zhou et al., 1990, Macromolecules, 23:3399), poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633), and poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J.
  • the polymeric particle is between about 0.1 nm to about 10000 nm, between about 1 nm to about 1000 nm, between about 10 nm and 1000 nm, between about 1 and 100 nm, between about 1 and 10 nm, between about 1 and 50 nm, between about 100 nm and 800 nm, between about 400 nm and 600 nm, or about 500 nm.
  • the micro-particles are no more than about 0.1 nm, 0.5 nm, 1.0 nm, 5.0 nm, 10 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 450 nm, 500 nm, 550 nm, 600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm, 1000 nm, 1250 nm, 1500 nm, 1750 nm, or 2000 nm.
  • a compound described herein may be covalently coupled to a polymer used in the nanoparticle, for example a polystyrene particle, PLGA particle, PLA particle, or other nanoparticle.
  • compositions can be formulated for oral administration. These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt. %) of the compound and usually at least about 5 wt. % of the compound. Some embodiments contain at least about 10%, 15%, 20%, 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the compound.
  • compositions suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
  • conventional solid carriers for example, cocoa butter
  • compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil.
  • Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
  • compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time.
  • Pharmaceutical compositions suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound.
  • microneedle patches or devices are provided for delivery of drugs across or into biological tissue, particularly the skin. The microneedle patches or devices permit drug delivery at clinically relevant rates across or into skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
  • compositions suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single/-multiple dose dry powder inhalers (DPI).
  • DPI dry powder inhalers
  • the devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers.
  • nebulizers include jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers.
  • Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.
  • inhalation drug delivery devices and methods include, for example, U.S. Pat. No. 7,383,837 titled “Inhalation device” (SmithKline Beecham Corporation); WO/2006/033584 titled “Powder inhaler” (Glaxo SmithKline Pharmaceuticals SA); WO/2005/044186 titled “Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same” (Glaxo Group Ltd and SmithKline Beecham Corporation); U.S. Pat. No. 9,095,670 titled “Inhalation device and method of dispensing medicament”, U.S. Pat. No.
  • WO/2010/009087 titled “Iontophoretic Delivery of a Controlled-Release Formulation in the Eye”, (Liquidia Technologies, Inc. and Eyegate Pharmaceuticals, Inc.) and WO/2009/132206 titled “Compositions and Methods for Intracellular Delivery and Release of Cargo”, WO/2007/133808 titled “Nano-particles for cosmetic applications”, WO/2007/056561 titled “Medical device, materials, and methods”, WO/2010/065748 titled “Method for producing patterned materials”, WO/2007/081876 titled “Nanostructured surfaces for biomedical/biomaterial applications and processes thereof” (Liquidia Technologies, Inc.).
  • Additional non-limiting examples of methods and devices for drug delivery to the eye include, for example, WO2011/106702 and U.S. Pat. No. 8,889,193 titled “Sustained delivery of therapeutic agents to an eye compartment”, WO2013/138343 and U.S. Pat. No. 8,962,577 titled “Controlled release formulations for the delivery of HIF-1 inhibitors”, WO/2013/138346 and US2013/0272994 titled “Non-Linear Multiblock Copolymer-Drug Conjugates for the Delivery of Active Agents”, WO2005/072710 and U.S. Pat. No.
  • drug delivery devices and methods include, for example, US20090203709 titled “Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor” (Abbott Laboratories); US20050009910 titled “Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug”, US 20130071349 titled “Biodegradable polymers for lowering intraocular pressure”, U.S. Pat. No. 8,481,069 titled “Tyrosine kinase microspheres”, U.S. Pat. No.
  • an effective amount of an active compound or its salt or composition as described herein is used to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade) including a complement factor D-related disorder or alternative complement pathway-related disorder, a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
  • a medical disorder which is an inflammatory or immune condition
  • a disorder mediated by the complement cascade including a dysfunctional cascade
  • a complement factor D-related disorder or alternative complement pathway-related disorder a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or
  • the disorder is selected from fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis and liver failure.
  • NASH nonalcoholic steatohepatitis
  • a method is provided for treating fatty liver disease in a host by administering an effective amount of an active compound or its salt or composition as described herein.
  • an active compound or its salt or composition as described herein is used to modulate an immune response prior to or during surgery or other medical procedure.
  • One non-limiting example is use in connection with acute or chronic graft versus host disease, which is a common complication as a result of allogeneic tissue transplant, and can also occur as a result of a blood transfusion.
  • the present invention provides a method of treating or preventing dermatomyositis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the present invention provides a method of treating or preventing amyotrophic lateral sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the present invention provides a method of treating or preventing abdominal aortic aneurysm, hemodialysis complications, hemolytic anemia, or hemodialysis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • a method for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceutical or biotherapeutic (e.g. CAR T-cell therapy or monoclonal antibody therapy) in a host by administering an effective amount of an active compound or its salt or composition as described herein.
  • cytokine or inflammatory reactions may occur in response to a number of factors, such as the administrations of biotherapeutics.
  • the cytokine or inflammatory reaction is cytokine release syndrome.
  • the cytokine or inflammatory reaction is tumor lysis syndrome (which also leads to cytokine release). Symptoms of cytokine release syndrome range from fever, headache, and skin rashes to bronchospasm, hypotension and even cardiac arrest. Severe cytokine release syndrome is described as cytokine storm, and can be fatal.
  • Fatal cytokine storms have been observed in response to infusion with several monoclonal antibody therapeutics. See, Abramowicz D, et al. “Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients” Transplantation (1989) 47(4):606-8; Chatenoud L, et al. “In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids” Transplantation (1990) 49(4):697-702; and Lim L C, Koh L P, and Tan P.
  • bi-specific T-cell engagers directs T-cells to target and bind with a specific antigen on the surface of a cancer cell.
  • Blinatumomab (Amgen)
  • Amgen a BiTE has recently been approved as a second line therapy in Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia.
  • Blinatumomab is given by continuous intravenous infusion in 4-week cycles.
  • the use of BiTE agents has been associated with adverse immune responses, including cytokine release syndrome.
  • cytokines in the CRS associated with ACT include IL-10, IL-6, and IFN- ⁇ (Klinger et al., Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (2012) 119:6226-6233).
  • the disorder is episcleritis, idiopathic episcleritis, anterior episcleritis, or posterior episcleritis.
  • the disorder is idiopathic anterior uveitis, HLA-B27 related uveitis, herpetic keratouveitis, Posner Schlossman syndrome, Fuch's heterochromic iridocyclitis, or cytomegalovirus anterior uveitis.
  • the present invention provides a method of treating or preventing a C3 glomurenopathy by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the disorder is selected from dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
  • the present invention provides a method of treating or preventing a IC-MPGN by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the present invention provides a method of treating or preventing a paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • PNH paroxysmal nocturnal hemoglobinuria
  • the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein. In one embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • AMD age-related macular degeneration
  • the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the present invention provides a method of treating or preventing myasthenia gravis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • the present invention provides a method of treating or preventing atypical hemolytic uremic syndrome (aHUS) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • aHUS atypical hemolytic uremic syndrome
  • the present invention provides a method of treating or preventing neuromyelitis optica (NMO) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
  • NMO neuromyelitis optica
  • the present invention provides a method of treating or preventing a disorder as described below by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein, including: vitritis, sarcoidosis, syphilis, tuberculosis, or Lyme disease; retinal vasculitis, Eales disease, tuberculosis, syphilis, or toxoplasmosis; neuroretinitis, viral retinitis, or acute retinal necrosis; varicella zoster virus, herpes simplex virus, cytomegalovirus, Epstein-Barr virus, lichen planus, or Dengue-associated disease (e.g., hemorraghic Dengue Fever); Masquerade syndrome, contact dermatitis, trauma induced inflammation, UVB induced inflammation, eczema, granuloma annulare, or acne.
  • an active compound or its salt or composition as described herein, including: vitritis, sarcoidos
  • the disorder is selected from: acute myocardial infarction, aneurysm, cardiopulmonary bypass, dilated cardiomyopathy, complement activation during cardiopulmonary bypass operations, coronary artery disease, restenosis following stent placement, or percutaneous transluminal coronary angioplasty (PTCA); antibody-mediated transplant rejection, anaphylactic shock, anaphylaxis, allogenic transplant, humoral and vascular transplant rejection, graft dysfunction, graft-versus-host disease, Graves' disease, adverse drug reactions, or chronic graft vasculopathy; allergic bronchopulmonary aspergillosis, allergic neuritis, drug allergy, radiation-induced lung injury, eosinophilic pneumonia, radiographic contrast media allergy, bronchiolitis obliterans, or interstitial pneumonia; parkinsonism-dementia complex, sporadic frontotemporal dementia, frontotemporal dementia with Parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, tangle only dementia, cerebral am

Abstract

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a continuation of U.S. application Ser. No. 16/555,914, filed Aug. 29, 2019, which is a continuation of International Application No. PCT/US2018/020528, filed Mar. 1, 2018, which claims the benefit of priority to U.S. Application No. 62/465,782, filed Mar. 1, 2017; and U.S. Application No. 62/466,301 filed Mar. 2, 2017; each of which are incorporated by reference herein for all purposes.
FIELD OF THE INVENTION
This invention provides aryl, heteroaryl and heterocyclic drugs to treat medical disorders, such as complement-mediated disorders.
BACKGROUND OF THE INVENTION
The complement system is a part of the innate immune system which does not adapt to changes over the course of the host's life, but is recruited and used by the adaptive immune system. For example, it assists, or complements, the ability of antibodies and phagocytic cells to clear pathogens. This sophisticated regulatory pathway allows rapid reaction to pathogenic organisms while protecting host cells from destruction. Over thirty proteins and protein fragments make up the complement system. These proteins act through opsonization (enhancing phagocytosis of antigens), chemotaxis (attracting macrophages and neutrophils), cell lysis (rupturing membranes of foreign cells), and agglutination (clustering and binding of pathogens together).
The complement system has three pathways: classical, alternative, and lectin. Complement Factor D plays an early and central role in activation of the alternative pathway of the complement cascade. Activation of the alternative complement pathway is initiated by spontaneous hydrolysis of a thioester bond within C3 to produce C3(H2O), which associates with Factor B to form the C3(H2O)B complex. Complement Factor D acts to cleave Factor B within the C3(H2O)B complex to form Ba and Bb. The Bb fragment remains associated with C3(H2O) to form the alternative pathway C3 convertase C3(H2O)Bb. Additionally, C3b generated by any of the C3 convertases also associates with Factor B to form C3bB, which Factor D cleaves to generate the later stage alternative pathway C3 convertase C3bBb. This latter form of the alternative pathway C3 convertase may provide important downstream amplification within all three of the defined complement pathways, leading ultimately to the recruitment and assembly of additional factors in the complement cascade pathway, including the cleavage of C5 to C5a and C5b. C5b acts in the assembly of factors C6, C7, C8, and C9 into the membrane attack complex, which can destroy pathogenic cells by lysing the cell.
The dysfunction of or excessive activation of complement has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer. For example, activation of the alternative pathway of the complement cascade contributes to the production of C3a and C5a, both potent anaphylatoxins, which also have roles in a number of inflammatory disorders. Therefore, in some instances, it is desirable to decrease the response of the complement pathway, including the alternative complement pathway. Some examples of disorders mediated by the complement pathway include age-related macular degeneration (AMD), paroxysmal nocturnal hemoglobinuria (PNH), multiple sclerosis, and rheumatoid arthritis.
Age-related macular degeneration (AMD) is a leading cause of vision loss in industrialized countries. Based on a number of genetic studies, there is evidence of the link between the complement cascade and macular degeneration. Individuals with mutations in the gene encoding complement Factor H have a fivefold increased risk of macular degeneration and individuals with mutations in other complement factor genes also have an increased risk of AMD. Individuals with mutant Factor H also have increased levels of C-reactive protein, a marker of inflammation. Without adequate functioning Factor H, the alternative pathway of the complement cascade is overly activated leading to cellular damage.
Paroxysmal nocturnal hemoglobinuria (PNH) is a non-malignant, hematological disorder characterized by the expansion of hematopoietic stem cells and progeny mature blood cells that are deficient in some surface proteins. PNH erythrocytes are not capable of modulating their surface complement activation, which leads to the typical hallmark of PNH—the chronic activation of complement mediated intravascular anemia. Currently, only one product, the anti-C5 monoclonal antibody eculizumab, has been approved in the U.S. for treatment of PNH. However, many of the patients treated with eculizumab remain anemic, and many patients continue to require blood transfusions. In addition, treatment with eculizumab requires life-long intravenous injections.
Additional complement-mediated disorders include those classified under component 3 glomerulopathy (C3G). C3G is a recently defined entity comprised of dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) which encompasses a population of chronic kidney diseases wherein elevated activity of the alternative complement pathway and terminal complement pathway results in glomerular deposits made solely of complement C3 and no immunoglobulin (Ig).
Immune-complex membranoproliferative glomerulonephritis (IC-MPGN) is a renal disease which shares many clinical, pathologic, genetic and laboratory features with C3G, and therefore can be considered a sister disease of C3G. In the majority of patients with IC-MPGN, an underlying disease or disorder—most commonly infections, autoimmune diseases, or monoclonal gammopathies—are identified to which the renal disease is secondary. Patients with idiopathic IC-MPGN can have low C3 and normal C4 levels, similar to those observed in C3G, as well as many of the same genetic or acquired factors that are associated with abnormal alternative pathway activity. Although there are current hypotheses suggesting that the majority of IC-MPGN is attributable to over activity of the classical pathway, those patients with a low C3 and a normal C4 are likely to have significant overactivity of the alternative pathway. IC-MPGN patients with a low C3 and a normal C4 may benefit from alternative pathway inhibition.
Other disorders that have been linked to the complement cascade include atypical hemolytic uremic syndrome (aHUS), hemolytic uremic syndrome (HUS), abdominal aortic aneurysm, hemodialysis complications, hemolytic anemia, or hemodialysis, neuromyelitis optica (NMO), myasthenia gravis (MG), fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, liver failure, dermatomyositis, and amyotrophic lateral sclerosis.
Factor D is an attractive target for inhibition or regulation of the complement cascade due to its early and essential role in the alternative complement pathway, and for its potential role in signal amplification within the classical and lectin complement pathways. Inhibition of Factor D effectively interrupts the pathway and attenuates the formation of the membrane attack complex.
While initial attempts have been made to develop inhibitors of Factor D, there are currently no clinically approved small molecule Factor D inhibitors. Examples of Factor D inhibitor compounds are described in the following disclosures.
Biocryst Pharmaceuticals U.S. Pat. No. 6,653,340 titled “Compounds useful in the complement, coagulate and kallikrein pathways and method for their preparation” describes fused bicyclic ring compounds that are potent inhibitors of Factor D. Development of the Factor D inhibitor BCX1470 was discontinued due to lack of specificity and short half-life of the compound.
Novartis PCT patent publication WO2012/093101 titled “Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration” describes certain Factor D inhibitors. Additional Factor D inhibitors are described in Novartis PCT patent publications WO2013/164802, WO2013/192345, WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054, WO2014/002057, WO2014/002058, WO2014/002059, WO2014/005150, WO2014/009833, WO2014/143638, WO2015/009616, WO2015/009977, and WO2015/066241.
A paper published by Novartis titled “Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors” (Vulpetti et al., J. Med. Chem. 10.1021/acs.jmedchem.6b01684) describes an in silico active site mapping for regions that contribute to a large fraction of binding energy using the Factor D crystal structure and NMR-based screening (structure-based drug design (SBDD) and fragment-based screening (FBD)). Another Novartis paper titled “Small-molecule factor D inhibitors targeting the alternative complement pathway” (Maibaum et al., Nat. Chem. Bio. 2016; 12; 1105) discloses small-molecule inhibitors designed by use of a structure-based design approach in combination with fragment-based screening.
Lifesci Pharmaceuticals PCT patent publication WO2017/098328 titled “Therapeutic Inhibitory Compounds” describes various Factor D inhibitors with variations in the central core ring heterocycle ring. PCT patent publication WO/2018/015818 is also titled “Therapeutic Inhibitory Compounds” and describes Factor D inhibitors without cyclic central core.
Bristol-Myers Squibb PCT patent publication WO2004/045518 titled “Open chain prolyl urea-related modulators of androgen receptor function” describes open chain prolyl urea and thiourea related compounds for the treatment of androgen receptor-associated conditions, such as age-related diseases, for example, sarcopenia.
Japan Tobacco Inc. PCT patent publication WO1999/048492 titled “Amide derivatives and nociceptin antagonists” describes compounds with a proline-like core and aromatic substituents connected to the proline core through amide linkages useful for the treatment of pain.
Ferring B. V. and Yamanouchi Pharmaceutical Co. lTD. PCT patent publication WO1993/020099 titled “CCK and/or gastrin receptor ligands” describes compounds with a proline-like core and heterocyclic substituents connected to the proline core through amide linkages for the treatment of, for example, gastric disorders or pain.
Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled “Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases” discloses antibodies directed to C5 of the complement pathway for the treatment of glomerulonephritis and inflammatory conditions involving pathologic activation of the complement system. Alexion Pharmaceutical's anti-C5 antibody eculizumab (Soliris®) is currently the only complement-specific antibody on the market, and is the first and only approved treatment for paroxysmal nocturnal hemoglobinuria (PNH).
On Feb. 25, 2015, Achillion Pharmaceuticals filed PCT Patent Application No. PCT/US2015/017523 and U.S. patent application Ser. No. 14/631,090 titled “Alkyne Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017538 and U.S. patent application Ser. No. 14/631,233 titled “Amide Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017554 and U.S. patent application Ser. No. 14/631,312 titled “Amino Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017583 and U.S. patent application Ser. No. 14/631,440 titled “Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017593 and U.S. patent application Ser. No. 14/631,625 titled “Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017597 and U.S. patent application Ser. No. 14/631,683 titled “Ether Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017600 and U.S. patent application Ser. No. 14/631,785 titled “Phosphonate Compounds for Treatment of Complement Mediated Disorders”; and PCT Patent Application No. PCT/US2015/017609 and U.S. patent application Ser. No. 14/631,828 titled “Compounds for Treatment of Complement Mediated Disorders” and U.S. patent application Ser. No. 14/630,959 titled “Factor D Inhibitors Useful for Treating Infectious Disorders.”
Additional complement factor D inhibitors are described in U.S. Pat. Nos. 9,828,396; 9,695,205; 9,598,446; 9,732,103; 9,796,741; 9,732,104; 9,663,543; 9,758,537; and 9,643,986; International Publication Nos. WO 2015/130784; WO 2015/130795; WO 2015/130806; WO 2015/130830; WO 2015/130838; WO 2015/130842; WO 2015/130845; and WO 2015/130854; and U.S. Patent Publication Nos. US 2017-0298084; US 2016-0362398; US 2017-0189410; US 2017-0298085; US 2018-0030075; US 2016-0362399; US 2018-0022766; US 2016-0362433; US 2017-0260219; US 2016-0362432; US 2018-0022767; US 2016-0361329; and US 2017-0226142; all owned by Achillion Pharmaceuticals, Inc.
Given the wide variety of medical disorders that are caused by detrimental immune or inflammatory responses, new compounds are needed for medical treatment.
SUMMARY
This invention includes a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, wherein at least one of R12 or R13 on the A group is an aryl, heteroaryl or heterocycle substituent, which is R32. In one embodiment, the compound or its salt or composition, as described herein is used to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity including the alternative complement pathway, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
In certain aspects of the invention, the compound presented herein has one or more of the following:
    • a. An A ring of the formula:
Figure US11708351-20230725-C00001
Figure US11708351-20230725-C00002
    • b. An A ring of the formula:
Figure US11708351-20230725-C00003
    • c. An A ring of the formula:
Figure US11708351-20230725-C00004
    • d. A B ring of the formula:
Figure US11708351-20230725-C00005
    • e. A C ring selected from:
Figure US11708351-20230725-C00006
    • f. A C ring of formula:
Figure US11708351-20230725-C00007
    • g. A C ring selected from a proline spirocycle (such as those described in the paper published by Litter et al. titled “Development of a Manufacturing Process for an HCV Protease Inhibitor Candidate Molecule” (Organic Process Research & Development 2015, 19, 270-283);
    • h. An R32 selected from a cyclic sulfonimidamide (such as those described in the paper published by Pemberton et al. titled “Synthesis and Functionalization of Cyclic Sulfonimidamides: A Novel Chiral Heterocyclic Carboxylic Acid Biostere” (ACS Med. Chem Letters 2012, 3, 574-578);
    • i. A compound of the invention with at least one R201 substituent selected from aminoalkyl-, alkylaminoalkyl-, heterocycloalkyl-, and hydroxyalkyl; -alkyl-O-alkyl including —CH2OCH3, -alkyl-S-alkyl, -alkyl-N(alkyl)-alkyl, -alkyl-NH-alkyl, -aliphatic-O-aliphatic, -aliphatic-S-aliphatic, -aliphatic-N(aliphatic)-aliphatic, -aliphatic-NH-aliphatic, -aliphatic-O-heterocycle, -aliphatic-S-heterocycle, -aliphatic-N(aliphatic)-heterocycle, -aliphatic-NH-heterocycle, -alkyl-NHC(O)haloalkyl, -alkyl-NR9C(O)haloalkyl, -alkyl-C(O)NHhaloalkyl, -alkyl-C(O)NR9haloalkyl, -alkyl-NHC(O)haloalkyl, -alkyl-NR9C(O)aliphatic, -alkyl-C(O)NHaliphatic, -alkyl-NR9C(O)aliphatic, -alkyl-NHC(O)aliphatic, -substituted alkyl-N(R9)-substituted alkyl, alkyl-heteroaryl, heteroaryl, heterocycle, alkyl-heterocycle, -alkyl-O-haloalkyl, —N(aliphatic)2; and wherein each R201 can be optionally substituted as defined in the Terminology section below, and wherein each R201 can be optionally substituted with R301, which can be directly linked to R201 or can be linked to R201 through an amino, hydroxyl, thio, carboxyl acid, phosphate, phosphonate or sulfonate linkage as desired and appropriate;
    • j. A compound with at least one R201 substituent on the A ring;
    • k. A compound with at least one R201 substituent on the B ring;
    • l. A compound with at least one R201 substituent on the C ring;
    • m. Certain stable acylated embodiments and acyl prodrugs of the present invention, that include an R301 substituent, as further described below.
These compounds can be used to treat medical conditions in a host in need thereof, typically a human. The active compound may act as an inhibitor of the complement factor D cascade. In one embodiment, a method for the treatment of such a disorder is provided that includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as described in more detail below.
In certain embodiments, compounds are provided that have minimal effect on BSEP (bile salt export pump protein) (e.g., with an IC50 of greater than about 20, 30, 40, 50, 60, 75 or 100 μM or greater), or with a therapeutic index of BSEP relative to complement D inhibition (e.g., IC50 inhibition of BSEP/IC50 inhibition of complement D inhibitor), of about at least 50, 100, 200, 300, 400, 500, 750 or 1000 or greater). BSEP inhibition correlates with cholestatic drug-induced liver injury. Certain compounds of the present invention with low BSEP inhibition have at least one R201.
In some embodiments, the compounds of the present invention exhibit minimal hydrolysis of the amide bond between the C ring and the B ring in vivo, for example, by including a proline that has a cis-substituent relative to the proline-carbonyl bond directed toward the B-ring. In certain embodiments, the cis-substituent is in the Q3 position or the Q2 position or is a group that bridges Q3 and Q2.
It has also been discovered that including a B-ring substituent in the position ortho to the amide (for example 2-(L1)-3-methyl-6-substituted-pyridine or 2-(L1)-3-cyclopropyl-6-substituted-pyridine) may decrease the potential for formation of reactive metabolites.
In one aspect of the invention, an R301 acylated embodiment of an active compound of the invention is provided that exhibits extended half-life or other advantageous pharmacokinetic properties, which may be achieved by albumin stabilization in vivo. In certain embodiments, the acylated analogue can include several linking moieties in linear, branched or cyclic manner. In certain embodiments, either one or a series of amino acids is used as a linker to a terminal fatty acid. In one non-limiting example a non-natural amino acid such as one described below, for example 8-amino-3,6-dioxaoctanoic acid (one or several in sequence) is covalently bound to the selected complement D inhibitor of the present invention through a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group. See generally Lau, et al., “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semiglutide”, J. Med. Chem., 2015, 58, 7370-7380. In this embodiment, the 8-amino-3,6-dioxaoctanoic acid or similar molecule is covalently linked to an aliphatic acid, including but not limited to a C16, C18, C20 aliphatic acid, or a dicarboxylic acid, including but not limited to a C8, C10, C12, C14, C16, C18 or C20 diacid. One or more amino acids can also be used in the selected configuration to add length or functionality. More generally, nonlimiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another linking moiety, and which may be albumin stabilized in vivo. In some embodiments, 2, 3, 4 or 5 linking moieties are covalently bound in sequence, branched or cyclic fashion to the parent compound. In some embodiments, an R301 acyl group is located in a position of the active compound that does not significantly adversely affect the complement D inhibition of the molecule, for example, as (i) a substituent on the R32 group or (ii) a substituent on a C-ring, such as proline, or as a substituent on a substituent on the C-ring, such as on an R1, R2 or R3 substituent, including for example, on a bridged moiety such as a fused cyclopropyl on the proline ring. In certain embodiments, the acyl group has an aliphatic or heteroaliphatic carbon range of C12, C14, C16, C18, C20, C22 or C24.
In one embodiment, the disorder is associated with the alternative complement cascade pathway. In yet another embodiment, the disorder is associated with the complement classical pathway. In a further embodiment, the disorder is associated with the complement lectin pathway. Alternatively, the active compound or its salt or prodrug may act through a different mechanism of action than the complement cascade, or in particular as a complement factor D inhibitor, to treat the disorder described herein.
In one embodiment, a method for the treatment of C3 glomerulonephritis (C3G) is provided that includes the administration of an effective amount of a compound to a host of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In one embodiment, a method for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) is provided that includes the administration of an effective amount of a compound to a host of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In another embodiment, a method for the treatment of wet or dry age-related macular degeneration (AMD) in a host is provided that includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In another embodiment, a method for the treatment of rheumatoid arthritis in a host is provided that includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. In another embodiment, a method for the treatment of multiple sclerosis in a host is provided that includes the administration of an effective amount of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition.
In other embodiments, an active compound or its salt or prodrug as described herein can be used to treat fatty liver and conditions stemming from fatty liver, nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, and liver failure, dermatomyositis, or amyotrophic lateral sclerosis.
The active compound or its pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, as disclosed herein is also useful for administration in combination (in the same or a different dosage form) or alternation with a second pharmaceutical agent for use in ameliorating or reducing a side effect of the second pharmaceutical agent. For example, in one embodiment, the active compound may be used in combination with an adoptive cell transfer therapy to reduce an inflammatory response associated with such therapy, for example, a cytokine mediated response such as cytokine response syndrome. In one embodiment, the adoptive cell transfer therapy is a chimeric antigen receptor T-Cell (CAR T) or a dendritic cell used to treat a hematologic or solid tumor, for example, a B-cell related hematologic cancer. In one embodiment, the hematologic or solid tumor is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), pancreatic cancer, glioblastoma, or a cancer that expresses CD19. In one embodiment, the associated inflammatory response is a cytokine mediated response.
Another embodiment is provided that includes the administration of an effective amount of an active compound or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition to a host to treat an ocular, pulmonary, gastrointestinal, or other disorder that can benefit from topical or local delivery.
Any of the compounds described herein (e.g. Formula I, Formula II, Formula III, Formula IV, or Formula V) can be administered to the eye in any desired form of administration, including via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, choroidal, subchoroidal, conjunctival, subconjunctival, episcleral, posterior juxtascleral, scleral, circumcorneal, and tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion. In certain embodiments, the active compound includes a lipophilic group, such as a lipophilic acyl group, which is delivered to the eye in a polymeric drug delivery system such as polylactic acid, polylactide-co-glycolide, polyglycolide or other erodible polymer, or a combination thereof, or in another type of lipophilic material for ocular delivery. In some embodiments, the lipophilic active molecule is more soluble in the polymeric or other form of delivery system than in ocular fluid.
In other embodiments of the invention, an active compound provided herein can be used to treat or prevent a disorder in a host mediated by complement factor D, or by an excessive or detrimental amount of the complement-C3 amplification loop of the complement pathway. As examples, the invention includes methods to treat or prevent complement associated disorders that are induced by antibody-antigen interactions, a component of an immune or autoimmune disorder or by ischemic injury. The invention also provides methods to decrease inflammation or an immune response, including an autoimmune response, where mediated or affected by factor D.
In another embodiment, a method is provided for treating a host, typically a human, with a disorder mediated by the complement system, that includes administration of a prophylactic antibiotic or vaccine to reduce the possibility of a bacterial infection during the treatment using one of the compounds described herein. In certain embodiments, the host, typically a human, is given a prophylactic vaccine prior to, during or after treatment with one of the compounds described herein. In certain embodiments, the host, typically a human, is given a prophylactic antibiotic prior to, during or after treatment with one of the compounds described herein. In some embodiments, the infection is a meningococcal infection (e.g., septicemia and/or meningitis), an Aspergillus infection, or an infection due to an encapsulated organism, for example, Streptococcus pneumoniae or Haemophilus influenza type b (Hib), especially in children. In other embodiments, the vaccine or antibiotic is administered to the patient after contracting an infection due to, or concommitent with inhibition of the complement system.
The disclosure provides a compound of Formula I, Formula II, or Formula III:
Figure US11708351-20230725-C00008
or a pharmaceutically acceptable salt, isotopic analog, prodrug, or isolated isomer thereof optionally in pharmaceutically acceptable carrier;
wherein:
A is selected from A1, A2, and A3;
B is selected from B1, B2, and B3;
or B is B4;
B4 is separately defined below;
C is selected from C1, C2, C3, and C4;
or C is C5;
C5 is separately defined below;
and wherein for compounds of Formula I at least one of the following limitations is present: A is A3, B is B3, or C is C4;
C1 is
Figure US11708351-20230725-C00009
Q1 is N(R1), C(R1R1′), C(R1R1′)C(R1R1′), C(R1R1′)C(R1R1′)C(R1R1′), S or O;
Q2 is C(R2R2′), C(R2R2′)C(R2R2′), C(R2R2′)C(R2R2′)C(R2R2′), N(R2), S, O, or C(R2R2′)O;
Q3 is N(R3), S, O, C(R3R3′), C(R3R3′)C(R3R3′), or C(R3R3′)C(R3R3′)C(R3R3′);
X1 and X2 are independently N, CH, or CZ;
or X1 and X2 together are C═C;
wherein X1 is directly bound to L3 and X2 is directly bound to L; and
wherein Q1, Q2, Q3, X1, and X2 are selected such that a stable compound results;
Z is F, Cl, NH2, CH3, CH2D, CHD2, or CD3;
R1, R1′, R2, R2′, R3, and R3′ are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R201, R301, halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, alkoxy including C1-C6alkoxy, alkanoyl including C2-C6alkanoyl, thioalkyl including C1-C6alkylthio, hydroxyC1-C6alkyl, aminoC1-C6alkyl, —C0-C4alkylNR9R10, —C(O)OR9, —OR′, —NR′R″, —OC(O)R9, —NR9C(O)R10, —C(O)NR9R10, —OC(O)NR9R10, —NR9C(O)OR10, haloalkyl including C1-C6haloalkyl, and C1-C6haloalkoxy;
or R1 and R1′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
or R3 and R3′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
or R2 and R2′ are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring;
wherein, each of the above spiro rings may be optionally substituted with 1 or more substituents independently selected from R201, halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C1-C4alkyl (and in particular methyl), alkenyl including C2-C4alkenyl, alkynyl including C2-C4alkynyl, alkoxy including C1-C6alkoxy, alkanoyl, including C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-alkylamino)C1-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), —O-alkyl(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
or in an alternative embodiment, each of the above spiro rings may be optionally substituted with an aryl ring;
or R1 and R2 are taken together to form a 3-membered carbocyclic ring, a 4- to 6-membered carbocyclic or aryl ring, or a 4- to 6-membered heterocyclic or heteroaryl ring containing 1 or 2 heteroatoms independently selected from N, O, and S;
or R2 and R3 are taken together to form a 3- to 6-membered carbocyclic or aryl ring or a 3- to 6-membered heterocyclic or heteroaryl ring;
wherein each of which fused R1 and R2 or R2 and R3 rings, or generally R1, R2, R3, R1′, R2′, or R3′, are optionally substituted with 1 or more substituents independently selected from R201, halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C1-C4alkyl (and in particular methyl), alkenyl including C2-C4alkenyl, alkynyl including C2-C4alkynyl, alkoxy including C1-C4alkoxy, alkanoyl including C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-alkylamino)C0-C4alkyl, alkyl(C3-C7cycloalkyl) including —C1-C4alkyl(C3-C7cycloalkyl), —O—(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
or R1 and R1′ are taken together to form a carbonyl group;
or R2 and R2′ are taken together to form a carbonyl group;
or R3 and R3′ are taken together to form a carbonyl group;
or R1 and R2 are taken together to form a carbon-carbon double bond;
or R2 and R3 are taken together to form a carbon-carbon double bond;
R and R′ are independently selected from H, R201, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl;
or in an alternative embodiment, R, R′, and R″ are independently selected from R301, heteroalkyl, H, R201, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl, and heteroaliphatic;
R9 and R10 are independently selected from hydrogen, alkyl including C1-C6alkyl, (C3-C7cycloalkyl)C0-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), and —O—C0-C4alkyl(C3-C7cycloalkyl);
C2 is selected from:
Figure US11708351-20230725-C00010
q is 0, 1, 2 or 3;
r is 1, 2 or 3;
R44, R44′, R45, R45′ are independently selected at each occurrence, as appropriate, and only where a stable compound results, from hydrogen, R201, halogen (and specifically fluoro, chloro, bromo), hydroxyl, nitro, cyano, amino, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, alkoxy including C1-C6alkoxy, alkanoyl including C2-C6alkanoyl, thioalkyl including —C1-C6alkylthio, hydroxyC1-C6alkyl, aminoC1-C6alkyl, —C0-C4alkylNR9R10, —C(O)OR9, —OC(O)R9, —NR9C(O)R10, —C(O)NR9R10, —OC(O)NR9R10, —NR9C(O)OR10, haloalkyl including C1-C6haloalkyl, and C1-C6haloalkoxy;
or R44 and R44′ or R45 and R45′, or two R47 groups are taken together to form a carbonyl group;
or R44 and R44′ or R45 and R45′ substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
wherein, each of the above spiro rings may be optionally substituted with 1 or more substituents independently selected from R201, halogen (and in particular F), hydroxyl, cyano, —COOH; alkyl including C1-C4alkyl (and in particular methyl), alkenyl including C2-C4alkenyl, alkynyl including C2-C4alkynyl, alkoxy including C1-C6alkoxy, alkanoyl including C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-alkylamino)C1-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), —O-alkyl(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
or R44 and R45 or R44′ and R45′ are taken together to form a 4- to 6-membered carbocyclic or aryl ring or a 4- to 6-membered heterocyclic or heteroaryl ring; each of which ring may be optionally substituted with 1 or more substituents;
each of which fused rings or generally R44, R44′, R45, or R45′ are optionally substituted with 1 or more substituents independently selected from R201, halogen (and in particular F), hydroxyl, cyano, —COOH, alkyl including C1-C4alkyl (and in particular methyl), alkenyl including C2-C4alkenyl, alkynyl including C2-C4alkynyl, alkoxy including C1-C4alkoxy, alkanoyl including C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-alkylamino)C0-C4alkyl, alkyl(C3-C7cycloalkyl) including —C1-C4alkyl(C3-C7cycloalkyl), —O—(C3-C7cycloalkyl), haloalkyl including —C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
C3 is selected from:
Figure US11708351-20230725-C00011
Figure US11708351-20230725-C00012
X3 is C(R1R1′);
X4 is N or CH;
X4a is N, CH or CZ;
X5 and X6 are C(R1R1′);
or X4 and X5 or X5 and X6 together are C═C;
X7 is SO or SO2;
X8 is C(R1R1′) or N(R43);
X5a is independently selected from C(R1R1′) and O;
Q4 is N or CH;
Q5 is N(R47) or C(R46R46′);
Q5a is independently selected from C(R47R47), N(R47), O, S, SO, and SO2;
Q6 is N(R47), C(R46R46′), S, or O;
Q7 is C(R46R46′), S or N(R47);
Q8, Q9, Q10, Q11 and Q12 are each independently C(R2R2′), S, SO, SO2, O, N(R2), B(R50), or Si(R49)2;
R40 is hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
R42 is halo, hydroxy, alkoxy including C1-C6alkoxy, haloalkoxy including C1-C6haloalkoxy, —SH, or —S(C1-C6alkyl);
R43 is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
R46 and R46′ are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
or R46 and R46′ are taken together to form an optionally substituted 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
R47 is hydrogen, acyl, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted;
or two R47 groups are taken together to form a carbonyl group;
R49 is halo, hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl wherein each group can be optionally substituted
R50 is hydroxy or C1-C6alkoxy;
or X1 and Q8 or Q8 and Q9 or Q9 and Q10 or Q10 and Q11 or Q11 and Q12 or Q12 and X2 can form a carbon-carbon double bond;
or two Q5a groups or a X4a and a Q5a group can form a carbon-carbon double bond;
and where any of these groups may be further optionally substituted as that term is defined in the Terminology Section below, if desired to achieve the target effect, results in a stable compound that makes chemical sense to the skilled artisan, and the group is not redundant (i.e., as known in the art, alkyl substituted with alkyl is redundant; however, for example, alkoxy substituted with alkoxy is not redundant);
or the central core moiety, C3, is a small mimetic of a beta-turn such as a benzodiazepine, a Friedinger lactam, a 2-oxo-1,3-oxazolidine-4-carboxylate or a β-D-glucose scaffold. See, De Marco, R. et al., “In-peptide synthesis of di-oxazolidinone and dehydroamino acid-oxazolidinone motifs as β-turn inducers”, J. Org. Biomol. Chem., 2013, 11, 4316-4326, Hirschmann, R. F. et al., The β-D-Glucose Scaffold as a β-Turn Mimetic, Accounts Chem. Res., 2009, 42, 1511-1520 and Smith, A. B, et al., Accounts of Chem. Res., 2011, 44, 180-193. In another embodiment, the central core moiety, C, can comprise a reverse turn mimetic that can include, but is not limited to; a non-peptidic residue, a metal chelation based mimic, or a foldamer. See, Nair, R. V. et al., “Synthetic turn mimetics and hairpin nucleators: Quo Vadimus?”, Chem. Comm., 2014, 50, 13874-13884. In some embodiments, the central core moiety, C, can comprise a conformationally constrained cyclic amino acid including but not limited to a (S)- or (R)-α-trifluoromethyl pyroglutamic acid derivative. See, Chaume, G. et al., “Concise access to enantiopure (S)- or (R)-α-trifluoromethyl pyroglutamic acids from ethyl trifluoropyruvate-base chiral CF3-oxazolidines (Fox)”, J. Fluor. Chem., 2008, 129, 1104-1109 and Andre, C. et al., “(S)-ABOC: A Rigid Bicyclic β-Amino Acid as Turn Inducer”, Org. Lett., 2012, 14, 960-963. In some embodiments, the central core moiety, C, can comprise a monomeric unit of a foldamer such as, but not limited to an oxazolidin-2-one. See, Tomasii, C., Angelicim G. and Castellucci, N., “Foldamers Based on Oxazolidin-2-ones”, Eur. J. Org. Chem., 2011, 3648-3669;
C4 is selected from:
Figure US11708351-20230725-C00013
or C4 is selected from:
Figure US11708351-20230725-C00014
or C4 is selected from:
Figure US11708351-20230725-C00015
Figure US11708351-20230725-P00001
is a single or double bond;
C5 is selected from:
Figure US11708351-20230725-C00016
A1 is selected from:
Figure US11708351-20230725-C00017
or A1 is selected from:
Figure US11708351-20230725-C00018
A2 is selected from:
Figure US11708351-20230725-C00019
Figure US11708351-20230725-C00020
A3 is selected from:
Figure US11708351-20230725-C00021
or A3 is selected from:
Figure US11708351-20230725-C00022
or A3 is selected from:
Figure US11708351-20230725-C00023
or A3 is selected from:
Figure US11708351-20230725-C00024
or A3 is selected from:
Figure US11708351-20230725-C00025
or A3 is selected from:
Figure US11708351-20230725-C00026
or A3 is selected from:
Figure US11708351-20230725-C00027
X51, X52, and X53 are independently selected from N, CR31, and CR201;
wherein at least one of X51, X52, and X53 is selected from CR201;
X54, X55, and X56 are independently selected from N, CR31, and CR201;
R104 is selected from R201, C1-C4 alkyl, C3-C6 cycloalkyl, C1-C4 haloalkyl, deuterium, —CO2H, CO2R9, heteroaryl, F, Cl, Br, and cyano;
R201 is selected from aminoalkyl-, alkylaminoalkyl-, heterocycloalkyl-, and hydroxyalkyl; -alkyl-O-alkyl including —CH2OCH3, -alkyl-S-alkyl, -alkyl-N(alkyl)-alkyl, -alkyl-NH-alkyl, -aliphatic-O-aliphatic, -aliphatic-S-aliphatic, -aliphatic-N(aliphatic)-aliphatic, -aliphatic-NH-aliphatic, -aliphatic-O-heterocycle, -aliphatic-S-heterocycle, -aliphatic-N(aliphatic)-heterocycle, -aliphatic-NH-heterocycle, -alkyl-NHC(O)haloalkyl, -alkyl-NR9C(O)haloalkyl, -alkyl-C(O)NHhaloalkyl, -alkyl-C(O)NR9haloalkyl, -alkyl-NHC(O)haloalkyl, -alkyl-NR9C(O)aliphatic, -alkyl-C(O)NHaliphatic, -alkyl-NR9C(O)aliphatic, -alkyl-NHC(O)aliphatic, -substituted alkyl-N(R9)-substituted alkyl, alkyl-heteroaryl, -alkyl-O-haloalkyl, heteroaryl, heterocycle, alkyl-heterocycle, —N(aliphatic)2; and wherein each R201 can be optionally substituted as defined in the Terminology section below, and wherein R201 can be optionally substituted with R301, which can be directly linked to R201 or can be linked to R201 through an amino, hydroxyl, thio, carboxylic acid, phosphate, phosphonate or sulfonate linkage;
In an alternative embodiment, R201 is selected from R301, -alkyl-CN, -alkyl-NR9C(O)alkenyl, -alkyl-SO2-alkyl; and -alkyl-S(O)NR9-alkyl;
In an alternative embodiment, R201 is substituted with an oxime, and —C(O)Oalkyl;
R202 is selected from aryl, heteroaryl, and heterocycle, wherein the aryl, heteroaryl, or heterocycle ring is substituted with R201;
R301 is selected from the following:
    • i. The residue of a fatty acid. Examples are short chain fatty acids with 3, 4, or 5 aliphatic carbons, medium-chain fatty acids with aliphatic tails of 6, 7, 8, 9, 10, 11 or 12 carbons, long chain fatty acids, which have aliphatic tails of 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 carbons, or a very long fatty acid, which has 22, 23, 24, 25, 26 27, or 28 or more aliphatic carbons. The aliphatic chain can be saturated, mono-unsaturated, di-unsaturated, tri-unsaturated, polyunsaturated, or alkynyl. Unsaturated fatty acids can be used in a cis or trans configuration, and include, but are not limited to oleic acid, ω6 fatty acid such as linoleic acid, ω3 fatty acid such as α-linolenic acid, docosahexaenoic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, eicosatetraenoic acid, myristoleic acid, palmitoleic acid, sapienic acid, elaidic acid, vaccenic acid, gadoleic acid, eicosenoic acid, nervonic acid, eicosadienoic acid, docasadienoic acid, linolenic acid, t-linolenic acid, pinolenic acid, eleosteric acid, β-eleostearic acid, mead acid, eicosatrienoic acid, linoleic acid, linoelaidic acid, α-linolenic acid, arachidonic acid, erucic acid and docosahexaenoic acid. Nonlimiting examples of saturated fatty acids that can be used to provide the prodrugs of the present invention are caprylic acid, capric acid, lauric acid, myristic acid, palmitic, stearic acid, arachidic acid, behenic acid, lignoceric acid and cerotic acid.
    • ii. The residue of an amino acid that is naturally occurring or synthetic, and includes for example, α, β γ or δ amino acids. Naturally occurring amino acids include those found in proteins, e.g., glycine, alanine, valine, leucine, isoleucine, methionine, phenylalanine, tryptophan, proline, serine, threonine, cysteine, tyrosine, asparagine, glutamine, aspartate, glutamate, lysine, arginine and histidine. In some embodiments, the amino acid is in the L-configuration. Alternatively, the amino acid can be used in the D-configuration or in a mixture of L- and D-. Alternatively, the amino acid can be a derivative of alanyl, valinyl, leucinyl, isoleucinyl, prolinyl, phenylalaninyl, tryptophanyl, methioninyl, glycinyl, serinyl, threoninyl, cysteinyl, tyrosinyl, asparaginyl, glutaminyl, aspartoyl, glutaroyl, lysinyl, argininyl, histidinyl, β-alanyl, β-valinyl, β-leucinyl, β-isoleuccinyl, β-prolinyl, β-phenylalaninyl, β-tryptophanyl, β-methioninyl, β-glycinyl, β-serinyl, β-threoninyl, β-cysteinyl, β-tyrosinyl, β-asparaginyl, β-glutaminyl, β-aspartoyl, β-glutaroyl, β-lysinyl, β-argininyl or β-histidinyl. Additional amino acids include selenocysteine, pyrrolysine, N-formylmethionine, γ-aminobutyric acid (GABA), δ-aminolevulinic acid, aminobenzoic acid (including 4-aminobenzoic acid), aminoisobutyric acid, dehydroalanine, cystathionine, lanthionine, djenkolic acid, diaminopimelic acid, norvaline, alloisoleucine, t-leucine, α-amino-heptanoic acid, pipecolic acid, α, β-diaminopropionic acid, α,γ-diaminobutyric acid, ornithine, glutamic acid, allothreonine, homocysteine, β-aminobutyric acid, α-aminoisobutyric acid, isovaline, sarcosine, N-ethylglycine, N-propylglycine, N-isopropyl glycine, N-methyl alanine, N-ethyl alanine, N-methyl-β-alanine, isoserine, norleucine, homoserine, O-methyl-homoserine, O-ethyl-homoserine, homonorleucine, carboxyglutamic acid, hydroxyproline, hypusine, pyroglutamic acid, and α-hydroxy-γ-aminobutyric acid.
    • iii. The residue of a non-naturally occurring amino acid with an extended length between the amino group and the carboxylic acid, which can be used either alone or as a linker to another prodrug moiety. Examples include amino acids wherein the amino and carboxylic acid are separated by an aliphatic or heteroaliphatic moiety (nonlimiting example is 8-amino-3,6-dioxaoctanoic acid), for example an alkyl, alkenyl, alkynyl, ethylene glycol, propylene glycol, alkylene glycol, or the like, moiety, e.g., with 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or more straight, branched or cyclic atoms or moieties (e.g., alkylene glycol moieties), as appropriate to provide the desired properties. In some embodiments, the amino acid has one or more internal amine, carbonyl, carboxy, oxo, thio, phosphate or phosphonate moieties in the heteroaliphatic chain.
    • iv. The residue of one or a series of amino acids linked to a terminal fatty acid or to an endcap like hydrogen or alkyl. In one non-limiting example, 8-amino-3,6-dioxaoctanoic acid (one or several in sequence) is covalently bound to the selected complement D inhibitor of the present invention through a functional group such as a carboxylic acid, sulfonyl, hydroxyl or amino group. See generally Lau, et al., “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semiglutide”, J. Med. Chem., 2015, 58, 7370-7380. The 8-amino-3,6-dioxaoctanoic acid is covalently linked to an aliphatic acid, including but not limited to a C16, C18, C20 aliphatic acid, or a dicarboxylic acid, including but not limited to a C8, C10, C12, C14, C16, C18 or C20 diacid. One or more amino acids can also be used in the selected configuration to add length or functionality.
R4, R5, and R6 are selected from hydrogen, -JCHO, -JC(O)NH2, -JC2-C6alkanoyl, -JC(O)NH(CH3), -J-COOH, -JP(O)(OR9)2, -JOC(O)R9, -JC(O)OR9, -JC(O)N(CH2CH2R9)(R10), -JNR9C(O)R10, -JSO2NH2, -JS(O)NH2, -JC(CH2)2F, -JCH(CF3)NH2, -JC(O)C0-C2alkyl(C3-C7cycloalkyl), -JNR9(C2-C6alkanoyl), -JNR9C(O)NR9R10, -JSO2(C1-C6alkyl), -JSO2(C1-C6haloalkyl), -JSO2NR7R7, -JSO═NH(C1-C6alkyl), -J-nitro, -J-halogen, -J-hydroxyl, -J-phenyl, a 5- to 6-membered heteroaryl, -J-cyano, -J-cyanoimino, -J-amino, -J-imino, —C1-C6alkyl, —C0-C4alkyl(C3-C7heterocycloalkyl), —C0-C4alkyl(C3-C7cycloalkyl),
Figure US11708351-20230725-C00028
each of which R4, R5 and R6 other than hydrogen, nitro, halogen, cyano, cyanoimino, or —CHO, is optionally substituted with one or more of amino, imino, halogen, hydroxyl, cyano, cyanoimino, alkyl including C1-C6alkyl, alkoxy including C1-C6alkoxy, —C0-C2alkyl(mono- and di-C1-C4alkylamino), —C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
J is independently selected from a covalent bond, alkylene including C1-C4alkylene, O-alkylene including —OC1-C4alkylene, alkenylene including C2-C4alkenylene, and alkynylene C2-C4alkynylene;
R6′ is hydrogen, halogen, hydroxyl, C1-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), or C1-C4alkoxy;
or R6 and R6′ may be taken together to form an oxo, vinyl, or imino group;
R7 is hydrogen, alkyl including C1-C6alkyl, or —C0-C4alkyl(C3-C7cycloalkyl);
R8 and R8′ are selected from hydrogen, halogen, hydroxyl, alkyl including C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), alkoxy including C1-C6alkoxy, and (C1-C4alkylamino)C0-C2alkyl;
or R8 and R8′ are taken together to form an oxo group;
or R8 and R8′ are taken together with the carbon that they are bonded to form a 3-membered carbocyclic ring;
R16 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, —C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy,
—C0-C4alkyl(mono- and di-C1-C6alkylamino), —C0-C4alkyl(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
R19 is hydrogen, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, —SO2C1-C6alkyl, (mono- and di-C1-C6alkylamino)C1-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(C3-C7heterocycloalkyl), —C0-C4alkyl(aryl), or C0-C4alkyl(heteroaryl), wherein each R19 other than hydrogen is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, amino, —COOH, and —C(O)OC1-C4alkyl;
X11 is N or CR11;
X12 is N or CR12;
X13 is N or CR13;
X14 is N or CR14;
wherein no more than 2 of X11, X12, X13, and X14 are N;
wherein one of R12 and R13 is R32 and the other is R31 or R32;
and wherein if there is no R13 and no R32 on the A ring then R12 is R32;
and wherein if there is no R12 and no R32 on the A ring then R13 is R32;
R31 is independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, haloalkyl including C1-C6haloalkyl, haloalkoxy including C1-C6haloalkoxy, alkyl including C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, alkenyloxy including C2-C6alkenyloxy, —C(O)OR9, thioalkyl including C1-C6thioalkyl, —C0-C4alkylNR9R10, —C(O)NR9R10, —SO2R9, —SO2NR9R10, —OC(O)R9, and —C(NR9)NR9R10, each of which R31 other than hydrogen, halogen, hydroxyl, nitro, cyano, haloalkyl including C1-C6haloalkyl, and C1-C6haloalkoxy is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, —COOH, —C(O)NR9R10, haloalkyl including C1-C6haloalkyl, haloalkoxy including C1-C6haloalkoxy, phenyl, and 4- to 7-membered heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S; each of which phenyl or 4- to 7-membered heterocycle is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, alkylester including C1-C6alkylester, —C0-C4alkyl)(C3-C7cycloalkyl), C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
R32 is selected from aryl, heteroaryl, and heterocycle wherein the aryl, heteroaryl, or heterocycle ring can be optionally substituted;
in one embodiment R32 is substituted with R301, —CH2—R301, or R201;
R11, R14, and R15 are independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, —O(PO)(OR9)2, —(PO)(OR9)2, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, C2-C6alkenyl(aryl), C2-C6alkenyl(cycloalkyl), C2-C6alkenyl(heterocycle), C2-C6alkenyl(heteroaryl), C2-C6alkynyl(aryl), C2-C6alkynyl(cycloalkyl), C2-C6alkynyl(heterocycle), C2-C6alkynyl(heteroaryl), alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, thioalkyl including C1-C6thioalkyl, —C0-C4alkyl(mono- and di-C1-C6alkylamino), —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkoxy(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
X15 is NH, O, or S;
X16 is CR12;
X17 is N or CR13;
X18 is CR12;
X19 is N or CR13;
X20 is NH or O;
X21 is N or CR14;
X22 is N or CR13;
X23 is CR12;
X24 is O or S;
X26 is N or CR41;
X27 is CR12, NH, or O;
X28 is N or CH;
X30 is N or CR5;
X31 is N, C(R34)2, or CR54;
X32 is NH, C(R54)2, or CR54;
X33 is —CO—, —SO—, or —SO2—;
X34 is CHR13, NH, O, or S;
wherein no more than 2 of X28 are N;
R41 is hydrogen, alkyl including C1-C6alkyl, or —(C0-C2alkyl)(C3-C5cycloalkyl);
R48 and R48a is selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, alkyl including C1-C6alkyl, haloalkyl including C1-C6haloalkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, thioalkyl including C1-C6thioalkyl, alkoxy including C1-C6alkoxy, -JC3-C7cycloalkyl, —B(OH)2, -JC(O)NR9R23, -JOSO2OR21, —C(O)(CH2)1-4S(O)R21, —O(CH2)1-4S(O)NR21R22, -JOP(O)(OR21)(OR22), -JP(O))(OR21)(OR22), -JOP(O)(OR21)R22, -JP(O)(OR21)R22, -JOP(O)R21R22, -JP(O)R21R22, -JSP(O)(OR21)(OR22), -JSP(O)(OR21)(R22), -JSP(O)(R21))(R22), -JNR9P(O)(NHR21)(NHR22), -JNR9P(O)(OR21)(NHR22), -JNR9P(O)(OR21)(OR22), -JC(S)R21, -JNR21SO2R22, -JNR9S(O)NR10R22, -JNR9SO2NR10R22, -JSO2NR9COR22, -JSO2NR9CONR21R22, -JNR21SO2R22, -JC(O)NR21SO2R22, -JC(NH2)═NR22, -JCH(NH2)NR9S(O)2R22, -JOC(O)NR21R22, -JNR21C(O)OR22, -JNR21OC(O)R22, —(CH2)1-4C(O)NR21R22, -JC(O)NR24R30, -JNR9C(O)R21, -JC(O)R21, -JNR9C(O)NR10R22, —CCR21, —(CH2)1-4OC(O)R21, -JC(O)OR23, and R103; each of which R48 may be optionally substituted with one or more substituents selected from halogen, hydroxyl, nitro, cyano, amino, oxo, —B(OH)2, —Si(CH3)3, —COOH, —CONR9R10, —P(O)(OH)2, alkyl including C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), C1-C6alkoxy, —C0-C4alkyl(mono- and di-C1-C4alkylNR9R10), alkylester including C1-C6alkylester, C1-C4alkylamino, C1-C4hydroxylalkyl, haloalkyl including C1-C6haloalkyl, —OC(O)R9, —NR9C(O)R10, —C(O)NR9R10, —OC(O)NR9R10, —NR9C(O)OR10, haloalkyl including C1-C6haloalkyl, S(O)═NHR21, SF5, JC(R9)═NR21, SO2OR21, and haloalkoxy including C1-C6haloalkoxy;
R103 is independently C1-C4 alkyl, C3-C6 cycloalkyl, fluorine, chlorine, or bromine;
R54 is hydrogen, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, alkoxy including C1-C6alkoxy, C2-C6alkynyl, alkanoyl including C2-C6alkanoyl, thioalkyl including C1-C6thioalkyl, hydroxyC1-C6alkyl, aminoC1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), (phenyl)C0-C4alkyl-, (heterocycloalkyl)C0-C4alkyl or (heteroaryl)C0-C4alkyl- wherein each R54 is optionally substituted;
s is 1 or 2;
L is selected from L1 and L2;
L1 is a bond,
Figure US11708351-20230725-C00029
R17 is hydrogen, alkyl including C1-C6alkyl, or —C0-C4alkyl(C3-C7cycloalkyl);
R18 and R18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl;
m is 0, 1, 2, or 3;
L2 is selected from:
Figure US11708351-20230725-C00030
or L2 is selected from an optionally substituted monocyclic or bicyclic carbocyclic; an optionally substituted monocyclic or bicyclic carbocyclic-oxy group; an optionally substituted monocyclic or bicyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from N, O, and S and from 4 to 7 ring atoms per ring, an optionally substituted —(C0-C4alkyl)(aryl); an optionally substituted —(C0-C4alkyl)(5-membered heteroaryl); an optionally substituted —(C0-C4alkyl)(6-membered heteroaryl); an optionally substituted —(C0-C4alkyl)(8-membered heteroaryl); an optionally substituted —(C0-C4alkyl)(9-membered heteroaryl); and —(C0-C4alkyl)(10-membered heteroaryl);
q is 1, 2 or 3;
R51 is CH3, CH2F, CHF2 or CF3;
R53 is cyano, nitro, hydroxyl, or alkoxy including C1-C6alkoxy;
X29 can be O or S;
L3 is —C(O)—, —C(S)—, —P(O)OH—, —S(O)—, —S(O)2—, or —C(R52)2—;
each R52 is independently selected from halo, hydrogen, or optionally substituted alkyl including C1-C6alkyl;
or two R52 groups are taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S;
B1 is heteroaryl; aryl; biphenyl, a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including C2-C6alkenyl; or alkynyl including C2-C6alkynyl; each of which B1 is optionally substituted with one or more substituents independently selected from R33, R34, R35, and R36;
R33 is independently selected from halogen, hydroxyl, —COOH, cyano, alkyl including C1-C6alkyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, —C0-C4alkylNR9R10, —SO2R9, haloalkyl including C1-C6haloalkyl, S(O)═NHR21, SF5, and JC(R9)═NR21, and haloalkoxy including C1-C6haloalkoxy;
R34 is independently selected from nitro, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, thioalkyl including C1-C6thioalkyl, -JC3-C7cycloalkyl, -JB(OH)2, -JC(O)NR9R23, -JOSO2OR21, -JC(O)(CH2)1-4S(O)R21, —O(CH2)1-4S(O)NR21R22, -JOP(O)(OR21)(OR22), -JP(O)(OR21)(OR22), -JOP(O)(OR21)R22, -JP(O)(OR21)R22, -JOP(O)R21R22, -JP(O)R21R22, -JSP(O)(OR21)(OR22), -JSP(O)(OR21)(R22), -JSP(O)(R21)(R22), -JNR9P(O)(NHR21)(NHR22), -JNR9P(O)(OR21)(NHR22), -JNR9P(O)(OR21)(OR22), -JC(S)R21, -JNR21SO2R22, -JNR9S(O)NR10R22, -JNR9SO2NR10R22, -JSO2NR9COR22, -JSO2NR9CONR21R22, -JNR21SO2R22, -JC(O)NR21SO2R22, -JC(NH2)═NR22, -JCH(NH2)NR9S(O)2R22, -JOC(O)NR21R22, -JNR21C(O)OR22, -JNR21OC(O)R22, —(CH2)1-4C(O)NR21R22, -JC(O)R24R30, -JNR9C(O)R21, -JC(O)R21, -JNR9C(O)NR10R22, —CCR21, —(CH2)1-4OC(O)R21, —S(O)2OR21, and -JC(O)OR23; each of which R34 may be unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, oxo, —B(OH)2, —Si(CH3)3, —COOH, —CONR9R10, —P(O)(OH)2, C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), alkoxy including C1-C6alkoxy, —C0-C2alkyl(mono- and di-C1-C4alkylamino), C1-C6alkylester, C1-C4alkylamino, C1-C4hydroxylalkyl, haloalkyl including C1-C6haloalkyl, and C1-C6haloalkoxy;
R35 is independently selected from naphthyl, naphthyloxy, indanyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl containing 1 or 2 heteroatoms selected from N, O, and S, and bicyclic heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S, and containing 4- to 8-ring atoms in each ring; each of which R35 is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), —SO2R9, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
R36 is independently selected from tetrazolyl, (phenyl)C0-C2alkyl, (phenyl)C1-C6alkoxy, phenoxy, and 5- or 6-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O, Boron, Si, and S, each of which R36 is optionally substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, C1-C6alkylester, —C0-C4alkyl(C3-C7cycloalkyl), —SO2R9, —OSi(CH3)2C(CH3)3, —Si(CH3)2C(CH3)3, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
in an alternative embodiment R36 is a bicyclic heteroaryl such as a 9-membered heteroaryl;
R21 and R22 are independently selected from hydrogen, hydroxyl, cyano, amino, C1-C6alkyl, haloalkyl including C1-C6haloalkyl, alkoxy including C1-C6alkoxy, (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, —C1-C4alkylOC(O)OC1-C6alkyl, —C1-C4alkylOC(O)C1-C6alkyl, —C1-C4alkylC(O)OC1-C6alkyl, (4- to 8-membered heterocycloalkyl)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and each R21 and R22 can be optionally substituted;
or R21 and R22 can be taken together to form a carbocyclic or heterocyclic ring;
R23 is independently selected at each occurrence from alkyl including C1-C6alkyl, haloalkyl including C1-C6haloalkyl, (aryl)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, (4- to 8-membered heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, wherein each R23 can be optionally substituted;
R24 and R30 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycle, or a 6- to 10-membered bicyclic heterocycle group having fused, spiro, or bridged rings, wherein each ring can be optionally substituted;
B2 is selected from:
    • a. a 4-membered carbocycle fused to a 5- or 6-membered heteroaryl having 1, 2, or 3 heteroatoms independently selected from N, O, and S; wherein the 4-5 or 4-6 ring system can be optionally substituted;
    • b. (optionally substituted alkyl)-(optionally substituted cycloalkyl), (optionally substituted alkenyl)-(optionally substituted cycloalkyl), or (optionally substituted alkynyl)-(optionally substituted cycloalkyl);
    • c. a 4-membered carbocycle fused to a 6-membered aryl ring wherein the 4-6 ring system can be optionally substituted;
    • d. (cycloalkyl)-(optionally substituted aryl), (cycloalkyl)-(optionally substituted heteroaryl), (cycloalkyl)-(optionally substituted heterocycle), (alkyl)-alkenyl), cycloalkyl-alkenyl;
    • e. alkyl, alkyl(alkynyl), each of which can be optionally substituted;
wherein B2 can be further substituted 1, 2, 3, or 4 times or more with the substituents independently selected from R33, R34, R35, R36, and R48;
B3 is a monocyclic or bicyclic carbocycle; a monocyclic or bicyclic carbocyclic-oxy group; a monocyclic, bicyclic, or tricyclic heterocycle group having 1, 2, 3, or 4 heteroatoms independently selected from Boron, Si, N, O, and S and from 4 to 8 ring atoms per ring; alkenyl including C2-C6alkenyl; alkynyl including C2-C6alkynyl; —(C0-C4alkyl)(aryl); —(C0-C4alkyl)(heteroaryl); or —(C0-C4alkyl)(biphenyl), each of which B3 is substituted with at least one R201 and optionally substituted with one or more substituents independently selected from R33, R34, R35, and R36;
B4 is a six membered heteroaryl ring with at least two substituents selected from R25, R26, R27 and R28;
or B4 is a six membered heteroaryl ring with at least three substituents selected from R25, R26, R27 and R28;
or B4 is a pyridine with at least two substituents selected from R25, R26, R27 and R28;
or B4 is selected from:
Figure US11708351-20230725-C00031
R25, R26, R27, and R28 are independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, thioalkyl including C1-C6thioalkyl, (mono- and di-C1-C6alkylamino)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (aryl)C0-C4alkyl-, (heteroaryl)C0-C4alkyl-, and —C0-C4alkoxy(C3-C7cycloalkyl); each of which R25, R26, R27, and R28 other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C1-C6alkoxy, haloalkyl including C1-C6haloalkyl, (C3-C7cycloalkyl)C0-C4alkyl-, and haloalkoxy including C1-C6haloalkoxy;
or R25, R26, R27, and R28 are independently selected from tetrazole, halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, thioalkyl including C1-C6thioalkyl, (mono- and di-C1-C6alkylamino)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (aryl)C0-C4alkyl-, (heteroaryl)C0-C4alkyl-, and —C0-C4alkoxy(C3-C7cycloalkyl); each of which R25, R26, R27, and R28 other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C1-C6alkoxy, haloalkyl including C1-C6haloalkyl, (C3-C7cycloalkyl)C0-C4alkyl-, and haloalkoxy including C1-C6haloalkoxy;
and wherein any of these groups may be further optionally substituted as that term is defined in the Terminology Section below, if desired to achieve the target effect, results in a stable compound that makes chemical sense to the skilled artisan, and the group is not redundant (i.e., as known in the art, alkyl substituted with alkyl is redundant; however for examples, alkoxy substituted with alkoxy is not redundant); and
wherein any of the structures illustrated herein, e.g., A1, A2, A3, B1, B2, B3, B4, C1, C2, C3, C4, C5, L, L3, or any of the R moieties, can be optionally independently substituted with 0, 1, 2, 3, or 4, as appropriate, R48 substituents.
In another aspect the invention provides a compound of Formula IV:
Figure US11708351-20230725-C00032
or a pharmaceutically acceptable salt, isotopic analog, prodrug, or isolated isomer thereof optionally in pharmaceutically acceptable carrier;
wherein:
the R32 group on the A-ring is selected from
Figure US11708351-20230725-C00033
and wherein all other variables are as defined herein.
In another aspect the invention provides a compound of Formula V:
Figure US11708351-20230725-C00034
or a pharmaceutically acceptable salt, isotopic analog, prodrug, N-oxide, or isolated isomer thereof optionally in pharmaceutically acceptable carrier;
wherein:
B is as defined above.
C is as defined above.
L is as defined above.
L3 is as defined above.
A4 is selected from:
Figure US11708351-20230725-C00035
Figure US11708351-20230725-C00036
Figure US11708351-20230725-C00037
wherein all other variables are as defined herein.
Pharmaceutical compositions comprising a compound or salt of Formula I, Formula II, Formula III, Formula IV, or Formula V together with a pharmaceutically acceptable carrier are also disclosed.
The present invention thus includes at least the following features:
    • a. a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition,
    • b. a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, for use in treating or preventing a disorder including but not limited to the development of fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, or liver failure; dermatomyositis; amyotrophic lateral sclerosis; cytokine or inflammatory reactions in response to biotherapeutics (e.g. CAR T-cell therapy); paroxysmal nocturnal hemoglobinuria (PNH), rheumatoid arthritis, multiple sclerosis, age-related macular degeneration (AMD), retinal degeneration, other ophthalmic diseases (e.g., geographic atrophy), a respiratory disease or a cardiovascular disease;
    • c. a pharmaceutically acceptable composition of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V or its pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof in a pharmaceutically acceptable carrier;
    • d. a compound selected from Formula I, Formula II, Formula III, Formula IV, or Formula V or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, for use in treating or preventing a disorder mediated by the complement pathway, and for example, cascade Factor D;
    • e. use of a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V as described herein, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, in the manufacture of a medicament for treating or preventing a disorder, including but not limited to the development of fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis, liver failure; dermatomyositis; amyotrophic lateral sclerosis; cytokine or inflammatory reactions in response to biotherapeutics (e.g. CAR T-cell therapy); paroxysmal nocturnal hemoglobinuria (PNH), rheumatoid arthritis, multiple sclerosis, age-related macular degeneration (AMD), retinal degeneration, other ophthalmic diseases (e.g., geographic atrophy), a respiratory disease or a cardiovascular disease;
    • f. a process for manufacturing a medicament intended for the therapeutic use for treating or preventing a disorder, or generally for treating or preventing disorders mediated by complement cascade Factor D, characterized in that a compound selected from Formula I, Formula II, Formula III, Formula IV, or Formula V or an embodiment of the active compound is used in the manufacture;
    • g. a compound selected from Formula I, Formula II, Formula III, Formula IV, or Formula V or a salt thereof as described herein in substantially pure form (e.g., at least 90 or 95%):
    • h. a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V as described herein, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a carrier to form a pharmaceutically acceptable composition, for use in treating a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade), a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
    • i. For each of (a) through (i) above, and otherwise herein, each assembly of moieties in the Figures and each active compound made therefrom or its use is considered and deemed specifically and individually disclosed, as such depiction is for convenience of space only and not intended to describe a only a genus or even a subgenus for such indication.
BRIEF DESCRIPTION OF FIGURES
FIG. 1 is the six-step procedure to synthesize intermediate tert-butyl (1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate.
FIG. 2 is the two-step synthesis of intermediate 2-bromo-3-fluoro-5-methylpyridine 1-oxide (Compound 3 in FIG. 2 ).
FIG. 3 is the three-step procedure to synthesize the intermediate tert-butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate.
FIG. 4 is a seven-step procedure to synthesize the intermediate 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid.
FIG. 5 is the two-step procedure to synthesize the intermediate tert-butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate.
FIG. 6 is the six-step procedure to synthesize intermediate (S)-3-fluoro-4-methylpent-3-en-2-amine hydrochloric acid salt.
FIG. 7 is the six-step procedure to synthesize intermediate (R)-1-((R)-2,2-dichlorocyclopropyl)ethan-1-amine hydrochloric acid salt.
FIG. 8 is the expanded eight-step synthesis of Compound 208 shown in Scheme 153.
FIG. 9 is the eight-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-(oxetan-3-yl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
FIG. 10 is a four-step procedure to synthesize (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(oxetan-3-yl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide.
FIG. 11 is a three-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N—((S)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
FIG. 12 is a seven-step procedure to synthesize Compound 100.
FIG. 13 is a three-step procedure for synthesizing Compound 50 and is an alternative to a synthesis shown in Scheme 45.
FIG. 14 is the expanded six-step synthesis of Compound 107 shown in Scheme 80.
FIG. 15A is the eight-step procedure to synthesize intermediate 2-(3-acetyl-7-methyl-5-(2-(3-((trimethylsilyl)oxy)oxetan-3-yl)pyrimidin-5-yl)-1H-indazol-1-yl)acetic acid.
FIG. 15B is the final two steps of a synthesis of (1R,3S,5R)-2-(2-(3-acetyl-5-(2-(3-hydroxyoxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide from the intermediate shown in FIG. 18A.
FIG. 16 is the eight-step procedure to synthesize (1R,3S,5R)-2-(2-(3-acetyl-5-(2-(3-fluorooxetan-3-yl)pyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide.
FIG. 17 is a schematic showing the various potential attachment points for R301 functionality on the A-ring, B-ring, C-ring, or heteroaryl-containing R32 group. X9 as used in FIG. 17 is selected from —CH2—, —O—, —NH—, and —Nalkyl-.
FIGS. 18A, 18B, 18C, 18D, 18E, 18F, 18G, 18H, 18I, 18J, 18K, 18L, 18M, 18N, 18O, 18P, 18Q, 18R, 18S, 18T, 18U, and 18V are examples of compounds that exemplify Formula I, Formula II, or Formula III.
FIG. 19 depicts Formula I, Formula II, and Formula III.
 DETAILED DESCRIPTION Terminology
Compounds are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
The compounds in any of the Formulas described herein include enantiomers, mixtures of enantiomers, diastereomers, tautomers, racemates and other isomers, such as rotamers, as if each is specifically described, unless otherwise indicated or otherwise excluded by context.
The terms “a” and “an” do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term “or” means “and/or”. Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of examples, or exemplary language (e.g., “such as”), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.
The present invention includes compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V with at least one desired isotopic substitution of an atom, at an amount above the natural abundance of the isotope, i.e., enriched. Isotopes are atoms having the same atomic number but different mass numbers, i.e., the same number of protons but a different number of neutrons.
Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 2H, 3H, 11C, 13C, 14C, 15N, 18F 31P, 32P, 35S, 36CI, 125I respectively. In one embodiment, isotopically labelled compounds can be used in metabolic studies (with 14C), reaction kinetic studies (with, for example 2H or 3H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an 18F labeled compound may be particularly desirable for PET or SPECT studies. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
By way of general example and without limitation, isotopes of hydrogen, for example, deuterium (2H) and tritium (3H) may optionally be used anywhere in described structures that achieves the desired result. Alternatively or in addition, isotopes of carbon, e.g., 13C and 14C, may be used. In one embodiment, the isotopic substitution is replacing hydrogen with a deuterium at one or more locations on the molecule to improve the performance of the drug, for example, the pharmacodynamics, pharmacokinetics, biodistribution, half-life, stability, AUC, Tmax, Cmax, etc. For example, the deuterium can be bound to carbon in a location of bond breakage during metabolism (an α-deuterium kinetic isotope effect) or next to or near the site of bond breakage (a β-deuterium kinetic isotope effect).
Isotopic substitutions, for example deuterium substitutions, can be partial or complete. Partial deuterium substitution means that at least one hydrogen is substituted with deuterium. In certain embodiments, the isotope is 80, 85, 90, 95 or 99% or more enriched in an isotope at any location of interest. In one embodiments deuterium is 80, 85, 90, 95 or 99% enriched at a desired location. Unless otherwise stated, the enrichment at any point is above natural abundance. And in an embodiment is enough to alter a detectable property of the drug in a human.
In one embodiment, the substitution of a hydrogen atom for a deuterium atom can be provided in any of A1, A1′, A2, B1, B1′, B2, B3, B4, C1, C1′, C2, C3, C4, L1, L1′, L2, L2′, L4 or L5. In one embodiment, the substitution of a hydrogen atom for a deuterium atom occurs within any R group. In one embodiment the R group is selected from any of R1, R1′, R2, R2′, R3, R3′, R4, R4′, R5, R6, R6′, R7, R8, R8′, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R18′, R19, R21, R22, R23, R25, R26, R27, R28, R30, R31, R32, R33, R34, R35, R36, R40, R41, R42, R43, R44, R44′, R45, R45′, R46, R46′, R47, R48, R48a, R49, R50, R51, R52, R53, R54, R103, R104, R201, R202, and R301. For example, when any of R groups are, or contain for example through substitution, methyl, ethyl, or methoxy, the alkyl residue may be deuterated (in nonlimiting embodiments, CD3, CH2CD3, CD2CD3, CDH2, CD2H, CD3, CHDCH2D, CH2CD3, CHDCHD2, OCDH2, OCD2H, or OCD3 etc.). In certain other embodiments, an R group has a “′” or an “a” designation, which in one embodiment can be deuterated. In certain other embodiments, when two substituents of the central core ring are combined to form a cyclopropyl ring, the unsubstituted methylene carbon may be deuterated.
The compound of the present invention may form a solvate with solvents (including water). Therefore, in one embodiment, the invention includes a solvated form of the active compound. The term “solvate” refers to a molecular complex of a compound of the present invention (including a salt thereof) with one or more solvent molecules. Nonlimiting examples of solvents are water, ethanol, dimethyl sulfoxide, acetone and other common organic solvents. The term “hydrate” refers to a molecular complex comprising a compound of the invention and water. Pharmaceutically acceptable solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D2O, d6-acetone, d6-DMSO. A solvate can be in a liquid or solid form.
A dash (“-”) that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, —(C═O)NH2 is attached through carbon of the keto (C═O) group.
The term “substituted”, as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a moiety selected from the indicated group, provided that the designated atom's normal valence is not exceeded and the resulting compound is stable. For example, when the substituent is oxo (i.e., ═O) then two hydrogens on the atom are replaced. For example a pyridyl group substituted by oxo is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates.
A stable active compound refers to a compound that can be isolated and can be formulated into a dosage form with a shelf life of at least one month. A stable manufacturing intermediate or precursor to an active compound is stable if it does not degrade within the period needed for reaction or other use. A stable moiety or substituent group is one that does not degrade, react or fall apart within the period necessary for use. Nonlimiting examples of unstable moieties are those that combine heteroatoms in an unstable arrangement, as typically known and identifiable to those of skill in the art.
Any suitable group may be present on a “substituted” or “optionally substituted” position that forms a stable molecule and meets the desired purpose of the invention and includes, but is not limited to, e.g., halogen (which can independently be F, Cl, Br or I); cyano; hydroxyl; nitro; azido; alkanoyl (such as a C2-C6 alkanoyl group); carboxamide; alkyl, cycloalkyl, alkenyl, alkynyl, alkoxy, aryloxy such as phenoxy; thioalkyl including those having one or more thioether linkages; alkylsulfinyl; alkylsulfonyl groups including those having one or more sulfonyl linkages; aminoalkyl groups including groups having more than one N atoms; aryl (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted); arylalkyl having for example, 1 to 3 separate or fused rings and from 6 to about 14 or 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy, for example, having 1 to 3 separate or fused rings with benzyloxy being an exemplary arylalkoxy group; or a saturated or partially unsaturated heterocycle having 1 to 3 separate or fused rings with one or more N, O or S atoms, or a heteroaryl having 1 to 3 separate or fused rings with one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolinyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyl, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, morpholinyl, piperazinyl, and pyrrolidinyl. Such groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino. In certain embodiments “optionally substituted” includes one or more substituents independently selected from halogen, hydroxyl, amino, cyano, —CHO, —COOH, —CONH2, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkynyl including C2-C6alkynyl, —C1-C6alkoxy, alkanoyl including C2-C6alkanoyl, C1-C6alkylester, (mono- and di-C1-C6alkylamino)C0-C2alkyl, haloalkyl including C1-C6haloalkyl, hydroxyC1-C6alkyl, ester, carbamate, urea, sulfonamide, —C1-C6alkyl(heterocyclo), C1-C6alkyl(heteroaryl), —C1-C6alkyl(C3-C7cycloalkyl), O—C1-C6alkyl(C3-C7cycloalkyl), B(OH)2, phosphate, phosphonate and haloalkoxy including C1-C6haloalkoxy.
“Alkyl” is a branched or straight chain saturated aliphatic hydrocarbon group. In one embodiment, the alkyl contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the alkyl contains from 1 to about 8 carbon atoms. In certain embodiments, the alkyl is C1-C2, C1-C3, C1-C4, C1-C5 or C1-C6. The specified ranges as used herein indicate an alkyl group having each member of the range described as an independent species. For example, the term C1-C6 alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C1-C4alkyl as used herein indicates a straight or branched alkyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. When C0-Cn alkyl is used herein in conjunction with another group, for example, (C3-C7cycloalkyl)C0-C4 alkyl, or —C0-C4alkyl(C3-C7cycloalkyl), the indicated group, in this case cycloalkyl, is either directly bound by a single covalent bond (C0alkyl), or attached by an alkyl chain in this case 1, 2, 3, or 4 carbon atoms. Alkyls can also be attached via other groups such as heteroatoms as in —O—C0-C4alkyl(C3-C7cycloalkyl). Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, tert-pentyl, neopentyl, n-hexyl, 2-methylpentane, 3-methylpentane, 2,2-dimethylbutane, 2,3-dimethylbutane, and hexyl. In one embodiment, the alkyl group is optionally substituted as described above. In one embodiment, trimethylsilyl can be used instead of t-butyl.
“Aliphatic” refers to a saturated or unsaturated, straight, branched, or cyclic hydrocarbon. “Aliphatic” is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties, and thus incorporates each of these definitions. In one embodiment, “aliphatic” is used to indicate those aliphatic groups having 1-20 carbon atoms. The aliphatic chain can be, for example, mono-unsaturated, di-unsaturated, tri-unsaturated, polyunsaturated, or alkynyl. Unsaturated aliphatic groups can be in a cis or trans configuration. In one embodiment, the aliphatic group contains from 1 to about 12 carbon atoms, more generally from 1 to about 6 carbon atoms or from 1 to about 4 carbon atoms. In one embodiment, the aliphatic group contains from 1 to about 8 carbon atoms. In certain embodiments, the aliphatic group is C1-C2, C1-C3, C1-C4, C1-C5 or C1-C6. The specified ranges as used herein indicate an aliphatic group having each member of the range described as an independent species. For example, the term C1-C6 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, 4, 5, or 6 carbon atoms and is intended to mean that each of these is described as an independent species. For example, the term C1-C4 aliphatic as used herein indicates a straight or branched alkyl, alkenyl, or alkynyl group having from 1, 2, 3, or 4 carbon atoms and is intended to mean that each of these is described as an independent species. In one embodiment, the aliphatic group is substituted with one or more functional groups that results in the formation of a stable moiety.
The term “heteroaliphatic” refers to an aliphatic moiety that contains at least one heteroatom in the chain, for example, an amine, carbonyl, carboxy, oxo, thio, phosphate, phosphonate, nitrogen, phosphorus, silicon, or boron atoms in place of a carbon atom. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur. “Heteroaliphatic” is intended herein to include, but is not limited to, heteroalkyl, heteroalkenyl, heteroalkynyl, heterocycloalkyl, heterocycloalkenyl, and heterocycloalkynyl moieties. In one embodiment, “heteroaliphatic” is used to indicate a heteroaliphatic group (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-20 carbon atoms. In one embodiment, the heteroaliphatic group is optionally substituted in a manner that results in the formation of a stable moiety. Nonlimiting examples of heteroaliphatic moieties are polyethylene glycol, polyalkylene glycol, amide, polyamide, polylactide, polyglycolide, thioether, ether, alkyl-heterocycle-alkyl, —O-alkyl-O-alkyl, alkyl-O-haloalkyl, etc.
In one embodiment, when a term is used that includes “alk” it should be understood that “cycloalkyl” or “carbocyclic” can be considered part of the definition, unless unambiguously excluded by the context. For example and without limitation, the terms alkyl, alkenyl, alkynyl, alkoxy, alkanoyl, alkenyloxy, haloalkyl, aminoalkyl, alkylene, alkenylene, alkynylene, etc. can all be considered to include the cyclic forms of alkyl, unless unambiguously excluded by context.
“Alkenyl” is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon double bonds that may occur at a stable point along the chain. Nonlimiting examples are C2-C8alkenyl, C2-C7alkenyl, C2-C6alkenyl, C2-C5alkenyl and C2-C4alkenyl. The specified ranges as used herein indicate an alkenyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkenyl include, but are not limited to, ethenyl and propenyl. In one embodiment, the alkenyl group is optionally substituted as described above.
“Alkynyl” is a branched or straight chain aliphatic hydrocarbon group having one or more carbon-carbon triple bonds that may occur at any stable point along the chain, for example, C2-C8alkynyl or C2-C6alkynyl. The specified ranges as used herein indicate an alkynyl group having each member of the range described as an independent species, as described above for the alkyl moiety. Examples of alkynyl include, but are not limited to, ethynyl, propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl. In one embodiment, the alkynyl group is optionally substituted as described above.
“Alkylene” is a bivalent saturated hydrocarbon. Alkylenes, for example, can be a 1, 2, 3, 4, 5, 6, 7 to 8 carbon moiety, 1 to 6 carbon moiety, or an indicated number of carbon atoms, for example C1-C2alkylene, C1-C3alkylene, C1-C4alkylene, C1-C5alkylene, or C1-C6alkylene.
“Alkenylene” is a bivalent hydrocarbon having at least one carbon-carbon double bond. Alkenylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C2-C4alkenylene.
“Alkynylene” is a bivalent hydrocarbon having at least one carbon-carbon triple bond. Alkynylenes, for example, can be a 2 to 8 carbon moiety, 2 to 6 carbon moiety, or an indicated number of carbon atoms, for example C2-C4alkynylene.
“Alkoxy” is an alkyl group as defined above covalently bound through an oxygen bridge (—O—). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2-pentoxy, 3-pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3-methylpentoxy. Similarly an “alkylthio” or a “thioalkyl” group is an alkyl group as defined above with the indicated number of carbon atoms covalently bound through a sulfur bridge (—S—). In one embodiment, the alkoxy group is optionally substituted as described above.
“Alkenyloxy” is an alkenyl group as defined covalently bound to the group it substitutes by an oxygen bridge (—O—).
“Alkanoyl” is an alkyl group as defined above covalently bound through a carbonyl (C═O) bridge. The carbonyl carbon is included in the number of carbons, that is C2alkanoyl is a CH3(C═O)— group. In one embodiment, the alkanoyl group is optionally substituted as described above.
“Alkylester” is an alkyl group as defined herein covalently bound through an ester linkage. The ester linkage may be in either orientation, e.g., a group of the formula —O(C═O)alkyl or a group of the formula —(C═O)Oalkyl.
“Amide” or “carboxamide” is —C(O)NRaRb wherein Ra and Rb are each independently selected from hydrogen, alkyl, for example, alkyl including C1-C6alkyl, alkenyl, for example, C2-C6alkenyl, alkynyl, for example, C2-C6alkynyl, —C0-C4alkyl(C3-C7cycloalkyl), —C0-C4alkyl(C3-C7heterocycloalkyl), —C0-C4alkyl(aryl), and —C0-C4alkyl(heteroaryl); or together with the nitrogen to which they are bonded, Ra and Rb can form a C3-C7heterocyclic ring. In one embodiment, the Ra and Rb groups are each independently be optionally substituted as described herein.
“Carbocyclic group”, “carbocyclic ring”, or “cycloalkyl” is a saturated or partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms. A carbocyclic group typically contains 1 ring of 3 to 7 carbon atoms or 2 fused rings each containing 3 to 7 carbon atoms. Cycloalkyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents can have a cycloalkyl group, which is attached as a spiro group. Examples of carbocyclic rings include cyclohexenyl, cyclohexyl, cyclopentenyl, cyclopentyl, cyclobutenyl, cyclobutyl and cyclopropyl rings. In one embodiment, the carbocyclic ring is optionally substituted as described above. In one embodiment, the cycloalkyl is a partially unsaturated (i.e., not aromatic) group containing all carbon ring atoms. In another embodiment, the cycloalkyl is a saturated group containing all carbon ring atoms.
“Carbocyclic-oxy group” is a monocyclic carbocyclic ring or a mono- or bi-cyclic carbocyclic group as defined above attached to the group it substitutes via an oxygen, —O—, linker.
“Haloalkyl” indicates both branched and straight-chain alkyl groups substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifluoromethyl, monofluoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.
“Haloalkoxy” indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).
“Hydroxyalkyl” is an alkyl group as previously described, substituted with at least one hydroxyl substituent.
“Aminoalkyl” is an alkyl group as previously described, substituted with at least one amino substituent.
“Halo” or “halogen” indicates independently, any of fluoro, chloro, bromo or iodo.
“Aryl” indicates an aromatic group containing only carbon in the aromatic ring or rings. In one embodiment, the aryl group contains 1 to 3 separate or fused rings and is 6 to about 14 or 18 ring atoms, without heteroatoms as ring members. When indicated, such aryl groups may be further substituted with carbon or non-carbon atoms or groups. Such substitution may include fusion to a 4 to 7 or a 5 to 7-membered saturated or partially unsaturated cyclic group that optionally contains 1, 2 or 3 heteroatoms independently selected from N, O, B, P, Si and/or S, to form, for example, a 3,4-methylenedioxyphenyl group. Aryl groups include, for example, phenyl and naphthyl, including 1-naphthyl and 2-naphthyl. In one embodiment, aryl groups are pendant. An example of a pendant ring is a phenyl group substituted with a phenyl group. In one embodiment, the aryl group is optionally substituted as described above.
The term “heterocycle,” or “heterocyclic ring” as used herein refers to a saturated or a partially unsaturated (i.e., having one or more double and/or triple bonds within the ring without aromaticity) carbocyclic moiety of 3 to about 12, and more typically 3, 4, 5, 6, 7, 8 to 10 ring atoms in which at least one ring atom is a heteroatom selected from nitrogen, oxygen, phosphorus sulfur, silicon and boron, the remaining ring atoms being C, where one or more ring atoms is optionally substituted independently with one or more substituents described above. A heterocycle may be a monocycle having 3 to 7 ring members (2 to 6 carbon atoms and 1 to 4 heteroatoms selected from N, O, P, S, Si and B) or a bicycle having 6 to 10 ring members (4 to 9 carbon atoms and 1 to 6 heteroatoms selected from N, O, P, S, Si and B), for example: a bicyclo [4,5], [5,5], [5,6], or [6,6] system. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur, boron or silicon. Heterocycles are described in Paquette, Leo A.; “Principles of Modern Heterocyclic Chemistry” (W. A. Benjamin, New York, 1968), particularly Chapters 1, 3, 4, 6, 7, and 9; “The Chemistry of Heterocyclic Compounds, A series of Monographs” (John Wiley & Sons, New York, 1950 to present), in particular Volumes 13, 14, 16, 19, and 28; and J. Am. Chem. Soc. (1960) 82:5566. Examples of heterocyclic rings include, but are not limited to, pyrrolidinyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, piperidonyl, morpholino, thiomorpholino, thioxanyl, piperazinyl, homopiperazinyl, azetidinyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, dihydroisoquinolinyl, tetrahydroisoquinolinyl, pyrazolidinylimidazolinyl, imidazolidinyl, 2-oxa-5-azabicyclo[2.2.2]octane, 3-oxa-8-azabicyclo[3.2.1]octane, 8-oxa-3-azabicyclo[3.2.1]octane, 6-oxa-3-azabicyclo[3.1.1]heptane, 2-oxa-5-azabicyclo[2.2.1]heptane, 3-azabicyco[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, azabicyclo[2.2.2]hexanyl, 3H-indolyl, quinolizinyl, N-pyridyl ureas, and pyrrolopyrimidine. Spiro moieties are also included within the scope of this definition. Examples of a heterocyclic group wherein 1 or 2 ring carbon atoms are substituted with oxo (═O) moieties are pyrimidinonyl and 1,1-dioxo-thiomorpholinyl. The heterocycle groups herein are optionally substituted independently with one or more substituents described herein, for example, 1, 2, or 3 substituents.
“Heterocyclicoxy group” is a monocyclic heterocyclic ring or a bicyclic heterocyclic group as described previously linked to the group it substitutes via an oxygen, —O—, linker.
“Heteroaryl” refers to a stable monocyclic, bicyclic, or multicyclic aromatic ring which contains from 1 to 3, or in some embodiments from 1, 2, or 3 heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5, 6, or 7 membered aromatic ring which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms selected from N, O, S, B or P with remaining ring atoms being carbon. In one embodiment, the only heteroatom is nitrogen. In one embodiment, the only heteroatom is oxygen. In one embodiment, the only heteroatom is sulfur. Monocyclic heteroaryl groups typically have from 5, 6, or 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 8- to 10-membered heteroaryl groups, that is, groups containing 8 or 10 ring atoms in which one 5, 6, or 7 member aromatic ring is fused to a second aromatic or non-aromatic ring. When the total number of S and O atoms in the heteroaryl group exceeds 1, these heteroatoms are not adjacent to one another. In one embodiment, the total number of S and O atoms in the heteroaryl group is not more than 2. In another embodiment, the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, pyridinyl (including, for example, 2-hydroxypyridinyl), imidazolyl, imidazopyridinyl, pyrimidinyl (including, for example, 4-hydroxypyrimidinyl), pyrazolyl, triazolyl, pyrazinyl, furyl, thienyl, isoxazolyl, thiazolyl, oxadiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, tetrahydroisoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, triazolyl, thiadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, tetrahydrofuranyl, and furopyridinyl. Heteroaryl groups are optionally substituted independently with one or more substituents described herein. “Heteroaryloxy” is a heteroaryl group as described bound to the group it substituted via an oxygen, —O—, linker.
“Heterocycloalkyl” is a fully saturated heterocycle as defined herein. It may have, for example, include 1, 2, 3, or 4 heteroatoms independently selected from N, S, O, Si and B with the remaining ring atoms being carbon. In a typical embodiment, nitrogen is the heteroatom. Monocyclic heterocycloalkyl groups typically have from 3 to about 8 ring atoms or from 4 to 6 ring atoms.
The term “mono- and/or di-alkylamino” indicate a secondary or tertiary alkylamino group, wherein the alkyl groups are independently selected as defined herein. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.
A “dosage form” means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, implants, particles, spheres, creams, ointments, suppositories, inhalable forms, transdermal forms, buccal, sublingual, topical, gel, mucosal, and the like. A “dosage form” can also include an implant, for example an optical implant.
“Pharmaceutical compositions” are compositions comprising at least one active agent, and at least one other substance, such as a carrier. “Pharmaceutical combinations” are combinations of at least two active agents which may be combined in a single dosage form or provided together in separate dosage forms with instructions that the active agents are to be used together to treat any disorder described herein.
A “pharmaceutically acceptable salt” is a derivative of the disclosed compound in which the parent compound is modified by making inorganic and organic, pharmaceutically acceptable, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are typical, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.
Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include salts which are acceptable for human consumption and the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic acids. Examples, of such salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC—(CH2)n—COOH where n is 0-4, and the like, or using a different acid that produces the same counterion. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).
The term “carrier” applied to pharmaceutical compositions/combinations of the invention refers to a diluent, excipient, or vehicle with which an active compound is provided.
A “pharmaceutically acceptable excipient” means an excipient that is useful in preparing a pharmaceutical composition/combination that is generally safe, acceptable for human consumption, and neither biologically nor otherwise inappropriate for administration to a host, typically a human. In one embodiment, an excipient is used that is acceptable for veterinary use.
A “patient” or “host” or “subject” is a human or non-human animal in need of treatment or prevention of any of the disorders as specifically described herein, including but not limited to by modulation of the complement Factor D pathway or with a condition that is treatable with one of the compounds described herein. Typically the host is a human. A “patient” or “host” or “subject” also refers to for example, a mammal, primate (e.g., human), cows, sheep, goat, horse, dog, cat, rabbit, rat, mice, bird and the like.
A “prodrug” as used herein, means a compound which when administered to a host in vivo is converted into a parent drug. As used herein, the term “parent drug” means any of the presently described chemical compounds herein. Prodrugs can be used to achieve any desired effect, including to enhance properties of the parent drug or to improve the pharmaceutic or pharmacokinetic properties of the parent, including to increase the half-life of the drug in vivo. Prodrug strategies provide choices in modulating the conditions for in vivo generation of the parent drug. Nonlimiting examples of prodrug strategies include covalent attachment of removable groups, or removable portions of groups, for example, but not limited to acylation, phosphorylation, phosphonylation, phosphoramidate derivatives, amidation, reduction, oxidation, esterification, alkylation, other carboxy derivatives, sulfoxy or sulfone derivatives, carbonylation or anhydride, among others. In certain embodiments, the prodrug renders the parent compound more lipophilic. In certain embodiments, a prodrug can be provided that has several prodrug moieties in linear, branched or cyclic manner. For example, nonlimiting embodiments include the use of a divalent linker moiety such as a dicarboxylic acid, amino acid, diamine, hydroxycarboxylic acid, hydroxyamine, di-hydroxy compound, or other compound that has at least two functional groups that can link the parent molecule with another prodrug moiety, and is typically biodegradable in vivo. In some embodiments, 2, 3, 4 or 5 prodrug biodegradable moieties are covalently bound in sequence, branched or cyclic fashion to the parent compound. Nonlimiting examples of prodrugs according to the present invention are formed with:
    • i. a carboxylic acid on the parent drug and a hydroxylated prodrug moiety to form an ester;
    • ii. a carboxylic acid on the parent drug and an amine prodrug to form an amide;
    • iii. an amino on the parent drug and a carboxylic acid prodrug moiety to form an amide,
    • iv. an amino on the parent drug and a sulfonic acid to form a sulfonamide;
    • v. a sulfonic acid on the parent drug and an amino on the prodrug moiety to form a sulfonamide;
    • vi. a hydroxyl group on the parent drug and a carboxylic acid on the prodrug moiety to form an ester;
    • vii. a hydroxyl on the parent drug and a hydroxylated prodrug moiety to form an ether;
    • viii. a phosphonate on the parent drug and a hydroxylated prodrug moiety to form a phosphonate ester;
    • ix. a phosphoric acid on the parent drug and a hydroxylated prodrug moiety to form a phosphate ester;
    • x. a hydroxyl on the parent drug and a phosphonate on the prodrug to form a phosphonate ester;
    • xi. a hydroxyl on the parent drug and a phosphoric acid prodrug moiety to form a phosphate ester;
    • xii. a carboxylic acid on the parent drug and a prodrug of the structure HO—(CH2)2—O—(C2-24 aliphatic group), for example, HO—(CH2)2—O—(C2-24 alkyl group) to form an ester;
    • xiii. a carboxylic acid on the parent drug and a prodrug of the structure HO—(CH2)2—S—(C2-24 aliphatic group), for example, HO—(CH2)2—S—(C2-24 alkyl group) to form a thioester;
    • xiv. a hydroxyl on the parent drug and a prodrug of the structure HO—(CH2)2—O—(C2-24 aliphatic group), for example, HO—(CH2)2—O—(C2-24 alkyl group) to form an ether;
    • xv. a carboxylic acid on the parent drug and a prodrug of the structure HO—(CH2)2—S—(C2-24 aliphatic group), for example, HO—(CH2)2—S—(C2-24 alkyl group), to form a thioether; and
    • xvi. a carboxylic acid, oxime, hydrazide, hydrazone, amine or hydroxyl on the parent compound and a prodrug moiety that is a biodegradable polymer or oligomer including but not limited to polylactic acid, polylactide-co-glycolide, polyglycolide, polyethylene glycol, polyanhydride, polyester, polyamide or a peptide. An exemplary synthesis of Oxime linkages is provided in the paper published by Jin et. al. titled “Oxime Linkage: A Robust Tool for the Design of PH-Sensitive Polymeric Drug Carriers” in BioMacromolecules, 2011, 12(10), 3460-3468.
In one embodiment, a prodrug is provided by attaching a natural or non-natural amino acid to an appropriate functional moiety on the parent compound, for example, oxygen, nitrogen or sulfur, and typically oxygen or nitrogen, usually in a manner such that the amino acid can be cleaved in vivo to provide the parent drug. The amino acid can be used alone or covalently linked (straight, branched or cyclic) to one or more other prodrug moieties to modify the parent drug to achieve the desired performance, such as increased half-life, lipophilicity, or other drug delivery or pharmacokinetic properties. The amino acid can be any compound with an amino group and a carboxylic acid, which includes an aliphatic amino acid, alkyl amino acid, aromatic amino acid, heteroaliphatic amino acid, heteroalkyl amino acid, or heterocyclic amino acid or heteroaryl amino acid.
“Providing a compound with at least one additional active agent,” for example, in one embodiment can mean that the compound and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration. In one embodiment, the compound administrations are separated by some amount of time that is within the time in which both the compound and the at least one additional active agent are within the blood stream of a patient. In certain embodiments the compound and the additional active agent need not be prescribed for a patient by the same medical care worker. In certain embodiments the additional active agent or agents need not require a prescription. Administration of the compound or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories, parenteral, sublingual, buccal, intravenous, intraaortal, transdermal, polymeric controlled delivery, non-polymeric controlled delivery, nano or microparticles, liposomes, and/or topical contact. In one embodiment, the instructions for administration in a form of combination therapy is provided in the drug labeling.
A “therapeutically effective amount” of a pharmaceutical composition/combination of this invention means an amount effective, when administered to a host, provides a therapeutic benefit such as an amelioration of symptoms or reduction or dimunition of the disease itself. In one embodiment, a therapeutically effective amount is an amount sufficient to prevent a significant increase or will significantly reduce the detectable level of complement Factor D in the patient's blood, serum, or tissues.
Detailed Description of the Active Compounds
N-Oxides
In certain embodiments, any of the active compounds can be provided in its N-oxide form to a patient in need thereof. In one embodiment, an N-oxide of an active compound or a precursor of the active compound is used in a manufacturing scheme. In yet another embodiment, the N-oxide is a metabolite of administration of one of the active compounds herein, and may have independent activity. The N-oxide can be formed by treating the compound of interest with an oxidizing agent, for example a suitable peroxyacid or peroxide, to generate an N-oxide compound. For example, a heteroaryl group, for example a pyridyl group, can be treated with an oxidizing agent such as sodium percarbonate in the presence of a rhenium-based catalyst under mild reaction conditions to generate an N-oxide compound. A person skilled in the art will understand that appropriate protecting groups may be necessary to carry out the chemistry. See, Jain, S. L. et al., “Rhenium-Catalyzed Highly Efficient Oxidations of Tertiary Nitrogen Compounds to N-Oxides Using Sodium Percarbonate as Oxygen Source, Synlett, 2261-2663, 2006.
In one embodiment the N-oxide is in the A-Ring. In one embodiment the N-oxide is in the B-Ring. In one embodiment the N-oxide is on the R32 group.
In other embodiments, any of the active compounds with a sulfur can be provided in its sulfoxide or sulfone form to a patient in need thereof. In a different embodiment, a sulfoxide or sulfone of one of the active compounds or a precursor of the active compound is used in a manufacturing scheme. A sulfur atom in a selected compound as described herein can be oxidized to form a sulfoxide
Figure US11708351-20230725-C00038
or a sulfon
Figure US11708351-20230725-C00039
using known methods. For example, the compound 1,3,5-triazo-2,4,6-triphosphorine-2,2,4,4,6,6-tetrachloride (TAPC) is an efficient promoter for the oxidation of sulfides to sulfoxides. See, Bahrami, M. et al., “TAPC-Promoted Oxidation of sulfides and Deoxygenation of Sulfoxides”, J. Org. Chem., 75, 6208-6213 (2010). Oxidation of sulfides with 30% hydrogen peroxide catalyzed by tantalum carbide provides sulfoxides in high yields, see, Kirihara, A., et al., “Tantalum Carbide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones”, Synlett, 1557-1561 (2010). Sulfides can be oxidized to sulfones using, for example, niobium carbide as the catalyst, see, Kirihara, A., et al., “Tantalum Cardide or Niobium Carbide Catalyzed Oxidation of Sulfides with Hydrogen Peroxide: Highly Efficient and Chemoselective Syntheses of Sulfoxides and Sulfones”, Synlett, 1557-1561 (2010). Urea-hydrogen peroxide adduct is a stable inexpensive and easily handled reagent for the oxidation of sulfides to sulfones, see Varma, R. S. and Naicker, K. P., “The Urea-Hydrogen Peroxide Complex: Solid-State Oxidative Protocols for Hydroxylated Aldehydes and Ketones (Dakin Reaction), Nitriles, Sulfides, and Nitrogen Heterocycles”, Org. Lett., 1, 189-191 (1999). One skilled in the art will appreciate that other heteroatoms, such as nitrogen, may need to be protected and then deprotected while carrying out the oxidation of a sulfur atom to produce the desired compound.
Embodiments of “Alkyl”
In one embodiment “alkyl” is a C1-C10alkyl, C1-C9alkyl, C1-C8alkyl, C1-C7alkyl, C1-C6alkyl, C1-C5alkyl, C1-C4alkyl, C1-C3alkyl, or C1-C2alkyl.
In one embodiment “alkyl” has one carbon.
In one embodiment “alkyl” has two carbons.
In one embodiment “alkyl” has three carbons.
In one embodiment “alkyl” has four carbons.
In one embodiment “alkyl” has five carbons.
In one embodiment “alkyl” has six carbons.
Non-limiting examples of “alkyl” include: methyl, ethyl, propyl, butyl, pentyl, and hexyl.
Additional non-limiting examples of “alkyl” include: isopropyl, isobutyl, isopentyl, and isohexyl.
Additional non-limiting examples of “alkyl” include: sec-butyl, sec-pentyl, and sec-hexyl.
Additional non-limiting examples of “alkyl” include: tert-butyl, tert-pentyl, and tert-hexyl.
Additional non-limiting examples of “alkyl” include: neopentyl, 3-pentyl, and active pentyl.
In one embodiment “alkyl” is “substituted alkyl”
In one embodiment “alkenyl” is “substituted alkenyl”
In one embodiment “alkynyl” is “substituted alkynyl”
Embodiments of “Haloalkyl”
In one embodiment “haloalkyl” is a C1-C10haloalkyl, C1-C9haloalkyl, C1-C8haloalkyl, C1-C7haloalkyl, C1-C6haloalkyl, C1-C5haloalkyl, C1-C4haloalkyl, C1-C3haloalkyl, and C1-C2haloalkyl.
In one embodiment “haloalkyl” has one carbon.
In one embodiment “haloalkyl” has one carbon and one halogen.
In one embodiment “haloalkyl” has one carbon and two halogens.
In one embodiment “haloalkyl” has one carbon and three halogens.
In one embodiment “haloalkyl” has two carbons.
In one embodiment “haloalkyl” has three carbons.
In one embodiment “haloalkyl” has four carbons.
In one embodiment “haloalkyl” has five carbons.
In one embodiment “haloalkyl” has six carbons.
Non-limiting examples of “haloalkyl” include:
Figure US11708351-20230725-C00040
Additional non-limiting examples of “haloalkyl” include:
Figure US11708351-20230725-C00041
Additional non-limiting examples of “haloalkyl” include:
Figure US11708351-20230725-C00042
Additional non-limiting examples of “haloalkyl” include:
Figure US11708351-20230725-C00043
Embodiments of “Aryl”
In one embodiment “aryl” is a 6 carbon aromatic group (phenyl)
In one embodiment “aryl” is a 10 carbon aromatic group (napthyl)
In one embodiment “aryl” is “substituted aryl”.
Embodiments of “Heteroaryl”
In one embodiment “heteroaryl” is a 5 membered aromatic group containing 1, 2, or 3, nitrogen atoms.
Non-limiting examples of 5 membered “heteroaryl” groups include pyrrole, furan, thiophene, pyrazole, imidazole, triazole, isoxazole, oxazole, oxadiazole, oxatriazole, isothiazole, thiazole, thiadiazole, and thiatriazole.
Additional non-limiting examples of 5 membered “heteroaryl” groups include:
Figure US11708351-20230725-C00044
Figure US11708351-20230725-C00045
In one embodiment “heteroaryl” is a 6 membered aromatic group containing 1, 2, or 3 nitrogen atoms (i.e. pyridinyl, pyridazinyl, triazinyl, pyrimidinyl, and pyrazinyl).
Non-limiting examples of 6 membered “heteroaryl” groups with 1 or 2 nitrogen atoms include:
Figure US11708351-20230725-C00046
In one embodiment “heteroaryl” is a 9 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
Non-limiting examples of“heteroaryl” groups that are bicyclic include indole, benzofuran, isoindole, indazole, benzimidazole, azaindole, azaindazole, purine, isobenzofuran, benzothiophene, benzoisoxazole, benzoisothiazole, benzooxazole, and benzothiazole.
Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:
Figure US11708351-20230725-C00047
Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:
Figure US11708351-20230725-C00048
Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:
Figure US11708351-20230725-C00049
In one embodiment “heteroaryl” is a 10 membered bicyclic aromatic group containing 1 or 2 atoms selected from nitrogen, oxygen, and sulfur.
Non-limiting examples of “heteroaryl” groups that are bicyclic include quinoline, isoquinoline, quinoxaline, phthalazine, quinazoline, cinnoline, and naphthyridine.
Additional non-limiting examples of “heteroaryl” groups that are bicyclic include:
Figure US11708351-20230725-C00050
In one embodiment “heteroaryl” is “substituted heteroaryl.”
In an alternative embodiment heteroaryl is tetrazole.
Embodiments of “Cycloalkyl”
In one embodiment “cycloalkyl” is a C3-C8cycloalkyl, C3-C7cycloalkyl, C3-C6cycloalkyl, C3-C5cycloalkyl, C3-C4cycloalkyl, C4-C8cycloalkyl, C5-C8cycloalkyl, or C6-C8cycloalkyl.
In one embodiment “cycloalkyl” has three carbons.
In one embodiment “cycloalkyl” has four carbons.
In one embodiment “cycloalkyl” has five carbons.
In one embodiment “cycloalkyl” has six carbons.
In one embodiment “cycloalkyl” has seven carbons.
In one embodiment “cycloalkyl” has eight carbons.
In one embodiment “cycloalkyl” has nine carbons.
In one embodiment “cycloalkyl” has ten carbons.
Non-limiting examples of “cycloalkyl” include: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, and cyclodecyl.
In one embodiment “cycloalkyl” is a “substituted cycloalkyl”
Embodiments of “Heterocycle”
In one embodiment “heterocycle” refers to a cyclic ring with one nitrogen and 3, 4, 5, 6, 7, or 8 carbon atoms.
In one embodiment “heterocycle” refers to a cyclic ring with one nitrogen and one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
In one embodiment “heterocycle” refers to a cyclic ring with two nitrogens and 3, 4, 5, 6, 7, or 8 carbon atoms.
In one embodiment “heterocycle” refers to a cyclic ring with one oxygen and 3, 4, 5, 6, 7, or 8 carbon atoms.
In one embodiment “heterocycle” refers to a cyclic ring with one sulfur and 3, 4, 5, 6, 7, or 8 carbon atoms.
Non-limiting examples of “heterocycle” include aziridine, oxirane, thiirane, azetidine, 1,3-diazetidine, oxetane, and thietane.
Additional non-limiting examples of “heterocycle” include pyrrolidine, 3-pyrroline, 2-pyrroline, pyrazolidine, and imidazolidine.
Additional non-limiting examples of “heterocycle” include tetrahydrofuran, 1,3-dioxolane, tetrahydrothiophene, 1,2-oxathiolane, and 1,3-oxathiolane.
Additional non-limiting examples of “heterocycle” include piperidine, piperazine, tetrahydropyran, 1,4-dioxane, thiane, 1,3-dithiane, 1,4-dithiane, morpholine, and thiomorpholine.
Non-limiting examples of “heterocycle” also include:
Figure US11708351-20230725-C00051
Additional non-limiting examples of “heterocycle” include:
Figure US11708351-20230725-C00052
Additional non-limiting examples of “heterocycle” include:
Figure US11708351-20230725-C00053
Non-limiting examples of “heterocycle” also include:
Figure US11708351-20230725-C00054
Non-limiting examples of “heterocycle” also include:
Figure US11708351-20230725-C00055
Additional non-limiting examples of “heterocycle” include:
Figure US11708351-20230725-C00056
Additional non-limiting examples of “heterocycle” include:
Figure US11708351-20230725-C00057
In one embodiment “heterocycle” is “substituted heterocycle”.
Embodiments of R201
In one embodiment R201 is selected from —(CH2)m—O-heterocycle, —(CH2)m—NH-heterocycle, or —(CH2)m—NR9-heterocycle;
In one embodiment R201 is selected from —(CH2)m—NR9R10, —(CH2)m—OR9, or —(CH2)m-heterocycle;
In one embodiment R201 is selected from —CH2—O-heterocycle, —CH2—NH-heterocycle, or —CH2—NR9-heterocycle;
In one embodiment R201 is selected from —CH2—NR9R10, —CH2—OR9, or —CH2-heterocycle;
In one embodiment R201 is selected from —(CH2)m—NH2, —(CH2)m—OH, or —(CH2)m—OC1-C6alkyl;
In one embodiment m is 1, 2, or 3.
In one embodiment m is 1.
In one embodiment m is 2.
In one embodiment m is 3.
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00058
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00059
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00060
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00061
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00062
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00063
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00064
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00065
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00066
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00067
In one embodiment R201 is selected from:
Figure US11708351-20230725-C00068
Figure US11708351-20230725-C00069
Figure US11708351-20230725-C00070
Embodiments of C
In one embodiment C5 is
Figure US11708351-20230725-C00071
In one embodiment C5 is
Figure US11708351-20230725-C00072
In one embodiment C5 is
Figure US11708351-20230725-C00073
In one embodiment C5 is
Figure US11708351-20230725-C00074
In one embodiment C1 is selected from:
Figure US11708351-20230725-C00075
Figure US11708351-20230725-C00076
Figure US11708351-20230725-C00077
In one embodiment C1 is selected from:
Figure US11708351-20230725-C00078
Figure US11708351-20230725-C00079
Figure US11708351-20230725-C00080
Figure US11708351-20230725-C00081
In one embodiment, a methyl group in a structure illustrated above can be replaced with a different alkyl group, as defined herein. In another embodiment, the fluoro atoms in the structures illustrated above can be replaced with any other halogen. Any of the structures illustrated above or otherwise can be optionally substituted with 0, 1, 2, 3, or 4, as appropriate, and independently, with an R48 substituent.
Examples of central core small mimetics of a beta-turn, beta turn inducers, reverse turn mimetics and foldamer monomers include:
Figure US11708351-20230725-C00082
Figure US11708351-20230725-C00083
In one embodiment C is selected from:
Figure US11708351-20230725-C00084
Figure US11708351-20230725-C00085
Figure US11708351-20230725-C00086
Figure US11708351-20230725-C00087
Figure US11708351-20230725-C00088
Figure US11708351-20230725-C00089
wherein:
R101 is C1-C4 alkyl or C3-C7 cycloalkyl; and
R102 is C1-C4alkyl, fluorine, chlorine, or bromine.
In one embodiment C4 is selected from:
Figure US11708351-20230725-C00090
In one embodiment C4 is selected from:
Figure US11708351-20230725-C00091
Figure US11708351-20230725-C00092
In one embodiment C4 is selected from:
Figure US11708351-20230725-C00093
Figure US11708351-20230725-C00094
In one embodiment C4 is selected from:
Figure US11708351-20230725-C00095
Figure US11708351-20230725-C00096
In one embodiment C is selected from:
Figure US11708351-20230725-C00097
Figure US11708351-20230725-C00098
Figure US11708351-20230725-C00099
Figure US11708351-20230725-C00100
Figure US11708351-20230725-C00101
In one embodiment R1 is selected from F, Cl, Br, and C1-C6alkyl.
In one embodiment R1 is selected from hydroxyl and C1-C6alkoxy.
In one embodiment R1 is selected from C2-C6alkynyl, C2-C6alkanoyl, and C1-C6thioalkyl.
In one embodiment R1 is selected from aminoC1-C6alkyl and —C0-C4alkylNR9R10.
In an alternative embodiment, C is selected from
Figure US11708351-20230725-C00102
Embodiments of A
Non-limiting examples of A1 include:
Figure US11708351-20230725-C00103
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00104
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00105
Figure US11708351-20230725-C00106
Figure US11708351-20230725-C00107
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00108
Figure US11708351-20230725-C00109
Figure US11708351-20230725-C00110
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00111
Figure US11708351-20230725-C00112
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00113
Figure US11708351-20230725-C00114
Figure US11708351-20230725-C00115
Figure US11708351-20230725-C00116
Figure US11708351-20230725-C00117
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00118
Figure US11708351-20230725-C00119
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00120
Figure US11708351-20230725-C00121
Figure US11708351-20230725-C00122
In one embodiment A3 is selected from:
Figure US11708351-20230725-C00123
Figure US11708351-20230725-C00124
Figure US11708351-20230725-C00125
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00126
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00127
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00128
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00129
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00130
In one embodiment A1 is selected from:
Figure US11708351-20230725-C00131
In the above embodiments and throughout this specification R101 is C1-C4 alkyl or C3-C7 cycloalkyl.
In another embodiment A1 is selected from:
Figure US11708351-20230725-C00132
Figure US11708351-20230725-C00133
Figure US11708351-20230725-C00134
Figure US11708351-20230725-C00135
Figure US11708351-20230725-C00136
Figure US11708351-20230725-C00137
Figure US11708351-20230725-C00138
Figure US11708351-20230725-C00139
Figure US11708351-20230725-C00140
Figure US11708351-20230725-C00141
Figure US11708351-20230725-C00142
Figure US11708351-20230725-C00143
Figure US11708351-20230725-C00144
Figure US11708351-20230725-C00145
Figure US11708351-20230725-C00146
Figure US11708351-20230725-C00147
In another embodiment A is selected from:
Figure US11708351-20230725-C00148
Figure US11708351-20230725-C00149
In one embodiment A4 is selected from:
Figure US11708351-20230725-C00150
In one embodiment A4 is
Figure US11708351-20230725-C00151
In one embodiment A4 is selected from:
Figure US11708351-20230725-C00152
In one embodiment A4 is selected from:
Figure US11708351-20230725-C00153
Figure US11708351-20230725-C00154
In one embodiment A4 is selected from:
Figure US11708351-20230725-C00155
In one embodiment A4 is
Figure US11708351-20230725-C00156
Embodiments of L
In one embodiment L1 is selected from:
Figure US11708351-20230725-C00157
Figure US11708351-20230725-C00158
Figure US11708351-20230725-C00159
In one embodiment L1 is selected from:
Figure US11708351-20230725-C00160
Figure US11708351-20230725-C00161
Figure US11708351-20230725-C00162
In one embodiment L1 is selected from:
Figure US11708351-20230725-C00163
Figure US11708351-20230725-C00164
In one embodiment L1 is selected from:
Figure US11708351-20230725-C00165
Figure US11708351-20230725-C00166
In one embodiment, L1 is selected from:
Figure US11708351-20230725-C00167
Figure US11708351-20230725-C00168
Figure US11708351-20230725-C00169
Figure US11708351-20230725-C00170
In one embodiment, the methyl groups in the structures illustrated above can be replaced with another alkyl group, as defined herein.
In one embodiment L2 is selected from:
Figure US11708351-20230725-C00171
Figure US11708351-20230725-C00172
Non-limiting examples of L2 include:
Figure US11708351-20230725-C00173
Figure US11708351-20230725-C00174
Figure US11708351-20230725-C00175
Non-limiting examples of L2 include:
Figure US11708351-20230725-C00176
Figure US11708351-20230725-C00177
Figure US11708351-20230725-C00178
Non-limiting examples of L2 include:
Figure US11708351-20230725-C00179
Figure US11708351-20230725-C00180
Figure US11708351-20230725-C00181
Non-limiting examples of L2 include:
Figure US11708351-20230725-C00182
Non-limiting examples of L2 include:
Figure US11708351-20230725-C00183
In one embodiment, the methyl groups in the structures illustrated above can be replaced with another alkyl or acyl, as defined herein. In another embodiment, the carbocyclic, heterocyclic, aryl or heteroaryl rings can be optionally substituted. As indicated above, any of the structures illustrated above or below can be optionally substituted with 0, 1, 2, 3, or 4, as appropriate, and independently, of an R48 substituent.
In certain embodiment, L2 is a bond. In certain embodiments, if L2 is heterocyclic or heteroaryl, then B can be hydrogen.
Embodiments of B
In one additional alternative embodiment B is selected from:
Figure US11708351-20230725-C00184
In another embodiment, B1 is selected from:
Figure US11708351-20230725-C00185
In one additional alternative embodiment R36 is selected from:
Figure US11708351-20230725-C00186
In one embodiment, B is selected from:
Figure US11708351-20230725-C00187
Figure US11708351-20230725-C00188
Figure US11708351-20230725-C00189
wherein R27 is hydrogen, methyl, or trifluoromethyl; R28 is hydrogen or halogen; and R29 is hydrogen, methyl, trifluoromethyl, or —Si(CH3)2C(CH3)3.
In one embodiment, B is selected from:
Figure US11708351-20230725-C00190
Figure US11708351-20230725-C00191
Examples of B moieties include, but are not limited to
Figure US11708351-20230725-C00192
Figure US11708351-20230725-C00193
In one embodiment, B4 is
Figure US11708351-20230725-C00194
In one embodiment, B4 is
Figure US11708351-20230725-C00195
In one embodiment, B4 is
Figure US11708351-20230725-C00196
In one embodiment, B4 is
Figure US11708351-20230725-C00197
In one embodiment, B4 is
Figure US11708351-20230725-C00198
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00199
Figure US11708351-20230725-C00200
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00201
Figure US11708351-20230725-C00202
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00203
Figure US11708351-20230725-C00204
Figure US11708351-20230725-C00205
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00206
Figure US11708351-20230725-C00207
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00208
Figure US11708351-20230725-C00209
Figure US11708351-20230725-C00210
Figure US11708351-20230725-C00211
Figure US11708351-20230725-C00212
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00213
Figure US11708351-20230725-C00214
Figure US11708351-20230725-C00215
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00216
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00217
Figure US11708351-20230725-C00218
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00219
Figure US11708351-20230725-C00220
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00221
Figure US11708351-20230725-C00222
In one embodiment B4 is selected from:
Figure US11708351-20230725-C00223
Figure US11708351-20230725-C00224
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00225
Figure US11708351-20230725-C00226
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00227
Figure US11708351-20230725-C00228
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00229
Figure US11708351-20230725-C00230
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00231
Figure US11708351-20230725-C00232
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00233
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00234
Figure US11708351-20230725-C00235
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00236
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00237
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00238
Figure US11708351-20230725-C00239
Figure US11708351-20230725-C00240
Figure US11708351-20230725-C00241
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00242
Figure US11708351-20230725-C00243
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00244
Figure US11708351-20230725-C00245
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00246
Figure US11708351-20230725-C00247
Figure US11708351-20230725-C00248
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00249
Figure US11708351-20230725-C00250
Figure US11708351-20230725-C00251
Figure US11708351-20230725-C00252
Figure US11708351-20230725-C00253
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00254
Figure US11708351-20230725-C00255
Figure US11708351-20230725-C00256
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00257
Figure US11708351-20230725-C00258
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00259
Figure US11708351-20230725-C00260
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00261
Figure US11708351-20230725-C00262
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00263
Figure US11708351-20230725-C00264
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00265
Figure US11708351-20230725-C00266
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00267
Figure US11708351-20230725-C00268
Figure US11708351-20230725-C00269
Figure US11708351-20230725-C00270
Figure US11708351-20230725-C00271
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00272
Figure US11708351-20230725-C00273
Figure US11708351-20230725-C00274
Figure US11708351-20230725-C00275
Figure US11708351-20230725-C00276
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00277
Figure US11708351-20230725-C00278
Figure US11708351-20230725-C00279
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00280
Figure US11708351-20230725-C00281
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00282
Figure US11708351-20230725-C00283
In one embodiment, B4 is selected from:
Figure US11708351-20230725-C00284
Figure US11708351-20230725-C00285
Figure US11708351-20230725-C00286
Figure US11708351-20230725-C00287
In one embodiment R25, R26, R27, and R28 are independently selected from hydrogen, halogen, and C1-C6alkyl.
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00288
Figure US11708351-20230725-C00289
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00290
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00291
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00292
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00293
In another embodiment, B4 is selected from:
Figure US11708351-20230725-C00294
In an alternative embodiment, B4 is selected from:
Figure US11708351-20230725-C00295
In an alternative embodiment, B4 is selected from:
Figure US11708351-20230725-C00296
In an alternative embodiment, B4 is -alkyl-Si(alkyl)3 or -alkyl-SF5.
In an alternative embodiment, B4 is a B ring substituted with oxo. In this embodiment if the B ring is a nitrogen containing heteroaryl group then the nitrogen may also be substituted as defined herein. For example:
Figure US11708351-20230725-C00297
substituted with an oxo can be selected from the following compounds:
Figure US11708351-20230725-C00298
And examples of
Figure US11708351-20230725-C00299
include:
Figure US11708351-20230725-C00300
In another alternative embodiment, B4 is selected from:
Figure US11708351-20230725-C00301
In another alternative embodiment, R32 is a heteroaryl ring substituted with oxo as allowed by valence. In this embodiment if the R32 ring is a nitrogen containing heteroaryl group then the nitrogen may also be substituted as defined herein. For example:
Figure US11708351-20230725-C00302
substituted with an oxo can be selected from the following compounds:
Figure US11708351-20230725-C00303
And examples of
Figure US11708351-20230725-C00304
include:
Figure US11708351-20230725-C00305
In another alternative embodiment, R32 is selected from:
Figure US11708351-20230725-C00306
In another alternative embodiment, B4 is an alkyl group.
In another alternative embodiment, B4 is an alkenyl group.
In another embodiment, C4 is selected from:
Figure US11708351-20230725-C00307
In one embodiment L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula I is:
Figure US11708351-20230725-C00308
In one embodiment L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula II is:
Figure US11708351-20230725-C00309
In one embodiment L2 is a spirocyclic linker attached to the C ring so that the resultant compound of Formula III is:
Figure US11708351-20230725-C00310
In one embodiment a compound of Formula
Figure US11708351-20230725-C00311
is provided.
In one embodiment R32 is selected from:
Figure US11708351-20230725-C00312
In one embodiment R32 is selected from:
Figure US11708351-20230725-C00313
In an alternative embodiment R32 is selected from:
Figure US11708351-20230725-C00314
In an alternative embodiment R11, R12, R13, R14, or R15 is -alkyl-R32 or —O-alkyl-R32.
In an alternative embodiment R11, R12, R13, R14, or R15 is
Figure US11708351-20230725-C00315
In one embodiment R11, R12, R13, R14, or R15 is
Figure US11708351-20230725-C00316
In one embodiment X31 is selected from N and CR54;
In another embodiment X31 is C(R54)2;
In one embodiment X25 is O or S;
In one embodiment R4′ is selected from -JCHO, -JCONH2, -JCONR9R10, JC2-C6alkanoyl, -JSO2NH2, -JSO2NR21R22, -JC(CH2)2F, -JCH(CF3)NH2, -J-haloalkyl-NH2, -J-haloalkyl-NR9R10, alkyl including C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), -JC(O)C0-C2alkyl(C3-C7cycloalkyl), -JNR9(C2-C6alkanoyl), -JNR9C(O)NR9R10,
Figure US11708351-20230725-C00317
each of which R4′ other than —CHO, is optionally substituted with one or more of amino, imino, halogen, hydroxyl, cyano, cyanoimino, alkyl including C1-C6alkyl, alkoxy including C1-C6alkoxy, —C0-C2alkyl(mono- and di-C1-C6alkylamino), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
Additional Embodiments of R32
In one embodiment R32 is
Figure US11708351-20230725-C00318
Embodiments of B
In one embodiment B is selected from:
Figure US11708351-20230725-C00319
Figure US11708351-20230725-C00320
Embodiments of R301
Examples of R301 are provided below. In the compounds of the present invention, R301 is monovalently attached to the molecule. The divalent species below are presented to illustrate that the R301 can be linked at either point and the other is capped for example with H, alkyl, halogen, haloalkyl, aryl, heteroaryl, and heterocycle, each of which may be optionally substituted as described herein. In one embodiment R301 is selected from:
Figure US11708351-20230725-C00321
Figure US11708351-20230725-C00322
Figure US11708351-20230725-C00323
Figure US11708351-20230725-C00324
wherein if the moiety is shown as a divalent species, it can also be capped with hydrogen, methyl, alkyl, haloalkyl, aryl, heteroaryl, heterocyclic, other capping moiety of another bioactive moiety, or an additional prodrug moiety.
In one embodiment R301 is selected from:
Figure US11708351-20230725-C00325
Figure US11708351-20230725-C00326
In one embodiment R301 is
Figure US11708351-20230725-C00327
wherein R302, R303, R304, R305, R306, R307, and R308 are selected from: bond, polyethylene glycol, a natural amino acid, an unnatural amino acid,
Figure US11708351-20230725-C00328
Figure US11708351-20230725-C00329
Figure US11708351-20230725-C00330
R309 is selected from: alkyl, hydrogen,
Figure US11708351-20230725-C00331
n2 is independently selected at each instance from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20; and
X300 is selected from bond, —NH—, —N(alkyl)-, O, —CH2—O—, —CH2—NH—, and —CH2—N(alkyl).
In one embodiment only 1, 2, 3, 4, or 5 of R302, R303, R30, R305, R306, R307, and R308 are selected to be bond.
In one embodiment none of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
In one embodiment only 1 of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
In one embodiment only 2 of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
In one embodiment only 3 of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
In one embodiment only 4 of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
In one embodiment only 5 of R302, R303, R304, R305, R306, R307, and R308 are selected to be bond.
Non-limiting examples of compounds of the present invention with a R301 group include:
Figure US11708351-20230725-C00332
Figure US11708351-20230725-C00333
Figure US11708351-20230725-C00334
Figure US11708351-20230725-C00335
Figure US11708351-20230725-C00336
Figure US11708351-20230725-C00337
Figure US11708351-20230725-C00338
Figure US11708351-20230725-C00339
Figure US11708351-20230725-C00340
Figure US11708351-20230725-C00341
Figure US11708351-20230725-C00342
Figure US11708351-20230725-C00343
Figure US11708351-20230725-C00344
Figure US11708351-20230725-C00345
Figure US11708351-20230725-C00346
Figure US11708351-20230725-C00347
Figure US11708351-20230725-C00348
Figure US11708351-20230725-C00349
Figure US11708351-20230725-C00350
Figure US11708351-20230725-C00351
Figure US11708351-20230725-C00352
Figure US11708351-20230725-C00353
Figure US11708351-20230725-C00354
Figure US11708351-20230725-C00355
Figure US11708351-20230725-C00356
Figure US11708351-20230725-C00357
Figure US11708351-20230725-C00358
Figure US11708351-20230725-C00359
Figure US11708351-20230725-C00360
Figure US11708351-20230725-C00361
Figure US11708351-20230725-C00362
Figure US11708351-20230725-C00363
Figure US11708351-20230725-C00364
Figure US11708351-20230725-C00365
Figure US11708351-20230725-C00366
Figure US11708351-20230725-C00367
Figure US11708351-20230725-C00368
Figure US11708351-20230725-C00369
Figure US11708351-20230725-C00370
Figure US11708351-20230725-C00371
Figure US11708351-20230725-C00372
Figure US11708351-20230725-C00373
Figure US11708351-20230725-C00374
Figure US11708351-20230725-C00375
Figure US11708351-20230725-C00376
Figure US11708351-20230725-C00377
Figure US11708351-20230725-C00378
Figure US11708351-20230725-C00379
Non-limiting examples of compounds of the present invention with a R301 group include:
Figure US11708351-20230725-C00380
Non-limiting examples of compounds of the present invention with a R301 group include:
Figure US11708351-20230725-C00381
Non-limiting examples of compounds of the present invention with a R301 group include:
Figure US11708351-20230725-C00382
Figure US11708351-20230725-C00383
Figure US11708351-20230725-C00384
Non-limiting examples of compounds of the present invention with a R301 group include:
Figure US11708351-20230725-C00385
Figure US11708351-20230725-C00386
Figure US11708351-20230725-C00387
Figure US11708351-20230725-C00388
In one embodiment C is selected from:
Figure US11708351-20230725-C00389
Figure US11708351-20230725-C00390
In one embodiment A is selected from:
Figure US11708351-20230725-C00391
In one embodiment B is selected from:
Figure US11708351-20230725-C00392
In one embodiment R32 is:
Figure US11708351-20230725-C00393
Additional Formulas
In one aspect, the disclosure includes compounds and salts of Formulas in Table 1 for any use and in any composition described in this application.
In some of the below Formulas for convenience and space purposes only, R32 is illustrated as
Figure US11708351-20230725-C00394
however each described or illustrated R32 in this application is considered to be independently shown in each of these Formulas.
TABLE 1
Additional Exemplary Formulas within the Present Invention.
Figure US11708351-20230725-C00395
 		Formula I-1
Figure US11708351-20230725-C00396
 		Formula I-2
Figure US11708351-20230725-C00397
 		Formula I-3
Figure US11708351-20230725-C00398
 		Formula I-4
Figure US11708351-20230725-C00399
 		Formula I-5
Figure US11708351-20230725-C00400
 		Formula I-6
Figure US11708351-20230725-C00401
 		Formula I-7
Figure US11708351-20230725-C00402
 		Formula I-8
Figure US11708351-20230725-C00403
 		Formula I-9
Figure US11708351-20230725-C00404
 		Formula I-10
Figure US11708351-20230725-C00405
 		Formula I-11
Figure US11708351-20230725-C00406
 		Formula I-12
Figure US11708351-20230725-C00407
 		Formula I-13
Figure US11708351-20230725-C00408
 		Formula I-14
Figure US11708351-20230725-C00409
 		Formula I-15
Figure US11708351-20230725-C00410
 		Formula I-16
Figure US11708351-20230725-C00411
 		Formula I-17
Figure US11708351-20230725-C00412
 		Formula I-18
Figure US11708351-20230725-C00413
 		Formula I-19
Figure US11708351-20230725-C00414
 		Formula I-20
Figure US11708351-20230725-C00415
 		Formula I-21
Figure US11708351-20230725-C00416
 		Formula I-22
Figure US11708351-20230725-C00417
 		Formula I-23
Figure US11708351-20230725-C00418
 		Formula I-24
Figure US11708351-20230725-C00419
 		Formula I-25
Figure US11708351-20230725-C00420
 		Formula I-26
Figure US11708351-20230725-C00421
 		Formula I-27
Figure US11708351-20230725-C00422
 		Formula I-28
Figure US11708351-20230725-C00423
 		Formula I-29
Figure US11708351-20230725-C00424
 		Formula I-30
Figure US11708351-20230725-C00425
 		Formula I-31
Figure US11708351-20230725-C00426
 		Formula I-32
Figure US11708351-20230725-C00427
 		Formula I-33
Figure US11708351-20230725-C00428
 		Formula I-34
Figure US11708351-20230725-C00429
 		Formula I-35
Figure US11708351-20230725-C00430
 		Formula I-36
Figure US11708351-20230725-C00431
 		Formula I-37
Figure US11708351-20230725-C00432
 		Formula I-38
Figure US11708351-20230725-C00433
 		Formula I-39
Figure US11708351-20230725-C00434
 		Formula I-40
Figure US11708351-20230725-C00435
 		Formula I-41
Figure US11708351-20230725-C00436
 		Formula I-42
Figure US11708351-20230725-C00437
 		Formula I-43
Figure US11708351-20230725-C00438
 		Formula I-44
Figure US11708351-20230725-C00439
 		Formula I-45
Figure US11708351-20230725-C00440
 		Formula I-46
Figure US11708351-20230725-C00441
 		Formula I-47
Figure US11708351-20230725-C00442
 		Formula I-48
Figure US11708351-20230725-C00443
 		Formula I-49
Figure US11708351-20230725-C00444
 		Formula I-50
Figure US11708351-20230725-C00445
 		Formula I-51
Figure US11708351-20230725-C00446
 		Formula I-52
Figure US11708351-20230725-C00447
 		Formula I-53
Figure US11708351-20230725-C00448
 		Formula I-54
Figure US11708351-20230725-C00449
 		Formula I-55
Figure US11708351-20230725-C00450
 		Formula I-56
Figure US11708351-20230725-C00451
 		Formula I-57
Figure US11708351-20230725-C00452
 		Formula I-58
Figure US11708351-20230725-C00453
 		Formula I-59
Figure US11708351-20230725-C00454
 		Formula I-60
Figure US11708351-20230725-C00455
 		Formula I-61
Figure US11708351-20230725-C00456
 		Formula I-62
Figure US11708351-20230725-C00457
 		Formula I-63
Figure US11708351-20230725-C00458
 		Formula I-64
Figure US11708351-20230725-C00459
 		Formula I-65
Figure US11708351-20230725-C00460
 		Formula I-66
Figure US11708351-20230725-C00461
 		Formula I-67
Figure US11708351-20230725-C00462
 		Formula I-68
Figure US11708351-20230725-C00463
 		Formula I-69
Figure US11708351-20230725-C00464
 		Formula I-70
Figure US11708351-20230725-C00465
 		Formula I-71
Figure US11708351-20230725-C00466
 		Formula I-72
Figure US11708351-20230725-C00467
 		Formula I-73
Figure US11708351-20230725-C00468
 		Formula I-74
Figure US11708351-20230725-C00469
 		Formula I-75
Figure US11708351-20230725-C00470
 		Formula I-76
Figure US11708351-20230725-C00471
 		Formula I-77
Figure US11708351-20230725-C00472
 		Formula I-78
Figure US11708351-20230725-C00473
 		Formula I-79
Figure US11708351-20230725-C00474
 		Formula I-80
Figure US11708351-20230725-C00475
 		Formula I-81
Figure US11708351-20230725-C00476
 		Formula I-82
Figure US11708351-20230725-C00477
 		Formula I-83
Figure US11708351-20230725-C00478
 		Formula I-84
Figure US11708351-20230725-C00479
 		Formula I-85
Figure US11708351-20230725-C00480
 		Formula I-86
Figure US11708351-20230725-C00481
 		Formula I-87
Figure US11708351-20230725-C00482
 		Formula I-88
Figure US11708351-20230725-C00483
 		Formula I-89
Figure US11708351-20230725-C00484
 		Formula I-90
Figure US11708351-20230725-C00485
 		Formula I-91
Figure US11708351-20230725-C00486
 		Formula I-92
Figure US11708351-20230725-C00487
 		Formula I-93
Figure US11708351-20230725-C00488
 		Formula I-94
Figure US11708351-20230725-C00489
 		Formula I-95
Figure US11708351-20230725-C00490
 		Formula I-96
Figure US11708351-20230725-C00491
 		Formula I-97
Figure US11708351-20230725-C00492
 		Formula I-98
Figure US11708351-20230725-C00493
 		Formula I-99
Figure US11708351-20230725-C00494
 		Formula I-100
Figure US11708351-20230725-C00495
 		Formula I-101
Figure US11708351-20230725-C00496
 		Formula I-102
Figure US11708351-20230725-C00497
 		Formula I-103
Figure US11708351-20230725-C00498
 		Formula I-104
Figure US11708351-20230725-C00499
 		Formula I-105
Figure US11708351-20230725-C00500
 		Formula I-106
Figure US11708351-20230725-C00501
 		Formula I-107
Figure US11708351-20230725-C00502
 		Formula I-108
Figure US11708351-20230725-C00503
 		Formula I-109
Figure US11708351-20230725-C00504
 		Formula I-110
Figure US11708351-20230725-C00505
 		Formula I-111
Figure US11708351-20230725-C00506
 		Formula I-112
Figure US11708351-20230725-C00507
 		Formula I-113
Figure US11708351-20230725-C00508
 		Formula I-114
Figure US11708351-20230725-C00509
 		Formula I-115
Figure US11708351-20230725-C00510
 		Formula I-116
Figure US11708351-20230725-C00511
 		Formula I-117
Figure US11708351-20230725-C00512
 		Formula I-118
Figure US11708351-20230725-C00513
 		Formula I-119
Figure US11708351-20230725-C00514
 		Formula I-120
Figure US11708351-20230725-C00515
 		Formula I-121
Figure US11708351-20230725-C00516
 		Formula I-122
Figure US11708351-20230725-C00517
 		Formula I-123
Figure US11708351-20230725-C00518
 		Formula I-124
Figure US11708351-20230725-C00519
 		Formula I-125
Figure US11708351-20230725-C00520
 		Formula I-126
Figure US11708351-20230725-C00521
 		Formula I-127
Figure US11708351-20230725-C00522
 		Formula I-128
Figure US11708351-20230725-C00523
 		Formula I-129
Figure US11708351-20230725-C00524
 		Formula I-130
Figure US11708351-20230725-C00525
 		Formula I-131
Figure US11708351-20230725-C00526
 		Formula I-132
Figure US11708351-20230725-C00527
 		Formula I-133
Figure US11708351-20230725-C00528
 		Formula I-134
Figure US11708351-20230725-C00529
 		Formula I-135
Figure US11708351-20230725-C00530
 		Formula I-136
Figure US11708351-20230725-C00531
 		Formula I-137
Figure US11708351-20230725-C00532
 		Formula I-138
Figure US11708351-20230725-C00533
 		Formula I-139
Figure US11708351-20230725-C00534
 		Formula I-140
Figure US11708351-20230725-C00535
 		Formula I-141
Figure US11708351-20230725-C00536
 		Formula I-142
Figure US11708351-20230725-C00537
 		Formula I-143
Figure US11708351-20230725-C00538
 		Formula I-144
Figure US11708351-20230725-C00539
 		Formula I-145
Figure US11708351-20230725-C00540
 		Formula I-146
Figure US11708351-20230725-C00541
 		Formula I-147
Figure US11708351-20230725-C00542
 		Formula I-148
Figure US11708351-20230725-C00543
 		Formula I-149
Figure US11708351-20230725-C00544
 		Formula I-150
Figure US11708351-20230725-C00545
 		Formula I-151
Figure US11708351-20230725-C00546
 		Formula I-152
Figure US11708351-20230725-C00547
 		Formula I-153
Figure US11708351-20230725-C00548
 		Formula I-154
Figure US11708351-20230725-C00549
 		Formula I-155
Figure US11708351-20230725-C00550
 		Formula I-156
Figure US11708351-20230725-C00551
 		Formula I-157
Figure US11708351-20230725-C00552
 		Formula I-158
Figure US11708351-20230725-C00553
 		Formula I-159
Figure US11708351-20230725-C00554
 		Formula I-160
Figure US11708351-20230725-C00555
 		Formula I-161
Figure US11708351-20230725-C00556
 		Formula I-162
Figure US11708351-20230725-C00557
 		Formula I-163
Figure US11708351-20230725-C00558
 		Formula I-164
Figure US11708351-20230725-C00559
 		Formula I-165
Figure US11708351-20230725-C00560
 		Formula I-166
Figure US11708351-20230725-C00561
 		Formula I-167
Figure US11708351-20230725-C00562
 		Formula I-168
Figure US11708351-20230725-C00563
 		Formula I-169
Figure US11708351-20230725-C00564
 		Formula I-170
Figure US11708351-20230725-C00565
 		Formula I-171
Figure US11708351-20230725-C00566
 		Formula I-172
Figure US11708351-20230725-C00567
 		Formula I-173
Figure US11708351-20230725-C00568
 		Formula I-174
Figure US11708351-20230725-C00569
 		Formula I-175
Figure US11708351-20230725-C00570
 		Formula I-176
Figure US11708351-20230725-C00571
 		Formula I-177
Figure US11708351-20230725-C00572
 		Formula I-178
Figure US11708351-20230725-C00573
 		Formula I-179
Figure US11708351-20230725-C00574
 		Formula I-180
Figure US11708351-20230725-C00575
 		Formula I-181
Figure US11708351-20230725-C00576
 		Formula I-182
Figure US11708351-20230725-C00577
 		Formula I-183
Figure US11708351-20230725-C00578
 		Formula I-184
Figure US11708351-20230725-C00579
 		Formula I-185
Figure US11708351-20230725-C00580
 		Formula I-186
Figure US11708351-20230725-C00581
 		Formula I-187
Figure US11708351-20230725-C00582
 		Formula I-188
Figure US11708351-20230725-C00583
 		Formula I-189
Figure US11708351-20230725-C00584
 		Formula I-190
Figure US11708351-20230725-C00585
 		Formula I-191
Figure US11708351-20230725-C00586
 		Formula I-192
Figure US11708351-20230725-C00587
 		Formula I-193
Figure US11708351-20230725-C00588
 		Formula I-194
Figure US11708351-20230725-C00589
 		Formula I-195
Figure US11708351-20230725-C00590
 		Formula I-196
Figure US11708351-20230725-C00591
 		Formula I-197
Figure US11708351-20230725-C00592
 		Formula I-198
Figure US11708351-20230725-C00593
 		Formula I-199
Figure US11708351-20230725-C00594
 		Formula I-200
Figure US11708351-20230725-C00595
 		Formula I-201
Figure US11708351-20230725-C00596
 		Formula I-202
Figure US11708351-20230725-C00597
 		Formula I-203
Figure US11708351-20230725-C00598
 		Formula I-204
Figure US11708351-20230725-C00599
 		Formula I-205
Figure US11708351-20230725-C00600
 		Formula I-206
Figure US11708351-20230725-C00601
 		Formula I-207
Figure US11708351-20230725-C00602
 		Formula I-208
Figure US11708351-20230725-C00603
 		Formula I-209
Figure US11708351-20230725-C00604
 		Formula I-210
Figure US11708351-20230725-C00605
 		Formula I-211
Figure US11708351-20230725-C00606
 		Formula I-212
Figure US11708351-20230725-C00607
 		Formula I-213
Figure US11708351-20230725-C00608
 		Formula I-214
Figure US11708351-20230725-C00609
 		Formula I-215
Figure US11708351-20230725-C00610
 		Formula I-216
Figure US11708351-20230725-C00611
 		Formula I-217
Figure US11708351-20230725-C00612
 		Formula I-218
Figure US11708351-20230725-C00613
 		Formula I-219
Figure US11708351-20230725-C00614
 		Formula I-220
Figure US11708351-20230725-C00615
 		Formula I-221
Figure US11708351-20230725-C00616
 		Formula I-222
Figure US11708351-20230725-C00617
 		Formula I-223
Figure US11708351-20230725-C00618
 		Formula I-224
Figure US11708351-20230725-C00619
 		Formula I-225
Figure US11708351-20230725-C00620
 		Formula I-226
Figure US11708351-20230725-C00621
 		Formula I-227
Figure US11708351-20230725-C00622
 		Formula I-228
Figure US11708351-20230725-C00623
 		Formula I-229
Figure US11708351-20230725-C00624
 		Formula I-230
Figure US11708351-20230725-C00625
 		Formula I-232
Figure US11708351-20230725-C00626
 		Formula I-233
Figure US11708351-20230725-C00627
 		Formula I-234
Figure US11708351-20230725-C00628
 		Formula I-235
Figure US11708351-20230725-C00629
 		Formula I-236
Figure US11708351-20230725-C00630
 		Formula I-237
Figure US11708351-20230725-C00631
 		Formula I-238
Figure US11708351-20230725-C00632
 		Formula I-239
wherein R103 is C1-C4 alkyl, C3-C6 cycloalkyl, fluorine, chlorine, or bromine.
TABLE 2
Additional Exemplary Formulas within the Present Invention.
Figure US11708351-20230725-C00633
 		Formula II-1
Figure US11708351-20230725-C00634
 		Formula II-2
Figure US11708351-20230725-C00635
 		Formula II-3
Figure US11708351-20230725-C00636
 		Formula II-4
Figure US11708351-20230725-C00637
 		Formula II-5
Figure US11708351-20230725-C00638
 		Formula II-6
Figure US11708351-20230725-C00639
 		Formula II-7
Figure US11708351-20230725-C00640
 		Formula II-8
Figure US11708351-20230725-C00641
 		Formula II-9
Figure US11708351-20230725-C00642
 		Formula II-10
Figure US11708351-20230725-C00643
 		Formula II-11
Figure US11708351-20230725-C00644
 		Formula II-12
Figure US11708351-20230725-C00645
 		Formula II-13
Figure US11708351-20230725-C00646
 		Formula II-14
Figure US11708351-20230725-C00647
 		Formula II-15
Figure US11708351-20230725-C00648
 		Formula II-16
Figure US11708351-20230725-C00649
 		Formula II-17
Figure US11708351-20230725-C00650
 		Formula II-18
Figure US11708351-20230725-C00651
 		Formula II-19
Figure US11708351-20230725-C00652
 		Formula II-20
Figure US11708351-20230725-C00653
 		Formula II-21
Figure US11708351-20230725-C00654
 		Formula II-22
Figure US11708351-20230725-C00655
 		Formula II-23
Figure US11708351-20230725-C00656
 		Formula II-24
Figure US11708351-20230725-C00657
 		Formula II-25
Figure US11708351-20230725-C00658
 		Formula II-26
Figure US11708351-20230725-C00659
 		Formula II-27
Figure US11708351-20230725-C00660
 		Formula II-28
Figure US11708351-20230725-C00661
 		Formula II-29
Figure US11708351-20230725-C00662
 		Formula II-30
Figure US11708351-20230725-C00663
 		Formula II-31
Figure US11708351-20230725-C00664
 		Formula II-32
Figure US11708351-20230725-C00665
 		Formula II-33
Figure US11708351-20230725-C00666
 		Formula II-34
Figure US11708351-20230725-C00667
 		Formula II-35
Figure US11708351-20230725-C00668
 		Formula II-36
Figure US11708351-20230725-C00669
 		Formula II-37
Figure US11708351-20230725-C00670
 		Formula II-38
Figure US11708351-20230725-C00671
 		Formula II-39
Figure US11708351-20230725-C00672
 		Formula II-40
Figure US11708351-20230725-C00673
 		Formula II-41
Figure US11708351-20230725-C00674
 		Formula II-42
Figure US11708351-20230725-C00675
 		Formula II-43
Figure US11708351-20230725-C00676
 		Formula II-44
Figure US11708351-20230725-C00677
 		Formula II-45
Figure US11708351-20230725-C00678
 		Formula II-46
Figure US11708351-20230725-C00679
 		Formula II-47
Figure US11708351-20230725-C00680
 		Formula II-48
Figure US11708351-20230725-C00681
 		Formula II-49
Figure US11708351-20230725-C00682
 		Formula II-50
Figure US11708351-20230725-C00683
 		Formula II-51
Figure US11708351-20230725-C00684
 		Formula II-52
Figure US11708351-20230725-C00685
 		Formula II-53
Figure US11708351-20230725-C00686
 		Formula II-54
Figure US11708351-20230725-C00687
 		Formula II-55
Figure US11708351-20230725-C00688
 		Formula II-56
Figure US11708351-20230725-C00689
 		Formula II-57
Figure US11708351-20230725-C00690
 		Formula II-58
Figure US11708351-20230725-C00691
 		Formula II-59
Figure US11708351-20230725-C00692
 		Formula II-60
Figure US11708351-20230725-C00693
 		Formula II-61
Figure US11708351-20230725-C00694
 		Formula II-62
Figure US11708351-20230725-C00695
 		Formula II-63
Figure US11708351-20230725-C00696
 		Formula II-64
Figure US11708351-20230725-C00697
 		Formula II-65
Figure US11708351-20230725-C00698
 		Formula II-66
Figure US11708351-20230725-C00699
 		Formula II-67
Figure US11708351-20230725-C00700
 		Formula II-68
Figure US11708351-20230725-C00701
 		Formula II-69
Figure US11708351-20230725-C00702
 		Formula II-70
Figure US11708351-20230725-C00703
 		Formula II-71
Figure US11708351-20230725-C00704
 		Formula II-72
Figure US11708351-20230725-C00705
 		Formula II-73
Figure US11708351-20230725-C00706
 		Formula II-74
Figure US11708351-20230725-C00707
 		Formula II-75
Figure US11708351-20230725-C00708
 		Formula II-76
Figure US11708351-20230725-C00709
 		Formula II-77
Figure US11708351-20230725-C00710
 		Formula II-78
Figure US11708351-20230725-C00711
 		Formula II-79
Figure US11708351-20230725-C00712
 		Formula II-80
Figure US11708351-20230725-C00713
 		Formula II-81
Figure US11708351-20230725-C00714
 		Formula II-82
Figure US11708351-20230725-C00715
 		Formula II-83
Figure US11708351-20230725-C00716
 		Formula II-84
Figure US11708351-20230725-C00717
 		Formula II-85
Figure US11708351-20230725-C00718
 		Formula II-86
Figure US11708351-20230725-C00719
 		Formula II-87
Figure US11708351-20230725-C00720
 		Formula II-88
Figure US11708351-20230725-C00721
 		Formula II-89
Figure US11708351-20230725-C00722
 		Formula II-90
Figure US11708351-20230725-C00723
 		Formula II-91
Figure US11708351-20230725-C00724
 		Formula II-92
Figure US11708351-20230725-C00725
 		Formula II-93
Figure US11708351-20230725-C00726
 		Formula II-94
Figure US11708351-20230725-C00727
 		Formula II-95
Figure US11708351-20230725-C00728
 		Formula II-96
Figure US11708351-20230725-C00729
 		Formula II-97
Figure US11708351-20230725-C00730
 		Formula II-98
Figure US11708351-20230725-C00731
 		Formula II-99
Figure US11708351-20230725-C00732
 		Formula II-100
Figure US11708351-20230725-C00733
 		Formula II-101
Figure US11708351-20230725-C00734
 		Formula II-102
Figure US11708351-20230725-C00735
 		Formula II-103
Figure US11708351-20230725-C00736
 		Formula II-104
Figure US11708351-20230725-C00737
 		Formula II-105
Figure US11708351-20230725-C00738
 		Formula II-106
Figure US11708351-20230725-C00739
 		Formula II-107
Figure US11708351-20230725-C00740
 		Formula II-108
Figure US11708351-20230725-C00741
 		Formula II-109
Figure US11708351-20230725-C00742
 		Formula II-110
Figure US11708351-20230725-C00743
 		Formula II-111
Figure US11708351-20230725-C00744
 		Formula II-112
Figure US11708351-20230725-C00745
 		Formula II-113
Figure US11708351-20230725-C00746
 		Formula II-114
Figure US11708351-20230725-C00747
 		Formula II-115
Figure US11708351-20230725-C00748
 		Formula II-116
Figure US11708351-20230725-C00749
 		Formula II-117
Figure US11708351-20230725-C00750
 		Formula II-118
Figure US11708351-20230725-C00751
 		Formula II-119
Figure US11708351-20230725-C00752
 		Formula II-120
Figure US11708351-20230725-C00753
 		Formula II-121
Figure US11708351-20230725-C00754
 		Formula II-122
Figure US11708351-20230725-C00755
 		Formula II-123
Figure US11708351-20230725-C00756
 		Formula II-124
Figure US11708351-20230725-C00757
 		Formula II-125
Figure US11708351-20230725-C00758
 		Formula II-126
Figure US11708351-20230725-C00759
 		Formula II-127
Figure US11708351-20230725-C00760
 		Formula II-128
Figure US11708351-20230725-C00761
 		Formula II-129

wherein R103 is C1-C4 alkyl, C3-C6 cycloalkyl, fluorine, chlorine, or bromine.
TABLE 3
Additional Exemplary Formulas within the Present Invention.
Figure US11708351-20230725-C00762
 		Formula III-1
Figure US11708351-20230725-C00763
 		Formula III-2
Figure US11708351-20230725-C00764
 		Formula III-3
Figure US11708351-20230725-C00765
 		Formula III-4
Figure US11708351-20230725-C00766
 		Formula III-5
Figure US11708351-20230725-C00767
 		Formula III-6
Figure US11708351-20230725-C00768
 		Formula III-7
Figure US11708351-20230725-C00769
 		Formula III-8
Figure US11708351-20230725-C00770
 		Formula III-9
Figure US11708351-20230725-C00771
 		Formula III-10
Figure US11708351-20230725-C00772
 		Formula III-11
Figure US11708351-20230725-C00773
 		Formula III-12
Figure US11708351-20230725-C00774
 		Formula III-13
Figure US11708351-20230725-C00775
 		Formula III-14
Figure US11708351-20230725-C00776
 		Formula III-15
Figure US11708351-20230725-C00777
 		Formula III-16
Figure US11708351-20230725-C00778
 		Formula III-17
Figure US11708351-20230725-C00779
 		Formula III-18
Figure US11708351-20230725-C00780
 		Formula III-19
Figure US11708351-20230725-C00781
 		Formula III-20
Figure US11708351-20230725-C00782
 		Formula III-21
Figure US11708351-20230725-C00783
 		Formula III-22
Figure US11708351-20230725-C00784
 		Formula III-23
Figure US11708351-20230725-C00785
 		Formula III-24
Figure US11708351-20230725-C00786
 		Formula III-25
Figure US11708351-20230725-C00787
 		Formula III-26
Figure US11708351-20230725-C00788
 		Formula III-27
Figure US11708351-20230725-C00789
 		Formula III-28
Figure US11708351-20230725-C00790
 		Formula III-29
Figure US11708351-20230725-C00791
 		Formula III-30
Figure US11708351-20230725-C00792
 		Formula III-31
Figure US11708351-20230725-C00793
 		Formula III-32
Figure US11708351-20230725-C00794
 		Formula III-33
Figure US11708351-20230725-C00795
 		Formula III-34
Figure US11708351-20230725-C00796
 		Formula III-35
Figure US11708351-20230725-C00797
 		Formula III-36
Figure US11708351-20230725-C00798
 		Formula III-37
Figure US11708351-20230725-C00799
 		Formula III-38
Figure US11708351-20230725-C00800
 		Formula III-39
Figure US11708351-20230725-C00801
 		Formula III-40
Figure US11708351-20230725-C00802
 		Formula III-41
Figure US11708351-20230725-C00803
 		Formula III-42
Figure US11708351-20230725-C00804
 		Formula III-43
Figure US11708351-20230725-C00805
 		Formula III-44
Figure US11708351-20230725-C00806
 		Formula III-45
Figure US11708351-20230725-C00807
 		Formula III-46
Figure US11708351-20230725-C00808
 		Formula III-47
Figure US11708351-20230725-C00809
 		Formula III-48
Figure US11708351-20230725-C00810
 		Formula III-49

wherein R103 is independently C1-C4 alkyl, C3-C6 cycloalkyl, fluorine, chlorine, or bromine.
TABLE 4
Additional Exemplary Formulas within the Present Invention.
Figure US11708351-20230725-C00811
Figure US11708351-20230725-C00812
Figure US11708351-20230725-C00813
Figure US11708351-20230725-C00814
Figure US11708351-20230725-C00815
Figure US11708351-20230725-C00816
Figure US11708351-20230725-C00817
Figure US11708351-20230725-C00818
Figure US11708351-20230725-C00819
Figure US11708351-20230725-C00820
Figure US11708351-20230725-C00821
Figure US11708351-20230725-C00822
Figure US11708351-20230725-C00823
Figure US11708351-20230725-C00824
Figure US11708351-20230725-C00825
Figure US11708351-20230725-C00826
Figure US11708351-20230725-C00827
Figure US11708351-20230725-C00828
Figure US11708351-20230725-C00829
Figure US11708351-20230725-C00830
Figure US11708351-20230725-C00831
Figure US11708351-20230725-C00832
Figure US11708351-20230725-C00833
Figure US11708351-20230725-C00834
Figure US11708351-20230725-C00835
Figure US11708351-20230725-C00836
Figure US11708351-20230725-C00837
Figure US11708351-20230725-C00838
Figure US11708351-20230725-C00839
Figure US11708351-20230725-C00840
Figure US11708351-20230725-C00841
Figure US11708351-20230725-C00842
Figure US11708351-20230725-C00843
Figure US11708351-20230725-C00844
Figure US11708351-20230725-C00845
Figure US11708351-20230725-C00846
Figure US11708351-20230725-C00847
Figure US11708351-20230725-C00848
Figure US11708351-20230725-C00849
Figure US11708351-20230725-C00850
Figure US11708351-20230725-C00851
Figure US11708351-20230725-C00852
Figure US11708351-20230725-C00853
Figure US11708351-20230725-C00854
Figure US11708351-20230725-C00855
Figure US11708351-20230725-C00856
Figure US11708351-20230725-C00857
Figure US11708351-20230725-C00858
Figure US11708351-20230725-C00859
Figure US11708351-20230725-C00860
Figure US11708351-20230725-C00861
Figure US11708351-20230725-C00862
Figure US11708351-20230725-C00863
Figure US11708351-20230725-C00864
Figure US11708351-20230725-C00865
Figure US11708351-20230725-C00866
Figure US11708351-20230725-C00867
Figure US11708351-20230725-C00868
Figure US11708351-20230725-C00869
Figure US11708351-20230725-C00870
Figure US11708351-20230725-C00871
Figure US11708351-20230725-C00872
Figure US11708351-20230725-C00873
Figure US11708351-20230725-C00874
Figure US11708351-20230725-C00875
Figure US11708351-20230725-C00876
Figure US11708351-20230725-C00877
Figure US11708351-20230725-C00878
Figure US11708351-20230725-C00879
Figure US11708351-20230725-C00880
Figure US11708351-20230725-C00881
Figure US11708351-20230725-C00882
Figure US11708351-20230725-C00883
Figure US11708351-20230725-C00884
Figure US11708351-20230725-C00885
Figure US11708351-20230725-C00886
Figure US11708351-20230725-C00887
Figure US11708351-20230725-C00888
Figure US11708351-20230725-C00889
Figure US11708351-20230725-C00890
Figure US11708351-20230725-C00891
Figure US11708351-20230725-C00892
Figure US11708351-20230725-C00893
Figure US11708351-20230725-C00894
Figure US11708351-20230725-C00895
Figure US11708351-20230725-C00896
Figure US11708351-20230725-C00897
Figure US11708351-20230725-C00898
Figure US11708351-20230725-C00899
Figure US11708351-20230725-C00900
Figure US11708351-20230725-C00901
Figure US11708351-20230725-C00902
Figure US11708351-20230725-C00903
Figure US11708351-20230725-C00904
Figure US11708351-20230725-C00905
Figure US11708351-20230725-C00906
Figure US11708351-20230725-C00907
Figure US11708351-20230725-C00908
Figure US11708351-20230725-C00909
Figure US11708351-20230725-C00910
Figure US11708351-20230725-C00911
Figure US11708351-20230725-C00912
Figure US11708351-20230725-C00913
Figure US11708351-20230725-C00914
Figure US11708351-20230725-C00915
Figure US11708351-20230725-C00916
Figure US11708351-20230725-C00917
Figure US11708351-20230725-C00918
Figure US11708351-20230725-C00919
Figure US11708351-20230725-C00920
Figure US11708351-20230725-C00921
Figure US11708351-20230725-C00922
Figure US11708351-20230725-C00923
Figure US11708351-20230725-C00924
Figure US11708351-20230725-C00925
Figure US11708351-20230725-C00926
Figure US11708351-20230725-C00927
Figure US11708351-20230725-C00928
Figure US11708351-20230725-C00929
Figure US11708351-20230725-C00930
Figure US11708351-20230725-C00931
Figure US11708351-20230725-C00932
Figure US11708351-20230725-C00933
Figure US11708351-20230725-C00934
Figure US11708351-20230725-C00935
Figure US11708351-20230725-C00936
Figure US11708351-20230725-C00937
Figure US11708351-20230725-C00938
Figure US11708351-20230725-C00939
Figure US11708351-20230725-C00940
Figure US11708351-20230725-C00941
Figure US11708351-20230725-C00942
Figure US11708351-20230725-C00943
Figure US11708351-20230725-C00944
Figure US11708351-20230725-C00945
Figure US11708351-20230725-C00946
Figure US11708351-20230725-C00947
Figure US11708351-20230725-C00948
TABLE 5
Additional Exemplary Formulas within the Present Invention.
Figure US11708351-20230725-C00949
Figure US11708351-20230725-C00950
Figure US11708351-20230725-C00951
Figure US11708351-20230725-C00952
Figure US11708351-20230725-C00953
Figure US11708351-20230725-C00954
Figure US11708351-20230725-C00955
Figure US11708351-20230725-C00956
Figure US11708351-20230725-C00957
Figure US11708351-20230725-C00958
Figure US11708351-20230725-C00959
Figure US11708351-20230725-C00960
Figure US11708351-20230725-C00961
Figure US11708351-20230725-C00962
Figure US11708351-20230725-C00963
Figure US11708351-20230725-C00964
Figure US11708351-20230725-C00965
Figure US11708351-20230725-C00966
Figure US11708351-20230725-C00967
Figure US11708351-20230725-C00968
Figure US11708351-20230725-C00969
Figure US11708351-20230725-C00970
Figure US11708351-20230725-C00971
Figure US11708351-20230725-C00972
Figure US11708351-20230725-C00973
Figure US11708351-20230725-C00974
Figure US11708351-20230725-C00975
Figure US11708351-20230725-C00976
Figure US11708351-20230725-C00977
Figure US11708351-20230725-C00978
Figure US11708351-20230725-C00979
Figure US11708351-20230725-C00980
Figure US11708351-20230725-C00981
Figure US11708351-20230725-C00982
Figure US11708351-20230725-C00983
Figure US11708351-20230725-C00984
The R12 and R13 Heteroaryl, and Heterocycle Substituents
The invention includes a compound of Formula I, Formula II, Formula III, Formula IV, or Formula V a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition, wherein at least one of R12 or R13 on the A group is an heteroaryl, or heterocycle for example, R32.
One of R12 and R13 is selected from R31 and the other of R12 and R13 is selected from R32. In another embodiment, each of R12 and R13 can be independently selected from R32.
R31 is selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, —COOH, haloalkyl including C1-C6haloalkyl, haloalkoxy including C1-C6haloalkoxy, alkyl including C1-C6alkyl, —C0-C4alkyl(C3-C7cycloalkyl), alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, alkenyloxy including C2-C6alkenyloxy, —C(O)OR9, thioalkyl including C1-C6thioalkyl, —C0-C4alkylNR9R10, —C(O)NR9R10, —SO2R9, —SO2NR9R10, —OC(O)R9, and —C(NR9)NR9R10, each of which R31 other than hydrogen, halogen, hydroxyl, nitro, cyano, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, —COOH, —CONH2, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy, and each of which R31 is also optionally substituted with one substituent selected from phenyl and 4- to 7-membered heterocycle containing 1, 2, or 3 heteroatoms independently selected from N, O, and S; which phenyl or 4- to 7-membered heterocycle is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, (mono- and di-C1-C6alkylamino)C0-C4alkyl, C1-C6alkylester, —C0-C4alkyl)(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy;
R32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl, saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
Non-Limiting R12/R13 Embodiments
In one embodiment, R12 is R32.
In one embodiment, R13 is R32.
In one embodiment, R12 is an optionally substituted heteroaryl.
In one embodiment, R13 is an optionally substituted heteroaryl.
In one embodiment, R12 is R32.
In one embodiment, R12 is R32, which is (4- to 7-membered heterocycloalkyl) having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
In one embodiment, the disclosure provides compounds of Formula I, wherein;
one of R12 and R13 is H and the other of R12 and R13 is R32, where
R32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
In another embodiment, the disclosure provides compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V wherein;
R1, R1′, R2, and R3′ are all hydrogen;
R2 is fluoro and R3 is hydrogen, —C0-C4alkyl(C3-C7cycloalkyl), or —O—C0-C4alkyl(C3-C7cycloalkyl);
R5 is hydrogen, halogen, or C1-C6alkyl;
R11, R13, R14, and R15 if present, are independently selected at each occurrence from hydrogen, halogen, hydroxyl, amino, C1-C4alkyl, C1-C4alkoxy, —C0-C2alkyl(mono- and di-C1-C6alkylamino), trifluoromethyl, and trifluoromethoxy;
X12 is CR12; and
R12 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring can be optionally substituted.
In one embodiment, the disclosure provides compounds of Formula I, wherein;
m is 0 or 1;
R2 is halogen, R2′ is hydrogen or halogen, and R3 is hydrogen, halogen, —C0-C4alkyl(C3-C7cycloalkyl), or —O—C0-C4alkyl(C3-C7cycloalkyl);
R6 is —C(O)C1-C4alkyl, —C(O)NH2, —C(O)CF3, —C(O)(C3-C7cycloalkyl), or -ethyl(cyanoimino);
one of R12 and R13 is selected from hydrogen, halogen, C1-C4alkyl, C1-C4alkoxy, trifluoromethyl, and trifluoromethoxy; the other of R12 and R13 is R32, where
R32 is selected from aryl, heteroaryl; saturated or unsaturated heterocycle; wherein the aryl, heteroaryl, saturated or unsaturated heterocycle ring can be optionally substituted.
In one embodiment, the disclosure provides compounds of Formula I, Formula II, Formula III, Formula IV, or Formula V, wherein one of R12 and R13 is hydrogen, hydroxyl, halogen, methyl, or methoxy; and the other of R12 and R13 is R32, where
R32 is selected from heteroaryl; saturated heterocycle or partially unsaturated heterocycle; wherein the heteroaryl; saturated heterocycle or partially unsaturated heterocycle ring, can be optionally substituted.
In one embodiment, R32 may be unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, nitro, cyano, amino, oxo, —B(OH)2, —Si(CH3)3, —COOH, —CONH2, —P(O)(OH)2, C1-C6alkyl, alkoxy including C1-C6alkoxy, —C0-C2alkyl(mono- and di-C1-C4alkylamino), C1-C6alkylester, C1-C4alkylamino, C1-C4hydroxylalkyl, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
In one embodiment, R31 is hydrogen and R32 is pyrimidinyl.
In another embodiment, R31 is hydrogen and R32 is pyrimidine substituted with a methyl group.
Non-Limiting Central Core Embodiments
In certain embodiments, R1 and R1′ or R3 and R3′ may be taken together to form a 3- to 6-membered carbocyclic spiro ring or a 3- to 6-membered heterocyclic spiro ring containing 1 or 2 heteroatoms independently selected from N, O, or S; R2 and R2′ may be taken together to form a 3- to 6-membered carbocyclic spiro ring; or R2 and R2′ may be taken together to form a 3- to 6-membered heterocyclic spiro ring; each of which ring may be unsubstituted or substituted with 1 or more substituents independently selected from halogen (and in particular F), hydroxyl, cyano, —COOH, C1-C4alkyl (including in particular methyl), C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-C1-C4alkylamino)C0-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
In other embodiments, R1 and R2 may be taken together to form a 3-membered carbocyclic ring; R1 and R2 may be taken together to form a 4, 5 or 6-membered carbocyclic or an aryl ring or a 4, 5 to 6-membered heterocyclic or heteroaryl ring containing 1 or 2 heteroatoms independently selected from N, O, and S; or R2 and R3, if bound to adjacent carbon atoms, may be taken together to form a 3- to 6-membered carbocyclic or aryl ring or a 3- to 6-membered heterocyclic or heteroaryl ring;
each of which ring may be unsubstituted or substituted with 1 or more substituents independently selected from halogen (and in particular F), hydroxyl, cyano, —COOH, C1-C4alkyl (including in particular methyl), C2-C4alkenyl, C2-C4alkynyl, C1-C4alkoxy, C2-C4alkanoyl, hydroxyC1-C4alkyl, (mono- and di-C1-C4alkylamino)C0-C4alkyl, —C0-C4alkyl(C3-C7cycloalkyl), —O—C0-C4alkyl(C3-C7cycloalkyl), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
In one embodiment, the central core moiety is proline.
In one embodiment, the central core moiety is 4-fluoroproline.
In one embodiment, R1, R1′, R2′, R3, and R3′, if present, are all hydrogen; and R2 is fluoro.
In one embodiment, R1, R1′, R2′, and R3′, if present, are all hydrogen; and R2 is fluoro and R3 is —C0-C4alkyl(C3-C7cycloalkyl) or —O—C0-C4alkyl(C3-C7cycloalkyl).
In one embodiment, R1 and R2 are taken together to form a 3- to 6-membered cycloalkyl group, and R1′, R2′, R3, and R3′, where present, are all hydrogen. In one embodiment, the bicycle is fused in a cis fashion. In one embodiment, the bicyclic ring is fused in a trans fashion.
In one embodiment, R1 and R2 are taken together to form a 3- to 6-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00985
In one embodiment, R1 and R2 are taken together to form a 3- to 6-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00986
In one embodiment, R1, R1′, R3, and R3′, if present, are all hydrogen, and R2 and R2′ are taken together to form a 5- or 6-membered heterocycloalkyl group having 1 or 2 oxygen atoms.
In one embodiment, R1 is hydrogen and R2 is fluoro.
In one embodiment, R1 and R2 are joined to form a 3 membered ring.
In one embodiment, R1 and R2 are taken together to form a 3-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00987
In one embodiment, R1 and R2 are taken together to form a 3-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00988
In one embodiment, R2 and R3 are taken together to form a 3- to 6-membered cycloalkyl group, and R1, R1′, R2′ and R3′, where present, are selected from hydrogen, C1-C3 alkyl or C1-C3 alkoxy.
In one embodiment, R2 and R3 are taken together to form a 3- to 6-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00989
In one embodiment, R2 and R3 are taken together to form a 3- to 6-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00990
In one embodiment, R2 and R3 are taken together to form a 3-membered cycloalkyl group that is cis with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00991
In one embodiment, R2 and R3 are taken together to form a 3-membered cycloalkyl group that is trans with respect to the carboxyl group of L-proline as shown below:
Figure US11708351-20230725-C00992
In one embodiment, R1, R1′, R3, and R3′, if present, are all hydrogen, and R2 and R2′ are taken together to form a 5- or 6-membered heterocycloalkyl group having 1 or 2 oxygen atoms.
In one embodiment, R1 is hydrogen and R2 is fluoro.
In one embodiment, R1 and R2 are joined to form a 3 membered ring.
Central Core L-B Substituents
Illustrative core L substituents and B substituents in Formula I are described below:
Figure US11708351-20230725-C00993
L is a bond or is selected from the formulas:
Figure US11708351-20230725-C00994
where R17 is hydrogen, C1-C6alkyl, or —C0-C4alkyl(C3-C7cycloalkyl) and R18 and R18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0, 1, 2, or 3.
Non-Limiting L-B Embodiments
In one embodiment, -L1-B1- is:
Figure US11708351-20230725-C00995
Figure US11708351-20230725-C00996
wherein
R18 and R18′ are independently selected from hydrogen, halogen, hydroxymethyl, and methyl; and m is 0 or 1; and
R26, R27, and R28 are independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, thioalkyl including C1-C6thioalkyl, (mono- and di-C1-C6alkylamino)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (aryl)C0-C4alkyl-, (heteroaryl)C0-C4alkyl-, and —C0-C4alkoxy(C3-C7cycloalkyl); each of which R26, R27, and R28 other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C1-C6alkoxy, haloalkyl including C1-C6haloalkyl, (C3-C7cycloalkyl)C0-C4alkyl-, and haloalkoxy including C1-C6haloalkoxy; and
R29 is hydrogen, alkyl including C1-C6alkyl, C1C2haloalkyl or —Si(CH3)2C(CH3)3.
In one embodiment, -L-B1- moiety is selected:
Figure US11708351-20230725-C00997
Figure US11708351-20230725-C00998
In one embodiment, -L1-B1- moiety is selected:
Figure US11708351-20230725-C00999
Figure US11708351-20230725-C01000
In one embodiment, -L2-B1- moiety is selected:
Figure US11708351-20230725-C01001
Figure US11708351-20230725-C01002
In one embodiment, -L2-B1- moiety is selected:
Figure US11708351-20230725-C01003
In one embodiment, m is 0.
In one embodiment, the disclosure further includes compounds and salts of Formula I in which B1 is 2-fluoro-3-chlorophenyl. In another embodiment, another carbocyclic, aryl, heterocyclic, or heteroaryl group such as 2-bromo-pyridin-6-yl, 1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl, 2,2-dichlorocyclopropylmethyl, or 2-fluoro-3-trimethylsilylphenyl is used.
In another embodiment, B1 is phenyl, pyridyl, or indanyl each of which is unsubstituted or substituted with one or more substituents independently selected from hydrogen, halogen, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, alkoxy including C1-C6alkoxy, thioalkyl including C1-C6thioalkyl, (mono- and di-C1-C6alkylamino)C0-C4alkyl, (C3-C7cycycloalkyl)C0-C4alkyl, —C0-C4alkoxy(C3-C7cycycloalkyl), (phenyl)C0-C2alkyl, (pyridyl)C0-C2alkyl; each of which substituents other than hydrogen, halogen, hydroxyl, nitro, cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkyl including C1-C6alkyl, alkoxy including C1-C6alkoxy, —OSi(CH3)2C(CH3)3, —Si(CH3)2C(CH3)3, haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
In another embodiment, B1 is phenyl or pyridyl substituted with 1, 2, or 3 substituents selected from chloro, bromo, hydroxyl, —SCF3, C1-C6alkyl, C1-C6alkoxy, trifluoromethyl, phenyl and trifluoromethoxy each of which substituents other than chloro, bromo, hydroxyl, —SCF3, can be optionally substituted.
In certain embodiments, B1 is a 2-fluoro-3-chlorophenyl or a 2-fluoro-3-trifluoromethoxyphenyl group.
In one embodiment, B1 is pyridyl, optionally substituted with halogen, C1-C6alkoxy, and trifluoromethyl.
In one embodiment, B1 is phenyl, substituted with 1, 2, or 3 substituents independently selected from halogen, C1-C6alkyl, C1-C6alkoxy, trifluoromethyl, and optionally substituted phenyl.
In one embodiment, R23 is independently selected at each occurrence from (C3-C7cycloalkyl)C0-C4alkyl, (phenyl)C0-C4alkyl, (4- to 7-membered heterocycloalkyl)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S, and (5- or 6-membered unsaturated or aromatic heterocycle)C0-C4alkyl having 1, 2, or 3 heteroatoms independently selected from N, O, and S.
In one embodiment, L1-B3 is:
Figure US11708351-20230725-C01004
R27′, and R28′ are independently selected from hydrogen, fluoro, bromo, iodo, hydroxyl, nitro, cyano, alkyl including C1-C6alkyl, alkenyl including C2-C6alkenyl, alkanoyl including C2-C6alkanoyl, C2-C6alkoxy, C2-C6thioalkyl, (mono- and di-C1-C6alkylamino)C0-C4alkyl, (C3-C7cycloalkyl)C0-C4alkyl, (aryl)C0-C4alkyl-, (heteroaryl)C0-C4alkyl-, and —C0-C4alkoxy(C3-C7cycloalkyl); each of which R27′, and R28′ other than hydrogen, fluoro, bromo, iodo, hydroxyl, nitro, and cyano, is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, alkoxy including C1-C6alkoxy, haloalkyl including C1-C6haloalkyl, (C3-C7cycloalkyl)C0-C4alkyl-, and haloalkoxy including C1-C6haloalkoxy.
Central Core (L3)-A Substituent
The central core (L3)-A substituent in Formula I is illustrated below:
Figure US11708351-20230725-C01005
In one embodiment, R5 and R6 are independently selected from —CHO, —C(O)NH2, —C(O)NH(CH3), C2-C6alkanoyl, and hydrogen.
In one embodiment, each R5 and R6 other than hydrogen, hydroxyl, cyano, and —COOH is unsubstituted or substituted with one or more substituents independently selected from halogen, hydroxyl, amino, imino, cyano, cyanoimino, alkyl including C1-C6alkyl, C1-C4alkoxy, —C0-C2alkyl(mono- and di-C1-C4alkylamino), haloalkyl including C1-C6haloalkyl, and haloalkoxy including C1-C6haloalkoxy.
In one embodiment, R8 and R8′ are independently hydrogen or methyl.
In one embodiment, R8 and R8′ are hydrogen.
In one embodiment, R7 is hydrogen or methyl.
In one embodiment, R7 is hydrogen.
Additional Compounds of the Present Invention
In one embodiment the compound of the present invention is selected from:
Figure US11708351-20230725-C01006
Figure US11708351-20230725-C01007
Figure US11708351-20230725-C01008
Figure US11708351-20230725-C01009
Figure US11708351-20230725-C01010
Figure US11708351-20230725-C01011
In one embodiment the compound of the present invention is selected from:
Figure US11708351-20230725-C01012
Figure US11708351-20230725-C01013
Figure US11708351-20230725-C01014
Figure US11708351-20230725-C01015
In one embodiment the compound of the present invention is selected from:
Figure US11708351-20230725-C01016
Figure US11708351-20230725-C01017
Figure US11708351-20230725-C01018
Figure US11708351-20230725-C01019
Figure US11708351-20230725-C01020
Figure US11708351-20230725-C01021
Figure US11708351-20230725-C01022
Figure US11708351-20230725-C01023
Figure US11708351-20230725-C01024
In one embodiment the compound of the present invention is selected from:
Figure US11708351-20230725-C01025
Figure US11708351-20230725-C01026
Pharmaceutical Preparations
Active compounds described herein can be administered to a host in need thereof as the neat chemical, but are more typically administered as a pharmaceutical composition that includes an effective amount for a host, typically a human, in need of such treatment of an active compound as described herein or its pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof. Thus, in one embodiment, the disclosure provides pharmaceutical compositions comprising an effective amount of compound or pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof together with at least one pharmaceutically acceptable carrier for any of the uses described herein. The pharmaceutical composition may contain a compound or salt as the only active agent, or, in an alternative embodiment, the compound and at least one additional active agent.
An effective amount of an active compound as described herein, or the active compound described herein in combination or alternation with, or preceded by, concomitant with or followed by another active agent, can be used in an amount sufficient to (a) inhibit the progression of a disorder mediated by the complement pathway, including an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (b) cause a regression of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; (c) cause a cure of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder; or inhibit or prevent the development of an inflammatory, immune, including an autoimmune, disorder or complement Factor D related disorder.
Accordingly, an effective amount of an active compound or its salt or composition described herein will provide a sufficient amount of the active agent when administered to a patient to provide a clinical benefit.
The exact amount of the active compound or pharmaceutical composition described herein to be delivered to the host, typically a human, in need thereof, will be determined by the health care provider to achieve the desired clinical benefit.
In certain embodiments the pharmaceutical composition is in a dosage form that contains from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of the active compound and optionally from about 0.1 mg to about 2000 mg, from about 10 mg to about 1000 mg, from about 100 mg to about 800 mg, or from about 200 mg to about 600 mg of an additional active agent in a unit dosage form. Examples are dosage forms with at least about 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 15, 20, 25, 50, 75, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 900, 1000, 1100, 1200, 1250, 1300, 1400, 1500, or 1600 mg of active compound, or its salt or prodrug. In one embodiment, the dosage form has at least about 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 200 mg, 400 mg, 500 mg, 600 mg, 1000 mg, 1200 mg, or 1600 mg of active compound, or its salt. The amount of active compound in the dosage form is calculated without reference to the salt. The dosage form can be administered, for example, once a day (q.d.), twice a day (b.i.d.), three times a day (t.i.d.), four times a day (q.i.d.), once every other day (Q2d), once every third day (Q3d), as needed, or any dosage schedule that provides treatment of a disorder described herein.
The pharmaceutical composition may for example include a molar ratio of the active compound and an additional active agent that achieves the desired result. For example, the pharmaceutical composition may contain a molar ratio of about 0.5:1, about 1:1, about 2:1, about 3:1 or from about 1.5:1 to about 4:1 of an additional active agent in combination with the active compound (additional active agent: active compound), or its salt, described herein. In one embodiment, the additional active agent is an anti-inflammatory or immunosuppressing agent.
Compounds disclosed herein or used as described herein may be administered orally, topically, parenterally, by inhalation or spray, sublingually, via implant, including ocular implant, transdermally, via buccal administration, rectally, as an ophthalmic solution, injection, including ocular injection, intravenous, intra-aortal, intracranial, subdermal, intraperitoneal, subcutaneous, transnasal, sublingual, intrathecal, or rectal or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers. For ocular delivery, the compound can be administered, as desired, for example, as a solution, suspension, or other formulation via intravitreal, intrastromal, intracameral, sub-tenon, sub-retinal, retro-bulbar, peribulbar, suprachoroidal, subchoroidal, choroidal, conjunctival, subconjunctival, episcleral, periocular, transscleral, retrobulbar, posterior juxtascleral, circumcorneal, or tear duct injections, or through a mucus, mucin, or a mucosal barrier, in an immediate or controlled release fashion or via an ocular device, injection, or topically administered formulation, for example a solution or suspension provided as an eye drop.
The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a gel cap, a pill, a microparticle, a nanoparticle, an injection or infusion solution, a capsule, a tablet, a syrup, a transdermal patch, a subcutaneous patch, a dry powder, an inhalation formulation, in a medical device, suppository, buccal, or sublingual formulation, parenteral formulation, or an ophthalmic solution or suspension. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.
Pharmaceutical compositions, and methods of manufacturing such compositions, suitable for administration as contemplated herein are known in the art. Examples of known techniques include, for example, U.S. Pat. Nos. 4,983,593, 5,013,557, 5,456,923, 5,576,025, 5,723,269, 5,858,411, 6,254,889, 6,303,148, 6,395,302, 6,497,903, 7,060,296, 7,078,057, 7,404,828, 8,202,912, 8,257,741, 8,263,128, 8,337,899, 8,431,159, 9,028,870, 9,060,938, 9,211,261, 9,265,731, 9,358,478, and 9,387,252, incorporated by reference herein.
The pharmaceutical compositions contemplated here can optionally include a carrier. Carriers must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound. Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, fillers, flavorants, glidents, lubricants, pH modifiers, preservatives, stabilizers, surfactants, solubilizers, tableting agents, and wetting agents. Some carriers may be listed in more than one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils. Examples of other matrix materials, fillers, or diluents include lactose, mannitol, xylitol, microcrystalline cellulose, calcium diphosphate, and starch. Examples of surface active agents include sodium lauryl sulfate and polysorbate 80. Examples of drug complexing agents or solubilizers include the polyethylene glycols, caffeine, xanthene, gentisic acid and cylodextrins. Examples of disintegrants include sodium starch glycolate, sodium alginate, carboxymethyl cellulose sodium, methyl cellulose, colloidal silicon dioxide, and croscarmellose sodium. Examples of binders include methyl cellulose, microcrystalline cellulose, starch, and gums such as guar gum, and tragacanth. Examples of lubricants include magnesium stearate and calcium stearate. Examples of pH modifiers include acids such as citric acid, acetic acid, ascorbic acid, lactic acid, aspartic acid, succinic acid, phosphoric acid, and the like; bases such as sodium acetate, potassium acetate, calcium oxide, magnesium oxide, trisodium phosphate, sodium hydroxide, calcium hydroxide, aluminum hydroxide, and the like, and buffers generally comprising mixtures of acids and the salts of said acids. Optional other active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.
In certain embodiments, the pharmaceutical composition for administration further includes a compound or salt of Formula I, II, or III and optionally comprises one or more of a phosphoglyceride; phosphatidylcholine; dipalmitoyl phosphatidylcholine (DPPC); dioleoylphosphatidyl ethanolamine (DOPE); dioleoyloxypropyltriethylammonium (DOTMA); dioleoylphosphatidylcholine; cholesterol; cholesterol ester; diacylglycerol; diacylglycerolsuccinate; diphosphatidyl glycerol (DPPG); hexanedecanol; fatty alcohol such as polyethylene glycol (PEG); polyoxyethylene-9-lauryl ether; a surface active fatty acid, such as palmitic acid or oleic acid; fatty acid; fatty acid monoglyceride; fatty acid diglyceride; fatty acid amide; sorbitan trioleate (Span®85) glycocholate; sorbitan monolaurate (Span®20); polysorbate 20 (Tween®20); polysorbate 60 (Tween®60); polysorbate 65 (Tween®65); polysorbate 80 (Tween®80); polysorbate 85 (Tween®85); polyoxyethylene monostearate; surfactin; a poloxomer; a sorbitan fatty acid ester such as sorbitan trioleate; lecithin; lysolecithin; phosphatidylserine; phosphatidylinositol; sphingomyelin; phosphatidylethanolamine (cephalin); cardiolipin; phosphatidic acid; cerebroside; dicetylphosphate; dipalmitoylphosphatidylglycerol; stearylamine; dodecylamine; hexadecyl-amine; acetyl palmitate; glycerol ricinoleate; hexadecyl stearate; isopropyl myristate; tyloxapol; poly(ethylene glycol)5000-phosphatidylethanolamine; poly(ethylene glycol)400-monostearate; phospholipid; synthetic and/or natural detergent having high surfactant properties; deoxycholate; cyclodextrin; chaotropic salt; ion pairing agent; glucose, fructose, galactose, ribose, lactose, sucrose, maltose, trehalose, cellbiose, mannose, xylose, arabinose, glucoronic acid, galactoronic acid, mannuronic acid, glucosamine, galatosamine, and neuramic acid; pullulan, cellulose, microcrystalline cellulose, hydroxypropyl methylcellulose (HPMC), hydroxycellulose (HC), methylcellulose (MC), dextran, cyclodextran, glycogen, hydroxyethylstarch, carageenan, glycon, amylose, chitosan, N,O-carboxylmethylchitosan, algin and alginic acid, starch, chitin, inulin, konjac, glucommannan, pustulan, heparin, hyaluronic acid, curdlan, and xanthan, mannitol, sorbitol, xylitol, erythritol, maltitol, and lactitol, a pluronic polymer, polyethylene, polycarbonate (e.g. poly(1,3-dioxan-2one)), polyanhydride (e.g. poly(sebacic anhydride)), polypropylfumerate, polyamide (e.g. polycaprolactam), polyacetal, polyether, polyester (e.g., polylactide, polyglycolide, polylactide-co-glycolide, polycaprolactone, polyhydroxyacid (e.g. poly((β-hydroxyalkanoate))), poly(orthoester), polycyanoacrylate, polyvinyl alcohol, polyurethane, polyphosphazene, polyacrylate, polymethacrylate, polyurea, polystyrene, and polyamine, polylysine, polylysine-PEG copolymer, and poly(ethyleneimine), poly(ethylene imine)-PEG copolymer, glycerol monocaprylocaprate, propylene glycol, Vitamin E TPGS (also known as d-α-Tocopheryl polyethylene glycol 1000 succinate), gelatin, titanium dioxide, polyvinylpyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose (MC), block copolymers of ethylene oxide and propylene oxide (PEO/PPO), polyethyleneglycol (PEG), sodium carboxymethylcellulose (NaCMC), hydroxypropylmethyl cellulose acetate succinate (HPMCAS).
In some embodiments, the pharmaceutical preparation may include polymers for controlled delivery of the described compounds, including, but not limited to pluronic polymers, polyesters (e.g., polylactic acid, poly(lactic-co-glycolic acid), polycaprolactone, polyvalerolactone, poly(1,3-dioxan-2one)); polyanhydrides (e.g., poly(sebacic anhydride)); polyethers (e.g., polyethylene glycol); polyurethanes; polymethacrylates; polyacrylates; and polycyanoacrylates. In some embodiments, polymers may be modified with polyethylene glycol (PEG), with a carbohydrate, and/or with acyclic polyacetals derived from polysaccharides. See, e.g., Papisov, 2001, ACS Symposium Series, 786:301, incorporated by reference herein.
The compounds of the present invention can be formulated as particles. In one embodiment the particles are or include microparticles. In an alternative embodiment the particles are or include nanoparticles.
In an additional alternative embodiment, common techniques for preparing particles include, but are not limited to, solvent evaporation, solvent removal, spray drying, phase inversion, coacervation, and low temperature casting. Suitable methods of particle formulation are briefly described below. Pharmaceutically acceptable excipients, including pH modifying agents, disintegrants, preservatives, and antioxidants, can optionally be incorporated into the particles during particle formation.
In one embodiment, the particles are derived through a solvent evaporation method. In this method, a compound described herein (or polymer matrix and one or more compounds described herein) is dissolved in a volatile organic solvent, such as methylene chloride. The organic solution containing a compound described herein is then suspended in an aqueous solution that contains a surface active agent such as poly(vinyl alcohol). The resulting emulsion is stirred until most of the organic solvent evaporated, leaving solid nanoparticles or microparticles. The resulting nanoparticles or microparticles are washed with water and dried overnight in a lyophilizer. Nanoparticles with different sizes and morphologies can be obtained by this method.
Pharmaceutical compositions which contain labile polymers, such as certain polyanhydrides, may degrade during the fabrication process due to the presence of water. For these polymers, methods which are performed in completely or substantially anhydrous organic solvents can be used to make the particles.
Solvent removal can also be used to prepare particles from a compound that is hydrolytically unstable. In this method, the compound (or polymer matrix and one or more compounds) is dispersed or dissolved in a volatile organic solvent such as methylene chloride. This mixture is then suspended by stirring in an organic oil (such as silicon oil) to form an emulsion. Solid particles form from the emulsion, which can subsequently be isolated from the supernatant. The external morphology of spheres produced with this technique is highly dependent on the identity of the drug.
In one embodiment an active compound as described herein is administered to a patient in need thereof as particles formed by solvent removal. In another embodiment the present invention provides particles formed by solvent removal comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by solvent removal comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by solvent removal comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by solvent removal can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by solvent removal are formulated into a tablet but the tablet is uncoated.
In one embodiment, the particles are derived by spray drying. In this method, a compound (or polymer matrix and one or more compounds) is dissolved in an organic solvent such as methylene chloride. The solution is pumped through a micronizing nozzle driven by a flow of compressed gas, and the resulting aerosol is suspended in a heated cyclone of air, allowing the solvent to evaporate from the micro droplets, forming particles. Microparticles and nanoparticles can be obtained using this method.
In one embodiment an active compound as described herein is administered to a patient in need thereof as a spray dried dispersion (SDD). In another embodiment the present invention provides a spray dried dispersion (SDD) comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the SDD comprises a compound of the present invention and an additional therapeutic agent. In a further embodiment the SDD comprises a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described spray dried dispersions can be coated to form a coated tablet. In an alternative embodiment the spray dried dispersion is formulated into a tablet but is uncoated. Particles can be formed from the active compound as described herein using a phase inversion method. In this method, the compound (or polymer matrix and one or more active compounds) is dissolved in a suitable solvent, and the solution is poured into a strong non-solvent for the compound to spontaneously produce, under favorable conditions, microparticles or nanoparticles. The method can be used to produce nanoparticles in a wide range of sizes, including, for example, from nanoparticles to microparticles, typically possessing a narrow particle size distribution.
In one embodiment, an active compound as described herein is administered to a patient in need thereof as particles formed by phase inversion. In another embodiment the present invention provides particles formed by phase inversion comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by phase inversion comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by phase inversion comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by phase inversion can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by phase inversion are formulated into a tablet but the tablet is uncoated.
Techniques for particle formation using coacervation are known in the art, for example, as described in GB-B-929 406; GB-B-929 401; and U.S. Pat. Nos. 3,266,987, 4,794,000, and 4,460,563. Coacervation involves the separation of a compound (or polymer matrix and one or more compounds) solution into two immiscible liquid phases. One phase is a dense coacervate phase, which contains a high concentration of the compound, while the second phase contains a low concentration of the compound. Within the dense coacervate phase, the compound forms nanoscale or microscale droplets, which harden into particles. Coacervation may be induced by a temperature change, addition of a non-solvent or addition of a micro-salt (simple coacervation), or by the addition of another polymer thereby forming an interpolymer complex (complex coacervation).
In one embodiment an active compound as described herein is administered to a patient in need thereof as particles formed by coacervation. In another embodiment the present invention provides particles formed by coacervation comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by coacervation comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by coacervation comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by coacervation can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by coacervation are formulated into a tablet but the tablet is uncoated.
Methods for very low temperature casting of controlled release microspheres are described in U.S. Pat. No. 5,019,400 to Gombotz et al. In this method, the compound is dissolved in a solvent. The mixture is then atomized into a vessel containing a liquid non-solvent at a temperature below the freezing point of the drug solution which freezes the compound droplets. As the droplets and non-solvent for the compound are warmed, the solvent in the droplets thaws and is extracted into the non-solvent, hardening the microspheres.
In one embodiment, a compound of the present invention is administered to a patient in need thereof as particles formed by low temperature casting. In another embodiment the present invention provides particles formed by low temperature casting comprising a compound of the present invention and one or more pharmaceutically acceptable excipients as defined herein. In another embodiment the particles formed by low temperature casting comprise a compound of the present invention and an additional therapeutic agent. In a further embodiment the particles formed by low temperature casting comprise a compound of the present invention, an additional therapeutic agent, and one or more pharmaceutically acceptable excipients. In another embodiment any of the described particles formed by low temperature casting can be formulated into a tablet and then coated to form a coated tablet. In an alternative embodiment the particles formed by low temperature casting are formulated into a tablet but the tablet is uncoated.
In one aspect of the present invention, an effective amount of an active compound as described herein is incorporated into a nanoparticle, e.g. for convenience of delivery and/or extended release delivery. The use of materials in nanoscale provides one the ability to modify fundamental physical properties such as solubility, diffusivity, blood circulation half-life, drug release characteristics, and/or immunogenicity. A number of nanoparticle-based therapeutic and diagnostic agents have been developed for the treatment of cancer, diabetes, pain, asthma, allergy, and infections. These nanoscale agents may provide more effective and/or more convenient routes of administration, lower therapeutic toxicity, extend the product life cycle, and ultimately reduce health-care costs. As therapeutic delivery systems, nanoparticles can allow targeted delivery and controlled release.
In addition, nanoparticle-based compound delivery can be used to release compounds at a sustained rate and thus lower the frequency of administration, deliver drugs in a targeted manner to minimize systemic side effects, or deliver two or more drugs simultaneously for combination therapy to generate a synergistic effect and suppress drug resistance. A number of nanotechnology-based therapeutic products have been approved for clinical use. Among these products, liposomal drugs and polymer-based conjugates account for a large proportion of the products. See, Zhang, L., et al., Nanoparticles in Medicine: Therapeutic Applications and Developments, Clin. Pharm. and Ther., 83(5):761-769, 2008.
Methods for producing nanoparticles are known in the art. For example, see Muller, R. H., et al., Solid lipid nanoparticles (SLN) for controlled drug delivery—a review of the state of the art, Eur. H. Pharm. Biopharm., 50:161-177, 2000; U.S. Pat. No. 8,691,750 to Consien et al.; WO 2012/145801 to Kanwar. U.S. Pat. No. 8,580,311 to Armes, S. et al.; Petros, R. A. and DeSimone, J. M., Strategies in the design of nanoparticles for therapeutic applications, Nature Reviews/Drug Discovery, vol. 9:615-627, 2010; U.S. Pat. Nos. 8,465,775; 8,444,899; 8,420,124; 8,263,129; 8,158,728; 8,268,446; Pellegrino et al., 2005, Small, 1:48; Murray et al., 2000, Ann. Rev. Mat. Sci., 30:545; and Trindade et al., 2001, Chem. Mat., 13:3843; all incorporated herein by reference. Additional methods have been described in the literature (see, e.g., Doubrow, Ed., “Microcapsules and Nanoparticles in Medicine and Pharmacy,” CRC Press, Boca Raton, 1992; Mathiowitz et al., 1987, J. Control. Release, 5:13; Mathiowitz et al., 1987, Reactive Polymers, 6:275; and Mathiowitz et al., 1988, J. Appl. Polymer Sci., 35:755; U.S. Pat. Nos. 5,578,325 and 6,007,845; P. Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles” Nanomedicine. 5(6):843-853 (2010)), U.S. Pat. No. 5,543,158 to Gref et al., or WO publication WO2009/051837 by Von Andrian et al. Zauner et al., 1998, Adv. Drug Del. Rev., 30:97; and Kabanov et al., 1995, Bioconjugate Chem., 6:7; (PEI; Boussif et al., 1995, Proc. Natl. Acad. Sci., USA, 1995, 92:7297), and poly(amidoamine) dendrimers (Kukowska-Latallo et al., 1996, Proc. Natl. Acad. Sci., USA, 93:4897; Tang et al., 1996, Bioconjugate Chem., 7:703; and Haensler et al., 1993, Bioconjugate Chem., 4:372; Putnam et al., 1999, Macromolecules, 32:3658; Barrera et al., 1993, J. Am. Chem. Soc., 115:11010; Kwon et al., 1989, Macromolecules, 22:3250; Lim et al., 1999, J. Am. Chem. Soc., 121:5633; and Zhou et al., 1990, Macromolecules, 23:3399). Examples of these polyesters include poly(L-lactide-co-L-lysine) (Barrera et al., 1993, J. Am. Chem. Soc., 115:11010), poly(serine ester)(Zhou et al., 1990, Macromolecules, 23:3399), poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633), and poly(4-hydroxy-L-proline ester) (Putnam et al., 1999, Macromolecules, 32:3658; and Lim et al., 1999, J. Am. Chem. Soc., 121:5633; U.S. Pat. Nos. 6,123,727; 5,804,178; 5,770,417; 5,736,372; 5,716,404; 6,095,148; 5,837,752; 5,902,599; 5,696,175; 5,514,378; 5,512,600; 5,399,665; 5,019,379; 5,010,167; 4,806,621; 4,638,045; and 4,946,929; Wang et al., 2001, J. Am. Chem. Soc., 123:9480; Lim et al., 2001, J. Am. Chem. Soc., 123:2460; Langer, 2000, Acc. Chem. Res., 33:94; Langer, 1999, J. Control. Release, 62:7; and Uhrich et al., 1999, Chem. Rev., 99:3181; Concise Encyclopedia of Polymer Science and Polymeric Amines and Ammonium Salts, Ed. by Goethals, Pergamon Press, 1980; Principles of Polymerization by Odian, John Wiley & Sons, Fourth Edition, 2004; Contemporary Polymer Chemistry by Allcock et al., Prentice-Hall, 1981; Deming et al., 1997, Nature, 390:386; and in U.S. Pat. Nos. 6,506,577, 6,632,922, 6,686,446, and 6,818,732; C. Astete et al., “Synthesis and characterization of PLGA nanoparticles” J. Biomater. Sci. Polymer Edn, Vol. 17, No. 3, pp. 247-289 (2006); K. Avgoustakis “Pegylated Poly(Lactide) and Poly(Lactide-Co-Glycolide) Nanoparticles: Preparation, Properties and Possible Applications in Drug Delivery” Current Drug Delivery 1:321-333 (2004); C. Reis et al., “Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles” Nanomedicine 2:8-21 (2006); P. Paolicelli et al., “Surface-modified PLGA-based Nanoparticles that can Efficiently Associate and Deliver Virus-like Particles” Nanomedicine. 5(6):843-853 (2010); U.S. Pat. No. 6,632,671 to Unger Oct. 14, 2003, all incorporated herein by reference.
In one embodiment, the polymeric particle is between about 0.1 nm to about 10000 nm, between about 1 nm to about 1000 nm, between about 10 nm and 1000 nm, between about 1 and 100 nm, between about 1 and 10 nm, between about 1 and 50 nm, between about 100 nm and 800 nm, between about 400 nm and 600 nm, or about 500 nm. In one embodiment, the micro-particles are no more than about 0.1 nm, 0.5 nm, 1.0 nm, 5.0 nm, 10 nm, 25 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 400 nm, 450 nm, 500 nm, 550 nm, 600 nm, 650 nm, 700 nm, 750 nm, 800 nm, 850 nm, 900 nm, 950 nm, 1000 nm, 1250 nm, 1500 nm, 1750 nm, or 2000 nm. In some embodiments, a compound described herein may be covalently coupled to a polymer used in the nanoparticle, for example a polystyrene particle, PLGA particle, PLA particle, or other nanoparticle.
The pharmaceutical compositions can be formulated for oral administration. These compositions can contain any amount of active compound that achieves the desired result, for example between 0.1 and 99 weight % (wt. %) of the compound and usually at least about 5 wt. % of the compound. Some embodiments contain at least about 10%, 15%, 20%, 25 wt. % to about 50 wt. % or from about 5 wt. % to about 75 wt. % of the compound.
Pharmaceutical compositions suitable for rectal administration are typically presented as unit dose suppositories. These may be prepared by admixing the active compound with one or more conventional solid carriers, for example, cocoa butter, and then shaping the resulting mixture.
Pharmaceutical compositions suitable for topical application to the skin preferably take the form of an ointment, cream, lotion, paste, gel, spray, aerosol, or oil. Carriers which may be used include petroleum jelly, lanoline, polyethylene glycols, alcohols, transdermal enhancers, and combinations of two or more thereof.
Pharmaceutical compositions suitable for transdermal administration may be presented as discrete patches adapted to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. Pharmaceutical compositions suitable for transdermal administration may also be delivered by iontophoresis (see, for example, Pharmaceutical Research 3 (6):318 (1986)) and typically take the form of an optionally buffered aqueous solution of the active compound. In one embodiment, microneedle patches or devices are provided for delivery of drugs across or into biological tissue, particularly the skin. The microneedle patches or devices permit drug delivery at clinically relevant rates across or into skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue.
Pharmaceutical compositions suitable for administration to the lungs can be delivered by a wide range of passive breath driven and active power driven single/-multiple dose dry powder inhalers (DPI). The devices most commonly used for respiratory delivery include nebulizers, metered-dose inhalers, and dry powder inhalers. Several types of nebulizers are available, including jet nebulizers, ultrasonic nebulizers, and vibrating mesh nebulizers. Selection of a suitable lung delivery device depends on parameters, such as nature of the drug and its formulation, the site of action, and pathophysiology of the lung.
Additional non-limiting examples of inhalation drug delivery devices and methods include, for example, U.S. Pat. No. 7,383,837 titled “Inhalation device” (SmithKline Beecham Corporation); WO/2006/033584 titled “Powder inhaler” (Glaxo SmithKline Pharmaceuticals SA); WO/2005/044186 titled “Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same” (Glaxo Group Ltd and SmithKline Beecham Corporation); U.S. Pat. No. 9,095,670 titled “Inhalation device and method of dispensing medicament”, U.S. Pat. No. 8,205,611 titled “Dry powder inhaler” (Astrazeneca AB); WO/2013/038170 titled “Inhaler” (Astrazeneca AB and Astrazeneca UK Ltd.); US/2014/0352690 titled “Inhalation Device with Feedback System”, U.S. Pat. No. 8,910,625 and US/2015/0165137 titled “Inhalation Device for Use in Aerosol Therapy” (Vectura GmbH); U.S. Pat. No. 6,948,496 titled “Inhalers”, US/2005/0152849 titled “Powders comprising anti-adherent materials for use in dry powder inhalers”, U.S. Pat. Nos. 6,582,678, 8,137,657, US/2003/0202944, and US/2010/0330188 titled “Carrier particles for use in dry powder inhalers”, U.S. Pat. No. 6,221,338 titled “Method of producing particles for use in dry powder inhalers”, U.S. Pat. No. 6,989,155 titled “Powders”, US/2007/0043030 titled “Pharmaceutical compositions for treating premature ejaculation by pulmonary inhalation”, U.S. Pat. No. 7,845,349 titled “Inhaler”, US/2012/0114709 and U.S. Pat. No. 8,101,160 titled “Formulations for Use in Inhaler Devices”, US/2013/0287854 titled “Compositions and Uses”, US/2014/0037737 and U.S. Pat. No. 8,580,306 titled “Particles for Use in a Pharmaceutical Composition”, US/2015/0174343 titled “Mixing Channel for an Inhalation Device”, U.S. Pat. No. 7,744,855 and US/2010/0285142 titled “Method of making particles for use in a pharmaceutical composition”, U.S. Pat. No. 7,541,022, US/2009/0269412, and US/2015/0050350 titled “Pharmaceutical formulations for dry powder inhalers” (Vectura Limited).
Many methods and devices for drug delivery to the eye are known in the art. Non-limiting examples are described in the following patents and patent applications (fully incorporated herein by reference). Examples are U.S. Pat. No. 8,192,408 titled “Ocular trocar assembly” (Psivida Us, Inc.); U.S. Pat. No. 7,585,517 titled “Transcleral delivery” (Macusight, Inc.); U.S. Pat. Nos. 5,710,182 and 5,795,913 titled “Ophthalmic composition” (Santen OY); U.S. Pat. No. 8,663,639 titled “Formulations for treating ocular diseases and conditions”, U.S. Pat. No. 8,486,960 titled “Formulations and methods for vascular permeability-related diseases or conditions”, U.S. Pat. Nos. 8,367,097 and 8,927,005 titled “Liquid formulations for treatment of diseases or conditions”, U.S. Pat. No. 7,455,855 titled “Delivering substance and drug delivery system using the same” (Santen Pharmaceutical Co., Ltd.); WO/2011/050365 titled “Conformable Therapeutic Shield For Vision and Pain” and WO/2009/145842 titled “Therapeutic Device for Pain Management and Vision” (Forsight Labs, LLC); U.S. Pat. Nos. 9,066,779 and 8,623,395 titled “Implantable therapeutic device”, WO/2014/160884 titled “Ophthalmic Implant for Delivering Therapeutic Substances”, U.S. Pat. Nos. 8,399,006, 8,277,830, 8,795,712, 8,808,727, 8,298,578, and WO/2010/088548 titled “Posterior segment drug delivery”, WO/2014/152959 and US20140276482 titled “Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant”, U.S. Pat. Nos. 8,905,963 and 9,033,911 titled “Injector apparatus and method for drug delivery”, WO/2015/057554 titled “Formulations and Methods for Increasing or Reducing Mucus”, U.S. Pat. Nos. 8,715,712 and 8,939,948 titled “Ocular insert apparatus and methods”, WO/2013/116061 titled “Insertion and Removal Methods and Apparatus for Therapeutic Devices”, WO/2014/066775 titled “Ophthalmic System for Sustained Release of Drug to the Eye”, WO/2015/085234 and WO/2012/019176 titled “Implantable Therapeutic Device”, WO/2012/065006 titled “Methods and Apparatus to determine Porous Structures for Drug Delivery”, WO/2010/141729 titled “Anterior Segment Drug Delivery”, WO/2011/050327 titled “Corneal Denervation for Treatment of Ocular Pain”, WO/2013/022801 titled “Small Molecule Delivery with Implantable Therapeutic Device”, WO/2012/019047 titled “Subconjunctival Implant for Posterior Segment Drug Delivery”, WO/2012/068549 titled “Therapeutic Agent Formulations for Implanted Devices”, WO/2012/019139 titled “Combined Delivery Methods and Apparatus”, WO/2013/040426 titled “Ocular Insert Apparatus and Methods”, WO/2012/019136 titled “Injector Apparatus and Method for Drug Delivery”, WO/2013/040247 titled “Fluid Exchange Apparatus and Methods” (ForSight Vision4, Inc.).
Additional non-limiting examples of how to deliver the active compounds are provided in WO/2015/085251 titled “Intracameral Implant for Treatment of an Ocular Condition” (Envisia Therapeutics, Inc.); WO/2011/008737 titled “Engineered Aerosol Particles, and Associated Methods”, WO/2013/082111 titled “Geometrically Engineered Particles and Methods for Modulating Macrophage or Immune Responses”, WO/2009/132265 titled “Degradable compounds and methods of use thereof, particularly with particle replication in non-wetting templates”, WO/2010/099321 titled “Interventional drug delivery system and associated methods”, WO/2008/100304 titled “Polymer particle composite having high fidelity order, size, and shape particles”, WO/2007/024323 titled “Nanoparticle fabrication methods, systems, and materials” (Liquidia Technologies, Inc. and the University of North Carolina at Chapel Hill); WO/2010/009087 titled “Iontophoretic Delivery of a Controlled-Release Formulation in the Eye”, (Liquidia Technologies, Inc. and Eyegate Pharmaceuticals, Inc.) and WO/2009/132206 titled “Compositions and Methods for Intracellular Delivery and Release of Cargo”, WO/2007/133808 titled “Nano-particles for cosmetic applications”, WO/2007/056561 titled “Medical device, materials, and methods”, WO/2010/065748 titled “Method for producing patterned materials”, WO/2007/081876 titled “Nanostructured surfaces for biomedical/biomaterial applications and processes thereof” (Liquidia Technologies, Inc.).
Additional non-limiting examples of methods and devices for drug delivery to the eye include, for example, WO2011/106702 and U.S. Pat. No. 8,889,193 titled “Sustained delivery of therapeutic agents to an eye compartment”, WO2013/138343 and U.S. Pat. No. 8,962,577 titled “Controlled release formulations for the delivery of HIF-1 inhibitors”, WO/2013/138346 and US2013/0272994 titled “Non-Linear Multiblock Copolymer-Drug Conjugates for the Delivery of Active Agents”, WO2005/072710 and U.S. Pat. No. 8,957,034 titled “Drug and Gene Carrier Particles that Rapidly Move Through Mucus Barriers”, WO2008/030557, US2010/0215580, US2013/0164343 titled “Compositions and Methods for Enhancing Transport Through Mucous”, WO2012/061703, US2012/0121718, and US2013/0236556 titled “Compositions and Methods Relating to Reduced Mucoadhesion”, WO2012/039979 and US2013/0183244 titled “Rapid Diffusion of Large Polymeric Nanoparticles in the Mammalian Brain”, WO2012/109363 and US2013/0323313 titled “Mucus Penetrating Gene Carriers”, WO 2013/090804 and US2014/0329913 titled “Nanoparticles with enhanced mucosal penetration or decreased inflammation”, WO2013/110028 titled “Nanoparticle formulations with enhanced mucosal penetration”, WO2013/166498 and US2015/0086484 titled “Lipid-based drug carriers for rapid penetration through mucus linings” (The Johns Hopkins University); WO2013/166385 titled “Pharmaceutical Nanoparticles Showing Improved Mucosal Transport”, US2013/0323179 titled “Nanocrystals, Compositions, And Methods that Aid Particle Transport in Mucus” (The Johns Hopkins University and Kala Pharmaceuticals, Inc.); WO/2015/066444 titled “Compositions and methods for ophthalmic and/or other applications”, WO/2014/020210 and WO/2013/166408 titled “Pharmaceutical nanoparticles showing improved mucosal transport” (Kala Pharmaceuticals, Inc.); U.S. Pat. No. 9,022,970 titled “Ophthalmic injection device including dosage control device”, WO/2011/153349 titled “Ophthalmic compositions comprising pbo-peo-pbo block copolymers”, WO/2011/140203 titled “Stabilized ophthalmic galactomannan formulations”, WO/2011/068955 titled “Ophthalmic emulsion”, WO/2011/037908 titled “Injectable aqueous ophthalmic composition and method of use therefor”, US2007/0149593 titled “Pharmaceutical Formulation for Delivery of Receptor Tyrosine Kinase Inhibiting (RTKi) Compounds to the Eye”, U.S. Pat. No. 8,632,809 titled “Water insoluble polymer matrix for drug delivery” (Alcon, Inc.).
Additional non-limiting examples of drug delivery devices and methods include, for example, US20090203709 titled “Pharmaceutical Dosage Form For Oral Administration Of Tyrosine Kinase Inhibitor” (Abbott Laboratories); US20050009910 titled “Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug”, US 20130071349 titled “Biodegradable polymers for lowering intraocular pressure”, U.S. Pat. No. 8,481,069 titled “Tyrosine kinase microspheres”, U.S. Pat. No. 8,465,778 titled “Method of making tyrosine kinase microspheres”, U.S. Pat. No. 8,409,607 titled “Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods”, U.S. Pat. No. 8,512,738 and US 2014/0031408 titled “Biodegradable intravitreal tyrosine kinase implants”, US 2014/0294986 titled “Microsphere Drug Delivery System for Sustained Intraocular Release”, U.S. Pat. No. 8,911,768 titled “Methods For Treating Retinopathy With Extended Therapeutic Effect” (Allergan, Inc.); U.S. Pat. No. 6,495,164 titled “Preparation of injectable suspensions having improved injectability” (Alkermes Controlled Therapeutics, Inc.); WO 2014/047439 titled “Biodegradable Microcapsules Containing Filling Material” (Akina, Inc.); WO 2010/132664 titled “Compositions And Methods For Drug Delivery” (Baxter International Inc. Baxter Healthcare SA); US20120052041 titled “Polymeric nanoparticles with enhanced drugloading and methods of use thereof” (The Brigham and Women's Hospital, Inc.); US20140178475, US20140248358, and US20140249158 titled “Therapeutic Nanoparticles Comprising a Therapeutic Agent and Methods of Making and Using Same” (BIND Therapeutics, Inc.); U.S. Pat. No. 5,869,103 titled “Polymer microparticles for drug delivery” (Danbiosyst UK Ltd.); U.S. Pat. No. 8,628,801 titled “Pegylated Nanoparticles” (Universidad de Navarra); US2014/0107025 titled “Ocular drug delivery system” (Jade Therapeutics, LLC); U.S. Pat. No. 6,287,588 titled “Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof”, U.S. Pat. No. 6,589,549 titled “Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles” (Macromed, Inc.); U.S. Pat. Nos. 6,007,845 and 5,578,325 titled “Nanoparticles and microparticles of non-linear hydrophilichydrophobic multiblock copolymers” (Massachusetts Institute of Technology); US20040234611, US20080305172, US20120269894, and US20130122064 titled “Ophthalmic depot formulations for periocular or subconjunctival administration (Novartis Ag); U.S. Pat. No. 6,413,539 titled “Block polymer” (Poly-Med, Inc.); US 20070071756 titled “Delivery of an agent to ameliorate inflammation” (Peyman); US 20080166411 titled “Injectable Depot Formulations And Methods For Providing Sustained Release Of Poorly Soluble Drugs Comprising Nanoparticles” (Pfizer, Inc.); U.S. Pat. No. 6,706,289 titled “Methods and compositions for enhanced delivery of bioactive molecules” (PR Pharmaceuticals, Inc.); and U.S. Pat. No. 8,663,674 titled “Microparticle containing matrices for drug delivery” (Surmodics).
Uses of Active Compounds for Treatment of Selected Disorders
In one aspect, an effective amount of an active compound or its salt or composition as described herein is used to treat a medical disorder which is an inflammatory or immune condition, a disorder mediated by the complement cascade (including a dysfunctional cascade) including a complement factor D-related disorder or alternative complement pathway-related disorder, a disorder or abnormality of a cell that adversely affects the ability of the cell to engage in or respond to normal complement activity, or an undesired complement-mediated response to a medical treatment, such as surgery or other medical procedure or a pharmaceutical or biopharmaceutical drug administration, a blood transfusion, or other allogenic tissue or fluid administration.
In one embodiment, the disorder is selected from fatty liver and conditions stemming from fatty liver, such as nonalcoholic steatohepatitis (NASH), liver inflammation, cirrhosis and liver failure. In one embodiment of the present invention, a method is provided for treating fatty liver disease in a host by administering an effective amount of an active compound or its salt or composition as described herein.
In another embodiment, an active compound or its salt or composition as described herein is used to modulate an immune response prior to or during surgery or other medical procedure. One non-limiting example is use in connection with acute or chronic graft versus host disease, which is a common complication as a result of allogeneic tissue transplant, and can also occur as a result of a blood transfusion.
In one embodiment, the present invention provides a method of treating or preventing dermatomyositis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing amyotrophic lateral sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing abdominal aortic aneurysm, hemodialysis complications, hemolytic anemia, or hemodialysis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In another embodiment, a method is provided for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceutical or biotherapeutic (e.g. CAR T-cell therapy or monoclonal antibody therapy) in a host by administering an effective amount of an active compound or its salt or composition as described herein. Various types of cytokine or inflammatory reactions may occur in response to a number of factors, such as the administrations of biotherapeutics. In one embodiment, the cytokine or inflammatory reaction is cytokine release syndrome. In one embodiment, the cytokine or inflammatory reaction is tumor lysis syndrome (which also leads to cytokine release). Symptoms of cytokine release syndrome range from fever, headache, and skin rashes to bronchospasm, hypotension and even cardiac arrest. Severe cytokine release syndrome is described as cytokine storm, and can be fatal.
Fatal cytokine storms have been observed in response to infusion with several monoclonal antibody therapeutics. See, Abramowicz D, et al. “Release of tumor necrosis factor, interleukin-2, and gamma-interferon in serum after injection of OKT3 monoclonal antibody in kidney transplant recipients” Transplantation (1989) 47(4):606-8; Chatenoud L, et al. “In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids” Transplantation (1990) 49(4):697-702; and Lim L C, Koh L P, and Tan P. “Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia” J. Clin Oncol. (1999) 17(6):1962-3.
Also contemplated herein, is the use of an active compound or its salt or composition as described herein to mediate an adverse immune response in patients receiving bi-specific T-cell engagers (BiTE). A bi-specific T-cell engager directs T-cells to target and bind with a specific antigen on the surface of a cancer cell. For example, Blinatumomab (Amgen), a BiTE has recently been approved as a second line therapy in Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. Blinatumomab is given by continuous intravenous infusion in 4-week cycles. The use of BiTE agents has been associated with adverse immune responses, including cytokine release syndrome. The most significantly elevated cytokines in the CRS associated with ACT include IL-10, IL-6, and IFN-γ (Klinger et al., Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood (2012) 119:6226-6233).
In another embodiment, the disorder is episcleritis, idiopathic episcleritis, anterior episcleritis, or posterior episcleritis. In one embodiment, the disorder is idiopathic anterior uveitis, HLA-B27 related uveitis, herpetic keratouveitis, Posner Schlossman syndrome, Fuch's heterochromic iridocyclitis, or cytomegalovirus anterior uveitis.
In one embodiment, the present invention provides a method of treating or preventing a C3 glomurenopathy by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein. In one embodiment, the disorder is selected from dense deposit disease (DDD) and C3 glomerulonephritis (C3GN).
In one embodiment, the present invention provides a method of treating or preventing a IC-MPGN by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing a paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing myasthenia gravis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing atypical hemolytic uremic syndrome (aHUS) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In one embodiment, the present invention provides a method of treating or preventing neuromyelitis optica (NMO) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein.
In yet another embodiment, the present invention provides a method of treating or preventing a disorder as described below by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein, including:
vitritis, sarcoidosis, syphilis, tuberculosis, or Lyme disease; retinal vasculitis, Eales disease, tuberculosis, syphilis, or toxoplasmosis; neuroretinitis, viral retinitis, or acute retinal necrosis; varicella zoster virus, herpes simplex virus, cytomegalovirus, Epstein-Barr virus, lichen planus, or Dengue-associated disease (e.g., hemorraghic Dengue Fever); Masquerade syndrome, contact dermatitis, trauma induced inflammation, UVB induced inflammation, eczema, granuloma annulare, or acne.
In an additional embodiment, the disorder is selected from: acute myocardial infarction, aneurysm, cardiopulmonary bypass, dilated cardiomyopathy, complement activation during cardiopulmonary bypass operations, coronary artery disease, restenosis following stent placement, or percutaneous transluminal coronary angioplasty (PTCA); antibody-mediated transplant rejection, anaphylactic shock, anaphylaxis, allogenic transplant, humoral and vascular transplant rejection, graft dysfunction, graft-versus-host disease, Graves' disease, adverse drug reactions, or chronic graft vasculopathy; allergic bronchopulmonary aspergillosis, allergic neuritis, drug allergy, radiation-induced lung injury, eosinophilic pneumonia, radiographic contrast media allergy, bronchiolitis obliterans, or interstitial pneumonia; parkinsonism-dementia complex, sporadic frontotemporal dementia, frontotemporal dementia with Parkinsonism linked to chromosome 17, frontotemporal lobar degeneration, tangle only dementia, cerebral amyloid angiopathy, cerebrovascular disorder, certain forms of frontotemporal dementia, chronic traumatic encephalopathy (CTE), PD with dementia (PDD), argyrophilic grain dementia, dementia pugilistica, dementia with Lewy Bodies (DLB), or multi-infarct dementia; Creutzfeldt-Jakob disease, Huntington's disease, multifocal motor neuropathy (MMN), prion protein cerebral amyloid angiopathy, polymyositis, postencephalitic parkinsonism, subacute sclerosing panencephalitis, non-Guamanian motor neuron disease with neurofibrillary tangles, neural regeneration, or diffuse neurofibrillary tangles with calcification.
In one embodiment, the disorder is selected from: atopic dermatitis, dermatitis, dermatomyositis bullous pemphigoid, scleroderma, sclerodermatomyositis, psoriatic arthritis, pemphigus vulgaris, Discoid lupus erythematosus, cutaneous lupus, chilblain lupus erythematosus, or lupus erythematosus-lichen planus overlap syndrome; cryoglobulinemic vasculitis, mesenteric/enteric vascular disorder, peripheral vascular disorder, antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), IL-2 induced vascular leakage syndrome, or immune complex vasculitis; angioedema, low platelets (HELLP) syndrome, sickle cell disease, platelet refractoriness, red cell casts, or typical or infectious hemolytic uremic syndrome (tHUS); hematuria, hemorrhagic shock, drug-induced thrombocytopenia, autoimmune hemolytic anemia (AIHA), azotemia, blood vessel and/or lymph vessel inflammation, rotational atherectomy, or delayed hemolytic transfusion reaction; British type amyloid angiopathy, Buerger's disease, bullous pemphigoid, C1q nephropathy, cancer, or catastrophic antiphospholipid syndrome.
In another embodiment, the disorder is selected from: wet (exudative) AMD, dry (non-exudative) AMD, chorioretinal degeneration, choroidal neovascularization (CNV), choroiditis, loss of RPE function, loss of vision (including loss of visual acuity or visual field), loss of vision from AMD, retinal damage in response to light exposure, retinal degeneration, retinal detachment, retinal dysfunction, retinal neovascularization (RNV), retinopathy of prematurity, pathological myopia, or RPE degeneration; pseudophakic bullous keratopathy, symptomatic macular degeneration related disorder, optic nerve degeneration, photoreceptor degeneration, cone degeneration, loss of photoreceptor cells, pars planitis, scleritis, proliferative vitreoretinopathy, or formation of ocular drusen; chronic urticaria, Churg-Strauss syndrome, cold agglutinin disease (CAD), corticobasal degeneration (CBD), cryoglobulinemia, cyclitis, damage of the Bruch's membrane, Degos disease, diabetic angiopathy, elevated liver enzymes, endotoxemia, epidermolysis bullosa, or epidermolysis bullosa acquisita; essential mixed cryoglobulinemia, excessive blood urea nitrogen-BUN, focal segmental glomerulosclerosis, Gerstmann-Straussler-Scheinker disease, giant cell arteritis, gout, Hallervorden-Spatz disease, Hashimoto's thyroiditis, Henoch-Schonlein purpura nephritis, or abnormal urinary sediments; hepatitis, hepatitis A, hepatitis B, hepatitis C or human immunodeficiency virus (HIV), a viral infection more generally, for example selected from Flaviviridae, Retroviruses, Coronaviridae, Poxviridae, Adenoviridae, Herpesviridae, Caliciviridae, Reoviridae, Picornaviridae, Togaviridae, Orthomyxoviridae, Rhabdoviridae, or Hepadnaviridae; Neisseria meningitidis, shiga toxin E. coli-related hemolytic uremic syndrome (STEC-HUS), hemolytic uremic syndrome (HUS); Streptococcus, or poststreptococcal glomerulonephritis.
In a further embodiment, the disorder is selected from: hyperlipidemia, hypertension, hypoalbuminemia, hypobolemic shock, hypocomplementemic urticarial vasculitis syndrome, hypophosphastasis, hypovolemic shock, idiopathic pneumonia syndrome, or idiopathic pulmonary fibrosis; inclusion body myositis, intestinal ischemia, iridocyclitis, iritis, juvenile chronic arthritis, Kawasaki's disease (arteritis), or lipiduria; membranoproliferative glomerulonephritis (MPGN) I, microscopic polyangiitis, mixed cryoglobulinemia, molybdenum cofactor deficiency (MoCD) type A, pancreatitis, panniculitis, Pick's disease, polyarteritis nodosa (PAN), progressive subcortical gliosis, proteinuria, reduced glomerular filtration rate (GFR), or renovascular disorder; multiple organ failure, multiple system atrophy (MSA), myotonic dystrophy, Niemann-Pick disease type C, chronic demyelinating diseases, or progressive supranuclear palsy; spinal cord injury, spinal muscular atrophy, spondyloarthropathies, Reiter's syndrome, spontaneous fetal loss, recurrent fetal loss, pre-eclampsia, synucleinopathy, Takayasu's arteritis, post-partum thryoiditis, thyroiditis, Type I cryoglobulinemia, Type II mixed cryoglobulinemia, Type III mixed cryoglobulinemia, ulcerative colitis, uremia, urticaria, venous gas embolus (VGE), or Wegener's granulomatosis; von Hippel-Lindau disease, histoplasmosis of the eye, hard drusen, soft drusen, pigment clumping, or photoreceptor and/or retinal pigmented epithelia (RPE) loss.
In one embodiment, an active compound or its salt or composition as described herein is useful for treating or preventing a disorder selected from autoimmune oophoritis, endometriosis, autoimmune orchitis, Ord's thyroiditis, autoimmune enteropathy, coeliac disease, Hashimoto's encephalopathy, antiphospholipid syndrome (APLS) (Hughes syndrome), aplastic anemia, autoimmune lymphoproliferative syndrome (Canale-Smith syndrome), autoimmune neutropenia, Evans syndrome, pernicious anemia, pure red cell aplasia, thrombocytopenia, adipose dolorosa (Dercum's disease), adult onset Still's disease, ankylosing spondylitis, CREST syndrome, drug-induced lupus, eosinophilic fasciitis (Shulman's syndrome), Felty syndrome, IgG4-related disease, mixed connective tissue disease (MCTD), palindromic rheumatism (Hench-Rosenberg syndrome), Parry-Romberg syndrome, Parsonage-Turner syndrome, relapsing polychondritis (Meyenburg-Altherr-Uehlinger syndrome), retroperitonial fibrosis, rheumatic fever, Schnitzler syndrome, fibromyalgia, neuromyotonia (Isaac's disease), paraneoplastic degeneration, autoimmune inner ear disease, Meniere's disease, interstitial cystitis, autoimmune pancreatitis, zika virus-related disorders, chikungunya virus-related disorders, subacute bacterial endocarditis (SBE), IgA nephropathy, IgA vasculitis, polymyalgia rheumatic, rheumatoid vasculitis, alopecia areata, autoimmune progesterone dermatitis, dermatitis herpetiformis, erythema nodosum, gestational pemphigoid, hidradenitis suppurativa, lichen sclerosus, linear IgA disease (LAD), morphea, myositis, pityriasis lichenoides et varioliformis acuta, vitiligo post-myocardial infarction syndrome (Dressler's syndrome), post-pericardiotomy syndrome, autoimmune retinopathy, Cogan syndrome, Graves opthalmopathy, ligneous conjunctivitis, Mooren's ulcer, opsoclonus myoclonus syndrome, optic neuritis, retinocochleocerebral vasculopathy (Susac's syndrome), sympathetic opthalmia, Tolosa-Hunt syndrome, interstitial lung disease, antisynthetase syndrome, Addison's disease, autoimmune polyendocrine syndrome (APS) type I, autoimmune polyendocrine syndrome (APS) type II, autoimmune polyendocrine syndrome (APS) type III, disseminated sclerosis (multiple sclerosis, pattern II), rapidly progressing glomerulonephritis (RPGN), juvenile rheumatoid arthritis, enthesitis-related arthritis, reactive arthritis (Reiter's syndrome), autoimmune hepatitis or lupoid hepatitis, primary biliary cirrhosis (PBS), primary sclerosing cholangitis, microscopic colitis, latent lupus (undifferentiated connective tissue disease (UCTD)), acute disseminated encephalomyelitis (ADEM), acute motor axonal neuropathy, anti-n-methyl-D-aspartate receptor encephalitis, Balo concentric sclerosis (Schilders disease), Bickerstaff's encephalitis, chronic inflammatory demyelinating polyneuropathy, idiopathic inflammatory demyelinating disease, Lambert-Eaton mysathenic syndrome, Oshtoran syndrome, pediatric autoimmune neuropsychiatric disorder associated with Streptococcus (PANDAS), progressive inflammatory neuropathy, restless leg syndrome, stiff person syndrome, Sydenhem syndrome, transverse myelitis, lupus vasculitis, leukocytoclastic vasculitis, Microscopic Polyangiitis, polymyositis or ischemic-reperfusion injury of the eye.
Examples of eye disorders that may be treated according to the compositions and methods disclosed herein include amoebic keratitis, fungal keratitis, bacterial keratitis, viral keratitis, onchorcercal keratitis, bacterial keratoconjunctivitis, viral keratoconjunctivitis, corneal dystrophic diseases, Fuchs' endothelial dystrophy, Sjogren's syndrome, Stevens-Johnson syndrome, autoimmune dry eye diseases, environmental dry eye diseases, corneal neovascularization diseases, post-corneal transplant rejection prophylaxis and treatment, autoimmune uveitis, infectious uveitis, posterior uveitis (including toxoplasmosis), pan-uveitis, an inflammatory disease of the vitreous or retina, endophthalmitis prophylaxis and treatment, macular edema, macular degeneration, age related macular degeneration, proliferative and non-proliferative diabetic retinopathy, hypertensive retinopathy, an autoimmune disease of the retina, primary and metastatic intraocular melanoma, other intraocular metastatic tumors, open angle glaucoma, closed angle glaucoma, pigmentary glaucoma and combinations thereof.
In a further embodiment, the disorder is selected from glaucoma, diabetic retinopathy, blistering cutaneous diseases (including bullous pemphigoid, pemphigus, and epidermolysis bullosa), ocular cicatrical pemphigoid, uveitis, adult macular degeneration, diabetic retinopa retinitis pigmentosa, macular edema, diabetic macular edema, Behcet's uveitis, multifocal choroiditis, Vogt-Koyangi-Harada syndrome, intermediate uveitis, birdshot retino-chorioditis, sympathetic ophthalmia, ocular dicatricial pemphigoid, ocular pemphigus, nonartertic ischemic optic neuropathy, postoperative inflammation, and retinal vein occlusion, or central retinal vein occlusion (CVRO).
In some embodiments, complement mediated diseases include ophthalmic diseases (including early or neovascular age-related macular degeneration and geographic atrophy), autoimmune diseases (including arthritis, rheumatoid arthritis), respiratory diseases, cardiovascular diseases. In other embodiments, the compounds of the invention are suitable for use in the treatment of diseases and disorders associated with fatty acid metabolism, including obesity and other metabolic disorders.
Disorders that may be treated or prevented by an active compound or its salt or composition as described herein also include, but are not limited to: hereditary angioedema, capillary leak syndrome, hemolytic uremic syndrome (HUS), neurological disorders, Guillain Barre Syndrome, diseases of the central nervous system and other neurodegenerative conditions, glomerulonephritis (including membrane proliferative glomerulonephritis), SLE nephritis, proliferative nephritis, liver fibrosis, tissue regeneration and neural regeneration, or Barraquer-Simons Syndrome; inflammatory effects of sepsis, systemic inflammatory response syndrome (SIRS), disorders of inappropriate or undesirable complement activation, interleukin-2 induced toxicity during IL-2 therapy, inflammatory disorders, inflammation of autoimmune diseases, system lupus erythematosus (SLE), lupus nephritides, arthritis, immune complex disorders and autoimmune diseases, systemic lupus, or lupus erythematosus; ischemia/reperfusion injury (I/R injury), myocardial infarction, myocarditis, post-ischemic reperfusion conditions, balloon angioplasty, atherosclerosis, post-pump syndrome in cardiopulmonary bypass or renal bypass, renal ischemia, mesenteric artery reperfusion after aortic reconstruction, antiphospholipid syndrome, autoimmune heart disease, ischemia-reperfusion injuries, obesity, or diabetes; Alzheimer's dementia, stroke, schizophrenia, traumatic brain injury, trauma, Parkinson's disease, epilepsy, transplant rejection, prevention of fetal loss, biomaterial reactions (e.g. in hemodialysis, in plants), hyperacute allograft rejection, xenograft rejection, transplantation, psoriasis, burn injury, thermal injury including burns or frostbite, or crush injury; asthma, allergy, acute respiratory distress syndrome (ARDS), cystic fibrosis, adult respiratory distress syndrome, dyspnea, hemoptysis, chronic obstructive pulmonary disease (COPD), emphysema, pulmonary embolisms and infarcts, pneumonia, fibrogenic dust diseases, inert dusts and minerals (e.g., silicon, coal dust, beryllium, and asbestos), pulmonary fibrosis, organic dust diseases, chemical injury (due to irritant gases and chemicals, e.g., chlorine, phosgene, sulfur dioxide, hydrogen sulfide, nitrogen dioxide, ammonia, and hydrochloric acid), smoke injury, thermal injury (e.g., burn, freeze), bronchoconstriction, hypersensitivity pneumonitis, parasitic diseases, Goodpasture's Syndrome (anti-glomerular basement membrane nephritis), pulmonary vasculitis, Pauci-immune vasculitis, or immune complex-associated inflammation.
In one embodiment, a method for the treatment of sickle cell in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of immunothrombocytopenic purpura (ITP), thrombotic thrombocytopenic purpura (TTP), or idiopathic thrombocytopenic purpura (ITP) in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of ANCA-vasculitis in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of IgA nephropathy in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of rapidly progressing glomerulonephritis (RPGN), in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of lupus nephritis, in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein. In one embodiment, a method for the treatment of hemorraghic dengue fever, in a host is provided that includes the administration of an effective amount of an active compound or its salt or composition as described herein.
In an additional alternative embodiment, an active compound or its salt or composition as described herein is used in the treatment of an autoimmune disorder.
The complement pathway enhances the ability of antibodies and phagocytic cells to clear microbes and damaged cells from the body. It is part of the innate immune system and in healthy individuals is an essential process. Inhibiting the complement pathway will decrease the body's immune system response. Therefore, it is an object of the present invention to treat autoimmune disorders by administering an effective does of an active compound or its salt or composition as described herein to a subject in need thereof.
In one embodiment the autoimmune disorder is caused by activity of the complement system. In one embodiment the autoimmune disorder is caused by activity of the alternative complement pathway. In one embodiment the autoimmune disorder is caused by activity of the classical complement pathway. In another embodiment the autoimmune disorder is caused by a mechanism of action that is not directly related to the complement system, such as the over-proliferation of T-lymphocytes or the over-production of cytokines.
Non-limiting examples of autoimmune disorders include: lupus, allograft rejection, autoimmune thyroid diseases (such as Graves' disease and Hashimoto's thyroiditis), autoimmune uveoretinitis, giant cell arteritis, inflammatory bowel diseases (including Crohn's disease, ulcerative colitis, regional enteritis, granulomatous enteritis, distal ileitis, regional ileitis, and terminal ileitis), diabetes, multiple sclerosis, pernicious anemia, psoriasis, rheumatoid arthritis, sarcoidosis, and scleroderma.
In one embodiment, an active compound or its salt or composition as described herein is used in the treatment of lupus. Non-limiting examples of lupus include lupus erythematosus, cutaneous lupus, discoid lupus erythematosus, chilblain lupus erythematosus, or lupus erythematosus-lichen planus overlap syndrome.
Lupus erythematosus is a general category of disease that includes both systemic and cutaneous disorders. The systemic form of the disease can have cutaneous as well as systemic manifestations. However, there are also forms of the disease that are only cutaneous without systemic involvement. For example, SLE is an inflammatory disorder of unknown etiology that occurs predominantly in women, and is characterized by articular symptoms, butterfly erythema, recurrent pleurisy, pericarditis, generalized adenopathy, splenomegaly, as well as CNS involvement and progressive renal failure. The sera of most patients (over 98%) contain antinuclear antibodies, including anti-DNA antibodies. High titers of anti-DNA antibodies are essentially specific for SLE. Conventional treatment for this disease has been the administration of corticosteroids or immunosuppressants.
There are three forms of cutaneous lupus: chronic cutaneous lupus (also known as discoid lupus erythematosus or DLE), subacute cutaneous lupus, and acute cutaneous lupus. DLE is a disfiguring chronic disorder primarily affecting the skin with sharply circumscribed macules and plaques that display erythema, follicular plugging, scales, telangiectasia and atrophy. The condition is often precipitated by sun exposure, and the early lesions are erythematous, round scaling papules that are 5 to 10 mm in diameter and display follicular plugging. DLE lesions appear most commonly on the cheeks, nose, scalp, and ears, but they may also be generalized over the upper portion of the trunk, extensor surfaces of the extremities, and on the mucous membranes of the mouth. If left untreated, the central lesion atrophies and leaves a scar. Unlike SLE, antibodies against double-stranded DNA (e.g., DNA-binding test) are almost invariably absent in DLE.
Multiple Sclerosis is an autoimmune demyelinating disorder that is believed to be T lymphocyte dependent. MS generally exhibits a relapsing-remitting course or a chronic progressive course. The etiology of MS is unknown, however, viral infections, genetic predisposition, environment, and autoimmunity all appear to contribute to the disorder. Lesions in MS patients contain infiltrates of predominantly T lymphocyte mediated microglial cells and infiltrating macrophages. CD4+ T lymphocytes are the predominant cell type present at these lesions. The hallmark of the MS lesion is plaque, an area of demyelination sharply demarcated from the usual white matter seen in MRI scans. Histological appearance of MS plaques varies with different stages of the disease. In active lesions, the blood-brain barrier is damaged, thereby permitting extravasation of serum proteins into extracellular spaces. Inflammatory cells can be seen in perivascular cuffs and throughout white matter. CD4+ T-cells, especially Th1, accumulate around postcapillary venules at the edge of the plaque and are also scattered in the white matter. In active lesions, up-regulation of adhesion molecules and markers of lymphocyte and monocyte activation, such as IL2-R and CD26 have also been observed. Demyelination in active lesions is not accompanied by destruction of oligodendrocytes. In contrast, during chronic phases of the disease, lesions are characterized by a loss of oligodendrocytes and hence, the presence of myelin oligodendrocyte glycoprotein (MOG) antibodies in the blood.
Diabetes can refer to either type 1 or type 2 diabetes. In one embodiment an active compound or its salt or composition as described herein is provided at an effective dose to treat a patient with type 1 diabetes. In one embodiment an active compound or its salt or composition as described herein is provided at an effective dose to treat a patient with type 2 diabetes. Type 1 diabetes is an autoimmune disease. An autoimmune disease results when the body's system for fighting infection (the immune system) attacks a part of the body. In the case of diabetes type 1, the pancreas then produces little or no insulin.
Combination Therapy
In one embodiment an active compound or its salt or composition as described herein may be provided in combination or alternation with or preceded by, concomitant with or followed by, an effective amount of at least one additional therapeutic agent, for example, for treatment of a disorder listed herein. Non-limiting examples of second active agents for such combination therapy are provided below.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination or alternation with at least one additional inhibitor of the complement system or a second active compound with a different biological mechanism of action. In the description below and herein generally, whenever any of the terms referring to an active compound or its salt or composition as described herein are used, it should be understood that pharmaceutically acceptable salts, prodrugs or compositions are considered included, unless otherwise stated or inconsistent with the text.
In non-limiting embodiments, an active compound or its salt or composition as described herein may be provided together with a protease inhibitor, a soluble complement regulator, a therapeutic antibody (monoclonal or polyclonal), complement component inhibitor, receptor agonist, or siRNA.
In other embodiments, an active compound described herein is administered in combination or alternation with an antibody against tumor necrosis factor (TNF), including but not limited to infliximab (Remicade), adalimumab, certolizumab, golimumab, or a receptor fusion protein such as etanercept (Embrel).
In another embodiment, an active compound as described herein can be administered in combination or alternation with an anti-CD20 antibody, including but not limited to rituximab (Rituxan), adalimumab (Humira), ofatumumab (Arzerra), tositumomab (Bexxar), obinutuzumab (Gazyva), or ibritumomab (Zevalin).
In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an anti-IL6 antibody, including but not limited to tocilizumab (Actemra) and siltuximab (Sylvant).
In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with an IL17 inhibitor, including but not limited to secukibumab (Cosentyx).
In an alternative embodiment, an active compound as described herein can be administered in combination or alternation with a p40 (IL12/IL23) inhibitor, including but not limited to ustekinumab (Stelara).
In an alternative embodiment, an active compound as described herein can be administered in combination or alteration with an IL23 inhibitor, including but not limited to risankizumab.
In an alternative embodiment, an active compound as described herein can be administered in combination or alteration with an anti-interferon α antibody, for example but not limited to sifalimumab.
In an alternative embodiment, an active compound as described herein can be administered in combination or alteration with a kinase inhibitor, for example but not limited to a JAK1/JAK3 inhibitor, for example but not limited to tofacitinib (Xelianz). In an alternative embodiment, an active compound as described herein can be administered in combination or alteration with a JAK1/JAK2 inhibitor, for example but not limited to baracitibib.
In an alternative embodiment, an active compound as described herein can be administered in combination or alteration with an anti-VEGF agent, for example but not limited to: aflibercept (Eylea®; Regeneron Pharmaceuticals); ranibizumab (Lucentis®: Genentech and Novartis); pegaptanib (Macugen®; OSI Pharmaceuticals and Pfizer); bevacizumab (Avastin; Genentech/Roche); lapatinib (Tykerb); sunitinib (Sutent); axitinib (Inlyta); pazopanib; sorafenib (Nexavar); ponatinib (Inclusig); regorafenib (Stivarga); cabozantinib (Abometyx; Cometriq); vendetanib (Caprelsa); ramucirumab (Cyramza); lenvatinib (Lenvima); ziv-aflibercept (Zaltrap); cediranib (Recentin); anecortane acetate, squalamine lactate, and corticosteroids.
In another embodiment, an active compound as described herein can be administered in combination or alternation with an immune checkpoint inhibitor. Non-limiting examples of checkpoint inhibitors include anti-PD-1 or anti-PDL1 antibodies, for example, nivolumab (Opdivo), pembrolizumab (Keytruda), pidilizumab, AMP-224 (AstraZeneca and MedImmune), PF-06801591 (Pfizer), MEDIO680 (AstraZeneca), PDR001 (Novartis), REGN2810 (Regeneron), SHR-12-1 (Jiangsu Hengrui Medicine Company and Incyte Corporation), TSR-042 (Tesaro), and the PD-L1/VISTA inhibitor CA-170 (Curis Inc.), atezolizumab, durvalumab, and KN035, or anti-CTLA4 antibodies, for example Ipilimumab, Tremelimumab, AGEN1884 and AGEN2041 (Agenus).
Non-limiting examples of active agents that can be used in combination with active compounds described herein are:
Protease inhibitors: plasma-derived C1-INH concentrates, for example Cetor® (Sanquin), Berinert-P® (CSL Behring, Lev Pharma), and Cinryze®; recombinant human C1-inhibitors, for example Rhucin®; ritonavir (Norvir®, Abbvie, Inc.);
Soluble complement regulators: Soluble complement receptor 1 (TP10) (Avant Immunotherapeutics); sCR1-sLeX/TP-20 (Avant Immunotherapeutics); MLN-2222/CAB-2 (Millenium Pharmaceuticals); Mirococept (Inflazyme Pharmaceuticals);
Therapeutic antibodies: Eculizumab/Soliris (Alexion Pharmaceuticals); Pexelizumab (Alexion Pharmaceuticals); Ofatumumab (Genmab A/S); TNX-234 (Tanox); TNX-558 (Tanox); TA106 (Taligen Therapeutics); Neutrazumab (G2 Therapies); Anti-properdin (Novelmed Therapeutics); HuMax-CD38 (Genmab A/S);
Complement component inhibitors: Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas);
PDGF inhibitors: Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trapidil;
Anti-factor H or anti-factor B agents: Anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas);
Complement C3 or CAP C3 Convertase targeting molecules: TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikaciomab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CRIg/CFH; Anti-CR3, anti-MASP2, anti C1s, and anti-C1n molecules: Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera);
Receptor agonists: PMX-53 (Peptech Ltd.); JPE-137 (Jerini); JSM-7717 (Jerini);
Others: Recombinant human MBL (rhMBL; Enzon Pharmaceuticals); Imides and glutarimide derivatives such as thalidomide, lenalidomide, pomalidomide; Additional non-limiting examples that can be used in combination or alternation with an active compound or its salt or composition as described herein include the following.
Non-limiting examples of potential therapeutics for combination therapy
Name Target Company Class of Molecule
LFG316 C5 Novartis/Morphosys Monoclonal antibody
4(1MEW)APL-1, APL-2 C3/C3b Apellis Compstatin Family
4(1MeW)POT-4 C3/C3b Potentia Compstatin Family
Anti-C5 siRNA C5 Alnylam Si-RNA
Anti-FB siRNA CFB Alnylam SiRNA
ARC1005 C5 Novo Nordisk Aptamers
ATA C5 N.A. Chemical
Coversin C5 Volution Immuno- Small animal protein
Pharmaceuticals
CP40/AMY-101, PEG- C3/C3b Amyndas Compstatin Family
Cp40
CRIg/CFH CAP C3 NA CFH-based protein
convertase
Cynryze C1n/C1s ViroPharma/Baxter Human purified protein
FCFD4514S CFD Genentech/Roche Monoclonal antibody
H17 C3 EluSys Therapeutics Monoclonal antibody
(C3b/iC3b)
Mini-CFH CAP C3 Amyndas CFH-based protein
convertase
Mirococept (APT070) CAP and CCP NA CR1-based protein
C3
Mubodine C5 Adienne Monoclonal antibody
RA101348 C5 Rapharma Small molecule
sCR1 (CDX-1135) CAP and CP Celldex CR1-based protein
C3
SOBI002 C5 Swedish Orphan Affibody
Biovitrum
SOMAmers C5 SomaLogic Aptamers
SOMAmers CFB and CFD SomaLogic Aptamers (SELEX)
TA106 CFB Alexion Monoclonal antibody
Pharmaceuticals
TNT003 C1s True North Monoclonal antibody
TT30 (CR2/CFH) CAP C3 Alexion CFH-based protein
convertase
TT32 (CR2/CR1) CAP and CCP Alexion CR1-based protein
C3 Pharmaceuticals
Nafamostat (FUT-175, C1s, CFD, Torri Pharmaceuticals Small molecule
Futhan) other proteases
OMS721 MASP-2 Omeros Monoclonal antibody
OMS906 MASP-2 Omeros Monoclonal antibody
Bikaciomab, NM9308 CFB Novelmed Monoclonal antibody
NM9401 Properdin Novelmed Monoclonal antibody
CVF, HC-1496 C3 InCode Recombinant peptide
ALXN1102/ALXN1103 C3-conv, C3b Alexion Regulator
(TT30) Pharmaceuticals
rFH C3-conv, C3b Optherion Regulator
5C6, AMY-301 CFH Amyndas Regulator
Erdigna C5 Adienne Pharma Antibody
ARC1905 C5 Opthotech Monoclonal Antibody
MEDI7814 C5/C5a MedImmune Monoclonal Antibody
NOX-D19 C5a Noxxon Aptamer (Spiegelmer)
IFX-1, CaCP29 C5a InflaRx Monoclonal Antibody
PMX53, PMX205 C5aR Cephalon, Teva Peptidomimetic
CCX168 C5aR ChemoCentryx Small molecule
ADC-1004 C5aR Alligator Bioscience Small molecule
Anti-C5aR-151, C5aR Novo Nordisk Monoclonal Antibody
NN8209; Anti-C5aR-
215, NN8210
Imprime PGG CR3 Biothera Soluble beta-glucan
ANX005; ANX007 C1q Annexon Monoclonal Antibody
Lampalizumab fD Roche Monoclonal Antibody
avacincaptad pegol C5 Opthotech Aptamer
regenemab C6 Regenesance Monoclonal Antibody
BIVV020 C1s Bioverativ Monoclonal Antibody
PRO-02 C2 Broteio/Argen-x Monoclonal Antibody
5C6, compsorbin fH Amyndas Peptide
SOBI005 C5 Sobi Protein
ISU305 C5 ISU ABXIS Monoclonal Antibody
Mubodina C5 Adienne Monoclonal Antibody
IFX-2, IFX-3 C5a InflaRx Monoclonal Antibody
ALS-205 C5aR1 Alsonex Peptide
DF2593A C5aR1 Dompé Small Molecule
IPH5401 C5aR1 Innate Pharma Monoclonal Antibody
C6-LNA C6 Regenesance Oligonucleotide
SKY59 C5 Roche Monoclonal Antibody
REGN3918 C5 Regeneron Monoclonal Antibody
Aptamers to Factor D fD Vitrisa Therapeutics Aptamer
CLG561 Properdin Novartis Monoclonal Antibody
Tesidolumab; LFG316 C5 Novartis and Monoclonal Antibody
MorphoSys
In one embodiment, an active compound or its salt or composition as described herein may be provided together with a compound that inhibits an enzyme that metabolizes an administered protease inhibitor. In one embodiment, a compound or salt may be provided together with ritonavir.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a complement C5 inhibitor or C5 convertase inhibitor. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with eculizumab, a monoclonal antibody directed to the complement factor C5 and manufactured and marketed by Alexion Pharmaceuticals under the tradename Soliris. Eculizumab has been approved by the U.S. FDA for the treatment of PNH and aHUS.
In one embodiment, an active compound or its salt or composition as described herein may be provided together with a compound that inhibits Complement Factor D. In one embodiment of the invention, an active compound or its salt or composition as described herein as described herein can be used in combination or alternation with a compound described in Biocryst Pharmaceuticals U.S. Pat. No. 6,653,340 titled “Compounds useful in the complement, coagulate and kallikrein pathways and method for their preparation” describes fused bicyclic ring compounds that are potent inhibitors of Factor D; Novartis PCT patent publication WO2012/093101 titled “Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration” describes certain Factor D inhibitors; Novartis PCT patent publications WO2013/164802, WO2013/192345, WO2014/002051, WO2014/002052, WO2014/002053, WO2014/002054, WO2014/002057, WO2014/002058, WO2014/002059, WO2014/005150, WO2014/009833, WO2014/143638, WO2015/009616, WO2015/009977, WO2015/066241, Bristol-Myers Squibb PCT patent publication WO2004/045518 titled “Open chain prolyl urea-related modulators of androgen receptor function”; Japan Tobacco Inc. PCT patent publication WO1999/048492 titled “Amide derivatives and nociceptin antagonists”; Ferring B. V. and Yamanouchi Pharmaceutical Co. LTD. PCT patent publication WO1993/020099 titled “CCK and/or gastrin receptor ligands”; Alexion Pharmaceuticals PCT patent publication WO1995/029697 titled “Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases”; or Achillion Pharmaceuticals filed PCT Patent Application No. PCT/US2015/017523 and U.S. patent application Ser. No. 14/631,090 titled “Alkyne Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017538 and U.S. patent application Ser. No. 14/631,233 titled “Amide Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017554 and U.S. patent application Ser. No. 14/631,312 titled “Amino Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017583 and U.S. patent application Ser. No. 14/631,440 titled “Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017593 and U.S. patent application Ser. No. 14/631,625 titled “Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017597 and U.S. patent application Ser. No. 14/631,683 titled “Ether Compounds for Treatment of Complement Mediated Disorders”; PCT Patent Application No. PCT/US2015/017600 and U.S. patent application Ser. No. 14/631,785 titled “Phosphonate Compounds for Treatment of Complement Mediated Disorders”; and PCT Patent Application No. PCT/US2015/017609 and U.S. patent application Ser. No. 14/631,828 titled “Compounds for Treatment of Complement Mediated Disorders.”
In one embodiment, an active compound or its salt or composition as described herein is administered in combination with an anti-inflammatory drug, antimicrobial agent, anti-angiogenesis agent, immunosuppressant, antibody, steroid, ocular antihypertensive drug or combinations thereof. Examples of such agents include amikacin, anecortane acetate, anthracenedione, anthracycline, an azole, amphotericin B, bevacizumab, camptothecin, cefuroxime, chloramphenicol, chlorhexidine, chlorhexidine digluconate, clortrimazole, a clotrimazole cephalosporin, corticosteroids, dexamethasone, desamethazone, econazole, eftazidime, epipodophyllotoxin, fluconazole, flucytosine, fluoropyrimidines, fluoroquinolines, gatifloxacin, glycopeptides, imidazoles, itraconazole, ivermectin, ketoconazole, levofloxacin, macrolides, miconazole, miconazole nitrate, moxifloxacin, natamycin, neomycin, nystatin, ofloxacin, polyhexamethylene biguanide, prednisolone, prednisolone acetate, pegaptanib, platinum analogues, polymicin B, propamidine isethionate, pyrimidine nucleoside, ranibizumab, squalamine lactate, sulfonamides, triamcinolone, triamcinolone acetonide, triazoles, vancomycin, anti-vascular endothelial growth factor (VEGF) agents, VEGF antibodies, VEGF antibody fragments, vinca alkaloid, timolol, betaxolol, travoprost, latanoprost, bimatoprost, brimonidine, dorzolamide, acetazolamide, pilocarpine, ciprofloxacin, azithromycin, gentamycin, tobramycin, cefazolin, voriconazole, gancyclovir, cidofovir, foscarnet, diclofenac, nepafenac, ketorolac, ibuprofen, indomethacin, fluoromethalone, rimexolone, anecortave, cyclosporine, methotrexate, tacrolimus, anti-PDGFR molecule, and combinations thereof.
In one embodiment of the present invention, an active compound or its salt or composition as described herein can be administered in combination or alternation with at least one immunosuppressive agent. The immunosuppressive agent as non-limiting examples, may be a calcineurin inhibitor, e.g. a cyclosporin or an ascomycin, e.g. Cyclosporin A (NEORAL®), FK506 (tacrolimus), pimecrolimus, a mTOR inhibitor, e.g. rapamycin or a derivative thereof, e.g. Sirolimus (RAPAMUNE®), Everolimus (Certican®), temsirolimus, zotarolimus, biolimus-7, biolimus-9, a rapalog, e.g. ridaforolimus, azathioprine, campath 1H, a S1P receptor modulator, e.g. fingolimod or an analogue thereof, an anti IL-8 antibody, mycophenolic acid or a salt thereof, e.g. sodium salt, or a prodrug thereof, e.g. Mycophenolate Mofetil (CELLCEPT®), OKT3 (ORTHOCLONE OKT3®), Prednisone, ATGAM®, THYMOGLOBULIN®, Brequinar Sodium, OKT4, T10B9.A-3A, 33B3.1, 15-deoxyspergualin, tresperimus, Leflunomide ARAVA®, CTLAI-Ig, anti-CD25, anti-IL2R, Basiliximab (SIMULECT®), Daclizumab (ZENAPAX®), mizorbine, methotrexate, dexamethasone, ISAtx-247, SDZ ASM 981 (pimecrolimus, Elidel®), CTLA4lg (Abatacept), belatacept, LFA3lg, etanercept (sold as Enbrel® by Immunex), adalimumab (Humira®), infliximab (Remicade®), an anti-LFA-1 antibody, natalizumab (Antegren®), Enlimomab, gavilimomab, antithymocyte immunoglobulin, siplizumab, Alefacept efalizumab, pentasa, mesalazine, asacol, codeine phosphate, benorylate, fenbufen, naprosyn, diclofenac, etodolac and indomethacin, tocilizumab (Actemra), siltuximab (Sylvant), secukibumab (Cosentyx), ustekinumab (Stelara), risankizumab, sifalimumab, aspirin and ibuprofen.
Examples of anti-inflammatory agents include methotrexate, dexamethasone, dexamethasone alcohol, dexamethasone sodium phosphate, fluromethalone acetate, fluromethalone alcohol, lotoprendol etabonate, medrysone, prednisolone acetate, prednisolone sodium phosphate, difluprednate, rimexolone, hydrocortisone, hydrocortisone acetate, lodoxamide tromethamine, aspirin, ibuprofen, suprofen, piroxicam, meloxicam, flubiprofen, naproxan, ketoprofen, tenoxicam, diclofenac sodium, ketotifen fumarate, diclofenac sodium, nepafenac, bromfenac, flurbiprofen sodium, suprofen, celecoxib, naproxen, rofecoxib, glucocorticoids, diclofenac, and any combination thereof. In one embodiment, an active compound or its salt or composition as described herein is combined with one or more non-steroidal anti-inflammatory drugs (NSAIDs) selected from naproxen sodium (Anaprox), celecoxib (Celebrex), sulindac (Clinoril), oxaprozin (Daypro), salsalate (Disalcid), diflunisal (Dolobid), piroxicam (Feldene), indomethacin (Indocin), etodolac (Lodine), meloxicam (Mobic), naproxen (Naprosyn), nabumetone (Relafen), ketorolac tromethamine (Toradol), naproxen/esomeprazole (Vimovo), and diclofenac (Voltaren), and combinations thereof.
In one embodiment, an active compound or its salt or composition as described herein is administered in combination or alteration with an omega-3 fatty acid or a peroxisome proliferator-activated receptor (PPARs) agonist. Omega-3 fatty acids are known to reduce serum triglycerides by inhibiting DGAT and by stimulating peroxisomal and mitochondrial beta oxidation. Two omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been found to have high affinity for both PPAR-alpha and PPAR-gamma. Marine oils, e.g., fish oils, are a good source of EPA and DHA, which have been found to regulate lipid metabolism. Omega-3 fatty acids have been found to have beneficial effects on the risk factors for cardiovascular diseases, especially mild hypertension, hypertriglyceridemia and on the coagulation factor VII phospholipid complex activity. Omega-3 fatty acids lower serum triglycerides, increase serum HDL-cholesterol, lower systolic and diastolic blood pressure and the pulse rate, and lower the activity of the blood coagulation factor VII-phospholipid complex. Further, omega-3 fatty acids seem to be well tolerated, without giving rise to any severe side effects. One such form of omega-3 fatty acid is a concentrate of omega-3, long chain, polyunsaturated fatty acids from fish oil containing DHA and EPA and is sold under the trademark Omacor®. Such a form of omega-3 fatty acid is described, for example, in U.S. Pat. Nos. 5,502,077, 5,656,667 and 5,698,594, the disclosures of which are incorporated herein by reference.
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors. There are three distinct PPAR subtypes that are the products of different genes and are commonly designated PPAR-alpha, PPAR-beta/delta (or merely, delta) and PPAR-gamma. General classes of pharmacological agents that stimulate peroxisomal activity are known as PPAR agonists, e.g., PPAR-alpha agonists, PPAR-gamma agonists and PPAR-delta agonists. Some pharmacological agents are combinations of PPAR agonists, such as alpha/gamma agonists, etc., and some other pharmacological agents have dual agonist/antagonist activity. Fibrates such as fenofibrate, bezafibrate, clofibrate and gemfibrozil, are PPAR-alpha agonists and are used in patients to decrease lipoproteins rich in triglycerides, to increase HDL and to decrease atherogenic-dense LDL. Fibrates are typically orally administered to such patients. Fenofibrate or 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, 1-methylethyl ester, has been known for many years as a medicinally active principle because of its efficacy in lowering blood triglyceride and cholesterol levels.
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-VEGF agent. Non-limiting examples of anti-VEGF agents include, but are not limited to, aflibercept (Eylea®; Regeneron Pharmaceuticals); ranibizumab (Lucentis®: Genentech and Novartis); pegaptanib (Macugen®; OSI Pharmaceuticals and Pfizer); bevacizumab (Avastin; Genentech/Roche); lapatinib (Tykerb); sunitinib (Sutent); axitinib (Inlyta); pazopanib; sorafenib (Nexavar); ponatinib (Inclusig); regorafenib (Stivarga); Cabozantinib (Abometyx; Cometriq); vendetanib (Caprelsa); ramucirumab (Cyramza); lenvatinib (Lenvima); ziv-aflibercept (Zaltrap); cediranib (Recentin); anecortane acetate, squalamine lactate, and corticosteroids, including, but not limited to, triamcinolone acetonide.
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with a complement C5 inhibitor, for example, a complement C5 inhibitor described herein and in the table above titled Non-limiting examples of potential therapeutics for combination therapy, including, but not limited to, eculizumab; LFG316 (Novartis/Morphosys); Anti-C5 siRNA (Alnylam); ARC1005 (Novo Nordisk); Coversin (Volution Immuno-Pharmaceuticals); Mubodine (Adienne Pharma); RA101348 (Ra Pharma); SOBI002 (Swedish Orphan Biovitrum); SOMAmers (SomaLogic); Erdigna (Adienne Pharma); ARC1905 (Opthotech); MED17814 (MedImmune); NOX-D19 (Noxxon); IFX-1, CaCP29 (InflaRx); PMX53, PMX205 (Cephalon, Teva); CCX168 (ChemoCentryx); ADC-1004 (Alligator Bioscience); and Anti-C5aR-151, NN8209; Anti-C5aR-215, NN8210 (Novo Nordisk).
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with anti-properidin agent, for example, an anti-properidin agent as described above, including but not limited to NM9401 (Novelmed).
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with a complement C3 inhibitor for example, a complement C3 inhibitor described above, including, but not limited to, a compstatin or compstatin analogue, for example Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas) Complement C3 or CAP C3 Convertase targeting molecules: TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikaciomab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30)(Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); and CRIg/CFH.
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-factor H or anti-factor B agent selected from Anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas).
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an anti-MASP2, anti-C1s or anti-CR3 molecules, for example, but not limited to: Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera).
In one embodiment, the present invention provides a method of treating or preventing age-related macular degeneration (AMD) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination with an PDGF inhibitor, for example as described herein including but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trapidil.
In one embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein with an additional inhibitor of the complement system or another active compound with a different biological mechanism of action. In another embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with eculizumab. In another embodiment, the present invention provides a method of treating or preventing paroxysmal nocturnal hemoglobinuria (PNH) by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with CP40. In one embodiment, the additional agent is PEGylated-CP40. CP40 is a peptide inhibitor that shows a strong binding affinity for C3b and inhibits hemolysis of paroxysmal nocturnal hemoglobinuria (PNH) erythrocytes. In one embodiment, the additional agent is a complement component inhibitor, for example but not limited to Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas); a PDGF inhibitor, for example, but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trapidil; an anti-factor H or anti-factor B agent, for example anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas); a complement C3 or CAP C3 convertase targeting molecule, for example but not limited to TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikaciomab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CRIg/CFH, an anti-CR3, anti-MASP2, anti C1s, or anti-C1n molecule, for example but not limited to Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera)
In one embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of a composition comprising an active compound or its salt or composition as described herein in combination or alternation with an additional inhibitor of the complement system, or an active agent that functions through a different mechanism of action. In another embodiment, the present invention provides a method of treating or preventing rheumatoid arthritis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with methotrexate. In certain embodiments, an active compound or its salt or composition as described herein is administered in combination or alternation with at least one additional therapeutic agent selected from: salicylates including aspirin (Anacin, Ascriptin, Bayer Aspirin, Ecotrin) and salsalate (Mono-Gesic, Salgesic); nonsteroidal anti-inflammatory drugs (NSAIDs); nonselective inhibitors of the cyclo-oxygenase (COX-1 and COX-2) enzymes, including diclofenac (Cataflam, Voltaren), ibuprofen (Advil, Motrin), ketoprofen (Orudis), naproxen (Aleve, Naprosyn), piroxicam (Feldene), etodolac (Lodine), indomethacin, oxaprozin (Daypro), nabumetone (Relafen), and meloxicam (Mobic); selective cyclo-oxygenase-2 (COX-2) inhibitors including Celecoxib (Celebrex); disease-modifying antirheumatic drugs (DMARDs), including azathioprine (Imuran), cyclosporine (Sandimmune, Neoral), gold salts (Ridaura, Solganal, Aurolate, Myochrysine), hydroxychloroquine (Plaquenil), leflunomide (Arava), methotrexate (Rheumatrex), penicillamine (Cuprimine), and sulfasalazine (Azulfidine); biologic drugs including abatacept (Orencia), etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), and anakinra (Kineret); corticosteroids including betamethasone (Celestone Soluspan), cortisone (Cortone), dexamethasone (Decadron), methylprednisolone (SoluMedrol, DepoMedrol), prednisolone (Delta-Cortef), prednisone (Deltasone, Orasone), and triamcinolone (Aristocort); gold salts, including Auranofin (Ridaura); Aurothioglucose (Solganal); Aurolate; Myochrysine; or any combination thereof.
In one embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with an additional inhibitor of the complement system, or an active agent that functions through a different mechanism of action. In another embodiment, the present invention provides a method of treating or preventing multiple sclerosis by administering to a subject in need thereof an effective amount of an active compound or its salt or composition as described herein in combination or alternation with a corticosteroid. Examples of corticosteroids include, but are not limited to, prednisone, dexamethasone, solumedrol, and methylprednisolone. In one embodiment, an active compound or its salt or composition as described herein is combined with at least one anti-multiple sclerosis drug, for example, selected from: Aubagio (teriflunomide), Avonex (interferon beta-1a), Betaseron (interferon beta-1b), Copaxone (glatiramer acetate), Extavia (interferon beta-1b), Gilenya (fingolimod), Lemtrada (alemtuzumab), Novantrone (mitoxantrone), Plegridy (peginterferon beta-1a), Rebif (interferon beta-1a), Tecfidera (dimethyl fumarate), Tysabri (natalizumab), Solu-Medrol (methylprednisolone), High-dose oral Deltasone (prednisone), H.P. Acthar Gel (ACTH), or a combination thereof.
In one embodiment, an active compound or its salt or composition as described herein is useful in a combination with another pharmaceutical agent to ameliorate or reduce a side effect of the agent. For example, in one embodiment, an active compound or its salt or composition as described herein may be used in combination with adoptive cell transfer therapies to reduce an associated inflammatory response associated with such therapies, for example, a cytokine mediated response such as cytokine release syndrome. In one embodiment, the adoptive cell transfer therapy includes the use of a chimeric antigen receptor T-Cell (CAR T). In one embodiment, the adoptive cell transfer therapy includes the use of a chimeric antigen receptor T-Cell (CAR T) or a dendritic cell to treat a hematologic or solid tumor, for example, a B-cell related hematologic cancer. In one embodiment, the hematologic or solid tumor is acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), pancreatic cancer, glioblastoma, or a cancer that expresses CD19.
In an additional alternative embodiment, an active compound or its salt or composition as described herein may be provided in combination with eculizumab for the treatment of PNH, aHUSs, STEC-HUS, ANCA-vasculitis, AMD, CAD, C3 glomerulopathy, for example DDD or C3GN, chronic hemolysis, neuromyelitis optica, or transplantation rejection. In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with compstatin or a compstatin derivative for the treatment of PNH, aHUSs, STEC-HUS, ANCA-vasculitis, AMD, CAD, C3 glomerulopathy, for example DDD or C3GN, chronic hemolysis, neuromyelitis optica, or transplantation rejection. In one embodiment, the additional agent is a complement component inhibitor, for example but not limited to Compstatin/POT-4 (Potentia Pharmaceuticals); ARC1905 (Archemix); 4(1MEW)APL-1, APL-2 (Appelis); CP40/AMY-101, PEG-Cp40 (Amyndas); a PDGF inhibitor, for example, but not limited to Sorafenib Tosylate; Imatinib Mesylate (STI571); Sunitinib Malate; Ponatinib (AP24534); Axitinib; Imatinib (STI571); Nintedanib (BIBF 1120); Pazopanib HCl (GW786034 HCl); Dovitinib (TKI-258, CHIR-258); Linifanib (ABT-869); Crenolanib (CP-868596); Masitinib (AB1010); Tivozanib (AV-951); Motesanib Diphosphate (AMG-706); Amuvatinib (MP-470); TSU-68 (SU6668, Orantinib); CP-673451; Ki8751; Telatinib; PP121; Pazopanib; KRN 633; Dovitinib (TKI-258) Dilactic Acid; MK-2461; Tyrphostin (AG 1296); Dovitinib (TKI258) Lactate; Sennoside B; Sunitinib; AZD2932; and Trapidil; an anti-factor H or anti-factor B agent, for example anti-FB siRNA (Alnylam); FCFD4514S (Genentech/Roche) SOMAmers for CFB and CFD (SomaLogic); TA106 (Alexion Pharmaceuticals); 5C6, and AMY-301 (Amyndas); a complement C3 or CAP C3 convertase targeting molecule, for example but not limited to TT30 (CR2/CFH) (Alexion); TT32 (CR2/CR1) (Alexion Pharmaceuticals); Nafamostat (FUT-175, Futhan) (Torri Pharmaceuticals); Bikaciomab, NM9308 (Novelmed); CVF, HC-1496 (InCode) ALXN1102/ALXN1103 (TT30) (Alexion Pharmaceuticals); rFH (Optherion); H17 C3 (C3b/iC3b) (EluSys Therapeutics); Mini-CFH (Amyndas) Mirococept (APT070); sCR1 (CDX-1135) (Celldex); CRIg/CFH, an anti-CR3, anti-MASP2, anti C1s, or anti-C1n molecule, for example but not limited to Cynryze (ViroPharma/Baxter); TNT003 (True North); OMS721 (Omeros); OMS906 (Omeros); and Imprime PGG (Biothera).
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with rituxan for the treatment of a complement mediated disorder. In one embodiment, the complement mediated disorder is, for example, rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). In one embodiment, the disorder is Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with cyclophosphamide for the treatment of a complement mediated disorder. In one embodiment, the disorder is an autoimmune disease. In one embodiment, the complement mediated disorder is, for example, rheumatoid arthritis, Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis), and Microscopic Polyangiitis (MPA). In one embodiment, the disorder is Lupus.
In one embodiment, an active compound or its salt or composition as described herein is dosed in combination with a conventional DLE treatment for the treatment of lupus to a subject in need thereof.
Examples of conventional DLE treatments include topical corticosteroid ointments or creams, such as triamcinolone acetonide, fluocinolone, flurandrenolide, betamethasone valerate, or betamethasone dipropionate. Resistant plaques can be injected with an intradermal corticosteroid. Other potential DLE treatments include calcineurin inhibitors such as pimecrolimus cream or tacrolimus ointment. Particularly resistant cases can be treated with systemic antimalarial drugs, such as hydroxychloroquine (PLAQUENIL).
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with methotrexate for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with azathioprine for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a non-steroidal anti-inflammatory drug for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a belimumab (Benlysta) for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with hydroxychloroquine (Plaquenil) for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with sifalimumab for the treatment of Lupus.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with OMS721 (Omeros) for the treatment of a complement mediated disorder. In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with OMS906 (Omeros) for the treatment of a complement mediated disorder. In one embodiment, the complement mediated disorder is, for example, thrombotic thrombocytopenic purpura (TTP) or aHUS.
In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with an anti-inflammatory agent, immunosuppressive agent, or anti-cytokine agent for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics (e.g. adoptive T-cell therapy (ACT) such as CAR T-cell therapy, or monoclonal antibody therapy). In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid, for example prednisone, dexamethasone, solumedrol, and methylprednisolone, and/or anti-cytokine compounds targeting, e.g., IL-4, IL-10, IL-11, IL-13 and TGFβ. In one embodiment, an active compound or its salt or composition as described herein may be provided in combination with an anti-cytokine inhibitor including, but are not limited to, adalimumab, infliximab, etanercept, protopic, efalizumab, alefacept, anakinra, siltuximab, secukibumab, ustekinumab, golimumab, and tocilizumab, or a combination thereof. Additional anti-inflammatory agents that can be used in combination with an active compound or its salt or composition as described herein include, but are not limited to, non-steroidal anti-inflammatory drug(s) (NSAIDs); cytokine suppressive anti-inflammatory drug(s) (CSAIDs); CDP-571/BAY-10-3356 (humanized anti-TNFα antibody; Celltech/Bayer); cA2/infliximab (chimeric anti-TNFα antibody; Centocor); 75 kdTNFR-IgG/etanercept (75 kD TNF receptor-IgG fusion protein; Immunex); 55 kdTNF-IgG (55 kD TNF receptor-IgG fusion protein; Hoffmann-LaRoche); IDEC-CE9.1/SB 210396 (non-depleting primatized anti-CD4 antibody; IDEC/SmithKline); DAB 486-IL-2 and/or DAB 389-IL-2 (IL-2 fusion proteins; Seragen); Anti-Tac (humanized anti-IL-2Rα; Protein Design Labs/Roche); IL-4 (anti-inflammatory cytokine; DNAX/Schering); IL-10 (SCH 52000; recombinant IL-10, anti-inflammatory cytokine; DNAX/Schering); IL-4; IL-10 and/or IL-4 agonists (e.g., agonist antibodies); IL-IRA (IL-1 receptor antagonist; Synergen/Amgen); anakinra (Kineret®/Amgen); TNF-bp/s-TNF (soluble TNF binding protein); R973401 (phosphodiesterase Type IV inhibitor); MK-966 (COX-2 Inhibitor); Iloprost, leflunomide (anti-inflammatory and cytokine inhibition); tranexamic acid (inhibitor of plasminogen activation); T-614 (cytokine inhibitor); prostaglandin E1; Tenidap (non-steroidal anti-inflammatory drug); Naproxen (non-steroidal anti-inflammatory drug); Meloxicam (non-steroidal anti-inflammatory drug); Ibuprofen (non-steroidal anti-inflammatory drug); Piroxicam (non-steroidal anti-inflammatory drug); Diclofenac (non-steroidal anti-inflammatory drug); Indomethacin (non-steroidal anti-inflammatory drug); Sulfasalazine; Azathioprine; ICE inhibitor (inhibitor of the enzyme interleukin-1β converting enzyme); zap-70 and/or lck inhibitor (inhibitor of the tyrosine kinase zap-70 or lck); TNF-convertase inhibitors; anti-IL-12 antibodies; anti-IL-18 antibodies; interleukin-11; interleukin-13; interleukin-17 inhibitors; gold; penicillamine; chloroquine; chlorambucil; hydroxychloroquine; cyclosporine; cyclophosphamide; anti-thymocyte globulin; anti-CD4 antibodies; CD5-toxins; orally-administered peptides and collagen; lobenzarit disodium; Cytokine Regulating Agents (CRAB) HP228 and HP466 (Houghten Pharmaceuticals, Inc.); ICAM-1 antisense phosphorothioate oligo-deoxynucleotides (ISIS 2302; Isis Pharmaceuticals, Inc.); soluble complement receptor 1 (TP10; T Cell Sciences, Inc.); prednisone; orgotein; glycosaminoglycan polysulphate; minocycline; anti-IL2R antibodies; marine and botanical lipids (fish and plant seed fatty acids); auranofin; phenylbutazone; meclofenamic acid; flufenamic acid; intravenous immune globulin; zileuton; azaribine; mycophenolic acid (RS-61443); tacrolimus (FK-506); sirolimus (rapamycin); amiprilose (therafectin); cladribine (2-chlorodeoxyadenosine).
In a specific embodiment, an active compound or its salt or composition as described herein may be provided in combination with a corticosteroid for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with etarnercept for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with tocilizumab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with etarnercept and tocilizumab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with infliximab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics. In another embodiment, an active compound or its salt or composition as described herein may be provided in combination with golimumab for the treatment or prevention of cytokine or inflammatory reactions in response to the administration of pharmaceuticals or biotherapeutics.
Combinations for Prophylactic or Concommitant Anti-Bacterial Therapy
In one aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of a prophylactic anti-bacterial vaccine prior to administration of an active compound or its salt or composition for any of the disorders described herein. In another aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of a prophylactic anti-bacterial drug, such as a pharmaceutical drug, prior to administration of an active compound or its salt or composition for any of the disorders described herein. In one aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of an anti-bacterial vaccine after administration of an active compound or its salt or composition for any of the disorders described herein. In another aspect of the present invention, a method is provided for treating a host in need thereof that comprises administering an effective amount of an anti-bacterial drug, such as a pharmaceutical drug, after administration of an active compound or its salt or composition for any of the disorders described herein. In one embodiment, the disorder is PNH, C3G, or aHUS. In one embodiment, the host has received an organ or other tissue or biological fluid transplant. In one embodiment, the host is also administered eculizumab.
In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a host concomitantly to a subject following the prophylactic administration of a vaccine against a bacterial infection. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.
In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject concomitantly with the prophylactic administration of a vaccine against a bacterial infection. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.
In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject and, during the administration period of the compound or salt, a vaccine against a bacterial infection is administered to the subject. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.
In one aspect of the present invention, the subject is administered an active compound or its salt or composition as described herein in combination with an antibiotic compound for the duration of Factor D inhibitor administration. In one embodiment, the complement mediated disorder is PNH, C3G, or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab.
In one aspect of the present invention, an active compound or its salt or composition as described herein is administered to a subject following the prophylactic administration of a vaccine against a bacterial infection, and in combination with an antibiotic compound for the duration of Factor D inhibitor administration. In one embodiment, the complement mediated disorder is PNH or aHUS. In one embodiment, the subject has received an organ or other tissue or biological fluid transplant. In one embodiment, the subject is also administered eculizumab. In one embodiment, the subject, prior to receiving an active compound or its salt or composition as described herein, is vaccinated against a bacterial infection caused by the bacterium Neisseria meningitidis. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium Haemophilus influenzae. In one embodiment, the Haemophilus influenzae is Haemophilus influenzae serotype B (Hib). In one embodiment, the subject is vaccinated against a bacterial infection caused by Streptococcus pneumoniae. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium Neisseria meningitidis, Haemophilus influenzae, or Streptococcus pneumoniae, or a combination of one or more of Neisseria meningitidis, Haemophilus influenzae, or Streptococcus pneumoniae. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium Neisseria meningitidis, Haemophilus influenzae, and Streptococcus pneumoniae.
In other embodiments, the subject is vaccinated against a bacterial infection caused by a bacterium selected from a Gram-negative bacterium. In one embodiment, the subject is vaccinated against a bacterial infection caused by a bacterium selected from a Gram-positive bacterium. In one embodiment, the subject is vaccinated against a bacterial infection caused by the bacterium Neisseria meningitidis, Haemophilus influenzae, or Streptococcus pneunemoniae, or a combination of one or more of Neisseria meningitidis, Haemophilus influenzae, or Streptococcus pneumoniae, and one or more of, but not limited to, Bacillus anthracis, Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheria, Coxiella burnetii, Mycobacterium tuberculosis, Salmonella typhi, Vibrio cholerae, Anaplasma phagocytophilum, Ehrlichia ewingii, Ehrlichia chaffeensis, Ehrlichia canis, Neorickettsia sennetsu, Mycobacterium leprae, Borrelia burgdorferi, Borrelia mayonii, Borrelia afzelii, Borrelia garinii, Mycobacterium bovis, Staphylococcus aureus, Streptococcus pyogenes, Treponema pallidum, Francisella tularensis, Yersinia pestis,
In one embodiment, the subject is vaccinated with one or more vaccines selected from, but not limited to, typhoid vaccine, live (Vivotif Berna Vaccine, PaxVax), typhoid Vi polysaccharide vaccine (Typhim Vi, Sanofi), pneumococcal 23-polyvalent vaccine, PCV13 (Pneumovax 23, Merck), pneumococcal 7-valent vaccine, PCV7 (Prevnar, Pfizer), pneumococcal 13-valent vaccine, PCV13 (Prevnar 13, Pfizer), Haemophilus b conjugate (prp-t) vaccine (ActHIB, Sanofi; Hibrix, GSK), Haemophilus b conjugate (hboc) vaccine (HibTITER, Neuron Biotech), Haemophilus b conjugate (prp-omp) vaccine (PedvaxHIB, Merck), Haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine (MenHibrix, GSK), Haemophilus b conjugate (prp-t) vaccine/meningococcal conjugate vaccine/Hepatitis B vaccine (Comvax, Merck), meningococcal polysaccharide vaccine (Menomune A/C/Y/W-135, Sanofi), meningococcal conjugate vaccine/diphtheria CRM197 conjugate (Menveo, GSK; Menactra, Sanofi), meningococcal group B vaccine (Bexsero, GSK; Trumenba, Pfizer), anthrax vaccine adsorbed (Biothrax, Emergent Biosolutions), tetanus toxoid (Te Anatoxal Berna, Hendricks Regional Health), Bacillus Calmette and Guérin, live, intravesical (TheraCys, Sanofi; Tice BCG, Organon), cholera vaccine, live, oral (Vachora, Sanofi; Dukoral, SBL Vaccines; ShanChol, Shantha Biotec; Micromedex, Truven Health), tetanus toxoids and diphtheria absorbed (Tdap; Decavac, Sanofi; Tenivac, Sanofi; td, Massachusetts Biological Labs), diphtheria and tetanus toxois and pertussis (DTap; Daptacel, Sanofi; Infanrix, GSK; Tripedia, Sanofi), diphtheria and tetanus toxois and pertussis/polio (Kinrix, GSK; Quadracel, Sanofi), diphtheria and tetanus toxois and pertussis tetanus/hepatitis B/polio (Pediarix, GSK), diphtheria and tetanus toxois and pertussis/polio, Haemophilus influenza tybe b (Pentacel, Sanofi), and/or diphtheria, and pertussis (Tdap; Boostrix, GSK; Adacel, Sanofi), or a combination thereof.
As described above, a subject receiving a compound of the present invention to treat a disorder is prophylactically administered an antibiotic compound in addition to a Factor D inhibitor described herein. In one embodiment, the subject is administered an antibiotic compound for the duration of administration of the active compound to reduce the development of a bacterial infection. Antibiotic compounds for concomitant administration with a Factor D inhibitor described herein can be any antibiotic useful in preventing or reducing the effect of a bacterial infection. Antibiotics are well known in the art and include, but are not limited to, amikacin (Amikin), gentamicin (Garamycin), kanamycin (Kantrex), neomycin (Neo-Fradin), netilmicin (Netromycin), tobramycin (Nebcin), paromomycin (Humatin), streptomycin, spectinomycin (Trobicin), geldanamycin, herbimycin, rifaximin (Xifaxan), loracarbef (Lorabid), ertapenem (Invanz), doripenem (Doribax), imipenem/cilastatin (Primaxin), meropenem (Merrem), cefadroxil (Duricef), cefazolin (Ancef), cefalotin/cefalothin (Keflin), cephalexin (Keflex), cefaclor (Distaclor), cefamandole (Mandol), cefoxitin (Mefoxin), cefprozil (Cefzil), cefuroxime (Ceftin, Zinnat), cefixime (Cefspan), cefdinir (Omnicef, Cefdiel), cefditoren (Spectracef, Meiact), cefoperazone (Cefobid), cefotaxime (Claforan), cefpodoxime (Vantin) ceftazidime (Fortaz), ceftibuten (Cedax), ceftizoxime (Cefizox), ceftriaxone (Rocephin), cefepime (Maxipime), ceftaroline fosamil (Teflaro), ceftobiprole (Zeftera), teicoplanin (Targocid), vancomycin (Vancocin), telavancin (Vibativ), dalbavancin (Dalvance), oritavancin (Orbactiv), clindamycin (Cleocin), lincomycin (Lincocin), daptomycin (Cubicin), azithromycin (Zithromax, Sumamed, Xithrone), clarithromycin (Biaxin), dirithromycin (Dynabac), erythromycin (Erythocin, Erythroped), roxithromycin, troleandomycin (Tao), telithromycin (Ketek), spiramycin (Rovamycine), aztreonam (Azactam), furazolidone (Furoxone), nitrofurantoin (Macrodantin, Macrobid), linezolid (Zyvox), posizolid, radezolid, torezolid, amoxicillin (Novamox, Amoxil), ampicillin (Principen), azlocillin, carbenicillin (Geocillin), cloxacillin (Tegopen), dicloxacillin (Dynapen), flucloxacillin (Floxapen), mezlocillin (Mezlin), methicillin (Staphcillin), nafcillin (Unipen), oxacillin (Prostaphlin), penicillin G (Pentids), penicillin V (Veetids (Pen-Vee-K), piperacillin (Pipracil), penicillin G (Pfizerpen), temocillin (Negaban), ticarcillin (Ticar), amoxicillin/clavulanate (Augmentin), ampicillin/sulbactam (Unasyn), piperacillin/tazobactam (Zosyn), ticarcillin/clavulanate (Timentin), bacitracin, colistin (Coly-Mycin-S), polymyxin B, ciprofloxacin (Cipro, Ciproxin, Ciprobay), enoxacin (Penetrex), gatifloxacin (Tequin), gemifloxacin (Factive), levofloxacin (Levaquin), lomefloxacin (Maxaquin), moxifloxacin (Avelox), nalidixic acid (NegGram), norfloxacin (Noroxin), ofloxacin (Floxin, Ocuflox), trovafloxacin (Trovan), grepafloxacin (Raxar), sparfloxacin (Zagam), temafloxacin (Omniflox), mafenide (Sulfamylon), sulfacetamide (Sulamyd, Bleph-10), sulfadiazine (Micro-Sulfon), silver sulfadiazine (Silvadene), sulfadimethoxine (Di-Methox, Albon), sulfamethizole (Thiosulfil Forte), sulfamethoxazole (Gantanol), sulfanilamide, sulfasalazine (Azulfidine), sulfisoxazole (Gantrisin), trimethoprim-sulfamethoxazole (Co-trimoxazole) (TMP-SMX) (Bactrim, Septra), sulfonamidochrysoidine (Prontosil), demeclocycline (Declomycin), doxycycline (Vibramycin), minocycline (Minocin), oxytetracycline (Terramycin), tetracycline (Sumycin, Achromycin V, Steclin), clofazimine (Lamprene), dapsone (Avlosulfon), capreomycin (Capastat), cycloserine (Seromycin), ethambutol (Myambutol), ethionamide (Trecator), isoniazid (I.N.H.), pyrazinamide (Aldinamide), rifampicin (Rifadin, Rimactane), rifabutin (Mycobutin), rifapentine (Priftin), streptomycin, arsphenamine (Salvarsan), chloramphenicol (Chloromycetin), fosfomycin (Monurol, Monuril), fusidic acid (Fucidin), metronidazole (Flagyl), mupirocin (Bactroban), platensimycin, quinupristin/dalfopristin (Synercid), thiamphenicol, tigecycline (Tigacyl), tinidazole (Tindamax Fasigyn), trimethoprim (Proloprim, Trimpex), and/or teixobactin, or a combination thereof.
In one embodiment, the subject is administered a prophylactic antibiotic selected from cephalosporin, for example, ceftriaxone or cefotaxime, ampicillin-sulbactam, Penicillin G, ampicillin, chloramphenicol, fluoroquinolone, aztreonam, levofloxacin, moxifloxacin, gemifloxacin, vancomycin, clindamycin, cefazolin, azithromycin, meropenem, ceftaroline, tigecycline, clarithromycin, moxifloxacin, trimethoprim/sulfamethoxazole, cefuroxime, axetil, ciprofloxacin, rifampin, minocycline, spiramycin, and cefixime, or a combination of two or more thereof.
Process of Preparation of Compounds of the Present Invention
Abbreviations
    • ACN Acetonitrile
    • Ac Acetyl
    • Ac2O Acetic anhydride
    • AcOEt, EtOAc ethyl acetate
    • AcOH Acetic acid
    • Boc2O di-tert-butyl dicarbonate
    • Bu Butyl
    • CAN Ceric ammonium nitrate
    • CBz Carboxybenzyl
    • CDI Carbonyldiimidazole
    • CH3OH, MeOH Methanol
    • CsF Cesium fluoride
    • CuI Cuprous iodide
    • DCM, CH2Cl2 Dichloromethane
    • DIEA, DIPEA N,N-diisopropylethylamine
    • DMA N,N-dimethylacetamide
    • DMAP 4-Dimethylaminopyridine
    • DMF N,N-dimethylformamide
    • DMS Dimethyl sulfide
    • DMSO Dimethylsulfoxide
    • DPPA Diphenyl phosphoryl azide
    • EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
    • EEDQ N-Ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline
    • Et Ethyl
    • Et3N, TEA Triethylamine
    • EtOAc Ethylacetate
    • EtOH Ethanol
    • HATU 1-[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide hexafluorophosphate
    • HCl Hydrochloric acid
    • HOBT Hydroxybenzotriazole
    • iBu, i-Bu, isoBu Isobutyl
    • iPr, i-Pr, isoPr Isopropyl
    • iPr2NEt N,N-diisopropylethylamine
    • K2CO3 Potassium carbonate
    • K2CO3 Potassium carbonate
    • LiOH Lithium hydroxide
    • Me Methyl
    • MeI Methyl iodide
    • Ms Mesyl
    • MsCl Mesylchloride
    • MTBE Methyl tbutylether
    • Na2SO4 Sodium sulfate
    • NaCl Sodium chloride
    • NaH Sodium hydride
    • NaHCO3Sodium bicarbonate
    • NBS N-bromo succinimide
    • NCS N-chloro succinimide
    • NEt3 Trimethylamine
    • NMP N-Methyl-2-pyrrolidone
    • PCC Pyridinium chlorochromate
    • Pd (OAc)2 Palladium acetate
    • Pd(dppf)Cl2 [1,1′-Bis(diphenylphosphino) ferrocene]dichloropalladium(II)
    • Pd(PPh3)2Cl2 Bis(triphenylphosphine)palladium(II) dichloride
    • Pd(PPh3)4 Tetrakis(triphenylphosphine)palladium(0)
    • Pd/C Palladium on carbon
    • Pd2 (dba)3 Tris(dibenzylideneacetone)dipalladium(0)
    • PMB 4-Methoxybenzyl ether
    • PPh3 Triphenylphosphine
    • Pr Propyl
    • Py, py Pyridine
    • RT Room temperature
    • T3P Propane phosphonic acid anhydride
    • TBAF Tetra-n-butylammonium fluoride
    • TBAT Tetrabutylammonium difluorotriphenylsilicate
    • tBu, t-Bu tertbutyl
    • tBuOK Potassium tert-butoxide
    • TEA Trimethylamine
    • Tf2O Trifluoromethanesulfonic anhydride
    • TFA Trifluoroacetic acid
    • THF Tetrahydrofuran
    • TMS Trimethylsilane
    • TMSBr Bromotrimethylsilane
    • tR Retention time
    • Troc 2,2,2-Trichlorethoxycarbonyl chloride
    • Zn (CN)2 Zinc cyanide
      General Methods
All nonaqueous reactions were performed under an atmosphere of dry argon or nitrogen gas using anhydrous solvents. The progress of reactions and the purity of target compounds were determined using one of the two liquid chromatography (LC) methods listed below. The structure of starting materials, intermediates, and final products was confirmed by standard analytical techniques, including NMR spectroscopy and mass spectrometry.
LC Method A
Instrument: Waters Acquity Ultra Performance LC
Column: ACQUITY UPLC BEH C18 2.1×50 mm, 1.7 μm
Column Temperature: 40° C.
Mobile Phase: Solvent A: H2O+0.05% FA; Solvent B: CH3CN+0.05% FA
Flow Rate: 0.8 mL/min
Gradient: 0.24 min @ 15% B, 3.26 min gradient (15-85% B), then 0.5 min @ 85% B.
Detection: UV (PDA), ELS, and MS (SQ in EI mode)
LC Method B
Instrument: Shimadzu LC-2010A HT
Column: Athena, C18-WP, 50×4.6 mm, 5 μm
Column Temperature: 40° C.
Mobile Phase: Solvent A: H2O/CH3OH/FA=90/10/0.1; Solvent B: H2O/CH3OH/FA=10/90/0.1
Flow Rate: 3 mL/min
Gradient: 0.4 min @ 30% B, 3.4 min gradient (30-100% B), then 0.8 min @ 100% B
Detection: UV (220/254 nm)
LC Method C
Instrument: Agilent 1100/1200 series LC system with DAD detector
Column: Atlantis dC18 (250×4.6) mm, 5 μm
Column Temperature: Ambient
Mobile Phase A: 0.1% TFA in water, Mobile Phase B: Acetonitrile
Flow Rate: 1.0 m/min
Gradient:
Time (min) 0.0 15 20 23 30
% B 10 100 100 10 10

Detection: (210-400 nm)
LC Method D
Instrument: Shimadzu LC 20AD system with PDA detector
Column: Phenomenex Gemini NX C18 (150×4.6) mm, 5 μm
Column Temperature: Ambient
Mobile Phase A: 10 mM NH4OAC in water, Mobile Phase B: Acetonitrile
Flow Rate: 1.0 m/min
Gradient:
Time (min) 0.0 15 20 23 30
% B 10 100 100 10 10

Detection: (210-400 nm)
Example 1. General Route of Synthesis
A compound of the present invention can be prepared, for example, from a central core. In one embodiment, for example, the central core Structure 1 is an N-protected aminoacid where X1 is nitrogen and PG=protecting group. In one embodiment, the central core is coupled to an amine to generate an amide of Structure 2 (wherein L-B includes a C(O)N moiety). Structure 2 can then be deprotected to generate Structure 3. Structure 3 is coupled to Structure 4(A-COOH) to generate a second amide bond, forming a compound within Formula I. The chemistry is illustrated in Route 1.
Figure US11708351-20230725-C01027
In an alternative embodiment, central core Structure 5 is reacted with a heterocyclic or heteroaryl compound to generate a compound of Structure 6. In one embodiment, Structure 6 is deprotected to generate a carboxylic acid, Structure 7. In one embodiment, Structure 7 is coupled to an amine to generate a compound of Formula I. This chemistry is illustrated in Route 2.
Figure US11708351-20230725-C01028
In an alternative embodiment, Structure 8 is deprotected to generate an amine which is Structure 9. Structure 9 is then coupled to generate an amide which is Structure 6. Structure 6 is then deprotected to generate a carboxylic acid which is Structure 7. Structure 7 is then coupled to form the amide which falls within Formula I. The chemistry is illustrated in Route 3.
Figure US11708351-20230725-C01029
In an alternate embodiment, a heteroaryl or aryl moiety, 4-1, is coupled to a central core to generate 4-2. The protected acid, 4-2 is deblocked to form the carboxylic acid, 4-3. The carboxylic acid is then coupled to form an amide (L-B) which is 4-4. The heteroaryl or aryl moiety, A′, can then be further derivatized to add substituents at the X11, X12, X13 and X14 positions to generate compounds of Formula I. This chemistry is illustrated in Route 4.
Figure US11708351-20230725-C01030
In an alternate embodiment, Structure 5-1 is coupled to an acid, Structure 5-2, to generate Structure 5-3. The carboxylic acid, Structure 5-3, is deblocked to generate a carboxylic acid which is Structure 5-4. Carboxylic acid Structure 5-4 is coupled to an amine to form the product amide (L-B) which is a compound within Formula I. This chemistry is illustrated in Route 5.
Figure US11708351-20230725-C01031
In an alternate embodiment, a heteroaryl compound of Structure 10 is acylated to generate a compound of Structure 11, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 11 is coupled to Structure 12 to generate Structure 13. In some embodiments, LG1 is a leaving group. In some embodiments, the LG1 is a halide. Structure 13 is coupled to an aryl, heteroaryl or heterocylic compound to generate Structure 14. In some embodiments, Structure 13 is treated with an aryl, heteroaryl or heterocylic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 14 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 15. Structure 15 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 6.
Figure US11708351-20230725-C01032
In an alternate embodiment, a heteroaryl compound of Structure 17 is acylated to generate a compound of Structure 18, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 18 is coupled to an activated ester, Structure 12 from Route 6, wherein LG1 can be a halogen to generate Structure 19.
Structure 19 is coupled to an aryl, heteroaryl or heterocylic compound to generate Structure 20. In some embodiments, Structure 19 is treated with an aryl, heteroaryl or heterocylic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 20 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 21. Structure 21 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 7.
Figure US11708351-20230725-C01033
In an alternate embodiment, a heteroaryl compound of Structure 8-1 is acylated to generate a compound of Structure 8-2, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 8-2 is coupled to Structure 8-3 to generate Structure 8-4. In some embodiments, LG1 is a leaving group. In some embodiments, the LG1 is a halide.
Structure 8-4 is coupled to an aryl, heteroaryl or heterocylic compound to generate Structure 8-5. In some embodiments, Structure 8-4 is treated with an aryl, heteroaryl or heterocylic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 8-5 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 8-6. Structure 8-6 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 8.
Figure US11708351-20230725-C01034
Route 8
In an alternate embodiment, a heteroaryl compound of Structure 9-1 is acylated to generate a compound of Structure 9-2, wherein LG is a leaving group. As an example, the leaving group can be a halide, for example bromide. Structure 9-2 is coupled to an activated ester, Structure 9-3, wherein LG1 can be a halide to generate Structure 9-4. Structure 9-4 is coupled to an aryl, heteroaryl or heterocylic compound to generate Structure 9-5. In some embodiments, Structure 9-4 is treated with an aryl, heteroaryl or heterocylic boronic acid, an organometallic catalyst, a base and an organic solvent. In some embodiments, the organometallic catalyst is tetrakis(triphenylphosphine)palladium (0). In some embodiments, the base is cesium carbonate. In some embodiments, the organic solvent is DMF. Structure 9-5 is treated with an organic acid such as, but not limited to, trifluoroacetic acid to generate Structure 9-6. Structure 9-6 is coupled to Structure 3 from Route 1 to generate a compound within Formula I. This chemistry is illustrated in Route 9.
Figure US11708351-20230725-C01035
In an alternate embodiment, Structure 10-1 is coupled to an amine to generate an amide (L-B), and Structure 10-2. Structure 10-2, is coupled to an amine to generate compounds within Formula I. This chemistry is illustrated in Route 10.
Figure US11708351-20230725-C01036
Example 2. Examples of Central Synthons
Figure US11708351-20230725-C01037
Figure US11708351-20230725-C01038
ZA is halogen.
In one embodiment, deuterated L-proline synthons are disclosed. Deuterated synthons include, but are not limited to, for example, the following compounds:
Figure US11708351-20230725-C01039
Structure A can be treated with deuterium oxide to generate Structure B. See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655; Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491 and WO 2014/037480 (p. 103). Structure B can be reduced to generate Structure C. See, Barraclough, P. et al. Tetrahedron Lett. 2005, 46, 4653-4655; Barraclough, P. et al. Org. Biomol. Chem. 2006, 4, 1483-1491. Structure C can be treated with Mitsunobu reaction conditions to generate Structure D. Structure B can be treated with DAST to generate Structure E. See, WO 2014/037480. Structure A can be treated with sodium borodeuteride to generate Structure F. See, Dormoy, J.-R.; Castro, B. Synthesis 1986, 81-82. Compound F can be used to generate Structure K. See, Dormoy, J.-R.; Castro, B. Synthesis 1986, 81-82. Structure B can be treated with a deuterated reducing agent, for example sodium borodeuteride to generate Structure G. Structure G can be treated with DAST to generate Structure H. Structure F can be used to generate Structure K. See, Dormoy, J.-R.; Castro, B. Synthesis 1986, 81-82. Structure G can be used to generate Structure I. Structure J can be prepared according to Hruby, V. J. et al. J. Am. Chem. Soc. 1979, 101, 202-212. Structures A-J can be used to prepare compounds of Formula I.
Example 3. Preparation of Central-L-B Synthons
Figure US11708351-20230725-C01040
Routes 1a, 1b and 1c.
In Route 1a, 5-azaspiro[2.4]heptane-4,5-dicarboxylic acid, 5-(1,1-dimethylethyl) ester, (4S)—, CAS 209269-08-9, can be prepared as described in Tandon, M. et al. Bioorg. Med. Chem. Lett. 1998, 8, 1139-1144. In Step 2, the protected azaspiro[2.4]heptane is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
In Route 1b, (4S) 4-oxazolidinecarboxylic acid, hydrochloride is treated with an amine protecting reagent. In one embodiment, the amine protecting reagent is di-tert-butyl dicarbonate. In another embodiment, 3,4-oxazolidinedicarboxylic acid, 3-(1,1-dimethylethyl) ester, (4S)—, is commercially available from JPM2 Pharmaceuticals. In one embodiment the reaction is carried out in an organic solvent in the presence of a base. In one embodiment, the organic solvent is acetonitrile. In one embodiment, the base is 4-dimentylaminopyridine (DMAP). In Step 2, the protected 4-oxazolidinecarboxylic acid is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
In Route 1c, (S)-5-(tert-Butoxycarbonyl)-5-azaspiro[2.4]heptane-6-caboxylic acid, CAS 1129634-44-1, is commercially available from Ark Pharm. In Step 2, the carboxylic acid is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 3, the protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
Figure US11708351-20230725-C01041
Routes 2a, 2b, 2c, and 2d.
In Route 2a, commercially available Boc-L-proline is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DWF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
In Route 2b, commercially available (1R, 3S, 5R)-2-[(tert-butoxy)carbonyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid, from Enamine, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DWF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
In Route 2c, commercially available (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid, from Manchester Organics, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane.
In Route 2d, commercially available (S)-1-(tert-butoxycarbonyl)indoline-2-carboxylic acid, from Chem-Impex, is coupled to an amine in the presence of an organic solvent, a base and a coupling reagent to generate an amide bond; the L-B moiety. In one embodiment, the amine is (3-chloro-2-fluorophenyl) methanamine. In one embodiment, the organic solvent is DMF. In one embodiment, the base is diisopropylethylamine. In one embodiment, the coupling reagent is HATU. In Step 2, the Boc protecting group is removed. In one embodiment, the starting material is reacted with an acid in the presence of an organic solvent. In one embodiment, the acid is 4N hydrochloric acid. In one embodiment, the organic solvent is dioxane. This chemistry is illustrated in Scheme 2.
Additional starting materials that can readily be converted to Central-L-B-Synthons include, but are not limited to: (S)-1-(tert-butoxycarbonyl)-2,3-dihydro-1H-pyrrole-2-carboxylic acid, CAS 90104-21-5, available from Ark Pharm; cyclopent-1-ene-1,2-dicarboxylic acid, CAS 3128-15-2, purchased from Ark Pharm; imidazole, 1H-imidazole-1,2-dicarboxylic acid, 1-(1,1-dimethylethyl) 2-ethyl ester, CAS 553650-00-3, commercially available from FCH Group; Boc-L-octahydroindole-2-carboxylic acid can be purchased from Chem Impex. The compound,
Figure US11708351-20230725-C01042
can be prepared according to the procedures disclosed in WO 2004/111041; (S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the Aldrich Chemical Co.; (1S,2S,5R)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.3.0]hexane-2-carboxylic acid is available from Ark Pharm; (S)-3-Boc-thiazolidine-2-carboxylic acid is available from Alfa Aesar; (2S,4R)-1-(tert-butoxycarbonyl)-4-chloropyrrolidine-2-carboxylic acid is available from Arch Bioscience; (1S,3aR,6aS)-2-(tert-butoxycarbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid is available from Ark Pharm; 1,2-pyrrolidinedicarboxylic acid, 3-[[(phenylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (2S,3R) can be prepared as disclosed in WO 2004/007501. The Cbz group can be removed and the amino group can be alkylated to generate central core compounds of the present invention.
The compound
Figure US11708351-20230725-C01043
can be prepared as disclosed by Braun, J. V.; Heymons, Albrecht Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1930) 63B, 502-7.
The compounds (2S,3S,4S)-4-fluoro-3-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester and (2R,3R,4R)-3-fluoro-4-methoxy-pyrrolidine-1,2-dicarboxylic acid 1-tert-butyl ester can be prepared as a mixture according to WO 2012/093101 to Novartis and the regioisomers can be ultimately separated once coupled to generate the central core-L-B synthons. The compound (S)-Boc-5-oxopyrrolidine-2-carboxylic acid is available from the Aldrich Chemical Co.
Example 4. Synthesis of L-B Moieties
Figure US11708351-20230725-C01044
Scheme 4-1: In Step 1 the appropriately substituted dibromo species is coupled with an appropriate boronic acid as known in the art to form a mixture of biaryl and triaryl products from which the desired biaryl compound is isolated. In Step 2 the appropriately substituted biaryl species is converted to the Grignard reagent with activated magnesium. In Step 3 the appropriately substituted aldehyde is treated with the previously prepared Grignard reagent to form an alcohol. In Step 4 the appropriately substituted alcohol is converted to a bromide as known in the art with carbon tetrabromide and triphenyl phosphine. In Step 5 the appropriately substituted bromide is converted to the Grignard reagent with activated magnesium.
Example 5. Synthesis of C-L-B Moieties
Figure US11708351-20230725-C01045
Figure US11708351-20230725-C01046
Scheme 5-1: In Step 1 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 2 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine. In Step 3 the appropriately substituted amine is Cbz-protected as known in the art to form a protected carboxylic acid. In Step 4 the appropriately substituted carboxylic acid can be orthogonally protected as known in the art to form an ester. In Step 5 the appropriately substituted and protected alkene is subjected to a carbene to form a bicyclic ring. In Step 6 the appropriately substituted ester is saponified with acid to liberate the carboxylic acid. In Step 7 the appropriately substituted Cbz-protected species is deprotected with hydrogen to liberate the free amine.
Figure US11708351-20230725-C01047
Scheme 5-2: In Step 1 the appropriately substituted sulfide is oxidized to a sulfoxide as known in the art. Alternatively, in Step 2 the appropriately substituted sulfide is oxidized to a sulfone as known in the art. In Step 3 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 4 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine.
Figure US11708351-20230725-C01048
Scheme 5-3: In Step 1 the appropriately substituted carboxylic acid is converted to the acyl chloride as known in the art. In Step 2 the appropriately substituted acyl chloride is converted to the Weinreb amide as known in the art. In Step 3 the appropriately substituted Weinreb amide is reacted with a Grignard reagent to afford a ketone. The synthesis of complex Grignard reagents is described in Example 4. In Step 4 the appropriately substituted carbamate protected amine is deprotected to liberate the free amine.
Figure US11708351-20230725-C01049
Scheme 5-4: In Step 1 the appropriately substituted amide is converted to a thioamide with Lawesson's reagent. In Step 2 the appropriately substituted Boc-protected amine is deprotected with acid to liberate the free amine.
Figure US11708351-20230725-C01050
Scheme 5-5: In Step 1 the appropriately substituted carboxylic acid is converted to a Weinreb amide as known in the art. In Step 2 the appropriately substituted Weinreb amide is reduced as known in the art to afford an aldehyde. In Step 3 the appropriately substituted aldehyde is subjected to an amine to form a Schiff base which is subsequently quenched in Step 4. In Step 4 the appropriately substituted Schiff base is subjected to an appropriate nucleophile to form a complex amine. In Step 5 the appropriately substituted Boc-protected species is deprotected with acid to liberate the free amine.
Figure US11708351-20230725-C01051
Figure US11708351-20230725-C01052
Scheme 5-6: In Step 1 the appropriately substituted alcohol is subjected to TMS-Cl as known in the art to afford a silyl ether. In Step 2 the appropriately substituted silyl ether is subjected with sodium cyanide to afford a cyano species. In Step 3 the appropriately substituted cyano species is reduced as known in the art to afford an aldehyde. In Step 4 the appropriately substituted aldehyde is further reduced with borane to afford an alcohol. In Step 5 the appropriately substituted alcohol is oxidized as known in the art to afford a carboxylic acid. In Step 6 the appropriately substituted carboxylic acid is coupled to the appropriately substituted amine as known in the art to form an amide. In Step 7 the appropriately substituted ester is converted to a methyl ketone by insitu formation of the Weinreb amide with subsequent attack by the methyl Grignard reagent. In Step 8 the appropriately substituted methyl ketone is subjected to bromine to afford a bromide. By choice of the appropriate starting material all mixtures of chiral centers may be prepared as described.
Example 6. Synthesis of A Moieties
Figure US11708351-20230725-C01053
Scheme 6-1: In Step 1 the appropriately substituted nitro species is reduced with palladium as known in the art to afford an amine. In Step 2 the appropriately substituted alkene species is brominated with concurrent addition of ethanol as known in the art to afford the bromide species. In Step 3 the appropriately substituted mixture of tautomers is subjected to the previously prepared bromide species as known in the art to afford the two isomers. The appropriately substituted isomers corresponding to each tautomer may either be separated or used as a mixture in the subsequent reactions with separation at a later step. In Step 4 the appropriately substituted ketal species is deprotected and subsequently cyclized in the presence of acid as known in the art. In Step 5 the appropriately substituted cyano species is subjected to strong acid to afford a primary amide. In Step 6 the appropriately substituted heterocycle is subjected to a bromide species of the appropriate linker to afford the appropriately protected species. Various 5-5 fused bicyclic systems can be appropriately prepared by slight modifications of this synthetic protocol, another non-limiting example is presented in Steps 5 through 12 with the same conditions for formation of a primary amide and installation of linker. In Step 7 the appropriately substituted aryl species is brominated as known in the art. In Step 8 the appropriately substituted ether species is deprotected with palladium as known in the art to afford an alcohol. In Step 9 the appropriately substituted alcohol is oxidized as known in the art to afford an aldehyde. In Step 10 the appropriately substituted aldehyde is subjected to hydrazine to first form a Schiff base and subsequently cyclize to afford a bicyclic system. In Step 11 the appropriately substituted bicyclic system is iodinated as known in the art. In Step 12 the appropriately substituted iodide is subjected to sodium cyanide to afford the cyano species.
Figure US11708351-20230725-C01054
Figure US11708351-20230725-C01055
Scheme 6-2: Non-limiting examples of aryl substituents are provided demonstrating the robust nature of the synthetic protocol. Boronic acids 1-8 are subjected to an appropriately substituted aryl bromide to afford a biaryl system.
Figure US11708351-20230725-C01056
Scheme 6-3: In Step 1 the appropriately substituted and protected aniline is converted as known in the art to a sulfonamide. In Step 2 the appropriately substituted alcohol is converted as known in the art to a triflouro sulfonamide. In Step 3 the previously prepared reagents are subjected to sodium hydride to afford their adduct. In Step 4 the appropriately substituted ketal is subjected to a strong lewis acid to afford deprotection and subsequent cyclization to a biaryl species. In Step 5 the appropriately substituted sulfonamide is deprotected in the presence of base to afford a free amine. In an alternative embodiment this synthetic protocol can be applied to other aniline isomers to afford substituents on alternative positions.
Figure US11708351-20230725-C01057
Figure US11708351-20230725-C01058
Scheme 6-4: In Step 1 the appropriately substituted indole is acylated as known in the art. In Step 2 the appropriately substituted heterocycle is subjected to a bromide species of the appropriate linker to afford the appropriately protected species. In Step 3 the appropriately substituted aryl bromide is subjected to a boronic acid to afford an aryl species. In Step 4 the appropriately substituted benzyl alcohol is deprotected in the presence of hydrogen gas and palladium to afford a free alcohol. In Step 5 the appropriately substituted phenol is subjected to a sulfonic anhydride to afford a leaving group. In Step 6 the appropriately substituted aryl species is converted to a boronic acid as known in the art. In Step 7 the appropriately substituted boronic acid is subjected to copper bromide to afford an aryl bromide species. In an alternative embodiment this synthetic protocol can simply be applied to other indole isomers to afford substituents on alternative positions.
Figure US11708351-20230725-C01059
Figure US11708351-20230725-C01060
Scheme 6-5: Non-limiting examples of aryl substituents are provided demonstrating the robust nature of the synthetic protocol. Boronic acids 1-8 are subjected to an appropriately substituted aryl bromide to afford an aryl system.
Example 7. Synthesis of L3-A Moieties
Figure US11708351-20230725-C01061
Scheme 7-1: In Step 1 the appropriately substituted aryl compound is subjected to a bromide to afford a sulfonic acid substituted species. In Step 2 the appropriately substituted sulfonic acid species is chlorinated as known in the art.
Figure US11708351-20230725-C01062
Scheme 7-2: In Step 1 the appropriately substituted aryl compound is subjected to a chloride to afford a phosphonic acid substituted species. In Step 2 the appropriately substituted phosphonic acid species is chlorinated as known in the art.
Example 8. Non-Limiting Synthetic Examples of Prodrug Compounds of the Present Invention Step 1: (((2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-o-carborane (1)
To a solution of (((2S,4R)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-o-carborane hydrochloride (8-S1, 1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (8-S2, 1.2 equiv), HATU (1.5 equiv) and DIPEA (3 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was separated, washed with brine, dried over anhydrous Na2SO4, filtered and then concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 1. 1H NMR (400 MHz, DMSO-d6) δ: 9.04 (s, 2H), 8.86 (t, J=6.2 Hz, 1H), 8.43 (s, 1H), 7.88-7.81 (m, 2H), 5.86-5.82 (m, 1H), 5.61-5.47 (m, 2H), 4.68-4.67 (m, 1H), 4.38 (t, J=8.6 Hz, 1H), 4.25-4.16 (m, 1H), 3.92-3.77 (m, 4H), 2.69 (s, 3H), 2.65 (s, 3H), 2.30-1.30 (br, 10H).
Step 2: Lithium (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carbonyl)amino)methyl)-nido-dodecahydroundecaborate (8)
To a solution of compound 1 (1 equiv) in EtOH (10 vol) at room temperature was added lithium hydroxide mono hydrate (0.9 equiv). The reaction mixture was stirred at 80° C. for 16 hours. After completion of the reaction, the reaction mixture was concentrated and the residue was purified by preparative HPLC to afford compound 8. 1H NMR (400 MHz, D2O) δ: 8.30 (s, 2H), 7.66-7.60 (m, 1H), 7.16-6.95 (m, 2H), 5.47-4.99 (m, 3H), 4.67-4.65 (m, 2H), 4.62-3.95 (m, 2H), 3.49-3.09 (m, 3H), 2.49 (s, 3H), 2.47 (s, 3H), 2.02-1.30 (br, 10H).
Figure US11708351-20230725-C01063
Figure US11708351-20230725-C01064
Figure US11708351-20230725-C01065
Step 1: (S)-Methyl 4-(methylthio)-2-(prop-2-yn-1-ylamino)butanoate (2-S2)
To a mixture of LiOH·H2O (6.6 g, 157.7 mmol), 4 Å molecular sieves (39 g), and DMF (70 mL) that was stirred at 0° C. for 20 minutes was added L-methionine methyl ester hydrochloride (2-S1, 15.0 g, 75.1 mmol). The mixture was stirred for 45 minutes at 0° C. and then to this mixture was added 3-bromoprop-1-yne (10.6 g, 90.1). The resulting mixture was stirred at room temperature overnight and filtered. The filtrate was partitioned between EtOAc (100 mL) and water (200 mL). The organic layer was washed with brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 15:1) to afford 2-S2 (8.8 g, 58.6% yield) as light oil. LC/MS (ESI) m/z: 202 (M+H)+.
Step 2: (S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylthio)butanoate (2-S3)
To a mixture of (S)-methyl 4-(methylthio)-2-(prop-2-yn-1-ylamino)butanoate (2-S2, 8.8 g, 43.8 mmol), K2CO3 (18.1 g, 131.4 mmol), EtOAc (150 mL), and water (150 mL) was added CbzCl (11.2 g, 65.7 mmol) dropwise at 0° C. The reaction mixture was stirred at 0° C. overnight. The mixture was quenched by the addition of 10% aqueous HCl until pH ˜3 at 0° C. The mixture was extracted with EtOAc (2×100 mL) and the combined organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=10:1) to afford 2-S3 (12.9 g, 87.9% yield) as light oil. LC/MS (ESI) m/z: 336 (M+H)+.
Step 3: (2S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl)butanoate (2-S4)
To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylthio) butanoate (2-S3, 12.9 g, 38.5 mmol) in MeOH (100 mL) and water (100 mL) was added NaIO4 (8.7 g, 40.4 mmol) in portions at 0° C. The mixture was stirred at this temperature for 4 hours. The mixture was extracted with EtOAc (2×50 mL) and the combined layers were washed with brine, dried over Na2SO4, and evaporated under reduced pressure to afford S4 (12 g, 88.8% yield) as a yellow oil. This crude product was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 352 (M+H)+.
Step 4: (S)-Methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)but-3-enoate (2-S5)
A solution of (2S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)-4-(methylsulfinyl) butanoate (2-S4, 2.0 g, 5.69 mmol) in xylene (8 mL) was stirred at 140° C. for 2 days. The mixture was evaporated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=25:1 to 20:1) to afford 2-S5 (480 mg, 23.5% yield) as a yellow oil. LC/MS (ESI) m/z: 288 (M+H)+.
Step 5: (1S)-2-Benzyl 1-methyl 5-oxo-1,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2 (3H)-dicarboxylate (2-S6)
To a solution of (S)-methyl 2-(((benzyloxy)carbonyl)(prop-2-yn-1-yl)amino)but-3-enoate (2-S5, 480 mg, 1.65 mmol) in THF (8 mL) was added Co2(CO)8 (81.4 mg, 0.24 mmol). The reaction mixture was pressurized with a CO atmosphere (50 psi) and mixed at 100° C. overnight. The mixture was filtered and the filtrate was evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=4:1 to 2:1) to afford 2-S6 (130 mg, 18.8% yield) as a brown oil. LC/MS (ESI) m/z: 316 (M+H)+.
Step 6: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-oxohexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S7)
To a solution of (1S)-2-benzyl 1-methyl 5-oxo-1,5,6,6a-tetrahydrocyclopenta[c]pyrrole-1,2 (3H)-dicarboxylate (2-S6, 130 mg, 0.41 mmol) in MeOH (1 mL) and THF (1 mL) was added Pd/C (13 mg) and the reaction mixture was stirred at 0° C. under an atmosphere of hydrogen (balloon) for 30 minutes. The mixture was filtered and the filtrate was evaporated under reduced pressure to afford 2-S7 (120 mg, 92.6% yield) as a yellow oil. This crude product was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 318 (M+H)+.
Step 7: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-hydroxyhexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S8)
To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-oxohexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S7, 120 mg, 0.38 mmol) in MeOH (3 mL) was added NaBH4 (14.3 mg) at 0° C. under an atmosphere of nitrogen and the reaction mixture was stirred at 0° C. for 30 minutes. The mixture was quenched by the addition of aqueous NH4Cl solution (15 mL) and extracted with EtOAc (2×10 mL). The combined organic layers were washed with brine, dried over Na2SO4, and evaporated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=3:1 to 2:1) to afford 2-S8 (90 mg, yield 74.4%) as a yellow oil. LC/MS (ESI) m/z: 320 (M+H)+.
Step 8: (1S,3aS,6aR)-2-Benzyl 1-methyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S9)
To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-hydroxyhexahydrocyclopenta [c]pyrrole-1,2(1H)-dicarboxylate (2-S8, 143 mg, 0.45 mmol) in DCM (5 mL) were added 4-fluorophenylthionochloroformate (127.7 mg, 0.67 mmol) and DMAP (164.3 mg, 1.34 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with DCM (20 mL), washed successively with 0.5 N aqueous HCl (10 mL), water (10 mL), and brine, dried over Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc=20:1 to 4:1) to afford 2-S9 (110 mg, yield 51.6%) as a white solid. LC/MS (ESI) m/z: 496 (M+Na)+.
Step 9: (1S,3aS,6aR)-2-Benzyl 1-methyl hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S10)
To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S9, 110 mg, 0.23 mmol) in 1,4-dioxane (3 mL) were added 1,1′-azobis(cyclohexanecarbonitrile) (Vazo, 18.9 mg, 0.12 mmol) and tris(trimethylsilyl)silane (86.8 mg, 0.35 mmol). The reaction mixture was stirred at 105° C. for 40 minutes. The reaction mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=40:1 to 10:1) to afford 2-S10 (68 mg, 97.5% yield) as light oil. LC/MS (ESI) m/z: 304 (M+H)+.
Step 10: (1S,3aS,6aR)-2-((Benzyloxy)carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (2-S11)
To a solution of (1S,3aS,6aR)-2-benzyl 1-methyl hexahydrocyclopenta[c]pyrrole-1,2(1H)-dicarboxylate (2-S10, 68 mg, 0.22 mmol) in THF (3 mL) was added a 1 M aqueous NaOH solution (0.44 mL, 0.44 mmol) at 0° C. and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with water (15 mL) and concentrated under reduced pressure. The remaining residue was washed with Et2O (2×10 mL). The aqueous layer was acidified with 2 N aqueous HCl until pH ˜3 and extracted with EtOAc (2×15 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford 2-S11 (40 mg, 61.7% yield) as light oil. This crude product was carried forward without further purification. LC/MS (ESI) m/z: 290 (M+H)+.
Step 11: (1S,3aS,6aR)-Benzyl 1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (2-S12)
To a mixture of (1S,3aS,6aR)-2-((benzyloxy)carbonyl)octahydrocyclopenta[c]pyrrole-1-carboxylic acid (2-S11, 40 mg, 0.14 mmol), 6-bromopyridin-2-amine (25 mg, 0.14 mmol), and EEDQ (69.2 mg, 0.28 mmol) in DCE (4 mL) was added DIPEA (54.2 mg, 0.42 mmol) and the reaction mixture was stirred at 90° C. under an atmosphere of nitrogen overnight. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 10:1) to afford 2-S12 (30 mg, 48.4% yield) as a light oil. LC/MS (ESI) m/z: 444 (M+H)+.
Step 12: (1S,3aS,6aR)—N-(6-Bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (2-S13)
To a solution of (1S,3aS,6aR)-benzyl 1-((6-bromopyridin-2-yl)carbamoyl)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (2-S12, 30 mg, 0.07 mmol) in AcOH (1.5 mL) was added a 30% HBr/AcOH solution (0.3 mL) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was poured into ice-cooled aqueous NaHCO3 solution and extracted with EtOAc (2×15 mL). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure to afford 2-S13 (25 mg, crude) as a brown oil. This crude product was used directly in the next reaction without further purification. LC/MS (ESI) m/z: 310 (M+H)+.
Step 13: (1S,3aS,6aR)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (2)
To a mixture of (1S,3aS,6aR)—N-(6-bromopyridin-2-yl)octahydrocyclopenta[c]pyrrole-1-carboxamide (2-S13, 25 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (25 mg, 0.08 mmol), and HATU (45.6 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (31 mg, 0.24 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford 2 (5 mg, 16.6% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.97 (s, 1H), 9.04 (s, 2H), 8.43 (s, 1H), 8.05 (d, J=8.2 Hz, 1H), 7.87-7.85 (m, 2H), 7.72 (t, J=8.0 Hz, 1H), 7.32 (d, J=7.7 Hz, 1H), 5.74 (d, J=17.3 Hz, 1H), 5.62 (d, J=17.2 Hz, 1H), 4.42 (d, J=2.8 Hz, 1H), 4.09-4.03 (m, 1H), 3.67-3.63 (m, 1H), 2.87-2.84 (m, 1H), 2.69 (s, 3H), 2.65 (s, 3H), 1.98-1.58 (m, 7H). LC/MS (ESI) m/z: 602 (M+H)+.
Figure US11708351-20230725-C01066
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the following steps: 1) the formation of an amide bond between the B-ring and the C-ring by utilizing a coupling reagent such as EEDQ ot HATU; 2) the removal of the Boc-group using an acid; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.
Step 1: (S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[2.2.2]octane-2-carboxylate (3-S2)
To a mixture of 3-S1 (230 mg, 0.902 mmol), 6-bromo-3-methylpyridin-2-amine (169 mg, 0.902 mmol), and EEDQ (446 mg, 1.80 mmol) in DCE (10 mL) was added DIPEA (0.6 mL, 3.61 mmol). The reaction mixture was stirred at 90° C. overnight. The mixture was then concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 10:1) to afford 3-S2 (100 mg, 26.2% yield) as a yellow solid. LC/MS (ESI) m/z: 424 (M+H)+.
Step 2: (S)—N-(6-Bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (3-S3)
To a solution of 3-S2 (100 mg, 0.236 mmol) in dioxane (2 mL) was added HCl/dioxane solution (1 mL, 2 M) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford 3-S3 (105 mg, 100% yield) as a brown solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z: 324 (M+H)+.
Step 3: (S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[2.2.2]octane-3-carboxamide (3)
To a mixture of 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (24 mg, 0.078 mmol) in DMF were added DIPEA (0.03 mL, 0.195 mmol), HATU (37.0 mg, 0.097 mmol), and 3-S3 (21.0 mg, 0.065 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford 3 (2.5 mg, 6.27% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.54 (s, 1H), 7.79 (s, 2H), 7.54 (d, J=7.9 Hz, 1H), 7.36 (d, J=7.9 Hz, 1H), 5.63 (q, J=16.8 Hz, 2H), 4.50 (s, 1H), 4.22 (s, 1H), 2.75 (s, 3H), 2.71-2.66 (m, 3H), 2.41 (s, 1H), 2.30 (d, J=15.1 Hz, 1H), 2.09 (m, 3H), 1.88 (m, 5H), 1.69 (d, J=6.7 Hz, 1H), 1.34 (m, 1H). LC/MS (ESI) m/z: 616 (M+H)+.
(1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (49)
1H NMR (400 MHz, CD3OD) δ 9.01 (d, J=6.9 Hz, 2H), 8.54 (s, 1H), 8.04 (d, J=8.2 Hz, 1H), 7.80 (d, J=9.8 Hz, 2H), 7.27 (d, J=8.1 Hz, 1H), 5.81 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.1 Hz, 1H), 4.76 (s, 1H), 4.46 (s, 2H), 3.79 (s, 1H), 3.74-3.69 (m, 1H), 3.63 (d, J=10.2 Hz, 1H), 3.51 (d, J=10.3 Hz, 1H), 3.43 (s, 3H), 3.40 (s, 3H), 2.75 (s, 3H), 2.70 (s, 3H), 2.59 (dd, J=16.6, 6.7 Hz, 2H), 2.19 (t, J=7.6 Hz, 1H), 1.16-1.11 (m, 1H), 0.90 (t, J=6.8 Hz, 1H). LC/MS (ESI) m/z: 662 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-(3-chloro-2-fluorophenyl)propan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 0.87 (dd, J=2.3, 5.4 Hz, 1H), 1.14 (t, J=5.5 Hz, 1H), 1.32 (s, 3H), 1.62 (s, 3H), 1.68 (s, 3H), 2.07 (dd, J=8.6, 13.3 Hz, 1H), 2.55 (dd, J=2.7, 13.3 Hz, 1H), 2.72 (s, 3H), 2.76 (s, 3H), 2.80 (s, 3H), 3.05 (dd, J=2.3, 5.5 Hz, 1H), 4.58 (dd, J=2.7, 8.7 Hz, 1H), 5.68 (s, 2H), 7.01 (t, J=8.0 Hz, 1H), 7.10 (s, 1H), 7.23-7.29 (m, 2H), 7.35 (s, 1H), 8.47 (d, J=1.6 Hz, 1H), 8.90 (s, 2H). 19F δ−115.9.
(S)-2-((1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-4-methylpentanoic Acid
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.53 (s, 1H), 5.90-5.94 (d, J=17.6 Hz, 1H), 5.73-5.78 (d, J=17.6 Hz, 1H), 4.43-4.35 (m, 2H), 3.46-3.44 (m, 1H), 2.72 (s, 6H), 2.68 (s, 3H), 2.48 (m, 1H), 2.17 (dd, J=13.2, 4.4 Hz, 1H), 1.65 (m, 1H), 1.62-1.53 (m, 2H), 1.35 (s, 3H), 1.09 (m, 1H), 0.90 (m, 1H), 0.85 (s, 3H), 0.84 (s, 3H). LC/MS (ESI) m/z: 561 (M+H)+.
(S)-2-((1R,3R,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-3-phenylpropanoic Acid
1H-NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (t, J=4.8 Hz, 1H), 8.04 (d, J=8.0 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.35-7.04 (m, 5H), 5.95-5.99 (d, J=18 Hz, 1H), 5.61-5.66 (d, J=17.6 Hz, 1H), 4.28-4.41 (m, 2H), 3.43-3.44 (m, 1H), 3.01 (dd, J=14, 5.2 Hz, 1H), 2.89 (dd, J=14.4, 6 Hz, 1H), 2.68 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.34 (dd, J=13.2, 9.6 Hz, 2H), 1.91 (m, 1H), 1.17 (s, 3H), 0.97-1.00 (m, 1H), 0.82-0.84 (m, 1H). LC/MS (ESI) m/z: 595 (M+H)+.
(R)-2-((1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-4-methylpentanoic Acid
1H-NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.39 (s, 1H), 7.52 (s, 1H), 5.90 (d, J=17.6 Hz, 1H), 5.78 (d, J=18.0 Hz, 1H), 4.46-4.37 (m, 2H), 3.46-3.48 (m, 1H), 2.74 (s, 3H), 2.73 (s, 3H), 2.67 (s, 3H), 2.48-2.54 (m, 1H), 2.09-2.14 (m, 1H), 1.61-1.64 (m, 3H), 1.36 (s, 3H), 1.12-1.07 (m, 1H), 1.00 (m, 1H), 0.92-0.87 (m, 6H). LC/MS (ESI) m/z: 561 (M+H)+.
(2R)-2-{[(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-2-azabicyclo[3.1.0]hexan-3-yl]formamido}-3-phenylpropanoic Acid
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.52 (s, 1H), 7.30-7.16 (m, 5H), 5.88 (d, J=17.7 Hz, 1H), 5.75 (d, J=17.8 Hz, 1H), 4.72-4.68 (m, 1H), 4.37-4.32 (m, 1H), 3.38-3.36 (m, 1H), 3.25-3.20 (m, 1H), 2.97-2.91 (m, 1H), 2.81-2.65 (m, 9H), 2.34-2.28 (m, 1H), 1.75-1.70 (m, 1H), 1.22 (s, 3H), 1.07-1.02 (m, 1H), 0.87-0.83 (m, 1H). LC/MS (ESI) m/z: 595 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.52 (s, 1H), 7.29 (dd, J=11.0, 4.1 Hz, 1H), 7.21 (t, J=6.9 Hz, 1H), 6.97 (t, J=7.8 Hz, 1H), 5.93 (d, J=17.7 Hz, 1H), 5.79 (d, J=17.7 Hz, 1H), 4.57-4.35 (m, 3H), 3.79 (dd, J=5.7, 2.7 Hz, 1H), 3.12 (d, J=16.0 Hz, 1H), 2.75 (s, 3H), 2.69 (d, J=6.1 Hz, 3H), 2.65 (d, J=11.2 Hz, 3H), 2.62-2.55 (m, 1H), 2.37 (s, 3H), 2.29 (dd, J=13.8, 4.6 Hz, 1H), 1.36 (m, 1H), 1.13 (m, 1H). LC/MS (ESI) m/z: 671 [M+H]+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.42-8.45 (t, 1H), 8.32 (s, 1H), 7.62 (s, 1H), 7.41-7.45 (t, 1H), 7.17-7.20 (t, 1H), 7.04-7.08 (t, 1H), 5.97-6.01 (d, J=17.6 Hz, 1H), 5.67-5.71 (d, J=17.6 Hz, 1H), 4.25-4.33 (m, 3H), 3.73-3.76 (m, 1H), 3.15-3.16 (d, J=16 Hz, 1H), 3.02-3.06 (d, J=16 Hz, 1H), 2.68 (s, 3H), 2.65 (s, 3H), 2.63 (s, 3H), 2.48 (s, 3H), 2.46-2.47 (m, 1H), 2.06-2.10 (m, 1H), 1.24-1.25 (m, 1H), 1.07-1.09 (m, 1H). LC/MS (ESI) m/z: 671 (M+H)+.
(1R,2S,5S)-3-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(3-chloro-2-fluorophenyl)methyl]-3-azabicyclo[3.1.0]hexane-2-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (d, J=2.0 Hz, 1H), 7.53-7.50 (m, 1H), 7.31-7.24 (m, 2H), 6.94 (td, J=1.2, 1.2 Hz, 1H), 5.65 (s, 2H), 4.57 (d, J=6.0 Hz, 1H), 4.47 (d, J=15.2 Hz, 1H), 4.37 (d, J=15.6 Hz, 1H), 4.03 (dd, J=5.6, 5.6 Hz, 1H), 3.90 (d, J=10.0 Hz, 1H), 2.74 (s, 3H), 2.71 (s, 3H), 2.66 (s, 3H), 2.04-2.00 (m, 1H), 1.95-1.90 (m, 1H), 0.89 (q, J=4.6 Hz, 1H), 0.83-0.79 (m, 1H). LC/MS (ESI) m/z: 575 (M+H)+.
(2S,4R)—N-(5′-Acetyl-2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.04 (s, 1H), 9.03 (s, 2H), 8.43 (s, 1H), 8.02-8.00 (m, 2H), 7.98 (s, 1H), 7.97-7.96 (m, 2H), 7.76-7.73 (m, 1H), 7.28-7.24 (m, 1H), 7.14-7.11 (m, 1H), 5.86 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.2 Hz, 1H), 4.79-4.75 (m, 1H), 4.30-4.21 (m, 1H), 4.08-3.97 (m, 1H), 2.69 (s, 3H), 2.64 (s, 3H), 2.61-2.60 (m, 2H), 2.58 (s, 3H), 2.26-2.22 (m, 1H).
Figure US11708351-20230725-C01067
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with nucleophilic R201 groups on the C-ring. The skilled artisan will recognize that piperidine can be replaced with other nucleophilic reagents to afford additional compounds of the present invention. Non-limiting examples of groups the skilled artisan can use instead of piperidine include azetidine, 6-azaspiro[2.5]octane, and 2-azaspiro[3.3]heptane.
Step 1: (3S)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (4-S2)
To a mixture of 4-S1 (25 mg, 0.05 mmol) in MeCN (2 mL) were added DIPEA (0.035 mL, 0.2 mmol), piperidine (4 mg, 0.055 mmol), and NaI at 0° C. The reaction mixture was stirred at room temperature for 4 hours. The mixture was concentrated, diluted with DCM, and washed with water and brine. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=40:1 to 30:1) to afford the title compound (8 mg, 33.3% yield) as a yellow solid. LC/MS (ESI) m/z: 493 (M+H)+.
Step 2: (3S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (4-S3)
To a solution of 4-S2 (8 mg, 0.016 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (10 mg, 100% yield) as a brown solid. The crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 393 (M+H)+.
Step 3: (3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperidin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (4)
To a solution of 4-S3 (10 mg, 0.025 mmol) and 4-S4 (7.75 mg, 0.025 mmol) in DMF (2 mL) was added HATU (17.1 mg, 0.045 mmol) and DIPEA (0.018 mL, 0.10 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 4 (2.1 mg, 12.3% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.56 (s, 1H), 7.81 (s, 2H), 7.57 (d, J=7.9 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.67 (d, J=17.2 Hz, 1H), 5.35-5.33 (m, 1H), 4.68 (t, J=7.2 Hz, 1H), 3.04 (d, J=7.3 Hz, 2H), 2.75 (s, 3H), 2.70 (d, J=2.0 Hz, 4H), 2.66 (d, J=8.4 Hz, 2H), 2.20 (t, J=7.2 Hz, 2H), 2.13 (s, 3H), 2.04 (s, 2H), 1.83 (s, 4H), 1.60 (s, 4H). LC/MS (ESI) m/z: 685 (M+H)+.
(3S)-5-(6-Azaspiro[2.5]octan-6-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (5)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.57 (s, 1H), 7.80 (s, 2H), 7.59 (d, J=8.2 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 5.82 (d, J=17.1 Hz, 1H), 5.67 (d, J=16.9 Hz, 1H), 2.75 (s, 3H), 2.70 (s, 3H), 2.67 (s, 1H), 2.13 (s, 3H), 1.48 (s, 2H), 1.33 (s, 2H), 1.29 (s, 6H), 0.90 (s, 3H), 0.51 (s, 3H). LC/MS (ESI) m/z: 711 (M+H)+.
(3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (6)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (s, 2H), 7.59 (d, J=7.9 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 5.81 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.1 Hz, 1H), 5.35 (d, J=5.0 Hz, 1H), 4.72-4.65 (m, 1H), 4.30 (s, 2H), 3.53 (d, J=13.3 Hz, 1H), 3.46 (t, J=6.8 Hz, 2H), 2.75 (s, 3H), 2.70 (s, 3H), 2.66-2.59 (m, 1H), 2.54-2.50 (m, 1H), 2.20 (dd, J=15.8, 8.3 Hz, 2H), 2.12 (s, 3H), 2.04 (s, 2H), 1.60 (s, 2H), 1.41 (d, J=6.2 Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 657 (M+H)+.
(3S)-5-(3-Azabicyclo[3.1.1]heptan-3-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (13)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.55 (s, 1H), 7.84-7.76 (m, 2H), 7.59 (d, J=8.2 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 5.88 (d, J=17.2 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.64 (dd, J=9.0, 4.2 Hz, 1H), 4.22 (s, 3H), 4.01 (d, J=3.2 Hz, 1H), 3.52-3.37 (m, 2H), 2.75 (s, 3H), 2.69 (s, 3H), 2.61 (d, J=9.2 Hz, 1H), 2.54 (d, J=3.8 Hz, 1H), 2.34 (s, 4H), 2.12 (s, 3H), 1.90 (t, J=7.6 Hz, 2H), 1.40 (s, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 697 (M+H)+.
(3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (24)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (d, J=1.2 Hz, 2H), 7.56 (d, J=7.8 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.80 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.2 Hz, 1H), 4.65-4.61 (m, 4.7 Hz, 1H), 3.66-3.64 (m, 1H), 3.28 (s, 3H), 2.99 (s, 4H), 2.75 (s, 4H), 2.72 (s, 1H), 2.69 (s, 4H), 2.65 (s, 3H), 2.54-2.44 (m, 2H), 2.12 (s, 3H), 1.20-1.02 (m, 2H). LC/MS (ESI) m/z: 700 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methylpiperazin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (69)
1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.40 (s, 1H), 7.50-7.53 (m, 2H), 7.35 (d, J=8.0 Hz, 1H), 5.87 (s, 2H), 4.85-5.03 (m, 1H), 3.63-3.66 (m, 1H), 3.29-3.33 (m, 5H), 2.67-2.92 (m, 17H), 2.32-2.48 (m, 2H), 2.04 (s, 3H), 1.72-1.74 (m, 1H), 1.03-1.06 (m, 1H). LC/MS (ESI) m/z: 714/716 (M+H)+.
Figure US11708351-20230725-C01068
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU or a different peptide coupling reagent, such as TBTU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.
To a solution of 9-S1 (45 mg, 0.086 mmol) and 9-S2 (26.7 mg, 0.086 mmol) in DMF (2 mL) was added HATU (58.9 mg, 0.155 mmol) and DIPEA (0.06 mL, 0.344 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 9 (23 mg, 41.5% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.35 (s, 1H), 9.51 (s, 1H), 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.63 (d, J=8.1 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.94 (d, J=17.3 Hz, 1H), 5.62 (d, J=17.3 Hz, 1H), 4.47 (dd, J=9.0, 5.0 Hz, 1H), 2.82 (s, 2H), 2.69 (s, 3H), 2.66 (s, 3H), 2.66-2.64 (m, 1H), 2.51 (d, J=1.7 Hz, 6H), 2.42-2.31 (m, 2H), 2.04 (s, 3H), 2.00 (d, J=7.7 Hz, 1H), 1.34 (d, J=6.1 Hz, 1H). LC/MS (ESI) m/z: 645 (M+H)+.
(2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(cuban-1-ylmethyl)-4-fluoropyrrolidine-2-carboxamide (16)
1H NMR (400 MHz, DMSO-d6) δ: 9.05 (s, 2H), 8.44 (s, 1H), 8.02-8.01 (m, 1H), 7.89-7.82 (m, 2H), 5.82-5.78 (m, 1H), 5.61-5.43 (m, 2H), 4.39 (t, J=8.3 Hz, 1H), 4.22-3.80 (m, 4H), 3.73-3.72 (m, 3H), 3.51-3.36 (m, 2H), 3.17-3.10 (m, 3H), 2.69 (s, 3H), 2.64 (s, 3H), 2.11-1.98 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (30)
1H NMR (400 MHz CD3OD) δ 9.05 (s, 2H), 8.68 (t, J=1.9 Hz, 1H), 8.09 (d, J=8.2 Hz, 1H), 7.87 (dd, J=3.1, 1.7 Hz, 1H), 7.63 (t, J=8.0 Hz, 1H), 7.27 (d, J=7.7 Hz, 1H), 5.60-6.05 (m, 4H), 4.52 (dd, J=9.0, 5.8 Hz, 1H), 3.56 (dd, J=5.5, 2.4 Hz, 1H), 2.77 (s, 3H), 2.73 (s, 3H), 2.61 (dd, J=13.4, 9.3 Hz, 1H), 2.18-2.24 (m, 1H), 1.41 (s, 3H), 1.10-1.16 (m, 1H), 1.01-1.04 (m, 1H). LC/MS (ESI) m/z: 620/622 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2-fluoro-3-(trifluoromethoxy)phenyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (33)
1H NMR (400 MHz, CD3OD) δ: 9.01 (s, 2H), 8.42 (s, 1H), 7.92-7.89 (m, 1H), 7.54 (s, 1H), 7.21-7.19 (m, 2H), 5.98 (d, J=17.6 Hz, 1H), 5.82 (d, J=17.6 Hz, 1H), 4.60 (m, 1H), 3.57-3.55 (m, 1H), 2.76 (s, 3H), 2.74 (s, 3H), 2.71 (s, 3H), 2.63-2.57 (m, 1H), 2.28-2.23 (m, 1H), 1.42 (s, 3H), 1.15-1.13 (m, 1H), 1.00-0.99 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-3-fluoro-4-methylpent-3-en-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (34)
1H NMR (400 MHz, CD3OD) δ: 9.00 (s, 2H), 8.42 (s, 1H), 7.54 (s, 1H), 5.92 (d, J=17.6 Hz, 1H), 5.78 (d, J=17.6 Hz, 1H), 4.36-4.32 (m, 1H), 3.48-3.46 (m, 1H), 2.76 (s, 3H), 2.74 (s, 3H), 2.69 (s, 3H), 2.50-2.47 (m, 1H), 2.12-2.00 (m, 1H), 1.67 (s, 3H), 1.57 (s, 3H), 1.40 (s, 3H), 1.24 (s, 3H), 1.22-1.21 (m, 1H), 1.10-1.09 (m, 1H), 0.92-0.90 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (35)
1H NMR (400 MHz, CD3OD) δ: 9.01 (s, 2H), 8.42 (s, 1H), 7.61 (s, 1H), 7.55 (s, 1H), 6.67 (s, 1H), 5.98 (d, J=18.0 Hz, 1H), 5.83 (d, J=18.0 Hz, 1H), 4.81-4.76 (m, 1H), 4.51-4.47 (m, 1H), 3.56-3.54 (m, 1H), 2.77 (s, 3H), 2.76 (s, 3H), 2.70 (s, 3H), 2.62-2.56 (m, 1H), 2.22-2.17 (m, 1H), 1.40 (s, 3H), 1.22-1.20 (m, 1H), 1.19-1.10 (m, 1H), 0.97-0.99 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (36)
1H NMR (400 MHz, CD3OD) δ: 9.01 (s, 2H), 8.42-8.36 (m, 2H), 7.99-7.95 (m, 1H), 7.54 (s, 1H), 7.48 (d, J=7.6 Hz, 1H), 6.01 (d, J=18.0 Hz, 1H), 5.81 (d, J=20.0 Hz, 1H), 4.54-4.52 (m, 1H), 3.59-3.58 (m, 1H), 2.78 (s, 3H), 2.75 (s, 3H), 2.68 (s, 3H), 2.61-2.59 (m, 1H), 2.23-2.19 (m, 1H), 1.40 (s, 3H), 1.14-1.11 (m, 1H), 1.00-0.98 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (37)
1H NMR (400 MHz, CD3OD) δ: 9.05-9.02 (m, 2H), 8.43 (s, 1H), 8.11-8.09 (m, 1H), 7.91-7.87 (m, 1H), 7.54 (s, 1H), 6.83 (d, J=7.6 Hz, 1H), 6.00 (d, J=18.0 Hz, 1H), 5.80 (d, J=17.6 Hz, 1H), 4.55-4.54 (m, 1H), 3.74-3.58 (m, 1H), 3.57-3.56 (m, 1H), 2.77 (s, 3H), 2.75 (s, 3H), 2.74-2.73 (m, 2H), 2.61-2.57 (m, 1H), 2.21-2.16 (m, 1H), 1.40 (s, 3H), 1.14-1.11 (m, 1H), 0.98-0.97 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (38)
1H NMR (400 MHz, DMSO-d6) δ: 9.80 (s, 1H), 9.01 (s, 2H), 8.31 (s, 1H), 7.95-7.94 (m, 1H), 7.61-7.37 (m, 5H), 7.13-7.21 (m, 1H), 7.07-7.06 (m, 1H), 6.08 (d, J=18.0 Hz, 1H), 5.67 (d, J=18.0 Hz, 1H), 4.55-4.52 (m, 1H), 3.63-3.61 (m, 1H), 2.69 (s, 3H), 2.68 (s, 3H), 2.63 (s, 3H), 2.11-2.09 (m, 1H), 1.32 (s, 3H), 1.26-1.24 (m, 1H), 0.94-0.92 (m, 1H), 0.86-0.83 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(2′-chloro-2-fluoro-[1,1′-biphenyl]-3-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (39)
1H NMR (400 MHz, DMSO-d6) δ: 9.77 (s, 1H), 9.03 (s, 2H), 8.43 (s, 1H), 7.91-7.80 (m, 3H), 7.57 (d, J=8.0 Hz, 1H), 7.45-7.37 (m, 3H), 7.25-7.21 (m, 1H), 7.08-7.06 (m, 1H), 5.95 (d, J=17.2 Hz, 1H), 5.58 (d, J=17.2 Hz, 1H), 4.58-4.56 (m, 1H), 3.62-3.60 (m, 1H), 2.69 (s, 3H), 2.64 (s, 3H), 2.47-2.46 (m, 1H), 2.11-2.09 (m, 1H), 1.32 (s, 3H), 1.01-1.00 (m, 1H), 0.86-0.83 (m, 1H).
1-(2-((1R,3S,5R)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (55)
1H NMR (400 MHz, DMSO-d6) δ: 10.28 (s, 1H), 9.03 (s, 2H), 8.44 (s, 1H), 7.83-7.76 (m, 3H), 7.62 (d, J=8.0 Hz, 1H), 7.49-7.44 (m, 2H), 5.82 (d, J=17.6 Hz, 1H), 5.49 (d, J=17.2 Hz, 1H), 4.41-4.37 (m, 1H), 3.58-3.56 (m, 1H), 2.68 (s, 3H), 2.57-2.54 (m, 1H), 2.04 (s, 3H), 2.03-2.00 (m, 1H), 1.32 (s, 3H), 1.00-0.96 (m, 2H).
1-(2-((1R,2S,5S)-2-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (56)
1H NMR (400 MHz, DMSO-d6) δ: 10.31 (s, 1H), 9.03 (s, 2H), 8.42 (s, 1H), 7.79-7.74 (m, 2H), 7.69 (s, 1H), 7.59 (d, J=8.0 Hz, 1H), 7.47 (s, 1H), 7.41 (d, J=7.6 Hz, 1H), 5.58-5.47 (m, 2H), 4.58-4.57 (m, 1H), 4.01-4.00 (m, 1H), 3.88-3.81 (m, 1H), 2.77 (s, 3H), 2.03 (s, 3H), 2.02-2.01 (m, 1H), 1.89-1.82 (m, 1H), 0.92-0.69 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((R)-1-((R)-2,2-dichlorocyclopropyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (52)
1H NMR (400 MHz, DMSO-d6) δ: 9.03 (s, 2H), 8.32 (s, 1H), 7.98 (d, J=8.0 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=18.0 Hz, 1H), 5.70 (d, J=18.0 Hz, 1H), 4.25-4.22 (m, 1H), 3.52-3.51 (m, 2H), 2.68 (s, 3H), 2.65 (s, 6H), 2.45-2.42 (m, 1H), 1.96-1.92 (m, 2H), 1.74-1.72 (m, 1H), 1.45-1.43 (m, 1H), 1.41-1.31 (m, 2H), 1.27-1.24 (m, 2H), 1.15-1.13 (m, 2H), 1.09-1.08 (m, 1H), 1.04-0.88 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (53)
1H NMR (400 MHz, DMSO-d6) δ: 11.18 (s, 1H), 9.26 (s, 1H), 9.01 (s, 2H), 8.53 (s, 1H), 8.30 (s, 1H), 7.61 (s, 1H), 6.07 (d, J=18.0 Hz, 1H), 5.66 (d, J=18.0 Hz, 1H), 4.44 (t, J=14.0 Hz, 1H), 3.65-3.59 (m, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.63 (s, 3H), 2.62-2.61 (m, 1H), 2.05-2.00 (m, 1H), 1.35 (s, 3H), 0.99-0.92 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-methylpyrazin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (54)
1H NMR (400 MHz, DMSO-d6) δ: 11.06 (s, 1H), 9.13 (s, 1H), 9.03 (s, 2H), 8.31 (s, 1H), 7.62 (s, 1H), 6.07 (d, J=18.0 Hz, 1H), 5.67 (d, J=18.0 Hz, 1H), 4.45-4.41 (m, 1H), 3.65-3.64 (m, 1H), 2.73 (s, 3H), 2.69 (s, 3H), 2.68 (s, 3H), 2.61 (s, 3H), 2.60-2.59 (m, 1H), 2.04-2.00 (m, 1H), 1.31 (s, 3H), 0.99-0.98 (m, 2H).
1-(2-((1R,3S,5R)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (57)
1H NMR (400 MHz, DMSO-d6) δ: 10.33 (s, 1H), 9.02 (s, 2H), 8.32 (s, 1H), 7.73 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.56 (s, 1H), 7.46-7.42 (m, 2H), 5.94 (d, J=18.0 Hz, 1H), 5.59 (d, J=17.6 Hz, 1H), 4.41-4.37 (m, 1H), 3.60-3.58 (m, 1H), 2.68 (s, 3H), 2.66 (s, 3H), 2.66-2.53 (m, 1H), 2.01 (s, 3H), 2.00-1.99 (m, 1H), 1.32 (s, 3H), 1.03-1.00 (m, 1H), 0.89-0.88 (m, 1H).
1-(2-((1R,3S,5R)-3-((6-Bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (58)
1H NMR (400 MHz, DMSO-d6) δ: 10.82 (s, 1H), 9.00 (s, 2H), 8.30 (s, 1H), 8.03 (d, J=8.0 Hz, 1H), 7.74-7.70 (m, 2H), 7.56 (s, 1H), 7.46 (s, 1H), 7.32 (d, J=7.6 Hz, 1H), 5.97 (d, J=18.0 Hz, 1H), 5.57 (d, J=18.0 Hz, 1H), 4.40 (t, J=14.8 Hz, 1H), 3.62 (t, J=8.8 Hz, 1H), 2.67 (s, 6H), 2.00-1.96 (m, 1H), 1.30 (s, 3H), 1.29-1.27 (m, 1H), 1.00-0.84 (m, 2H).
(2S,4R)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide (66)
1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.44 (s, 1H), 7.56 (d, J=7.8 Hz, 2H), 7.39 (d, J=8.0 Hz, 1H), 5.84 (d, J=17.6 Hz, 1H), 5.74 (d, J=17.5 Hz, 1H), 4.74-4.70 (m, 2H), 4.35-4.31 (m, 1H), 4.17-4.15 (m, 1H), 4.10-4.07 (m, 1H), 2.77 (s, 6H), 2.70 (s, 3H), 2.50-2.44 (m, 1H), 2.42-2.36 (m, 1H), 2.12 (s, 3H). LC/MS (ESI) m/z: 640 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3,3-dimethylbutyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (80)
1H NMR (400 MHz, DMSO-d6) δ: 9.03 (s, 2H), 8.32 (s, 1H), 7.75-7.73 (m, 1H), 7.63 (s, 1H), 5.96 (d, J=17.2 Hz, 1H), 5.67 (d, J=17.2 Hz, 1H), 4.14-4.12 (m, 1H), 3.86-3.75 (m, 4H), 3.50-3.49 (m, 1H), 3.06-3.00 (m, 2H), 2.66 (s, 3H), 2.61 (s, 3H), 2.49-2.33 (m, 1H), 1.90-1.89 (m, 1H), 1.30-1.28 (s, 5H), 1.00-0.99 (m, 1H), 0.98 (s, 9H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(2-(trifluoromethoxy)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (81)
1H NMR (400 MHz, DMSO-d6) δ: 9.03 (s, 2H), 8.31 (s, 1H), 8.15-8.12 (m, 1H), 7.62 (s, 1H), 5.96 (d, J=18 Hz, 1H), 5.67 (d, J=18 Hz, 1H), 4.22-4.02 (m, 4H), 3.51-3.49 (m, 1H), 3.36-3.24 (m, 2H), 2.68 (s, 3H), 2.64 (s, 3H), 2.49-2.33 (m, 3H), 1.89-1.85 (m, 1H), 1.26 (s, 3H), 1.00-0.99 (m, 1H), 0.88-0.87 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-methoxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (82)
1H NMR (400 MHz, DMSO-d6) δ: 10.20 (s, 1H), 9.01 (s, 2H), 8.30 (s, 1H), 7.67-7.61 (m, 3H), 6.49 (d, J=7.6 Hz, 1H), 6.08 (d, J=16 Hz, 1H), 5.65 (d, J=17.6 Hz, 1H), 4.51-4.48 (m, 1H), 3.78 (s, 3H), 3.63-3.62 (m, 1H), 2.67 (s, 3H), 2.61 (s, 3H), 2.55 (s, 3H), 2.02-1.97 (m, 1H), 1.31 (s, 3H), 0.88-0.86 (m, 3H).
(2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoro-N-(6-hydroxypyridin-2-yl)pyrrolidine-2-carboxamide (83)
1H NMR (400 MHz, DMSO-d6) δ: 10.38 (s, 1H), 9.04 (s, 2H), 8.43 (s, 1H), 7.89-7.83 (m, 2H), 7.54-7.50 (m, 1H), 7.25-7.18 (m, 1H), 6.28 (d, J=8.0 Hz, 1H), 5.85 (d, J=17.2 Hz, 1H), 5.65 (d, J=17.2 Hz, 1H), 4.69-4.65 (m, 1H), 4.28-4.19 (m, 1H), 4.06-3.94 (m, 2H), 2.68 (s, 3H), 2.64 (s, 3H), 2.18-2.04 (m, 1H).
(1R,3S,5S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (98)
1H NMR (400 MHz CD3OD) δ 9.00 (s, 2H), 8.42 (d, J=1.1 Hz, 1H), 7.57-7.51 (m, 2H), 7.39 (d, J=8.0 Hz, 1H), 5.98 (d, J=16.0 Hz, 1H), 5.82 (d, J=16.0 Hz, 1H), 4.64 (m, 1H), 3.73 (m, 1H), 3.58 (d, J=1.2 Hz, 2H), 3.43 (s, 3H), 2.76 (s, 6H), 2.70 (s, 3H), 2.62 (m, 1H), 2.54 (m, 1H), 2.14 (s, 3H), 1.34 (t, J=5.5 Hz, 1H), 1.09 (m, 1H). LC/MS (ESI) m/z: 646 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-hydroxypyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (105)
1H NMR (400 MHz, DMSO-d6) δ: 10.20 (s, 1H), 9.02 (s, 2H), 8.31 (s, 1H), 7.55 (s, 1H), 7.53-7.50 (m, 1H), 7.21-7.20 (m, 1H), 6.27-6.26 (m, 1H), 6.08 (d, J=20 Hz, 1H), 5.66 (d, J=20 Hz, 1H), 4.47-4.43 (m, 2H), 3.77-3.62 (m, 1H), 2.68 (s, 9H), 2.04-2.00 (m, 1H), 1.24 (s, 3H), 1.01-0.98 (m, 1H), 0.89-0.88 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (106)
1H NMR (400 MHz, DMSO-d6) δ: 10.29 (s, 1H), 8.66 (s, 2H), 8.30 (s, 1H), 7.90-7.72 (m, 2H), 7.63 (d, J=7.6 Hz, 1H), 7.45 (d, J=7.6 Hz, 1H), 5.90 (d, J=17.6 Hz, 1H), 5.55 (d, J=17.6 Hz, 1H), 4.42-4.38 (m, 1H), 3.59-3.58 (m, 1H), 2.64 (s, 3H), 2.04 (s, 3H), 1.32-1.24 (m, 5H), 1.03-1.00 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (108)
1H NMR (400 MHz, DMSO-d6) δ: 10.77 (s, 1H), 8.94 (s, 1H), 8.37 (s, 1H), 8.07 (d, J=8.0 Hz, 1H), 7.85-7.79 (m, 2H), 7.72-7.70 (m, 1H), 7.31 (d, J=8.0 Hz, 1H), 5.94 (d, J=17.2 Hz, 1H), 5.55 (d, J=17.2 Hz, 1H), 4.43-4.39 (m, 1H), 3.97 (s, 3H), 3.67-3.61 (m, 1H), 2.68 (s, 3H), 2.00-1.96 (m, 1H), 1.29 (s, 3H), 0.95-0.83 (m, 3H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (109)
1H NMR (400 MHz, DMSO-d6) δ: 10.79 (s, 1H), 8.74 (s, 2H), 8.30 (s, 1H), 8.04 (d, J=8.4 Hz, 1H), 7.82-7.69 (m, 2H), 7.33 (d, J=8.0 Hz, 1H), 5.94 (d, J=17.2 Hz, 1H), 5.55 (d, J=17.2 Hz, 1H), 4.43-4.39 (m, 1H), 3.64-3.62 (m, 1H), 2.67 (s, 3H), 2.01-1.96 (m, 1H), 1.30 (s, 3H), 0.97-0.86 (m, 3H).
(1R,3S,5S)-2-(2-(3-Acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (114)
1H NMR (400 MHz, CD3OD) δ 9.04 (s, 2H), 8.61 (d, J=2.0 Hz, 1H), 7.75 (d, J=2.0 Hz, 1H), 7.56 (d, J=8.0 Hz, 1H), 7.39 (d, J=8.0 Hz, 1H), 6.04 (d, J=16.0 Hz, 1H), 5.89 (d, J=16.0 Hz, 1H), 4.98 (d, J=12.0 Hz, 1H), 4.71 (d, J=12.0 Hz, 1H), 4.63 (m, 1H), 3.69 (m, 1H), 3.58 (m, 2H), 3.43 (s, 3H), 3.39 (s, 3H), 2.77 (s, 3H), 2.71 (s, 3H), 2.58 (m, 2H), 2.15 (s, 3H), 1.33 (m, 1H), 1.15 (m, 1H). LC/MS (ESI) m/z: 676 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-7-methyl-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (121)
1H NMR (400 MHz, DMSO-d6) δ: 10.32 (s, 1H), 8.72 (s, 2H), 8.19 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.49 (s, 1H), 7.44 (d, J=8.0 Hz, 1H), 6.01 (d, J=17.6 Hz, 1H), 5.66 (d, J=18.0 Hz, 1H), 4.42-4.38 (m, 1H), 2.67 (s, 3H), 2.64 (s, 3H), 2.63-2.58 (m, 1H), 2.04 (s, 3H), 2.01-1.99 (m, 1H), 1.32 (s, 3H), 1.01-0.94 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (130)
1H NMR (400 MHz, CD3OD) δ 8.92 (d, J=1.1 Hz, 2H), 7.60 (m, 3H), 7.38 (d, J=7.9 Hz, 1H), 5.80 (m, 1H), 5.65 (m, 1H), 4.53 (m, 1H), 3.53 (m, 1H), 2.76 (s, 3H), 2.71 (s, 3H), 2.63 (m, 1H), 2.31 (m, 1H), 2.12 (s, 3H), 1.40 (s, 3H), 1.10 (m, 1H), 1.00 (m, 1H). LC/MS (ESI) m/z: 620 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-cyclopropyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (131)
1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.03 (S, 2H), 8.32 (d, J=1.2 Hz, 1H), 7.62 (d, J=7.6 Hz, 1H), 7.48 (s, 1H), 7.44 (d, J=7.6 Hz, 1H), 6.14 (d, J=17.6 Hz, 1H), 5.87 (d, J=17.6 Hz, 1H), 4.42-4.38 (m, 1H), 3.61-3.59 (m, 1H), 2.68 (s, 3H), 2.65 (s, 3H), 2.58-2.52 (m, 1H), 2.30 (m, 1H), 2.04 (m, 4H), 1.32 (m, 3H), 1.04-1.00 (m, 4H), 0.91-0.89 (m, 2H). LC/MS (ESI) m/z: 642 (M+H)+.
(1R,2S,5S)-3-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide (141)
1H NMR (400 MHz, DMSO-d6) δ 0.73-0.89 (m, 2H), 1.88-1.96 (m, 1H), 2.03 (s, 4H), 2.67 (s, 3H), 2.70 (s, 3H), 3.91 (d, J=9.6 Hz, 1H), 4.02-4.11 (m, 1H), 4.62 (d, J=5.4 Hz, 1H), 5.65-5.80 (m, 2H), 7.41 (d, J=7.9 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 8.60 (s, 1H), 9.26 (d, J=1.3 Hz, 1H), 9.34 (s, 2H), 10.30 (s, 1H).
(1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (152)
1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.78 (d, J=1.2 Hz, 2H), 7.75 (d, J=8.0 Hz, 1H), 7.46 (d, J=8.0 Hz, 1H), 5.81 (d, J=16.0 Hz, 1H), 5.66 (d, J=16.0 Hz, 1H), 4.58 (m, 1H), 4.28 (m, 2H), 3.73 (m, 1H), 3.55 (m, 2H), 3.42 (s, 3H), 3.17 (s, 3H), 2.75 (s, 3H), 2.69 (s, 3H), 2.63-2.50 (m, 2H), 1.32 (d, J=4.0 Hz, 1H), 1.11 (m, 1H). LC/MS (ESI) m/z: 662 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (159)
1H NMR (400 MHz, CD3OD) δ 8.93 (s, 2H), 8.47 (s, 1H), 7.71 (s, 2H), 7.47 (d, J=7.9 Hz, 1H), 7.31 (dd, J=7.9, 2.2 Hz, 1H), 5.69 (m, 1H), 5.57 (m, 1H), 4.54 (m, 1H), 3.67-3.29 (m, 3H), 3.05-2.88 (m, 1H), 2.66 (s, 3H), 2.61 (s, 3H), 2.18-1.88 (m, 6H), 1.94-1.73 (m, 2H), 1.65 (m, 1H), 1.21 (m, 1H), 1.06-0.93 (m, 1H). LC/MS (ESI) m/z: 749 (M+H)+.
(1R,2S,5S)-3-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide (172)
1H NMR (400 MHz, DMSO-d6) δ 0.74-0.88 (m, 2H), 1.88-1.98 (m, 1H), 2.02-2.09 (m, 4H), 2.68 (s, 3H), 2.70 (s, 3H), 3.91 (d, J=9.6 Hz, 1H), 4.01-4.09 (m, 1H), 4.60 (d, J=5.4 Hz, 1H), 5.67-5.83 (m, 2H), 7.80 (d, J=8.4 Hz, 1H), 8.60 (d, J=1.3 Hz, 1H), 9.26 (s, 1H), 9.34 (s, 2H), 10.30 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (182)
1H NMR (400 MHz, DMSO-d6) δ 0.94-0.98 (m, 1H), 1.02-1.08 (m, 1H), 1.33 (s, 3H), 1.97-2.14 (m, 4H), 2.54-2.60 (m, 1H), 2.68 (s, 3H), 2.71 (s, 3H), 3.59-3.66 (m, 1H), 4.40 (dd, J=5.1, 9.2 Hz, 1H), 5.62 (d, J=17.0 Hz, 1H), 5.91 (d, J=17.1 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 8.84 (d, J=2.0 Hz, 1H), 9.02 (d, J=2.0 Hz, 1H), 9.14 (s, 2H), 10.27 (s, 1H).
(1R,2S,5S)-3-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide (183)
1H NMR (400 MHz, DMSO-d6) δ 0.73-0.81 (m, 1H), 0.82-0.92 (m, 2H), 1.89 (s, 1H), 2.04 (s, 3H), 2.66 (s, 3H), 2.71 (s, 3H), 3.93 (d, J=9.8 Hz, 1H), 4.05-4.13 (m, 1H), 4.60 (d, J=5.4 Hz, 1H), 5.59 (s, 2H), 7.40 (d, J=7.9 Hz, 1H), 7.59 (d, J=7.9 Hz, 1H), 8.82 (d, J=2.0 Hz, 1H), 8.99 (d, J=2.0 Hz, 1H), 9.13 (s, 2H), 10.27 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (185)
1H NMR (400 MHz, DMSO-d6) δ 0.96-1.08 (m, 2H), 1.31-1.35 (m, 3H), 2.07 (s, 4H), 2.53-2.60 (m, 1H), 2.73 (s, 3H), 2.82 (s, 3H), 3.53-3.60 (m, 1H), 4.35-4.43 (m, 1H), 5.61 (d, J=17.2 Hz, 1H), 5.93 (d, J=17.2 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 8.23 (d, J=9.0 Hz, 1H), 8.35 (d, J=8.9 Hz, 1H), 9.44 (s, 2H), 10.26 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (192)
1H NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.36 (s, 2H), 9.33 (s, 1H), 8.63 (s, 1H), 7.77 (d, 1H, J=8.4 Hz), 7.47 (d, 1H, J=8.4 Hz), 6.08 (d, 1H, J=17.7 Hz), 5.74 (d, 1H, J=17.7 Hz), 4.44-4.49 (m, 1H), 3.61-3.65 (m 1H), 3.42-3.46 (m, 4H), 3.28 (s, 2H), 2.70 (s, 3H), 2.69 (s, 3H), 2.54-2.59 (m, 1H), 2.07-2.18 (m, 5H), 1.35 (s, 3H), 0.99-1.13 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-aminopyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (195)
1H NMR (400 MHz, DMSO-d6) δ 0.98-1.04 (m, 1H), 1.07-1.12 (m, 1H), 1.33 (s, 3H), 2.01-2.12 (m, 4H), 2.54-2.61 (m, 1H), 2.67 (s, 3H), 3.56-3.65 (m, 1H), 4.38-4.45 (m, 1H), 5.69 (d, J=17.2 Hz, 1H), 6.00 (d, J=17.2 Hz, 1H), 6.90 (s, 2H), 7.83 (d, J=8.4 Hz, 1H), 8.37 (s, 1H), 8.93 (s, 2H), 9.20 (s, 1H), 10.27 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (198)
1H NMR (400 MHz, DMSO-d6) δ 0.99-1.06 (m, 1H), 1.07-1.12 (m, 1H), 1.34 (s, 3H), 2.00-2.12 (m, 4H), 2.53-2.61 (m, 1H), 2.69 (s, 3H), 3.55-3.63 (m, 1H), 4.01 (s, 3H), 4.29-4.49 (m, 1H), 5.73 (d, J=17.2 Hz, 1H), 6.04 (d, J=17.3 Hz, 1H), 7.83 (d, J=8.4 Hz, 1H), 8.55 (d, J=1.3 Hz, 1H), 9.20-9.33 (m, 3H), 10.27 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 9.26 (s, 2H), 8.49 (d, J=6.0 Hz, 2H), 7.82 (d, J=8.3 Hz, 1H), 5.79 (d, J=17.9 Hz, 1H), 5.48 (d, J=17.8 Hz, 1H), 4.39 (m, 1H), 3.57 (m, 1H), 2.82 (s, 3H), 2.67 (s, 3H), 2.60-2.52 (m, 1H), 2.10-1.97 (m, 4H), 1.33 (s, 3H), 1.02 (m, 1H), 0.91 (m, 1H). LC/MS (ESI) m/z: 634/636 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.39 (s, 1H), 7.91 (s, 1H), 7.52 (s, 1H), 7.11 (s, 1H), 5.95-6.00 (d, J=18 Hz, 1H), 5.76-5.80 (d, J=18 Hz, 1H), 4.46-4.50 (m, 1H), 3.53-3.55 (m, 1H), 2.75 (s, 3H), 2.73 (s, 3H), 2.67 (s, 3H), 2.53-2.59 (m, 1H), 2.31 (s, 3H), 2.15-2.19 (m, 1H), 1.38 (s, 3H), 1.08-1.11 (m, 1H), 0.94-0.96 (m, 1H). LC/MS (ESI) m/z: 616/618 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.31 (s, 2H), 9.20 (s, 1H), 8.63 (s, 1H), 7.90 (s, 1H), 7.10 (s, 1H), 5.93-5.98 (d, J=17.6 Hz, 1H), 5.72-5.77 (d, J=17.2 Hz, 1H), 4.48-4.51 (m, 1H), 3.54-3.56 (m, 1H), 2.74 (s, 3H), 2.70 (s, 3H), 2.53-2.59 (m, 1H), 2.29 (s, 3H), 2.15-2.20 (m, 1H), 1.38 (s, 3H), 1.08-1.11 (m, 1H), 1.00-1.02 (m, 1H). LC/MS (ESI) m/z: 603/605 (M+H)+.
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl] acetyl}-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.97 (d, J=7.1 Hz, 2H), 8.54-8.48 (m, 1H), 7.90 (s, 1H), 7.77 (d, J=1.2 Hz, 2H), 7.11 (s, 1H), 5.80 (d, J=17.2 Hz, 1H), 5.63 (d, J=17.2 Hz, 1H), 4.53-4.44 (m, 1H), 3.57-3.52 (m, 1H), 2.74 (s, 3H), 2.69 (s, 3H), 2.59-2.52 (m, 1H), 2.30 (s, 3H), 2.21-2.14 (m, 1H), 1.37 (s, 3H), 1.10-1.04 (m, 1H), 0.99-0.95 (m, 1H). LC/MS (ESI) m/z: 602/604 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 11.14 (s, 1H), 9.32 (s, 2H), 8.48 (s, 1H), 7.84-7.87 (dd, J=11.2 Hz, 1.6 Hz, 1H), 7.41-7.43 (dd, J=7.6 Hz, 1.2 Hz, 1H), 6.16-6.20 (d, J=18.0 Hz, 1H) 5.75-5.79 (d, J=18.0 Hz, 1H), 4.35-4.45 (m, 1H), 3.66-3.67 (m, 1H), 2.92 (s, 3H), 2.68 (s, 3H), 2.67 (s, 3H), 2.64-2.65 (m, 1H), 2.02-2.03 (m, 1H), 1.31 (s, 3H), 0.99-1.01 (m, 1H), 0.92-0.94 (m, 1H). LC/MS (ESI) m/z: 621/623 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.33 (s, 2H), 8.50 (s, 1H), 7.82 (d, J=8.4 Hz, 1H), 6.17 (d, J=18.0 Hz, 1H), 5.80 (d, J=18.0 Hz, 1H), 4.45 (m, 1H), 3.86 (m, 1H), 3.25 (d, J=16.0 Hz, 1H), 3.10 (d, J=16.0 Hz, 1H), 2.92 (s, 3H), 2.68 (s, 3H), 2.67 (s, 3H), 2.66-2.62 (m, 1H), 2.46 (s, 3H), 2.18 (m, 1H), 2.03 (s, 3H), 1.25 (m, 1H), 1.16 (m, 1H). LC/MS (ESI) m/z: 717/719 (M+H)+.
(2S,4R)-1-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)pyrazolo[3,4-c]pyridin-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.51 (s, 1H), 9.33 (d, J=5.4 Hz, 2H), 8.49 (d, J=6.9 Hz, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 6.01 (d, J=17.9 Hz, 1H), 5.82 (d, J=17.8 Hz, 1H), 4.68-4.62 (m, 1H), 4.30-4.22 (m, 1H), 3.94-3.83 (m, 1H), 2.89 (s, 3H), 2.68 (s, 3H), 2.67 (s, 3H), 2.24-2.16 (m, 1H), 2.13-2.04 (m, 1H), 1.99 (s, 3H), 1.64 (d, J=21.0 Hz, 3H). LC/MS (ESI) m/z: 623 (M+H)+.
(2S,4R)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.50 (s, 1H), 9.02 (d, J=6.8 Hz, 2H), 8.30 (d, J=1.1 Hz, 1H), 7.63-7.56 (m, 2H), 7.42 (d, J=7.9 Hz, 1H), 5.89 (d, J=17.9 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.67-4.62 (m, 1H), 4.28-4.20 (m, 1H), 3.92-3.80 (m, 1H), 2.68 (s, 3H), 2.66 (s, 3H), 2.64 (s, 3H), 2.24-2.14 (m, 1H), 2.13-2.02 (m, 1H), 2.00 (s, 3H), 1.63 (d, J=21.0 Hz, 3H). LC/MS (ESI) m/z: 622 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.40 (d, J=1.1 Hz, 1H), 7.58-7.48 (m, 2H), 5.98 (d, J=17.7 Hz, 1H), 5.80 (d, J=17.7 Hz, 1H), 4.59-4.56 (m, 1H), 3.85 (dd, J=5.7, 2.7 Hz, 1H), 3.37 (d, J=16.1 Hz, 1H), 3.16 (d, J=16.1 Hz, 1H), 2.73 (dd, J=11.1, 3.4 Hz, 7H), 2.67 (s, 3H), 2.48 (dd, J=13.7, 4.3 Hz, 1H), 2.36 (s, 3H), 2.12 (s, 3H), 1.37 (t, J=5.7 Hz, 1H), 1.29 (m, 1H), 1.18 (m, 1H). LC/MS (ESI) m/z: 717/719 [M+H]+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.07 (s, 2H), 8.58 (s, 1H), 8.01 (s, 1H), 7.62 (d, J=8.3 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.72-5.97 (m, 3H), 5.62-5.70 (m, 1H), 4.45 (dd, J=9.3, 5.3 Hz, 1H), 3.82 (dd, J=5.6, 2.7 Hz, 1H), 3.09-3.23 (m, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.51-2.52 (m, 1H), 2.45 (s, 3H), 2.14-2.21 (m, 1H), 1.99 (s, 3H), 1.22-1.26 (m, 1H), 1.13-1.20 (m, 1H). LC/MS (ESI) m/z: 716/718 (M+H)+.
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-{2-[3-carbamoyl-5-(2-methylpyrimidin-5-yl)pyrazolo[3,4-c]pyridin-1-yl]acetyl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.34 (s, 2H), 9.21 (d, J=1.2 Hz, 1H), 8.69 (d, J=1.2 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 5.90 (d, J=20.0 Hz, 1H), 5.75 (d, J=20.0 Hz, 1H), 4.54 (m, 1H), 3.54 (m, 1H), 2.76 (s, 3H), 2.63 (m, 1H), 2.31 (m, 1H), 2.11 (s, 3H), 1.41 (s, 3H), 1.10 (t, J=4.0 Hz, 1H), 1.00 (m, 1H). LC/MS (ESI) m/z: 604/606 (M+H)+.
(1R, 2S, 5S)-3-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl) pyrazolo [3, 4-c]pyridin-1-yl] acetyl}-N-[(3-chloro-2-fluorophenyl) methyl]-3-azabicyclo [3.1.0] hexane-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 9.33 (s, 2H), 8.49 (s, 1H), 8.43 (t, J=5.7 Hz, 1H), 7.40 (dd, J=14.7, 7.8 Hz, 1H), 7.23 (dd, J=14.0, 7.4 Hz, 1H), 7.00 (t, J=7.5 Hz, 1H), 5.87-5.70 (m, 2H), 4.47 (t, J=9.6 Hz, 1H), 4.35 (dd, J=15.6, 5.9 Hz, 1H), 4.24 (dd, J=15.6, 5.6 Hz, 1H), 4.00 (dd, J=9.7, 5.1 Hz, 1H), 3.85 (d, J=9.8 Hz, 1H), 2.88 (s, 3H), 2.66 (t, J=9.4 Hz, 6H), 1.93 (d, J=12.2 Hz, 1H), 1.84 (s, 1H), 0.81-0.67 (m, 2H). LC/MS (ESI) m/z: 576 (M+H)+.
(1R,2S,5S)-3-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-chloro-2-fluorobenzyl)-3-azabicyclo[3.1.0]hexane-2-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.53 (s, 1H), 7.75 (s, 2H), 7.31-7.23 (m, 2H), 6.97-6.91 (m, 1H), 5.48 (t, J=13.4 Hz, 2H), 4.56 (d, J=5.6 Hz, 1H), 4.49 (d, J=15.6 Hz, 1H), 4.38 (d, J=15.6 Hz, 1H), 4.08-4.03 (m, 1H), 3.91 (d, J=9.7 Hz, 1H), 2.75 (s, 3H), 2.67 (s, 3H), 2.05-2.00 (m, 1H), 1.96-1.90 (m, 1H), 0.87-0.78 (m, 2H). LC/MS (ESI) m/z: 561 (M+H)+.
(2S)-1-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)pyrazolo [3,4-c]pyridin-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.56 (s, 1H), 9.32 (s, 2H), 8.48 (s, 1H), 7.60 (d, J=8.4 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 6.06 (d, J=17.9 Hz, 1H), 5.88 (d, J=17.8 Hz, 1H), 4.96 (d, J=22.5 Hz, 1H), 4.84 (d, J=21.2 Hz, 1H), 4.72 (t, J=8.4 Hz, 1H), 4.41-4.31 (m, 1H), 4.14-4.03 (m, 1H), 2.90 (s, 3H), 2.69 (s, 3H), 2.67 (s, 3H), 2.37-2.15 (m, 2H), 1.99 (s, 3H). LC/MS (ESI) m/z: 641/643 (M+H)+.
2-{2-[3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl) indazol-1-yl] acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-[(3-methyl-1, 2, 4-oxadiazol-5-yl) methyl]-2-azabicyclo [3.1.0] hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.04 (s, 2H), 8.67 (t, J=1.9 Hz, 1H), 7.85 (d, J=1.7 Hz, 1H), 7.54 (d, J=7.9 Hz, 1H), 7.41-7.33 (m, 1H), 5.98-5.64 (m, 4H), 4.59 (dd, J=9.2, 4.9 Hz, 1H), 3.84 (dd, J=5.7, 2.7 Hz, 1H), 3.39 (d, J=16.1 Hz, 1H), 3.16 (d, J=16.1 Hz, 1H), 2.85-2.62 (m, 6H), 2.52 (dd, J=13.5, 5.2 Hz, 1H), 2.33 (d, J=20.8 Hz, 3H), 2.13-1.98 (m, 3H), 1.60 (s, 1H), 1.42-1.37 (m, 1H), 1.22 (dd, J=5.9, 2.6 Hz, 1H). LC/MS (ESI) m/z: 716 (M+H)+.
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(3-cyano-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.13 (s, 2H), 8.13 (s, 1H), 7.73 (s, 1H), 7.61 (d, J=8.0 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 7.24-7.22 (m, 1H), 7.17-7.10 (m, 1H), 6.05 (d, J=18.0 Hz, 1H), 5.70 (d, J=18.0 Hz, 1H), 4.40-4.37 (m, 1H), 3.57-3.56 (m, 1H), 2.68 (s, 3H), 2.67 (s, 3H), 2.66-2.65 (m, 1H), 2.02 (s, 3H), 2.01-2.02 (m, 1H), 1.31 (s, 3H), 1.01-0.98 (m, 1H), 0.93-0.92 (m, 1H).
Figure US11708351-20230725-C01069
Figure US11708351-20230725-C01070
Step 1: (3S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S2)
To a solution of 10-S1 (1 g, 2.34 mmol), isoindoline-1,3-dione (517 mg, 3.52 mmol), and PPh3 (1.22 g, 4.68 mmol) in THF (15 mL) was added DIAD (0.92 mL, 4.68 mmol) dropwise at 0° C. under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=10:1 to 3:1) to afford the title compound (1.25 g, 96.1% yield) as a light yellow solid. LC/MS (ESI) m/z: 555/557 (M+H)+.
Step 2: (3S)-tert-Butyl 5-(aminomethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S3)
To a solution of 10-S2 (1.2 g, 2.16 mmol) in EtOH (10 mL) was added hydrazine hydrate (1 mL, 85%). The reaction mixture was stirred at 60° C. for 3 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=80:1 to 5:1) to afford 10-S3 (500 mg, 52.4% yield) as a light yellow oil. LC/MS (ESI) m/z: 425/427 (M+H)+.
Step 3: (3S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (10-S4)
To a solution of 10-S3 (500 mg, 1.18 mmol) in MeOH (5 mL) were added NaBH3CN (148 mg, 2.36 mmol) and 15% aqueous formaldehyde solution (0.3 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) followed by preparative HPLC to afford 10-S4 (90 mg, 16.8% yield) as a white solid. LC/MS (ESI) m/z: 453/455 (M+H)+.
Step 4: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (10-S5)
To a solution of 10-S4 (90 mg, 0.21 mmol) in DCM (3 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 10-S5 (65 mg, 94.6% yield) as a yellow solid. The crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 353/355 (M+H)+.
Step 5: (1S,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (10)
To a solution of 10-S5 (90 mg, 0.20 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (75 mg, 0.24 mmol), and HATU (152 mg, 0.40 mmol) in DMF (3 mL) was added DIPEA (0.13 mL, 0.80 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative TLC to afford 10 (35 mg, 27.3% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.52 (s, 1H), 7.75 (s, 2H), 7.53 (d, J=7.6 Hz, 1H), 7.37 (d, J=8.0 Hz, 1H), 5.78-5.82 (m, 1H), 5.62-5.67 (m, 1H), 5.10-5.12 (m, 1H), 3.82-3.85 (m, 1H), 3.42-3.48 (m, 1H), 2.73-2.86 (m, 10H), 2.69 (s, 3H), 2.47-2.52 (m, 1H), 2.06 (s, 3H), 1.79-1.81 (m, 1H), 0.89-0.92 (m, 2H). LC/MS (ESI) m/z: 645/647 (M+H)+.
Figure US11708351-20230725-C01071
Figure US11708351-20230725-C01072
Step 1: (3aR,6aS)-tert-Butyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydrocyclopenta[c] pyrrole-2(1H)-carboxylate (11-S2)
To a solution of (3aR,6aS)-tert-butyl 5-hydroxy-3a-methylhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (11-S1, 300 mg, 0.94 mmol) in DCM (5 mL) were added 4-fluorophenylthionochloroformate (213.5 mg, 1.12 mmol) and DMAP (344.6 mg, 2.82 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with DCM (20 mL), washed with 0.5 N aqueous HCl (10 mL), water (10 mL), and brine, dried over Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 10:1) to afford 11-S2 (338 mg, 94.3% yield) as a white solid. LC/MS (ESI) m/z: 404 (M+Na)+.
Step 2: (3aR,6aS)-tert-Butyl hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (11-S3)
To a solution of (3aR,6aS)-tert-butyl 5-(((4-fluorophenoxy)carbonothioyl)oxy)hexahydro cyclopenta[c]pyrrole-2(1H)-carboxylate (11-S2, 338 mg, 0.89 mmol) in 1,4-dioxane (3 mL) were added 1,1′-azobis(cyclohexanecarbonitrile) (Vazo, 73.0 mg, 0.45 mmol) and tris(trimethylsilyl)silane (330.9 mg, 1.33 mmol). The reaction mixture was stirred at 105° C. for 40 minutes at room temperature for 30 minutes. The mixture was concentrated to dryness to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=40:1 to 10:1) to afford 11-S3 (73 mg, 38.8% yield) as a yellow oil. LC/MS (ESI) m/z: 156 (M+H−56)+.
Step 3: (3aR,6aS)-Octahydrocyclopenta[c]pyrrole (11-S4)
To a solution of (3aR,6aS)-tert-butyl hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate (11-S3, 73 mg, 0.14 mmol) in DCM (3 mL) was added TFA (1 mL) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was evaporated under reduced pressure to afford 11-S4 (70 mg, 100% yield). This crude material was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 112 (M+H)+.
Step 4: (3S)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((hexahydrocyclopenta [c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (11-S6)
To a mixture of (3aR,6aS)-octahydrocyclopenta[c]pyrrole (11-S4, 35 mg, 0.3 mmol) and DIPEA (77.4 mmol, 0.6 mmol) in MeCN (3 mL) was added (3S)-tert-butyl 3-((6-bromo-3-methylpyridin-2-yl) carbamoyl)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (S5, 100 mg, 0.20 mmol) and NaI (32 mg, 0.2 mmol) at 0° C. After stirring at room temperature overnight, the mixture was evaporated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (PE/EtOAc=5:1 to 1:1) to afford 11-S6 (30 mg, 28.9% yield) as a brown oil. LC/MS (ESI) m/z: 519 (M+H)+.
Step 5: (3S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11-S7)
To a solution of (3S)-tert-butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (11-S6, 30 mg) in 1,4-dioxane (1 mL) was added a 4 N solution of HCl in 1,4-dioxane (1 mL) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford 11-S7 (30 mg, 100% yield), which was used in the next synthetic step without further purification.
Step 6: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11)
To a mixture of (3S)—N-(6-bromo-3-methylpyridin-2-yl)-5-((hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (11-S7, 20 mg, 0.05 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic acid (14.8 mg, 0.05 mmol), and HATU (28.5 mg, 0.08 mmol) in DMF (2 mL) was added DIPEA (19.3 mg, 0.15 mmol) and the mixture was stirred at room temperature overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative TLC to afford 11 (1.1 mg, 3.1% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (d, J=2.8 Hz, 2H), 8.56 (d, J=5.3 Hz, 1H), 7.79-7.76 (m, 2H), 7.58-7.54 (m, 1H), 7.44-7.39 (m, 1H), 5.83-5.79 (d, 1H), 5.69-5.64 (s, 1H), 3.93-3.86 (m, 2H), 3.49-3.46 (m, 1H), 2.97-2.93 (m, 2H), 2.75 (s, 3H), 2.70 (s, 3H), 2.10 (d, J=18.6 Hz, 3H), 1.40-1.26 (m, 13H). LC/MS (ESI) m/z: 711 (M+H)+.
Figure US11708351-20230725-C01073
Figure US11708351-20230725-C01074
Figure US11708351-20230725-C01075
Step 1: Methyl 1-benzyl-6-oxo-1,4,5,6-tetrahydropyridine-3-carboxylate (12-S2)
To a solution of benzylamine (6 g, 56.1 mmol) in THF (50 mL) was added 12-S1 (4.55 g, 56.1 mmol) at 0° C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated under reduced pressure and dissolved in THF (100 mL). Acryloyl chloride (5.55 g, 61.7 mmol) was added to the solution at 0° C. and the reaction mixture was stirred at room temperature overnight. The solution was diluted with EtOAc and washed with saturated aqueous NaHCO3. The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=5:1 to 3:1) to afford the title compound (3.5 g, 25.5% yield) as a yellow oil. LC/MS (ESI) m/z: 246 (M+H)+.
Step 2: Methyl 1-benzyl-6-oxopiperidine-3-carboxylate (12-S3)
To a solution of 12-S2 (3.5 g, 14.3 mmol) in EtOH (30 mL) was added Pd/C (10% mol, 151 mg). The mixture was purged with nitrogen, purged with hydrogen, and stirred under an atmosphere of hydrogen (balloon) at room temperature for 1.5 hours. The mixture was filtered through a pad of Celite and washed with EtOH. The filtrate was concentrated to dryness to afford the title compound (3.2 g, 90.2% yield) as a colorless oil. LC/MS (ESI) m/z: 248 (M+H)+.
Step 3: 1-Benzyl-5-(hydroxymethyl)piperidin-2-one (12-S4)
To a solution of 12-S3 (3.2 g, 13.0 mmol) in THF (45 mL) was added LiBH4 (566 mg, 26.0 mmol) at 0° C. The reaction mixture was stirred under an atmosphere of nitrogen at room temperature overnight. The reaction mixture was quenched with water and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried over anhydrous Na2SO4, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=50:1) to afford the title compound (2.2 g, 77.3% yield) as a yellow oil. LC/MS (ESI) m/z: 220 (M+H)+.
Step 4: 1-Benzyl-5-(iodomethyl)piperidin-2-one (12-S5)
To a solution of 12-S4 (2.2 g, 10.0 mmol) in DCM (45 mL) under an atmosphere of nitrogen were added Et3N (3.47 mL, 25.0 mmol) and MsCl (1.72 g, 15 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight under an atmosphere of nitrogen. Ice water was added and the organic layer was separated, washed with brine, dried over anhydrous Na2SO4, and filtered. The filtrate was concentrated and diluted with acetone (25 mL). After NaI (4.50 g, 30.0 mmol) was added, the mixture was stirred at reflux for 24 hours. The mixture was cooled to room temperature and concentrated. The remaining residue was diluted with water and extracted with EtOAc. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=5:1 to 3:1) to afford the title compound (1.5 g, 45.5% yield) as a yellow oil. LC/MS (ESI) m/z: 330 (M+H)+.
Step 5: 3-Benzyl-3-azabicyclo[3.1.1]heptan-2-one (12-S6)
To a solution of 12-S5 (1.5 g, 4.56 mmol) in THF (45 mL) under an atmosphere of nitrogen was added LiHMDS (1 M solution in THF, 13.68 mL, 13.68 mmol) at −20° C. The reaction mixture was stirred at −20° C. for 1.5 hours under an atmosphere of nitrogen. The reaction mixture was quenched by addition of water and extracted with EtOAc (50 mL). The organic phase was washed with brine, dried with anhydrous Na2SO4, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=8:1) to afford the title compound (600 mg, 65.5% yield) as a colorless oil. LC/MS (ESI) m/z: 202 (M+H)+.
Step 6: 3-Benzyl-3-azabicyclo[3.1.1]heptane (12-S7)
To a solution of 12-S6 (600 mg, 2.99 mmol) in THF (45 mL) under an atmosphere of nitrogen was added BH3.THF (1 M solution in THF, 8.97 mL, 8.97 mmol) at 0° C. The reaction mixture was stirred at room temperature for 3 hours under an atmosphere of nitrogen. The reaction mixture was quenched with MeOH at 0° C. and concentrated. The remaining residue was diluted with EtOH (4.5 mL) and water (0.5 mL) and then stirred at 100° C. for 3 hours. The mixture was concentrated, diluted with EtOAc, and washed with water and brine. The organic phase was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=50:1) to afford the title compound (300 mg, 53.7% yield) as a colorless oil. LC/MS (ESI) m/z: 188 (M+H)+.
Step 7: 3-Benzyl-3-azabicyclo[3.1.1]heptane hydrochloride (12-S8)
To a solution of compound 12-S7 (300 mg, 1.6 mmol) and concentrated HCl (0.27 mL) in EtOH (35 mL) was added Pd/C (60 mg). The mixture was purged with nitrogen and stirred under an atmosphere of hydrogen (balloon) at room temperature for 2 hours. The mixture was filtered and filtrate was evaporated to afford the title compound (180 mg, 65.9% yield) as a light a brown solid. LC/MS (ESI) m/z: 98 (M+H)+.
Step 8: (3S)-tert-Butyl 5-(azetidin-1-ylmethyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (12-S10)
To a solution of 12-S9 (80 mg, 0.19 mmol) in MeCN (2 mL) were added DIPEA (0.13 mL, 0.76 mmol), 12-S8 (18.5 mg, 0.19 mmol), and NaI at 0° C. The reaction mixture was stirred at room temperature for 4 hours. The mixture was concentrated and the remaining residue was diluted with DCM and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=50:1) to afford the title compound (21 mg, 21.9% yield) as a yellow solid. LC/MS (ESI) m/z: 505 (M+H)+.
Step 9: (3S)-5-(Azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (12-S11)
To a solution of 12-S10 (21 mg, 0.042 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (25 mg, 100% yield) as a brown solid. LC/MS (ESI) m/z: 405 (M+H)+.
Step 10: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (12)
To a solution of 12-S11 (25 mg, 0.042 mmol) and 12-S12 (13.02 mg, 0.042 mmol) in DMF (2 mL) were added HATU (28.7 mg, 0.076 mmol) and DIPEA (0.029 mL, 0.168 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 12 (2.1 mg, 7.2% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (s, 2H), 7.58 (d, J=8.2 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 5.82 (d, J=17.1 Hz, 1H), 5.67 (d, J=17.1 Hz, 1H), 5.34 (t, J=4.6 Hz, 1H), 4.70 (d, J=4.2 Hz, 1H), 2.75 (d, J=5.0 Hz, 4H), 2.70 (s, 3H), 2.57-2.47 (m, 4H), 2.38-2.27 (m, 4H), 2.22-2.17 (m, 2H), 2.12 (s, 3H), 2.02 (d, J=7.8 Hz, 2H), 1.49-1.46 (m, 1H), 1.39 (d, J=6.8 Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 697 (M+H)+.
Figure US11708351-20230725-C01076
Figure US11708351-20230725-C01077
Step 1: 2-Bromo-5-isopropyl-1-(oxidanyl)-pyridine (14-S2)
To a stirred solution of 2-bromo-5-isopropylpyridine (14-S1, 3 g, 1 equiv) in CHCl3 (200 mL) was added 3-chlorobenzoperoxoic acid (10 g, 3 equiv). The reaction mixture was heated to 50° C. until completion. The reaction mixture was cooled and saturated aqueous NaHCO3 solution (100 mL) was added. The organic and aqueous layers were separated and the organic layer was washed with saturated aqueous NaHCO3 (100 mL×3). The combined organic layers were concentrated to dryness. The residue was purified by column chromatography on SiO2 gel (eluted with 5% MeOH in DCM) to afford 14-S2 (2.6 g, 80%).
Step 2: 5-Bromo-N-(tert-butyl)-2-isopropylaniline (14-S3)
To a stirred solution of 14-S2 (812 mg, 1 equiv) and 2-methylpropan-2-amine (1.97 mL, 5 equiv) in DCM (100 mL), trifluoroacidic anhydride (0.7 mL, 1.1 equiv) was added dropwise at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at 0-5° C. for 1 hour and TFAA solution was added (0.7 mL in 5 mL DCM, I equiv)) followed by 2-methylpropan-2-amine (0.4 mL, 1 equiv). The reaction mixture was neutralized with aqueous saturated NaHCO3 solution (50 mL). The organic layer was washed with brine (50 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/EtOAc=3:1 to afford 14-S3 (397 mg, 39%).
Step 3: 5-Bromo-N-(tert-butyl)-2-isopropylaniline (14-S4)
TFA (10 mL) was added to 14-S3 (397 mg) and the reaction mixture was heated at 70° C. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15 mL), washed with aqueous saturated NaHCO3 solution (15 mL). The organic layer was dried over Na2SO4 and concentrated to dryness to afford 14-S4 (316 mg, quantitative yield)
Step 4: tert-Butyl (1R,3S,5R)-3-((6-Bromo-3-isopropylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (14-S5)
To a stirred solution of (1R, 3S, 5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (99 mg, 1 equiv), 14-S4 (89 mg, 1 equiv) in DCM (8 mL) and pyridine (0.17 mL, 5 equiv) was added. POCl3 was then added dropwise (0.04 mL, 2 equiv) at 0-5° C. under an atmosphere of argon. The reaction mixture was warmed to room temperature and stirred for 2 hours. The reaction was then diluted with DCM (10 mL), neutralized with aqueous saturated NaHCO3 solution (10 mL), and the aqueous layer was extracted with DCM (1×10 mL). The combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 14-S5 (130 mg, 73%).
Step 5: (1R,3S,5R)—N-(6-Bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (14-S6)
To a solution of 14-S5 (130 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 3 hours. The reaction mixture was concentrated to dryness to afford 14-S6 as TFA salt (135 mg, quantitative yield).
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-isopropylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (14)
To a solution of 14-S6 (72 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (50 mg, 1.2 equiv) in DMF (8 mL) and DIPEA (0.17 ml, 5 equiv) was added HATU (70 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (25 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 14 (84 mg, 82%). 1H NMR (400 MHz, DMSO-d6) δ 10.11 (s, 1H), 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.75 (d, 1H, J=8.3 Hz), 7.54 (d, 1H, J=8.3 Hz), 5.91 (d, 1H, J=17.5 Hz), 5.59 (d, 1H, J=17.5 Hz), 4.41-4.46 (m, 1H), 3.58 (t, 11H, J=5.4 Hz), 3.16-3.19 (m, 1H), 2.89-2.97 (m, 1H), 2.70 (s, 3H), 2.68 (s, 3H), 2.54-2.58 (m, 1H), 2.01-2.09 (m, 1H), 1.33 (s, 3H), 1.16-1.27 (m, 1H), 1.03-1.09 (m, 6H).
Figure US11708351-20230725-C01078
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds via the following steps: 1) the formation of an amide bond between the B-ring and the C-ring by first generating an acyl chloride B-ring with POCl3; 2) the removal of the Boc-group using an acid; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will further recognize that the B-ring linked to the C-ring can be further functionalized prior to the HATU coupling. Additional functionalization includes a Stille cross-coupling and an Ullmann cross-coupling.
Step 1: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (15-S3)
(1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (15-S1, 483 mg, 2.0 mmol) and 6-bromo-3-methylpyridin-2-amine (15-S2, 374 mg, 2.0 mmol) were dissolved in anhydrous DCM (15 mL). The reaction was cooled in an ice bath and dry pyridine (0.5 mL, 6.0 mmol) was added in one portion, followed by POCl3 (200 μL, 2.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0° C., and the reaction was quenched with water (15 mL). The aqueous phase was extracted with DCM (15 mL×2) and the combined organic layers was washed with brine dried over MgSO4. The solution was filtered and concentrated and the resulting residue was purified to afford 15-S3 (595 mg). 1H NMR (400 MHz, DMSO-d6): (major rotamer) δ 0.61 (dd, J=2.4, 5.3 Hz, 1H), 0.68 (t, J=5.6 Hz, 1H), 1.20 (s, 3H), 1.38 (s, 9H), 1.88-1.98 (m, 1H), 2.11 (s, 3H), 2.37-2.45 (m, 1H), 3.12 (s, 1H), 4.06 (dd, J=6.6, 8.9 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 10.17 (s, 1H) ppm.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (15-S4)
tert-Butyl (1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (15-S3, 595 mg) was taken up in 4N HCl dioxane (3.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue (15-S4) was carried forward without additional purification and used directly in the next step.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (15)
To the solution of (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (15-S4, 87 mg, 0.25 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (15-S5, 78 mg, 0.25 mmol) in DMF (2.0 mL), HATU (114 mg, 0.3 mmol) was added, followed by the dropwise addition of DIEA (4.0 eq) at room temperature. The mixture was stirred for 1 hour at room temperature before the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with EtOAc. The combined organic solutions were successively washed with water, brine, and dried over MgSO4. The solution was filtered and the solvent was removed. The residue was purified to afford 15 (136.1 mg). 1H NMR (400 MHz, DMSO-d6): (major rotamer) δ 1.02 (t, J=5.4 Hz, 1H), 1.07-1.13 (m, 1H 1.33 (s, 3H), 2.04 (s, 3H), 2.05-2.11 (m, 1H), 2.56 (dd, J=9.2, 13.3 Hz, 1H), 2.69 (s, 3H), 2.70 (s, 3H), 3.54-3.62 (m, 1H), 4.35-4.48 (m, 1H), 5.72 (d, J=17.2 Hz, 1H), 6.04 (d, J=17.3 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.62 (d, J=8.0 Hz, 1H), 8.60 (s, 1H), 9.30 (s, 1H), 9.34 (s, 2H), 10.27 (s, 1H) ppm. LC (method A): tR=1.71 min. LC/MS (EI) m/z: [M+H]+ 605.44.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromoisoquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (73)
1H NMR (400 MHz, DMSO-d6) δ 10.75 (s, 1H), 9.04 (s, 2H), 8.46 (s, 1H), 8.09 (s, 1H), 7.82-7.96 (m, 4H), 7.74-7.80 (m, 1H), 7.51 (t, 1H, J=7.7 Hz), 5.97 (d, 1H, J=17.5 Hz), 5.62 (d, 1H, J=17.5 Hz), 4.51-4.58 (m, 1H), 3.64-3.67 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.61-2.65 (m, 1H), 2.14-2.20 (m, 1H), 1.38 (s, 3H), 1.00-1.10 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 0.87 (dd, J=2.4, 5.4 Hz, 1H), 1.15 (t, J=5.4 Hz, 1H), 1.42 (s, 3H), 2.08 (s, 3H), 2.30-2.36 (m, 1H), 2.53 (s, 3H), 2.67 (d, J=14.8 Hz, 1H), 2.72 (s, 3H), 2.79 (s, 3H), 3.10 (d, J=2.8, 1H), 4.83 (d, J=8.3 Hz, 1H), 5.30 (d, J=17.7 Hz, 1H), 5.46 (d, J=17.7 Hz, 1H), 7.16-7.26 (m, 2H), 7.34 (d, J=7.9 Hz, 1H), 7.71 (s, 1H), 8.55 (s, 1H), 8.56 (brs, 1H), 8.89 (s, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 0.97-1.08 (m, 2H), 1.34 (s, 3H), 1.77 (s, 3H), 2.06 (m, 1H), 2.56 (m, 1H), 2.66 (s, 3H), 2.70 (s, 3H), 3.60 (m, 1H), 4.00-4.80 (m, 2H), 4.40 (m, 1H), 5.59 (m, 1H), 5.92 (m, 1H), 7.85-7.96 (m, 3H), 8.45 (s, 1H), 9.05 (s, 2H), 10.35 (s, 1H).
(2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-H-indazol-1-yl)acetyl)-4-fluoro-N-(6-iodopyridin-2-yl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.95 (s, 1H), 9.03 (s, 2H), 8.42 (s, 1H), 8.00-8.02 (d, J=7.2 Hz, 1H), 7.85-7.86 (m, 2H), 7.51-7.53 (d, J=7.2 Hz, 1H), 7.42-7.46 (t, 1H), 5.82-5.86 (d, J=13.2 Hz, 1H), 5.62-5.66 (d, J=13.2 Hz, 1H), 5.48-5.61 (m, 1H), 4.65-4.69 (m, 1H), 4.18-4.27 (m, 1H), 3.96-4.08 (m, 1H), 2.68 (s, 3H), 2.64 (s, 3H), 2.51-2.56 (m, 1H), 2.06-2.23 (m, 1H). LC/MS (ESI) m/z: 628 (M+H)+.
(2S,4R)-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1-H-pyrazolo[3,4-c]pyridine-1-yl)acetyl)-4-fluoro-N-(pyridine-2-yl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.66 (s, 1H), 9.03 (s, 2H), 8.41 (s, 1H), 8.28-8.29 (m, 1H), 8.01-8.03 (d, J=8.4 Hz, 1H), 7.85 (m, 2H), 7.72-7.76 (m, 1H), 7.06-7.09 (m, 1H), 5.82-5.86 (d, J=17.2 Hz, 1H), 5.63-5.74 (d, J=17.2 Hz, 1H), 5.62 (m, 0.5H), 5.49 (m, 0.5H), 4.69-4.73 (m, 1H), 4.23-4.28 (m, 1H), 3.95-4.08 (m, 1H), 2.67 (s, 3H), 2.64 (s, 3H), 2.53-2.58 (m, 1H), 2.11-2.21 (m, 1H). LC/MS (ESI) m/z: 502 (M+H)+.
(2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1-H-pyrazolo[3,4-c]pyridine-1-yl)acetyl)-N-(6-bromopyridin-2-yl)4-fluoro-N-methylpyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.12 (s, 2H), 8.43 (s, 1H), 7.77-7.92 (m, 3H), 7.53-7.55 (d, J=8.0 Hz, 1H), 7.45-7.47 (d, J=8.0 Hz, 1H), 5.76-5.81 (d, J=17.2 Hz, 1H), 5.58-5.62 (d, J=17.2 Hz, 1H), 5.49-5.51 (m, 1H), 4.60-4.63 (m, 1H), 4.18-4.27 (m, 1H), 3.92-4.05 (m, 1H), 3.23 (s, 3H), 2.72 (s, 1H), 2.71 (s, 1H), 2.63-2.69 (m, 1H), 2.20-2.33 (m, 1H). LC/MS (ESI) m/z: 595/597 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-4-methylpyridin-2-yl)-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.54 (s, 2H), 7.91 (s, 1H), 7.11 (s, 1H), 6.04-6.08 (d, J=17.6 Hz, 1H), 5.84-5.88 (d, J=17.6 Hz, 1H), 4.48-4.49 (m, 1H), 3.56-3.58 (m, 1H), 2.97 (s, 3H), 2.74 (s, 3H), 2.69 (s, 3H), 2.55-2.60 (m, 1H), 2.31 (s, 3H), 2.16-2.21 (m, 1H), 1.39 (s, 3H), 1.10-1.13 (m, 1H), 0.97-0.99 (m, 1H). LC/MS (ESI) m/z: 617/619 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(5-methyl-[2,2′-bipyridin]-6-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.96 (s, 2H), 8.58 (d, J=4.8 Hz, 1H), 8.52-8.49 (m, 1H), 8.25 (d, J=8.0 Hz, 1H), 8.09 (d, J=8.0 Hz, 1H), 7.82 (t, J=7.6 Hz, 1H), 7.77-7.69 (m, 3H), 7.36 (t, J=6.4 Hz, 1H), 5.79 (d, J=17.2 Hz, 1H), 5.63 (d, J=17.2 Hz, 1H), 4.67-4.55 (m, 2H), 3.56-3.52 (m, 1H), 2.74 (s, 3H), 2.69 (s, 3H), 2.35 (dd, J=13.6, 13.6 Hz, 1H), 2.23 (s, 3H), 1.42 (s, 3H), 1.11 (t, J=5.2 Hz, 1H), 1.03-0.99 (m, 1H). LC/MS (ESI) m/z: 601 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(6-(pyridin-2-yloxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.42 (s, 1H), 9.01 (s, 2H), 8.30 (d, J=2.0 Hz, 1H), 8.18 (m, 1H), 7.91-7.82 (m, 3H), 7.60 (dd, J=1.6, 1.6 Hz, 1H), 7.16 (m, 1H), 7.07 (m, 1H), 6.81-6.77 (m, 1H), 6.07 (d, J=17.6 Hz, 1H), 5.64 (d, J=17.6 Hz, 1H), 4.41 (dd, J=9.2, 9.2 Hz, 1H), 3.62 (dd, J=5.6, 5.6 Hz, 1H), 2.72-2.62 (m, 9H), 2.43 (d, J=12.0 Hz, 1H), 1.96 (dd, J=13.2, 13.2 Hz, 1H), 1.29 (s, 3H), 0.98 (t, J=5.2 Hz, 1H), 0.86-0.82 (m, 1H). LC/MS (ESI) m/z: 617 (M+H)+.
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl) indazol-1-yl]acetyl}-5-methyl-N-{2-oxo-[1,2′-bipyridine]-6′-yl}-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.70 (s, 1H), 9.01 (s, 2H), 8.30 (s, 1H), 8.09 (d, J=8.2 Hz, 1H), 7.98-7.93 (m, 1H), 7.77 (d, J=5.4 Hz, 1H), 7.61 (s, 1H), 7.52-7.47 (m, 1H), 7.38 (d, J=7.7 Hz, 1H), 6.47 (d, J=9.2 Hz, 1H), 6.33-6.28 (m, 1H), 6.09 (d, J=17.9 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.48-4.43 (m, 1H), 3.64 (m, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.64 (s, 3H), 2.05-1.99 (m, 1H), 1.81 (m, 1H), 1.31 (s, 3H), 1.02-0.97 (m, 1H), 0.90 (m, 1H). LC/MS (ESI) m/z: 617 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.33 (s, 2H), 8.50 (s, 1H), 7.82 (d, J=8.4 Hz, 1H), 6.17 (d, J=18.0 Hz, 1H), 5.80 (d, J=18.0 Hz, 1H), 4.45 (m, 1H), 3.86 (m, 1H), 3.25 (d, J=16.0 Hz, 1H), 3.10 (d, J=16.0 Hz, 1H), 2.92 (s, 3H), 2.68 (s, 3H), 2.67 (s, 3H), 2.66-2.62 (m, 1H), 2.46 (s, 3H), 2.18 (m, 1H), 2.03 (s, 3H), 1.25 (m, 1H), 1.16 (m, 1H). LC/MS (ESI) m/z: 717/719 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-chloropyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.42 (s, 1H), 7.75 (d, J=8.3 Hz, 1H), 7.54 (s, 1H), 7.43 (d, J=8.3 Hz, 1H), 6.01 (d, J=17.7 Hz, 1H), 5.83 (d, J=17.8 Hz, 1H), 4.76 (m, 1H), 3.87-3.84 (m, 1H), 3.20 (s, 2H), 2.78 (s, 3H), 2.74 (s, 3H), 2.69 (s, 3H), 2.67 (d, J=4.3 Hz, 1H), 2.54 (s, 3H), 2.47 (d, J=10.3 Hz, 1H), 1.42 (m, 1H), 1.21 (m, 1H). LC/MS (ESI) m/z: 718/720 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ: 9.27 (s, 1H), 8.98 (s, 2H), 8.42 (s, 1H), 8.40 (d, J=1.1 Hz, 1H), 7.53 (s, 1H), 6.01 (d, J=17.7 Hz, 1H), 5.80 (d, J=17.7 Hz, 1H), 4.68-4.49 (m, 2H), 3.87 (dd, J=5.8, 2.7 Hz, 1H), 3.23 (d, J=1.9 Hz, 2H), 2.77 (s, 3H), 2.73 (s, 3H), 2.68 (s, 3H), 2.67-2.62 (m, 1H), 2.45 (dd, J=13.8, 3.6 Hz, 1H), 2.31 (s, 3H), 1.40 (m, 1H), 1.20 (m, 1H). LC/MS (ESI) m/z: 685/687 [M+H]+.
(2S,4S)-1-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl) indazol-1-yl] acetyl}-N-(6-bromopyridin-2-yl)-4-fluoro-4-(1,2,3-triazol-1-ylmethyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.54 (s, 1H), 8.13 (s, 1H), 7.85 (s, 1H), 7.82-7.79 (m, 2H), 7.55 (d, J=8.3 Hz, 1H), 7.38 (d, J=7.9 Hz, 1H), 5.67-5.55 (m, 2H), 5.11 (d, J=10.4 Hz, 1H), 5.05 (d, J=4.8 Hz, 1H), 5.01-4.97 (m, 1H), 4.38-4.28 (m, 1H), 4.16-4.08 (m, 1H), 2.76 (s, 3H), 2.70 (s, 3H), 2.67-2.50 (m, 2H), 2.10 (s, 3H). LC/MS (ESI) m/z: 675 (M+H)+.
(2S,4R)-1-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-4-[(dimethylamino)methyl]-4-fluoropyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.19 (s, 1H), 9.05 (s, 2H), 8.44 (s, 1H), 7.92-7.85 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 5.74 (d, J=16.4 Hz, 1H), 5.62 (d, J=17.2 Hz, 1H), 4.70 (d, J=9.6 Hz, 1H), 4.20-4.08 (m, 2H), 2.78-2.71 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.47-2.35 (m, 2H), 2.32 (s, 6H), 2.02 (s, 3H), LC/MS (ESI) m/z: 651 (M+H)+.
(2S,4R)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 9.32 (s, 2H), 8.49 (s, 1H), 7.80 (d, J=8.8 Hz, 1H), 6.06 (d, J=18.0 Hz, 1H), 5.88 (d, J=17.8 Hz, 1H), 4.85-4.68 (m, 3H), 4.36 (dd, J=19.0, 12.3 Hz, 1H), 4.14-4.05 (m, 1H), 2.90 (s, 3H), 2.68 (d, J=6.5 Hz, 6H), 2.35-2.24 (m, 2H), 2.02 (s, 3H). LC/MS (ESI) m/z: 659 (M+H)+.
(2S,4R)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromopyrazin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 11.41 (s, 1H), 9.32 (s, 2H), 9.25 (s, 1H), 8.56-8.53 (m, 1H), 8.48 (s, 1H), 6.09 (d, J=18.0 Hz, 1H), 5.91 (d, J=17.9 Hz, 1H), 4.94-4.78 (m, 3H), 4.38 (dd, J=18.6, 12.2 Hz, 1H), 4.17-4.06 (m, 1H), 2.92 (s, 3H), 2.68 (s, 3H), 2.67 (s, 3H), 2.63-2.56 (m, 1H), 2.33-2.23 (m, 1H). LC/MS (ESI) m/z: 628 (M+H)+.
(2S,4S)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(fluoromethyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H), 9.05 (s, 2H), 8.44 (d, J=1.2 Hz, 1H), 7.64 (d, J=8.4 Hz, 1H), 7.47 (d, J=7.9 Hz, 1H), 5.75 (d, J=17.3 Hz, 1H), 5.63 (d, J=17.3 Hz, 1H), 4.88-4.72 (m, 3H), 4.30-4.16 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.63-2.53 (m, 1H), 2.43-2.34 (m, 1H), 2.03 (s, 3H). LC/MS (ESI) m/z: 626 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (d, J=5.2 Hz, 2H), 8.40 (d, J=1.1 Hz, 1H), 7.61-7.46 (m, 2H), 5.98 (d, J=17.7 Hz, 1H), 5.80 (d, J=17.7 Hz, 1H), 4.57 (dd, J=9.2, 5.0 Hz, 2H), 3.85 (dd, J=5.7, 2.7 Hz, 1H), 3.37 (d, J=16.1 Hz, 1H), 3.16 (d, J=16.1 Hz, 1H), 2.75 (s, 3H), 2.73 (d, J=7.8 Hz, 3H), 2.72-2.68 (m, 1H), 2.67 (s, 3H), 2.48 (dd, J=13.7, 4.3 Hz, 1H), 2.36 (s, 3H), 2.12 (s, 3H), 1.37 (m, 1H), 1.29 (m, 1H), 1.18 (m, 1H). LC/MS (ESI) m/z: 716/718 [M+H]+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-chloropyridin-2-yl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.42 (s, 1H), 7.76 (d, J=8.3 Hz, 1H), 7.54 (s, 1H), 7.44 (d, J=8.3 Hz, 1H), 6.00 (d, J=17.6 Hz, 1H), 5.82 (d, J=17.8 Hz, 1H), 4.74 (d, J=8.2 Hz, 1H), 3.85 (d, J=3.1 Hz, 1H), 3.40 (s, 1H), 3.14 (d, J=15.9 Hz, 1H), 2.77 (s, 3H), 2.74 (s, 3H), 2.68 (s, 3H), 2.57-2.50 (m, 1H), 2.35 (s, 3H), 1.41 (t, J=5.5 Hz, 1H), 1.34-1.26 (m, 1H), 1.20 (m, 1H). LC/MS (ESI) m/z: 718/720 [M+H]+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((3-methyl-1,2,4-oxadiazol-5-yl)methyl)-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.86 (d, J=7.8 Hz, 1H), 7.59 (d, J=7.8 Hz, 1H), 7.53 (s, 1H), 6.00 (M, 1H), 5.82 (M, 1H), 4.66-4.61 (m, 1H), 3.86 (m, 1H), 3.38 (m, 1H), 3.15 (m, 1H), 2.75 (m, 6H), 2.68 (s, 3H), 2.54-2.49 (m, 1H), 2.33 (s, 4H), 2.23 (s, 3H), 1.38 (m, 1H), 1.18 (m, 1H). LC/MS (ESI) m/z: 688 (M+H)+.
(1R, 3S, 5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) cetyl)-5-((5-methyl-1, 3, 4-oxadiazol-2-yl) methyl)-N-(3-methyl-6-(trifluoromethyl) pyridin-2-yl)-2-azabicyclo 13.1.01 hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 9.02 (s, 2H), 8.32 (d, J=0.9 Hz, 1H), 7.94 (d, J=7.6 Hz, 1H), 7.70 (d, J=7.6 Hz, 1H), 7.62 (s, 1H), 6.08 (d, J=17.6 Hz, 1H), 5.70 (d, J=18.0 Hz, 1H), 5.32 (t, J=4.4 Hz, 1H), 4.51 (dd, J=9.6, 5.2 Hz, 1H), 3.85 (dd, J=5.2, 2.4 Hz, 1H), 3.27-3.22 (m, 1H), 3.12-3.06 (m, 1H), 2.92-2.51 (m, 9H), 2.45 (s, 3H), 2.22-2.11 (m, 3H), 2.03-1.96 (m, 2H), 1.48-1.42 (m, 1H), 1.16-1.12 (m, 1H). LC/MS (ESI) m/z: 688 (M+H)+.
(1R, 3S, 5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo [3, 4-c] pyridin-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(2-oxopropyl)-2-azabicyclo 13.1.01 hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.35 (s, 2H), 9.32 (d, J=1.2 Hz, 1H), 8.62 (d, J=1.2 Hz, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.44 (d, J=8.0 Hz, 1H), 6.07 (d, J=17.2 Hz, 1H), 5.74 (d, J=17.2 Hz, 1H), 4.43 (dd, J=9.6, 5.2 Hz, 1H), 3.71 (dd, J=5.6, 2.4 Hz, 1H), 2.93 (d, J=16.8 Hz, 1H), 2.69 (d, J=3.2 Hz, 6H), 2.64-2.56 (m, 2H), 2.16 (s, 3H), 2.11-2.05 (m, 1H), 2.03 (s, 3H), 1.21-1.18 (m, 1H), 1.13-1.08 (m, 1H). LC/MS (ESI) m/z: 646 (M+H)+.
(1R,2S,5S)-3-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-3-azabicyclo[3.1.0]hexane-2-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.87 (s, 1H), 9.03 (s, 2H), 8.41 (s, 1H), 7.86-7.85 (m, 2H), 7.59 (d, J=8.0 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.63-5.53 (m, 2H), 4.59-4.58 (m, 1H), 4.05-4.01 (m, 1H), 3.89-3.87 (m, 1H), 2.67 (s, 3H), 2.63 (s, 3H), 2.00 (s, 3H), 1.92-1.91 (m, 1H), 1.90-1.85 (m, 1H), 0.86-0.75 (m, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-ethyl-1, 3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 8.89 (s, 2H), 8.83 (s, 1H), 8.56 (t, J=1.3 Hz, 1H), 7.61 (d, J=1.3 Hz, 2H), 7.42 (d, J=1.1 Hz, 1H), 7.33 (dd, J=0.8, 7.9 Hz, 1H), 7.20 (s, 0H), 5.58-5.44 (m, 2H), 4.78 (dd, J=3.5, 9.3 Hz, 1H), 3.54 (dd, J=2.7, 5.7 Hz, 1H), 3.41 (d, J=15.8 Hz, 1H), 3.24-3.11 (m, 2H), 2.80 (s, 4H), 2.68 (s, 3H), 2.41 (dd, J=9.0, 13.7 Hz, 1H), 1.33 (d, J=6.8 Hz, 6H), 0.99 (dd, J=2.7, 5.9 Hz, 1H). LC (method A): tR=2.20 min. LC/MS (EI) m/z: [M+H]+ 727.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.55 (s, 1H), 9.35 (s, 2H), 9.32 (d, J=1.2 Hz, 1H), 8.62 (d, J=1.2 Hz, 1H), 7.81-7.75 (m, 1H), 7.57 (dd, J=8.4, 3.2 Hz, 1H), 6.06 (d, J=17.2 Hz, 1H), 5.74 (d, J=17.2 Hz, 1H), 4.45 (m, 1H), 3.59 (m, 1H), 2.71 (s, 3H), 2.69 (s, 3H), 2.53-2.60 (m, 1H), 2.03 (dd, J=13.2, 5.2 Hz, 1H), 1.31 (s, 3H), 1.11 (m, 1H), 1.02 (t, m, 1H). LC/MS (ESI) m/z: 607 (M+H)+.
(1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((diisopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.43 (s, 1H), 7.54 (d, J=7.4 Hz, 2H), 7.37 (d, J=8.0 Hz, 1H), 5.98 (d, J=17.7 Hz, 1H), 5.81 (d, J=17.7 Hz, 1H), 4.59-4.57 (m, 1H), 3.52 (dd, J=4.9, 2.0 Hz, 1H), 3.21-3.19 (m, 1H), 3.14-3.11 (m, 1H), 2.77 (s, 3H), 2.74 (s, 3H), 2.68 (s, 3H), 2.64-2.62 (m, 1H), 2.60-2.58 (m, 1H), 2.48-2.43 (m, 2H), 2.13 (s, 3H), 1.30-1.29 (m, 1H), 1.20-1.18 (m, 1H), 1.08-1.00 (m, 12H). LC/MS (ESI) m/z: 715 (M+H)+.
Figure US11708351-20230725-C01079
The three-part synthesis shown below and the accompanying detailed description depicts one non-limiting method for synthesizing compounds by first generating intermediate 17-S7 by using Ghosez's reagent to generate an amide bond. Intermediate 17-S7 is the coupled to the A-ring using a coupling reagent, such as HATU. The skilled artisan will recognize that the A-ring synthetic intermediate shown below can be replaced with other A-ring synthetic intermediates to afford additional compounds of the present invention.
Synthesis of tert-Butyl (1R,3S,5R)-3-(((E)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (Intermediate 17-S7) Step 1: Ethyl (E)-2-fluoro-3-phenylbut-2-enoate (S2) and Ethyl (Z)-2-fluoro-3-phenylbut-2-enoate (17-S3)
Ethyl 2-(diethoxyphosphoryl)-2-fluoroacetate (5 g) was added dropwise to a stirred solution of NaH (0.9 g, 60% in mineral oil) in DME (50 mL) at 0° C. The cooling bath was removed and the reaction mixture was stirred at room temperature for 1 hour. Benzaldehyde (3.6 mL) was added at room temperature and the reaction mixture was stirred at 90° C. overnight. The reaction mixture was cooled to room temperature, diluted with ether, washed with water, dried (Na2SO4), and concentrated. The resultant residue was purified by silica gel flash column chromatography (eluent: 0-0.5% EtOAc in hexanes). Ethyl (Z)-2-fluoro-3-phenylbut-2-enoate (17-S3) eluted first as colorless liquid (0.37 g) and ethyl (E)-2-fluoro-3-phenylbut-2-enoate (17-S2) eluted second as light yellow liquid (1.3 g). (Ref. WO 2014/002052 and J. Org. Chem. 2009, 74, 4124-4131)
Step 2: (E)-2-Fluoro-3-phenylbut-2-en-1-ol (17-S4)
To a stirred solution of LAH (0.221 g) in ether (20 mL) at room temperature, ethyl (E)-2-fluoro-3-phenylbut-2-enoate (17-S2) (1.3 g) in ether (10 mL) was added dropwise. The reaction mixture was stirred at room temperature for 1 hour and quenched with the careful addition of saturated aqueous NH4Cl solution. The heterogeneous mixture was then extracted with ether, washed with water and brine, and dried with Na2SO4. Upon concentration of the organic layer, the residue was carried forward without additional purification and carried forward in the next step.
Step 3: (E)-2-(2-Fluoro-3-phenylbut-2-en-1-yl)isoindoline-1,3-dione (17-S5)
DEAD (1.52 mL) was added dropwise to a stirred solution of (E)-2-fluoro-3-phenylbut-2-en-1-ol (1 g), phthalimide (1.06 g) and triphenylphosphine (2.4 g) in THF (20 mL). After stirring for 16 hours at room temperature, the reaction mixture was concentrated under reduced pressure. The residue obtained was purified by silica gel flash column chromatography (eluent: 0-2.5% EtOAc in hexanes) to afford 1.5 g of 17-S5 as white solid.
Step 4: (E)-2-Fluoro-3-phenylbut-2-en-1-amine Hydrochloride (17-S6)
Hydrazine hydrate (0.74 mL) was added to heterogeneous solution of (E)-2-(2-fluoro-3-phenylbut-2-en-1-yl)isoindoline-1,3-dione (1.7 g) in EtOH (30 mL) and stirred at room temperature overnight. The precipitate was filtered off and the filtrate was concentrated. The residue was triturated with 4N HCl in dioxane (10 mL) and the volatiles were removed under reduced pressure. The resulting white solid was dried under high vacuum to afford 17-S6.
Step 5: tert-Butyl (1R,3S5R)-3-(((E)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (17-S7)
To an ice cold solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (17-S6a) (0.25 g) in 6 mL of CH2Cl2, 1-chloro-N,N,2-trimethyl-1-propenylamine (0.16 mL, 1.1 equiv.) was added dropwise with stirring. After stirring for 3 hours at same temperature, solid (E)-2-fluoro-3-phenylbut-2-en-1-amine hydrochloride (17-S6) (0.2 g, 1.0 equiv.) was added followed by 0.7 mL of DIPEA (4 equiv.). The cooling bath was removed and the reaction mixture was stirred overnight at room temperature. The solvent was co-evaporated with MeOH (1 mL) and the crude product was purified by silica gel flash column chromatography (eluent: 0-0.5% MeOH in CH2Cl2) to afford 0.18 g of a colorless resin.
Synthesis of tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (Intermediate 17-S12)
Figure US11708351-20230725-C01080
Step 6: 7-Methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (17-S9)
A mixture of 0.5 g of bromoindazole (1 equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.782 g, 1.5 equiv), cesium carbonate (2.315 g, 3 equiv) in dioxane (10 mL) and water (1.0 mL) was purged with argon in a pressure vessel for 5 minutes. Tetrakis(triphenylphosphine)palladium (0) (0.550 g, 0.2 equiv) was then added under argon and the pressure vessel was sealed and heated at 90° C. overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by silica gel flash column chromatography (eluent: 0-3% MeOH in CH2Cl2) to afford 0.395 g of the product as a white solid.
Step 7: 3-Bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (17-S10)
To a stirred solution of indazole 17-S9 (1.75 g) in DMF (20 mL), NBS (1.05 g) was added. The reaction mixture was stirred at room temperature for 2 hours and additional NBS (0.209 g) was added followed by stirring for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration, dried and purified by silica gel flash column chromatography (eluent: 0-5% MeOH in CH2Cl2) to afford 17-S10 as a white solid.
Step 8: tert-Butyl 2-(3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate 17-(S11)
A mixture of 3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.215 g), tert-butyl bromoacetate (115 μL), and potassium carbonate (0.196 g) in anhydrous acetonitrile (10 mL) was refluxed for 4 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1% MeOH in CH2Cl2) to afford the product as a white foam.
Step 9: tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S12)
A solution of tert-butyl 2-(3-bromo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S11) (0.170 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.249 g, 2 equiv) and PdCI2(PPh3)2 (28 mg, 0.1 equiv) in DMF (3 mL) was heated at 80° C. overnight under argon atmosphere. The mixture was concentrated under reduced pressure, diluted with CH2Cl2, and washed with cold aqueous HCI (1N). The organic layer was dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1% MeOH in CH2Cl2) to afford a yellow solid.
Synthesis of (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (17)
Figure US11708351-20230725-C01081
Step 10: (1R,3S,5R)—N-((E)-2-Fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (17-S13)
tert-Butyl (1R,3S,5R)-3-(((E)-2-fluoro-3-phenylbut-2-en-1-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.1 g) was dissolved in CH2Cl2 (1 mL) and an equal volume of TFA was added. The mixture was stirred for 30 minutes at room temperature. Then the volatiles were removed under reduced pressure and the residue was carried forward without additional purification in the next step.
Step 11: 2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (17-S14)
tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (17-S12, 0.13 g) was stirred in CH2Cl2 (1 mL) and TFA (2 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was used in the next synthetic step without purification.
Step 12: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (17)
Compound 17-S14 was dissolved in DMF (1 mL) and iPr2NEt (0.297 mL, 5 equiv) was added, followed by the addition 17-S13 at 5° C. HATU (0.156 g, 1.2 equiv) was then added slowly at 5° C. and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.5% MeOH in CH2Cl2) to afford 17 as a cream colored solid. 1H NMR (400 MHz, DMSO) δ 0.65-0.71 (m, 1H), 0.78 (s, 0H), 1.02-1.07 (m, 1H), 1.15-1.26 (m, 1H), 1.81-1.98 (m, 1H), 1.93 (d, J=3.2 Hz, 3H), 2.06-2.12 (m, 1H), 2.23-2.26 (m, 1H), 2.64 (s, 3H), 2.68 (s, 6H), 3.70-3.93 (m, 2H), 4.24 (dd, J=5.0, 9.1 Hz, 1H), 5.70 (d, J=17.7 Hz, 1H), 6.03 (d, J=17.8 Hz, 1H), 7.20-7.33 (m, 5H), 7.63 (s, 1H), 8.15 (t, J=5.3 Hz, 1H), 8.32 (d, J=1.6 Hz, 1H), 9.02 (s, 2H). 19F-NMR (DMSO-d6): δ−113.2.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 0.85 (dd, J=2.4, 5.4 Hz, 1H), 1.13 (t, J=5.3 Hz, 1H), 1.41 (s, 3H), 1.95 (d, J=3.7 Hz, 3H), 2.13 (dd, J=8.7, 13.4 Hz, 1H), 2.64-2.68 (m, 1H), 2.72 (s, 3H), 2.81 (s, 3H), 3.11 (dd, J=2.4, 5.5 Hz, 1H), 3.85-4.07 (m, 2H), 4.55 (dd, J=3.0, 8.7 Hz, 1H), 5.45 (d, J=2.7 Hz, 2H), 6.78 (t, J=5.2 Hz, 1H), 7.08-7.15 (m, 2H), 7.18-7.32 (m, 3H), 7.51 (d, J=8.7 Hz, 1H), 7.61 (dd, J=1.7, 8.7 Hz, 1H), 8.59 (s, 1H), 8.89 (s, 2H). 19F δ−115.9.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-C]pyridine-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 0.94 (dd, J=2.4, 5.4 Hz, 1H), 1.00 (t, J=5.4 Hz, 1H), 1.28 (s, 3H), 1.84-1.97 (m, 1H), 1.94 (d, J=3.2 Hz, 3H), 2.39 (dd, J=9.1, 13.2 Hz, 1H), 2.53 (s, 3H), 2.68 (s, 3H), 3.48 (d, J=3.2 Hz, 1H), 3.84 (dd, J=5.3, 20.8 Hz, 2H), 4.21 (dd, J=4.9, 9.2 Hz, 1H), 5.36 (d, J=17.1 Hz, 1H), 5.63 (d, J=17.2 Hz, 1H), 7.20-7.35 (m, 5H), 8.17 (t, J=5.4 Hz, 1H), 8.52 (s, 1H), 8.58 (s, 1H), 8.98 (s, 1H), 9.29 (s, 2H). 19F δ−113.6.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-((E)-2-fluoro-3-phenylbut-2-en-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 0.87 (dd, J=2.4, 5.5 Hz, 1H), 1.15 (t, J=5.4 Hz, 1H), 1.42 (s, 3H), 1.94 (d, J=3.6 Hz, 3H), 2.14 (dd, J=8.7, 13.4 Hz, 1H), 2.68 (s, 3H), 2.71 (s, 3H), 2.80 (s, 3H), 3.08 (dd, J=2.4, 5.5 Hz, 1H), 3.96 (dd, J=5.3, 20.9 Hz, 2H), 4.55 (dd, J=3.0, 8.7 Hz, 1H), 5.64 (s, 2H), 6.81 (t, J=5.4 Hz, 1H), 7.07-7.14 (m, 2H), 7.18-7.31 (m, 4H), 7.32 (s, 1H), 8.47 (s, 1H), 8.88 (s, 2H). 19F δ−115.6.
Figure US11708351-20230725-C01082
Figure US11708351-20230725-C01083
Figure US11708351-20230725-C01084
Step 1: 2-Amino-5-bromo-3-methylbenzoic Acid (19-S2)
To a solution of 19-S1 (15 g, 0.1 mol) in AcOH (80 mL) was added Br2 (5.1 mL, 0.1 mol) dropwise at 0° C. The reaction mixture was stirred at room temperature for 4 h. The mixture was diluted with EtOAc and basified with aqueous NaOH solution (4 N) to pH 7. The mixture was extracted with EtOAc, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH=100:0 to 50:1) to afford 19-S2 (12.0 g, 52.2% yield) as a white solid. LC/MS (ESI) m/z: 230 (M+H)+.
Step 2: Methyl 2-amino-5-bromo-3-methylbenzoate (19-S3)
To a solution of 19-S2 (12 g, 52.2 mmol) in DMF (60 mL) was added Cs2CO3 (25.5 g, 78.3 mmol) and CH3I (7.79 g, 54.8 mmol) at 0° C. The reaction mixture was stirred at room temperature for 16 hours. The mixture was then diluted with EtOAc, washed with 5% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=50:1 to 20:1) to afford 19-S3 (11.0 g, 86.6% yield) as a white solid. LC/MS (ESI) m/z: 244 (M+H)+.
Step 3: Methyl 5-bromo-1H-indazole-7-carboxylate (19-S4)
To a mixture of 19-S3 (10.9 g, 44.7 mmol) and AcOK (1.32 g, 13.41 mmol) in CHCl3 (50 mL) was added Ac2O (10.6 g, 103 mmol) at 0° C. slowly under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then heated to 60° C. and t-BuONO (10.2 g, 98.3 mmol) was added to the above mixture. The resulting mixture was stirred at 60° C. for 4 hours. After cooling, the mixture was quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:0 to 10:1) to afford 19-S4 (8.0 g 70.5% yield) as a yellow solid. LC/MS (ESI) m/z: 255 (M+H)+.
Step 4: (5-Bromo-1H-indazol-7-yl) methanol (19-S5)
To a solution of 19-S4 (5 g, 19.6 mmol) in anhydrous THF (50 mL) was added LiAlH4 (1.49 g 39.2 mmol) in portions at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes and at room temperature for 1 hour. The mixture was then quenched with water (1.5 mL), 10% aqueous NaOH solution (3 g), and water (4.5 mL). The mixture was filtered and the filter cake was washed with EtOAc. The filtrate was dried and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH=100:0 to 20:1) to afford 19-S5 (3.36 g, 76.1% yield) as a white solid. LC/MS (ESI) m/z: 227 (M+H)+.
Step 5: (5-Bromo-3-iodo-1H-indazol-7-yl) methanol (19-S6)
To a solution of 19-S5 (2.27 g 10 mmol) in DMF (25 mL) were added KOH (1.26 g, 22.5 mmol) and I2 (3.81 g. 15 mmol) at 0° C. The mixture was stirred at room temperature for 16 hours. The mixture was then quenched with 5% aqueous Na2S2O3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was recrystallized with EtOAc/PE (1:2) to afford 19-S6 (2.85 g. 81.0% yield) as a brown solid. LC/MS (ESI) m/z: 353 (M+H)+.
Step 6: Methyl 2-(5-bromo-7-(hydroxymethyl)-3-iodo-1H-indazol-1-yl)acetate (19-S7)
To a solution of 19-S6 (1.98 g. 5.6 mmol) in DMF (20 mL) was added K2CO3 (1.38 g, 10 mmol) and methyl 2-bromoacetate (900 mg, 5.88 mmol). The reaction mixture was stirred at room temperature for 2.5 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=10:1 to 3:1) to afford 19-S7 (1.34 g, 56.4% yield) as colorless oil. LC/MS (ESI) m/z: 425 (M+H)+.
Step 7: Methyl 2-(5-bromo-7-(chloromethyl)-3-iodo-1H-indazol-1-yl)acetate (19-S8)
To a mixture of 19-S7 (424 mg, 1 mol) in dry DCM (10 mL) was added Et3N (250 mg, 2.5 mmol) followed by dropwise addition of MsCl (173 mg, 1.5 mmol) at 0° C. The reaction mixture was stirred at room temperature for 16 hours. The mixture was quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:0 to 15:1) to afford 19-S8 (360 mg, 81.1% yield) as a brown solid. LC/MS (ESI) m/z: 443 (M+H)+.
Step 8: Methyl 2-(5-bromo-7-((dimethylamino)methyl)-3-iodo-1H-indazol-1-yl)acetate (19-S9)
To a solution of 19-S8 (360 mg, 0.82 mol) in MeCN (10 mL) were added Et3N (249 mg, 2.46 mmol) and dimethylamine hydrochloride (133 mg, 1.64 mmol) at 0° C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 10:1) to afford 19-S9 (328 mg, 88.5% yield) as a brown solid. LC/MS (ESI) m/z: 452 (M+H)+.
Step 9: 2-(3-Acetyl-5-bromo-7-((dimethylamino)methyl)-1H-indazol-1-yl)acetic Acid (19-S10)
To a mixture of 19-S9 (68 mg, 0.15 mol) in dry toluene (10 mL) were added tributyl(1-ethoxyvinyl)stannane (82 mg, 0.226 mmol) and Pd(PPh3)4 (14 mg, 0.012 mmol). The reaction mixture was stirred at 95° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was extracted with DCM/MeOH (20:1), dried over anhydrous Na2SO4, filtered, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH=20:1) to afford 19-S10 (38 mg, 71.7% yield) as colorless oil. LC/MS (ESI) m/z: 354 (M+H)+.
Step 10: 2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (19-S11)
To a solution of 19-S10 (38 mg, 0.11 mol) in 1,4-dioxane/H2O (7 mL, 6:1) were added 2-methylpyrimidin-5-ylboronic acid (23 mg, 0.162 mmol), K2CO3 (46 mg, 0.33 mmol), and Pd(PPh3)4 (12 mg, 0.011 mmol). The reaction mixture was stirred at 90° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was acidified with 10% aqueous HCl solution and extracted with DCM/MeOH (10:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH=5:1) to afford 19-S11 (21 mg, 52.0% yield) as a yellow solid. LC/MS (ESI) m/z: 368 (M+H)+.
Step 11: (2S,4R)-1-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (19)
To a mixture of 19-S11 (21 mg, 0.057 mmol) and (2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (19 mg, 0.057 mmol) in DMF (1 mL) were added DIPEA (23 mg, 0.171 mmol) followed by HATU (43 mg, 0.114 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 h. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford 19 (6 mg, 16.7% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 11.12 (s, 1H), 9.10 (s, 2H), 8.50 (d, J=1.7 Hz, 1H), 8.09 (d, J=8.3 Hz, 1H), 7.73-7.83 (m, 2H), 7.39 (d, J=7.7 Hz, 1H), 6.31 (d, J=17.4 Hz, 1H), 6.09 (d, J=17.3 Hz, 1H), 5.55-5.68 (m, 1H), 4.80 (t, J=8.7 Hz, 1H), 4.30-4.39 (m, 1H), 3.86-3.99 (m, 2H), 3.43-3.48 (m, 1H), 2.73 (s, 3H), 2.68 (s, 3H), 2.57-2.66 (m, 1H), 2.29 (s, 6H), 2.13-2.19 (m, 1H). LC/MS (ESI) m/z: 637 (M+H)+.
Figure US11708351-20230725-C01085
Figure US11708351-20230725-C01086
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds by 1) a Stille carbonylative cross-coupling using tributyl(1-ethoxyvinyl)stannane to functionalize the R6 position of the A-ring; 2) a Suzuki cross-coupling to functionalize the R32 of the A-ring; and, 3) the formation of an amide bond between the C-ring (already linked to the B-ring) and A-ring utilizing HATU. The skilled artisan will recognize that the C- and B-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring synthetic intermediate can be replaced with other synthetic intermediates to afford additional compounds of the present invention.
Step 1: Methyl 2-(5-bromo-7-(fluoromethyl)-3-iodo-1H-indazol-1-yl)acetate (20-S2)
To a solution of 20-S1 (85 mg, 0.2 mmol) in dry DCM (6 mL) was added DAST (64 mg, 0.4 mmol) dropwise at −30° C. The resulting mixture was stirred from −30° C. to room temperature for 1 hour. The mixture was then quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=20:1 to 10:1) to afford 20-S2 (73 mg, 85.7% yield) as a yellow oil. LC/MS (ESI) m/z: 427 (M+H)+.
Step 2: 2-(3-Acetyl-5-bromo-7-(fluoromethyl)-1H-indazol-1-yl)acetic Acid (20-S3)
To a mixture of 20-S2 (73 mg, 0.171 mol) in dry toluene (8 mL) were added tributyl(1-ethoxyvinyl)stannane (87 mg, 0.24 mmol) and Pd(PPh3)4 (16 mg, 0.0137 mmol). The reaction mixture was stirred at 95° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was then extracted with DCM/MeOH (15:1), the organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH=15:1) to afford 20-S3 (50 mg, 88.8% yield) as colorless oil. LC/MS (ESI) m/z: 329 (M+H)+.
Step 3: 2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (2-S4) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-((2-methylpyrimidin-5-yl)methyl)-1H-indazol-1-yl)acetic Acid (20-S4A)
To a mixture of 20-S3 (50 mg, 0.152 mol) in 1,4-dioxane/H2O (7 mL, 6:1) was added 2-methylpyrimidin-5-ylboronic acid (26 mg, 0.182 mmol), K2CO3 (63 mg, 0.456 mmol), and Pd(PPh3)4 (18 mg, 0.0152 mmol). The reaction mixture was stirred at 90° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was acidified with 10% aqueous HCl solution and extracted with DCM/MeOH (10:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by preparative TLC (DCM/MeOH=5:1) to afford 20-S4 (30 mg, 57.5% yield) and 20-S4A (25 mg, 39.4% yield) as colorless oils. LC/MS (ESI) m/z: 343 (M+H)+, 417 (M+H)+.
Step 4: (2S,4R)-1-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (20)
To a mixture of 20-S4 (30 mg, 0.088 mmol) and (2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (30 mg, 0.088 mmol) in DMF (1 mL) was added DIPEA (36 mg, 0.264 mmol) followed by HATU (52 mg, 0.132 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford 20 (6 mg, 11.1% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 11.07 (s, 1H), 9.06 (s, 2H), 8.55 (s, 1H), 8.06-7.94 (m, 2H), 7.72 (t, J=8.0 Hz, 1H), 7.33 (d, J=7.3 Hz, 1H), 5.94 (d, J=18.0 Hz, 1H), 5.78-5.88 (m, 1H), 5.47-5.71 (m, 3H), 4.68-4.74 (m, 1H), 4.24-4.33 (m, 1H), 3.86-4.02 (m, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.18-2.27 (m, 1H), 2.07-2.16 (m, 1H). LC/MS (ESI) m/z: 612 (M+H)+.
3-Acetyl-1-(2-((3S)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylic Acid (63)
1H NMR (400 MHz, DMSO-d6) δ 10.53 (s, 1H), 8.99 (s, 2H), 8.46 (d, J=1.6 Hz, 1H), 7.96 (s, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 6.08 (d, J=16.8 Hz, 1H), 5.93 (d, J=16.8 Hz, 1H), 5.82-5.85 (m, 1H), 4.33-4.40 (m, 1H), 3.62-3.66 (m, 1H), 3.57-3.61 (m, 1H), 2.68 (s, 3H), 2.66 (s, 3H), 2.40-2.44 (m, 1H), 2.37 (s, 3H), 2.33 (s, 3H), 2.17-2.22 (m, 1H), 2.01 (s, 3H), 1.21-1.25 (m, 1H), 1.10-1.15 (m, 1H). LC/MS (ESI) m/z: 689/691 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (155)
1H NMR (400 MHz, CD3OD) δ 8.84 (s, 2H), 7.61-7.44 (m, 3H), 7.30 (d, J=7.9 Hz, 1H), 5.73 (d, J=17.3 Hz, 1H), 5.58 (d, J=17.5 Hz, 1H), 4.55 (m, 1H), 3.63 (m, 1H), 2.96 (m, 1H), 2.67 (s, 3H), 2.62 (s, 3H), 2.59-2.47 (m, 3H), 2.44 (m, 6H), 2.04 (s, 3H), 1.20 (d, J=19.2 Hz, 2H). LC/MS (ESI) m/z: 662 (M+H)+.
(1S,3S,5S)-2-(2-(3-Acetyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (156)
1H NMR (400 MHz, CD3OD) δ 8.83 (s, 2H), 7.57-7.44 (m, 3H), 7.28 (d, J=7.9 Hz, 1H), 5.74 (d, J=17.0 Hz, 1H), 5.55 (d, J=17.1 Hz, 1H), 4.99 (d, J=9.5 Hz, 1H), 3.59 (s, 1H), 2.81 (s, 1H), 2.67 (s, 3H), 2.62 (s, 3H), 2.33 (m, 9H), 1.99 (m, 3H), 1.60 (m, 1H), 1.01 (m, 1H). LC/MS (ESI) m/z: 662 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (181)
1H NMR (400 MHz, DMSO-d6) δ 0.93-0.99 (m, 1H), 1.02-1.08 (m, 1H), 1.33 (s, 3H), 2.07 (s, 4H), 2.52-2.61 (m, 1H), 2.68 (s, 3H), 2.71 (s, 3H), 3.62 (dd, J=2.4, 5.7 Hz, 1H), 4.42 (dd, J=5.0, 9.3 Hz, 1H), 5.62 (d, J=17.0 Hz, 1H), 5.91 (d, J=17.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 8.84 (d, J=2.2 Hz, 1H), 9.02 (d, J=2.1 Hz, 1H), 9.14 (s, 2H), 10.26 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[4,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (184)
1H NMR (400 MHz, DMSO-d6) δ 0.97-1.07 (m, 2H), 1.33 (s, 3H), 2.00-2.10 (m, 4H), 2.53-2.59 (m, 1H), 2.72 (s, 3H), 2.82 (s, 3H), 3.54-3.63 (m, 1H), 4.37-4.50 (m, 1H), 5.61 (d, J=17.2 Hz, 1H), 5.94 (d, J=17.2 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 8.23 (d, J=9.0 Hz, 1H), 8.34 (d, J=8.9 Hz, 1H), 9.44 (s, 2H), 10.26 (s, 1H).
(2S,4R)—N-(6-bromopyridin-2-yl)-1-(2-(3-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.98 (s, 1H), 9.05 (s, 2H), 8.15 (s, 1H), 8.02-8.04 (d, J=8.4 Hz, 1H), 7.68-7.75 (m, 2H), 7.59-7.62 (d, J=8.8 Hz, 1H), 7.31-7.33 (d, J=7.6 Hz, 1H), 5.45-5.58 (m, 1H), 5.50-5.54 (m, J=17.2 Hz, 1H), 5.30-5.34 (d, J=17.2 Hz, 1H), 4.61-4.65 (m, 1H), 4.13-4.22 (m, 1H), 3.88-3.98 (m, 1H), 2.94-2.97 (m, 2H), 2.66 (s, 3H), 2.07-2.17 (m, 1H), 1.29-1.35 (t, 3H). LC/MS (ESI) m/z: 566/568 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-6-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 8.91 (s, 2H), 8.30 (d, J=8 Hz, 1H), 7.84 (d, J=12 Hz, 1H), 7.64 (d, J=8 Hz, 1H), 7.45 (d, J=8 Hz, 1H), 5.92 (d, J=20 Hz, 1H), 5.56 (d, J=20 Hz, 1H), 4.40 (t, J=4 Hz, 1H), 3.57 (t, J=3.2 Hz, 1H), 2.70 (S, 3H), 2.64 (S, 3H), 2.04 (S, 3H), 1.32 (S, 3H), 1.08-1.05 (m, 2H). LC/MS (ESI) m/z: 620 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-chloro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.57 (s, 1H), 9.06 (s, 2H), 8.44 (d, J=1.6 Hz, 1H), 8.00 (d, J=1.6 Hz, 1H), 7.71 (d, J=7.2 Hz, 1H), 7.43 (d, J=6.8 Hz, 1H), 6.02 (d, J=17.6 Hz, 1H), 5.87 (d, J=17.6 Hz, 1H), 5.32 (t, J=4.8 Hz, 1H), 4.47-4.34 (m, 1H), 3.64-3.56 (m, 1H), 3.41-3.37 (m, 1H), 3.04-2.52 (m, 6H), 2.08 (s, 3H), 2.04-1.87 (m, 2H), 1.23 (s, 3H), 1.10-1.00 (m, 1H), 0.99-0.88 (m, 1H). LC/MS (ESI) m/z: 679 (M+H)+.
(1R,3S,5R)-2-{2-[3-Acetyl-6-chloro-5-(2-methylpyrimidin-5-yl) indazol-1-yl]acetyl}-N-{6-bromo-3-[(dimethylamino)methyl]pyridin-2-yl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.61 (s, 1H), 8.81 (d, J=5.5 Hz, 2H), 8.19 (s, 1H), 8.17 (s, 1H), 7.71 (d, J=8.0 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 5.95 (d, J=17.3 Hz, 1H), 5.60 (d, J=17.2 Hz, 1H), 4.43 (s, 1H), 3.61-3.59 (m, 1H), 3.23-3.19 (m, 1H), 2.71 (s, 3H), 2.62 (s, 3H), 2.59-2.55 (m, 1H), 2.12-2.09 (m, 1H), 2.06 (s, 6H), 1.34 (s, 3H), 1.23 (m, 1H), 1.11-1.08 (m, 1H), 1.00 (t, J=5.3 Hz, 1H). LC/MS (ESI) m/z: 681 (M+H)+.
Figure US11708351-20230725-C01087
The title compound (21) was prepared according to the procedure described in Step 4 of Scheme 13 using appropriate starting materials. 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 8.94 (s, 2H), 8.55 (s, 2H), 8.37-8.44 (m, 1H), 8.01 (d, J=8.0 Hz, 1H), 7.73 (t, J=8.0 Hz, 1H), 7.35 (d, J=7.3 Hz, 1H), 7.24 (s, 1H), 5.92 (d, J=18.1 Hz, 1H), 5.45-5.61 (m, 2H), 4.67-4.76 (m, 1H), 4.51 (d, J=16.9 Hz, 1H), 4.34 (d, J=16.7 Hz, 1H), 4.23 (dd, J=20.8, 13.0 Hz, 1H), 3.84-3.94 (m, 1H), 2.68 (s, 3H), 2.62 (s, 3H), 2.52 (s, 3H), 2.18-2.26 (m, 1H), 2.06-2.15 (m, 1H). LC/MS (ESI) m/z: 686 (M+H)+.
Figure US11708351-20230725-C01088
Step 1: 1-Allyl 4-tert-butyl piperazine-1,4-dicarboxylate (22-S2)
To a solution of 22-S1 (375 mg, 2.02 mmol) in DCM (10 mL) were added DIPEA (0.032 mL, 10.10 mmol) and allyl chloroformate (727 mg, 6.06 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was washed with water and brine. The organic phase was dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=30:1 to 20:1) to afford the title compound (400 mg, 73.4% yield) as a yellow oil. LC/MS (ESI) m/z: 271 (M+H)+.
Step 2: Allyl piperazine-1-carboxylate Hydrochloride (22-S3)
To a solution of 22-S2 (400 mg, 1.48 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (450 mg, 100% yield) as a brown oil. LC/MS (ESI) m/z: 171 (M+H)+.
Step 3: (3S)-tert-Butyl 5-((4-((allyloxy)carbonyl)piperazin-1-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (22-S5)
To a solution of 22-S4 (280 mg, 0.66 mmol) in MeCN (5 mL) were added DIPEA (0.45 mL, 2.64 mmol), 22-S3 (179 mg, 0.66 mmol), and NaI at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was concentrated, diluted with DCM, and washed with water. The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=20:1) to afford the title compound (45 mg, 11.8% yield) as a yellow solid. LC/MS (ESI) m/z: 578 (M+H)+.
Step 4: Allyl 4-(((3S)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)piperazine-1-carboxylate (22-S6)
To a solution of 22-S5 (45 mg, 0.078 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford the title compound (65 mg, 100% yield) as a brown oil. LC/MS (ESI) m/z: 477 (M+H)+.
Step 5: Allyl 4-(((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)piperazine-1-carboxylate (22-S8)
To a solution of 22-S6 (65 mg, 0.078 mmol) and 22-S7 (24.18 mg, 0.078 mmol) in DMF (3 mL) were added HATU (53.4 mg, 0.14 mmol) and DIPEA (0.054 mL, 0.312 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with water and extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=20:1) to afford the title compound (30 mg, 50.0% yield) as a white solid. LC/MS (ESI) m/z: 697 (M+H)+.
Step 6: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (22)
To a solution of 22-S8 (30 mg, 0.039 mmol) in dry THF (5 mL) were added morpholine (33.93 mg, 0.39 mmol) and Pd(PPh3)4 (2.3 mg, 0.0020 mmol) under an atmosphere of nitrogen at 0° C. The reaction mixture continued to stir at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 22 (3.5 mg, 13.1% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.56 (s, 1H), 7.80 (d, J=1.2 Hz, 2H), 7.55 (d, J=8.0 Hz, 1H), 7.38 (d, J=7.9 Hz, 1H), 5.80 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.1 Hz, 1H), 4.65-4.62 (m, 1H), 3.64-3.66 m, 1H), 2.93 (t, J=4.9 Hz, 4H), 2.75 (s, 3H), 2.72-2.61 (m, 6H), 2.56 (d, J=6.9 Hz, 5H), 2.14 (d, J=8.2 Hz, 3H), 1.15 (t, J=5.6 Hz, 1H), 1.10-1.08 (m, 1H). LC/MS (ESI) m/z: 686 (M+H)+.
Figure US11708351-20230725-C01089
Step 1: 2-(6-Bromo-1-(1-oxidanyl)-pyridin-3-yl)acetonitrile (23-S2)
To a stirred solution of 2-(6-bromopyridin-3-yl) acetonitrile (23-S1, 1 g, 1 equiv) in CHCl3 (100 mL) was added 3-chlorobenzoperoxoic acid (1.72 g, 77%, 1.5 equiv). The reaction mixture was heated to 50° C. The reaction mixture was cooled and neutralized with saturated aqueous NaHCO3 solution (100 mL). The organic layer was washed with brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by chromatography on silica gel (5% CH3OH in DCM, gradient) to afford 23-S2 (99 mg, 10%).
Step 2: 2-(6-Bromo-2-(tert-butylamino)pyridin-3-yl)acetonitrile (23-S3)
To a stirred solution of 23-S2 (99 mg, 1 equiv) and 2-methylpropan-2-amine (0.24 mL, 5 equiv) in DCM (8 mL) was added trifluoroacidic anhydride (0.08 mL, 1.1 equiv) solution in DCM (3 mL) dropwise at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at 0-5° C. for 1 hour and TFAA (0.07 mL, 1 equiv) was added followed by 2-methylpropan-2-amine (0.02 mL, 1 equiv). The reaction mixture was diluted with DCM (25 mL) and neutralized with aqeuous saturated NaHCO3 solution (10 mL). The organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/EtOAc=3/1) to afford 23-S3 (80 mg, 30%)
Step 3: 2-(2-Amino-6-bromopyridin-3-yl)acetonitrile (23-S4)
TFA (10 mL) was added to solid 23-S3 (80 mg) and the reaction mixture was heated at 70° C. The reaction mixture was concentrated to dryness. The residue was dissolved in DCM (15 mL) and washed with an aqueous saturated solution of NaHCO3 (8 mL). The organic layer was dried over Na2SO4 and concentrated to dryness to afford 23-S4 (63 mg, quantitative yield)
Step 4: tert-Butyl (2S,4R)-2-((6-bromo-3-(cyanomethyl)pyridin-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (23-S5)
To a stirred solution of (2S, 4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (69 mg, 1 equiv) and 23-S4 (63 mg, 1 equiv) in DCM (10 mL), was added pyridine (0.12 mL, 5 equiv). The reaction was cooled to 0-5° C. and POCl3 was added dropwise (0.024 mL, 2 equiv) under an atmosphere of argon. The reaction mixture was warmed to room temperature, diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 23-S5 (56 mg, 26%).
Step 5: (2S,4R)—N-(6-Bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide Hydrochloride (23-S6)
To a solution of 23-S5 was added 4N HCl in dioxane (10 mL). The resulting solution was stirred at room temperature for 6 hours and then concentrated to dryness to afford 23-S6 (61 mg).
Step 6: (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(cyanomethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (23)
To a solution of 23-S6 (61 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (50 mg, 1.2 equiv) in DMF (8 ml) and DIPEA (0.12 mL, 5 equiv) was added HATU (63 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (25 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine (15 mL×3), dried over anhydrous Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 23. 1H NMR (400 MHz, DMSO-d6) δ 10.93 (s, 1H), 9.04 (s, 2H), 8.45 (s, 1H), 7.77-7.90 (m, 3H), 7.63 (d, 1H, J=8.2 Hz), 5.52-5.89 (m, 3H), 4.57-4.64 (m, 1H), 4.19-4.31 (m, 1H), 3.95-4.13 (m, 1H), 3.61-3.74 (m, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.65-2.68 (m, 1H), 2.24-2.33 (m, 1H), 0.84-0.90 (m, 2H); 19F NMR (376 MHz, DMSO-d6) δ−176.02 (s, 1F).
Figure US11708351-20230725-C01090
Figure US11708351-20230725-C01091
Step 1: Methyl 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S2)
A mixture of methyl 5-bromo-1H-indazole-7-carboxylate (0.95 g), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.231 g, 1.5 equiv), cesium carbonate (3.64 g, 3 equiv) in dioxane (20 mL) and water (2.0 mL) was purged with argon in a pressure vessel for 5 minutes. Tetrakis(triphenylphosphine)palladium (0) (0.842 g, 0.2 equiv) was added under argon and the pressure vessel was sealed and heated at 90° C. overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by silica gel flash column chromatography (eluent: 0-4.5% MeOH in CH2Cl2) to afford 0.538 g of the product as white solid.
Step 2: Methyl 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S3)
To an ice cooled solution of methyl 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (0.538 g) in DMF (15 mL), bromine (113 μL) was added dropwise. The resulting slurry was stirred at room temperature for 2 hours and quenched with the addition of saturated sodium thiosulfate solution. The solid was isolated by filtration, washed with water, and dried. The material was carried forward in the next step without additional purification.
Step 3: Methyl 3-bromo-1-(2-(tert-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S4)
A mixture of methyl 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (0.150 g), tert-butyl bromoacetate (67 μL) and potassium carbonate (0.090 g) in anhydrous acetonitrile (10 mL) and DMF (1 mL) was refluxed for 4 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was triturated with water, filtered and dried. The material was carried forward in the next step without additional purification.
Step 4: Methyl 3-acetyl-1-(2-(tert-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S5)
A solution of methyl 3-bromo-1-(2-(tert-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (0.100 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.15 mL, 2 equiv) and PdCI2(PPh3)2 (15 mg, 0.1 equiv) in DMF (2 mL) was heated at 80° C. overnight under argon atmosphere. The reaction was then concentrated under reduced pressure and diluted with CH2Cl2 and washed with cold aqueous HCI (1N). The organic layer was dried (Na2SO4), filtered, concentrated, and the residue was purified by silica gel flash column chromatography (eluent: 0-1.5% MeOH in CH2Cl2) to afford a yellow solid.
Step 5: 2-(3-Acetyl-7-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (25-S6)
Methyl 3-acetyl-1-(2-(tert-butoxy)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25-S5) (0.08 g) was stirred in CH2Cl2 (1 mL) and TFA (2 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was used directly in the next synthetic step without purification.
Step 6: Methyl 3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25)
Compound 25-S6 from above was dissolved in DMF (1 mL) and iPr2NEt (0.164 mL, 5 equiv) was added, followed by the addition of 25-S7 at 5° C. HATU (86 mg, 1.2 equiv) was then added slowly at 5° C. and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.0% MeOH in CH2Cl2) to afford 25 as white solid. 1H NMR (400 MHz, DMSO) δ 2.05-2.23 (m, 1H), 2.50-2.59 (m, 1H), 2.68 (s, 3H), 2.69 (s, 3H), 3.88-4.03 (m, 1H), 3.94 (s, 3H), 4.19 (dd, J=12.4, 21.8 Hz, 1H), 4.64 (t, J=8.4 Hz, 1H), 5.54 (d, J=52 Hz, 1H), 5.76 (d, J=17.4 Hz, 1H), 5.95 (d, J=17.4 Hz, 1H), 7.31 (d, J=7.7 Hz, 1H), 7.70 (t, J=8.0 Hz, 1H), 8.00 (d, J=8.2 Hz, 1H), 8.22 (d, J=2 Hz, 1H), 8.70 (d, J=1.8 Hz, 1H), 9.06 (s, 2H), 10.95 (s, 1H). 19F NMR (DMSO-d6): δ−176.1.
Figure US11708351-20230725-C01092
Figure US11708351-20230725-C01093
Step 1: (3S)-3-Benzyl 2-tert-butyl 5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (26-S2)
To a solution of 26-S1 (300 mg, 0.86 mmol), isoindoline-1,3-dione (190 mg, 1.29 mmol), and PPh3 (452 mg, 1.72 mmol) in THF (6 mL) was added DIAD (0.34 mL, 1.72 mmol) dropwise at 0° C. under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 16 hours. The resulting mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=6:1) to afford 26-S2 (400 mg, 97.1% yield) as a light yellow viscous oil. LC/MS (ESI) m/z: 377 (M+H−100)+.
Step 2: (3S)-2-(tert-Butoxycarbonyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (26-S3)
A solution of 26-S2 (400 mg, 0.83 mmol) in MeOH (10 mL) was purged with nitrogen and Pd/C (60 mg, 5% wt) was added. The mixture was then purged with hydrogen and stirred under an atmosphere of hydrogen (balloon) at room temperature for 12 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=40:1) to afford 26-S3 (170 mg, 32.3% yield) as a light yellow oil. LC/MS (ESI) m/z: 287 (M+H−100)+.
Step 3: (3S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (26-S4)
To a solution of 26-S3 (170 mg, 0.44 mmol) and 6-methylpyridin-2-amine (90 mg, 0.48 mmol) in DCE (5 mL) were added DIPEA (0.29 mL, 1.76 mmol) and EEDQ (217 mg, 0.88 mmol). The reaction mixture was stirred at 90° C. overnight and concentrated under high vacuum. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=4:1) to afford 26-S4 (103 mg, 41% yield) as a yellow solid. LC/MS (ESI) m/z: 555/557 (M+H)+.
Step 4: (3S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (26-S5)
To a solution of 26-S4 (100 mg, 0.18 mmol) in dioxane (1 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at room temperature for 1 hour and concentrated to afford 26-S5 (82 mg, 100% yield) as a white solid. The crude material was carried forward in the next synthetic step without purification.
Step 5: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (26-S6)
To a solution of 26-S5 (82 mg, 0.18 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (67 mg, 0.21 mmol), and HATU (136 mg, 0.36 mmol) in DMF (2 mL) was added DIPEA (0.12 mL, 0.72 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) to afford 26-S6 (60 mg, 44.7% yield) as an off-white solid.
Step 6: (3S)-5-(Aminomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-(2-(3-((Z)-1-hydrazonoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (26-S7)
To a solution of 26-S6 (60 mg, 0.08 mmol) in EtOH (3 mL) was added hydrazine hydrate (0.1 mL, 85%). The reaction mixture was stirred at 50° C. for 12 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=20:1) to afford 26-S7 (30 mg, 60.1% yield) as a yellow oil.
Step 7: (3S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(aminomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (26)
To a solution of 26-S7 (30 mg, 0.047 mmol) in THF/H2O (1 mL/1 mL) was added copper(II) sulfate (38 mg, 0.24 mmol). The reaction mixture was stirred at 50° C. for 12 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by preparative TLC to afford 26 (3.6 mg, 12.4% yield) as a yellow solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.55 (s, 1H), 7.78 (s, 2H), 7.54 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 5.65-5.79 (m, 2H), 5.14-5.19 (m, 1H), 3.90-3.94 (m, 1H), 3.40-3.43 (m, 1H), 3.01-3.05 (m, 1H), 2.75 (s, 3H), 2.70 (s, 3H), 2.47-2.51 (m, 1H), 2.29-2.39 (m, 1H), 2.08 (s, 3H), 0.83-0.90 (m, 2H). LC/MS (ESI) ml/z: 617 (M+H)+.
Figure US11708351-20230725-C01094
HATU (128 mg, 1.2 equiv) was added at 0° C. under an atmosphere of argon to a solution of 27-S6 (102 mg, 1 equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (92 mg, 1.2 equiv), and DIPEA (0.24 mL, 5 equiv) in DMF (8 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=10:1) to afford 27 (70 mg, 39%). 1H NMR (400 MHz, DMSO-d6) δ 10.31 (s, 1H), 9.03 (s, 2H), 8.35 (s, 1H), 7.82 (d, 1H, J=8.4 Hz), 7.62 (s, 1H), 6.03 (d, 1H, J=18.0 Hz), 5.69 (d, 1H, J=18.0 Hz), 4.37-4.43 (m, 1H), 3.59-3.62 (m, 1H), 2.69 (s, 6H), 2.65 (s, 3H), 2.53-2.60 (m, 1H), 2.08 (s, 3H), 2.02-2.10 (m, 1H), 1.33 (s, 3H), 0.93-1.05 (m, 2H). 19F NMR (376 MHz, DMSO-d6): δ−119.12 (s, 1F).
Figure US11708351-20230725-C01095
Figure US11708351-20230725-C01096
Step 1: 2-(tert-Butyl) 3-ethyl (1S,3S,5R)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S4)
Anhydrous DCM (12.5 mL) was cooled in an ice bath, and to the flask, a solution of ZnEt2 in hexane (1.0M) (2.27 mL, 2.27 mmol) was added, followed by the careful dropwise addition of CH2I2 (4.54 mmol) under an argon atmosphere. After completion of the addition, the mixture was stirred at 0° C. for 10 minutes at which time a white precipitate appeared. A solution of 1-(tert-butyl) 2-ethyl (S)-4-(hydroxymethyl)-2,3-dihydro-1H-pyrrole-1,2-dicarboxylate (29-S1, 279 mg, 1.03 mmol) and L-dioxaborolane 29-S2 (316 mg, 1.17 mmol) was added quickly and the mixture was stirred for 30 minutes at 0° C. The reaction was then allowed to warm to room temperature and stir for 2 hours. The reaction was quenched with saturated aqueous NH4Cl (15 mL) at 0° C. and the aqueous phase was extracted with DCM (15 mL×2). The combined DCM solutions were washed with brine and dried over MgSO4. The solution was filtered and concentrated and the resulting residue was purified to afford 29-S4 (153 mg).
Step 2: 2-(tert-Butyl) 3-ethyl (1S,3S,5R)-5-((allyloxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S5)
To the solution of 2-(tert-butyl) 3-ethyl (1S,3S,5R)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (29-S4, 153 mg, 0.53 mmol) in THF at 0° C., NaH (60%, 2.65 mmol) was added under argon. The mixture was stirred for 30 minutes, allyl bromide (3.0 mmol) was added, and the reaction was warmed to 40° C. for 4 hours. The reaction was cooled in an ice bath and quenched carefully with aqueous NH4C1. The mixture was extracted with ethyl acetate (15 mL×3) and the combined organic layers were washed with water, brine, and dried over MgSO4. The solution was concentrated and the residue was purified to afford 29-S5 (137 mg). 1H NMR (400 MHz, DMSO-d6, 300 K): δ 0.77-0.85 (m, 1H), 1.18-1.94 (m, 1H), 1.27 (t, J=7.2 Hz, 3H), 1.41 (s, 9H), 2.09-2.14 (m, 1H), 2.57-2.71 (m, 1H), 3.33-3.45 (m, 3H), 3.97 (d, J=5.2 Hz, 2H), 4.10-4.20 (m, 2H), 4.52-4.64 (m, 1H), 5.18 (d, J=10.4 hz, 1H), 5.26 (d, J=17.2 Hz, 1H), 5.84-5.93 (m, 1H) ppm.
Step 3: (1S,3S,5R)-5-((Allyloxy)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (29-S6)
Compound 29-S5 (137 mg, 0.42 mmol) was dissolved in a mixture of CH3OH-THF—H2O (2 mL-2 mL-2 mL) and treated with LiOH (40 mg, 1.67 mmol). The reaction mixture was stirred overnight at room temperature before the volatiles were evaporated under reduced pressure and the remaining residue was acidified with 10% citric acid (10 mL). The mixture was extracted with ethyl acetate (15 mL×3) and the combined organic layers were washed with water, brine and dried over MgSO4. The solution was concentrated and the residue 29-S6 (108 mg) was dried and carried forward without additional purification. LC (method A): tR=1.66 min. LC/MS (EI) m/z: [M+H]+ 298.4
Step 4: tert-Butyl (1S,3S,5R)-5-((allyloxy)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (29-S8)
(1S,3S,5R)-5-((Allyloxy)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (29-S6, 108 mg, 0.36 mmol), 3-((allyloxy)methyl)-6-bromopyridin-2-amine (29-S7, 97 mg, 0.40 mmol) were dissolved in anhydrous DCM (5 mL) in a pre-dried flask. The flask was cooled using an ice bath and dry pyridine (0.25 mL) was added in one portion, followed by POCl3 (100 μL, 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0° C. and the reaction was quenched with water (15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL×2). The combined DCM solutions were washed with brine and dried over MgSO4. The solution was filtered and concentrated and the resulting residue was purified to afford 29-S8 (126 mg). 1H NMR (400 MHz, Chloroform-d) δ 0.75-0.92 (m, 1H), 1.02-1.17 (m, 1H), 1.51 (s, 9H), 2.35-2.80 (m, 2H), 3.42 (d, J=10.4 Hz, 1H), 3.52-3.63 (m, 2H), 3.90-4.11 (m, 4H), 4.36-4.44 (m, 2H), 4.74-4.87 (br, 1H), 5.18-5.31 (m, 4H), 5.85-5.92 (m, 2H), 7.29 (d, J=8.0 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 9.16 (s, 1H) ppm. LC (method A): tR=2.68 min. LC/MS (EI) m/z: [M+H]+ 524.44
Step 5: (1S,3S,5R)-5-((Allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (29-S9)
tert-Butyl (1S,3S,5R)-5-((allyloxy)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (29-S8, 104 mg) was dissolved in DCM (4 mL) and treated with TFA (1 mL). The mixture was stirred overnight at room temperature. The volatiles were evaporated under reduced pressure. The remaining material was co-evaporated with toluene twice and the residue (29-S9) was carried forward in the next step without additional purification.
Step 6: (1S,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (29)
To the solution of (1S,3S,5R)-5-((allyloxy)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (29-S9, 0.2 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (29-S10, 62 mg, 0.2 mmol) in DMF (2.0 mL), HATU (114 mg, 0.3 mmol) was added, followed by the dropwise addition of DIEA (5.0 eq) at room temperature. The mixture was stirred for 1 hour at room temperature and the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solution was successively washed with water and brine and dried over MgSO4. The solution was filtered and the solvent was removed. The residue was purified to afford 29 (31.1 mg). 1H NMR (400 MHz, DMSO-d6): (major rotamer) δ 1.05 (t, J=5.7 Hz, 1H), 1.44-1.46 (m, 1H), 2.07 (dd, J=13.5, 3.6 Hz, 1H), 2.64 (s, 3H), 2.68 (s, 4H), 3.41-3.76 (m, 4H), 3.79 (dd, J=6.0, 2.6 Hz, 1H), 4.03 (d, J=5.5 Hz, 2H), 4.16 (s, 2H), 4.91 (dd, J=11.4, 3.6 Hz, 1H), 4.96-5.13 (m, 2H), 5.20-5.36 (m, 2H), 5.58 (d, J=17.2 Hz, 1H), 5.69-5.74 (m 1H), 5.91-5.98 (m, 2H), 7.52 (d, J=8.0 Hz, 1H), 7.75-7.88 (m, 3H), 8.43 (s, 1H), 9.03 (s, 2H), 10.55 (s, 1H) ppm. LC (method A): tR=2.28 min. LC/MS (EI) m/z: [M+H]+ 714.44, 716.47.
Figure US11708351-20230725-C01097
Step 1: tert-Butyl 2-(3-acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (31-S2)
To a mixture of 31-S1 (163 mg, 0.38 mmol) in dry DCM (10 mL) was added DAST (124 mg, 0.76 mmol) at −30° C. under an atmosphere of nitrogen. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford 31-S2 (140 mg, 92% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z: 399 (M+H)+.
Step 2: 2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (31-S3)
To a solution of 31-S2 (65 mg, 0.16 mmol) in THF/H2O (3:1 v/v, 4 mL) was added NaOH (14 mg, 0.32 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and washed with diethyl ether twice. The aqueous layer was adjusted to pH 5 with 10% aqueous HCl solution and extracted with DCM twice. The organic layer was dried over Na2SO4 and concentrated to afford 31-S3 (35 mg, 63.8% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z: 343 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (31)
To a solution of 31-S3 (35 mg, 0.1 mmol), (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (46 mg, 0.13 mmol), and HATU (57 mg, 0.15 mmol) in DMF (3 mL) was added DIPEA (39 mg, 0.3 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed successively with 10% aqueous LiCl solution and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 31 (8 mg, 12.6% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.08 (s, 2H), 8.58 (s, 1H), 8.01 (s, 1H), 7.63 (d, J=8.1 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.95 (t, J=5.7 Hz, 1H), 5.81-5.91 (m, 1H), 5.72-5.78 (m, 1H), 5.61-5.69 (m, 1H), 4.38-4.44 (m, 1H), 3.58 (d, J=2.9 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.55-2.62 (m, 1H), 1.98-2.13 (m, 4H), 1.33 (s, 3H), 0.97-1.06 (m, 2H). LC/MS (ESI) m/z: 634 (M+H)+.
Figure US11708351-20230725-C01098
Figure US11708351-20230725-C01099
Step 1: 2-(tert-Butyl) 3-ethyl (3S)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (32-S2)
To a solution of 32-S1 (500 mg, 1.75 mmol) in THF (5 mL) was added NaH (105.4 mg, 4.39 mmol) at 0° C. under an atmosphere of nitrogen and the mixture was stirred at 0° C. for 20 minutes. Iodomethane (740 mg, 5.25 mmol) was added and the resulting mixture was stirred at 0° C. under an atmosphere of nitrogen for 3 hours. The reaction mixture was quenched by aqueous NH4Cl solution and diluted with EtOAc. The mixture was washed with water and brine, dried over Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=5:1) to afford 32-S2 (160 mg, 30.5% yield) as a colorless oil. LC/MS (ESI) m/z: 300 (M+H)+.
Step 2: (3S)-2-(tert-Butoxycarbonyl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (32-S3)
To a mixture of 32-S2 (160 mg, 0.5 mmol) in THF (2 mL) and water (2 mL) was added LiOH (62.7 mg, 1.5 mmol) at 0° C. The reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated to half volume and washed with EtOAc twice. The mixture was acidified by 2 N aqueous HCl and extracted with DCM twice. The combined organic layers were concentrated to dryness to afford 32-S3 (120 mg, 88.9% yield) as a colorless oil. LC/MS (ESI) m/z: 272 (M+H)+.
Step 3: tert-Butyl (3S)-3-((6-bromopyridin-2-yl)carbamoyl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (32-S4)
To a mixture of 32-S3 (100 mg, 0.37 mmol) and 6-bromopyridin-2-amine (24.6 mg, 0.37 mmol) in DCE (5 mL) were added DIPEA (0.25 mL, 1.48 mmol) and EEDQ (183 mg, 0.74 mmol) at 0° C. The reaction mixture was stirred at 90° C. overnight. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=1:1) to afford 32-S4 (110 mg, 69.8% yield) as a yellow solid. LC/MS (ESI) m/z: 426 (M+H)+.
Step 4: (3S)—N-(6-Bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (32-S5)
To a solution of 32-S4 (95 mg, 0.223 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL, 2 M) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford 32-S5 (114 mg, 100% yield) as a brown syrup, which was used in the next synthetic step without purification. LC/MS (ESI) m/z: 326 (M+H)+.
Step 5: (3S)-2-(2-(3-Acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-5-(methoxymethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (32)
To a mixture of 32-S5 (57 mg, 0.11 mmol), 2-(3-acetyl-7-(methoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (39 mg, 0.078 mmol), and HATU (75 mg, 0.198 mmol) in DMF (3 mL) was added DIPEA (0.076 mL, 0.44 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 32 (19 mg, 50.4% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.59 (d, J=1.7 Hz, 1H), 8.08 (d, J=7.9 Hz, 1H), 7.73 (d, J=1.7 Hz, 1H), 7.61 (t, J=8.0 Hz, 1H), 7.25 (d, J=7.3 Hz, 1H), 6.04 (d, J=17.5 Hz, 1H), 5.86 (d, J=17.4 Hz, 1H), 4.99 (s, 1H), 4.72 (d, J=12.6 Hz, 1H), 4.56 (d, J=9.0 Hz, 1H), 3.69 (dd, J=5.7, 2.6 Hz, 1H), 3.53 (q, J=10.3 Hz, 2H), 3.39 (d, J=3.1 Hz, 6H), 2.75 (s, 3H), 2.70 (d, J=2.5 Hz, 3H), 2.53 (dd, J=13.5, 9.2 Hz, 1H), 2.41 (dd, J=12.8, 5.1 Hz, 1H), 1.15-1.11 (m, 1H), 0.90 (t, J=6.8 Hz, 1H). LC/MS (ESI) m/z: 662 (M+H)+.
Figure US11708351-20230725-C01100
To a suspension of methyl 3-acetyl-1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carboxylate (25, 0.13 g) in THF (3 mL) was added a solution of LiOH (25 mg) in water (1 mL). The resulting homogeneous solution was stirred overnight at room temperature. The organic solvent was removed and the residue was diluted with water (2 mL). The white solid obtained by the acidification of the aqueous solution with 2N aqueous HCl was isolated and purified by reverse phase HPLC to afford 41. 1H NMR (400 MHz, DMSO) δ 2.03-2.25 (m, 1H), 2.50-2.58 (m, 1H), 2.68 (s, 3H), 2.69 (s, 3H), 3.56-3.68 (m, 1H), 3.91-4.13 (m, 2H), 4.64 (t, J=8.4 Hz, 1H), 5.53 (d, J=52.4 Hz, 1H), 5.74 (d, J=17.1 Hz, 1H), 6.10 (d, J=17.1 Hz, 1H), 7.30 (d, J=7.7 Hz, 1H), 7.68 (t, J=8.0 Hz, 1H), 7.99 (d, J=8.3 Hz, 1H), 8.26 (d, J=1.8 Hz, 1H), 8.69 (d, J=1.8 Hz, 1H), 9.05 (s, 2H), 10.96 (s, 1H), 13.72 (s, 1H). 19F-NMR (DMSO-d6): δ−175.2.
Figure US11708351-20230725-C01101
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with nucleophilic R201 groups on the C-ring. The skilled artisan will recognize that MeNH2 can be replaced with other nucleophilic reagents to afford additional compounds of the present invention. Non-limiting examples of groups the skilled artisan can use instead of MeNH2 include ethanamine, 2-fluoroethan-1-amine, 2,2,2-trifluoroethanamine, N-ethylpropan-1-amine, cyclopropanamine, piperazine, azetidine, azetidin-3-ol, 3,3-difluoroazetidine, 2-azaspiro[3.3]heptane, 2-azaspiro[3.4]octane, (3aR,6aS)-octahydrocyclopenta[c]pyrrole, 2-oxa-6-azaspiro[3.3]heptane, 2-azaspiro[3.4]octane, phenylmethanamine, (2-fluorophenyl)methanamine, and sodium cyanide
To a solution of 42-S1 (84 mg, 0.12 mmol) in MeCN (3 mL) were added DIPEA (0.04 mL, 0.24 mmol), NaI (18 mg, 0.12 mmol), and MeNH2·HCl (16 mg, 0.24 mmol). The reaction mixture was stirred at 30° C. overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=10:1) and further purified by preparative HPLC to afford 42 (1.5 mg, 3.3% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.57 (s, 1H), 7.76-7.83 (m, 2H), 7.58 (d, J=8.0 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 5.65-5.79 (m, 2H), 4.72-4.75 (m, 1H), 3.85-3.87 (m, 1H), 2.61-2.79 (m, 11H), 2.59-2.60 (m, 2H), 2.12 (s, 3H), 1.28-1.45 (m, 2H). LC/MS (ESI) m/z: 631/633 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(piperazin-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (88)
1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.55 (s, 1H), 8.45 (s, 1H), 7.58 (d, J=8.5 Hz, 2H), 7.41 (d, J=7.9 Hz, 1H), 6.00 (m, 1H), 5.83 (m, 1H), 4.66 (m, 1H), 3.68 (m, 1H), 3.25 (m, 4H), 2.91 (m, 2H), 2.77 (d, J=4.9 Hz, 6H), 2.74 (d, J=3.9 Hz, 2H), 2.70 (s, 3H), 2.68 (s, 2H), 2.51 (m, 2H), 2.14 (s, 3H), 1.20 (m, 1H), 1.10 (m, 1H). LC/MS (ESI) m/z: 700 (M+H)+.
(1R,3S,5R)-5-(2-Azaspiro[3.3]heptan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (89)
1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.45 (s, 1H), 7.64-7.52 (m, 2H), 7.42 (d, J=7.9 Hz, 1H), 5.99 (m, 1H), 5.82 (m, 1H), 4.64 (m, 1H), 3.79 (m, 4H), 3.16-3.06 (m, 1H), 2.77 (d, J=2.9 Hz, 6H), 2.70 (s, 3H), 2.66 (s, 2H), 2.63-2.49 (m, 2H), 2.26 (m, 4H), 2.15 (s, 3H), 1.93-1.85 (m, 2H), 1.35 (m, 1H), 1.16 (m, 1H). LC/MS (ESI) m/z: 711 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (94)
1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.45 (d, J=6.7 Hz, 1H), 7.67-7.45 (m, 2H), 7.40 (m, 1H), 6.03-5.77 (m, 2H), 3.84 (s, 1H), 3.15 (m, 1H), 2.93 (m, 1H), 2.79 (d, J=10.8 Hz, 2H), 2.75 (m, 4H), 2.77-2.68 (m, 4H), 2.70-2.63 (m, 2H), 2.66-2.56 (m, 1H), 2.47 (dd, J=13.8, 3.5 Hz, 1H), 2.10 (m, 3H), 1.79 (m, 1H), 1.30 (m, 2H). LC/MS (ESI) m/z: 645 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluoroethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (113)
1H NMR (400 MHz CD3OD) δ 9.01 (s, 2H), 8.43 (s, 1H), 7.66-7.47 (m, 3H), 7.41 (d, J=7.9 Hz, 2H), 5.99 (m, 1H), 5.82 (m, 1H), 4.71 (m, 1H), 4.66 (m, 1H), 4.60 (m, 1H), 3.77 (m, 1H), 3.19 (m, 1H), 3.15-3.09 (m, 2H), 3.00 (d, J=12.9 Hz, 1H), 2.76 (s, 6H), 2.70 (s, 3H), 2.63 (m, 2H), 2.14 (s, 3H), 1.18 (m, 1H), 0.92 (m, 1H). LC/MS (ESI) m/z: 677 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((diethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (118)
1H NMR (400 MHz, CD3OD) δ 8.89 (s, 2H), 8.33 (s, 1H), 7.51-7.42 (m, 2H), 7.30 (d, J=7.9 Hz, 1H), 5.80 (dd, J=18.0, 18.0 Hz, 2H), 4.59 (dd, J=8.9, 4.5 Hz, 1H), 3.76 (d, J=3.2 Hz, 1H), 3.36 (d, J=14.6 Hz, 1H), 3.10 (s, 5H), 2.65 (d, J=5.3 Hz, 6H), 2.57 (d, J=7.6 Hz, 4H), 2.48 (dd, J=13.3, 4.3 Hz, 1H), 2.06 (s, 6H), 2.02 (s, 3H), 1.40-1.36 (m, 1H), 0.82-0.78 (m, 1H). LC/MS (ESI) m/z: 687 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (119)
1H NMR (400 MHz, CD3OD) δ 8.92 (s, 2H), 8.47 (s, 1H), 7.72 (s, 2H), 7.49 (d, J=8.2 Hz, 1H), 7.32 (d, J=8.0 Hz, 1H), 5.74 (d, J=16.7 Hz, 1H), 5.57 (d, J=17.2 Hz, 1H), (dd, J=8.9, 4.5 Hz, 1H), 3.80 (d, J=5.2 Hz, 1H), 3.63 (s, 2H), 3.54 (s, 2H), 3.40-3.38 (m, 1H), 3.04-3.03 (m, 1H), 2.80 (s, 3H), 2.66 (s, 4H), 2.62-2.55 (m, 6H), 2.04 (s, 3H), 1.64 (s, 4H), 1.50 (s, 2H), 1.36-1.31 (m, 1H), 1.21-1.18 (s, 1H). LC/MS (ESI) m/z: 711 (M+H)+.
(1R,3S,5R)-5-(2-Oxa-6-azaspiro[3.3]heptan-6-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (127)
1H NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.57 (d, J=8.0 Hz, 1H), 7.53 (s, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.94-5.99 (m, 1H), 5.76-5.81 (m, 1H), 4.80 (s, 4H), 4.63-4.65 (m, 1H), 4.08-4.15 (m, 4H), 3.81-3.83 (m, 1H), 3.13 (s, 2H), 2.74 (s, 6H), 2.65 (s, 3H), 2.49-2.59 (m, 2H), 2.12 (s, 3H), 1.30-1.33 (m, 1H), 0.95-0.98 (m, 1H). LC/MS (ESI) m/z: 713 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((3aR,6aS)-hexahydrocyclopenta[c]pyrrol-2(1H)-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (128)
1H NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.53-7.58 (m, 2H), 7.40 (d, J=8.0 Hz, 1H), 5.96-6.01 (m, 2H), 5.77-5.81 (m, 1H), 4.66-4.70 (m, 1H), 3.86-3.89 (m, 3H), 2.63-2.89 (m, 17H), 2.12 (s, 3H), 1.59-1.76 (m, 6H), 1.43-1.46 (m, 1H), 1.27-1.30 (m, 1H). LC/MS (ESI) m/z: 725 (M+H)+.
(1R,3S,5R)-5-(2-Azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (129)
1H NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.41 (s, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.52 (s, 1H), 7.41 (d, J=8.0 Hz, 1H), 5.97 (m, 1H), 5.79 (m, 1H), 4.67 (m, 1H), 4.07-4.04 (m, 1H), 4.03-3.90 (m, 1H), 3.44 (q, J=13.6 Hz, 2H), 2.74 (m, 6H), 2.67 (s, 3H), 2.61-2.55 (m, 1H), 2.12 (s, 3H), 1.94 (m, 4H), 1.66 (m, 5H), 1.45 (m, 1H), 1.29-1.20 (m, 1H). LC/MS (ESI) m/z: 725 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((ethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (132)
1H NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.44 (s, 1H), 7.60-7.44 (m, 2H), 7.43 (d, J=7.9 Hz, 1H), 5.98 (d, J=17.6 Hz, 1H), 5.83 (d, J=17.6 Hz, 1H), 4.74 (dd, J=8.3, 4.4 Hz, 1H), 3.91 (dd, J=5.8, 2.8 Hz, 1H), 3.28-3.07 (m, 3H), 2.77 (s, 6H), 2.70 (s, 3H), 2.68-2.59 (m, 2H), 2.14 (s, 3H), 1.50 (d, J=5.9 Hz, 1H), 1.39 (t, J=7.3 Hz, 3H), 1.35 (dd, J=5.9, 2.8 Hz, 1H). LC/MS (ESI) m/z: 658 (M+H)+.
(1R,3S,5R)-5-(2-Azaspiro[3.4]octan-2-ylmethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (142)
1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.77 (s, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.41 (d, J=8.0 Hz, 1H), 5.77-5.81 (m, 1H), 5.62-5.66 (m, 1H), 4.65-4.68 (m, 1H), 3.99-4.07 (m, 4H), 3.88-3.90 (m, 1H), 3.36 (s, 2H), 2.75 (s, 3H), 2.68 (s, 3H), 2.57-2.60 (m, 2H), 2.12 (s, 3H), 1.91-1.95 (m, 4H), 1.63-1.67 (m, 4H), 1.37-1.39 (m, 1H), 1.23-1.25 (m, 1H). LC/MS (ESI) m/z: 711 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(azetidin-1-ylmethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (149)
1H NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.42 (s, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.55 (s, 1H), 7.42 (d, J=8.0 Hz, 1H), 5.96-6.01 (m, 1H), 5.78-5.83 (m, 1H), 4.64-4.68 (m, 1H), 4.04-4.09 (m, 4H), 3.86-3.88 (m, 1H), 3.32-3.34 (m, 1H), 3.18-3.21 (m, 1H), 2.76 (s, 6H), 2.71 (s, 4H), 2.44-2.53 (m, 3H), 2.13 (s, 3H), 1.39-1.42 (m, 1H), 1.21-1.23 (m, 1H). LC/MS (ESI) m/z: 671 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3-difluoroazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (150)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.43 (s, 1H), 7.55-7.57 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 5.97-6.02 (m, 1H), 5.78-5.83 (m, 1H), 4.59-4.63 (m, 1H), 3.67-3.82 (m, 5H), 2.70-2.81 (m, 11H), 2.58-2.60 (m, 2H), 2.16 (s, 3H), 1.24-1.27 (m, 1H), 1.03-1.05 (m, 1H). LC/MS (ESI) m/z: 707 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((cyclopropylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (151)
1H NMR (400 MHz, CD3OD) δ 9.03 (s, 2H), 8.58 (s, 1H), 7.81 (s, 2H), 7.58 (d, J=8.0 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.68 (d, J=17.1 Hz, 1H), 4.68-4.57 (m, 1H), 3.69 (s, 1H), 3.16-3.01 (m, 1H), 2.84 (d, J=12.7 Hz, 1H), 2.77 (s, 3H), 2.72 (s, 3H), 2.66-2.56 (m, 2H), 2.35 (s, 1H), 1.30 (s, 1H), 1.13 (s, 1H), 0.58 (d, J=5.5 Hz, 2H), 0.47 (s, 2H). LC/MS (ESI) m/z: 657 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((2,2,2-trifluoroethyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (160)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.44 (s, 1H), 7.56-7.58 (m, 2H), 7.40 (d, J=8.0 Hz, 1H), 5.97-6.02 (m, 1H), 5.80-5.85 (m, 1H), 4.61-4.64 (m, 1H), 3.66-3.69 (m, 1H), 3.32-3.34 (m, 2H), 2.94-2.96 (m, 2H), 2.78 (s, 6H), 2.76 (s, 3H), 2.59-2.61 (m, 2H), 2.15 (s, 3H), 1.29-1.32 (m, 1H), 1.05-1.08 (m, 1H). LC/MS (ESI) m/z: 713 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((benzylamino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (161)
1H NMR (400 MHz, CD3OD) δ 8.85 (s, 2H), 8.27 (s, 1H), 7.28-7.46 (m, 8H), 5.81-5.86 (m, 1H), 5.64-5.69 (m, 1H), 4.56-4.58 (m, 1H), 4.01-4.11 (m, 2H), 3.71-3.74 (m, 1H), 3.01 (s, 2H), 2.63 (s, 6H), 2.56 (s, 3H), 2.50-2.54 (m, 2H), 1.99 (s, 3H), 1.29-1.31 (m, 1H), 1.14-1.17 (m, 1H). LC/MS (ESI) m/z: 721 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (162)
1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.53-7.56 (m, 2H), 7.39 (d, J=8.0 Hz, 1H), 5.96-6.00 (m, 1H), 5.77-5.82 (m, 1H), 4.62-4.66 (m, 1H), 3.82-3.84 (m, 1H), 3.04-3.08 (m, 1H), 2.87-2.91 (m, 1H), 2.69-2.78 (m, 10H), 2.46-2.50 (m, 1H), 2.14 (s, 3H), 1.40-1.43 (m, 1H), 1.22-1.25 (m, 1H). LC/MS (ESI) m/z: 641 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-hydroxyazetidin-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (164)
1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.44 (s, 1H), 7.63-7.53 (m, 2H), 7.42 (d, J=7.9 Hz, 1H), 6.00 (d, J=17.7 Hz, 1H), 5.82 (d, J=17.7 Hz, 1H), 4.70-4.48 (m, 2H), 4.15 (d, J=26.0 Hz, 2H), 3.81 (s, 1H), 3.50 (s, 2H), 3.24-3.12 (m, 1H), 3.03 (d, J=13.0 Hz, 1H), 2.77 (d, J=2.9 Hz, 6H), 2.70 (s, 3H), 2.61 (d, J=8.8 Hz, 1H), 2.53 (dd, J=13.5, 4.8 Hz, 1H), 2.14 (s, 3H), 1.34 (d, J=22.4 Hz, 2H), 1.17 (s, 1H). LC/MS (ESI) m/z: 687 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((2-fluorobenzyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (170)
1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.43 (s, 1H), 7.59-7.54 (m, 3H), 7.48-7.41 (m, 2H), 7.29-7.22 (m, 2H), 5.96 (d, J=12.8 Hz, 1H), 5.81 (d, J=9 Hz, 1H), 4.70 (s, 1H), 4.26 (d, J=3 Hz, 2H), 3.86-3.84 (m, 1H), 3.24 (d, J=2.4 Hz, 2H), 2.76 (d, J=2.8 Hz, 6H), 2.69 (s, 3H), 2.66-2.63 (m, 2), 2.12 (s, 3H), 1.45 (s, 1H), 1.28-1.26 (m, 1H). LC/MS (ESI) m/z: 739 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(((1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.53 (d, J=7.4 Hz, 2H), 7.42 (d, J=2.5 Hz, 1H), 7.37 (d, J=7.9 Hz, 1H), 5.95 (d, J=17.8 Hz, 1H), 5.80 (d, J=17.7 Hz, 1H), 5.72 (d, J=2.5 Hz, 1H), 4.71-4.58 (m, 3H), 3.74-3.65 (m, 1H), 3.48 (d, J=13.6 Hz, 1H), 3.34 (s, 1H), 2.75 (d, J=4.4 Hz, 6H), 2.68 (s, 3H), 2.63-2.49 (m, 2H), 2.11 (s, 3H), 1.38-1.35 (m, 1H), 1.10-1.01 (m, 1H). LC/MS (ESI) m/z: 779 (M+H)+.
Figure US11708351-20230725-C01102
Step 1: (3S)-tert-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (44-S2)
To a solution of 44-S1 (250 mg, 0.64 mmol) and 6-bromopyridin-2-amine (123 mg, 0.71 mmol) in DCE (5 mL) were added DIPEA (0.43 mL, 2.58 mmol) and EEDQ (319 mg, 1.29 mmol). The reaction mixture was stirred at 90° C. overnight and concentrated under vacuum. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=4:1) to afford 44-S2 (300 mg, 85.9% yield) as a white solid. LC/MS (ESI) m/z: 541/543 (M+H)+.
Step 2: (3S)-tert-Butyl 5-(aminomethyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (44-S3)
To a solution of 44-S2 (300 mg, 0.55 mmol) in EtOH (6 mL) was added hydrazine hydrate (0.3 mL, 85% w/w). The reaction mixture was stirred at 75° C. for 2 hours and then cooled to room temperature. The mixture was filtered, the filtrate was concentrated to dryness, and the remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=10:1) to afford 44-S3 (210 mg, 92.5% yield) as light a yellow oil. LC/MS (ESI) m/z: 411/413 (M+H)+.
Step 3: (3S)-tert-Butyl 5-(Acetamidomethyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (44-S4)
To a mixture of 44-S3 (100 mg, 0.24 mmol) in dry DCM (3 mL) were added DIPEA (0.08 mL, 0.48 mmol) and acetyl chloride (0.02 mL, 0.28 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (4 mL×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) to afford 44-S4 (94 mg, 85.4% yield) as a white solid. LC/MS (ESI) m/z: 453/455 (M+H)+.
Step 4: (3S)-5-(Acetamidomethyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44-S5)
To a solution of 44-S4 (90 mg, 0.2 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 44-S5 (80 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 353/355 (M+H)+.
Step 5: (1S,3S,5S)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (43) and (1R,3S,5R)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44)
To a solution of 44-S5 (35 mg, 0.078 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (44-S6, 29 mg, 0.093 mmol), and HATU (59 mg, 0.155 mmol) in DMF (2 mL) was added DIPEA (0.065 mL, 0.40 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 43 (25 mg, 49.8% yield) and 44 (2 mg, 3.98% yield) as white solids.
(1S,3S,5S)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (43)
1H NMR (400 MHz, DMSO-d6) δ 10.91 (s, 1H), 9.04 (s, 2H), 8.48 (s, 1H), 8.02-8.05 (m, 2H), 7.83-7.89 (m, 2H), 7.70 (t, J=8.0 Hz, 1H), 7.31 (d, J=7.6 Hz, 1H), 5.86-5.90 (m, 1H), 5.58-5.63 (m, 1H), 4.92-4.95 (m, 1H), 3.72-3.74 (m, 1H), 3.37-3.40 (m, 2H), 2.62-2.68 (m, 6H), 2.01-2.05 (m, 1H), 1.86 (s, 3H), 1.40-1.42 (m, 1H), 0.89-1.01 (m, 2H). LC/MS (ESI) m/z: 645/647 (M+H)+.
(1R,3S,5R)-5-(acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (44)
1H NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.54 (s, 1H), 8.08-8.10 (m, 1H), 7.79 (s, 2H), 7.62 (t, J=8.0 Hz, 1H), 7.26 (d, J=7.6 Hz, 1H), 5.77-5.82 (m, 1H), 5.63-5.68 (m, 1H), 4.57-4.62 (m, 1H), 3.70-3.72 (m, 1H), 3.46-3.50 (m, 1H), 3.20-3.23 (m, 1H), 2.73-2.75 (m, 6H), 2.30-2.52 (m, 2H), 1.92 (s, 3H), 1.26-1.29 (m, 1H), 1.06-1.08 (m, 1H). LC/MS (ESI) m/z: 645/647 (M+H)+.
Figure US11708351-20230725-C01103
Step 1: (3S)-tert-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-(((S)-2-(methoxycarbonylamino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (45-S2)
To a mixture of 45-S1 (100 mg, 0.24 mmol), (S)-2-(methoxycarbonylamino)-3-methylbutanoic acid (51 mg, 0.29 mmol), and HATU (182 mg, 0.48 mmol) in DMF (2 mL) was added DIPEA (0.16 mL, 0.96 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue product was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) to afford 45-S2 (105 mg, 76.0% yield) as a white solid. LC/MS (ESI) m/z: 568/570 (M+H)+.
Step 2: Methyl (2S)-1-(((3S)-3-(6-Bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methylamino)-3-methyl-1-oxobutan-2-ylcarbamate (S3)
To a solution of 45-S2 (105 mg, 0.18 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 45-S3 (85 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 468/470 (M+H)+.
Step 3: Methyl (2S)-1-(((3S)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-(6-bromopyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methylamino)-3-methyl-1-oxobutan-2-ylcarbamate (45)
To a solution of 45-S3 (35 mg, 0.074 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (45-S4, 28 mg, 0.089 mmol) and HATU (57 mg, 0.15 mmol) in DMF (2 mL) was added DIPEA (0.05 mL, 0.29 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 45 (39 mg, 68.6% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.9 (s, 1H), 9.04 (s, 2H), 8.47 (s, 1H), 8.01-8.25 (m, 2H), 7.70-7.89 (m, 3H), 7.30-7.33 (m, 1H), 7.11-7.24 (m, 1H), 5.84-5.91 (m, 1H), 5.57-5.64 (m, 1H), 4.92-4.95 (m, 1H), 3.71-3.79 (m, 2H), 3.49 (s, 4H), 3.29-3.33 (m, 1H), 2.65-2.68 (m, 7H), 1.97-2.02 (m, 2H), 1.05-1.36 (m, 2H), 0.87-0.95 (m, 6H). LC/MS (ESI) m/z: 760/762 (M+H)+.
Figure US11708351-20230725-C01104
Figure US11708351-20230725-C01105
Step 1: 4-Bromo-2-ethyl-6-methylaniline (47-S2)
To a solution of 47-S1 (12 g, 88.7 mmol) in AcOH (250 mL) was added dropwise Br2 (5.1 mL) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was filtered and the filter cake was washed with diethyl ether. The solid was suspended in water and neutralized with saturated aqueous K2CO3 solution. The mixture was extracted with EtOAc twice and the combined organic layers were dried over anhydrous Na2SO4 and concentrated to dryness to afford 47-S2 (12.2 g, 57.0% yield) as a purple oil. LC/MS (ESI) m/z: 214 (M+H)+.
Step 2: 5-Bromo-7-ethyl-1H-indazole (47-S3)
To a solution of 47-S2 (6 g, 28.2 mmol) and KOAc (3.3 g 33.8 mmol) in CHCl3 (60 mL) was added dropwise acetic anhydride (8.6 g, 86.4 mmol) at 0° C. under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60° C. and tert-butyl nitrite (5.8 g, 56.4 mmol) was added. The resulting mixture was stirred at 60° C. overnight. The mixture was diluted with DCM and washed with water and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated. The remaining residue was dissolved in MeOH and 6 N aqueous HCl (20 mL) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated to afford 47-S3 (5.0 g, 79.2% yield) as a light a yellow solid. LC/MS (ESI) m/z: 225 (M+H)+.
Step 3: 5-Bromo-7-ethyl-3-iodo-1H-indazole (47-S4)
To a solution of 47-S3 (4.5 g, 20.1 mmol) in DMF (50 mL) were added KOH (2.53 g, 45.23 mmol) and iodine (7.65 g, 30.15 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes. The reaction mixture was quenched by addition of saturated aqueous Na2S2O3 solution (15 mL). The mixture was diluted with DCM and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness to afford 47-S4 (6.56 g, 93.2% yield) as a white solid. LC/MS (ESI) m/z: 351 (M+H)+.
Step 4: tert-Butyl 2-(5-bromo-7-ethyl-3-iodo-H-indazol-1-yl)acetate (47-S5)
To a solution of 47-S4 (6.56 g, 18.75 mmol) in DMF (70 mL) were added K2CO3 (7.76 g, 56.2 mmol) and tert-butyl 2-bromoacetate (2.73 mL, 18.75 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=10:1) to afford 47-S5 (3.5 g, 40.2% yield) as a yellow solid. LC/MS (ESI) m/z: 465 (M+H)+.
Step 5: tert-Butyl 2-(3-acetyl-5-bromo-7-ethyl-1H-indazol-1-yl)acetate (47-S6)
To a solution of 47-S5 (1.5 g, 3.23 mmol) in toluene (15 mL) were added tributyl(1-ethoxyvinyl)stannane (1.75 g, 4.85 mmol) and Pd(PPh3)4 (373 mg, 0.32 mmol). The mixture was stirred at 100° C. under an atmosphere of nitrogen overnight. The mixture was cooled to room temperature and 0.5 M aqueous HCl was added. The resulting mixture was stirred for another 30 minutes, diluted with EtOAc, and washed with brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=60:1) to afford 47-S6 (976 mg, 79.5% yield) as a brown solid. LC/MS (ESI) m/z: 381 (M+H)+.
Step 6: tert-Butyl 2-(3-acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (47-S7)
To a solution of 47-S6 (500 mg, 1.32 mmol) and (2-methylpyrimidin-5-yl)boronic acid (182 mg, 1.32 mmol) in dioxane (6 mL) and water (0.6 mL) were added K2CO3 (455 mg, 3.3 mmol) and Pd(PPh3)4. The reaction mixture was stirred at 90° C. under an atmosphere of nitrogen overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4 and concentrated to afford 47-S7 (210 mg, 40.4% yield) as a white solid. LC/MS (ESI) m/z: 395 (M+H)+.
Step 7: 2-(3-Acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (47-S8)
To a solution of 47-S7 (170 mg, 0.43 mmol) in THF (3 mL) was added 1 M aqueous NaOH solution (0.86 mL, 0.86 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to dryness, diluted with water, and washed with diethyl ether twice. The aqueous layer was acidified by addition of 1 N aqueous HCl and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness to afford 47-S8 (106 mg, 72.9% yield) as a white solid. LC/MS (ESI) m/z: 339 (M+H)+.
Step 8: (1R,3S,5R)-2-(2-(3-Acetyl-7-ethyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (47)
To a solution of 47-S8 (30 mg, 0.089 mmol), 47-S9 (32 mg, 0.093 mmol), and HATU (50.0 mg, 0.133 mmol) in DMF (3 mL) was added DIPEA (34 mg, 0.267 mmol) and the reaction mixture was stirred at room temperature under an atmosphere of nitrogen for 2 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine. The organic layer was dried over anhydrous Na2SO4 and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 47 (8 mg, 10.7% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.04 (s, 2H), 8.35 (d, J=1.5 Hz, 1H), 7.64-7.60 (m, 2H), 7.45 (d, J=8.0 Hz, 1H), 5.96 (d, J=16.0 Hz, 1H), 5.68 (d, J=20.0 Hz, 1H), 4.40 (m, 1H), 3.60 (m, 2H), 3.03-2.97 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.58 (m, 2H), 2.04 (s, 4H), 1.33 (d, J=8.0 Hz, 6H), 1.06 (t, J=5.3 Hz, 1H), 0.93 (m, 1H). LC/MS (ESI) m/z: 630 (M+H)+.
Figure US11708351-20230725-C01106
Step 1: 5-(3-Acetyl-1-(2-tert-butoxy-2-oxoethyl)-7-methyl-1H-indazol-5-yl)-2-methylpyrimidine 1-oxide (50-S2)
To a mixture of 50-S1 (130 mg, 0.39 mmol) in CHCl3 (10 mL) was added m-CPBA (67 mg, 0.39 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was adjusted to pH 10 with aqueous NaHCO3. The mixture was partitioned with DCM/MeOH (20:1) and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=120:1) to afford the title product (77 mg, 49.2% yield) as a white solid. LC/MS (ESI) m/z: 397 (M+H)+.
Step 2: 5-(3-Acetyl-1-(carboxymethyl)-7-methyl-1H-indazol-5-yl)-2-methylpyrimidine 1-oxide (50-S3)
To a solution of 50-S2 (77 mg, 0.18 mmol) in DCM (2 mL) was added TFA (2 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford the title product (60 mg, 88.4% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 341 (M+H)+.
Step 3: 5-(3-Acetyl-1-(2-((1R,3S,5R)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)-2-methylpyrimidine 1-oxide (50)
To a solution of 50-S3 (60 mg, 0.145 mmol), (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (50 mg, 0.145 mmol), and HATU (84 mg, 0.22 mmol) in DMF (3 mL) was added DIPEA (57 mg, 0.43 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was partitioned with DCM/MeOH (20:1) and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 50 (2.2 mg, 1.6% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 8.95 (d, J=1.9 Hz, 1H), 8.57 (d, J=1.9 Hz, 1H), 8.35 (s, 1H), 7.62 (d, J=8.0 Hz, 2H), 7.44 (d, J=7.9 Hz, 1H), 6.03 (d, J=17.9 Hz, 1H), 5.69 (d, J=17.8 Hz, 1H), 4.41 (dd, J=9.1, 5.5 Hz, 1H), 3.56-3.61 (m, 1H), 2.67 (s, 3H), 2.65 (s, 3H), 2.61 (s, 3H), 2.53-2.59 (m, 1H), 2.04 (s, 3H), 1.97-2.03 (m, 1H), 1.33 (s, 3H), 1.00-1.05 (m, 1H), 0.91-0.97 (m, 1H). LC/MS (ESI) m/z: 632/634 (M+H)+.
Figure US11708351-20230725-C01107
Figure US11708351-20230725-C01108
Step 1: 5-Bromo-7-methyl-1H-indazole (51-S2)
To a solution of 4-bromo-2,6-dimethylaniline (51-S1, 10 g, 0.05 mol) and potassium acetate (5.88 g, 0.06 mol) in CHCl3 (120 mL) was added acetic anhydride (15.3 g, 0.15 mol) dropwise at 0° C. under an atmosphere of nitrogen and the resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60° C. and tert-butyl nitrite (10.3 g, 0.1 mol) was added dropwise. The resulting mixture was stirred overnight at 60° C. The mixture was cooled to room temperature, diluted with H2O, and extracted with DCM twice. The combined organic layers were washed by brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining residue was dissolved in MeOH and 6 N aqueous HCl (50 mL, v/v=1:1) and the resulting mixture was stirred at room temperature for 4 hour. The reaction mixture was basified with 10 N aqueous NaOH and extracted with DCM. The organic layer was washed by brine, dried over anhydrous Na2SO4, and concentrated to afford 51-S2 (10.1 g, 95.7% yield) as light a yellow solid. LC/MS (ESI) m/z: 212 (M+H)+.
Step 2: 5-Bromo-3-iodo-7-methyl-1H-indazole (51-S3)
To a solution of 51-S2 (10 g, 0.047 mol) in DMF (50 mL) was added KOH (6.63 g, 0.18 mol) followed by I2 (18.06 g, 0.071 mol) at 0° C. The mixture was stirred at room temperature for 1.5 hour. The reaction mixture was quenched by aqueous Na2S2O3 and diluted with EtOAc. The mixture was washed with water and brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining residue was washed with a mixture of PE/EtOAc (50 mL, 5:1) and dried under vacuum to afford 51-S3 (15.1 g, 94.6% yield) as light a yellow solid. LC/MS (ESI) m/z: 338 (M+H)+.
Step 3: tert-Butyl 2-(5-bromo-3-iodo-7-methyl-1H-indazol-1-yl) acetate (51-S4)
To a solution of 51-S3 (6.9 g, 0.02 mol) in DMF (20 mL) were added K2CO3 (8.48 g, 0.06 mol) and tert-butyl 2-bromoacetate (3.97 g, 0.02 mol) and the resulting mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with water and brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc=200:1 to 70:1) to afford 51-S4 (5.66 g, 61.3% yield) as light a yellow solid. LC/MS (ESI) m/z: 452 (M+H)+.
Step 4: tert-Butyl 2-(3-acetyl-5-bromo-7-methyl-1H-indazol-1-yl) acetate (51-S5)
To a solution of 51-S4 (4.63 g, 10.27 mmol) in dry toluene (25 mL) were added tributyl(1-ethoxyvinyl)stannane (5.19 g, 14.38 mmol) and Pd(PPh3)4 (0.83 g, 0.72 mmol). The reaction mixture was degassed with nitrogen and stirred at 100° C. under an atmosphere of nitrogen overnight. The mixture was cooled to room temperature, 0.5 M aqueous HCl (20 mL) was added, and then stirred at room temperature for 20 minutes. The reaction mixture was diluted with H2O and extracted with EtOAc twice. The combined organic layers were washed by brine, dried over anhydrous Na2SO4, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc=150:1 to 60:1) to afford 51-S5 (2.63 g, 70.0% yield) as milky a white solid. LC/MS (ESI) m/z: 367 (M+H)+.
Step 5: tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetate (51-S6)
A round-bottom flask was charged with 51-S5 (2.63 g, 7.18 mmol), 2-methylpyrimidin-5-ylboronic acid (0.99 g, 7.18 mmol), K2CO3 (2.48 g, 17.96 mmol), and dioxane/H2O (20 mL, v/v=9:1) under an atmosphere of nitrogen. To this mixture was added tetrakis(triphenylphosphine) palladium(0) (0.42 g, 0.36 mmol) and the resulting mixture was stirred at 90° C. overnight under an atmosphere of nitrogen. The mixture was diluted with EtOAc and filtered. The filtrate was diluted with EtOAc, washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining crude product was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:1 to 3:1) to afford 51-S6 (1.93 g, 70.7% yield) as light a yellow solid. LC/MS (ESI) m/z: 381 (M+H)+.
Step 6: 2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic Acid (51-S7)
Compound 51-S6 (1.45 g, 3.81 mmol) was treated with HCl/dioxane (9 mL) and stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and the remaining residue was washed with ether and dried under vacuum to afford 51-S7 (1.23 g, 99.8% yield) as light a yellow solid. LC/MS (ESI) m/z: 324 (M+H)+.
Step 7: (3S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino) methyl)-2-azabicyclo [3.1.0] hexane-3-carboxamide (51)
To a mixture of 51-S7 (30 mg, 0.093 mmol) and 51-S8 (33 mg, 0.093 mmol) in DMF (1 mL) was added DIPEA (60 mg, 0.46 mmol) followed by HATU (77 mg, 0.20 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford 51 (2 mg, 3.28% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.46 (s, 1H), 7.64-7.55 (m, 2H), 7.43 (d, J=8.0 Hz, 1H), 6.01 (d, J=17.6 Hz, 1H), 5.83 (d, J=17.6 Hz, 1H), 4.72 (dd, J=8.8, 4.4 Hz, 1H), 3.95 (dd, J=5.6, 2.8 Hz, 1H), 3.59 (d, J=14.0 Hz, 1H), 3.24 (d, J=13.6 Hz, 1H), 2.98 (s, 6H), 2.78 (s, 3H), 2.77 (s, 3H), 2.75-2.73 (m, 1H), 2.70 (s, 3H), 2.59 (dd, J=13.6, 4.0 Hz, 1H), 2.14 (s, 3H), 1.52 (t, J=5.6 Hz, 1H), 1.42-1.39 (m, 1H). LC/MS (ESI) m/z: 660 (M+H)+.
Figure US11708351-20230725-C01109
Step 1: (2S,4R)-1-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (59-S3)
To a solution of 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (59-S1, 1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (2S,4R)—N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (59-S2, 1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 59-S3. 1H NMR (400 MHz, DMSO-d6) δ: 10.47 (s, 1H), 8.95 (s, 2H), 8.38 (s, 1H), 7.81 (s, 2H), 7.71 (d, J=8.0 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 5.85 (d, J=17.2 Hz, 1H), 5.62 (d, J=16.8 Hz, 1H), 5.50 (s, 1H), 4.60 (t, J=16.8 Hz, 1H), 4.29-4.21 (m, 1H), 4.08-4.05 (m, 1H), 3.98 (s, 3H), 2.67 (s, 3H), 2.66-2.65 (m, 1H), 2.25-2.14 (m, 1H), 2.00 (s, 3H).
Step 2: (2S,4R)-1-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (59)
To a solution of compound 59-S3 (1 equiv) in ACN (10 vol) at 0° C. under nitrogen atmosphere was added TMSCl (2.5 equiv) and NaI (2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered and dried to afford compound 59. 1H NMR (400 MHz, DMSO-d6) δ: 10.47 (s, 1H), 8.65 (s, 2H), 8.29 (s, 1H), 7.75 (s, 2H), 7.61 (d, J=8.4 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.62 (d, J=16.8 Hz, 1H), 5.50 (s, 1H), 4.59 (t, J=16.8 Hz, 1H), 4.28-4.20 (m, 1H), 4.07-4.04 (m, 1H), 2.55-2.54 (m, 1H), 2.53 (s, 3H), 2.33-2.21 (m, 1H), 2.00 (s, 3H).
Figure US11708351-20230725-C01110
Figure US11708351-20230725-C01111
Step 1: 2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S2)
K2CO3 (1 g) was added to a mixture of 2-(tert-butyl) 3-ethyl (1R,3S,5S)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S1, 0.77 mmol) and N-methylprop-2-en-1-amine (0.663 mL, 6.93 mmol) in ACN (8 mL) and the reaction was heated at 40° C. under argon for 4 hours. EtOAc was added and the diluted reaction mixture was filtered through Celite to remove any solids. Solvents were removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 2-(tert-butyl) 3-ethyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 70-S2 (0.211 g) as yellow amorphous solid.
Step 2: (1R,3S,5R)-5-((Allyl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (70-S3)
2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (70-S2, 0.211 g, 0.624 mmol) was dissolved in a mixture of THF-EtOH-water (3 mL-0.75 mL-0.7 mL) and treated with LiOH monohydrate (32 mg, 0.75 mmol). The reaction stirred at room temperature for 6 hours before Amberlite (weakly acidic cation exchanger H form, 1 g) was added. After stirring for 20 minutes, the reaction was filtered and the resulting resin was washed with MeOH. The combined filtrates were concentrated under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as an eluent to afford (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 70-S3 (0.188 g) as colorless amorphous solid.
Step 3: tert-Butyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (70-S5)
To a mixture of 70-S3 (188 mg, 0.61 mmol) and 70-S4 (148 mg, 0.61 mmol) in DCM (10 mL), pyridine (0.246 mL, 3.05 mmol) was added followed by POCl3 (0.057 mL, 0.61 mmol) at 0° C. under argon. The reaction mixture was stirred at room temperature for 2 hours before NaHCO3 aqueous solution was added and the mixture was extracted with DCM. After washing with brine, the organic layer was dried over anhydrous Na2SO4. The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as eluent to afford tert-butyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (70-S5, 173.5 mg).
Step 4: (1R,3S,5R)-5-((Allyl(methyl)amino)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (70-S6)
tert-Butyl (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (70-S5, 29.5 mg) in DCM (2 mL) was treated with TFA (2 mL) at room temperature for 1 hour. The volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 70-S6. The material was carried forward without additional purification.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyl(methyl)amino)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (70)
To a mixture of (1R,3S,5R)-5-((allyl(methyl)amino)methyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 70-S6 and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (70-S7, 17 mg, 0.055 mmol) in DMF (1 mL), TBTU (26.5 mg) was added at room temperature followed by the addition of DIEA (0.096 mL) with stirring. After the reaction was complete, NaHCO3 aqueous solution (10 mL) was added to form a precipitation that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 70 (29 mg) as an off-white solid. 1H NMR (400 MHz, Chloroform-d) δ 8.89 (s, 3H), 8.56 (dd, J=1.7, 0.9 Hz, 1H), 7.61 (qd, J=8.7, 1.3 Hz, 2H), 7.48 (d, J=8.0 Hz, 1H), 7.23 (d, J=7.8 Hz, 1H), 5.91-5.76 (m, 2H), 5.50 (d, J=2.7 Hz, 2H), 5.25-5.11 (m, 4H), 4.95 (s, 1H), 4.41-4.26 (m, 2H), 3.88 (d, J=5.7 Hz, 2H), 3.29 (dd, J=5.5, 2.5 Hz, 1H), 3.06 (dt, J=6.4, 1.4 Hz, 2H), 2.80 (m, 6H), 2.72 (s, 3H), 1.21 (t, J=5.6 Hz, 1H), 0.99 (dd, J=5.5, 2.5 Hz, 1H). LC (method A): tR=1.35 min. LC/MS (EI) m/z: [M+H]+ 727.
Figure US11708351-20230725-C01112
Step 1: (3S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (75-S2)
To a solution of 75-S1 (150 mg, 0.33 mmol) in dioxane (1.5 mL) was added HCl/dioxane (1.5 mL, 2 M). The reaction mixture was stirred at room temperature for 30 minutes. The mixture was concentrated to dryness, diluted with DCM, washed with aqueous NaHCO3 solution, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (DCM/MeOH=60:1) to afford 75-S2 (100 mg, 86.2% yield) as a yellow oil. LC/MS (ESI) m/z: 352 (M+H)+.
Step 2: (1R,3S,5R)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (74) and (1S,3S,5S)-2-(2-(3-Acetyl-7-(fluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (75)
To a solution of 75-S2 (40 mg, 0.105 mmol), 75-S3 (30 mg, 0.087 mmol), and HATU (50.0 mg, 0.13 mmol) in DMF (3 mL) was added DIPEA (34 mg, 0.26 mmol). The reaction mixture was stirred at room temperature under an atmosphere of nitrogen for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over anhydrous Na2SO4, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 74 (2.0 mg, 3.4% yield) and 75 (2.2 mg, 3.8% yield) as white solids.
Compound 74
1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.07 (s, 2H), 8.58 (s, 1H), 8.01 (s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 5.97-5.93 (m, 1H), 5.85-5.76 (m, 1H), 5.75-5.62 (m, 2H), 4.46 (m, 1H), 3.63 (m, 1H), 2.69 (d, J=8.0 Hz, 6H), 2.46-2.31 (m, 4H), 2.24 (s, 6H), 2.05 (s, 3H), 1.09-1.02 (m, 2H).
Compound 75
1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 9.05 (s, 2H), 8.56 (s, 1H), 7.98 (s, 1H), 7.60 (d, J=8.0 Hz, 1H), 7.42 (d, J=8.0 Hz, 1H), 6.09 (d, J=20.0 Hz, 1H), 5.96 (m, 1H), 5.78-5.65 (m, 1H), 5.64-5.59 (m, 1H), 4.92 (d, J=8.0 Hz, 1H), 3.73-3.68 (m, 1H), 2.77 (t, J=12.0 Hz, 1H), 2.68 (d, J=4.0 Hz, 6H), 2.38 (s, 2H), 2.23 (s, 6H), 2.00 (m, 1H), 1.96 (s, 3H), 1.46 (d, J=4.0 Hz, 1H), 0.93 (m, 1H).
Figure US11708351-20230725-C01113
Step 1: (2S,4R)-1-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84-S3)
To a solution of 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (84-S1, 1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (2S,4R)—N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84-S2, 1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 84-S3.
Step 2: (2S,4R)-1-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84-S4)
To a solution of compound 84-S3 (1 equiv) in ACN (10 vol) at 0° C. under nitrogen atmosphere was added TMSCl (2.5 equiv) and NaI (2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered and dried to afford compound 84-54.
Step 3: (2S,4R)-1-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (84)
To a solution of compound 84-S4 (1 equiv) in ACN (10 vol) was added cesium carbonate (3 equiv) and 3-bromothietane 1,1-dioxide (84-S5, 2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered, dried and then purified by preparative purification to afford compound 84. 1H NMR (400 MHz, DMSO-d6) δ: 10.84 (s, 1H), 9.02 (s, 1H), 8.59 (s, 1H), 8.36 (s, 1H), 7.78-7.72 (m, 2H), 7.61 (d, J=8.0 Hz, 1H), 7.43 (d, J=7.6 Hz, 1H), 5.83 (d, J=17.2 Hz, 1H), 5.62 (d, J=17.2 Hz, 1H), 5.58-5.50 (m, 1H), 5.30-5.28 (m, 1H), 5.02-4.96 (m, 2H), 4.61-4.55 (m, 3H), 4.28-3.88 (m, 2H), 2.63 (s, 3H), 2.30-2.12 (m, 1H), 2.00 (s, 3H), 0.98-0.95 (m, 1H).
Figure US11708351-20230725-C01114
Figure US11708351-20230725-C01115
Step 1: 2-Amino-6-bromonicotinaldehyde (93-S2)
(2-Amino-6-bromopyridin-3-yl)methanol (93-S1, 1.0 g, 4.93 mmol) was treated with activated MnO2 (4.29 g, 49.3 mmol) in DCM (50 mL) at room temperature overnight. The mixture was filtered through Celite and the solvent was removed under reduced pressure to afford 2-amino-6-bromonicotinaldehyde 93-S2 (0.9 g) as a yellow solid.
Step 2: 6-Bromo-3-vinylpyridin-2-amine (93-S3)
Into a suspension of methyltriphenylphosphonium bromide (1.28 g, 3.6 mmol) in THF (10 mL), n-BuLi (1.6M in hexane, 2.25 mL, 3.6 mmol) was added with stirring at 0° C. under argon. After 1 hour, 2-amino-6-bromonicotinaldehyde (93-S2, 0.18 g, 0.9 mmol) in THF (5 mL) was added and the mixture was stirred at room temperature for 2 hours. The reaction was cooled in an ice bath and saturated NH4Cl aqueous solution (10 mL) was added. The mixture was extracted with EtOAc and the organic layer was washed with water and brine, and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 6-bromo-3-vinylpyridin-2-amine 93-S3 (0.13 g) as a white solid.
Step 3: tert-Butyl (1R,3S,5S)-5-((Allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (93-S5)
To a mixture of 93-S4 (97 mg, 0.33 mmol) and 93-S3 (65 mg, 0.33 mmol) in DCM (4 mL), pyridine (0.133 mL) was added followed by POCl3 (0.031 mL, 0.33 mmol) at 0° C. under argon. The reaction mixture was stirred overnight at room temperature. Water was added and the mixture was extracted with AcOEt. After washing with brine, the organic layer was dried over anhydrous Na2SO4. The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with EtOAc in hexane (0-50%) as the eluent to afford tert-butyl (1R,3S,5S)-5-((allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 93-S5 (88 mg) as colorless oil.
Step 4: (1R,3S,5S)-5-((Allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (93-S6)
tert-Butyl (1R,3S,5S)-5-((allyloxy)methyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (93-S5, 23 mg, 0.048 mmol) was dissolved in DCM (2 mL) and treated with TFA (1 mL) at room temperature. The reaction was stirred for 1 hour and the volatiles were removed under reduced pressure. The residue was co-evaporated with toluene (5 mL) twice to afford (1R,3S,5S)-5-((allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 93-S6. The crude material was carried forward in the next step without additional purification.
Step 5: (1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (93)
To a mixture of (1R,3S,5S)-5-((allyloxy)methyl)-N-(6-bromo-3-vinylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 93-S6 and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (S7 15.5 mg, 0.05 mmol) in DMF (1 mL), TBTU (32.1 mg, 0.1 mmol) followed by DIEA (0.0435 mL) was added at room temperature with stirring. After 1 h, NaHCO3 aqueous solution (10 mL) was added to form precipitation. Solid was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as eluent to afford 93 (21 mg). 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.75 (s, 1H), 8.58 (dd, J=1.7, 0.9 Hz, 1H), 7.71-7.58 (m, 3H), 7.30 (d, J=8.1 Hz, 1H), 6.45 (dd, J=17.4, 11.0 Hz, 1H), 5.89 (ddt, J=17.3, 10.4, 5.7 Hz, 1H), 5.65 (dd, J=17.5, 0.8 Hz, 1H), 5.52 (s, 2H), 5.32-5.15 (m, 3H), 4.91 (dd, J=8.8, 2.9 Hz, 1H), 4.01 (dq, J=5.7, 1.5 Hz, 2H), 3.73 (d, J=9.8 Hz, 1H), 3.56 (d, J=9.8 Hz, 1H), 3.42 (dd, J=5.6, 2.6 Hz, 1H), 2.80 (s, 3H), 2.72 (s, 3H), 2.29 (dd, J=13.8, 8.8 Hz, 1H), 1.46 (t, J=5.5 Hz, 1H), 0.99 (dd, J=5.5, 2.7 Hz, 1H). LC (method A): tR=2.01 min. LC/MS (EI) m/z: [M+H]+ 670.
Figure US11708351-20230725-C01116
Step 1: (1R,3S,5R)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (95-S2)
To a mixture of 95-S1 (30 mg, 0.07 mmol), 2,2-difluorocyclopentanecarboxylic acid (11 mg, 0.07 mmol), and HATU (40 mg, 0.48 mmol) in DMF (2 mL) was added DIPEA (0.03 mL, 0.21 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=80:1) to afford 95-S2 (15 mg, 40.0% yield) as a white solid. LC/MS (ESI) m/z: 537 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (95-S3)
To a solution of 95-S2 (15 mg, 0.03 mmol) in dioxane (0.5 mL) was added HCl/dioxane (2 M, 2 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure to afford 95-S3 (15 mg, 100% yield) as a white solid, which was carried forward in the next synthetic step without purification. LC/MS (ESI) m/z: 437 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorocyclopent-1-enecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (95)
To a mixture of 95-S3 (15 mg, 0.03 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (19 mg, 0.05 mmol), and HATU (27 mg, 0.07 mmol) in DMF (3 mL) was added DIPEA (0.02 mL, 0.11 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) and further purified by preparative HPLC to afford 95 (4.0 mg, 15.0% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.91 (s, 2H), 8.33 (d, J=1.1 Hz, 1H), 7.46 (d, J=8.0 Hz, 2H), 7.29 (d, J=7.9 Hz, 1H), 5.88 (m, 1H), 5.72 (m, 1H), 4.54 (m, 1H), 3.68-3.53 (m, 2H), 2.67 (m, 6H), 2.60 (s, 3H), 2.53-2.34 (m, 6H), 2.03 (s, 3H), 1.80 (dt, J=15.4, 7.9 Hz, 2H), 1.24 (m, 2H), 0.98 (m, 1H). LC/MS (ESI) m/z: 743 (M+H)+.
Figure US11708351-20230725-C01117
Step 1: (1R,3S,5R)-tert-Butyl 5-(acetamidomethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (96-S2)
To a solution of 96-S1 (30 mg, 0.071 mmol) in DCM (2 mL) was added DIPEA (18 mg, 0.14 mmol) followed by acetyl chloride (7 mg, 0.089 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with DCM, washed with water and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) to afford 96-S2 (31 mg, 93.9% yield) as a white solid. LC/MS (ESI) m/z: 467 (M+H)+.
Step 2: (1R,3S,5R)-5-(Acetamidomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (96-S3)
To a solution of 96-S2 (31 mg, 0.067 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 96-S3 (24 mg, 100.0% yield) as light a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 367 (M+H)+.
Step 3: (1R,3S,5R)-5-(Acetamidomethyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (96)
To a solution of 96-S3 (24 mg, 0.066 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (23 mg, 0.071 mmol), and HATU (50 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (25 mg, 0.20 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 96 (5.5 mg, 12.5% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.89 (d, J=3.3 Hz, 2H), 8.32 (s, 1H), 7.53-7.57 (m, 2H), 7.29 (d, J=8 Hz, 1H), 5.86 (d, J=17.6 Hz, 1H), 5.71 (d, J=17.6 Hz, 1H), 4.53 (m, 1H), 3.61 (m, 1H), 3.45 (d, J=14.2 Hz, 1H), 3.18-3.05 (m, 1H), 2.66 (s, 3H), 2.65 (s, 3H), 2.58 (s, 3H), 2.42 (m, 2H), 2.02 (s, 3H), 1.90 (s, 3H), 1.22 (m, 1H), 0.98 (m, 1H). LC/MS (ESI) m/z: 673 (M+H)+.
Figure US11708351-20230725-C01118
Step 1: (1R,3S,5R)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (97-S2)
To a mixture of 97-S1 (30 mg, 0.071 mmol), 2-fluorobenzoic acid (12 mg, 0.086 mmol), and HATU (54 mg, 0.14 mmol) in DMF (2 mL) was added DIPEA (27 mg, 0.21 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=20:1) to afford 97-S2 (31 mg, 80.3% yield) as a white solid. LC/MS (ESI) m/z: 547 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (97-S3)
To a solution of 97-S2 (31 mg, 0.057 mmol) in dioxane (2 mL) was added HCl/dioxane (2 mL, 2 M) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford 97-S3 (25 mg, 100% yield) as a brown oil, which was carried forward in the next synthetic step without purification. LC/MS (ESI) m/z: 447 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-fluorobenzamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (97)
To a solution of 97-S3 (25 mg, 0.056 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (20 mg, 0.062 mmol), and HATU (32 mg, 0.084 mmol) in DMF (2 mL) was added DIPEA (15 mg, 0.12 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 97 (4.2 mg, 10.00 yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.44 (s, 1H), 7.72 (td, J=7.5, 1.7 Hz, 1H), 7.52 (m, 3H), 7.38 (d, J=7.9 Hz, 1H), 7.27-7.15 (m, 2H), 6.00 (d, J=18 Hz, 1H), 5.84 (d, J=18 Hz, 1H), 4.64 (m, 1H), 3.85-3.75 (m, 2H), 3.58-3.49 (m, 1H), 2.78 (s, 3H), 2.76 (s, 3H), 2.70 (s, 3H), 2.67-2.54 (m, 2H), 2.09 (s, 3H), 1.42 (m, 1H), 1.13 (m, 1H). LC/MS (ESI) m/z: 753 (M+H)+.
Figure US11708351-20230725-C01119
Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (101-S2)
To a solution of 101-S1 (40 mg, 0.09 mmol) in dry DCM (3 mL) was added Et3N (0.03 mL, 0.18 mmol) followed by methanesulfonyl chloride (0.01 mL, 0.11 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour. The mixture was then diluted with water (4 mL) and extracted with DCM (3 mL×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=60:1) to afford 101-S2 (30 mg, 62.5% yield) as a light a yellow oil. LC/MS (ESI) m/z: 503 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (101-S3)
To a solution of 101-S2 (30 mg, 0.06 mmol) in DCM (0.5 mL) was added TFA (0.2 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 101-S3 (24 mg, 100.0% yield) as a yellow oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 403 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(methylsulfonamidomethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (101)
To a solution of 101-S3 (24 mg, 0.06 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (101-S4, 23 mg, 0.07 mmol), and HATU (45 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 101 (5.3 mg, 12.6% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.41 (s, 1H), 7.52-7.56 (m, 2H), 7.38 (d, J=8.0 Hz, 1H), 5.94-5.99 (m, 1H), 5.78-5.83 (m, 1H), 4.63-4.65 (m, 1H), 3.72-3.75 (m, 1H), 3.35-3.43 (m, 2H), 3.01 (s, 3H), 2.76 (s, 6H), 2.69 (s, 3H), 2.53-2.59 (m, 2H), 2.15 (s, 3H), 1.36-1.39 (m, 1H), 1.11-1.13 (m, 1H). LC/MS (ESI) m/z: 709 (M+H)+.
Figure US11708351-20230725-C01120
Step 1: (MS)-tert-Butyl 3-(6-bromopyridin-2-ylcarbamoyl)-5-(((S)-2-(methoxycarbonylamino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (102-S2)
To a mixture of 102-S1 (70 mg, 0.16 mmol), 3,3,3-trifluoropropanoic acid (25 mg, 0.19 mmol), and HATU (122 mg, 0.32 mmol) in DMF (2 mL) was added DIPEA (0.05 mL, 0.32 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue product was purified by column chromatography on silica gel (eluted with DCM/MeOH=80:1) to afford 102-S2 (75 mg, 85.2% yield) as a white solid. LC/MS (ESI) m/z: 535 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropanamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (102-S3)
To a solution of 102-S2 (75 mg, 0.14 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 102-S3 (61 mg, 100.0% yield) as a yellow oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 435 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3,3,3-trifluoropropanamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (102)
To a solution of 102-S3 (30 mg, 0.07 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (102-S4, 27 mg, 0.08 mmol), and HATU (53 mg, 0.14 mmol) in DMF (2 mL) was added DIPEA (0.06 mL, 0.35 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 102 (4.5 mg, 12.8% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.36 (s, 1H), 7.45-7.47 (m, 2H), 7.29 (d, J=8.0 Hz, 1H), 5.85-5.89 (m, 1H), 5.69-5.73 (m, 1H), 4.75-4.79 (m, 1H), 3.62-3.64 (m, 1H), 3.24-3.46 (m, 4H), 2.69 (s, 3H), 2.63 (s, 3H), 2.58 (s, 3H), 2.39-2.47 (m, 2H), 1.23-1.25 (m, 1H), 1.00-1.02 (m, 1H). LC/MS (ESI) m/z: 741 (M+H)+
Figure US11708351-20230725-C01121
Figure US11708351-20230725-C01122
Step 1: tert-Butyl 2-(3-acetyl-5-(2-(hydroxymethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (103-S3)
To a solution of (5-bromopyrimidin-2-yl)methanol (103-S2, 1 equiv) in DMF/H2O (9:1, 10 vol) was added compound 103-S1 (1 equiv), K2CO3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel to afford compound 103-S3.
Step 2: tert-Butyl 2-(3-acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (103-S4)
To a mixture of compound 103-S3 (1 equiv) in dry DCM (10 vol) was added Et3N (1 equiv) followed by the drop-wise addition of MsCl (1.5 equiv) at 0° C. and the reaction mixture was stirred for 2 hours at same temperature. Dimethylamine hydrochloride (1.1 equiv) at 0° C. was added and the reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was quenched with saturated aqueous NaHCO3 solution and extracted with DCM. The combined organic layers were separated, dried, and concentrated to afford crude product, which was purified by silica gel column (eluted with DCM/EtOAc) to afford compound 103-S4.
Step 3: 2-(3-Acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (103-S5)
To a solution of compound 103-S4 (1 equiv) under an atmosphere of argon was added 4N dioxane HCl (10 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-((dimethylamino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (103)
To a solution of compound 103-S5 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon were added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 103. 1H NMR (400 MHz, DMSO-d6) δ 1.05-1.13 (m, 2H), 1.39 (s, 3H), 2.07-2.16 (m, 4H), 2.54-2.60 (m, 1H), 2.73 (s, 3H), 3.01 (s, 6H), 3.64-3.74 (m, 1H), 4.47 (dd, J=5.2, 9.3 Hz, 1H), 4.78 (s, 2H), 5.66 (d, J=17.2 Hz, 1H), 6.02 (d, J=17.3 Hz, 1H), 7.52 (d, J=7.9 Hz, 1H), 7.69 (d, J=7.9 Hz, 1H), 7.99 (q, J=8.8 Hz, 2H), 8.60 (s, 1H), 9.36 (s, 2H), 10.36 (s, 1H).
Figure US11708351-20230725-C01123
Figure US11708351-20230725-C01124
Step 1: tert-Butyl 2-(5-bromo-3-iodo-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (104-S2)
To a solution of 5-bromo-3-iodo-1H-pyrazolo[3,4-c]pyridine (1 equiv) in CH3CN (10 vol) was added tert-butyl 2-bromoacetate (1.1 equiv) and potassium carbonate (1.1 equiv). The mixture was refluxed overnight under an atmosphere of argon. After cooling the reaction mixture to room temperature, the mixture was filtered through Celite and washed with CH3CN. The filtrate was concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 104-S2.
Step 2: tert-Butyl 2-(3-acetyl-5-bromo-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (104-S3)
To a solution of tert-butyl 2-(5-bromo-3-iodo-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (1 equiv) in dry DMF (10 vol) were added tributyl (1-ethoxyvinyl) stannane (1.5 equiv) and PdCl2(PPh3)2 (0.05 equiv) and the resulting mixture was stirred at 80° C. under argon atmosphere overnight and concentrated to dryness. The remaining residue was diluted with DCM and washed with 2N aqueous HCl. The organic layer was separated, dried over anhydrous Na2SO4, and concentrated to dryness. The obtained crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 104-S3.
Step 3: tert-Butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (104-S5)
To a solution of 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (104-S4, 1 equiv) in dioxane/H2O (9:1, 10 vol) was added compound 104-S3 (1 equiv), Cs2CO3 (2 equiv), and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 104-S5.
Step 4: 2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic Acid (104-S6)
To a solution of compound 104-S5 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without additional purification and used directly in the next synthetic step.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (104)
To a solution of compound 104-S6 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon were added (1R,3S,5R)—N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (S7, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and then concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 104. 1H NMR (400 MHz, DMSO-d6) δ 0.90-0.97 (m, 1H), 1.00-1.05 (m, 1H), 1.26 (s, 3H), 2.00 (s, 4H), 2.45-2.52 (m, 1H), 2.62 (d, J=4.3 Hz, 6H), 3.47-3.56 (m, 1H), 4.27-4.39 (m, 1H), 5.66 (d, J=17.2 Hz, 1H), 5.97 (d, J=17.3 Hz, 1H), 7.75 (d, J=8.4 Hz, 1H), 8.51-8.57 (m, 1H), 9.23 (d, J=1.4 Hz, 1H), 9.27 (s, 2H), 10.20 (s, 1H).
Figure US11708351-20230725-C01125
Step 1: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107-S3)
To a solution of 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (107-S1, 1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107-S2, 1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and then concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 107-S3.
Step 2: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-hydroxypyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107-S4)
To a solution of compound 107-S3 (1 equiv) in ACN (10 vol) at 0° C. under nitrogen atmosphere was added TMSCl (2.5 equiv) and NaI (2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered and dried to afford compound 107-S4.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-((1,1-dioxidothietan-3-yl)oxy)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (107)
To a solution of compound 107-S4 (1 equiv) in ACN (10 vol) was added cesium carbonate (3 equiv) and 3-bromothietane 1,1-dioxide (107-S5, 2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and quenched with water. The resulting solid was filtered, dried and purified by preparative purification to afford compound 107. 1H NMR (400 MHz, DMSO-d6) δ: 10.29 (s, 1H), 9.03 (s, 1H), 8.60 (s, 1H), 8.37 (s, 1H), 7.82-7.14 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.46 (d, J=8.0 Hz, 1H), 5.91 (d, J=17.6 Hz, 1H), 5.56 (d, J=17.6 Hz, 1H), 5.29-5.27 (m, 1H), 5.02-4.97 (m, 2H), 4.62-4.56 (m, 2H), 4.42-4.38 (m, 1H), 2.67 (s, 3H), 2.05 (s, 3H), 1.32 (s, 3H), 1.04-1.00 (m, 2H), 0.99-0.85 (m, 2H).
Figure US11708351-20230725-C01126
Figure US11708351-20230725-C01127
Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S2)
To a mixture of 112-S1 (100 mg, 0.26 mmol) and 6-bromo-3-cyclopropylpyridin-2-amine (55.1 mg, 0.26 mmol) in dry DCM (3 mL) was added pyridine (0.1 mL, 1.30 mmol) followed by POCl3 (39.8 mg, 0.26 mmol) at 0° C. The reaction mixture was stirred at room temperature for 30 minutes. The mixture was poured into ice water and extracted with DCM twice. The organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (PE/EtOAc=6:1 to 2:1) to afford 112-S2 (127 mg, 84.2% yield) as a white solid. LC/MS (ESI) m/z: 581 (M+H)+.
Step 2: (1R,3S,5R)-tert-Butyl 5-(aminomethyl)-3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S3)
To a solution of 112-S2 (127 mg, 0.22 mmol) in EtOH (3 mL) was added hydrazine hydrate (21.9 mg, 0.44 mmol). The reaction mixture was stirred at 75° C. for 2 hours and then cooled to room temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=5:1) to afford 112-S3 (79 mg, 79.8% yield) as a white solid. LC/MS (ESI) m/z: 451 (M+H)+.
Step 3: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-cyclopropylpyridin-2-yl)carbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (112-S4)
To a solution of 112-S3 (79 mg, 0.18 mmol) in MeOH (3 mL) was added aqueous HCHO solution (42.6 mg, 0.53 mmol, ˜37% wt) and NaBH3CN (22 mg, 0.35 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (5 mL×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The remaining crude product was purified by column chromatography on silica gel (eluted with DCM/MeOH=10:1) to afford 112-S4 (55 mg, 63.9% yield) as a light oil. LC/MS (ESI) m/z: 479 (M+H)+.
Step 4: (1R,3S,5R)—N-(6-Bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (112-S5)
To a solution of 112-S4 (55 mg, 0.12 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 112-S5 (43 mg) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 379 (M+H)+.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-cyclopropylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (112)
To a mixture of 112-S5 (43 mg, 0.113 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (112-S6, 36.6 mg, 0.118 mmol), and HATU (64.6 mg, 0.17 mmol) in DMF (2 mL) was added DIPEA (0.06 mL, 0.339 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 112 (6.5 mg, 8.57% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.02 (s, 2H), 8.56 (s, 1H), 7.80 (d, J=1.2 Hz, 2H), 7.38 (d, J=8.1 Hz, 1H), 7.30 (d, J=8.1 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.67 (d, J=17.1 Hz, 1H), 4.71 (t, J=7.0 Hz, 1H), 3.68-3.66 (m, 1H), 2.95-2.90 (m, 1H), 2.77 (s, 3H), 2.71 (s, 3H), 2.66-2.60 (m, 2H), 2.40 (s, 6H), 2.35-2.30 (m, 1H), 1.87-1.84 (m, 1H), 1.28-1.25 (m, 1H), 1.22-1.20 (m, 1H), 0.87-0.84 (m, 2H), 0.60-0.568 (m, 2H). LC/MS (ESI) m/z: 671 (M+H)+.
Figure US11708351-20230725-C01128
Step 1: 2-Bromo-4-fluoro-1-oxidanylpyridine (116-S2)
To a stirred solution of 2-bromo-4-fluoropyridine (116-S1, 2 g, 1 equiv) in CHCl3 (130 mL) was added 3-chlorobenzoperoxoic acid (5 g, 2 equiv). The reaction mixture was heated to 50° C. The reaction was cooled and neutralized with saturated aqueous NaHCO3 solution (100 mL). The organic layer was washed with saturated aqueous NaHCO3 (50 mL×2) and the combined organic layers were washed with brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% CH3OH in DCM, gradient) to afford 116-S2 (622 mg, 31%).
Step 2: 6-Bromo-N-(tert-butyl)-4-fluoropyridin-2-amine (116-S3)
To a stirred solution of 116-S2 (622 mg, 1 equiv), 2-methylpropan-2-amine (1.7 mL, 5 equiv) in DCM (100 mL) was added trifluoroacidic anhydride solution (1.1 mL, 1.1 equiv) in DCM (10 mL) dropwise at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at 0-5° C. for 1 hour before TFA solution (1 mL, 1 equiv) in DCM (10 mL) was added followed by 2-methylpropan-2-amine (0.4 mL, 1.1 equiv). The reaction mixture was neutralized with aqueous saturated NaHCO3 solution (20 mL) and the organic layer was washed with brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes) to afford 116-S3 (81 mg, 10%).
Step 3: 6-Bromo-4-fluoropyridin-2-amine (116-S4)
TFA (6 mL) was added to solid 116-S3 and the reaction mixture was heated at 70° C. until completion. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15 mL) and washed with aqueous saturated NaHCO3 solution (10 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness to afford 116-S4 (63 mg).
Step 4: tert-Butyl (1R,3S,5R)-3-((6-bromo-4-fluoropyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (116-S5)
POCl3 (0.04 mL, 2 equiv) was added dropwise at 0-5° C. under an atmosphere of argon to a stirred solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (79 mg, 1 equiv) and 116-S4 (63 mg, 1 equiv) in DCM (15 mL) and pyridine (0.13 mL, 5 equiv). The reaction mixture was stirred at room temperature for 2 hours before the reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 116-S5 (97 mg, 71%).
Step 5: (1R,3S,5R)—N-(6-Bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (116-S6)
To a solution of 116-S5 (97 mg) was added 4N HCl in dioxane (10 mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 116-S6 (75 mg).
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-fluoropyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (116)
HATU (109 mg, 1.2 equiv) was added at 0° C. under an atmosphere of argon to a solution of 116-S6 (75 mg, 1 equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (78 mg, 1.1 equiv), and DIPEA (0.21 mL, 5 equiv) in DMF (8 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (35 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 116 (87 mg, 53%). 1H NMR (400 MHz, DMSO-d6) δ 11.11 (s, 1H), 9.02 (s, 2H), 8.31 (s, 1H), 7.86 (d, 1H, J=10.6 Hz), 7.63 (s, 1H), 7.43 (d, 1H, J=7.6 Hz), 6.08 (d, 1H, J=17.6 Hz), 5.67 (d, 1H, J=17.6 Hz), 4.39-4.45 (m, 1H), 3.62-3.66 (m, 1H), 2.70 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.08 (s, 3H), 1.98-2.03 (m, 1H), 1.31 (s, 3H), 1.17-1.21 (m, 1H), 0.86-1.03 (m, 2H); 19F NMR (376 MHz, DMSO-d6) δ−98.11 (s, 1F).
Figure US11708351-20230725-C01129
Figure US11708351-20230725-C01130
Step 1: Methyl 2-(6-bromo-1-oxidanyl)-pyridin-3-yl)acetate (117-S2)
To a stirred solution of methyl 2-(6-bromopyridin-3-yl) acetate (117-S1, 1 g, 1 equiv) in CHCl3 (100 mL) was added 3-chlorobenzoperoxoic acid (1.93 g, 2 equiv). The reaction mixture was heated to 50° C. until it was complete. The reaction was cooled and neutralized with saturated aqueous NaHCO3 solution (50 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (5% CH3OH in DCM, gradient) to afford 117-S2 (848 mg, 80%).
Step 2: Methyl 2-(6-bromo-2-(tert-butylamino)pyridin-3-yl)acetate (117-S3)
To a stirred solution of 117-S2 (848 mg, 1 equiv) and 2-methylpropan-2-amine (1.8 mL, 5 equiv) in DCM (90 mL) was added trifluoroacidic anhydride solution (0.87 mL, 1.5 equiv) in DCM (10 mL) at 0-5° C. dropwise under an atmosphere of argon. The reaction mixture was stirred at 0-5° C. for 2 hours before it was neutralized with a solution of aqueous saturated NaHCO3 (20 mL). The organic layer was washed with aqueous saturated NaHCO3 (40 mL) and brine (40 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes, gradient) to afford 117-S3 (104 mg, 10%).
Step 3: Methyl 2-(2-amino-6-bromopyridin-3-yl)acetate (117-S4)
TFA (10 mL) was added to solid 117-S3 (104 mg) and the reaction mixture was heated at 70° C. The reaction was concentrated to dryness and the residue was dissolved in DCM (25 mL) and neutralized with aqueous saturated NaHCO3 (20 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness to afford 117-S4 (96 mg).
Step-4: tert-Butyl (2S,4R)-2-((6-bromo-3-(2-methoxy-2-oxoethyl)pyridin-2-yl)carbamoyl)-4-fluoropyrrolidine-1-carboxylate (117-S5)
POCl3 (0.08 mL, 2 equiv) was added dropwise at 0-5° C. under an atmosphere of argon to a solution of (2S,4R)-1-(tert-butoxycarbonyl)-4-fluoropyrrolidine-2-carboxylic acid (91 mg, 1 equiv) and 117-S4 (96 mg, 1 equiv) in DCM (10 mL) and pyridine (0.16 mL, 5 equiv). The reaction mixture was warmed to room temperature and stirred until complete. The reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 117-S5 (146 mg, 82%).
Step 5: Methyl 2-(6-bromo-2-((2S,4R)-4-fluoropyrrolidine-2-carboxamido)pyridin-3-yl)acetate Hydrochloride (117-S6)
To a solution of 117-S5 (146 mg) was added 4N HCl in Dioxane (10 mL). The resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 117-S6 (117 mg).
Step 6: Methyl 2-(2-((2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetate (61)
To a solution of 117-S6 (117 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (92 mg, 1 equiv) and DIPEA (0.25 mL, 5 equiv) in DMF (15 mL) was added HATU (137 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (35 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 61 (99 mg, 50%). 1H NMR (400 MHz, DMSO-d6) δ 10.58 (s, 1H), 9.04 (s, 2H), 8.40 (s, 1H), 7.79-7.90 (m, 2H), 7.68 (d, 1H, J=8.1 Hz), 7.52 (d, 1H, J=8.1 Hz), 5.49-5.88 (m, 3H), 4.56-4.62 (m, 1H), 4.19-4.29 (m, 1H), 3.94-4.30 (m, 1H), 3.55 (s, 2H), 3.44 (s, 3H), 2.70 (s, 3H), 2.65 (s, 3H), 2.07-2.34 (m, 1H), 0.85-0.92 (m, 1H); 19F NMR (376 MHz, DMSO-d6) δ−176.07 (s, 1F).
Step 7: 2-(2-((2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-4-fluoropyrrolidine-2-carboxamido)-6-bromopyridin-3-yl)acetic Acid (62)
To a solution of 61 (45 mg, 1 equiv) in methanol (6 mL) was added aqueous LiOH solution in water (3 mL, 1M, 1.2 equiv) and the reaction mixture was stirred at room temperature. After completion of the reaction, the reaction mixture was acidified with HCl (1N) and extracted with DCM (10 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness to afford 62 (15 mg, 34%). 1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H), 8.98 (s, 2H), 8.36 (s, 1H), 7.69-7.82 (m, 2H), 7.60 (d, 1H, J=8.2 Hz), 7.44 (d, 1H, J=8.2 Hz), 5.42-5.77 (m, 3H), 4.52-4.58 (m, 1H), 4.11-4.23 (m, 1H), 3.86-4.01 (m, 1H), 3.41 (s, 2H), 2.62 (s, 3H), 2.58 (s, 3H), 2.46-2.56 (m, 1H), 2.01-2.21 (m, 1H); 19F NMR (376 MHz, DMSO-d6) δ−176.12 (s, 1F).
Step-8: (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(2-(dimethylamino)-2-oxoethyl)pyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide (117)
To a solution of 62 (44 mg, 1.2 equiv), dimethyl amine hydrochloride (33 mg, 1.0 equiv), and DIPEA (0.08 mL, 5 equiv) in DMF (10 mL) was added HATU (32 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (20 mL) and water (10 mL). The aqueous layer was extracted with EtOAC (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 117 (32 mg, 50%). 1H NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 8.98 (s, 2H), 8.38 (s, 1H), 7.70-7.84 (m, 1H), 7.78 (s, 1H), 7.48 (d, 1H, J=8.0 Hz), 7.40 (d, 1H, J=8.0 Hz), 5.42-5.81 (m, 3H), 4.46-4.52 (m, 1H), 4.11-4.21 (m, 1H), 3.89-4.04 (m, 1H), 2.57 (s, 2H), 2.61 (s, 3H), 2.58 (s, 3H), 2.51 (s, 3H), 2.36 (s, 3H), 1.96-2.15 (m, 2H); 19F NMR (376 MHz, DMSO-d6) δ−175.89 (s, 1F).
Figure US11708351-20230725-C01131
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a substituted pyrimidine in the R32 position via a Suzuki cross-coupling reaction where the A-ring is functionalized with a boronic ester. The skilled artisan will recognize that the aryl halide 5-bromo-N-methylpyrimidin-2-amine shown above can be replaced with other aryl halides to afford additional compounds of the present invention. Non-limiting examples of aryl halides that the skilled artisan can use include 5-bromo-2-methylpyrimide.
Step 1: tert-Butyl 2-(3-acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (120-S3)
To a solution of 5-bromo-N-methylpyrimidin-2-amine (120-S2, 1 equiv) in DMF/H2O (9:1, 10 vol) was added compound 120-S1 (1 equiv), K2CO3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 120-S3.
Step 2: 2-(3-Acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (120-S4)
To a solution of compound 120-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-(methylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (120)
To a solution of compound 120-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon were added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 120. 1H NMR (400 MHz, DMSO-d6) δ 0.97-1.06 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53-2.58 (m, 1H), 2.65 (s, 3H), 2.87 (d, J=4.5 Hz, 3H), 3.55-3.64 (m, 1H), 4.33-4.47 (m, 1H), 5.55 (d, J=17.2 Hz, 1H), 5.88 (d, J=17.3 Hz, 1H), 7.26 (q, J=4.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.69-7.80 (m, 2H), 8.29 (s, 1H), 8.64 (s, 2H), 10.26 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CDCl3): δ 0.86-0.88 (m, 1H), 1.16 (t, J=5.2 Hz, 1H), 1.41 (s, 3H), 2.08 (s, 3H), 2.33 (t, J=8.8 Hz, 1H) 2.55 (s, 3H), 2.67 (d, J=13.2 Hz, 1H), 2.81 (s, 3H), 3.14 (d, J=2.8 Hz, 1H), 4.83 (d, J=6.4 Hz, 1H), 5.18 (s, 2H), 7.23 (d, J=8 Hz, 1H), 7.35 (d, J=8 Hz, 1H), 7.39 (d, J=8.4 Hz, 1H), 7.49 (dd, J=8.4, 1.2 Hz, 1H), 7.88 (s, 1H), 8.57 (brs, 1H), 8.65 (s, 1H), 8.94 (s, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(pyridin-4-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H), 8.66 (dd, J=4.5, 1.6 Hz, 2H), 8.52 (d, J=0.8 Hz, 1H), 7.91 (dd, J=8.9, 1.7 Hz, 1H), 7.85 (d, J=8.6 Hz, 1H), 7.76 (dd, J=4.5, 1.6 Hz, 2H), 7.63 (d, J=8.1 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.92 (d, J=17.3 Hz, 1H), 5.58 (d, J=17.2 Hz, 1H), 4.41 (m, 1H), 3.59 (m, 1H), 2.66 (s, 3H), 2.60-2.52 (m, 1H), 2.11-1.99 (m, 4H), 1.32 (s, 3H), 1.07-0.96 (m, 2H). LC/MS (ESI) m/z: 587/589 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(5-methylpyridin-2-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.28 (s, 1H), 8.86 (s, 1H), 8.54 (s, 1H), 8.19 (dd, J=8.9, 1.6 Hz, 1H), 7.92 (d, J=8.2 Hz, 1H), 7.75 (dd, J=16.9, 8.5 Hz, 2H), 7.62 (d, J=7.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.89 (d, J=17.3 Hz, 1H), 5.55 (d, J=17.1 Hz, 1H), 4.41 (dd, J=9.3, 5.1 Hz, 1H), 3.59 (dd, J=5.3, 2.4 Hz, 1H), 2.64 (d, J=6.6 Hz, 3H), 2.58-2.51 (m, 1H), 2.35 (s, 3H), 2.04 (s, 3H), 1.32 (s, 3H), 1.18-1.14 (m, 1H), 1.04-1.00 (m, 1H). LC/MS (ESI) m/z: 601/603 (M+H)+.
Figure US11708351-20230725-C01132
Figure US11708351-20230725-C01133
Step 1: 2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (123-S2)
Cs2CO3 (0.8 g) was added to a mixture of 2-(tert-butyl) 3-ethyl (1R,3S,5S)-5-(((methylsulfonyl)oxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (123-S1, 0.807 mmol) and N-methylhex-5-en-1-amine HCl salt (0.145 g, 0.968 mmol) in ACN (10 mL). The reaction was heated and stirred in the presence at 50° C. under argon overnight. EtOAC was added and the diluted reaction mixture was filtered through Celite to remove solids. Solvents were removed under reduced pressure and the residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford 2-(tert-butyl) 3-ethyl (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 123-S2 (0.193 g) as a yellowish oil.
Step 2: (1R,3S,5R)-5-((Hex-5-en-1-yl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (123-S3)
2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (123-S2, 0.193 g, 0.508 mmol) was dissolved in a mixture of THF-EtOH-water (3 mL-0.5 mL-0.5 mL) and treated with LiOH monohydrate (25.6 mg, 0.609 mmol). The reaction was stirred at room temperature for 24 hours before Amberlite (the weakly acidic cation exchanger H form, 1 g) was added. After stirred for 5 minutes, the reaction was filtered and the resulting resin was washed with MeOH. The combined filtrates were concentrated under reduced pressure to afford (1R,3S,5R)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 123-S3 (0.171 g) as a colorless amorphous solid.
Step 3: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (123-S5)
To a mixture of 123-S3 (171 mg, 0.486 mmol) and 123-S4 (77 mg, 0.389 mmol) in DCM (10 mL), pyridine (0.196 mL, 2.43 mmol) was added followed by POCl3 (0.045 mL, 0.486 mmol) at 0° C. under argon. The reaction mixture was stirred at room temperature for 2 hours. NaHCO3 aqueous solution was added and the mixture was extracted with DCM. After washing with brine, the organic layer was dried over anhydrous Na2SO4. The solution was filtered and the solvent was removed under reduced pressure. The remaining residue was purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford tert-butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 123-S5 (99 mg).
Step 4: (1R,3S,5R)—N-(6-Bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (123-S6)
tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (123-S5, 5.7 mg) in DCM (1 mL) was treated with TFA (1 mL) at room temperature. The reaction stirred for 1 hour before the volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 123-S6. The material was carried forward without additional purification.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (123)
To a mixture of (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 123-S6 and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (123-S7, 3.4 mg, 0.011 mmol) in DMF (0.5 mL), TBTU (7.1 mg) was added followed by DIEA (0.0096 mL) with stirring. After the reaction was complete, NaHCO3 aqueous solution (10 mL) was added to form a precipitate that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((hex-5-en-1-yl(methyl)amino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (123) (6.2 mg) as an off-white solid. 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.67 (s, 1H), 8.58 (dd, J=0.9, 1.6 Hz, 1H), 7.69-7.59 (m, 4H), 7.30 (d, J=8.1 Hz, 1H), 6.46 (dd, J=11.0, 17.4 Hz, 1H), 5.80 (ddt, J=6.7, 10.2, 16.9 Hz, 1H), 5.66 (dd, J=0.8, 17.4 Hz, 1H), 5.51 (d, J=1.1 Hz, 2H), 5.27 (d, J=11.1 Hz, 1H), 5.05-4.91 (m, 2H), 4.88 (d, J=8.6 Hz, 1H), 3.25 (dd, J=2.5, 5.8 Hz, 1H), 2.91 (t, J=14.1 Hz, 2H), 2.80 (s, 3H), 2.72 (s, 3H), 2.41 (tt, J=5.7, 13.0 Hz, 1H), 2.28 (s, 4H), 2.11-2.01 (m, 2H), 1.54-1.34 (m, 4H), 1.30 (s, 0H), 1.02 (dt, J=2.1, 4.1 Hz, 1H), 0.93-0.76 (m, 1H). LC (method A): tR=1.48 min. LC/MS (EI) m/z: [M+H]+ 725.
Figure US11708351-20230725-C01134
Figure US11708351-20230725-C01135
Step 1: 5-Bromo-1H-indazole-7-carboxamide (124-S2)
5-Bromo-1H-indazole-7-carboxylic acid (1 g) was dissolved in DMF (10 mL) and iPr2NEt (3.42 mL, 5 equiv) was added, followed by the addition of NH4Cl (1.2 g) at 5° C. HATU (1.8 g, 1.2 equiv) was added slowly at 5° C. and the reaction mixture was stirred overnight at room temperature. Then the reaction mixture was poured into water and the precipitate was isolated by filtration. The white solid was dried and carried forward without additional purification in the next step.
Step 2: 5-Bromo-1H-indazole-7-carbonitrile (124-S3)
To a heterogeneous mixture of 5-bromo-1H-indazole-7-carboxamide (0.6 g) in CH2Cl2 (6 mL) and pyridine (6 mL), TFAA (0.87 mL) was added dropwise. The resulting homogeneous solution was stirred for 10 minutes at room temperature. The volatiles were removed and the residue was poured into water (60 mL). The precipitated white product was isolated by filtration, washed with water, and dried in vacuo. The solid carried forward without additional purification in the next step.
Step 3: 5-(2-Methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (124-S4)
A mixture of 5-bromo-1H-indazole-7-carbonitrile (0.32 g equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.708 g), cesium carbonate (1.4 g) in dioxane (12 mL) and water (3.0 mL) was purged with argon in a pressure vessel for 5 minutes. PdCl2(dppf) (0.4 g) was added under argon and the pressure vessel was sealed and heated at 90° C. overnight. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The crude product was purified by silica gel flash column chromatography (eluent: 0-30% MeOH in CH2Cl2) to afford 0.24 g of 124-S4 as white solid.
Step 4: 3-Bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (124-S5)
To a stirred solution of 5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (0.24 g) in DMF (4 mL), NBS (0.2 g) was added. The reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was then poured into water and the precipitate was isolated by filtration, washed with water, and dried. The solid carried forward without additional purification in the next step.
Step 5: tert-Butyl 2-(3-bromo-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (124-S6)
A mixture of 3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazole-7-carbonitrile (0.3 g), tert-butyl bromoacetate (148 μl) and potassium carbonate (0.264 g) in anhydrous acetonitrile (5 mL) was refluxed for 2 hours. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5% MeOH in CH2Cl2) to afford 124-S6 as white foam.
Step 6: tert-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (124-S7)
A solution of tert-butyl 2-(3-bromo-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (0.06 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin (0.101 g, 2 equiv) and PdCI2(PPh3)2 (10 mg, 0.1 equiv) in DMF (5 mL) was heated at 80° C. overnight under an argon atmosphere. The reaction mixture was concentrated under reduced pressure, diluted with CH2Cl2, and washed with cold aqueous HCI (1N). The organic layer was dried (Na2SO4), filtered and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5% MeOH in CH2Cl2) to afford the title compound.
Step 7: 2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (124-S8)
tert-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (124-S7, 45 mg) was stirred in CH2Cl2 (0.5 mL) and TFA (1 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure and the remaining residue was carried forward without additional purification in the next synthetic step.
Step 8: (1R,3S,5R)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (124)
Compound 124-S8 was dissolved in DMF (1 mL) and iPr2NEt (60 μL, 3 equiv) was added, followed by the addition of the TFA salt of (1R,3S,5R)—N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (124-S9, obtained by stirring 47 mg of tert-butyl (1R,3S,5R)-3-((6-bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate in 0.5 mL of TFA and 0.5 mL of CH2Cl2 for 15 minutes at room temperature and evaporating the volatiles) at 5° C. HATU (48 mg, 1.2 equiv) was then added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.0% MeOH in CH2Cl2) to afford 124 as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 1.01-1.06 (m, 2H), 1.32 (s, 3H), 2.05 (s, 3H), 2.07 (t, J=5.6 Hz, 1H), 2.51-2.56 (m, 1H), 2.69 (s, 3H), 2.70 (s, 3H), 3.59 (t, J=3.8 Hz, 1H), 4.41 (dd, J=5.3, 9.1 Hz, 1H), 5.88 (d, J=17.9 Hz, 1H), 6.09 (d, J=17.9 Hz, 1H), 7.43 (d, J=7.8 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 8.52 (s, 1H), 8.78 (s, 1H), 9.12 (s, 2H), 10.26 (s, 1H).
Figure US11708351-20230725-C01136
Step 1: tert-Butyl 2-(3-acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (125-S3)
To a solution of 5-bromo-N,N-dimethylpyrimidin-2-amine (125-S2, 1 equiv) in DMF/H2O (9:1, 10 vol) was added compound (125-S1, 1 equiv), K2CO3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 125-S3.
Step 2: 2-(3-Acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (125-S4)
To a solution of compound 125-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without additional purification and used directly in the next synthetic step.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-(dimethylamino)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (125)
To a solution of compound 125-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 125. 1H NMR (400 MHz, DMSO-d6) δ 0.97-1.05 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53-2.58 (m, 1H), 2.65 (s, 3H), 3.19 (s, 6H), 3.54-3.62 (m, 1H), 4.41 (dd, J=5.1, 9.3 Hz, 1H), 5.55 (d, J=17.2 Hz, 1H), 5.88 (d, J=17.3 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.71-7.81 (m, 2H), 8.30 (s, 1H), 8.71 (s, 2H), 10.26 (s, 1H).
Figure US11708351-20230725-C01137
Figure US11708351-20230725-C01138
Step 1: 4-Bromo-2-methyl-6-(trifluoromethyl)aniline (133-S2)
To a solution of 133-S1 (1.0 g, 5.7 mmol) in MeCN (15 mL) was added N-bromosuccinimide (1.0 g, 5.7 mmol) in portions at 0° C. The reaction mixture was allowed to stir for 1 hour at room temperature. The reaction mixture was poured into water and extracted with EtOAc twice. The combined organics were washed with brine, dried over Na2SO4, filtered, and concentrated. The remaining residue was purified by chromatography on silica gel (eluted with PE) to afford 133-S2 (1.3 g, 90.3% yield) as a brown oil. LC/MS (ESI) m/z: 254 (M+H)+.
Step 2: 5-Bromo-7-(trifluoromethyl)-1H-indazole (133-S3)
To a mixture of 133-S2 (700 mg, 2.77 mmol) and potassium acetate (325.8 mg, 3.32 mmol) in CHCl3 (20 mL) was added dropwise acetic anhydride (846.6 mg, 8.30 mmol) at 0° C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60° C. and tert-butyl nitrite (570.6 mg, 5.54 mmol) was added. After stirring overnight at 60° C., the mixture was diluted with water and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was dissolved in MeOH (5 mL) and 6 N HCl (5 mL). The mixture was stirred at room temperature for 4 hours, basified with 10 N aqueous NaOH solution, and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc=10:1 to 3:1) to afford 133-S3 (420 mg, 57.5% yield) as a yellow oil. LC/MS (ESI) m/z: 265 (M+H)+.
Step 3: 5-Bromo-3-iodo-7-(trifluoromethyl)-1H-indazole (133-S4)
To a solution of 133-S3 (420 mg, 1.6 mmol) in DMF (6 mL) was added KOH (201.6 mg, 3.6 mmol) followed by I2 (605.7 mg, 2.4 mmol) in portions at 0° C. The resulting mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with 5% aqueous Na2S2O3 solution and brine, dried over anhydrous Na2SO4, and concentrated to afford 133-S4 (610 mg, 97.7% yield) as a yellow solid, which was carried forward without further purification. LC/MS (ESI) m/z: 391 (M+H)+.
Step 4: tert-Butyl 2-(5-bromo-3-iodo-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S5a) and tert-butyl 2-(5-bromo-3-iodo-7-(trifluoromethyl)-2H-indazol-2-yl)acetate (133-S5b)
To a solution of 133-S4 (610 mg, 1.57 mmol) in DMF (8 mL) was added K2CO3 (541.7 mg, 3.93 mmol) followed by tert-butyl 2-bromoacetate (399.8 mg, 2.05 mmol). The resulting mixture was stirred at room temperature overnight, diluted with water, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc=1:0 to 50:1 to 30:1) to afford 133-S5a (173 mg, 21.8% yield) and 133-S5b (433 mg, 54.7% yield) as light yellow solids. LC/MS (ESI) m/z: 505 (M+H)+.
Step 5: tert-Butyl 2-(3-acetyl-5-bromo-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S6)
To a solution of 133-S5a (144 mg, 0.28 mmol) in dry toluene (9 mL) were added tributyl(1-ethoxyvinyl)stannane (155 mg, 0.43 mmol) and Pd(PPh3)4 (33 mg, 0.028 mmol). The resulting mixture was stirred at 100° C. under an atmosphere of nitrogen overnight. The cooled reaction mixture was diluted with H2O and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The remaining crude product was dissolved in THF (0.5 mL) and 0.5 M HCl (5 mL) and stirred for 1.5 hours at room temperature. The reaction mixture was basified with 2 N aqueous NaOH solution and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc=50:1 to 30:1) to afford 133-S6 (86 mg, 71.4% yield) as a brown solid. LC/MS (ESI) m/z: 421 (M+H)+.
Step 6: tert-Butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetate (133-S7)
To a mixture of 133-S6 (86 mg, 0.2 mmol), (2-methylpyrimidin-5-yl)boronic acid (42 mg, 0.31 mmol), and K2CO3 (70 mg, 0.51 mmol) in 1,4-dioxane (5 mL) and H2O (1 mL) was added Pd(PPh3)4 (23 mg, 0.02 mmol). The reaction mixture was stirred at 90° C. under an atmosphere of nitrogen overnight. The mixture was filtered and the filtrate was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by chromatography on silica gel (PE/EtOAc=3:1 to 1:1) to afford 133-S7 (67 mg, 75.5% yield) as a yellow solid. LC/MS (ESI) m/z: 435 (M+H)+.
Step 7: 2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetic Acid (133-S8)
To a solution of 133-S7 (35 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 133-S8 (31 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 335 (M+H)+.
Step 8: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-7-(trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (133)
To a mixture of 133-S8 (26 mg, 0.07 mmol) and 133-S9 (23 mg, 0.07 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.22 mmol) followed by HATU (41.8 mg, 0.11 mmol) and the reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified by preparative HPLC to afford 133 (11.0 mg, 3.28% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.13 (s, 2H), 8.82 (s, 1H), 8.28 (s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.99 (d, J=18.1 Hz, 1H), 5.59 (d, J=17.9 Hz, 1H), 4.34-4.31 (m, 1H), 3.59-3.55 (m, 1H), 2.71 (d, J=2.1 Hz, 6H), 2.59-2.53 (m, 1H), 2.09-2.07 (m, 1H), 2.05 (s, 3H), 1.33 (s, 3H), 1.09-1.06 (m, 1H), 0.85-0.83 (m, 1H). LC/MS (ESI) m/z: 670 (M+H)+.
Figure US11708351-20230725-C01139
Figure US11708351-20230725-C01140
Step 1: 2-(tert-Butyl) 3-ethyl (1R,3S,5S)-5-formyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (134-S2)
To the solution of 2-(tert-butyl) 3-ethyl (1R,3S,5S)-5-(hydroxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (134-S1, 67 mg, 0.23 mmol) in DCM (4 mL), Dess-Martin reagent (0.31 mmol) was added at 0° C. under argon. The mixture was stirred for an additional 3 hours, the reaction was diluted with DCM (20 mL), and quenched with aqueous NaHCO3 (10%, 15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL×2). The DCM phase was combined, washed with brine, and dried over magnesium sulfate. The solution was filtered and concentrated to afford crude product 134-S2 (62 mg) that was carried forward without additional purification.
Step 2: 2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-vinyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (134-S3)
To the suspension of methyltriphenylphosphonium bromide (111 mg, 0.31 mmol) in 5 mL of dry THF, BuLi (0.31 mmol) was added dropwise at 0° C. under argon. The mixture was stirred for 1 hour and a solution of aldehyde 134-S2 (62 mg) in THF (2 mL) was added dropwise. The mixture was warmed to room temperature and stirred overnight. The reaction was quenched with water (10 ml) and extracted with EtOAc (15 mL×3). The organic phases were combined, washed with brine and dried over magnesium sulfate. The solution was filtered, concentrated and purified to afford 134-S3 (31 mg). 1H NMR (400 MHz, CDCl3) δ 0.89-0.94 (m, 1H), 1.04-1.08 (m, 1H), 1.28 (t, J=7.2 Hz, 3H), 1.44 (s, 9H), 2.32 (dd, J=13.2, 7.0 Hz, 1H), 2.43 (dd, J=13.1, 8.8 Hz, 1H), 3.43 (s, 1H), 3.97-4.09 (m, 1H), 4.16-4.26 (m, 2H), 4.99 (d, J=7.8 Hz, 1H), 5.02 (s, 1H), 5.70 (dd, J=17.0, 10.7 Hz, 1H) ppm.
Step 3: (1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (134-S4)
Compound 134-S3 (31 mg, 0.11 mmol) was dissolved in a mixture of CH3OH-THF—H2O (2 mL-2 mL-2 mL) and treated with LiOH (24 mg). The reaction mixture was stirred overnight at room temperature. The volatiles were evaporated under reduced pressure and the remaining residue was acidified with 10% citric acid (10 mL). The mixture was extracted with EtOAc (15 mL×3) and the combined organic layers were washed with water and brine and dried over MgSO4. The solution was concentrated and the residue (134-S4, 26 mg) was dried and carried forward without additional purification.
Step 4: tert-Butyl (1R,3S,5R)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (134-S5)
(1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (134-S4, 26 mg, 0.10 mmol) and 3-((allyloxy)methyl)-6-bromopyridin-2-amine (27 mg, 0.11 mmol) were dissolved in anhydrous DCM (5 mL) in a pre-dried flask. The flask was cooled in an ice bath and dry pyridine (0.25 mL, 3.0 mmol) was added in one portion, followed by POCl3 (100 μL, 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0° C., and the reaction was quenched with water (15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL×2). The combined DCM solutions were washed with brine, and dried over MgSO4. The solution was filtered and concentrated and the resulting residue was purified to afford 134-S5 (35 mg).
Step 5: (1R,3S,5R)—N-(3-((Allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (134-S6)
tert-Butyl (1R,3S,5R)-3-((3-((allyloxy)methyl)-6-bromopyridin-2-yl)carbamoyl)-5-vinyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (134-S5, 28 mg, 0.058 mmol) was taken up in 4N HCl dioxane (2.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue 134-S6 was used carried forward without additional purification.
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (134)
To the solution of (1R,3S,5R)—N-(3-((allyloxy)methyl)-6-bromopyridin-2-yl)-5-vinyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (134-S6, 0.058 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (134-S7, 18 mg, 0.058 mmol) in DMF (2.0 mL), HATU (33 mg, 0.087 mmol) was added, followed by the dropwise addition of DIEA (5.0 eq) at room temperature. The mixture was stirred for 1 hour at room temperature and then the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solutions were successively washed with water and brine and dried over MgSO4. The solution was filtered and the solvent was removed. The residue was purified to afford 134 (8.1 mg). 1H NMR (400 MHz, DMSO-d6): (major rotamer) δ 1.21-1.25 (m, 1H), 1.35-1.41 (m, 1H), 2.37-2.44 (m, 1H), 2.52-2.57 (m, 1H), 2.65 (s, 3H), 2.69 (s, 3H), 3.62-3.79 (m, 2H), 3.87-3.93 (m, 1H), 4.20 (d, J=3.2 Hz, 2H), 4.42-4.46 (m, 1H), 4.96-5.23 (m, 4H), 5.60 (d, J=17.3 Hz, 1H), 5.65-5.79 (m, 1H), 5.84 (dd, J=17.3, 10.6 Hz, 1H), 5.95 (d, J=17.3 Hz, 1H), 7.54 (d, J=8.1 Hz, 1H), 7.78 (d, J=8.1 Hz, 1H), 7.86 (s, 2H), 8.44 (s, 1H), 9.03 (s, 2H), 10.48 (s, 1H) ppm. LC (method A): tR=2.15 min. LC/MS (EI) m/z: [M+H]+ 670.20, 672.16
Figure US11708351-20230725-C01141
Step 1: 6-Bromo-3-((dimethylamino)methyl)pyridin-2-amine (135-S2)
To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (133 mg, 1 equiv) in acetonitrile (10 mL) was added triethyl amine (0.3 mL, 3 equiv) and dimethyl amine hydrochloride (84 mg, 2 equiv) at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature before the reaction was diluted with DCM (10 mL) and basified with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (2×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4 and concentrated to dryness to afford 135-S2 (100 mg, 99%).
Step 2: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (135-S3)
POCl3 was added dropwise (0.08 mL, 2 equiv) at 0-5° C. under an atmosphere of argon to a stirred solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (106 mg, 1 equiv) and 135-S2 (100 mg, 1 equiv) in DCM (20 mL) and pyridine (0.18 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion before it was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 135-S3 (169 mg, 85%).
Step 3: (1R,3S,5R)—N-(6-Bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (135-S4) and (1R,3S,5R)—N-(6-Chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (136-S5)
To a solution of 135-S3 (169 mg) was added 4N HCl in dioxane (15 mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 135-S4 (133 mg).
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3-bromoisoquinolin-1-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (91) and (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (135)
HATU (233 mg, 1.2 equiv) was added at 0° C. under an atmosphere of argon to a solution of 135-S4 and 135-S5 (133 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (158 mg, 1.2 equiv), and DIPEA (0.53 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine (3×25 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by reverse phase chromatography on C18 (YMC pack, eluted with acetonitrile and water to afford 91 (60 mg, 24%) and 135 (15 mg).
Compound 91
1H NMR (400 MHz, DMSO-d6) δ 10.86 (s, 1H), 9.07 (s, 2H), 8.46 (s, 1H), 7.86-7.91 (m, 3H), 7.72 (d, 1H, J=8.3 Hz), 6.01 (d, 1H, J=17.1 Hz), 5.65 (d, 1H, J=17.1 Hz), 4.27 (t, 1H, J=8.5 Hz), 3.92-4.02 (m, 2H), 3.70-3.74 (m 1H), 2.71 (s, 3H), 2.66 (s, 3H), 2.54-2.61 (m, 1H), 2.32 (s, 3H), 2.16 (s, 3H), 1.98-2.05 (m, 1H), 1.35 (s, 3H), 0.96-1.07 (m, 2H).
Compound 135
1H NMR (400 MHz, DMSO-d6) δ 10.81 (s, 1H), 9.09 (s, 2H), 8.48 (s, 1H), 8.00 (d, 1H, J=8.4 Hz), 7.87-7.95 (m, 2H), 7.60 (d, 1H, J=8.4 Hz), 6.02 (d, 1H, J=16.8 Hz), 5.65 (d, 1H, J=16.8 Hz), 4.27 (t, 1H, J=8.2 Hz), 3.94-4.04 (m, 2H), 3.69-3.74 (m, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.54-2.61 (m, 1H), 2.31 (s, 3H), 2.16 (s, 3H), 1.98-2.05 (m, 1H), 1.35 (s, 3H), 0.95-1.07 (m, 2H).
Figure US11708351-20230725-C01142
Step 1: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (136) and (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-((dimethylamino)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (137)
HATU (100 mg, 1.2 equiv) was added at 0° C. under an atmosphere of argon to a solution of 136-S1 and 137-S2 (84 mg, 1 equiv), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (71 mg, 1 equiv), DIPEA (0.2 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (30 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (15 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by C18 HPLC column chromatography (eluted by ACN/water/TFA=20:80:0.1) to afford 136 (48 mg) and 137 (32 mg).
Compound 136
1H NMR (400 MHz, DMSO-d6) δ 10.89 (s, 1H), 9.06 (s, 2H), 8.33 (s, 1H), 7.95 (d, 1H, J=8.5 Hz), 7.72 (d, 11H, J=8.5 Hz), 7.65 (s, 1H), 6.13 (d, 11H, J=18.1 Hz), 5.73 (d, 1H, J=18.1 Hz), 4.26-4.31 (m, 1H), 3.91-4.03 (m, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 2.65 (s, 3H), 2.54-2.61 (m, 1H), 2.27 (s, 3H), 2.14 (s, 3H), 1.97-2.00 (m, 1H), 1.35 (s, 3H), 0.96-1.00 (m, 2H).
Compound 137
1H NMR (400 MHz, DMSO-d6): δ 10.85 (s, 1H), 9.05 (s, 2H), 8.34 (s, 1H), 7.99 (d, 1H, J=8.0 Hz), 7.65 (s, 1H), 7.59 (d, 1H, J=8.0 Hz), 6.13 (d, 1H, J=17.9 Hz), 5.72 (d, 1H, J=17.9 Hz), 4.25-4.31 (m, 1H), 3.94-4.03 (m, 3H), 2.73 (s, 3H), 2.70 (s, 3H), 2.66 (s, 3H), 2.55-2.60 (m, 1H), 2.28 (s, 3H), 2.15 (s, 3H), 1.96-2.06 (m, 1H), 1.35 (s, 3H), 0.97-1.03 (m, 2H).
Figure US11708351-20230725-C01143
Step 1: 6-Bromo-3-(morpholinomethyl)pyridin-2-amine (139-S2)
To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (241 mg, 1 equiv) and triethyl amine (0.48 mL, 3 equiv) in acetonitrile (20 mL) was added morpholine (162 mg, 2 equiv) at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (25 mL) and basified with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (2×10 mL) and the combined organic layers were washed with brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 139-S2 (215 mg, 85%).
Step 2: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-(morpholinomethyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (139-S3)
POCl3 was added dropwise (0.03 mL, 2 equiv) at 0-5° C. under an atmosphere of argon to a stirred solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (69 mg, 1 equiv) and 139-S2 (78 mg, 1 equiv) in DCM (10 mL) and pyridine (0.12 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction mixture was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 139-S3 (87 mg, 70%).
Step 3: (1R,3S,5R)—N-(6-Bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (138-S4) and (1R,3S,5R)—N-(6-Chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (139-S5)
To a solution of 139-S3 (87 mg) was added 4N HCl in dioxane (10 mL) and the resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 138-S4 and 139-S5.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (138) and (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-chloro-3-(morpholinomethyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (139)
HATU (68 mg, 1.2 equiv) was added at 0° C. under an atmosphere of argon to a solution of 138-S4 and 139-S5 (65 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (47 mg, 1.05 equiv), and DIPEA (0.13 mL, 5 equiv) in DMF (10 mL). The reaction mixture was stirred at room temperature for 3 hours before the reaction mixture was diluted with EtOAc (35 mL) and water (15 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by HPLC column chromatography on C18 (eluted with ACN/water/TFA=20/80/0.1) to afford 138 (30 mg) and 139 (12 mg).
Compound 138
1H NMR (400 MHz, DMSO-d6): δ 10.72 (s, 1H), 8.97 (s, 2H), 8.39 (s, 1H), 7.70-7.89 (m, 3H), 7.57 (s, 1H), 5.98 (d, 1H, J=17.5 Hz), 5.55 (d, 1H, J=17.5 Hz), 4.13-4.27 (m, 1H), 3.86-4.02 (m, 4H), 3.63-3.73 (m, 1H), 2.62 (s, 3H), 2.59 (s, 3H), 2.46-2.52 (m, 1H), 2.33 (s, 2H), 2.11-2.24 (m, 4H), 1.89-2.09 (m, 1H), 1.26 (s, 3H), 0.87-0.99 (m, 2H).
Compound 139
1H NMR (400 MHz, DMSO-d6): δ 10.69 (s, 1H), 8.98 (s, 2H), 9.33 (s, 1H), 8.38 (s, 1H), 7.79-7.93 (m, 3H), 7.46 (s, 1H), 5.96 (d, 1H, J=17.2 Hz), 5.55 (d, 1H, J=17.2 Hz), 4.14-4.32 (m, 1H), 3.80-4.02 (m 1H), 3.57-3.69 (m, 4H), 3.06 (s, 2H), 2.62 (s, 3H), 2.59 (s, 3H), 2.47-2.52 (m, 1H), 1.92-2.13 (m, 5H), 1.28 (s, 3H), 0.89-0.99 (m, 2H).
Figure US11708351-20230725-C01144
Figure US11708351-20230725-C01145
Step 1: tert-Butyl 2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (144-S2)
A sealable vial was charged with 144-S1 (50 mg, 0.112 mmol), Zn(CN)2 (53 mg, 0.449 mmol), Pd(PPh3)4 (7 mg, 0.056 mmol), and toluene (3 mL) under an atmosphere of nitrogen. The vial was sealed and irradiated in the microwave reactor at 150° C. for 2 hours. The mixture was diluted with EtOAc and filtered. The filtrate was concentrated and the remaining residue was purified by preparative TLC to afford 144-S2 (42 mg, 95.9% yield) as a white solid. LC/MS (ESI) m/z: 392 (M+H)+.
Step 2: 2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (144-S3)
To a solution of 144-S2 (42 mg, 0.102 mmol) in DCM (1 mL) was added TFA (1 mL). The resulting mixture was stirred at room temperature for 2 hours and concentrated to afford 144-S3 (36 mg, 100% yield) as a white solid, which was carried forward in the next synthetic step without purification. LC/MS (ESI) m/z: 336 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (143) and (1S,3S)-2-(2-(3-acetyl-7-cyano-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (144)
To a solution of 144-S3 (35 mg, 0.093 mmol), 144-S4 (37 mg, 0.093 mmol), and DIPEA (40 mg, 0.279 mmol) in DMF (1 mL) at room temperature was added HATU (79 mg, 0.186 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 5% aqueous LiCl solution and brine, dried over Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by preparative HPLC to afford 143 (3 mg, yield 4.8% yield) and 144 (1 mg, 1.6% yield) as white solids.
Compound 143
1H NMR (400 MHz, CD3OD) δ 9.06 (s, 2H), 8.89 (d, J=1.6 Hz, 1H), 8.32 (d, J=1.6 Hz, 1H), 7.59 (d, J=8.1 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 6.08 (d, J=17.8 Hz, 1H), 6.00 (d, J=17.8 Hz, 1H), 4.73 (m, 1H), 3.89-3.84 (m, 1H), 3.50 (m, 2H), 3.13 (d, J=14.0 Hz, 1H), 2.90 (s, 6H), 2.79 (s, 3H), 2.73 (s, 3H), 2.62 (m, 1H), 2.15 (s, 3H), 1.58 (d, J=3.1 Hz, 1H), 1.50 (m, 1H). LC/MS (ESI) m/z: 670 (M+H)+.
Compound 144
1H NMR (400 MHz, CD3OD) δ 9.07 (s, 2H), 8.90 (d, J=1.6 Hz, 1H), 8.34 (d, J=1.6 Hz, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 6.18 (d, J=17.7 Hz, 1H), 5.90 (d, J=17.6 Hz, 1H), 5.19 (m, 1H), 4.00 (m, 1H), 3.70 m, 1H), 3.50 (m, 1H), 3.21-3.15 (m, 1H), 2.98 (s, 6H), 2.79 (s, 3H), 2.73 (s, 3H), 2.62 (m, 1H), 2.19-2.08 (m, 3H), 1.90 (s, 1H), 1.42 (m, 1H). LC/MS (ESI) m/z: 670 (M+H)+.
Figure US11708351-20230725-C01146
Figure US11708351-20230725-C01147
Step 1: 5-Bromo-4-fluoro-1H-indazole-3-carbonitrile (145-S2)
To a solution of 145-S1 (800 mg, 2.346 mmol) in DMA (8 mL) was added Zn powder (18 mg, 0.28200 mmol), Zn(CN)2 (138 mg, 1.173 mmol), dppf (52 mg, 0.094 mmol), Pd2(dba)3 (43 mg, 0.0469 mmol) and the mixture was purged with nitrogen. The reaction mixture was heated at 100° C. overnight under an atmosphere of nitrogen. The solution was cooled to room temperature and partitioned between EtOAc and 0.5 N aqueous HCl. The organic phase was washed twice with 0.5 N aqueous HCl and brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=5:1) to afford 145-S2 (469 mg, 83.3% yield) as a white solid. LC/MS (ESI) m/z: 240 (M+H)+.
Step 2: 5-Bromo-4-fluoro-1H-indazole-3-carboxamide (145-S3)
To a solution of 145-S2 (469 mg, 1.95 mmol) in MeOH (25 mL) at 0° C. was added an ice-cooled solution of urea hydrogen peroxide (1.8 g, 19.54 mmol) in 1 N aqueous NaOH solution (25 mL, 19.54 mmol) and the reaction mixture was stirred at room temperature overnight. The mixture was concentrated to half volume and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to dryness to afford 145-S3 (270 mg, 54% yield) as a white solid. LC/MS (ESI) m/z: 258 (M+H)+.
Step 3: tert-Butyl 2-(5-bromo-3-carbamoyl-4-fluoro-1H-indazol-1-yl)acetate (145-S4)
To a solution of 145-S3 (270 mg, 1.05 mmol) in DMF (2 mL) were added tert-butyl 2-bromoacetate (0.18 mL, 1.26 mmol) and K2CO3 (363 mg, 2.625 mmol). The mixture was stirred at room temperature overnight. The mixture was diluted water, extracted with EtOAc, washed with 10% aqueous LiCl solution and brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=1:1) to afford 145-S4 (210 mg, 53.7% yield) as a white solid. LC/MS (ESI) m/z: 372 (M+H)+.
Step 4: tert-Butyl 2-(3-carbamoyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (145-S5)
To a solution of 145-S4 (41 mg, 0.11 mmol) and 2-methylpyrimidin-5-ylboronic acid (18 mg, 0.13 mmol) in DMF (2 mL) was added K3PO4 (0.17 mL, 2 N, 0.33 mmol) and Pd(dppf)Cl2 (4 mg, 0.005 mmol) under an atmosphere of nitrogen. The reaction mixture was further purged with nitrogen and stirred at 100° C. for 3 hours. The mixture was poured into ice water and extracted with EtOAc, washed with 10% aqueous LiCl solution and brine, and dried over Na2SO4. The mixture was filtered and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=50:1) to afford 145-S5 (32 mg, 76% yield) as a white solid. LC/MS (ESI) m/z: 386 (M+H)+.
Step 5: 2-(3-Carbamoyl-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (145-S6)
To a solution of 145-S5 in DCM (2 mL) was added TFA (1 mL) at 0° C. and the reaction mixture was stirred at room temperature for 3 hours. The mixture was concentrated to dryness under reduced pressure to afford 145-S6 (32 mg, 100% yield), which was carried forward in the next synthetic step without further purification LC/MS (ESI) m/z: 330 (M+H)+.
Step 6: 1-(2-((1R,3S,5R)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-4-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (145)
To a mixture of 145-S6 (32 mg, 0.097 mmol), 145-S7 (52 mg, 0.126 mmol), and HATU (74 mg, 0.194 mmol) in DMF (1 mLl) was added DIPEA (0.1 mL, 0.582 mmol) and the reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford 145 (7 mg, 12% yield) as a light a yellow solid. 1H NMR (400 MHz, CD3OD) δ 8.93 (s, 2H), 7.64-7.53 (m, 3H), 7.38 (d, J=8 Hz, 1H), 5.76-5.59 (m, 2H), 4.54-4.50 (m, 1H), 3.53-5.50 (m, 1H), 2.73 (s, 3H), 2.65-2.58 (m, 1H), 2.32-2.27 (m, 1H), 2.12 (s, 3H), 1.40 (s, 3H), 1.07 (t, J=5.6 Hz, 1H), 0.97-0.95 (m, 1H). LC/MS (ESI) m/z: 621 (M+H)+.
Figure US11708351-20230725-C01148
Figure US11708351-20230725-C01149
Figure US11708351-20230725-C01150
Step 1: Methyl 5-bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-7-carboxylate (146-S2)
To a solution of 146-S1 (765 mg, 3 mmol) in dry THF (2 mL) was added NaH (144 mg, 3.6 mmol, 60% dispersion in mineral oil) at 0° C. The reaction mixture was stirred at 0° C. for 30 minutes, SEMCl (648 mg, 3.9 mmol) was added into the above mixture, and the resulting mixture was stirred at room temperature for 2 hours. The mixture was then quenched with saturated NH4Cl solution and extracted with EtOAc. The organic layer was separated, dried over Na2SO4, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:0 to 7:1) to afford 146-S2 (750 mg, 65.1% yield) as a white solid. LC/MS (ESI) m/z: 385 (M+H)+.
Step 2: (5-Bromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methanol (146-S3)
To a solution of 146-S2 (750 mg, 1.95 mmol) in dry THF (20 mL) was added LiAlH4 (148 mg, 3.5 mmol) at 0° C. in small portions. The reaction mixture was stirred at 0° C. for 30 minutes and then warmed to room temperature for 1 hour. The mixture was then quenched slowly with water (0.75 mL), 10% aqueous NaOH solution (1.5 mL), and water (2.25 mL). The resulting mixture was filtered and the filtrate was diluted with EtOAc, dried over Na2SO4, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EA=100:1 to 5:1) to afford 146-S3 (494 mg, 71.1% yield) as a colorless oil. LC/MS (ESI) m/z: 357 (M+H)+.
Step 3: (5-(2-Methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-7-yl)methanol (146-S4)
To a solution of 146-S3 (494 mg, 1.384 mol) in 1,4-dioxane/H2O (28 mL, 6:1) was added 2-methylpyrimidin-5-ylboronic acid (210 mg, 1.52 mmol), K2CO3 (573 mg, 4.152 mmol), and Pd(PPh3)4 (128 mg, 0.111 mmol). The reaction mixture was stirred at 95° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was diluted with water and extracted with DCM/MeOH (20:1). The organic layer was separated, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH=100:0 to 50:1) to afford 146-S4 (288 mg, 56.2% yield) as a colorless oil. LC/MS (ESI) m/z: 371 (M+H)+.
Step 4: 5-(2-Methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-7-carbaldehyde (146-S5)
To a solution of 146-S4 (240 mg, 0.65 mmol) in CHCl3 (12 mL) was added MnO2 (565 mg, 6.5 mmol). The reaction mixture was stirred at room temperature for 3 hours. The mixture was then filtered and the filtrate was concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/EtOAc=100:1 to 8:1) to afford 146-S5 (150 mg, 62.7% yield) as a colorless oil. LC/MS (ESI) m/z: 369 (M+H)+.
Step 5: 7-(Difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole (146-S6)
To a solution of 146-S5 (150 mg, 0.41 mmol) in dry DCM (10 mL) was added DAST (198 mg, 1.23 mmol) at 0° C. slowly under an atmosphere of nitrogen. The resulting mixture was stirred from 0° C. to room temperature for 1 hour and then heated to 40° C. for 24 hours. The mixture was then quenched with saturated aqueous NaHCO3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to dryness. The remaining residue was purified by preparative TLC (eluted with DCM/MeOH=20:1) to afford 146-S6 (92 mg, 58.2% yield) as a colorless oil. LC/MS (ESI) m/z: 391 (M+H)+.
Step 6: 7-(Difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole (146-S7)
To a solution of 146-S6 (92 mg, 0.24 mmol) in dry DCM (2 mL) was added TFA (2 mL) at room temperature under an atmosphere of nitrogen. The resulting mixture was stirred at room temperature for 2 hours. The mixture was then concentrated to afford 146-S7 (62 mg, 68.8% yield) as a colorless oil. LC/MS (ESI) m/z: 261 (M+H)+.
Step 7: 7-(Difluoromethyl)-3-iodo-5-(2-methylpyrimidin-5-yl)-1H-indazole (146-S8)
To a solution of 146-S7 (62 mg, 0.24 mmol) in DMF (5 mL) were added KOH (41 mg, 0.72 mmol) and I2 (92 mg, 0.36 mmol) at 0° C. The mixture was stirred at room temperature for 16 hours. The mixture was then quenched with 5% aqueous Na2S2O3 solution and extracted with EtOAc. The organic layer was separated, dried, and concentrated to afford 146-S8 (85 mg, 91.7% yield) as a colorless oil. LC/MS (ESI) m/z: 387 (M+H)+.
Step 8: tert-Butyl 2-(7-(difluoromethyl)-3-iodo-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (146-S9)
To a solution of 146-S8 (85 mg, 0.22 mmol) in DMF (6 mL) were added K2CO3 (61 mg, 0.44 mmol) and tert-butyl 2-bromoacetate (65 mg, 0.33 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution, dried, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:0 to 4:1) to afford 146-S9 (66 mg, 60.0% yield) as a colorless oil. LC/MS (ESI) m/z: 501 (M+H)+.
Step 9: tert-Butyl 2-(3-acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (146-S10)
To a mixture of 146-S9 (66 mg, 0.132 mmol) in dry toluene (8 mL) were added tributyl(1-ethoxyvinyl)stannane (67 mg, 0.185 mmol) and Pd(PPh3)4 (13 mg, 0.01 mmol). The reaction mixture was stirred at 100° C. for 16 hours under an atmosphere of nitrogen. After cooling, the mixture was quenched with 1 N aqueous HCl solution and the mixture was stirred at room temperature for 15 minutes. The mixture was extracted with EtOAc and the organic layer was washed with brine, dried over Na2SO4, filtered, and concentrated to afford the crude product, which was purified by column chromatography on silica gel (eluted with DCM/MeOH=100:0 to 50:1) to afford 146-S10 (52 mg, 92.8% yield) as a colorless oil. LC/MS (ESI) m/z: 417 (M+H)+.
Step 10: 2-(3-Acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (146-S11)
To a mixture of 146-S10 (52 mg, 0.13 mmol) in THF/H2O (8 mL, 3:1, v/v) was added LiOH·H2O (12 mg, 0.26 mmol). The reaction mixture was stirred at room temperature for 20 hours. The mixture was diluted with water, washed with ether, and the aqueous layer was acidified with aqueous HCl solution (1 N) to pH 5. The resulting mixture was extracted with DCM/MeOH (5 mL×2, 10:1 v/v). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford 146-S11 (36 mg, yield 76.9%) as a white solid. LC/MS (ESI) m/z: 361 (M+H)+.
Step 11: (1R,3S,5R)-2-(2-(3-Acetyl-7-(difluoromethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (146)
To a solution of 146-S11 (36 mg, 0.1 mmol), 146-S12 (45 mg, 0.13 mmol), and HATU (57 mg, 0.15 mmol) in DMF (2 mL) was added DIPEA (40 mg, 0.3 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was then diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified via preparative HPLC to afford 146 (15 mg, 23.0% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.29 (s, 1H), 9.10 (s, 2H), 8.72 (s, 1H), 8.17 (s, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.27-7.55 (m, 2H), 5.95 (d, J=18.0 Hz, 1H), 5.72 (d, J=17.7 Hz, 1H), 4.35 (dd, J=9.1, 5.2 Hz, 1H), 3.53-3.58 (m, 1H), 2.71 (s, 3H), 2.69 (s, 3H), 2.53-2.59 (m, 1H), 2.05 (s, 3H), 1.96-2.03 (m, 1H), 1.33 (s, 3H), 1.02-1.07 (m, 1H), 0.87-0.94 (m, 1H). LC/MS (ESI) m/z: 652 (M+H)+.
Figure US11708351-20230725-C01151
Figure US11708351-20230725-C01152
Step 1: 7-Fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (147-S2)
A mixture of 5-bromo-7-fluoro-1H-indazole (0.32 g equiv), 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (0.384 g), cesium carbonate (1.14 g) in dioxane (8 mL) and water (2.0 mL) was purged with argon in a pressure vessel for 5 minutes. PdCl2(dppf) (0.190 g) was added under argon and the pressure vessel was sealed and heated at 90° C. overnight. The reaction mixture was cooled to room temperature and poured into water. The precipitated product was isolated by filtration, washed with water, and dried. The material was carried forward without additional purification and used directly in the next step.
Step 2: 3-Bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (147-S3)
To a stirred solution of 7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.39 g) in DMF (5 mL), NBS (0.335 g) was added. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was poured into water and the precipitate was isolated by filtration, washed with water, and dried. The material was carried forward without additional purification and used directly in the next step.
Step 3: tert-Butyl 2-(3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (147-S4)
A mixture of 3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazole (0.36 g), tert-butyl bromoacetate (181 μL), and potassium carbonate (0.323 g) in anhydrous acetonitrile (5 mL) and DMF (2 mL) was refluxed for 1 hour. The reaction mixture was then cooled to room temperature and the solvent was removed under reduced pressure. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5% MeOH in CH2Cl2) to afford 147-S4 as white solid.
Step 4: tert-Butyl 2-(3-acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (147-S5)
A solution of tert-butyl 2-(3-bromo-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (0.25 g 1 equiv), tri-butyl(1-ethoxyvinyl)tin 0.429 g, 2 equiv) and PdCI2(PPh3)2 (42 mg, 0.1 equiv) in DMF (3 mL) was heated at 80° C. overnight under argon atmosphere. Then concentrated under reduced pressure and diluted with CH2Cl2 and washed with cold aqueous HCI (1N). The organic layer was dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-1.5% MeOH in CH2Cl2) to afford 147-S5.
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (147)
tert-Butyl 2-(3-acetyl-7-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (70 mg) was stirred in CH2Cl2 (0.5 mL) and TFA (1.5 mL). After completion of the reaction (monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue was dissolved in DMF (1 mL) and iPr2NEt (95 μL, 3 equiv) was added, followed by the addition of the TFA salt of (1R,3S,5R)—N-(6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (obtained by stirring 74 mg of tert-butyl (1R,3S,5R)-3-((6-bromopyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate in 1 mL of TFA and 1 mL of CH2Cl2 for 15 minutes at room temperature and evaporating the volatiles) at 5° C. HATU (76 mg, 1.2 equiv) was added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. Then the reaction mixture was poured into water and the precipitate was isolated by filtration. The solid was dried and purified by silica gel flash column chromatography (eluent: 0-2.5% MeOH in CH2Cl2) to afford 147 as a light yellow solid. 1H NMR (400 MHz, DMSO-d6) δ 0.84-0.91 (m, 1H), 1.05 (t, J=5.4 Hz, 1H), 1.32 (s, 3H), 2.05 (s, 3H), 2.03-2.07 (m, 1H), 2.52-2.58 (m, 1H), 2.67 (s, 3H), 2.69 (s, 3H), 3.56 (d, J=4 Hz, 1H), 4.41 (dd, J=5.2, 9.2 Hz, 1H), 5.65 (d, J=17.4 Hz, 1H), 5.90 (d, J=17.4 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.79 (d, J=12.7 Hz, 1H), 8.28 (s, 1H), 9.06 (s, 2H), 10.26 (s, 1H). 19F NMR (DMSO-d6): δ−131.6.
Figure US11708351-20230725-C01153
Figure US11708351-20230725-C01154
Step 1: tert-Butyl 2-(3-acetyl-5-(2-(2-methoxy-2-oxoethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (148-S3)
To a solution of methyl 2-(5-bromopyrimidin-2-yl)acetate (148-S2, 1 equiv) in DMF/H2O (9:1, 10 vol) was added compound 148-S1 (1 equiv), K2CO3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 148-S3.
Step 2: 2-(3-Acetyl-5-(2-(2-methoxy-2-oxoethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (148-S4)
To a solution of compound 148-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without further purification and used directly in the next synthetic step.
Step 3: Methyl 2-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)acetate (148-S6)
To a solution of compound 148-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (148-S5, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 148-S6.
Step 4: 2-(5-(3-Acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)acetic Acid (148-S7)
To a solution of methyl 2-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)acetate (148-S6, 1 equiv) in THF/H2O (3:1, 10 vol) was added LiOH (2.1 equiv). The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure. The remaining residue was neutralized using 2N HCl and the precipitated solid was filtered, dried, and directly used in the next synthetic step.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-(2-(dimethylamino)-2-oxoethyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (148)
To a solution of compound 148-S7 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added dimethylamine hydrochloride (1.2 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 148. 1H NMR (400 MHz, DMSO-d6) δ 0.98-1.06 (m, 2H), 1.33 (s, 3H), 2.05 (s, 4H), 2.53-2.59 (m, 1H), 2.67 (s, 3H), 2.88 (s, 3H), 3.07 (s, 3H), 3.55-3.68 (m, 1H), 4.08 (s, 2H), 4.37-4.47 (m, 1H), 5.59 (d, J=17.2 Hz, 1H), 5.92 (d, J=17.2 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.87 (t, J=6.5 Hz, 2H), 8.47 (s, 1H), 9.10 (s, 2H), 10.26 (s, 1H).
Figure US11708351-20230725-C01155
Figure US11708351-20230725-C01156
Step 1: (5R,3S,5R)-tert-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S2)
To a mixture of 153-S1 (290 mg, 0.75 mmol) and 6-bromo-3-(methoxymethyl)pyridin-2-amine (162 mg, 0.75 mmol) in dry DCM (3 mL) was added pyridine (0.3 mL, 3.75 mmol) followed by POCl3 (114.7 mg, 0.75 mmol) at 0° C. The reaction mixture was stirred at room temperature for 30 minutes. The mixture was poured into ice water and extracted with DCM twice. The organic layers were washed with brine, dried over Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (PE/EtOAc=6:1 to 2:1) to afford 153-S2 (180 mg, 41.0% yield) as a white solid. LC/MS (ESI) m/z: 585 (M+H)+.
Step 2: (1R,3S,5R)-tert-Butyl 5-(aminomethyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S3)
To a solution of 153-S2 (180 mg, 0.31 mmol) in EtOH (3 mL) was added hydrazine hydrate (72.5 mg, 1.24 mmol). The reaction mixture was stirred at 75° C. for 2 hours and then cooled to room temperature. The mixture was filtered and the filtrate was concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=5:1) to afford 153-S3 (130 mg, 92.2% yield) as a white solid. LC/MS (ESI) m/z: 455/(M+H)+.
Step 3: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-(((S)-2-((methoxycarbonyl)amino)-3-methylbutanamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (153-S4)
To a mixture of 153-S3 (30 mg, 0.066 mmol), (S)-2-(meth oxycarbonylamino)-3-methylbutanoic acid (13.9 mg, 0.079 mmol), and HATU (37.6 mg, 0.099 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.198 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc=2:1 to 0:1) to afford 153-S4 (29 mg, 72.0% yield) as a light oil. LC/MS (ESI) m/z: 612 (M+H)+.
Step 4: Methyl ((S)-1-((((1R,3S,5R)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (153-S5)
To a solution of 153-S4 (29 mg, 0.05 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 153-S5 (25.6 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 512 (M+H)+.
Step 5: Methyl ((S)-1-((((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)methyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (153)
To a mixture of 153-S5 (25.6 mg, 0.05 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (153-S6, 16.1 mg, 0.05 mmol), and HATU (29.6 mg, 0.08 mmol) in DMF (2 mL) was added DIPEA (0.03 mL, 0.14 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 153 (5.2 mg, 12.9% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.43 (s, 1H), 9.04 (s, 2H), 8.44 (s, 1H), 8.16 (s, 1H), 7.87 (d, J=1.1 Hz, 2H), 7.77 (d, J=8.1 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 7.12 (d, J=9.1 Hz, 1H), 5.88 (d, J=17.2 Hz, 1H), 5.61 (d, J=17.1 Hz, 1H), 4.44-4.39 (m, 1H), 4.17 (s, 1H), 3.85-3.79 (m, 1H), 3.76-3.73 (m, 1H), 3.65-3.63 (m, 1H), 3.54 (s, 3H), 3.08 (s, 3H), 3.07-3.05 (m, 1H), 2.69 (s, 3H), 2.68-2.67 (m, 1H), 2.66 (s, 3H), 2.20-2.17 (m, 1H), 1.97-1.94 (m, 1H), 1.24 (s, 1H), 1.17 (t, J=5.6 Hz, 1H), 1.08 (s, 1H), 0.94-0.81 (m, 6H). LC/MS (ESI) m/z: 804 (M+H)+.
Figure US11708351-20230725-C01157
Figure US11708351-20230725-C01158
Step 1: (1R,3S,5S)-2-tert-Butyl 3-ethyl 5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S2)
To a solution of 157-S1 (200 mg, 0.70 mmol) in DMF (3 mL) was added NaH (56 mg, 60% dispersion in mineral oil, 1.40 mmol) at 0° C., and after 5 minutes, 2-bromo-N,N-dimethylacetamide (232 mg, 1.40 mmol) was added. The reaction mixture was stirred at room temperature for 3 hours. The mixture was partitioned with ice water and EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford 157-S2 (110 mg, 42.5% yield) as a yellow oil. LC/MS (ESI) m/z: 371 (M+H)+.
Step 2: (1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (157-S3)
To a solution of 157-S2 (110 mg, 0.30 mmol) in THF (3 mL) and water (3 mL) was added NaOH (36 mg, 0.90 mmol) at 0° C. The reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to half volume and washed with EtOAc twice. The mixture was acidified with 2 N aqueous HCl to pH 4 and extracted with DCM three times. The combined organic layers were concentrated to dryness to afford 157-S3 (85 mg, 83.3% yield) as a colorless oil. LC/MS (ESI) m/z: 343 (M+H)+.
Step 3: (1R,3S,5S)-3-Benzyl 2-tert-butyl 5-((2-(dimethylamino)-2-oxoethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S4)
To a solution of 157-S3 (85 mg, 0.25 mmol) in MeCN (2 mL) were added K2CO3 (69 mg, 0.50 mmol) and BnBr (58 mg, 0.34 mmol). The reaction mixture was stirred at room temperature for 16 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=2:1) to afford 157-S4 (95 mg, 88.0% yield) as a colorless oil. LC/MS (ESI) m/z: 433 (M+H)+.
Step 4: (1R,3S,5S)-3-Benzyl 2-tert-butyl 5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (157-S5)
To a solution of 157-S4 (95 mg, 0.22 mmol) in THF (5 mL) was added BH3.THF (0.66 mL, 0.66 mmol, 1 M). The reaction mixture was stirred at reflux for 16 hours. The reaction mixture was quenched with MeOH and concentrated to dryness. The remaining residue was diluted with EtOH (8 mL) and H2O (1 mL) and the mixture was stirred at reflux for 4 hours. The mixture was concentrated to dryness and the remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=30:1) to afford 157-S5 (90 mg, 97.8% yield) as a white solid. LC/MS (ESI) m/z: 419 (M+H)+.
Step 5: (1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (157-S6)
To a solution of 157-S5 (90 mg, 0.21 mmol) in MeOH (5 mL) was added Pd/C (10 mg, 10% wt). The reaction mixture was stirred at room temperature for 1 hour. The mixture was filtered and concentrated to dryness to afford 157-S6 (65 mg, 94.3% yield) as a white solid. LC/MS (ESI) m/z: 329 (M+H)+.
Step 6: (1R,3S,5S)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (157-S7)
To a solution of 157-S6 (65 mg, 0.20 mmol) and 6-bromo-3-methylpyridin-2-amine (23 mg, 0.24 mmol) in DCM (5 mL) was added pyridine (24 mg, 1.22 mmol) at 0° C. followed by dropwise addition of POCl3 (0.02 mL, 0.20 mmol). The reaction mixture was stirred at 0° C. for 30 minutes. The reaction mixture was quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=50:1) to afford 157-S7 (80 mg, 67.2% yield) as a white solid. LC/MS (ESI) m/z: 497 (M+H)+.
Step 7: (1R,3S,5S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (157-S8)
To a solution of 157-S7 (80 mg, 0.14 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 157-S8 (80 mg, 100.0% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 397 (M+H)+.
Step 8: (1R,3S,5S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2-(dimethylamino)ethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (157)
To a solution of 157-S8 (30 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (157-S9, 28 mg, 0.089 mmol) and HATU (46 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC to afford 157 (2.9 mg, 5.3% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.04 (s, 2H), 8.59 (s, 1H), 7.85-7.77 (m, 2H), 7.61 (d, J=7.5 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.82 (m, 1H), 5.71 (m, 1H), 5.36 (m, 1H), 4.72 (m, 1H), 3.98-3.89 (m, 2H), 3.87-3.76 (m, 2H), 3.41 (m, 2H), 2.94 (s, 6H), 2.78 (s, 3H), 2.67 (m, 1H), 2.59 (m, 1H), 2.14 (s, 3H), 1.20 (m, 1H), 0.91 (m, 1H). LC/MS (ESI) m/z: 689 (M+H)+.
Figure US11708351-20230725-C01159
Step 1: (1R,3S,5R)-tert-Butyl 3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (158-S2)
To a solution of 158-S1 (50 mg, 0.12 mmol) and 2,2-difluorocyclopentanecarboxylic acid (18 mg, 0.12 mmol) in DCM (3 mL) was added DCC (36 mg, 0.18 mmol) at 0° C. followed by DMAP (2 mg, 0.01 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under vacuum and the remaining residue was purified by silica gel chromatography (DCM/MeOH=80:1) to afford 158-S2 (60 mg, 89.8% yield) as a white solid. LC/MS (ESI) m/z: 557 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (158-S3)
To a solution of 158-S2 (60 mg, 0.11 mmol) in dioxane (1.5 mL) was added HCl/dioxane (2 M, 0.4 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to afford 158-S3 (60 mg, 100% yield) as a white solid, which was carried forward in the next synthetic step without purification. LC/MS (ESI) m/z: 457 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((2,2-difluorocyclopentanecarboxamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (158)
To a solution of 158-S3 (30 mg, 0.08 mmol) and 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (27 mg, 0.08 mmol) in DCM (3 mL) was added DCC (25 mg, 0.12 mmol) at 0° C. followed by DMAP (2 mg, 0.01 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness and the remaining residue was purified by preparative HPLC to afford 158 (10.1 mg, 16.6% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.40 (s, 1H), 7.61-7.48 (m, 2H), 7.39 (d, J=8.1 Hz, 1H), 5.96 (m, 1H), 5.80 (m, 1H), 4.65 (m, 1H), 3.58 (m, 3H), 3.13-3.00 (m, 1H), 2.76 (s, 6H), 2.69 (s, 3H), 2.62-2.41 (m, 2H), 2.21-2.06 (m, 6H), 1.99-1.86 (m, 2H), 1.73 (m, 1H), 1.34 (m, 1H), 1.10 (m, 1H). LC/MS (ESI) m/z: 763 (M+H)+.
Figure US11708351-20230725-C01160
A solution of 163-S1 (40 mg, 0.056 mmol) in TBAF/THF (3 mL, 1 M) was stirred at 60° C. for 1 hour. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue product was purified by preparative HPLC to afford 163 (5 mg, 13.8% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.98 (s, 2H), 8.40 (s, 1H), 7.52-7.55 (m, 2H), 7.37 (d, J=8.0 Hz, 1H), 5.94-5.99 (m, 1H), 5.78-5.83 (m, 1H), 4.64-4.68 (m, 1H), 4.59 (s, 1H), 4.47 (s, 1H), 3.81-3.83 (m, 1H), 2.74 (s, 6H), 2.69 (s, 4H), 2.56-2.59 (m, 1H), 2.12 (s, 3H), 1.38-1.42 (m, 1H), 1.18-1.20 (m, 1H). LC/MS (ESI) m/z: 634 (M+H)+.
Figure US11708351-20230725-C01161
Step 1: (1R,3S,5R)-tert-Butyl 5-(acetamidomethyl)-3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (165-S2)
To a mixture of 165-S1 (40 mg, 0.088 mmol) in dry DCM (3 mL) was added DIPEA (0.03 mL, 0.176 mmol) followed by a solution of acetyl chloride (8.3 mg, 0.106 mmol) in DCM (0.5 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was then diluted with water (20 mL) and extracted with DCM (4 mL×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The crude was purified by column chromatography on silica gel (eluted with DCM/MeOH=240:1) to afford 165-S2 (40 mg, 91.7% yield) as a white solid. LC/MS (ESI) m/z: 497 (M+H)+.
Step 2: (1R,3S,5R)-5-(Acetamidomethyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (165-S3)
To a solution of 165-S2 (40 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 165-S3 (35.6 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 397 (M+H)+.
Step 3: (1R,3S,5R)-5-(Acetamidomethyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (165)
To a mixture of 165-S3 (35.6 mg, 0.09 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (26.9 mg, 0.09 mmol), and HATU (49.6 mg, 0.13 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.26 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 165 (15.5 mg, 25.0% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.39 (s, 1H), 9.04 (s, 2H), 8.44 (s, 1H), 8.03 (t, J=5.9 Hz, 1H), 7.87 (d, J=1.6 Hz, 2H), 7.77 (d, J=8.1 Hz, 1H), 7.55 (d, J=8.0 Hz, 1H), 5.88 (d, J=17.3 Hz, 1H), 5.61 (d, J=17.2 Hz, 1H), 4.44-4.41 (m, 1H), 4.21-4.12 (m, 2H), 3.71-3.69 (m, 1H), 3.34-3.32 (m, 1H), 3.25-3.23 (m, 1H), 3.10 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.47-2.43 (m, 1H), 2.24-2.21 (m, 1H), 1.86 (s, 3H), 1.16-1.14 (m, 1H), 1.09-1.07 (m, 1H). LC/MS (ESI) m/z: 689 (M+H)+.
Figure US11708351-20230725-C01162
Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-(methoxymethyl)pyridin-2-yl)carbamoyl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (166-S2)
To a solution of 166-S1 (67 mg, 0.147 mmol) in MeOH (3 mL) were added aqueous HCHO solution (13.3 mg, 0.443 mmol) and NaBH3CN (18.5 mg, 0.294 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was then diluted with water (20 mL) and extracted with DCM (5 mL×2). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=20:1) to afford 166-S2 (60 mg, 84.6% yield) as a white solid. LC/MS (ESI) m/z: 483 (M+H)+.
Step 2: (1R,3S,5R)—N-(6-Bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (166-S3)
To a solution of 166-S2 (38.5 mg, 0.08 mmol) in DCM (2 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford 166-S3 (38 mg, 100% yield) as a yellow solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 383 (M+H)+.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(methoxymethyl)pyridin-2-yl)-5-((dimethylamino)methyl)-2-azabicyclo[3.1.0]hexane-3-carbonamide (166)
To a mixture of 166-S3 (30.5 mg, 0.08 mmol), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (25.3 mg, 0.08 mmol), and HATU (44.3 mg, 0.12 mmol) in DMF (2 mL) was added DIPEA (0.04 mL, 0.24 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford 166 (6.5 mg, 12.1% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.53 (s, 1H), 7.78 (s, 2H), 7.75 (d, J=8.1 Hz, 1H), 7.48 (d, J=8.0 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.66 (d, J=17.1 Hz, 1H), 4.67 (d, J=4.0 Hz, 1H), 4.30-4.22 (m, 2H), 3.87 (d, J=2.9 Hz, 1H), 3.46 (d, J=13.2 Hz, 1H), 3.14 (s, 3H), 3.03 (d, J=13.3 Hz, 1H), 2.83 (s, 6H), 2.76 (s, 3H), 2.70 (s, 3H), 2.67 (s, 1H), 2.59-2.55 (m, 1H), 1.46-1.43 (m, 1H), 1.37-1.35 (m, 1H). LC/MS (ESI) m/z: 675 (M+H)+.
Figure US11708351-20230725-C01163
Figure US11708351-20230725-C01164
Step 1: tert-Butyl 2-(3-acetyl-7-(hydroxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (167-S2)
To a solution of 167-S1 (1.19 g, 3.1 mmol) in dioxane/H2O (20 mL) was added Pd(PPh3)4 (358 mg, 0.31 mmol), K2CO3 (1.28 g, 9.3 mmol), and 2-methylpyrimidin-5-ylboronic acid (470 mg, 3.4 mmol). The reaction mixture was purged with nitrogen and stirred at 90° C. for 16 hours under an atmosphere of nitrogen. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by silica gel chromatography (DCM/EtOAc=5:1) to afford 167-S2 (400 mg, 32.5% yield) as a white solid. LC/MS (ESI) m/z: 397 (M+H)+.
Step 2: tert-Butyl 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7-((methylsulfonyloxy)methyl)-1H-indazol-1-yl)acetate (167-S3)
To a solution of 167-S2 (200 mg, 0.51 mmol) in dry DCM (8 mL) was added Et3N (128 mg, 1.26 mmol) followed by dropwise addition of MsCl (88 mg, 0.77 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour under an atmosphere of nitrogen. The mixture was diluted with DCM, washed with saturated aqueous NaHCO3 solution and brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure to afford 167-S3 (220 mg, 90.8% yield) as a white solid, which was used in the next synthetic step without further purification. LC/MS (ESI) m/z: 475 (M+H)+.
Step 3: tert-Butyl 2-(3-acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (167-S4)
To a solution of 167-S3 (110 mg, 0.3 mmol) in dry DCM (8 mL) were added Et3N (90 mg, 0.9 mmol) and dimethylamine hydrochloride (60 mg, 0.54 mmol) at 0° C. The reaction mixture was stirred at room temperature for 16 hours under an atmosphere of nitrogen. The mixture was partitioned with DCM and NaHCO3. The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=5:1) to afford 167-S4 (62 mg, 48.7% yield) as a white solid. LC/MS (ESI) m/z: 424 (M+H)+.
Step 4: 2-(3-Acetyl-7-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (167-S5)
To a solution of 167-S4 (62 mg, 0.15 mmol) in MeOH/THF/H2O (2:1:1, 4 mL) was added NaOH (18 mg, 0.45 mmol). The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with water and washed with diethyl ether twice. The aqueous layer was adjusted to pH 5 with 10% aqueous HCl solution and extracted with DCM twice. The combined organic layers were dried over Na2SO4 and concentrated to afford 167-S5 (50 mg, 90.6% yield) as a white solid, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 368 (M+H)+.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-7-((dimethylamino)methyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (167)
To a solution of 167-S5 (30 mg, 0.08 mmol) and (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (28 mg, 0.08 mmol) in DMF (3 mL) were added DIPEA (42 mg, 0.32 mmol) and HATU (61 mg, 0.16 mmol). The reaction mixture was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine successively, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by preparative HPLC (eluted with MeCN/water) to afford 167 (10 mg, 18.9% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.05 (s, 2H), 8.46 (d, J=1.6 Hz, 1H), 7.72 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 6.49 (d, J=17.3 Hz, 1H), 5.82 (d, J=17.1 Hz, 1H), 4.43 (dd, J=9.0, 5.5 Hz, 1H), 3.79 (d, J=12.8 Hz, 1H), 3.46-3.54 (m, 2H), 2.69 (s, 3H), 2.65 (s, 3H), 2.54-2.58 (m, 1H), 2.23 (s, 6H), 2.04 (s, 3H), 1.97-2.02 (m, 1H), 1.32 (s, 3H), 0.96-1.04 (m, 2H). LC/MS (ESI) m/z: 661 (M+H)+.
Figure US11708351-20230725-C01165
Step 1: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((2,2,2-trifluoroacetamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (168-S2)
To a mixture of 169-S1 (40 mg, 0.094 mmol), Et3N (23 mg, 0.24 mmol), and DMAP (1 mg, cat. amount) in dry DCM (2 mL) was added 2,2,2-trifluoroacetic anhydride (40 mg, 0.19 mmol) at 0° C. under an atmosphere of nitrogen. The reaction mixture was stirred at 0° C. for 2 hours. The mixture was diluted with DCM, washed with brine, dried, and concentrated to afford the crude product, which was purified by chromatography on silica gel (PE/EtOAc=10:1 to 5:1 to 4:1) to afford 168-S2 (35 mg, 71.5% yield) as a light oil. LC/MS (ESI) m/z: 521 (M+H)+.
Step 2: 3-(6-Bromo-3-methyl-pyridin-2-ylcarbamoyl)-5-[(2,2,2-trifluoro-acetylamino)-methyl]-2-aza-bicyclo[3.1.0]hexane-2-carboxylic Acid Tert-Butyl Ester (168-S3)
To a solution of 168-S2 (35 mg, 0.067 mmol) in DCM (2 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to afford 168-S3 (28 mg, 99.5% yield) as a light oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 421 (M+H)+.
Step 3: 2-{2-[3-Acetyl-7-methyl-5-(2-methyl-pyrimidin-5-yl)-indazol-1-yl]-acetyl}-5-[(2,2,2-trifluoro-acetylamino)-methyl]-2-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid (6-bromo-3-methyl-pyridin-2-yl)-amide (168)
To a mixture of 168-S3 (28 mg, 0.067 mmol), 165-S4 (22 mg, 0.067 mmol), and HATU (38 mg, 0.10 mmol) in DMF (3 mL) was added DIPEA (26 mg, 0.20 mmol). The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified with preparative HPLC to afford 168 (5.5 mg, 11.3% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.34 (s, 1H), 9.68 (s, 1H), 9.03 (s, 2H), 8.32 (s, 1H), 7.63 (d, J=8.0 Hz, 2H), 7.44 (d, J=8.0 Hz, 1H), 6.00 (d, J=20.0 Hz, 1H), 5.71 (d, J=20.0 Hz, 1H), 4.47 (m, 1H), 3.79 (m, 1H), 3.51 (m, 1H), 2.68 (s, 6H), 2.64 (d, J=8.0 Hz, 3H), 2.54 (d, J=8.0 Hz, 1H), 2.24 (m, 1H), 2.07 (d, J=12.0 Hz, 3H), 1.27-1.04 (m, 3H). LC/MS (ESI) m/z: 727 (M+H)+.
Figure US11708351-20230725-C01166
Figure US11708351-20230725-C01167
Step 1: 2-Bromo-5-bromomethyl-pyridine (169-S2)
To a solution of 169-S1 (5.0 g, 29.1 mmol) in CCl4 (40 mL) was added NBS (5.22 g, 29.1 mmol) and BPO (350 mg, 1.4 mmol). The reaction mixture was stirred at 80° C. under an atmosphere of nitrogen for 2 hours. The mixture was diluted with DCM, washed with water and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=120:1) to afford 169-S2 (3.81 g, 52.6% yield) as a yellow oil. LC/MS (ESI) m/z: 250 (M+H)+.
Step 2: 2-Bromo-5-methoxymethyl-pyridine (169-S3)
To a solution of 169-S2 (3.81 g, 15.3 mmol) in MeOH (38 mL) was added MeONa (4.1 mL, 30% wt in MeOH) at 0° C. The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was diluted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=100:1) to afford 169-S3 (2.7 g, 87.8% yield) as a yellow oil. LC/MS (ESI) m/z: 202 (M+H)+.
Step 3: 2-Bromo-5-methoxymethyl-pyridine 1-oxide (169-S4)
To a solution of 169-S3 (2.7 g, 13.4 mmol) in DCM (23 mL) was added m-CPBA (3.47 g, 20.1 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was filtered and the filtrate was diluted with DCM, washed with 1 N aqueous NaOH solution and brine, dried over Na2SO4, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH=40:1) to afford 169-S4 (2.5 g, 86.2% yield) as a yellow oil. LC/MS (ESI) m/z: 218 (M+H)+.
Step 4: (6-Bromo-3-methoxymethyl-pyridin-2-yl)-tert-butyl-amine (169-S5)
To a solution of 169-S4 (1.0 g, 4.6 mmol) in DCM/toluene (20 mL, v/v=5/2) was added tert-butylamine (2.42 g, 33.2 mmol) followed by dropwise addition of a solution of p-toluenesulfonic anhydride (4.96 g, 15.2 mmol) in DCM/toluene (240 mL, v/v=5/2) for 4 h at −15° C. The reaction mixture was stirred at room temperature overnight, washed with aqueous NaHCO3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=400:1) to afford 169-S5 (425 mg, 34.0% yield) as a yellow oil. LC/MS (ESI) m/z: 273 (M+H)+.
Step 5: 6-Bromo-3-methoxymethyl-pyridin-2-ylamine (169-S6)
To a solution of 169-S5 (214 mg, 0.78 mmol) in chloroform (3 mL) was added TFA (3 mL). The mixture was stirred at 90° C. for 20 minutes in a microwave reactor. The mixture was concentrated to dryness and diluted with DCM. The mixture was washed with aqueous NaHCO3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=6:1) to afford 169-S6 (65 mg, 38.4% yield) as a white solid. LC/MS (ESI) m/z: 217 (M+H)+.
Step 6: 3-(6-Bromo-3-methoxymethyl-pyridin-2-ylcarbamoyl)-5-methyl-2-aza-bicyclo[3.1.0]hexane-2-carboxylic Acid Tert-Butyl Ester (169-S8)
To a mixture of 169-S6 (40 mg, 0.18 mmol) and 169-S7 (45 mg, 0.186 mmol) in DCM (3 mL) was added pyridine (0.08 mL, 0.93 mmol) and POCl3 (0.02 mL, 0.186 mmol) under an atmosphere of nitrogen at 0° C. The mixture was stirred at room temperature for 30 minutes. The mixture was diluted with DCM, washed with aqueous NaHCO3 solution and brine, dried, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with PE/EtOAc=3:1) to afford 169-S8 (38 mg, 46.9% yield) as a white solid. LC/MS (ESI) m/z: 440 (M+H)+.
Step 7: 5-Methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid (6-bromo-3-methoxymethyl-pyridin-2-yl)-amide (169-S9)
To a solution of 169-S8 (38 mg, 0.086 mmol) in DCM (2 mL) was added TFA (1 mL) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was concentrated under reduced pressure to afford 169-S9 (29 mg, 99.5% yield) as a light oil, which was carried forward in the next synthetic step without further purification. LC/MS (ESI) m/z: 340 (M+H)+.
Step 8: 2-{2-[3-Acetyl-7-methoxymethyl-5-(2-methyl-pyrimidin-5-yl)-indazol-1-yl]-acetyl}-5-methyl-2-aza-bicyclo[3.1.0]hexane-3-carboxylic Acid (6-bromo-3-methoxymethyl-pyridin-2-yl)-amide (169)
To a mixture of 169-S9 (29 mg, 0.086 mmol), 169-S10 (40 mg, 0.11 mmol), and HATU (49 mg, 0.13 mmol) in DMF (3 mL) was added DIPEA (33 mg, 0.26 mmol). The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford the crude product, which was purified with preparative HPLC to afford 169 (5.3 mg, 9.1% yield) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 10.48 (s, 1H), 9.05 (s, 2H), 8.49 (d, J=2.0 Hz, 1H), 7.86 (d, J=1.5 Hz, 1H), 7.76 (d, J=8.0 Hz, 1H), 7.54 (d, J=12.0 Hz, 1H), 6.00 (d, J=16.0 Hz, 1H), 5.73 (d, J=20.0 Hz, 1H), 4.84 (d, J=12.0 Hz, 1H), 4.66 (d, J=12.0 Hz, 1H), 4.39 (m, 1H), 4.15 (d, J=4.0 Hz, 2H), 3.56 (m, 1H), 3.34-3.33 (m, 3H), 3.08 (s, 3H), 2.69 (s, 3H), 2.66 (s, 3H), 2.58-2.53 (m, 1H), 2.04 (m, 1H), 1.34 (s, 3H), 1.04-0.99 (m, 2H). LC/MS (ESI) m/z: 676 (M+H)+.
Figure US11708351-20230725-C01168
Figure US11708351-20230725-C01169
Step 1: tert-Butyl (1R,3S,5R)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S3)
To a mixture of 171-S1 (135 mg, 0.479 mmol) and 171-S2 (95.3 mg, 0.479 mmol) in DCM (5 mL), pyridine (0.193 mL, 2.4 mmol) was added followed by POCl3 (0.045 mL, 0.48 mmol) at 0° C. under argon. The reaction mixture was stirred at room temperature for 2 hours. NaHCO3 aqueous solution was added and the mixture was extracted with DCM. After washing with brine, the organic layer was dried over anhydrous Na2SO4. The solution was filtered and the solvent was removed under reduced pressure to afford tert-butyl (1R,3S,5R)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 171-S3 (0.23 g) as a foam. The material was carried forward without additional purification.
Step 2: tert-Butyl (1R,3S,5R)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S4)
tert-Butyl (1R,3S,5R)-5-(azidomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S3, 0.23 g) was treated with trimethylphosphane (1.0 M in THF, 0.958 mL, 0.958 mmol) in THF (10 mL) in the presence of water (0.017 mL, 0.958 mmol) at room temperature overnight. The mixture was extracted with EtOAc and the organic layer was washed with aqueous NaHCO3 and brine, and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to afford tert-butyl (1R,3S,5R)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 171-S4 (0.221 g) as pale yellow syrup. The material was carried forward in the next step without additional purification.
Step 3: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S5)
tert-Butyl (1R,3S,5R)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S4, 0.221 g) was treated with but-3-ene-1-sulfonyl chloride (46.5 mg, 0.30 mmol) in DCM (5 mL) in the presence of DIEA (0.066 mL, 0.378 mmol). The reaction was stirred at room temperature for 30 minutes before NaHCO3 aqueous was added and organic layer was washed with brine and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to afford tert-butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 171-S5 (0.158 g) as a pale yellow syrup. The material was carried forward in the next step without additional purification.
Step 4: (1R,3S,5R)—N-(6-Bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (171-S6)
tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (171-S5, 19.8 mg) in DCM (1 mL) was treated with TFA (1 mL). The reaction was stirred at room temperature for 1 hour before the volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 171-S6. for the next step. The material was carried forward in the next step without additional purification.
Step 5: (1R,3S5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (171)
To a mixture of (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (171-S6, 0.0356 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (171-S7, 11 mg) in DMF (1.0 mL), TBTU (23 mg) was added followed by DIEA (0.031 mL) with stirring. After the reaction was complete, NaHCO3 aqueous solution (10 mL) was added to form a precipitate that was collected by filtration and purified by column chromatography on silica gel with MeOH in DCM (0-10%) as the eluent to afford (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((but-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (171) (17 mg) as a pale yellow solid. 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.83 (s, 1H), 8.58 (t, J=1.2 Hz, 1H), 7.69-7.58 (m, 3H), 7.30 (d, J=8.2 Hz, 1H), 6.44 (dd, J=11.0, 17.4 Hz, 1H), 5.81 (ddt, J=6.5, 10.2, 16.8 Hz, 1H), 5.74 (s, 1H), 5.64 (d, J=17.4 Hz, 1H), 5.51 (d, J=3.1 Hz, 2H), 5.28 (d, J=11.1 Hz, 1H), 5.18-5.06 (m, 2H), 4.94 (d, J=8.3 Hz, 1H), 3.58 (dd, J=4.6, 13.7 Hz, 1H), 3.52 (dd, J=2.8, 5.7 Hz, 1H), 3.16-3.08 (m, 3H), 2.80 (s, 4H), 2.72 (s, 3H), 2.56 (q, J=7.0 Hz, 2H), 2.27 (dd, J=8.4, 13.9 Hz, 1H), 1.44 (t, J=5.8 Hz, 1H), 1.12 (dd, J=2.8, 5.9 Hz, 1H). LC (method A): tR=1.85 min. LC/MS (EI) m/z: [M+H]+ 747.
Figure US11708351-20230725-C01170
Step 1: 6-Bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-amine (177-S2)
To a stirred solution 6-bromo-3-(chloromethyl)pyridin-2-amine (204 mg, 1 equiv) and triethyl amine (0.4, 3 equiv) in acetonitrile (20 mL) was added 3,3-difluoroazetidine hydrochloride (230 mg, 2 equiv) at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (25 mL) and basified with aqueous saturated NaHCO3 solution (20 mL). The aqueous layer was extracted with DCM (2×10 mL) and the combined organic layers were washed with brine (25 mL), dried over Na2SO4 and concentrated to dryness to afford 177-S2 (96 mg, 40%).
Step 2: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (177-S3)
POCl3 (0.04 mL, 2 equiv) was added dropwise at 0-5° C. under an atmosphere of argon to a stirred solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (83 mg, 1 equiv) and 177-S2 (96 mg, 1 equiv) in DCM (10 mL) and pyridine (0.1 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (15 mL) and basified with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1×15 mL) and the combined organic layers were washed with brine (20 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 177-S3 (147 mg, 85%).
Step 3: (1R,3S,5R)—N-(6-Bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (TFA Salt) (177-S4)
To a solution of 177-S3 (147 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness to afford 177-S4.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-((3,3-difluoroazetidin-1-yl)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (177)
To a solution of 177-S4 (135 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (100 mg, 1.05 equiv), and DIPEA (0.26, 5 equiv) in DMF (10 mL) was added HATU (146 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours. The reaction was diluted with EtOAc (40 mL) and water (20 mL). The aqueous layer was extracted with EtOAc (25 mL) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 177 (25 mg, 12%). 1H NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 8.96 (s, 2H), 8.37 (s, 1H), 7.80 (m, 2H), 7.67 (d, 1H, J=8.2 Hz), 7.42 (d, 1H, J=8.2 Hz), 5.87 (d, 1H, J=17.5 Hz), 5.52 (d, 1H, J=17.5 Hz), 4.29-4.36 (m, 1H), 3.22-3.56 (m, 1H), 3.37-3.45 (m, 2H), 3.25-3.33 (m, 3H), 2.62 (s, 3H), 2.58 (s, 3H), 2.26 (s, 1H), 1.99-2.04 (m, 1H), 1.27 (s, 3H), 0.91-0.99 (m, 3H); 19F NMR (376 MHz, DMSO-d6) δ−97.89 (2F).
Figure US11708351-20230725-C01171
Step 1: 2-Bromo-3-fluoro-5-methyl-(1-oxidanyl)-pyridine (178-S2)
To a stirred solution of 2-bromo-3-fluoro-5-methylpyridine (175-S1, 10 g, 1 equiv) in CHCl3 (200 mL) was added 3-chlorobenzoperoxoic acid (24 g, 2 equiv). The reaction mixture was heated to 50° C. The reaction was cooled and neutralized with saturated aqueous NaHCO3 ((100 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography silica gel (5% CH3OH in DCM, gradient) to afford 178-S2 (9.4 g, 87%).
Step 2: 6-Bromo-N-(tert-butyl)-5-fluoro-3-methylpyridin-2-amine (178-S3)
To a stirred solution of 178-S2 (3.2 g, 1 equiv) and 2-methylpropan-2-amine (8.1 mL, 5 equiv) in DCM (100 mL) at 0-5° C. was slowly added trifluoroacetic anhydride (TFAA, 2.7 mL, 1.1 equiv) solution in DCM (20 mL) dropwise using an additional funnel over 40 minutes under an atmosphere of argon at 0-5° C. The reaction mixture was stirred at 0-5° C. for 1 hour and monitored by LC/MS. (If the reaction was not complete after 1 hour, TFAA ((2.5 mL, 1 equiv) solution in DCM (20 mL, added over 15 to 20 minutes) and 2-methylpropan-2-amine (1.6 mL, 1 equiv, added once) were added). The reaction was diluted with DCM (60 mL) and neutralized with aqueous saturated NaHCO3 (80 mL). The organic layer was washed with brine (80 mL), dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by hexanes/EtOAc=3:1) to afford 178-S3.
Step 3: 6-Bromo-5-fluoro-3-methylpyridin-2-amine (178-S4)
TFA (20 mL) was added to solid 178-S3 and the reaction mixture was heated at 70° C. until completion. The reaction was concentrated to dryness and the residue was dissolved in DCM (35 mL), washed with aqueous saturated NaHCO3 solution (15 mL×2) and brine, dried over Na2SO4, and concentrated to afford 178-S4 (838 mg, 26%).
Step 4: (1R,3S,5R)—N-(6-Bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (178-S5)
POCl3 (0.1 mL, 2 equiv) was added dropwise to a solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (121 mg, 1 equiv) and 178-S4 (101 mg, 1 equiv) in DCM (8 mL) and pyridine (0.2 mL, 5 equiv) cooled at 0-5° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (10 mL) and neutralized with aqueous saturated NaHCO3 solution (10 mL). The aqueous layer was extracted with DCM (1× mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 178-S5 (131 mg, 62%)
Step 5: (1R,3S,5R)—N-(6-Bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (178-S6)
To a solution of 178-S5 (131 mg) was added 4N HCl in dioxane (8 mL). The resulting solution was stirred at room temperature for 6 hours. The reaction mixture was concentrated to dryness to afford 178-S6.
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (178)
To a solution of 178-S6 (137 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (115 mg, 1.2 equiv) and DIPEA (0.3 mL, 5 equiv) in DMF (10 mL) was added HATU (141 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours before it was diluted with EtOAc (30 mL) and water (15 mL). The organic layer was washed with brine, dried over anhydrous Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 178 (79 mg, 41%). 1H NMR (400 MHz, DMSO-d6) δ 10.11 (s, 1H), 9.06 (s, 2H), 8.46 (s, 1H), 7.87 (s, 1H), 7.81-7.87 (m, 2H), 5.92 (d, 1H, J=17.4 Hz), 5.59 (d, 1H, J=17.4 Hz), 4.37-4.42 (m, 1H), 3.58 (d, 1H, J=5.4 Hz), 2.70 (s, 3H), 2.67 (s, 3H), 2.54-2.59 (m, 1H), 2.08 (s, 3H), 2.02-2.07 (m, 1H), 1.33 (s, 3H), 0.99-1.06 (m, 2H). 19F NMR (376 MHz, DMSO-d6) δ−118.95 (s, 1F).
Figure US11708351-20230725-C01172
Step 1: tert-butyl 2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-indazol-1-yl)acetate (180-S3)
To a solution of 6-bromo-2-methylpyrazolo[1,5-a]pyrimidine (180-S2, 1 equiv) in DMF/H2O (9:1, 10 vol) was added compound 180-S1 (1 equiv), K2CO3 (2 equiv) and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 180-S3.
Step 2: 2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-indazol-1-yl)acetic Acid (180-S4)
To a solution of compound 180-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was used directly in the next synthetic step.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrazolo[1,5-a]pyrimidin-6-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (180)
To a solution of compound 180-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 180. 1H NMR (400 MHz, DMSO-d6) δ 0.98-1.09 (m, 2H), 1.33 (s, 3H), 2.06 (s, 4H), 2.47 (s, 3H), 2.52-2.59 (m, 1H), 2.67 (s, 3H), 3.56-3.63 (m, 1H), 4.42 (dd, J=5.1, 9.3 Hz, 1H), 5.58 (d, J=17.2 Hz, 1H), 5.92 (d, J=17.3 Hz, 1H), 6.58 (s, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 7.84 (d, J=8.8 Hz, 1H), 7.90 (d, J=8.8 Hz, 1H), 8.48 (s, 1H), 8.86 (d, J=2.2 Hz, 1H), 9.35 (d, J=2.2 Hz, 1H), 10.26 (s, 1H).
Figure US11708351-20230725-C01173
Figure US11708351-20230725-C01174
Step 1: 2-Bromo-5-(difluoromethyl)-4-methyl-1-oxidanyl)pyridine (187-S2)
To a stirred solution of 2-bromo-5-(difluoromethyl)-4-methylpyridine (187-S1, 1 g, 1 equiv) in CHCl3 (150 mL) was added 3-chlorobenzoperoxoic acid (2.1 g, 2 equiv). The reaction mixture was heated to 50° C. until completion. The reaction was cooled and neutralized with saturated aqueous NaHCO3 solution (60 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% CH3OH in DCM, gradient) to afford 187-S2 (851 mg, 80%).
Step 2: 6-Bromo-N-(tert-butyl)-3-(difluoromethyl)-4-methylpyridin-2-amine (187-S3)
To a stirred solution of 187-S2 (222 mg, 1 equiv) and 2-methylpropan-2-amine (0.49 mL, 5 equiv) in DCM (100 mL) was added trifluoroacidic anhydride (0.3 mL, 2 equiv) solution in DCM (5 mL) at 0-5° C. dropwise under an atmosphere of argon. The reaction mixture was stirred at 0-5° C. for 2 hours before the reaction was neutralized with aqueous saturated NaHCO3 solution (15 mL). The organic layer was washed with brine (15 mL), dried over Na2SO4 and concentrated. The crude was purified by column chromatography on silica gel (eluted by 30% EtOAc in hexanes) to afford 187-S3 (130 mg, 48%)
Step 3: 6-Bromo-3-(difluoromethyl)-4-methylpyridin-2-amine (187-S4)
TFA (8 mL) was added to solid 187-S3 (130 mg) and the reaction mixture was heated at 70° C. until completion. The reaction mixture was concentrated to dryness and the residue was dissolved in DCM (15 mL) and neutralized with aqueous saturated NaHCO3 solution (15 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated to dryness to afford 187-S4 (92 mg, 87%).
Step 4: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (187-S5)
POCl3 was added dropwise (0.05 mL, 2 equiv) at 0-5° C. under an atmosphere of argon to a stirred solution of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (94 mg, 1 equiv) and 187-S4 (92 mg, 1 equiv) in DCM (10 mL) and pyridine (0.1 mL, 5 equiv). The reaction mixture was stirred at room temperature until completion. The reaction was diluted with DCM (20 mL) and neutralized with aqueous saturated NaHCO3 solution (15 mL). The aqueous layer was extracted with DCM (1×10 mL) and the combined organic layers were washed with brine (10 mL), dried over Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted by 5% MeOH in DCM gradient) to afford 187-S5 (109 mg, 61%).
Step 5: (1R,3S,5R)—N-(6-Bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (TFA Salt) (187-S6)
To a solution of S5 (109 mg) in DCM (5 mL) was added TFA (5 mL). The resulting solution was stirred at room temperature for 1 hour. The reaction mixture was concentrated to dryness to afford 187-S6 (65 mg).
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-(difluoromethyl)-4-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (187)
To a solution of 187-S6 (65 mg, 1 equiv), 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (44 mg, 1.05 equiv), and DIPEA (0.12 mL, 5 equiv) in DMF (8 mL) was added HATU (64 mg, 1.2 equiv) at 0° C. under an atmosphere of argon. The reaction mixture was stirred at room temperature for 3 hours. The reaction mixture was diluted with EtOAc (40 mL) and water (20 mL). The aqueous layer was extracted with EtOAc (20 mL) and the combined organic layers were washed with brine (3×20 mL), dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel (eluted by DCM/MeOH=10:1) to afford 187 (67 mg, 27%). 1H NMR (400 MHz, DMSO-d6) δ 10.70 (s, 1H), 9.04 (s, 2H), 8.46 (s, 1H), 7.87 (S, br, 2H), 7.64 (s, 1H), 6.66 (m, 1H), 5.93 (d, 1H, J=18.2 Hz), 5.61 (d, 1H, J=18.2 Hz), 4.28-4.34 (m, 1H), 3.62-3.66 (m, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.46 (s, 3H), 2.53-2.58 (m, 1H), 1.99-2.06 (M, 1H), 1.33 (s, 3H), 0.93-1.05 (m, 2H); 19F NMR (376 MHz, DMSO-d6) δ−112.35 (1F), −113.24 (1F).
Figure US11708351-20230725-C01175
Figure US11708351-20230725-C01176
Step 1: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (188-S2)
tert-Butyl (1R,3S,5R)-5-(aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (188-S1, 0.104 g, 0.238 mmol) was treated with methyl triflate (0.032 mL, 0.286 mmol) in 1,1,1,3,3,3-hexafluoro-2-propanol at room temperature. The reaction stirred at room temperature for 3 hours before EtOAc was added to dilute the reaction. The mixture was washed with NaHCO3 and brine and dried over anhydrous Na2SO4. The solvent was removed to afford tert-butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((methylamino)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 188-S2. The material was carried forward in the next step without additional purification.
Step 2: tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (188-S3)
tert-Butyl (1R,3S,5R)-5-((methylamino)aminomethyl)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 188-S2 was treated with but-3-ene-1-sulfonyl chloride (44 mg, 0.286 mmol) in DCM (5 mL) in the presence of DIEA (0.062 mL, 0.357 mmol). The reaction stirred at room temperature for 30 minutes before NaHCO3 aqueous was added. The organic layer was washed with brine and dried over anhydrous Na2SO4. The solvent was removed under reduced pressure to afford a mixture containing tert-butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 188-S3. The material was carried forward in the next step without additional purification.
Step 3: (1R,3S,5R)—N-(6-Bromo-3-vinylpyridin-2-yl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (188-S4)
tert-Butyl (1R,3S,5R)-3-((6-bromo-3-vinylpyridin-2-yl)carbamoyl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 188-S3 in DCM (3 mL) was treated with TFA (3 mL) at room temperature for 1 hour. The volatiles were removed under reduced pressure and the residue was co-evaporated with toluene (5 mL) twice to afford a mixture (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 188-S4. The material was carried forward in the next step without additional purification.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (188)
To a mixture of (1R,3S,5R)—N-(6-bromo-3-vinylpyridin-2-yl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 188-S4 and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (188-S5, 74 mg) in DMF (3.0 mL), TBTU (115 mg) was added followed by DIEA (0.414 mL) with stirring. After the reaction was complete, the mixture was purified by HPLC to afford (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-vinylpyridin-2-yl)-5-((N-methylbut-3-en-1-ylsulfonamido)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (188, 25.5 mg) as a white powder. 1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.74 (s, 1H), 8.58 (s, 1H), 7.71-7.55 (m, 3H), 7.30 (d, J=8.1 Hz, 1H), 6.44 (dd, J=11.0, 17.4 Hz, 1H), 5.91-5.70 (m, 1H), 5.65 (d, J=17.4 Hz, 1H), 5.51 (s, 2H), 5.27 (d, J=11.0 Hz, 1H), 5.19-5.02 (m, 2H), 4.93 (d, J=8.4 Hz, 1H), 3.48 (dd, J=6.8, 13.0 Hz, 3H), 3.01 (d, J=18.8 Hz, 5H), 2.80 (s, 4H), 2.72 (s, 3H), 2.54 (q, J=7.3 Hz, 2H), 2.31 (t, J=11.4 Hz, 1H), 1.48 (t, J=5.9 Hz, 1H), 1.06 (dd, J=2.7, 6.0 Hz, 1H). LC (method A): tR=2.01 min. LC/MS (EI) m/z: [M+H]+ 761.
Figure US11708351-20230725-C01177
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a substituted pyrimidine in the R32 position utilizing a boronic ester in a Suzuki cross-coupling. The skilled artisan will recognize that the boronic ester shown above can be replaced with other boronic esters or boronic acids to afford additional compounds of the present invention. The skilled artisan will also recognize that the A-ring shown can be replaced with other A-rings to afford additional compounds of the present invention. Non-limiting examples of boronic esters that the skilled artisan can use include 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-2-amine and 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine.
Step 1: tert-Butyl 2-(3-acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (193-S3)
To a solution of 2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (193-S2, 1 equiv) in dioxane/H2O (9:1, 10 vol) was added compound 193-S1 (1 equiv), Cs2CO3 (2 equiv), and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 193-S3.
Step 2: 2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic Acid (193-S4)
To a solution of compound 193-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material was carried forward without additional purification and used directly in the next synthetic step.
Step 3: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methoxypyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (193)
To a solution of compound 193-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (193-S5, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and then concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 193. 1H NMR (400 MHz, DMSO-d6) δ 1.02 (t, J=5.5 Hz, 1H), 1.10 (dd, J=2.4, 5.3 Hz, 1H), 1.34 (s, 3H), 2.01-2.10 (m, 4H), 2.56 (dd, J=9.3, 13.3 Hz, 1H), 2.69 (s, 3H), 3.58-3.65 (m, 1H), 4.01 (s, 3H), 4.35-4.52 (m, 1H), 5.72 (d, J=17.2 Hz, 1H), 6.04 (d, J=17.3 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 8.55 (d, J=1.3 Hz, 1H), 9.22-9.30 (m, 3H), 10.27 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-aminopyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (194)
1H NMR (400 MHz, DMSO-d6) δ 0.98-1.04 (m, 1H), 1.06-1.11 (m, 1H), 1.33 (s, 3H), 1.98-2.09 (m, 4H), 2.54-2.61 (m, 1H), 2.67 (s, 3H), 3.55-3.65 (m, 1H), 4.38-4.46 (m, 1H), 5.69 (d, J=17.2 Hz, 1H), 6.01 (d, J=17.3 Hz, 1H), 6.90 (s, 2H), 7.45 (d, J=7.9 Hz, 1H), 7.63 (d, J=7.9 Hz, 1H), 8.37 (s, 1H), 8.93 (s, 2H), 9.20 (s, 1H), 10.27 (s, 1H).
1-(2-((1R,3S,5R)-3-((6-Bromo-5-fluoro-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (199)
1H NMR (400 MHz, DMSO-d6) δ 0.89-0.98 (m, 2H), 1.26 (s, 3H), 1.93-2.02 (m, 4H), 2.47-2.51 (m, 1H), 2.62 (s, 3H), 3.47-3.54 (m, 1H), 4.27-4.40 (m, 1H), 5.57 (d, J=17.3 Hz, 1H), 5.87 (d, J=17.3 Hz, 1H), 7.55 (s, 1H), 7.75 (d, J=8.4 Hz, 1H), 7.81 (s, 1H), 8.53 (s, 1H), 9.18 (s, 1H), 9.26 (s, 2H), 10.19 (s, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CDCl3): δ 0.91-0.93 (m, 1H), 1.20 (t, J=5.6 Hz, 1H), 1.43 (s, 3H), 2.11 (s, 3H), 2.39 (t, J=8.4 Hz, 1H), 2.58 (s, 3H), 2.66 (d, J=11.6 Hz, 1H), 2.81 (s, 3H), 3.18 (d, J=4 Hz, 1H), 4.84 (d, J=7.6 Hz, 1H), 5.21 (d, J=16.8 Hz, 1H), 5.32 (d, J=17.2 Hz, 1H), 7.23 (d, J=8 Hz, 1H), 7.36 (d, J=7.6 Hz, 1H), 7.98 (s, 1H), 8.41 (brs, 1H), 8.71 (s, 1H), 8.81 (s, 1H), 9.29 (s, 2H).
((2S,4R)—N-(6-Bromopyridin-2-yl)-4-fluoro-1-(2-(5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)pyrrolidine-2-carboxamide
1H-NMR (400 MHz, CDCl3) δ 9.22 (s, 1H), 8.58 (s, 2H), 8.14 (s, 1H), 8.00 (d, J=8 Hz, 1H), 7.84 (s, 1H), 7.54-7.43 (m, 3H), 7.14 (d, J=8 Hz, 1H), 5.29-5.16 (dd, J=16 Hz, 2H), 4.81 (t, J=8 Hz, 1H), 4.03-3.95 (q, J=12 Hz, 1H), 3.52-3.39 (m, 1H), 2.8 (s, 3H), 2.51-2.45 (m, 3H). LC/MS (ESI) m/z: 537 (M+H)+.
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(2,2,2-trifluoroacetyl)-1H-indol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.29 (s, 1H), 9.02 (s, 2H), 8.66 (s, 1H), 8.45 (s, 1H), 7.73-7.79 (m, 2H), 7.61-7.63 (d, J=8 Hz, 1H), 7.43-7.45 (d, J=7.2 Hz, 1H), 5.67-5.71 (d, J=16.8 Hz, 1H), 5.44-5.48 (d, J=17.2 Hz, 1H), 4.37-4.41 (m, 1H), 3.57-3.58 (m, 1H), 2.68 (s, 3H), 2.02 (s, 3H), 1.95-2.07 (m, 2H), 1.33 (s, 3H), 0.98-1.05 (m, 2H). LC/MS (ESI) m/z: 657 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.55 (s, 1H), 8.25 (s, 1H), 7.55-7.58 (m, 3H), 5.45-5.48 (d, J=17.2 Hz, 1H), 5.34-5.39 (d, J=17.2 Hz, 1H), 4.48-4.51 (m, 1H), 3.51-3.53 (m, 1H), 2.73 (s, 3H), 2.60-2.64 (m, 1H), 2.54 (s, 3H), 2.28-2.29 (m, 1H), 2.14 (s, 3H), 1.40 (s, 3H), 1.08-1.11 (m, 1H), 0.97-0.099 (m, 2H). LC/MS (ESI) m/z: 619/621 (M+H)+.
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(2,2,2-trifluoroacetyl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.29 (s, 1H), 9.32 (s, 2H), 9.09 (s, 1H), 8.81 (d, J=1.5 Hz, 1H), 8.62 (s, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.81 (d, J=17.2 Hz, 1H), 5.57 (d, J=17.1 Hz, 1H), 4.41-4.42 (m, 1H), 3.55 (t, J=3.9 Hz, 1H), 2.69 (s, 3H), 2.52-2.54 (m, 1H), 2.03-2.04 (m, 1H), 2.02 (s, 3H), 1.33 (s, 3H), 1.04 (m, 2H). LC/MS (ESI) m/z: 656 (M+H)+.
(1R, 3S, 5R)-2-(2-(3-Acetyl-2-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.03 (s, 2H), 8.28 (s, 1H), 7.67-7.41 (m, 4H), 5.54 (d, J=17.8 Hz, 1H), 5.23 (d, J=17.8 Hz, 1H), 4.39 (m, 1H), 3.66 (m, 1H), 2.67 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.33 (m, 1H), 2.04-2.05 (m, 1H), 2.02 (s, 3H), 1.33 (s, 3H), 1.02 (m, 2H). LC/MS (ESI) m/z: 615/617 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 9.07 (s, 2H), 8.73 (d, J=2.2 Hz, 1H), 8.69 (d, J=2.2 Hz, 1H), 8.56 (s, 1H), 7.62 (d, J=8.1 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.56 (d, J=17.1 Hz, 1H), 5.36 (d, J=16.9 Hz, 1H), 4.41 (m, 1H), 3.59-3.55 (m, 1H), 2.67 (s, 3H), 2.53-2.55 (m, 1H), 2.51 (s, 3H), 2.07 (s, 3H), 2.02-2.05 (m, 1H), 1.32 (s, 3H), 1.06 (m, 1H), 0.95 (m, 1H). LC/MS (ESI) m/z: 602/604 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-6-fluoro-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6) δ 10.27 (s, 1H), 8.87 (s, 2H), 8.39 (s, 1H), 8.25-8.27 (d, J=7.8 Hz, 1H), 7.61 (dd, J=17.8, 9.7 Hz, 2H), 7.45 (d, J=7.9 Hz, 1H), 5.55 (d, J=17.2 Hz, 1H), 5.27 (d, J=17.2 Hz, 1H), 4.39 (m, 1H), 3.56-3.57 (m, 1H), 2.69 (s, 3H), 2.51 (s, 3H), 2.33-2.35 (m, 1H), 2.07-2.10 (m, 1H), 2.03 (s, 3H), 1.33 (s, 3H), 1.05-0.95 (m, 2H). LC/MS (ESI) m/z: 619/621 (M+H)+.
(1R,3S,5R)-2-{2-[1-Acetyl-6-(2-methylpyrimidin-5-yl)indazol-3-yl] acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.99 (d, J=4.9 Hz, 2H), 8.61 (s, 1H), 7.97-7.92 (m, 1H), 7.69-7.64 (m, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.37 (d, J=7.9 Hz, 1H), 4.54-4.48 (m, 1H), 4.42-4.27 (m, 2H), 3.56-3.51 (m, 1H), 2.75 (s, 3H), 2.74 (s, 3H), 2.63-2.55 (m, 1H), 2.32-2.25 (m, 1H), 2.14 (s, 3H), 1.36 (s, 3H), 1.02-0.97 (m, 1H), 0.88-0.83 (m, 1H). LC/MS (ESI) m/z: 602/604 (M+H)+.
(1R,3S,5R)-2-{2-[3-Acetyl-5-({2-oxo-[1,2′-bipyridine]-3-yl}amino) indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.64-8.60 (m, 1H), 8.10 (d, J=1.6 Hz, 1H), 8.05-8.01 (m, 1H), 7.80 (d, J=8.1 Hz, 1H), 7.59-7.50 (m, 3H), 7.39-7.33 (m, 2H), 7.28-7.25 (m, 1H), 7.24-7.21 (m, 1H), 6.44-6.40 (m, 1H), 5.71 (d, J=17.2 Hz, 1H), 5.58 (d, J=17.1 Hz, 1H), 4.60-4.51 (m, 2H), 3.52-3.49 (m, 1H), 2.66 (s, 3H), 2.64-2.58 (m, 1H), 2.33-2.28 (m, 1H), 2.12 (s, 3H), 1.39 (s, 3H), 1.08-1.04 (m, 1H), 0.98-0.95 (m, 1H). LC/MS (ESI) m/z: 695 (M+H)+.
Figure US11708351-20230725-C01178
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a trifluromethyl group on the B-ring by utilizing Togni reagent to generate the B-ring synthetic intermediate. The skilled artisan will recognize that other B-rings with trifluromethyl functionality can be prepared to afford additional compounds of the present invention. The skilled artisan will also recognize that other A-rings can be coupled with the C- and B-ring shown above to afford compounds of the present invention.
Step 1: 5-Methyl-2-(trifluoromethoxy)pyridine (196-S2)
A dried glass was charged with 5-methyl-pyridin-2-ol (0.518 g) and Togni reagent (0.5 g) in nitromethane (10 mL). The reaction mixture was stirred at 100° C. for 5 hours in presence of air. After cooling the reaction mixture to room temperature, the reaction was diluted with water and extracted repeatedly with CH2Cl2. The combined organic layer was dried (Na2SO4) and concentrated to afford 196-S2, which was carried forward without additional purification in the next synthetic step without purification.
Step 2: 2-Trifluoromethoxy-2-methyl-pyridine-N-oxide (196-S3)
Crude 5-methyl-2-(trifluoromethoxy)pyridine (196-S2) in CH2Cl2 was cooled in an ice bath and solid hydrogen peroxide urea complex (0.688 g) was added followed by the dropwise addition of TFAA (1.7 mL). After the addition was complete, the cooling bath was removed and the reaction mixture was stirred overnight at room temperature. Additional hydrogen peroxide urea complex (0.688 g) and TFAA (1.7 mL) was added and the reaction mixture was stirred for 24 hours. The reaction mixture was diluted with CH2Cl2. The organic layer was washed with water, saturated aqueous sodium metabisulfite solution, and dried (Na2SO4). The organic layer was filtered and concentrated to afford 196-S3, which was carried forward without additional purification and used as such for the next step.
Step 3. N-(tert-Butyl)-3-methyl-6-(trifluoromethoxy)pyridin-2-amine (196-S4)
To a solution of 196-S3 (0.46 g) at −20° C. in CH2Cl2 (10 mL), tert-butylamine (1.25 mL) was added, followed by the dropwise addition of trifluoromethanesulfonic anhydride (1.2 mL). After stirring for 1 hour at −20° C., the reaction mixture was quenched with the addition of water. The layers were separated and the organic layer was washed with saturated K2CO3 solution, dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: hexanes) to afford 196-S4 as colorless liquid.
Step 4. 3-Methyl-6-(trifluoromethoxy)pyridin-2-amine TFA Salt (196-S5)
A solution of 196-S4 (50 mg) in TFA (1.0 mL) was stirred at room temperature for 24 hours. Then the volatiles were removed under reduced pressure and the residue was carried forward without additional purification in the next step (196-S5).
Step 5: tert-Butyl (1R,3S,5R)-5-methyl-3-((3-methyl-6-(trifluoromethoxy)pyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (196-S7)
To an ice cooled solution of 196-S5 (50 mg) and (1R,2S,5S)-3-(tert-butoxycarbonyl)-3-azabicyclo[3.1.0]hexane-2-carboxylic acid (196-S6, 53 mg) in CH2Cl2 (1.5 ml) pyridine (82 μL) was added, followed by the slow dropwise addition of POCl3 (20 μL) at 5° C. and the reaction mixture was stirred for 3 hours. Then saturated aqueous NaHCO3 solution was added and stirred for 1 h at room temperature. The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (10 mL). The combined organic layers were dried (Na2SO4), filtered, and concentrated. The residue was purified by silica gel flash column chromatography (eluent: 0-2% EtOAc in hexanes) to afford 196-S7.
Step 6: (1R,3S,5R)-5-Methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (196-S8)
Compound 196-S7 (11 mg) was stirred in TFA (0.25 mL) and CH2Cl2 (0.25 mL) for 30 minutes at room temperature. The reaction mixture was evaporated to dryness under reduced pressure and the remaining residue was carried forward without additional purification in the next synthetic step.
Step 7: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (196)
To a solution of 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (12 mg) in DMF (0.5 mL), iPr2NEt (35 μL, 5 equiv) was added, followed by the addition of 196-S7 (from above) at 5° C. HATU (16 mg, 1.1 equiv) was added slowly at this same temperature and the reaction mixture was stirred for 30 minutes at room temperature. The reaction mixture was taken to dryness and the residue was dissolved in CH2Cl2. The organic layer was washed with 1% aq. LiOH solution and water and dried (Na2SO4). After the filtration, the filtrate was concentrated under reduced pressure and the residue was purified by silica gel flash column chromatography (eluent: 0-2.5% MeOH in CH2Cl2) to afford 196 as white solid. 1H NMR (400 MHz, Chloroform-d) δ 0.77-0.96 (m, 2H), 1.42 (s, 3H), 2.09 (s, 3H), 2.29 (dd, J=8.8, 13.6 Hz, 1H), 2.71 (s, 3H), 2.66-2.77 (m, 1H), 2.81 (s, 3H), 3.20 (dd, J=2.4, 5.4 Hz, 1H), 4.88 (d, J=7.7 Hz, 1H), 5.50 (s, 2H), 6.80 (d, J=8.1 Hz, 1H), 7.53-7.66 (m, 3H), 8.58 (s, 1H), 8.68 (s, 1H), 8.90 (s, 2H). 19F-NMR (Chloroform-d): δ−56.6.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethoxy)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CDCl3): δ 0.84-0.90 (m, 1H), 1.16 (t, J=5.4 Hz, 1H), 1.43 (s, 3H), 2.12 (s, 3H), 2.35 (t, J=8.4 Hz, 1H), 2.53 (s, 3H), 2.66 (brs, 1H), 2.69 (s, 3H), 2.79 (s, 3H), 3.11 (d, J=4.4 Hz, 1H), 4.93 (s, 1H), 5.35 (d, J=17.6 Hz, 1H), 5.42 (d, J=17.7 Hz, 1H), 6.79 (d, J=8.1 Hz, 1H), 7.17 (s, 1H), 7.57 (d, J=8.1 Hz, 1H), 7.69 (s, 1H), 8.49 (brs, 1H), 8.55 (s, 1H), 8.89 (s, 2H). 19F (CDCl3): δ−56.5.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indol-1-yl)acetyl)-5-methyl-N-(3-methyl-6-(trifluoromethyl)pyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 0.88 (dd, J=2.4, 5.5 Hz, 1H), 1.16 (t, J=5.4 Hz, 1H), 1.43 (s, 3H), 2.22 (s, 3H), 2.36-2.42 (m, 1H), 2.53 (s, 3H), 2.67 (d, J=14 Hz, 1H), 2.72 (s, 3H), 2.79 (s, 3H), 3.13 (d, J=4.0 Hz, 1H), 4.65 (d, J=5.2 Hz, 1H), 5.31 (d, J=17.6 Hz, 1H), 5.48 (d, J=17.5 Hz, 1H), 7.19 (s, 1H), 7.42 (d, J=7.7 Hz, 1H), 7.65 (d, J=8 Hz, 1H), 7.69 (s, 1H), 8.55 (s, 1H), 8.57 (brs, 1H), 8.89 (s, 2H). 19F: δ−67.6.
Figure US11708351-20230725-C01179
Step 1: (1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (197-S2)
To the solution of 2-(tert-butyl) 3-ethyl (1R,3S,5S)-5-formyl-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (197-S1, 142 mg, 0.50 mmol) and p-toluenesulfonylmethyl isocyanide (146.4 mg, 0.75 mmol) in MeOH (15 mL), solid K2CO3 (1.50 mmol) was added. The mixture was refluxed overnight under argon. The reaction was cooled to room temperature and the volatiles were evaporated. The residue was loaded on a pad of silica gel and purified to afford 197-S2 (72 mg).
Step 2: tert-Butyl (1R,3S,5S)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (197-S3)
(1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (197-S1, 72 mg, 0.24 mmol) and 6-bromo-3-methylpyridin-2-amine (197-S2, 46 mg, 0.24 mmol) were dissolved in anhydrous DCM (6.0 mL) in a pre-dried flask. The flask was cooled in an ice bath and dry pyridine (0.25 mL, 3.0 mmol) was added in one portion, followed by POCl3 (100 μL, 1.0 mmol). After completion of the addition, the mixture was stirred for 4 hours at 0° C., and then the reaction was quenched with water (15 mL). The DCM layer was collected and the aqueous phase was extracted with DCM (15 mL×2). The combined DCM solution was washed with brine and dried over MgSO4. The solution was filtered and concentrated and the resulting residue was purified to afford 197-S3 (59.3 mg).
Step 3: (1R,3S,5S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (197-S4)
tert-Butyl (1R,3S,5S)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (197-S3, 59.3 mg, 0.13 mmol) was taken up in 4N HCl dioxane (2.0 mL) and the resulting reaction mixture was stirred at room temperature for 2 hours. After completion of the reaction (as monitored by HPLC), the solvent was removed under reduced pressure. The remaining residue 197-S4 was carried forward without additional purification.
Step 4: (1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (197)
To the solution of (1R,3S,5S)—N-(6-bromo-3-methylpyridin-2-yl)-5-(oxazol-5-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (197-S4, 0.13 mmol) and 2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetic acid (197-S5, 40 mg, 0.13 mmol) in DMF (2.0 mL), HATU (1.5 equiv, 0.20 mmol) was added, followed by the dropwise addition of DIEA (5.0 equiv) at room temperature. The mixture was stirred for 1 hour at room temperature and then the volatiles were evaporated. The residue was diluted with 10% sodium carbonate (50 mL) and extracted with ethyl acetate. The combined organic solutions were successively washed with water and brine and dried over MgSO4. The solution was filtered and the solvent was removed. The residue was purified to afford 197 (29.2 mg). 1H NMR (400 MHz, DMSO-d6): (major rotamer) δ 1.71 (d, J=4.6 Hz, 2H), 2.03 (s, 3H), 2.59 (dd, J=13.5, 4.8 Hz, 1H), 2.66 (s, 3H), 2.69 (s, 3H), 2.82 (dd, J=13.5, 9.2 Hz, 1H), 4.20 (t, J=4.6 Hz, 1H), 4.60 (dd, J=9.2, 4.7 Hz, 1H), 5.65 (d, J=17.3 Hz, 1H), 5.97 (d, J=17.3 Hz, 1H), 7.15 (s, 1H), 7.44 (d, J=7.9 Hz, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.87 (s, 2H), 8.31 (s, 1H), 8.45 (s, 1H), 9.04 (s, 2H), 10.38 (s, 1H) ppm. LC (method A): tR=1.55 min. LC/MS (EI) m/z: [M+H]+ 655.07, 657.16
Figure US11708351-20230725-C01180
To a solution of 121 (1 equiv) in DMF (10 vol) was added potassium carbonate (3 equiv) and oxetan-3-yl 4-methylbenzenesulfonate (2 equiv). The reaction mixture was heated to 100° C. for 12 hours. The reaction mixture was quenched with water and the resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative purification to afford 208. 1H NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 8.94 (d, J=2.6 Hz, 1H), 8.42 (d, J=2.3 Hz, 1H), 8.21 (s, 1H), 7.62 (d, J=8.0 Hz, 1H), 7.51 (s, 1H), 7.44 (d, J=8.0 Hz, 1H), 6.02 (d, J=17.3 Hz, 1H), 5.65 (d, J=18.0 Hz, 1H), 5.41-5.38 (m, 1H), 4.93-4.84 (m, 4H), 4.34-4.32 (m, 1H), 3.59-3.58 (m, 1H), 2.65 (s, 3H), 2.64-2.63 (m, 1H), 2.58 (s, 3H), 2.04 (s, 3H), 2.01-1.98 (m, 1H), 1.32 (s, 3H), 1.01-0.94 (m, 2H).
Figure US11708351-20230725-C01181
Step 1: tert-Butyl 2-(3-carbamoyl-5-(pyridin-3-yl)-1H-pyrazol-1-yl)acetate (211-S3)
To a solution of 5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide (211-S1, 1 equiv) in CH3CN (10 vol) was added tert-butyl 2-bromoacetate (211-S2, 1.1 equiv) and potassium carbonate (1.1 equiv). The mixture was refluxed overnight under an atmosphere of argon. After cooling the reaction mixture to room temperature, the mixture was filtered through Celite and washed with CH3CN. The filtrate was concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with DCM/EtOAc) to afford compound 211-S3.
Step 2: 2-(3-Carbamoyl-5-(pyridin-3-yl)-1H-pyrazol-1-yl)acetic Acid (211-S4)
To a solution of compound 211-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material (211-S4) was carried forward in the next synthetic step without additional purification.
Step 3: 1-(2-((2S,4R)-2-((6-Bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(pyridin-3-yl)-1H-pyrazole-3-carboxamide (211)
To a solution of compound 211-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and then quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 211. 1H NMR (400 MHz, DMSO-d6) δ 2.02-2.24 (m, 1H), 2.54-2.61 (m, 1H), 3.73-3.89 (m, 1H), 4.00-4.17 (dd, J=12.9, 21.3 Hz, 1H), 4.62-4.71 (t, J=8.3 Hz, 1H), 5.03-5.13 (d, J=17.4 Hz, 1H), 5.34-5.58 (m, 2H), 6.81-6.92 (d, J=2.7 Hz, 1H), 7.26-7.31 (s, 1H), 7.33-7.37 (d, J=7.7 Hz, 1H), 7.46-7.57 (m, 2H), 7.71-7.78 (t, J=8.0 Hz, 1H), 7.84-7.89 (m, 1H), 8.03-8.12 (d, J=8.2 Hz, 1H), 8.57-8.75 (m, 2H), 10.18-11.70 (s, 1H).
Figure US11708351-20230725-C01182
Step 1: tert-Butyl 2-(3-carbamoyl-5-(furan-2-yl)-1H-pyrazol-1-yl)acetate and tert-butyl 2-(5-carbamoyl-3-(furan-2-yl)-1H-pyrazol-1-yl)acetate (212-S3 and 213-S4)
To a solution of 5-(furan-2-yl)-1H-pyrazole-3-carboxamide (213-S1, 1 equiv) in CH3CN (10 vol) was added tert-butyl 2-bromoacetate (213-S2, 1.1 equiv) and potassium carbonate (1.1 equiv). The mixture was refluxed overnight under an atmosphere of argon. After cooling the reaction mixture to room temperature, the mixture was filtered through Celite and washed with CH3CN. The filtrate was concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with EtOAc/DCM) to afford a mixture of compounds 212-S3 and 213-S4. This mixture was carried forward as mixture without additional purification.
Step 2: 2-(3-Carbamoyl-5-(furan-2-yl)-1H-pyrazol-1-yl)acetic Acid and 2-(5-carbamoyl-3-(furan-2-yl)-1H-pyrazol-1-yl)acetic Acid (212-S5 and 213-S6)
To a solution of compound 212-S3 and 213-S4 (1 equiv, Mixture) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material (a mixture of 212-S5 and 213-S6) was carried forward as mixture without additional purification.
Step 3: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(3-carbamoyl-5-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (212) and (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(5-carbamoyl-3-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (213)
To a solution of compound 212-S5 and 213-S6 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (213-S7, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compounds 212 and 213.
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(3-carbamoyl-5-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (212)
1H NMR (400 MHz, DMSO-d6) δ 0.87 (dd, J=2.4, 5.4 Hz, 1H), 0.99 (t, J=5.5 Hz, 1H), 1.21-1.34 (m, 4H), 1.94-2.08 (m, 4H), 3.51 (dd, J=2.4, 5.6 Hz, 1H), 4.36 (dd, J=5.5, 9.2 Hz, 1H), 5.38 (d, J=17.4 Hz, 1H), 5.52 (d, J=17.3 Hz, 1H), 6.60 (dd, J=1.8, 3.5 Hz, 1H), 6.79 (d, J=3.4 Hz, 1H), 6.96 (s, 1H), 7.28 (s, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.52 (s, 1H), 7.62 (d, J=7.9 Hz, 1H), 7.79 (d, J=1.7 Hz, 1H), 10.28 (s, 1H).
(1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(5-carbamoyl-3-(furan-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (213)
1H NMR (400 MHz, DMSO-d6) δ 0.83-0.93 (m, 1H), 0.99 (t, J=5.4 Hz, 1H), 1.20-1.32 (m, 4H), 1.98-2.10 (m, 4H), 3.37-3.43 (m, 1H), 4.35 (dd, J=5.0, 9.2 Hz, 1H), 5.51 (d, J=16.4 Hz, 1H), 5.69 (d, J=16.3 Hz, 1H), 6.58 (dd, J=1.7, 3.4 Hz, 1H), 6.69 (t, J=3.9 Hz, 1H), 7.19 (s, 1H), 7.42-7.50 (m, 2H), 7.63 (d, J=7.9 Hz, 1H), 7.73 (d, J=1.7 Hz, 1H), 8.02 (s, 1H), 10.18 (s, 1H).
Figure US11708351-20230725-C01183
Step 1: tert-Butyl 2-(3-carbamoyl-5-(thiophen-2-yl)-1H-pyrazol-1-yl)acetate (214-S3)
To a solution of 5-(thiophen-2-yl)-1H-pyrazole-3-carboxamide (214-S1, 1 equiv) in CH3CN (10 vol) was added tert-butyl 2-bromoacetate (214-S2, 1.1 equiv) and potassium carbonate (1.1 equiv). The mixture was refluxed overnight under an atmosphere of argon. After cooling the reaction mixture to room temperature, the mixture was filtered through Celite and washed with CH3CN. The filtrate was concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (eluted with DCM/EtOAc) to afford compound 214-S3.
Step 2: 2-(3-Carbamoyl-5-(thiophen-2-yl)-1H-pyrazol-1-yl)acetic acid (214-S4)
To a solution of compound 214-S3 (1 equiv) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material (214-S4) was used directly in the next synthetic step without additional purification.
Step 3: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-2-(2-(3-carbamoyl-5-(thiophen-2-yl)-1H-pyrazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (214)
To a solution of compound 214-S4 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (214-S5, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 214. 1H NMR (400 MHz, DMSO-d6) δ 0.77 (dd, J=2.3, 5.3 Hz, 1H), 0.93 (t, J=5.4 Hz, 1H), 1.09-1.32 (m, 4H), 1.98-2.05 (m, 1H), 2.07 (s, 3H), 3.47 (dd, J=2.3, 5.6 Hz, 1H), 4.38 (dd, J=5.5, 9.2 Hz, 1H), 5.24 (d, J=17.4 Hz, 1H), 5.44 (d, J=17.4 Hz, 1H), 6.86 (s, 1H), 7.13 (dd, J=3.7, 5.1 Hz, 1H), 7.24-7.33 (m, 2H), 7.46 (d, J=7.9 Hz, 1H), 7.53 (s, 1H), 7.64 (d, J=7.9 Hz, 1H), 7.70 (dd, J=1.1, 5.1 Hz, 1H), 10.30 (s, 1H)
Figure US11708351-20230725-C01184
Figure US11708351-20230725-C01185
Figure US11708351-20230725-C01186
Step 1: Ethyl 5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxylate (215-S3)
To a solution of ethyl 5-iodo-1H-pyrazole-3-carboxylate (215-S1, 1 equiv) in dioxane/H2O (9:1, 10 vol) was added compound 215-S2 (1 equiv), Cs2CO3 (3 equiv), and tetrakis(triphenylphosphine)palladium (0.1 equiv). The reaction mixture was stirred at 90° C. for 5 hours and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 215-S3.
Step 2: tert-Butyl 2-(3-carbamoyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl)acetate and ethyl 1-(2-(tert-Butoxy)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-5-carboxylate (215-S5 and 215-S6)
To a solution of ethyl 5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxylate (215-S3, 1 equiv) in CH3CN (10 vol) was added tert-butyl 2-bromoacetate (215-S2, 1.1 equiv) and potassium carbonate (1.1 equiv). The mixture was refluxed overnight under an atmosphere of argon. After cooling the reaction mixture to room temperature, the mixture was filtered through Celite and washed with CH3CN. The filtrate was concentrated under reduced pressure and the remaining residue was purified by column chromatography on silica gel (elute with DCM/EtOAc) to afford a mixture of compounds 215-S5 and 215-S6. The mixture was carried forward without additional purification.
Step 3: 2-(3-(Ethoxycarbonyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl)acetic Acid and 2-(5-(ethoxycarbonyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazol-1-yl)acetic Acid (215-S7 and 215-S8)
To a solution of compounds 215-S5 and 215-S6 (1 equiv, Mixture) in DCM (10 vol) at 0° C. under an atmosphere of argon was added TFA (5 vol). The reaction mixture was stirred at room temperature for 3 hours and concentrated to dryness. The remaining material (a mixture of 215-S7 and 215-S8) was carried forward without additional purification.
Step 4: Ethyl 1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxylate (215-S10) and Ethyl 1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-4-carboxylate (215-S11)
To a solution of compounds 215-S7 and 215-S8 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added (2S,4R)—N-(6-bromopyridin-2-yl)-4-fluoropyrrolidine-2-carboxamide hydrochloride (215-S9, 1 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford separate pure compounds 215-S10 and 215-S11.
Step 5: 1-(2-((2S,4R)-2-((6-Bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxylic Acid (215-S12)
To a solution of ethyl 1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxylate (215-S10, 1 equiv) in THF/H2O (3:1, 10 vol) was added LiOH (2.1 equiv). The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure to remove the volatiles. The remaining water was neutralized using 2N HCl before the solid was filtered and purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 215-S12.
Step 6: 1-(2-((2S,4R)-2-((6-Bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-pyrazole-3-carboxamide (215)
To a solution of compound 215-S12 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added NH4Cl (3 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 215. 1H NMR (400 MHz, DMSO-d6) δ 2.03-2.23 (m, 1H), 2.52-2.58 (m, 1H), 2.66 (s, 3H), 3.81-3.98 (m, 1H), 4.10 (dd, J=12.5, 21.9 Hz, 1H), 4.66 (t, J=8.4 Hz, 1H), 5.36 (d, J=16.5 Hz, 1H), 5.41-5.57 (m, 1H), 5.73 (d, J=16.5 Hz, 1H), 7.33 (d, J=7.7 Hz, 1H), 7.43 (s, 1H), 7.54 (s, 1H), 7.71 (t, J=8.0 Hz, 1H), 7.97-8.06 (m, 2H), 9.00 (d, J=3.7 Hz, 2H), 10.98 (s, 1H).
Figure US11708351-20230725-C01187
Step 1: 1-(2-((2S,4R)-2-((6-Bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-4-carboxylic Acid (216-S2)
To a solution of ethyl 1-(2-((2S,4R)-2-((6-bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-4-carboxylate (216-S1, 1 equiv) in THF/H2O (3:1, 10 vol) was added LiOH (2.1 equiv). The reaction mixture was stirred at room temperature for 5 hours and concentrated under reduced pressure to remove the volatiles. The remaining water was neutralized using 2N HCl before the solid was filtered and purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 216-S2.
Step 2: 1-(2-((2S,4R)-2-((6-Bromopyridin-2-yl)carbamoyl)-4-fluoropyrrolidin-1-yl)-2-oxoethyl)-3-(2-methylpyrimidin-5-yl)-1H-pyrazole-4-carboxamide (216)
To a solution of compound 216-S2 (1 equiv) in DMF (10 vol) at 0° C. under an atmosphere of argon was added NH4Cl (3 equiv), HATU (2.1 equiv), and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water (30 vol). The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The remaining residue was purified by column chromatography on silica gel (eluted with DCM/MeOH) to afford compound 216. 1H NMR (400 MHz, DMSO-d6) δ 1.92-2.12 (m, 1H), 2.45-2.50 (m, 1H), 2.61 (d, J=3.1 Hz, 3H), 3.64-3.83 (m, 1H), 3.94-4.08 (m, 1H), 4.57 (t, J=8.5 Hz, 1H), 5.10 (d, J=17.5 Hz, 1H), 5.31-5.50 (m, 2H), 6.89 (s, 1H), 7.19-7.29 (m, 2H), 7.44 (s, 1H), 7.62-7.71 (m, 1H), 7.95 (d, J=8.2 Hz, 1H), 8.69 (s, 2H), 10.94 (s, 1H).
Figure US11708351-20230725-C01188
Figure US11708351-20230725-C01189
Step 1: 4-Bromo-2-iodo-6-methylaniline (220-S2)
To a solution of compound 220-S1 (5 g, 26.88 mmol) in EtOH (100 mL) was added I2 (6.828 g, 26.88 mmol) and Ag2SO4 (8.382 g, 26.88 mmol). The mixture was stirred at room temperature overnight. The mixture was quenched with aqueous Na2S2O3 solution and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether to afford compound 220-S2 (6.31 g, 75.5%) as a light brown solid. LC/MS (ESI) m/z: 312 (M+H)+.
Step 2: 5-Bromo-7-iodo-1H-indazole (220-3)
To a solution of compound 220-S2 (6.31 g, 20.29 mmol) and potassium acetate (2.386 g, 24.35 mmol) in CHCl3 (100 mL) was added acetic anhydride (6.209 g, 60.87 mmol) dropwise at 0° C. under N2 atmosphere and the mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60° C. and tert-butyl nitrite (10.3 g, 0.1 mol) was added and the reaction was stirred at 60° C. overnight. The mixture was diluted with water and extracted with DCM (2×). The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was dissolved in MeOH and 6 N HCl (v/v=1:1), and the mixture was stirred at room temperature for 5 hours. The mixture was basified with 10 N aqueous NaOH solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100:1 to 8:1) to afford compound 220-S3 (3.73 g, 57.1%) as a light yellow solid. LC/MS (ESI) m/z: 323 (M+H)+.
Step 3: 5-Bromo-7-vinyl-1H-indazole (220-S4)
To a solution of compound 220-S3 (1.9 g, 5.92 mmol) in DME/H2O (40 mL, v/v=3/1) was added potassium trifluoro(vinyl)borate (0.793 g, 5.92 mmol), K2CO3 (0.980 g, 7.10 mmol) and Pd(PPh3)4 (0.684 g, 0.59 mmol). The mixture was degassed under N2 atmosphere three times and stirred at 85° C. under N2 atmosphere overnight. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100:1 to 8:1) to afford compound 220-S4 (0.78 g, 59.4%) as a light yellow solid. LC/MS (ESI) m/z: 223 (M+H)+.
Step 4: 1-(5-Bromo-1H-indazol-7-yl) ethanol (220-S5)
To a solution of compound 220-S4 (0.78 g, 3.51 mmol) in anhydrous THF (20 mL) was added BH3-THF (1.13 mL, 1 M in THF) dropwise at 0° C. under N2 atmosphere and the mixture was stirred at reflux overnight. The mixture was cooled to 0° C. and 3 N aqueous NaOH solution was added followed by 30% H2O2. The mixture was stirred at room temperature for 1 hour. The solvent was removed and the residue was dissolved in DCM. The mixture was washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100:1 to 6:1) to afford compound 220-S5 (170 mg, 20.1%) as a light brown solid. LC/MS (ESI) m/z: 242 (M+H)+.
Step 5: 5-Bromo-7-(1-fluoroethyl)-1H-indazole (220-S6)
To a solution of compound 220-S5 (0.16 g, 0.66 mmol) in anhydrous DCM (5 mL) was added DAST (0.22 g, 1.33 mmol) dropwise at −70° C. under N2 atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred for 2 hours. The reaction was quenched with aqueous NaHCO3 solution at 0° C. and diluted with DCM. The layers were separated and the organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100:1 to 6:1) to afford compound 220-S6 (70 mg, 43.5% yield) as a light white solid. LC/MS (ESI) m/z: 244 (M+H)+.
Step 6: 5-Bromo-7-(1-fluoroethyl)-3-iodo-1H-indazole (220-S7)
To a solution of compound 220-S6 (70 mg, 0.29 mmol) in DMF (2 mL) was added KOH (40 mg, 0.72 mmol) followed by I2 (110 mg, 0.43 mmol) at 0° C. and the mixture was stirred at room temperature for 2 hours. The reaction was quenched with aqueous Na2S2O3 solution, diluted with water, and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (80:1 to 6:1) to afford compound 220-S7 (80 mg, 75.5% yield) as a light yellow solid. LC/MS (ESI) m/z: 370 (M+H)+.
Step 7: tert-Butyl 2-(5-bromo-7-(1-fluoroethyl)-3-iodo-1H-indazol-1-yl) acetate (220-S8)
To a solution of compound 220-S7 (80 mg, 0.22 mmol) in DMF (2 mL) was added K2CO3 (75 mg, 0.54 mmol) and tert-butyl 2-bromoacetate (46 mg, 0.24 mmol). The mixture was stirred at room temperature overnight and then diluted with H2O and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated. The obtained crude product was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (100:1 to 20:1) to afford compound 220-S8 (50 mg, 47.7% yield) as a light yellow solid. LC/MS (ESI) m/z: 485 (M+H)+.
Step 8: tert-Butyl 2-(3-acetyl-5-bromo-7-(1-fluoroethyl)-1H-indazol-1-yl) acetate (220-S9)
To a solution of compound 220-S8 (50 mg, 0.10 mmol) in dry toluene (3 mL) was added tributyl(1-ethoxyvinyl)stannane (45 mg, 0.12 mmol) and Pd(PPh3)4 (12 mg, 0.01 mmol). The mixture was stirred at 100° C. under N2 atmosphere overnight. The mixture was cooled to room temperature, 0.5 M aqueous HCl was added, and the mixture was stirred at room temperature for 30 minutes. The reaction mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na2SO4, and concentrated. The obtained crude product is purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (80:1 to 8:1) to afford compound 220-S9 (30 mg, 73.2% yield) as a milky white solid. LC/MS (ESI) m/z: 399 (M+H)+.
Step 9: tert-Butyl 2-(3-acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetate (220-S10)
A round-bottom flask was charged with compound 220-S9 (30 mg, 0.075 mmol), 2-methylpyrimidin-5-ylboronic acid (11 mg, 0.083 mmol), K2CO3 (26 mg, 0.19 mmol) in dioxane/H2O (2 mL, v/v=5:1). Tetrakis(triphenylphosphine) palladium(0) (9 mg, 0.008 mmol) was added to the mixture under N2 atmosphere and the reaction was stirred at 90° C. overnight under N2 atmosphere. The mixture was diluted with EtOAc and washed with brine, dried over anhydrous Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel eluted with petroleum ether/EtOAc (50:1 to 3:1) to afford compound 220-S10 (18 mg, 58.1% yield) as a light yellow solid. LC/MS (ESI) m/z: 413 (M+H)+.
Step 10: 2-(3-Acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetic Acid (220-S11)
To a solution of compound 220-S10 (18 mg, 0.044 mol) in DCM (1 mL) was added TFA (0.5 mL) and the mixture was stirred at room temperature for 1.5 hours. The solvent was removed and the residue was washed with ether and dried under vacuum to afford compound 220-S11 (10 mg, 64.3% yield) as a light yellow solid. LC/MS (ESI) m/z: 357 (M+H)+.
Step 11: (1R, 3S, 5R)-2-(2-(3-Acetyl-7-(1-fluoroethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl) acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo 13.1.01 hexane-3-carboxamide (220)
To a mixture of compound 220-S11 (9 mg, 0.025 mmol) and compound 220-S12 (10 mg, 0.032 mmol) in DMF (1 mL) was added DIPEA (15 mg, 0.12 mmol) followed by HATU (24 mg, 0.064 mmol). The reaction was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by prep-HPLC to afford 220 (2 mg, 12.5%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 9.03 (s, 2H), 8.68-8.62 (m, 1H), 7.83 (s, 1H), 7.54 (d, J=8.0 Hz, 1H), 7.38 (d, J=8.0 Hz, 1H), 6.44-6.05 (m, 1H), 6.03-5.78 (m, 2H), 4.58-4.46 (m, 1H), 3.52 (dd, J=5.6, 2.4 Hz, 1H), 2.76 (s, 3H), 2.70 (d, J=1.6 Hz, 3H), 2.63 (dd, J=13.2, 9.2 Hz, 1H), 2.35-2.26 (m, 1H), 2.11 (s, 3H), 1.96-1.82 (m, 3H), 1.42 (s, 3H), 1.16-1.10 (m, 1H), 1.03-0.97 (m, 1H). LC/MS (ESI) m/z: 648 (M+H)+.
Figure US11708351-20230725-C01190
Figure US11708351-20230725-C01191
Step 1: (1R,3S,5S)-3-((6-Bromo-3-methylpyridin-2-yl)carbamoyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-5-carboxylic Acid (222-S2)
To a mixture of compound 222-S1 (380 mg, 0.89 mmol) in t-BuOH (10 mL) was added aqueous NaOH (3.12 mL, 1M, 3.12 mmol), followed by potassium permanganate (281 mg, 1.78 mmol) dissolved in water (20 mL) at 0° C. The reaction was stirred at 30° C. overnight and the solvent was removed under vacuum. The residue was acidified by 2N aqueous HCl and extracted with DCM/i-PrOH (3/1, v/v) twice. The combined organic layers were dried over anhydrous Na2SO4 and concentrated. The crude product was purified by silica gel column (eluted with DCM/MeOH=50/1) to afford compound 222-S2 (220 mg, 57.8% yield) as a white solid. LC/MS (ESI) m/z: 440/442 (M+H)+.
Step 2: (1R,3S,5S)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-carbamoyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (222-S3)
To a mixture of the compound 222-S2 (220 mg, 0.50 mmol) and ammonium chloride (53 mg, 2.50 mmol) in DMF (4 mL) was added HBTU (379 mg, 1.0 mmol) and DIPEA (0.16 mL, 1.0 mmol) at 0° C. The reaction was stirred at room temperature for 16 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The crude product was purified by silica gel column (eluted with DCM/MeOH=60/1) to afford compound 222-S3 (200 mg, 90.1% yield) as a white solid. LC/MS (ESI) m/z: 439/441 (M+H)+.
Step 3: (1R,3S,5S)—N3-(6-Bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3,5-dicarboxamide (222-4)
To a solution of compound 222-S3 (80 mg, 0.18 mmol) in dioxane (1 mL) was added HCl/dioxane (4 M, 1 mL). The reaction mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated to afford compound 222-S4 (80 mg, 100% yield) as a white solid, which was directly used to the next reaction without additional purification. LC/MS (ESI) m/z: 339/341 (M+H)+
Step 4: (1R,3S,5S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N3-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3,5-dicarboxamide (221)
To a solution of the compound 222-S4 (80 mg, 0.18 mmol), 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (59 mg, 0.18 mmol) and HATU (138 mg, 0.36 mmol) in DMF (2 mL) was added DIPEA (0.12 mL, 0.73 mmol). The reaction was stirred at room temperature for 2 hours. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column (eluted with DCM/MeOH=60/1) to afford 221 (30 mg, 25.6% yield) as a white solid. 1H-NMR (400 MHz, CD3OD) δ 9.04 (s, 2H), 8.43 (s, 1H), 7.65 (d, J=7.4 Hz, 1H), 7.57 (s, 1H), 7.44 (d, J=7.4 Hz, 1H), 5.82 (m, 1H), 5.71 (m, 1H), 5.36 (m, 1H), 4.72 (m, 1H), 3.29-3.31 (m, 2H), 2.67-2.80 (m, 10H), 2.26 (s, 3H), 0.85-0.89 (m, 2H). LC/MS (ESI) m/z: 645/647 (M+H)+.
Step 5: (1R,3S,5S)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-cyano-2-azabicyclo[3.1.0]hexane-3-carboxamide (222)
To a solution of 221 (20 mg, 0.03 mmol) and pyridine (4.9 mg, 0.06 mmol) in dry THF (3 mL) was added TFAA (31.5 mg, 0.25 mmol). The reaction was stirred at 60° C. for 12 hours and then concentrated under reduced pressure. The residue product was purified by prep-TLC to afford 222 (3.5 mg, 17.5% yield) as a white solid. 1H-NMR (400 MHz, CD3OD) δ 9.04 (s, 2H), 8.43 (s, 1H), 7.65 (d, J=7.4 Hz, 1H), 7.57 (s, 1H), 7.44 (d, J=7.4 Hz, 1H), 5.82 (m, 1H), 5.71 (m, 1H), 5.36 (m, 1H), 4.72 (m, 1H), 3.46-3.51 (m, 1H), 2.67-2.80 (m, 9H), 2.01-2.11 (m, 1H), 2.24 (s, 3H), 0.85-0.89 (m, 2H). LC/MS (ESI) m/z:627/629 (M+H)+.
Figure US11708351-20230725-C01192
Figure US11708351-20230725-C01193
Step 1: (2S,4R)-1-tert-Butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate (223-S2)
To a solution of compound 223-S1 (10 g, 43.7 mmol) in DMF (100 mL) was added K2CO3 (18.1 g, 131.3 mmol) followed by MeI (9.31 g, 65.6 mmol) at 0° C. and the reaction was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=5:1 to 2:1) to afford compound 223-S2 (10.1 g, 94.4% yield) as white solid. LC/MS (ESI) m/z: 246 (M+H)+.
Step 2: (S)-1-tert-Butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate (223-S3)
To a solution of compound 223-S2 (10 g, 41.2 mmol) in DCM (100 mL) was added TCCA (10.04 g, 43.2 mmol) followed by TEMPO (64.3 mg, 0.41 mmol) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was filtered, the filtrate was washed with saturated potassium carbonate solution and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=10:1) to afford compound 223-S3 (8 g, 80.7% yield) as a white solid. LC/MS (ESI) m/z: 244 (M+H)+.
Step 3: (2S)-1-tert-Butyl 2-methyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate (223-S4)
To a solution of compound 223-S3 (6 g, 24.7 mmol) in THF (100 mL) was added TMSCF3 (5.26 g, 37.0 mmol) followed by TBAF (0.15 mL, 0.15 mmol, 1 mol/L in THF) at 0° C. and the reaction was stirred at room temperature overnight. The reaction was quenched with aqueous NH4Cl solution and extracted with EtOAc twice. The combined organic layers were washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=20:1) to afford compound 223-S4 (4.4 g, 56.8% yield) as a yellow oil. LC/MS (ESI) m/z: 314 (M+H)+.
Step 4: (2S)-tert-Butyl 4-hydroxy-2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S5)
To a solution of compound 223-S4 (4.4 g, 14.1 mmol) in THF (56 mL) was added LiCl (1.31 g, 30.91 mmol) and NaBH4 (1.33 g, 35.1 mmol) followed by the dropwise addition of EtOH (112 mL) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour and was allowed to warm to room temperature and stir overnight. The mixture was cooled at 0° C. and acidified to pH=4 with 10% aqueous citric acid solution. The mixture was extracted with DCM and washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=15:1) to afford compound 223-S5 (3.4 g, 85.0% yield) as a yellow oil. LC/MS (ESI) m/z: 286 (M+H)+.
Step 5: (2S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-hydroxy-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S6)
To a solution of compound 223-S5 (3.4 g, 11.9 mmol) in DCM (50 mL) was added TEA (1.2 g, 11.9 mmol) and TBDMSCl (2.15 g, 14.28 mmol) at 0° C. and the reaction was stirred at room temperature overnight under N2 atmosphere. The reaction mixture was diluted with DCM, washed with saturated aqueous NH4Cl solution and brine, dried over Na2SO4, and concentrated under reduced pressure to remove the volatiles. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=60:1) to afford compound 223-S6 (4.2 g, 88.3% yield) as yellow oil. LC/MS (ESI) m/z: 400 (M+H)+.
Step 6: (2S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(tosyloxy)-4 (trifluoromethyl)pyrrolidine-1-carboxylate (223-S7)
To a solution of compound 223-S6 (4 g, 10.0 mmol) in THF (40 mL) was added NaH (802 mg, 20.0 mmol) at 0° C. The mixture was stirred at room temperature for 30 minutes and tosyl chloride (3.82 g, 20.0 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature overnight under N2 atmosphere. The reaction was quenched with saturated aqueous NH4Cl solution and the mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=80:1) to afford compound 223-S7 (4.9 g, 88.5%) as yellow oil. LC/MS (ESI) m/z: 554 (M+H)+.
Step 7: (S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(trifluoromethyl)-2,3-dihydro-1H-pyrrole-1-carboxylate (223-S8)
To a solution of compound 223-S7 (4.2 g, 7.59 mmol) in THF (40 mL) was added t-BuOK (1.70 g, 15.19 mmol) at −78° C. and the reaction was stirred at room temperature for 2 hours under N2 atmosphere. The reaction was quenched with cooled water and the mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=80:1) to afford compound 223-S8 (1.6 g, 55.3% yield) as a yellow oil. LC/MS (ESI) m/z: 382 (M+H)+.
Step 8: (2S,4S)-tert-Butyl 2-(((tert-butyldimethylsilyl)oxy)methyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S9)
To a solution of compound 223-S8 (300 mg, 0.78 mmol) in EtOAc (5 ml) was added Pd/C (15 mg, 10% wt). The reaction mixture was stirred under a H2 balloon at room temperature for 2 hours. The mixture was filtered and concentrated to dryness to afford compound 223-S9 (280 mg, 93.3%) as a brown oil. LC/MS (ESI) m/z: 384 (M+H)+.
Step 9: (2S,4S)-tert-Butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S10)
To a solution of compound 223-S9 (280 mg, 0.73 mmol) in THF (5 ml) was added TBAF (1 mol/L in THF)(3.65 mL, 3.65 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour under a nitrogen atmosphere. The reaction mixture was diluted with EtOAc, washed with saturated NH4Cl and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=20:1) to afford compound 223-S10 (200 mg, 96.6% yield) as a yellow oil. LC/MS (ESI) m/z: 270 (M+H)+.
Step 10: (2S,4S)-1-(tert-Butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic Acid (223-S11)
To a solution of compound 223-S10 (200 mg, 0.72 mmol) in THF (5 ml) was added NMO (842 mg, 7.20 mmol) and TPAP (25.2 mg, 0.073 mmol). The reaction mixture was stirred at room temperature for 2 hours under a nitrogen atmosphere. The reaction mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (DCM:CH+OH=50:1) to afford compound 223-S11 (150 mg, 71.4%) as a yellow oil. LC/MS (ESI) m/z: 284 (M+H)+.
Step 11: (2S,4S)-tert-Butyl 2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (223-S12)
To a solution of compound 223-S11 (50 mg, 0.18 mmol) and 6-bromo-3-methylpyridin-2-amine (33.3 mg, 0.18 mmol) in DCM (3 mL) was added pyridine (71.1 mg, 0.90 mmol) at 0° C. followed by the dropwise addition of POCl3 (27.54 mg, 0.18 mmol). The reaction mixture was stirred at 0° C. for 30 minutes. The reaction mixture was quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel column (eluted with DCM/MeOH=50/1) to afford compound 223-S12 (45 mg, 57.0%) as a white solid. LC/MS (ESI) m/z: 452/454 (M+H)+.
Step 12: (2S,4S)—N-(6-Bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide TFA Salt (223-S13)
To a solution of compound 223-S12 (45 mg, 0.10 mmol) in DCM (2.5 mL) was added TFA (1 mL). The reaction was stirred at room temperature for 1.5 hours and then concentrated under reduced pressure to afford compound 223-S13 (50 mg, 100.0% yield) as a yellow solid, which was directly carried forward in the next step without additional purification. LC/MS (ESI) m/z: 352/354 (M+H)+.
Step 13: (2S,4S)-1-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-(trifluoromethyl)pyrrolidine-2-carboxamide (223)
To a solution of the compound 223-S13 (50 mg, 0.10 mmol), compound 223-S14 (32.4 mg, 0.10 mmol) and HATU (76.0 mg, 0.20 mmol) in DMF (2 mL) was added DIPEA (0.07 mL, 0.40 mmol) at 0° C. The reaction was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by prep-HPLC to afford 233 (5.2 mg, 7.9% yield) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.99 (d, J=3.4 Hz, 2H), 8.41 (s, 1H), 7.53 (d, J=8.4 Hz, 2H), 7.37 (d, J=7.9 Hz, 1H), 5.78 (s, 2H), 4.72 (t, J=8.3 Hz, 1H), 4.37-4.29 (m, 1H), 3.87 (t, J=10.4 Hz, 1H), 3.48 (s, 1H), 2.74 (s, 7H), 2.67 (s, 3H), 2.28 (d, J=5.8 Hz, 1H), 2.08 (s, 3H). LC/MS (ESI) m/z:658/660 (M+H)+.
Figure US11708351-20230725-C01194
Figure US11708351-20230725-C01195
Step 1: tert-Butyl 2-fluoroethylcarbamate (227-S2)
To a solution of 227-S1 (500 mg, 5.03 mmol) in THF (5 mL)/H2O (5 mL) was added NaHCO3 (1.69 g, 20.1 mmol) and Boc2O (1.31 g, 6.03 mmol) at 0° C. The reaction mixture was stirred at room temperature overnight. The mixture was diluted with EtOAc and washed with H2O solution and brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by silica gel column (eluted with PE:EtOAc=20:1 to 10:1) to afford compound 227-S2 (400 mg, 48.8%) as a white solid. LC/MS (ESI) m/z: 108 (M−56+H)+.
Step 2: tert-Butyl bis(2-fluoroethyl)carbamate (227-S3)
To a solution of 227-S2 (200 mg, 1.23 mmol) in DMF (5 mL) was added NaH (59 mg, 1.47 mmol) at 0° C. After stirring at room temperature for 30 minutes, 1-fluoro-2-iodoethane (235 mg, 1.35 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours. The mixture was diluted with H2O at 0° C., extracted with EtOAc, washed with water and brine, dried over Na2SO4, and concentrated to dryness. The residue was purified by silica gel column (eluted with PE:EtOAc=30:1 to 20:1) to afford compound 227-S3 (130 mg, 50.6%) as a white solid. LC/MS (ESI) m/z: 154 (M−56+H)+.
Step 3: Bis(2-fluoroethyl)amine (227-S4)
To a solution of compound 227-S3 (130 mg, 0.62 mmol) in dioxane (1 mL) was added HCl/dioxane (1 mL, 4 M) and the reaction mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness to afford compound 227-S4 (120 mg, 100%) as a white solid, which was directly used in the next reaction without further purification. LC/MS (ESI) m/z: 110 (M+H)+.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-((bis(2-fluoroethyl)amino)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (227)
To a solution of compound 227-S5 (30 mg, 0.05 mmol) in MeCN (3 mL) was added DIPEA (0.03 mL, 0.21 mmol), NaI (8 mg, 0.05 mmol) and compound 227-S4 (120 mg, 0.62 mmol). The reaction mixture was stirred at 60° C. overnight. The mixture was partitioned with EtOAc and water. The organic layer was washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The residue was purified by silica gel column (eluted with DCM/MeOH=20/1) and further purified by prep-HPLC to afford 227 (1.3 mg, 3.6%) as a white solid. 1H NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.39 (d, J=1.0 Hz, 1H), 7.58-7.46 (m, 2H), 7.36 (d, J=7.9 Hz, 1H), 5.95 (m, 1H), 5.77 (m, 1H), 4.62 (m, 3H), 4.50 (m, 2H), 3.61 (m, 1H), 3.10-2.87 (m, 5H), 2.74 (s, 7H), 2.67 (s, 3H), 2.64-2.48 (m, 2H), 2.12 (s, 3H), 1.06 (m, 1H), 0.90 (m, 1H). LC/MS (ESI) m/z:723/725 (M+H)+.
Figure US11708351-20230725-C01196
Figure US11708351-20230725-C01197
Step 1: 4-Methyl-6-(2-methylpyrimidin-5-yl)pyridin-3-amine (229-S3)
To a mixture of compound 229-S1 (1.6 g, 8.6 mmol), (2-methylpyrimidin-5-yl) boronic acid (2.14 g, 15.5 mmol) and potassium carbonate (3.0 g, 21.5 mmol) in dioxane (18 mL) and water (2 mL) was added Pd(PPh3)4 (0.99 g, 0.86 mmol) and the mixture was stirred at 80° C. for 16 hours under N2 atmosphere. The mixture was cooled and filtered and the filtrate was diluted with water (20 mL) and extracted with EtOAc (50 mL×3). The organic layer was dried with Na2SO4 and concentrated to afford crude product, which was re-crystallized from EtOAc to afford compound 229-S3 (750 mg, 43.6%) as a white solid. LC/MS (ESI) m/z: 201 (M+H)+.
Step 2: 5-(2-Methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine (229-S4)
To a mixture of compound 229-S3 (750 mg, 3.55 mmol) and potassium acetate (107 mg, 1.09 mmol) in CHCl3 (15 mL) was added acetic anhydride (869 mg, 8.51 mmol) at 0° C. The mixture was stirred at 25° C. for 1 hour and then heated to 60° C. tert-Butyl nitrite (831 mg, 8.05 mmol) was added dropwise and the mixture was stirred at 60° C. for 16 hours. The mixture was cooled and extracted with EtOAc (20 mL×3). The combined organic layers were dried with Na2SO4 and concentrated to afford crude product, which was re-crystallized from EtOAc to afford compound 228-S4 (300 mg, 40.1%) as a white solid. LC/MS (ESI) m/z: 212 (M+H)+.
Step 3: 3-Iodo-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridine (228-S5)
To a mixture of compound 228-S4 (300 mg, 1.42 mmol) in DMF was added KOH (179 mg, 3.20 mmol) and I2 (541 mg, 2.13 mmol) at 0° C. The mixture was stirred at room temperature for 1.5 hours. The mixture was quenched with 5% aqueous Na2S2O3 solution (10 mL) and extracted with EtOAc (20 mL×3). The combined organic layers were dried with Na2SO4 and concentrated to afford compound 228-S5 (350 mg, 73.1%) as a yellow solid. LC/MS (ESI) m/z: 338 (M+H)+.
Step 4: tert-Butyl 2-(3-iodo-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (228-S6)
To a mixture of compound 228-S5 (350 mg, 1.04 mmol), tert-butyl 2-bromoacetate (304 mg, 1.56 mmol) in DMF (6 mL) was added K2CO3 (287 mg, 2.08 mmol) and the mixture was stirred at room temperature overnight. The reaction mixture was diluted with water and extracted with ethyl acetate twice. The combined organic layers were washed with brine, dried with Na2SO4, and concentrated to dryness. The residue was purified with silica gel column (eluted with petroleum ether:ethyl acetate=5:1 to 1:1) to afford compound 228-S6 (350 mg, 82.2%) as a white solid. LC/MS (ESI) m/z: 452 (M+H)+.
Step 5: tert-Butyl 2-(3-iodo-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetate (228-S8)
To a mixture of compound 228-S6 (350 mg, 0.78 mmol) in toluene (15 mL) was added Pd(PPh3)4 (72 mg, 0.062 mmol) and tributyl(1-ethoxyvinyl)stannane (336 mg, 0.93 mmol). The mixture was stirred at 100° C. for 16 hours under nitrogen atmosphere. The reaction mixture was quenched with 0.5 N hydrochloride (10 mL) and stirred at room temperature for 1 hour. The mixture was extracted with ethyl acetate twice and the combined organic layer were washed with brine, dried with Na2SO4, and concentrated to dryness. The residue was purified with silica gel column (eluted with petroleum ether:ethyl acetate=5:1 to 1:1) to afford compound 228-S8 (270 mg, 94.3%) as a white solid. LC/MS (ESI) m/z: 368 (M+H)+.
Step 6: 5-(3-Acetyl-1-(2-tert-butoxy-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-methylpyrimidine 1-oxide (228-S9)
To a solution of compound 228-S8 (270 mg, 0.73 mmol) was added m-CPBA (165 mg, 0.96 mmol). The mixture was stirred at room temperature for 16 hours and then quenched with a 5% Na2S2O3 solution and extracted with DCM. The organic layer was separated, dried, and concentrated to afford crude product, which was purified by silica gel column (eluted with DCM:MeOH=100:0 to 80:1) to afford compound 228-S9 (110 mg, 39.3%) as a white solid. LC/MS (ESI) m/z: 384 (M+H)+.
Step 7: 5-(3-Acetyl-1-(carboxymethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-methylpyrimidine 1-oxide (228-S10)
A solution of NaOH (34 mg, 0.86 mmol) in 1 mL of water was added into a solution of compound 228-S9 (110 mg, 0.29 mmol) in methanol (1 mL) and THF (1 mL). The mixture was stirred at room temperature for 16 hours. The solvent was removed under vacuum and the residue was taken up in ether (20 mL) and additional water (10 mL). The organic phase was separated and the aqueous phase was diluted with EtOAc and then acidified with 1 N HC1 to pH of approximately 5. The organic phase was washed with brine and dried, concentrated to afford compound 228-S10 (80 mg, 84.2%) as a white solid. LC/MS (ESI) m/z: 328 (M+H)+.
Step 8: 5-(3-Acetyl-1-(2-((1R,3S,5R)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)-2-methylpyrimidine 1-oxide (228)
To a solution of the compound 228-S10 (80 mg, 0.244 mmol), compound 228-S11 (75 mg, 0.244 mmol) and HATU (139 mg, 0.366 mmol) in DMF (3 mL) was added DIPEA (127 mg, 0.976 mmol). The reaction was stirred at room temperature for 16 hours. The reaction was diluted with EtOAc, washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified via pre-HPCL to afford compound 228 (14 mg, 9.3%) as a white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.32 (d, J=1.2 Hz, 1H), 9.17 (d, J=1.8 Hz, 1H), 8.91 (d, J=1.9 Hz, 1H), 8.69 (d, J=1.2 Hz, 1H), 7.63 (d, J=8.2 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 6.07 (d, J=17.3 Hz, 1H), 5.75 (d, J=17.2 Hz, 1H), 4.43 (dd, J=9.2, 5.1 Hz, 1H), 3.60 (dd, J=5.5, 2.3 Hz, 1H), 2.69 (s, 3H), 2.63 (s, 3H), 2.53-2.57 (m, 1H), 2.05-2.11 (m, 1H), 2.04 (s, 3H), 1.33 (s, 3H), 1.07-1.13 (m, 1H), 0.98-1.04 (m, 1H). LC/MS (ESI) m/z: 619/621 (M+H)+.
Figure US11708351-20230725-C01198
Figure US11708351-20230725-C01199
Step 1: tert-Butyl 2-(3-acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (229-3)
To a mixture of compound 229-S1 (267 mg, 0.6 mmol) and compound 229-S2 (222 mg, 1.32 mmol) in toluene (10 mL) and H2O (2 mL) was added K3PO4 (382 mg, 1.8 mmol) followed by the addition of Pd(dppf)Cl2 (44 mg, 0.06 mmol). The reaction was stirred at 100° C. for 16 hours under N2 atmosphere. The mixture was cooled, diluted with EtOAc, and washed with water and brine. The organic layer was separated, dried and concentrated to afford crude product, which was purified by silica gel column (eluted with PE:EtOAc=20:1 to 2:1) to afford compound 229-S3 (194 mg, 79.5%) as a white solid. LC/MS (ESI) m/z: 407 (M+H)+.
Step 2: 2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (229-S4)
To a mixture of compound 229-S3 (130 mg, 0.32 mmol) in MeOH/THF (4 mL, 1:1) was added aqueous NaOH solution (39 mg, 0.96 mmol in 2 mL of water). The mixture was stirred at room temperature for 4 hours and then diluted with water (3 mL) and extracted with ether. The aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The resulting mixture was extracted with DCM/MeOH (20 mL×2, 10:1, V/V) and the combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 229-S4 (73 mg, 65.2%) as a white solid. LC/MS (ESI) m/z: 351 (M+H)+.
Step 3: (1R,3S,5S)-2-tert-Butyl 3-ethyl 5-(allyloxymethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (229-S7)
To a mixture of compound 229-S5 (1.37 g, 4.8 mmol) in dry DMF (20 mL) was added NaH (384 mg, 9.6 mmol) at 0° C. under N2 atmosphere and the mixture was stirred at room temperature for 40 minutes before compound 229-S6 (3.24 g, 19.2 mmol) was added at 0° C. in portions. The mixture was stirred at room temperature for 2 hours and the mixture was quenched with saturated aqueous NH4Cl solution. The reaction was extracted with DCM and the organic layer was dried and concentrated to afford crude compound 229-S7 (1.56 g, 99.9% yield) as a colorless oil, which was carried forward without additional purification. LC/MS (ESI) m/z: 348 (M+Na)+.
Step 4: (1R,3S,5S)-5-(Allyloxymethyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (229-S8)
To a mixture of compound 229-S7 (1.56 g, 4.8 mmol) in MeOH/THF (20 mL, 1:1) was added aqueous NaOH solution (384 mg, 9.6 mmol in 10 mL of water). The mixture was stirred at room temperature for 4 hours and then diluted with water (20 mL). The reaction was extracted with ether and the aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The mixture was extracted with DCM/MeOH (20 mL×2, 10:1, V/V) and the combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 229-S8 (630 mg, 44.0%) as a colorless oil. LC/MS (ESI) m/z: 320 (M+Na)+.
Step 5: (1R,3S,5S)-tert-Butyl 5-(allyloxymethyl)-3-(6-bromo-3-methylpyridin-2-ylcarbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (229-S10)
To a solution of compound 229-S8 (210 mg, 0.71 mmol) and 6-bromo-3-methylpyridin-2-amine (133 mg, 0.71 mmol) in dry DCM (6 mL) was added pyridine (280 mg, 3.55 mmol) at 0° C. followed by the dropwise addition of POCl3 (120 mg, 0.78 mmol). The reaction mixture was stirred at room temperature for 30 minutes and then quenched with ice-cooled water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column (eluted with PE:EtOAc=12:1) to afford compound 229-S10 (150 mg, 67.2%) as a colorless oil. LC/MS (ESI) m/z: 466/468 (M+H)+.
Step 6: (1R,3S,5S)-5-(Allyloxymethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (229-S11)
To a solution of compound 229-S10 (150 mg, 0.32 mmol) in DCM (2 mL) was added TFA (2 mL) at room temperature under N2 atmosphere. The resulting mixture was stirred at room temperature for 2 hours and the mixture was concentrated to afford compound 229-S11 (100 mg, 85.5%) as a colorless oil, which was directly used in the next reaction without additional purification. LC/MS (ESI) m/z: 366 (M+H)+.
Step 7: (1R,3S,5S)-2-(2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(allyloxymethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (229)
To a solution of the compound 229-S11 (100 mg, 0.21 mmol), compound 229-S4 (73 mg, 0.21 mmol) and HATU (160 mg, 0.42 mmol) in DMF (2 mL) was added DIPEA (110 mg, 0.84 mmol). The reaction was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by silica gel column chromatography (eluted with DCM:MeOH=100:0 to 80:1) to afford compound 229 (130 mg, 88.4%) as a white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.32 (s, 1H), 9.03 (s, 2H), 8.40 (d, J=1.7 Hz, 1H), 7.56-7.66 (m, 2H), 7.45 (d, J=7.9 Hz, 1H), 6.17-6.26 (m, 1H), 5.86-5.97 (m, 2H), 5.65 (d, J=17.5 Hz, 1H), 5.29 (dd, J=17.3, 1.9 Hz, 1H), 5.18 (t, J=9.9 Hz, 2H), 4.91 (d, J=17.1 Hz, 1H), 4.48 (dd, J=9.4, 5.1 Hz, 1H), 4.07 (dd, J=13.2, 5.4 Hz, 1H), 3.99 (dd, J=13.2, 5.3 Hz, 1H), 3.78-3.86 (m, 1H), 3.67-3.75 (m, 2H), 3.58 (d, J=10.6 Hz, 1H), 3.47 (d, J=10.7 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.24-2.35 (m, 2H), 2.05 (s, 3H), 1.17-1.21 (m, 1H), 1.03-1.08 (m, 1H). LC/MS (ESI) m/z: 698/700 (M+H)+.
Figure US11708351-20230725-C01200
Step 1: tert-Butyl 2-(3-acetyl-7-(but-3-enyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (230-3)
To a mixture of compound 230-S1 (444 mg, 1 mmol) and compound 230-S2 (200 ms, 2 mmol) in toluene (15 mL) and H2O (3 mL) was added K3PO4 (637 mg, 3 mmol) followed by the addition of Pd(dppf)Cl2 (74 mg, 0.1 mmol). The reaction was stirred at 100° C. for 16 hours under N2 atmosphere before the mixture was cooled, diluted with EtOAc, and washed with water and brine. The organic layer was separated, dried and concentrated to afford crude product, which was purified by silica gel column (eluted with PE:acetone=20:1 to 12:1) to afford compound 230-S3 (354 mg, 84.1%) as a white solid. LC/MS (ESI) m/z: 421 (M+H)+.
Step 2: 2-(3-Acetyl-7-allyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (230-S4)
To a mixture of compound 230-S3 (354 mg, 0.843 mmol) in MeOH/THF (12 mL, 1:1) was added 3 mL of aqueous NaOH solution (101 mg, 2.53 mmol). The mixture was stirred at room temperature for 4 hours before the mixture was diluted with water (15 mL) and extracted with ether. The aqueous layer was collected and acidified with aqueous HCl solution (1 N) to a pH of approximately 5. The resulting mixture was extracted with DCM/MeOH (20 mL×2, 10:1, V/V). The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 230-S4 (280 mg, 90.9%) as a white solid. LC/MS (ESI) m/z: 365 (M+H)+.
Step 3: (1R,3S,5S)-2-(2-(3-Acetyl-7-(but-3-enyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(allyloxymethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (230)
To a solution of the compound 230-S4 (210 mg, 0.44 mmol), compound 230-S5 (160 mg, 0.44 mmol) and HATU (334 mg, 0.88 mmol) in DMF (4 mL) was added DIPEA (286 mg, 2.2 mmol). The reaction was stirred at room temperature for 16 hours. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried, and concentrated to afford crude product, which was purified by silica gel column (eluted with DCM:MeOH=100:0 to 80:1) to afford compound 230 (250 mg, 79.9%) as a white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.32 (d, J=8.1 Hz, 1H), 8.95-9.10 (m, 2H), 8.36-8.40 (m, 1H), 7.56-7.64 (m, 2H), 7.45 (d, J=7.9 Hz, 1H), 6.19-6.32 (m, 1H), 5.84-6.00 (m, 2H), 5.63-5.75 (m, 1H), 5.26-5.35 (m, 1H), 5.06-5.18 (m, 2H), 4.87-4.98 (m, 1H), 4.44-4.51 (m, 1H), 3.93-4.06 (m, 3H), 3.72-3.81 (m, 2H), 3.59 (d, J=10.5 Hz, 1H), 3.46-3.51 (m, 1H), 2.71 (s, 3H), 2.65 (s, 3H), 2.19-2.36 (m, 2H), 2.05 (s, 3H), 1.63-1.70 (m, 1H), 1.41-1.50 (m, 1H), 1.16-1.25 (m, 1H), 0.92-1.06 (m, 1H). LC/MS (ESI) m/z: 712/714 (M+H)+.
Figure US11708351-20230725-C01201
Figure US11708351-20230725-C01202
Figure US11708351-20230725-C01203
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds where the carboxylic acid in the R6 position is functionalized via a coupling with an amine using HATU. The skilled artisan will recognize that ethylamine can be replaced with other amines to afford additional compounds of the present invention. Non-limiting examples of amines include methylamine, 2,2,2-trifluoroethylamine, isobutylamine, propylamine, butylamine, pentylamine, cyclopropylmethanamine, cyclobutylmethanamine, 2,2-dimethyl-1-propylamine, ethylenediamine, N1-methylethane-1,2-diamine, (2-aminoethyl)dimethylamine, aminocyclopropane, isopropylamine, allylamine, propargylamine, 1-cyclopropylethanamine, 2-cyclopropylpropan-2-amine, 2-methylpent-3-yn-2-amine, and but-3-yn-2-amine.
Step 1: Methyl 5-bromo-1H-indazole-3-carboxylate (2)
To a stirring suspension of 5-bromo-1H-indazole-3-carboxylic acid (5.0 g, 21 mmol, 1 equiv.) in methanol (84 mL, 2.0 mol, 100 equiv.) was added sulfuric acid (10 g, 100 mmol, 5 equiv.). The mixture was heated to 60° C. and stirred overnight at which point the LCMS showed quantitative conversion to the desired product. The mixture was then concentrated to a residue that was taken up in EtOAc (20 mL) and washed with water (20 mL). The aqueous layer was neutralized with saturated sodium bicarbonate and then extracted with EtOAc (2×20 mL). The combined organic extracts were washed with saturated aqueous bicarbonate solution, brine, dried over NasSO4, filtered and concentrated to afford the desired product 2 as a tan solid which was used in the next step without purification.
Step 2: Methyl 5-bromo-1-[2-(tert-butoxy)-2-oxoethyl]indazole-3-carboxylate (4)
To a solution of methyl 5-bromo-1H-indazole-3-carboxylate (0.60 g, 2.4 mmol, 1 equiv.) in dimethyl-formamide (23 mL, 0.1 M, 39 Vols) at room temperature were added tert-butyl 2-bromoacetate (0.51 g, 0.38 mL, 2.6 mmol, 1.1 equiv.) and potassium carbonate (0.36 g, 2.6 mmol, 1.1 equiv.). The mixture was stirred overnight at room temperature under an atmosphere of argon. The mixture was then concentrated, diluted with DCM, filtered through a pad of Celite and then purified by column chromatography on silica gel (eluted with a 0-100% EtOAc in hexanes gradient) to afford 4.
Step 3: Methyl 1-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylate (6)
5-Bromo-2-methylpyrimidine (250 mg, 1.44 mmol, 1 equiv.), bis(pinacolato)diboron (0.385 g, 1.52 mmol, 1.05 equiv.), potassium acetate (0.425 g, 4.34 mmol, 3 equiv.), and 1,1′-bis(diphenylphosphino)ferrocene-dichloropalladium (1:1) (0.106 g, 0.144 mmol, 0.1 equiv.) were combined in a sealed reaction vessel, evacuated and charged with Ar gas. The mixture was then diluted with 1,4-dioxane (5.0 mL, 0.29 M, 20 Vols) and heated to 90° C. for 3 hours at which point the LCMS showed conversion to the desired boronate. To this mixture was added potassium carbonate (0.665 g, 4.81 mmol, 3 equiv.) followed by methyl 5-bromo-1-[2-(tert-butoxy)-2-oxoethyl]indazole-3-carboxylate (0.592 g, 1.60 mmol, 1 equiv.) and water (0.3 mL). The orange mixture was allowed to stir at 100° C. for 2 hours at which point the LCMS showed conversion to a peak with a mass corresponding to the desired product. The mixture was diluted with EtOAc (20 mL) and washed with water. The aqueous layer was extracted once with EtOAc (20 mL). The organic extracts were washed with brine, dried over Na2SO4, filtered and concentrated to afford an orange solid. This solid was then purified on silica gel chromatography eluting with a 0-100% EtOAc in hexanes gradient over 15 CVs to afford 6 as a colorless solid.
Step 4: [3-(Methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic Acid (7)
To a stirring solution of methyl 1-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylate (250 mg, 0.654 mmol, 1 equiv.) in 1,2-dichloroethane (6.54 mL, 0.1 M, 26 Vols) at room temperature was added trifluoroacetic acid (1.00 mL, 13.1 mmol, 20 equiv.). The solution was stirred at room temperature for 24 hours. The mixture was concentrated in vacuo azeotroping with toluene (2×15 mL) and DCM (2×15 mL) to afford 7 as a yellow solid. This material was carried on without further purification.
Alternatively, [3-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (7) was formed in the following manner: molecular iodine (14 g, 56 mmol, 3.5 equiv.) was taken up in methanol (160 mL, 0.1 M, 32 Vols) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (5.0 g, 16 mmol, 1 equiv.) was added. Next, sodium methoxide (5.0 g, 97 mmol, 6 equiv.) was added as a solution in MeOH (30 mL). The resulting slurry was vigorously stirred at room temperature for 1 hour. The mixture was concentrated and then taken up in a 3:1 mixture of acetonitrile and 2-propanol (100 mL). The mixture was acidified with 1M HCl and the layers were separated. The aqueous layer was extracted with a 3:1 mixture of acetonitrile and 2-propanol (2×30 mL). The combined organic extracts were washed with water, brine, dried over Na2SO4, filtered and concentrated to afford the desired product 7 as a tan solid. This material was carried on without further purification.
Step 5: Methyl 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylate (467)
To a stirring solution of [3-(methoxycarbonyl)-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (0.019 g, 0.058 mmol, 1 equiv.) and (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (0.022 g, 0.070 mmol, 1.2 equiv.) in dimethyl-formamide (0.58 mL, 0.1 M, 30 Vols) was added successively (2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (0.055 g, 0.15 mmol, 2.5 equiv.) followed by diisopropylethylamine (0.023 g, 0.18 mmol, 3 equiv.). The mixture was stirred at room temperature for 30 minutes at which point LCMS showed quantitative conversion to a peak corresponding to the desired product. The reaction solution was purified directly via reverse phase HPLC and concentrated to afford methyl 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylate (467) as a white film. 1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.06 (s, 2H), 8.35 (s, 1H), 7.86 (s, 2H), 7.62 (d, J=7.9 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.89 (d, J=17.2 Hz, 1H), 5.57 (d, J=17.2 Hz, 1H), 4.40 (dd, J=9.3, 5.1 Hz, 1H), 3.96 (s, 3H), 3.56 (t, J=4.0 Hz, 1H), 2.69 (s, 3H), 2.09-1.99 (m, 1H), 2.04 (s, 3H), 1.32 (s, 3H), 1.30-1.22 (m, 1H), 1.00 (d, J=4.6 Hz, 2H).
Step 6: 1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylic Acid (469)
Sodium hydroxide (0.23 mL, 0.23 mmol, 10 equiv.) (1M aq) was added to a stirring suspension of methyl 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylate (15 mg, 0.023 mmol, 1 equiv.) in methanol (1.0 mL, 0.023 M, 69 Vols) at room temperature. The mixture was stirred at room temperature for 2 hours, after which time the mixture had become a solution and LCMS showed no starting material. The solution was directly purified by reverse phase HPLC to afford 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylic acid (469) as a white solid. 1H NMR (400 MHz, DMSO-d6) δ 13.18 (s, 1H), 10.26 (s, 1H), 9.05 (s, 2H), 8.34 (d, J=1.2 Hz, 1H), 7.84 (s, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.88 (d, J=17.2 Hz, 1H), 5.55 (d, J=17.2 Hz, 1H), 4.41 (dd, J=9.2, 5.1 Hz, 1H), 3.57 (t, J=4.0 Hz, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.05 (dd, J=17.6, 4.2 Hz, 1H), 2.05 (s, 3H), 1.33 (s, 3H), 1.01 (d, J=4.1 Hz, 2H).
Step 7: 1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-ethyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide (474)
To a stirring solution of 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxylic acid (21 mg, 0.035 mmol) in dimethyl-formamide (1.5 mL) was added 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate N-oxide (0.026 g, 0.069 mmol) and diisopropylethylamine (0.024 mL, 0.139 mmol). The mixture was stirred at room temperature for 15 minutes and then ethylamine (0.17 mL, 0.35 mmol) was added. The mixture was stirred at room temperature for an additional 2 hours at which point the LCMS showed conversion to a peak with the desired mass. The solution was filtered and directly purified via reverse phase HPLC to afford 1-{2-[(1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-ethyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide (10 mg, 0.016 mmol, yield 46%) as a white solid. 1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 7.84-7.73 (m, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.73 (d, J=17.2 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.55 (dd, J=9.3, 5.3 Hz, 1H), 3.51 (dt, J=14.4, 6.3 Hz, 3H), 2.77 (s, 3H), 2.67 (s, 1H), 2.67-2.57 (m, 1H), 2.33 (dd, J=13.4, 5.1 Hz, 1H), 2.16 (d, J=13.7 Hz, 3H), 1.42 (s, 3H), 1.28 (t, J=7.2 Hz, 3H), 1.07 (t, J=5.5 Hz, 1H), 0.95 (dd, J=5.5, 2.5 Hz, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-methyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.57 (s, 1H), 8.47 (s, 3H), 7.79 (q, J=8.7 Hz, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 5.72 (d, J=17.1 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.55 (s, 1H), 3.53 (s, 1H), 3.00 (s, 3H), 2.77 (s, 3H), 2.37-2.29 (m, 1H), 2.14 (s, 3H), 1.41 (s, 3H), 1.25 (m, 1H), 1.07 (s, 1H), 0.94 (s, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-methyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 7.86-7.75 (m, 2H), 7.56 (d, J=7.9 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.76 (d, J=17.0 Hz, 1H), 5.66 (d, J=17.1 Hz, 1H), 4.55 (t, J=7.2 Hz, 1H), 4.14 (dd, J=13.7, 6.1 Hz, 2H), 3.54 (s, 1H), 2.77 (s, 3H), 2.70-2.54 (m, 2H), 2.38-2.28 (m, 1H), 2.14 (s, 3H), 1.42 (s, 3H), 1.07 (d, J=5.7 Hz, 1H), 0.96 (s, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(2-methylpropyl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.03 (s, 2H), 8.55 (d, J=1.4 Hz, 1H), 8.41 (t, J=6.3 Hz, 1H), 7.82-7.72 (m, 2H), 7.56 (d, J=7.9 Hz, 1H), 7.39 (d, J=7.9 Hz, 1H), 5.73 (d, J=17.1 Hz, 1H), 5.62 (d, J=17.2 Hz, 1H), 4.55 (dd, J=9.3, 5.2 Hz, 1H), 3.53 (dd, J=5.6, 2.4 Hz, 1H), 3.29 (t, J=6.4 Hz, 2H), 2.77 (s, 3H), 2.70-2.57 (m, 1H), 2.32 (dd, J=13.5, 5.2 Hz, 1H), 2.13 (s, 3H), 1.97 (hept, J=6.7 Hz, 1H), 1.41 (s, 3H), 1.11-0.98 (m, 7H), 0.95 (dd, J=5.5, 2.4 Hz, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)-N-propylindazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 8.45 (d, J=5.9 Hz, 1H), 8.30 (s, 1H), 7.84-7.73 (m, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.41 (d, J=7.9 Hz, 1H), 5.73 (d, J=17.1 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.55 (dd, J=9.2, 5.3 Hz, 1H), 3.57-3.50 (m, 1H), 3.48-3.34 (m, 2H), 2.77 (s, 3H), 2.70-2.57 (m, 2H), 2.33 (dd, J=13.7, 5.1 Hz, 1H), 2.14 (s, 3H), 1.70 (h, J=7.3 Hz, 2H), 1.41 (s, 3H), 1.11-0.92 (m, 5H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-butyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 8.41 (t, J=5.9 Hz, 1H), 8.24 (s, 1H), 7.84-7.73 (m, 2H), 7.57 (d, J=7.9 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.73 (d, J=17.1 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.55 (dd, J=9.3, 5.2 Hz, 1H), 3.57-3.42 (m, 3H), 3.23 (dt, J=34.7, 6.7 Hz, 1H), 2.77 (s, 3H), 2.74-2.57 (m, 2H), 2.38-2.28 (m, 1H), 2.14 (s, 3H), 1.66 (p, J=7.3 Hz, 2H), 1.60-1.49 (m, 1H), 1.41 (m, 3H), 1.11-0.90 (m, 6H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)-N-pentylindazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 8.42 (s, 1H), 8.28 (s, 1H), 7.84-7.73 (m, 2H), 7.57 (d, J=8.0 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.73 (d, J=17.1 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.55 (dd, J=9.3, 5.2 Hz, 1H), 3.56-3.50 (m, 1H), 3.46 (q, J=6.5 Hz, 2H), 2.77 (s, 3H), 2.70-2.57 (m, 2H), 2.33 (dd, J=13.8, 5.2 Hz, 1H), 2.14 (s, 3H), 1.68 (s, 2H), 1.42 (d, J=5.2 Hz, 2H), 1.41 (s, 3H), 1.35 (s, 1H), 1.07 (t, J=5.6 Hz, 1H), 1.00-0.92 (m, 4H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(cyclopropylmethyl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.56 (s, 1H), 8.46 (t, J=6.0 Hz, 1H), 8.23 (s, 1H), 7.84-7.73 (m, 2H), 7.56 (d, J=8.0 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.74 (d, J=17.2 Hz, 1H), 5.63 (d, J=17.1 Hz, 1H), 4.56 (dd, J=9.4, 5.2 Hz, 1H), 3.54 (dd, J=5.7, 2.4 Hz, 1H), 3.36 (d, J=5.7 Hz, 1H), 2.77 (s, 3H), 2.70-2.57 (m, 2H), 2.33 (dd, J=13.6, 5.2 Hz, 1H), 2.14 (s, 3H), 1.42 (s, 3H), 1.15 (q, J=6.4, 5.4 Hz, 1H), 1.08 (t, J=5.6 Hz, 1H), 0.96 (dd, J=5.6, 2.4 Hz, 1H), 0.61-0.51 (m, 2H), 0.34 (q, J=5.1 Hz, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(cyclobutylmethyl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.55 (d, J=1.5 Hz, 1H), 8.37 (dd, J=12.1, 6.1 Hz, 1H), 7.83-7.72 (m, 2H), 7.56 (d, J=8.0 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.73 (d, J=17.1 Hz, 1H), 5.62 (d, J=17.1 Hz, 1H), 4.55 (dd, J=9.2, 5.2 Hz, 1H), 3.57-3.45 (m, 3H), 2.77 (s, 3H), 2.74-2.57 (m, 2H), 2.32 (dd, J=13.6, 5.2 Hz, 1H), 2.13 (s, 3H), 2.19-2.06 (m, 2H), 2.02-1.78 (m, 4H), 1.41 (s, 3H), 1.07 (t, J=5.7 Hz, 1H), 0.95 (dd, J=5.6, 2.4 Hz, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(2,2-dimethylpropyl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.58-8.48 (m, 1H), 8.23 (t, J=6.6 Hz, 1H), 7.84-7.73 (m, 2H), 7.56 (d, J=8.0 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.75 (d, J=17.2 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.56 (dd, J=9.3, 5.3 Hz, 1H), 3.54 (dd, J=5.6, 2.4 Hz, 1H), 3.30 (d, J=5.5 Hz, 2H), 2.77 (s, 3H), 2.70-2.57 (m, 1H), 2.33 (dd, J=13.7, 5.3 Hz, 1H), 2.13 (s, 3H), 1.41 (s, 3H), 1.38 (s, 1H), 1.02 (s, 8H), 1.00-0.90 (m, 2H).
N-(2-aminoethyl)-1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.58 (s, 1H), 8.49 (s, 2H), 7.88-7.76 (m, 2H), 7.57 (d, J=7.9 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.77 (d, J=17.3 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.60-4.51 (m, 1H), 3.74 (t, J=5.6 Hz, 2H), 3.59-3.52 (m, 1H), 3.22 (t, J=5.8 Hz, 2H), 2.78 (s, 3H), 2.74-2.59 (m, 4H), 2.32 (dd, J=13.4, 5.4 Hz, 1H), 2.15 (s, 3H), 1.43 (s, 3H), 1.12 (t, J=5.5 Hz, 1H), 1.00-0.91 (m, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-[2-(methylamino)ethyl]-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.03 (s, 2H), 8.57 (s, 1H), 8.43 (s, 2H), 7.87-7.76 (m, 2H), 7.57 (d, J=7.9 Hz, 1H), 7.40 (d, J=7.9 Hz, 1H), 5.77 (d, J=17.2 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.55 (dd, J=9.1, 5.3 Hz, 1H), 3.77 (t, J=5.5 Hz, 2H), 3.59-3.52 (m, 1H), 3.29 (t, J=5.5 Hz, 2H), 2.78 (d, J=4.1 Hz, 6H), 2.74-2.57 (m, 2H), 2.32 (dd, J=13.5, 5.4 Hz, 1H), 2.15 (s, 3H), 1.42 (s, 3H), 1.12 (t, J=5.6 Hz, 1H), 0.97 (dd, J=5.6, 2.4 Hz, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-[2-(dimethylamino)ethyl]-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 9.04 (s, 2H), 8.57 (s, 1H), 8.44 (s, 2H), 7.86-7.75 (m, 2H), 7.57 (d, J=7.9 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 5.77 (d, J=17.2 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.55 (dd, J=9.1, 5.2 Hz, 1H), 3.81 (t, J=5.9 Hz, 2H), 3.55 (dd, J=5.8, 2.3 Hz, 1H), 3.30 (d, J=5.7 Hz, 2H), 2.92 (s, 6H), 2.78 (s, 3H), 2.74-2.59 (m, 2H), 2.32 (dd, J=13.6, 5.2 Hz, 1H), 2.15 (s, 3H), 1.42 (s, 3H), 1.11 (t, J=5.5 Hz, 1H), 0.97 (dd, J=5.5, 2.4 Hz, 1H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-cyclopropyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.24 (s, 1H), 9.03 (s, 2H), 8.45 (d, J=4.6 Hz, 2H), 7.86-7.73 (m, 2H), 7.62 (d, J=7.9 Hz, 1H), 7.44 (d, J=7.9 Hz, 1H), 5.80 (d, J=17.4 Hz, 1H), 5.75 (s, 1H), 5.47 (d, J=17.4 Hz, 1H), 4.38 (dd, J=9.2, 5.3 Hz, 1H), 3.55 (dd, J=5.5, 2.4 Hz, 1H), 2.91 (td, J=11.2, 4.4 Hz, 1H), 2.69 (s, 3H), 2.54 (dd, J=9.6, 3.7 Hz, 1H), 2.05 (d, J=13.6 Hz, 4H), 1.32 (s, 3H), 1.04-0.91 (m, 2H), 0.68 (tt, J=7.1, 2.2 Hz, 4H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-isopropyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.04 (s, 2H), 8.46 (d, J=1.5 Hz, 1H), 8.10 (d, J=8.3 Hz, 1H), 7.89-7.75 (m, 2H), 7.63 (d, J=7.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.83 (d, J=17.4 Hz, 1H), 5.76 (s, 0H), 5.50 (d, J=17.3 Hz, 1H), 4.40 (dd, J=9.3, 5.2 Hz, 1H), 4.19 (dt, J=13.5, 6.7 Hz, 1H), 3.56 (dd, J=5.6, 2.4 Hz, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.06 (d, J=12.4 Hz, 4H), 1.33 (s, 3H), 1.22 (dd, J=6.6, 1.4 Hz, 6H), 1.06-0.94 (m, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)-N-(prop-2-en-1-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.04 (s, 2H), 8.56 (t, J=6.0 Hz, 1H), 8.46 (d, J=1.5 Hz, 1H), 7.89-7.76 (m, 2H), 7.63 (d, J=7.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 6.00-5.73 (m, 2H), 5.51 (d, J=17.3 Hz, 1H), 5.19 (dt, J=17.2, 1.8 Hz, 1H), 5.09 (dd, J=10.2, 1.7 Hz, 1H), 4.41 (dd, J=9.2, 5.1 Hz, 1H), 3.99-3.91 (m, 2H), 3.57 (dd, J=5.5, 2.4 Hz, 1H), 2.69 (s, 3H), 2.55 (dd, J=9.2, 4.3 Hz, 1H), 2.05 (s, 3H), 1.33 (s, 3H), 1.05-0.93 (m, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)-N-(prop-2-yn-1-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.05 (s, 2H), 8.81 (t, J=6.0 Hz, 1H), 8.46 (d, J=1.5 Hz, 1H), 7.89-7.77 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.84 (d, J=17.3 Hz, 1H), 5.51 (d, J=17.2 Hz, 1H), 4.41 (dd, J=9.2, 5.2 Hz, 1H), 4.08 (dt, J=5.5, 2.5 Hz, 2H), 3.58 (dd, J=5.5, 2.4 Hz, 1H), 3.08 (t, J=2.5 Hz, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.05 (s, 3H), 2.10-1.96 (m, 1H), 1.33 (s, 3H), 1.05-0.93 (m, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(1-cyclopropylethyl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.05 (s, 2H), 8.47 (d, J=1.4 Hz, 1H), 8.23 (dd, J=8.7, 2.0 Hz, 1H), 7.88-7.75 (m, 2H), 7.64 (d, J=8.0 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 5.86 (dd, J=17.5, 3.7 Hz, 1H), 5.77 (s, 0H), 5.52 (dd, J=17.3, 3.9 Hz, 1H), 4.42 (dd, J=9.3, 5.2 Hz, 1H), 3.58 (dd, J=5.6, 2.4 Hz, 1H), 3.50 (q, J=8.1 Hz, 1H), 2.70 (s, 3H), 2.61-2.53 (m, 1H), 2.08 (s, 3H), 2.01 (m, 1H), 1.31, (s, 3H), 1.32-1.25 (m, 3H), 1.26-1.08 (m, 1H), 1.08-0.96 (m, 2H), 0.49 (m, 1H), 0.41 (m, 1H), 0.29 (ddt, J=29.4, 9.4, 4.5 Hz, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(2-methylbut-3-yn-2-yl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.06 (s, 2H), 8.46 (d, J=1.5 Hz, 1H), 7.92 (s, 1H), 7.89-7.75 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.85 (d, J=17.3 Hz, 1H), 5.51 (d, J=17.2 Hz, 1H), 4.40 (dd, J=9.2, 5.1 Hz, 1H), 3.57 (dd, J=5.3, 2.6 Hz, 1H), 3.19 (s, 1H), 2.70 (s, 3H), 2.60-2.51 (m, 1H), 2.05 (s, 3H), 2.00 (m, 1H), 1.68 (s, 6H), 1.33 (s, 3H), 1.06-0.96 (m, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(2-cyclopropylpropan-2-yl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.26 (s, 1H), 9.05 (s, 2H), 8.46 (d, J=1.5 Hz, 1H), 7.87-7.76 (m, 2H), 7.63 (d, J=7.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.25 (s, 1H), 5.84 (d, J=17.3 Hz, 1H), 5.51 (d, J=17.3 Hz, 1H), 4.40 (dd, J=9.2, 5.1 Hz, 1H), 3.58 (t, J=4.0 Hz, 1H), 3.18 (d, J=4.7 Hz, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.06 (m, 1H), 2.05 (s, 3H), 1.46 (dq, J=10.8, 6.2 Hz, 1H), 1.36 (s, 3H), 1.34 (s, 3H), 1.02 (d, J=4.0 Hz, 2H), 0.45-0.37 (m, 4H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-5-(2-methylpyrimidin-5-yl)-N-(sec-butyl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.04 (s, 2H), 8.46 (t, J=1.2 Hz, 1H), 8.05 (d, J=8.8 Hz, 1H), 7.87-7.75 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.84 (d, J=17.4 Hz, 1H), 5.50 (d, J=17.3 Hz, 1H), 4.40 (dd, J=9.3, 5.2 Hz, 1H), 4.01 (p, J=7.1 Hz, 1H), 3.57 (d, J=5.0 Hz, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.06 (m, 1H), 2.05 (s, 3H), 1.33 (s, 3H), 1.32-1.21 (m, 1H), 1.19 (dd, J=6.7, 1.7 Hz, 3H), 1.06-0.95 (m, 2H), 0.89 (td, J=7.4, 2.2 Hz, 3H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-tert-butyl-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.05 (s, 2H), 8.46 (t, J=1.2 Hz, 1H), 7.87-7.75 (m, 2H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 7.39 (s, 1H), 5.83 (d, J=17.4 Hz, 1H), 5.50 (d, J=17.3 Hz, 1H), 4.40 (dd, J=9.3, 5.1 Hz, 1H), 3.61-3.54 (m, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.06 (m, 1H), 2.05 (s, 3H), 1.45 (s, 9H), 1.33 (s, 3H), 1.05-0.98 (m, 2H).
1-{2-[(1R,3S,5R)-3-[(6-Bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl]-2-oxoethyl}-N-(but-3-yn-2-yl)-5-(2-methylpyrimidin-5-yl)indazole-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 10.25 (s, 1H), 9.04 (s, 2H), 8.73 (d, J=8.3 Hz, 1H), 8.45 (s, 1H), 7.89-7.77 (m, 2H), 7.63 (d, J=7.9 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 5.85 (d, J=17.7 Hz, 1H), 5.52 (d, J=17.7 Hz, 1H), 4.92 (t, J=7.6 Hz, 1H), 4.45-4.36 (m, 1H), 3.57 (dd, J=5.4, 2.4 Hz, 1H), 3.21-3.13 (m, 1H), 2.69 (s, 3H), 2.60-2.51 (m, 1H), 2.06 (m, 1H), 2.05 (s, 3H), 1.46 (dd, J=7.0, 2.4 Hz, 3H), 1.33 (s, 3H), 1.06-0.95 (m, 2H).
Figure US11708351-20230725-C01204
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds where the carboxylic acid on the C-ring is functionalized via a coupling with an amine using propane phosphonic acid anhydride (T3P). The skilled artisan will recognize that ethylamine can be replaced with other amines to afford additional compounds of the present invention. Non-limiting examples of amines include propylamine, butylamine, arylamine, cyclopropylmethanamine, 2,2-dimethyl-1-propylamine, isobutylamine, methylamine, 1,3-propanediamine, dimethylaminopropylamine, amylamine, benzyl amine, hexylamine, heptylamine, octylamine, and 2-phenylethylamine.
To a stirring solution of 1 (1 equiv) in DCM (10 vol) at 0° C. under nitrogen atmosphere was added N,N-diisopropylethylamine (DIEA) (3 equiv) and propane phosphonic acid anhydride (T3P) (1.5 equiv). The reaction mixture was stirred at 0° C. for 10 minutes. Ethylamine was added to the reaction mixture at 0° C. and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was concentrated and purified directly by reverse phase HPLC to afford Compound 506. 1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (d, J=1.6 Hz, 1H), 7.80 (t, J=5.6 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.8 Hz, 1H), 4.16 (dd, J=9.1, 5.0 Hz, 1H), 3.51 (dd, J=5.7, 2.3 Hz, 1H), 3.11-2.99 (m, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.38 (dd, J=13.1, 9.1 Hz, 1H), 1.90 (dd, J=13.1, 5.0 Hz, 1H), 1.28 (s, 3H), 1.01 (m, 1H), 0.98 (t, J=7.2 Hz, 3H), 0.85 (dd, J=5.4, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-propyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (d, J=1.6 Hz, 1H), 7.79 (t, J=5.8 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.8 Hz, 1H), 4.18 (dd, J=9.1, 5.0 Hz, 1H), 3.51 (dd, J=5.6, 2.4 Hz, 1H), 3.00 (q, J=6.6 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.40 (dd, J=13.1, 9.1 Hz, 1H), 1.90 (dd, J=13.0, 5.0 Hz, 1H), 1.38 (h, J=7.2 Hz, 2H), 1.28 (s, 3H), 1.01 (t, J=5.4 Hz, 1H), 0.86 (m, 1H), 0.81 (t, J=7.2 Hz, 3H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-butyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (d, J=1.6 Hz, 1H), 7.76 (t, J=5.7 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.7 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.50 (dd, J=5.6, 2.4 Hz, 1H), 3.03 (q, J=6.7 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.2, 9.1 Hz, 1H), 1.90 (dd, J=13.2, 4.9 Hz, 1H), 1.41-1.29 (m, 2H), 1.28 (s, 3H), 1.27-1.17 (m, 2H), 1.01 (t, J=5.4 Hz, 1H), 0.84 (t, J=7.2 Hz, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-pentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.77 (t, J=5.7 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.7 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.50 (dd, J=5.6, 2.4 Hz, 1H), 3.02 (q, J=6.6 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.1, 9.1 Hz, 1H), 1.90 (dd, J=13.2, 4.9 Hz, 1H), 1.37 (p, J=6.9 Hz, 2H), 1.31-1.14 (m, 7H), 1.01 (t, J=5.3 Hz, 1H), 0.89-0.78 (m, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(cyclopropylmethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 2H), 8.35 (d, J=1.6 Hz, 1H), 7.87 (t, J=5.8 Hz, 1H), 7.66 (s, 1H), 6.01 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.7 Hz, 1H), 4.23 (dd, J=9.1, 4.9 Hz, 1H), 3.54 (dd, J=5.6, 2.3 Hz, 1H), 2.98 (t, J=6.1 Hz, 2H), 2.74-2.63 (m, 9H), 2.43 (dd, J=13.1, 9.1 Hz, 1H), 1.94 (dd, J=13.3, 4.9 Hz, 1H), 1.32 (s, 3H), 1.04 (t, J=5.5 Hz, 1H), 0.89 (dq, J=6.2, 3.7 Hz, 2H), 0.38 (dt, J=8.6, 2.8 Hz, 2H), 0.16 (p, J=3.9, 3.3 Hz, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(2,2-dimethylpropyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.71 (t, J=6.4 Hz, 1H), 7.63 (s, 1H), 6.00 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.7 Hz, 1H), 4.27 (dd, J=9.1, 5.0 Hz, 1H), 3.53 (dd, J=5.6, 2.3 Hz, 1H), 2.93 (dd, J=13.1, 6.7 Hz, 1H), 2.79 (dd, J=13.0, 6.0 Hz, 1H), 2.72-2.59 (m, 9H), 2.42 (dd, J=13.1, 9.1 Hz, 1H), 1.92 (dd, J=13.1, 4.9 Hz, 1H), 1.29 (s, 3H), 1.01 (t, J=5.4 Hz, 1H), 0.94-0.72 (m, 2H), 0.80 (s, 8H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(2-methylpropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (d, J=1.6 Hz, 1H), 7.80 (t, J=5.9 Hz, 1H), 7.63 (s, 1H), 5.98 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.7 Hz, 1H), 4.21 (dd, J=9.1, 4.9 Hz, 1H), 3.51 (dd, J=5.6, 2.3 Hz, 1H), 2.86 (h, J=6.6 Hz, 2H), 2.72-2.60 (m, 9H), 2.41 (dd, J=13.2, 9.1 Hz, 1H), 1.91 (dd, J=13.1, 5.0 Hz, 1H), 1.66 (hept, J=6.7 Hz, 1H), 1.28 (s, 3H), 1.01 (t, J=5.4 Hz, 1H), 0.94-0.77 (m, 7H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N,5-dimethyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Methanol-d4) δ 8.97 (s, 2H), 8.41-8.35 (m, 1H), 7.52 (s, 1H), 5.89 (d, J=17.7 Hz, 1H), 5.78 (d, J=17.7 Hz, 1H), 4.30 (dd, J=9.2, 5.3 Hz, 1H), 3.46 (dd, J=5.6, 2.4 Hz, 1H), 2.78-2.65 (m, 12H), 2.51 (dd, J=13.4, 9.2 Hz, 1H), 2.09 (dd, J=13.3, 5.4 Hz, 1H), 1.38 (s, 3H), 1.10 (t, J=5.5 Hz, 1H), 0.91 (dd, J=5.5, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(3-aminopropyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 2H), 8.45 (s, 1H), 8.39 (s, 1H), 8.12 (t, J=5.9 Hz, 1H), 7.88 (d, J=7.6 Hz, 2H), 5.88 (dd, J=17.2, 12.1 Hz, 1H), 5.54 (d, J=17.2 Hz, 1H), 4.17 (dd, J=9.3, 4.8 Hz, 1H), 3.51 (m, 1H), 3.31 (m, 1H) 3.11 (m, 2H), 2.91 (d, J=6.6 Hz, 1H), 2.68 (d, J=14.6 Hz, 7H), 2.40 (dt, J=16.3, 8.3 Hz, 1H), 1.91 (dd, J=12.8, 5.2 Hz, 1H), 1.62 (t, J=6.9 Hz, 1H), 1.53-1.45 (m, 1H), 1.28 (s, 3H), 0.99 (p, J=5.1 Hz, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[3-(methylamino)propyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.35 (s, 1H), 8.05 (t, J=5.8 Hz, 1H), 7.88 (s, 2H), 5.89 (d, J=17.2 Hz, 1H), 5.54 (d, J=17.2 Hz, 1H), 4.16 (dd, J=9.2, 4.9 Hz, 1H), 3.51 (t, J=3.9 Hz, 1H), 3.11 (q, J=6.6 Hz, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.58-2.61 (m, 3H), 2.28 (s, 3H), 1.92 (dd, J=13.1, 4.9 Hz, 1H), 1.60 (p, J=6.9 Hz, 2H), 1.28 (s, 3H), 0.98 (s, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[3-(dimethylamino)propyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.23 (s, 1H), 7.87 (s, 2H), 5.87 (d, J=17.2 Hz, 1H), 5.54 (d, J=17.2 Hz, 1H), 4.17 (dd, J=9.2, 4.7 Hz, 1H), 3.49 (dd, J=5.4, 2.7 Hz, 1H), 3.07 (q, J=6.5 Hz, 2H), 2.70 (d, J=15.4 Hz, 3H), 2.66 (d, J=15.4 Hz, 3H), 2.38 (dd, J=13.2, 9.1 Hz, 1H), 2.20 (t, J=7.2 Hz, 2H), 2.09 (s, 6H), 1.92 (dd, J=13.1, 4.7 Hz, 1H), 1.51 (p, J=7.0 Hz, 2H), 1.28 (s, 3H), 1.03-0.94 (m, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-propyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (m, 2H), 7.82 (m, 1H), 5.87 (d, J=17.2 Hz, 1H), 5.53 (d, J=17.2 Hz, 1H), 4.18 (dd, J=9.2, 4.6 Hz, 1H), 3.48 (dd, J=5.5, 2.5 Hz, 1H), 3.01 (q, J=6.5 Hz, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.38 (dd, J=13.2, 9.1 Hz, 1H), 1.92 (dd, J=13.2, 4.6 Hz, 1H), 1.39 (h, J=7.2 Hz, 2H), 1.28 (s, 3H), 1.03-0.85 (m, 2H), 0.81 (t, J=7.4 Hz, 3H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-butyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.80 (t, J=5.8 Hz, 1H), 5.87 (d, J=17.2 Hz, 1H), 5.53 (d, J=17.2 Hz, 1H), 4.18 (dd, J=9.2, 4.5 Hz, 1H), 3.48 (dd, J=5.5, 2.5 Hz, 1H), 3.05 (q, J=6.7 Hz, 2H), 2.68 (d, J=14.0 Hz, 6H), 2.38 (dd, J=13.2, 9.2 Hz, 1H), 1.91 (dd, J=13.2, 4.6 Hz, 1H), 1.36 (p, J=7.0 Hz, 2H), 1.30-1.18 (m, 5H), 0.98 (dt, J=7.6, 5.0 Hz, 2H), 0.83 (t, J=7.3 Hz, 3H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-pentyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.80 (t, J=5.8 Hz, 1H), 5.87 (d, J=17.2 Hz, 1H), 5.53 (d, J=17.2 Hz, 1H), 4.18 (dd, J=9.2, 4.5 Hz, 1H), 3.48 (dd, J=5.5, 2.5 Hz, 1H), 3.04 (q, J=6.6 Hz, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.38 (dd, J=13.2, 9.2 Hz, 1H), 1.91 (dd, J=13.1, 4.5 Hz, 1H), 1.37 (td, J=13.0, 11.7, 6.0 Hz, 2H), 1.33-1.16 (m, 7H), 1.06-0.93 (m, 2H), 0.81 (t, J=6.8 Hz, 3H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(2,2-dimethylpropyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.44 (d, J=6.1 Hz, 1H), 7.86 (s, 2H), 7.69 (t, J=6.4 Hz, 1H), 5.90 (d, J=17.2 Hz, 1H), 5.54 (d, J=17.1 Hz, 1H), 4.27 (dd, J=9.2, 4.6 Hz, 1H), 3.51 (dd, J=5.6, 2.4 Hz, 1H), 2.94 (dd, J=13.0, 6.8 Hz, 1H), 2.81 (dd, J=13.0, 6.0 Hz, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.40 (dd, J=13.2, 9.2 Hz, 1H), 1.95 (dd, J=13.2, 4.6 Hz, 1H), 1.28 (s, 2H), 1.03-0.88 (m, 2H), 0.80 (s, 9H).
(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-benzyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.06 (s, 2H), 8.48-8.39 (m, 2H), 7.86 (s, 2H), 7.39-7.16 (m, 5H), 5.88 (d, J=17.2 Hz, 1H), 5.56 (d, J=17.2 Hz, 1H), 4.29 (m, 3H), 3.51 (t, J=4.1 Hz, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.44 (dd, J=13.2, 9.2 Hz, 1H), 1.97 (dd, J=13.2, 4.5 Hz, 1H), 1.28 (s, 3H), 1.01 (d, J=3.9 Hz, 2H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-hexyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.76 (t, J=5.7 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.67 (d, J=17.8 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.50 (dd, J=5.6, 2.3 Hz, 1H), 3.02 (q, J=6.5 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.1, 9.1 Hz, 1H), 1.89 (dd, J=13.1, 4.9 Hz, 1H), 1.36 (m, 2H), 1.28 (s, 3H), 1.29-1.21 (m, 6H), 1.01 (t, J=5.4 Hz, 1H), 0.88-0.77 (m, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-heptyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.76 (t, J=5.7 Hz, 1H), 7.63 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.7 Hz, 1H), 4.17 (dd, J=9.0, 4.9 Hz, 1H), 3.50 (dd, J=5.7, 2.3 Hz, 1H), 3.02 (q, J=6.5 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.2, 9.1 Hz, 1H), 1.89 (dd, J=13.2, 5.0 Hz, 1H), 1.36 (q, J=7.0 Hz, 2H), 1.28 (s, 3H), 1.21 (m, 8H), 1.01 (t, J=5.4 Hz, 1H), 0.88-0.77 (m, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-octyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (s, 1H), 7.76 (t, J=5.7 Hz, 1H), 7.62 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.17 (dd, J=9.2, 5.0 Hz, 1H), 3.50 (dd, J=5.9, 2.3 Hz, 1H), 3.02 (q, J=6.6 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H) 2.39 (dd, J=13.1, 9.1 Hz, 1H), 1.89 (dd, J=13.0, 4.9 Hz, 1H), 1.35 (s, 2H), 1.28 (s, 3H), 1.20 (m, 10H), 1.01 (t, J=5.5 Hz, 1H), 0.83 (dt, J=13.1, 5.9 Hz, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-nonyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.76 (t, J=5.8 Hz, 1H), 7.62 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.50 (dd, J=5.7, 2.3 Hz, 1H), 3.02 (q, J=6.6 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.1, 9.1 Hz, 1H), 1.89 (dd, J=13.2, 4.9 Hz, 1H), 1.35 (t, J=6.9 Hz, 2H), 1.28 (s, 3H), 1.28-1.16 (m, 12H), 1.01 (t, J=5.4 Hz, 1H), 0.83 (q, J=7.8, 7.0 Hz, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-decyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.76 (t, J=5.8 Hz, 1H), 7.62 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.50 (dd, J=5.7, 2.3 Hz, 1H), 3.02 (q, J=6.6 Hz, 2H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.39 (dd, J=13.1, 9.1 Hz, 1H), 1.89 (dd, J=13.2, 4.9 Hz, 1H), 1.35 (t, J=6.9 Hz, 2H), 1.28 (s, 3H), 1.28-1.16 (m, 14H), 1.01 (t, J=5.4 Hz, 1H), 0.83 (q, J=7.8, 7.0 Hz, 4H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(2-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (s, 1H), 7.89 (t, J=5.8 Hz, 1H), 7.63 (s, 1H), 7.22 (dd, J=25.8, 7.1 Hz, 5H), 5.96 (d, J=17.7 Hz, 1H), 5.67 (d, J=17.7 Hz, 1H), 4.17 (dd, J=9.2, 4.9 Hz, 1H), 3.48 (dd, J=5.6, 2.3 Hz, 1H), 3.24 (m, 2H), 2.73-2.63 (m, 11H), 2.35 (dd, J=13.2, 9.1 Hz, 1H), 1.81 (dd, J=13.2, 4.9 Hz, 1H), 1.24 (s, 3H), 0.99 (t, J=5.4 Hz, 1H), 0.84 (dd, J=5.1, 2.3 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(3-phenylpropyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 2H), 8.32 (s, 1H), 7.86 (t, J=5.5 Hz, 1H), 7.60 (s, 1H), 7.16 (m, 5H), 5.98 (d, J=17.8 Hz, 1H), 5.68 (d, J=17.7 Hz, 1H), 4.18 (dd, J=9.2, 5.1 Hz, 1H), 3.52 (dd, J=5.6, 2.3 Hz, 1H), 3.05 (q, J=6.5 Hz, 2H), 2.74-2.57 (m, 11H), 2.41 (dd, J=13.2, 9.1 Hz, 1H), 1.92 (dd, J=13.2, 5.2 Hz, 1H), 1.64 (dt, J=13.6, 6.7 Hz, 2H), 1.29 (s, 3H), 1.00 (t, J=5.5 Hz, 1H), 0.86 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(4-phenylbutyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 2H), 8.32 (d, J=1.6 Hz, 1H), 7.79 (t, J=5.8 Hz, 1H), 7.61 (s, 1H), 7.23-7.09 (m, 5H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.7 Hz, 1H), 4.16 (dd, J=9.1, 5.0 Hz, 1H), 3.50 (dd, J=5.6, 2.3 Hz, 1H), 3.06 (q, J=6.5 Hz, 2H), 2.71-2.57 (m, 11H), 2.38 (dd, J=13.2, 9.1 Hz, 1H), 1.88 (dd, J=13.1, 5.0 Hz, 1H), 1.52 (tt, J=8.4, 4.7 Hz, 2H), 1.39 (p, J=7.2 Hz, 2H), 1.27 (s, 3H), 1.00 (t, J=5.4 Hz, 1H), 0.85 (dd, J=5.2, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(5-phenylpentyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.01 (s, 2H), 8.32 (s, 1H), 7.77 (t, J=5.9 Hz, 1H), 7.61 (s, 1H), 7.30-7.09 (m, 5H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.16 (dd, J=9.1, 5.0 Hz, 1H), 3.50 (dd, J=5.6, 2.3 Hz, 1H), 3.02 (q, J=6.5 Hz, 2H), 2.71-2.53 (m, 11H), 2.37 (dd, J=13.2, 9.2 Hz, 1H), 1.87 (dd, J=13.1, 5.0 Hz, 1H), 1.52 (p, J=7.7 Hz, 2H), 1.40 (p, J=7.1 Hz, 2H), 1.26 (m, 5H), 1.00 (t, J=5.4 Hz, 1H), 0.85 (dd, J=5.5, 2.3 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(6-phenylhexyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.02 (s, 2H), 8.32 (s, 1H), 7.76 (t, J=5.7 Hz, 1H), 7.61 (s, 1H), 7.31-7.19 (m, 2H), 7.13 (m, 3H), 5.97 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.7 Hz, 1H), 4.17 (dd, J=9.1, 4.9 Hz, 1H), 3.53-3.46 (m, 1H), 3.01 (q, J=6.5 Hz, 2H), 2.71-2.54 (m, 11H), 2.38 (dd, J=13.2, 9.1 Hz, 1H), 1.89 (dd, J=13.2, 4.9 Hz, 1H), 1.50 (t, J=7.5 Hz, 2H), 1.35 (s, 2H), 1.36-1.18 (m, 7H), 1.00 (t, J=5.5 Hz, 1H), 0.85 (dd, J=5.0, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-benzyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (d, J=1.7 Hz, 2H), 8.42-8.31 (m, 2H), 7.63 (s, 1H), 7.32-7.19 (m, 5H), 5.98 (d, J=17.7 Hz, 1H), 5.78-5.65 (m, 1H), 4.28 (m, 3H), 3.55-3.49 (m, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.50-2.42 (m, 1H), 1.94 (dd, J=13.3, 4.8 Hz, 1H), 1.29 (s, 3H), 1.02 (d, J=5.5 Hz, 1H), 0.91-0.85 (m, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(2-methoxyphenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.34 (d, J=1.6 Hz, 1H), 8.19 (t, J=6.0 Hz, 1H), 7.63 (s, 1H), 7.30-6.86 (m, 4H), 6.81 (t, J=7.4 Hz, 1H), 5.99 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.31 (dd, J=9.2, 4.9 Hz, 1H), 4.29-4.15 (m, 2H), 3.78 (s, 3H), 3.56-3.49 (m, 1H), 3.18 (s, 1H), 2.72-2.61 (m, 9H), 2.44 (dd, J=13.2, 9.1 Hz, 1H), 2.08 (s, 1H), 1.97 (dd, J=13.3, 4.8 Hz, 1H), 1.30 (s, 3H), 1.03 (t, J=5.4 Hz, 1H), 0.88 (dd, J=5.2, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(3-methoxyphenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.43-8.31 (m, 2H), 7.62 (s, 1H), 7.16 (t, J=7.8 Hz, 1H), 6.81-6.70 (m, 3H), 5.99 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.39-4.17 (m, 3H), 3.54 (dd, J=5.6, 2.3 Hz, 1H), 3.52 (s, 3H), 3.18 (s, 1H), 2.69 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.45 (dd, J=13.1, 9.1 Hz, 1H), 1.94 (dd, J=13.2, 5.2 Hz, 1H), 1.29 (s, 3H), 1.02 (t, J=5.3 Hz, 1H), 0.88 (dd, J=5.4, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(4-methoxyphenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.36-8.25 (m, 2H), 7.63 (s, 1H), 7.13 (d, J=8.5 Hz, 2H), 6.81 (d, J=8.5 Hz, 2H), 5.98 (d, J=17.9 Hz, 1H), 5.68 (d, J=17.7 Hz, 1H), 4.83 (s, 6H), 4.23 (dd, J=22.3, 5.1 Hz, 3H), 3.69 (s, 3H), 3.52 (dd, J=5.7, 2.5 Hz, 1H), 3.18 (s, 1H), 2.72-2.61 (m, 9H), 2.43 (dd, J=13.2, 9.2 Hz, 1H), 2.08 (s, 2H), 1.93 (dd, J=13.1, 4.9 Hz, 1H), 1.28 (s, 3H), 1.22 (d, J=18.3 Hz, 0H), 1.01 (t, J=5.4 Hz, 1H), 0.87 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[(1S)-1-phenylethyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.33 (d, J=1.7 Hz, 1H), 8.22 (d, J=8.0 Hz, 1H), 7.64 (t, J=1.5 Hz, 1H), 7.41-7.17 (m, 5H), 6.02 (d, J=17.9 Hz, 1H), 5.65 (d, J=17.8 Hz, 1H), 4.87 (p, J=7.1 Hz, 1H), 4.25 (dd, J=9.0, 5.4 Hz, 1H), 3.53 (dd, J=5.6, 2.3 Hz, 1H), 2.69 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.41 (dd, J=13.1, 9.0 Hz, 1H), 1.83 (dd, J=13.0, 5.4 Hz, 1H), 1.30 (d, J=7.0 Hz, 3H), 1.23 (s, 3H), 0.99 (t, J=5.4 Hz, 1H), 0.86 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[(1R)-1-phenylethyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.03 (s, 2H), 8.33 (d, J=1.7 Hz, 1H), 8.18 (d, J=8.2 Hz, 1H), 7.62 (d, J=1.7 Hz, 1H), 7.32-7.18 (m, 4H), 7.22-7.13 (m, 1H), 5.99 (d, J=17.8 Hz, 1H), 5.66 (d, J=17.8 Hz, 1H), 4.91 (p, J=7.0 Hz, 1H), 4.29 (dd, J=9.1, 4.9 Hz, 1H), 3.54 (dd, J=5.5, 2.4 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.65 (s, 3H), 2.42 (dd, J=13.2, 9.2 Hz, 1H), 1.92 (dd, J=13.2, 4.8 Hz, 1H), 1.40-1.14 (m, 6H), 1.02 (t, J=5.4 Hz, 1H), 0.87 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(2-fluorophenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.42-8.31 (m, 2H), 7.63 (s, 1H), 7.27 (q, J=7.2 Hz, 2H), 7.24-7.12 (m, 1H), 7.15-7.02 (m, 1H), 5.98 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H) 4.39-4.24 (m, 3H), 3.53 (dd, J=5.5, 2.3 Hz, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.45 (dd, J=13.2, 9.1 Hz, 1H), 1.93 (dd, J=13.3, 5.0 Hz, 1H), 1.28 (s, 3H), 1.02 (t, J=5.4 Hz, 1H), 0.89 (dd, J=5.4, 2.3 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(3-fluorophenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.46 (t, J=6.0 Hz, 1H), 8.33 (d, J=1.7 Hz, 1H), 7.63 (s, 1H), 7.31 (td, J=8.5, 6.3 Hz, 1H), 7.10-6.98 (m, 3H), 5.98 (d, J=17.8 Hz, 1H), 5.71 (d, J=17.8 Hz, 1H), 4.33-4.24 (m, 3H), 3.53 (dd, J=5.7, 2.4 Hz, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.49-2.41 (m, 1H), 1.94 (dd, J=13.2, 5.0 Hz, 1H), 1.29 (s, 3H), 1.03 (t, J=5.4 Hz, 1H), 0.89 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-[(4-fluorophenyl)methyl]-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.44-8.31 (m, 2H), 7.63 (s, 1H), 7.29-7.20 (m, 2H), 7.12-7.02 (m, 2H), 5.98 (d, J=17.8 Hz, 1H), 5.68 (d, J=17.8 Hz, 1H), 4.26 (dd, J=7.9, 5.4 Hz, 3H), 3.52 (dd, J=5.5, 2.4 Hz, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.65 (s, 3H), 2.44 (dd, J=13.2, 9.1 Hz, 1H), 1.93 (dd, J=13.2, 4.9 Hz, 1H), 1.28 (s, 3H), 1.02 (t, J=5.3 Hz, 1H), 0.88 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[(2-methylphenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.34 (d, J=1.7 Hz, 1H), 8.24 (t, J=5.8 Hz, 1H), 7.63 (s, 1H), 7.19-7.02 (m, 4H), 5.99 (d, J=17.8 Hz, 1H), 5.69 (d, J=17.8 Hz, 1H), 4.34-4.16 (m, 3H), 3.53 (dd, J=5.7, 2.4 Hz, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.45 (dd, J=13.1, 9.2 Hz, 1H), 2.23 (s, 3H), 1.95 (dd, J=13.1, 5.0 Hz, 1H), 1.30 (s, 3H), 1.02 (t, J=5.4 Hz, 1H), 0.88 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[(3-methylphenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.39-8.31 (m, 2H), 7.63 (s, 1H), 7.15 (t, J=7.5 Hz, 1H), 7.01 (dd, J=13.2, 7.6 Hz, 3H), 5.98 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.32-4.16 (m, 3H), 3.53 (dd, J=5.6, 2.4 Hz, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.45 (dd, J=13.2, 9.1 Hz, 1H), 2.18 (s, 3H), 1.95 (dd, J=13.2, 4.9 Hz, 1H), 1.30 (s, 3H), 1.03 (t, J=5.5 Hz, 1H), 0.88 (dd, J=5.2, 2.5 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-[(4-methylphenyl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.36-8.29 (m, 2H), 7.63 (d, J=1.7 Hz, 1H), 7.08 (q, J=8.0 Hz, 4H), 5.98 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.25 (m, 3H), 3.52 (dd, J=5.5, 2.5 Hz, 1H), 2.70 (s, 3H), 2.67 (s, 3H), 2.65 (s, 3H), 2.44 (dd, J=13.2, 9.2 Hz, 1H), 2.24 (s, 3H), 1.94 (dd, J=13.2, 4.9 Hz, 1H), 1.29 (s, 3H), 1.02 (t, J=5.4 Hz, 1H), 0.88 (dd, J=5.4, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyrimidin-2-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.79-8.69 (m, 2H), 8.41-8.30 (m, 2H), 7.63 (s, 1H), 7.42-7.36 (m, 1H), 5.99 (d, J=17.8 Hz, 1H), 5.69 (d, J=17.7 Hz, 1H), 4.49-4.42 (m, 2H), 4.37 (dd, J=9.1, 4.5 Hz, 1H), 3.51 (dd, J=5.5, 2.4 Hz, 1H), 2.69 (s, 3H), 2.68 (s, 3H), 2.65 (s, 3H), 2.43 (dd, J=13.2, 9.1 Hz, 1H), 2.15-2.08 (m, 1H), 1.31 (s, 3H), 1.04 (t, J=5.2 Hz, 1H), 0.93-0.82 (m, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyrimidin-4-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.06 (m, 3H), 8.59 (m, 2H), 8.34 (s, 1H), 7.64 (m, 1H), 7.31 (d, J=5.3 Hz, 1H), 5.99 (d, J=17.8 Hz, 1H), 5.71 (d, J=17.8 Hz, 1H), 4.33 (m, 3H), 3.56-3.50 (m, 1H), 2.77-2.63 (m, 9H), 2.43-2.39 (m, 1H), 2.04-1.96 (m, 1H), 1.28 (s, 3H), 1.02 (t, J=5.6 Hz, 1H), 0.93-0.91 (m, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyrimidin-5-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (d, J=2.9 Hz, 3H), 8.64 (s, 2H), 8.53 (t, J=5.9 Hz, 1H), 8.33 (d, J=1.6 Hz, 1H), 7.62 (s, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.32 (d, J=5.9 Hz, 2H), 4.25 (dd, J=9.1, 5.3 Hz, 1H), 3.53 (dd, J=5.6, 2.3 Hz, 1H), 2.70 (s, 3H), 2.65 (s, 3H), 2.65 (s, 3H), 2.45 (dd, J=13.1, 9.1 Hz, 1H), 1.92 (dd, J=13.3, 5.4 Hz, 1H), 1.28 (s, 3H), 1.01 (t, J=5.4 Hz, 1H), 0.90 (dd, J=5.3, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyridin-2-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.60-8.51 (m, 2H), 8.34 (d, J=1.7 Hz, 1H), 7.80 (t, J=7.9 Hz, 1H), 7.63 (s, 1H), 7.41-7.31 (m, 2H), 5.99 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.41 (d, J=5.9 Hz, 2H), 4.31 (dd, J=9.2, 5.2 Hz, 1H), 3.54 (dd, J=5.6, 2.4 Hz, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.65 (s, 3H), 2.50-2.42 (m, 1H), 1.99 (dd, J=13.2, 5.2 Hz, 1H), 1.30 (s, 3H), 1.02 (t, J=5.5 Hz, 1H), 0.91 (dd, J=5.2, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyridin-3-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.56 (dd, J=6.6, 4.0 Hz, 3H), 8.34 (d, J=1.6 Hz, 1H), 7.93 (d, J=7.9 Hz, 1H), 7.63 (s, 1H), 7.55 (dd, J=7.9, 5.2 Hz, 1H), 5.97 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.38 (d, J=5.9 Hz, 2H), 4.26 (dd, J=9.1, 5.4 Hz, 1H), 3.53 (dd, J=5.5, 2.4 Hz, 1H), 2.70 (s, 3H), 2.65 (s, 3H), 2.64 (s, 3H), 2.50-2.41 (m, 1H), 1.93 (dd, J=13.0, 5.4 Hz, 1H), 1.29 (s, 3H), 1.01 (t, J=5.4 Hz, 1H), 0.90 (dd, J=5.2, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyridin-4-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.05 (s, 2H), 8.74-8.59 (m, 3H), 8.35 (d, J=1.6 Hz, 1H), 7.65-7.58 (m, 3H), 5.99 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.47 (d, J=5.9 Hz, 2H), 4.30 (dd, J=9.2, 5.5 Hz, 1H), 3.55 (dd, J=5.6, 2.4 Hz, 1H), 3.18 (s, 2H), 2.72-2.62 (m, 9H), 2.48 (s, 0H), 1.97 (dd, J=13.2, 5.5 Hz, 1H), 1.31 (s, 3H), 1.02 (t, J=5.4 Hz, 1H), 0.93 (dd, J=5.4, 2.4 Hz, 1H).
(1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-(pyridazin-3-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, DMSO-d6) δ 9.10 (dd, J=4.9, 1.6 Hz, 1H), 9.05 (s, 2H), 8.65 (t, J=6.0 Hz, 1H), 8.34 (d, J=1.7 Hz, 1H), 7.63 (s, 1H), 7.54 (dd, J=8.5, 4.8 Hz, 1H), 7.47 (dd, J=8.6, 1.7 Hz, 1H), 5.98 (d, J=17.8 Hz, 1H), 5.70 (d, J=17.8 Hz, 1H), 4.57 (d, J=5.9 Hz, 2H), 4.29 (dd, J=9.2, 5.3 Hz, 1H), 3.53 (dd, J=5.7, 2.4 Hz, 1H), 2.70 (s, 3H), 2.65 (s, 3H), 2.56 (s, 3H), 2.50-2.42 (m, 1H), 1.97 (dd, J=13.3, 5.2 Hz, 1H), 1.29 (s, 3H), 1.01 (t, J=5.5 Hz, 1H), 0.90 (dd, J=5.2, 2.5 Hz, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-isopentyl-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.81 (t, J=5.56 Hz, 1H), 5.87 (d, J=17.36 Hz, 1H), 5.53 (d, J=17.08 Hz, 1H), 4.16 (q, J=4.76 Hz, 1H), 3.07-3.05 (m, 2H), 2.68 (s, 3H), 2.66 (s, 3H), 2.40-2.34 (m, 2H), 1.92-1.87 (m, 1H), 1.55-1.48 (m, 1H), 1.30-1.24 (m, 5H), 0.99-0.98 (m, 2H), 0.88-0.82 (m, 6H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N—((S)-3-methylbutan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.07 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.51 (d, J=8.04 Hz, 1H), 5.91 (d, J=17.36 Hz, 1H), 5.53 (d, J=17.24 Hz, 1H), 4.19-4.16 (m, 1H), 3.57-3.53 (m, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.41-2.33 (m, 1H), 1.90-1.87 (m, 1H), 1.60-1.57 (m, 1H), 1.27 (s, 3H), 0.97-0.91 (m, 5H), 0.80 (t, J=3.76 Hz, 6H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-3,3-dimethylbutan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.38 (d, J=9.60 Hz, 1H), 5.93 (d, J=17.32 Hz, 1H), 5.53 (d, J=17.12 Hz, 1H), 4.23 (q, J=5.20 Hz, 1H), 3.64 (q, J=6.56 Hz, 1H), 3.55-3.54 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.38-2.33 (m, 2H), 1.90 (d, J=4.80 Hz, 1H), 1.27 (s, 3H), 0.93-0.92 (m, 4H), 0.79 (s, 9H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N—((S)-pentan-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.52 (d, J=8.44 Hz, 1H), 5.90 (d, J=17.16 Hz, 1H), 5.52 (d, J=17.12 Hz, 1H), 4.13 (q, J=5.00 Hz, 2H), 3.73 (q, J=6.52 Hz, 1H), 3.52-3.51 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.39-2.33 (m, 2H), 1.87 (d, J=4.76 Hz, 1H), 1.50-1.47 (m, 1H), 1.35-1.33 (m, 1H), 1.27 (s, 3H), 1.27-1.20 (m, 1H), 1.17-0.97 (m, 4H), 0.80 (t, J=7.16 Hz, 3H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-hexan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.52 (d, J=8.44 Hz, 1H), 5.90 (d, J=17.20 Hz, 1H), 5.52 (d, J=17.20 Hz, 1H), 4.14 (q, J=4.80 Hz, 1H), 3.73-3.69 (m, 1H), 3.52-3.51 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.41-2.34 (m, 1H), 1.87 (d, J=5.40 Hz, 1H), 1.37-1.32 (m, 3H), 1.27 (s, 3H), 1.25-1.21 (m, 4H), 1.19-0.99 (m, 4H), 0.77 (t, J=7.04 Hz, 3H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-heptan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.05 (s, 2H), 8.45 (s, 1H), 7.87 (s, 2H), 7.52 (d, J=8.44 Hz, 1H), 5.90 (d, J=17.36 Hz, 1H), 5.52 (d, J=16.88 Hz, 1H), 4.14 (q, J=4.84 Hz, 1H), 3.73-3.69 (m, 1H), 3.56-3.48 (m, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.41-2.34 (m, 2H), 1.87 (d, J=4.56 Hz, 1H), 1.34-1.33 (m, 2H), 1.27 (s, 3H), 1.24-1.10 (m, 6H), 1.00-0.96 (m, 4H), 0.77 (t, J=6.48 Hz, 3H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-1-(4-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.46 (s, 1H), 8.23 (d, J=8.04 Hz, 1H), 7.87 (s, 2H), 7.30-7.27 (m, 2H), 7.06 (t, J=8.84 Hz, 2H), 5.92 (d, J=17.24 Hz, 1H), 5.54 (d, J=17.16 Hz, 1H), 4.89 (t, J=7.36 Hz, 1H), 4.21 (q, J=5.24 Hz, 1H), 3.53 (t, J=3.96 Hz, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.42-2.34 (m, 1H), 1.84 (d, J=5.32 Hz, 1H), 1.32 (d, J=7.00 Hz, 3H), 1.24 (s, 3H), 0.97-0.96 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-1-(2,3-dimethylphenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.07 (s, 2H), 8.46 (s, 1H), 8.20 (d, J=7.64 Hz, 1H), 7.87 (s, 2H), 7.12-7.10 (m, 1H), 7.01-6.99 (m, 2H), 5.92 (d, J=17.28 Hz, 1H), 5.53 (d, J=17.04 Hz, 1H), 5.07 (t, J=7.16 Hz, 1H), 4.22 (q, J=5.52 Hz, 1H), 3.52-3.52 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.40-2.33 (m, 2H), 2.21 (s, 3H), 2.14 (s, 3H), 1.82 (d, J=5.00 Hz, 1H), 1.26-1.23 (m, 4H), 1.17-1.14 (m, 1H), 0.97-0.88 (m, 2H).
Figure US11708351-20230725-C01205
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds where the carboxylic acid on the C-ring is functionalized utilizing HATU and ammonium chloride. The skilled artisan will recognize that the A-ring can be replaced with other A-rings to afford additional compounds of the present invention. The skilled artisan will also recognize that the C-ring can be functionalized utilizing coupling reagents other than HATU.
To a mixture of Compound 493 (20 mg, 0.032 mmol) and NH4Cl (2 mg, 0.041 mmol) in DMF (2 mL) was added HATU (0.016 g, 0.041 mmol) and DIPEA (0.012 g, 0.095 mmol) and the mixture was stirred at 25° C. for 12 hrs. The mixture was diluted with EtOAc and washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to afford Compound 503 (6.5 mg, yield 32.5%) as white solid. 1H-NMR (400 MHz, CDCl3) δ 9.52 (s, 1H), 8.93 (s, 2H), 8.42 (s, 1H), 8.31 (s, 1H), 7.52-7.20 (m, 3H), 6.82 (s, 1H), 6.32 (s, 1H), 5.43 (dd, J=38.5, 16.2 Hz, 2H), 4.73 (m, 1H), 3.20 (m, 1H), 2.86 (s, 3H), 2.64 (s, 3H), 2.33 (m, 2H), 1.31 (s, 3H), 1.04 (m, 1H), 0.91 (m, 1H). LC/MS (ESI) m/z: 631/633 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(4-(2-amino-2-oxoethyl)-6-bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.54 (s, 1H), 8.06 (s, 1H), 7.80 (m, 2H), 7.24 (m, 1H), 5.82 (d, J=17.4 Hz, 1H), 5.64 (d, J=17.2 Hz, 1H), 4.48 (m, 1H), 3.55 (m, 1H), 3.51 (m, 2H), 2.75 (s, 3H), 2.70 (s, 3H), 2.63-2.49 (m, 1H), 2.20-2.16 (m, 1H), 1.37 (s, 3H), 1.07 (m, 1H), 0.99 (m, 1H). LC/MS (ESI) m/z: 645/647 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N—((S)-1-(p-tolyl)ethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD): δ 9.07 (s, 2H), 8.57 (s, 1H), 7.80 (s, 2H), 7.16 (d, J=8.00 Hz, 2H), 7.10 (d, J=8.40 Hz, 2H), 5.78 (d, J=17.20 Hz, 1H), 5.61 (d, J=17.20 Hz, 1H), 4.95-4.94 (m, 1H), 4.37-4.33 (m, 1H), 3.49-3.47 (m, 1H), 2.79 (s, 3H), 2.71 (s, 3H), 2.51-2.46 (m, 1H), 2.30 (s, 3H), 2.01-1.96 (m, 1H), 1.39 (d, J=6.80 Hz, 3H), 1.31 (s, 3H), 1.05 (t, J=5.60 Hz, 1H), 0.95-0.93 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-1-(3-chlorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD): δ 9.07 (s, 2H), 8.58 (s, 1H), 7.84-7.79 (m, 2H), 7.31-7.27 (m, 2H), 7.25-7.22 (m, 2H), 5.79 (d, J=17.20 Hz, 1H), 5.64 (d, J=17.20 Hz, 1H), 4.95-4.85 (m, 1H), 4.37-4.34 (m, 1H), 3.50-3.48 (m, 1H), 2.79 (s, 3H), 2.72 (s, 3H), 2.54-2.49 (m, 1H), 1.99 (d, J=5.60 Hz, 1H), 1.42 (d, J=7.20 Hz, 3H), 1.32 (s, 3H), 1.08-1.05 (m, 1H), 0.97-0.96 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N—((S)-1-(2-fluorophenyl)ethyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.07 (s, 2H), 8.46 (s, 1H), 8.31 (d, J=7.52 Hz, 1H), 7.90 (s, 2H), 7.32-7.22 (m, 2H), 7.12-7.04 (m, 2H), 5.94 (d, J=17.12 Hz, 1H), 5.54 (d, J=17.20 Hz, 1H), 5.08 (t, J=6.92 Hz, 1H), 4.22 (q, J=4.72 Hz, 1H), 3.53-3.43 (m, 1H), 2.70 (s, 3H), 2.66 (s, 3H), 2.43-2.33 (m, 1H), 1.85-1.81 (m, 1H), 1.32 (d, J=6.96 Hz, 3H), 1.13 (s, 3H), 0.96 (d, J=3.40 Hz, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N—((S)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD): δ 9.06 (s, 2H), 8.57 (s, 1H), 7.81 (s, 2H), 7.30-7.30 (m, 4H), 7.29-7.18 (m, 1H), 5.79 (d, J=17.20 Hz, 1H), 5.63 (d, J=17.20 Hz, 1H), 5.12-5.06 (m, 1H), 4.38-4.34 (m, 1H), 3.49-3.48 (m, 1H), 2.79 (s, 3H), 2.72 (s, 3H), 2.50 (q, J=9.20 Hz, 1H), 1.99 (q, J=5.20 Hz, 1H), 1.42 (d, J=6.80 Hz, 3H), 1.32 (s, 3H), 1.07-1.04 (m, 1H), 0.95-0.93 (m, 1H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-N—((R)-1-phenylethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.45 (s, 1H), 8.20 (d, J=8.24 Hz, 1H), 7.87 (s, 2H), 7.30-7.19 (m, 5H), 5.90 (d, J=17.24 Hz, 1H), 5.54 (d, J=17.20 Hz, 1H), 4.92 (t, J=7.88 Hz, 1H), 4.27 (q, J=4.76 Hz, 1H), 2.69 (s, 3H), 2.63 (s, 3H), 2.44-2.33 (m, 2H), 1.92 (d, J=4.72 Hz, 1H), 1.36-1.24 (m, 6H), 1.00-0.98 (m, 2H).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(3,3-dimethylbutyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, DMSO-d6): δ 9.06 (s, 2H), 8.45 (d, J=0.92 Hz, 1H), 7.87 (s, 2H), 7.79 (t, J=5.64 Hz, 1H), 5.87 (d, J=17.32 Hz, 1H), 5.53 (d, J=17.12 Hz, 1H), 4.17-4.13 (m, 1H), 3.47 (s, 1H), 3.05 (q, J=7.92 Hz, 2H), 2.70 (s, 3H), 2.66 (s, 3H), 2.39-2.33 (m, 1H), 2.09-2.08 (m, 1H), 1.31-1.26 (m, 4H), 0.99-0.97 (m, 2H), 0.96 (s, 1H), 0.87 (s, 9H).
Figure US11708351-20230725-C01206
Figure US11708351-20230725-C01207
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with nucleophilic R201 groups on the C-Ring. The skilled artisan will recognize that pyrazole can be replaced with other nucleophilic reagents to afford additional compounds of the present invention. Non-limiting examples of groups the skilled artisan can use instead of pyrazole include: triazole, imidazole, azetidine, or the like.
Step 1: 2-(tert-butyl) 3-ethyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (2)
Into pyrazole (0.035 g, 0.51 mmol) in DMF 0.5 ml, sodium hydride (0.02 g, 0.51 mmol) was added with stirring. After 20 minutes at room temperature, 2-tert-butyl 3-ethyl (1R,3S,5S)-5-[(methanesulfonyloxy)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 1 (0.124 g, 0.34 mmol) in DMF (2 mL) was added. The mixture was stirred at 60° C. for 3 hours to afford a racemic mixture. The resulting solid was removed by filtration and the filtrate was purified by HPLC to afford 2-tert-butyl 2-(tert-butyl) 3-ethyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 2 (24 mg).
Step 2: (1R,3S,5R)-5-((1H-Pyrazol-1-yl)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (3)
2-(tert-Butyl) 3-ethyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 2 (24 mg, 0.072 mmol) was treated with lithium hydroxide (1.5 N, 0.072 mL, 0.107 mmol) in THF (1 mL) and ethanol (0.1 mL) at room temperature overnight. After the reaction was completed, Amberlite CG-50 (0.1 g) was added and the mixture was stirred for 30 minutes. Resin was removed by filtration and washed with MeOH. Solvent was removed under reduced pressure to afford (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 3 (25 mg).
Step 3: tert-Butyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (4)
Into mixture of (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 3 (25 mg) and 6-bromo-3-methylpyridin-2-amine (15.2 mg) in DCM (1.5 mL), pyridine (0.033 mL, 0.407 mmol) followed by phosphoryl chloride (7.6 μL, 0.081 mmol) was added with stirring. After 2 hours, NaHCO3 aqueous solution was added. The mixture was extracted with DCM. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (MeOH in DCM 0-10%) to afford tert-butyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate S4 (23 mg).
Step 4: (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (5)
tert-Butyl (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate 4 (23 mg, 0.048 mmol) was treated with TFA (1.0 mL) in DCM (1 mL) at room temperature for 2 hours. Solvent was removed under reduced pressure and the residue was co-evaporated with toluene (5 ml×2) to afford (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 5 for next step.
Step 5: (1R,3S,5R)-5-((1H-Pyrazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (310)
Into mixture of (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-(pyrazol-1-ylmethyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 5 (0.048 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid 6 (0.015 g, 0.048 mmol) in DMF (1 mL), TBTU (0.023 g, 0.072 mmol) followed by N,N-diisopropylethylamine (0.062 g, 0.084 mL, 0.48 mmol) was added with stirring. After the reaction was complete, NaHCO3 aqueous solution was added. The mixture was extracted with EtOAc and solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (MeOH in DCM 0-10%) to afford (1R,3S,5R)-5-((1H-pyrazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (310) (25 mg). 1H NMR (400 MHz, Chloroform-d) δ 8.93-8.86 (m, 2H), 8.74 (s, 1H), 8.59-8.52 (m, 1H), 7.70-7.59 (m, 2H), 7.55-7.51 (m, 1H), 7.45 (q, J=2.1 Hz, 1H), 7.34 (dd, J=3.5, 8.3 Hz, 1H), 7.23 (dd, J=4.0, 7.9 Hz, 1H), 6.27 (p, J=2.2 Hz, 1H), 5.57-5.42 (m, 2H), 4.88 (s, 1H), 4.53 (dd, J=7.2, 14.1 Hz, 1H), 4.35 (dt, J=2.2, 14.3 Hz, 1H), 3.49 (dd, J=2.8, 5.8 Hz, 1H), 2.80 (d, J=2.3 Hz, 3H), 2.70 (dd, J=1.5, 2.6 Hz, 3H), 2.26 (dd, J=8.7, 13.7 Hz, 1H), 1.26 (q, J=6.3 Hz, 1H), 1.03 (dd, J=3.5, 6.0 Hz, 1H). LC (method A): tR=1.62 min. LC/MS (EI) m/z: [M+H]+ 668.
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((3-(tert-butyl)-1H-pyrazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.70 (d, J=14.2 Hz, 1H), 8.57 (dd, J=0.8, 1.7 Hz, 1H), 7.70-7.56 (m, 2H), 7.39-7.19 (m, 4H), 6.09 (d, J=2.3 Hz, 1H), 5.48 (s, 2H), 4.89 (d, J=7.9 Hz, 1H), 4.53 (d, J=14.4 Hz, 1H), 4.34 (d, J=14.3 Hz, 1H), 4.12 (q, J=7.1 Hz, 1H), 3.39 (dd, J=2.7, 5.8 Hz, 1H), 2.81 (s, 4H), 2.70 (s, 4H), 2.28 (t, J=11.3 Hz, 1H), 2.05 (d, J=3.5 Hz, 4H), 1.99 (s, 2H), 1.28 (s, 9H), 1.20-1.15 (m, 1H), 0.96 (dd, J=2.7, 5.9 Hz, 1H). LC (method A): tR=2.22 min. LC/MS (EI) m/z: [M+H]+ 724.
(1R,3S,5R)-5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 8.90 (d, J=2.6 Hz, 2H), 8.81 (s, 1H), 8.56 (t, J=2.2 Hz, 1H), 8.20 (s, 1H), 7.98 (d, J=2.0 Hz, 1H), 7.67-7.55 (m, 2H), 7.38-7.30 (m, 1H), 7.23 (d, J=8.0 Hz, 1H), 5.61-5.41 (m, 2H), 4.91 (d, J=8.2 Hz, 1H), 4.62 (d, J=14.0 Hz, 1H), 4.30 (d, J=14.4 Hz, 1H), 3.58 (dd, J=5.9, 2.8 Hz, 1H), 2.80 (d, J=2.0 Hz, 3H), 2.71 (d, J=2.1 Hz, 3H), 2.21 (q, J=15.8, 13.0 Hz, 2H), 2.03 (d, J=2.5 Hz, 3H), 1.38 (t, J=5.8 Hz, 1H), 1.12 (dd, J=6.1, 2.9 Hz, 1H). LC (method A): tR=1.36 min. LC/MS (EI) m/z: [M+H]+ 669.
(1R,3S,5R)-5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H NMR (400 MHz, Chloroform-d) δ 9.28 (s, 2H), 9.10 (d, J=1.3 Hz, 1H), 8.72 (s, 1H), 8.62 (d, J=1.3 Hz, 1H), 8.21 (s, 1H), 7.99 (s, 1H), 7.34 (dd, J=0.8, 7.9 Hz, 1H), 7.22 (d, J=7.9 Hz, 1H), 5.73-5.50 (m, 2H), 4.92 (d, J=8.4 Hz, 1H), 4.62 (d, J=14.4 Hz, 1H), 4.34 (d, J=14.4 Hz, 1H), 3.64 (dd, J=2.8, 5.9 Hz, 1H), 2.81 (s, 3H), 2.76 (s, 1H), 2.72 (s, 3H), 2.32 (s, 1H), 2.04 (s, 3H), 1.43 (t, J=6.0 Hz, 1H), 1.18 (dd, J=2.9, 6.1 Hz, 1H). LC (method A): tR=1.27 min. LC/MS (EI) m/z: [M+H]+ 670.
Figure US11708351-20230725-C01208
Figure US11708351-20230725-C01209
Step 1: 2-tert-Butyl 3-ethyl (1R,3S,5R)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (2)
Into 4-methyl-1H-imidazole (0.042 g, 0.51 mmol) in DMF (0.5 mL), sodium hydride (0.02 g, 0.51 mmol) was added at room temperature with stirring. After 15 minutes, 2-tert-butyl 3-ethyl (1R,3S,5S)-5-[(methanesulfonyloxy)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 1 (0.124 g, 0.34 mmol) in DMF (2 mL) was added and the mixture was stirred at 60° C. for 3 hours to afford a racemic mixture. Solid was removed by filtration and the filtrate was purified by HPLC to afford 2-tert-butyl 3-ethyl (1R,3S,5R)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 2 (59 mg).
Step 2: (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (3)
2-tert-Butyl 3-ethyl (1R,3S,5R)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate S2 (57.4 mg) was treated with lithium hydroxide (10 mg) in THF (2 mL), ethanol (0.15 mL), and water (0.15 mL) at room temperature for 4 days. Amberlite CG-50 (0.2 g) was added and the mixture was stirred for 30 minutes. Resin was removed by filtration and washed with MeOH. Solvent was removed under reduced pressure to afford (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 3 (59 mg).
Step 3: tert-butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate (4)
Into the mixture of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid S3 (53 mg, 0.164 mmol) and 6-bromo-3-methylpyridin-2-amine (34 mg, 0.18 mmol) in DCM (3.0 mL), pyridine (0.066 mL, 0.82 mmol) followed by phosphoryl chloride (15 μL, 0.16 mmol) was added at 0° C. with stirring. After 2 hours at room temperature, NaHCO3 aqueous solution was added. The mixture was extracted with DCM. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (MeOH in DCM 0-10%) to afford tert-butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 4 (35 mg) as white solid.
Step 4: (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (5)
tert-Butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 4 (35 mg, 0.065 mmol) was treated with TFA (2.0 mL) in DCM (2 mL) at room temperature for 2 hours. Solvent was removed under reduced pressure and the residue was co-evaporated with toluene (5 ml×2) to afford (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt S5 for next step.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (314) and (1R,3R,5R)-5-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (315)
Into a mixture of (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-methylimidazol-1-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt S5 (0.065 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid S6 (0.020 g, 0.065 mmol) in DMF (1 mL), TBTU (0.04 g, 0.098 mmol) followed by N,N-diisopropylethylamine (0.091 mL, 0.52 mmol) was added with stirring. After the reaction was complete, the mixture was purified with HPLC to afford (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (314) (17 mg) and (315) (18 mg).
(1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (314)
1H NMR (400 MHz, Chloroform-d) δ 8.90 (s, 2H), 8.80 (s, 1H), 8.57 (dt, J=0.8, 1.6 Hz, 1H), 7.71-7.56 (m, 2H), 7.53-7.33 (m, 2H), 7.28-7.20 (m, 2H), 6.84-6.64 (m, 1H), 5.59-5.38 (m, 2H), 4.96 (d, J=8.1 Hz, 1H), 4.44 (t, J=15.5 Hz, 1H), 4.00 (dd, J=14.5, 37.2 Hz, 1H), 3.41-3.25 (m, 1H), 2.81 (s, 3H), 2.71 (d, J=2.0 Hz, 3H), 2.22 (dd, J=0.9, 2.1 Hz, 3H), 2.05 (d, J=1.5 Hz, 3H), 2.04-1.97 (m, 4H), 1.28 (dd, J=5.4, 11.4 Hz, 1H), 1.13 (td, J=2.7, 6.0, 6.7 Hz, 1H). LC (method A): tR=1.12 min. LC/MS (EI) m/z: [M+H]+ 682.
(1R,3R,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((4-methyl-1H-imidazol-1-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (315)
1H NMR (400 MHz, Chloroform-d) δ 8.89 (s, 3H), 8.56 (dd, J=0.9, 1.8 Hz, 1H), 7.69-7.53 (m, 3H), 7.53-7.37 (m, 1H), 7.33 (d, J=7.9 Hz, 1H), 7.21 (d, J=7.9 Hz, 1H), 6.72 (d, J=74.9 Hz, 1H), 5.63-5.37 (m, 3H), 5.14 (t, J=19.5 Hz, 2H), 4.04 (d, J=6.7 Hz, 3H), 3.54 (ddd, J=2.7, 6.4, 16.7 Hz, 1H), 2.80 (s, 4H), 2.72 (d, J=1.3 Hz, 4H), 2.49 (d, J=13.5 Hz, 1H), 2.21 (s, 4H), 2.02 (d, J=6.5 Hz, 9H), 0.95 (t, J=6.4 Hz, 1H), 0.87 (t, J=6.2 Hz, 0H). LC (method A): tR=1.19 min. LC/MS (EI) m/z: [M+H]+ 682.
Figure US11708351-20230725-C01210
Figure US11708351-20230725-C01211
Step 1: 2-tert-butyl 3-ethyl (1R,3S,5R)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (2)
Into 2-tert-Butyl 3-ethyl (1R,3S,5S)-5-[(methanesulfonyloxy)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 1 (0.124 g, 0.34 mmol) in DMF (2.5 ml), sodium cyanide (0.083 g, 1.7 mmol) was added with stirring. The mixture was stirred at 60° C. for 3 hours. Solid was removed by filtration. Filtrate was diluted with water and extracted with EtOAc. Organic layer was washed with water, brine, and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (EtOAc in Hex 0-50%) to afford 2-tert-butyl 3-ethyl (1R,3S,5R)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 2 (81 mg) as colorless oil.
Step 2: 2-tert-Butyl 3-ethyl (1R,3S,5R)-5-(carbamothioylmethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (3)
2-tert-Butyl 3-ethyl (1R,3S,5R)-5-(cyanomethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (40 mg, 0.136 mmol) was dissolved in hydrochloric acid 4N in dioxane (0.34 mL, 1.36 mmol) and treated with diethyl phosphorodithioic acid (0.034 mL, 0.204 mmol) at room temperature for 1 day. Water (10 mL) was added followed by 1N NaOH aqueous solution to adjust the pH to approximately 9. Into the mixture, di-tert-butyl dicarbonate (0.297 g, 1.36 mmol) in EtOAc (10 mL) was added with vigorous stirring for 15 minutes. The EtOAc layer was separated and washed with brine. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (EtOAc in Hex, 0-50%) to afford 2-tert-butyl 3-ethyl (1R,3S,5R)-5-(carbamothioylmethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 3 (24 mg).
Step 3: 2-tert-Butyl 3-ethyl (1R,3S,5R)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (4)
A mixture of 2-tert-butyl 3-ethyl (1R,3S,5R)-5-(carbamothioylmethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (24 mg, 0.073 mmol), 1-bromopinacolone (0.015 g, 0.08 mmol), and triethylamine (0.011 mL, 0.08 mmol) was refluxed in ethanol (5 mL) under Ar for 1 hour. Solvent was removed under reduced pressure and residue was purified with column chromatography on silica gel to afford intermediate. The hydrate intermediate was refluxed in toluene (5 mL) for an additional 2 hours. Solvent was removed under reduced pressure to afford 2-tert-butyl 3-ethyl (1R,3S,5R)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate 4 (23 mg).
Step 4: (1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (5)
2-tert-Butyl 3-ethyl (1R,3S,5R)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (23 mg, 0.056 mmol) in tetrahydrofuran (0.5 mL) and ethanol 0.05 mL) was treated with lithium hydroxide (1.5 N, 0.056 mL, 0.084 mmol) at room temperature overnight. After the reaction was completed, Amberlite CG-50 (0.1 g, 1 equiv.) was added and stirred for 10 minutes. Resin was removed by filtration and washed with MeOH. Filtrate was concentrated and the residue was co-evaporated with toluene to afford (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid 5 (21 mg) for next step.
Step 5: tert-Butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate (6)
A mixture of (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (21 mg, 0.055 mmol) and 6-bromo-3-methylpyridin-2-amine (0.011 g, 0.058 mmol) in dichloromethane (2 mL) was treated with pyridine (0.022 mL, 0.276 mmol) followed by phosphoryl chloride (0.005 mL, 0.055 mmol) at 0° C. After the reaction was stirred at room temperature for 2 hours, NaHCO3 aqueous was added. The mixture was extracted with EtOAc. The organic layer was washed with brine and dried over anhydrous Na2SO4. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel to afford tert-butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate 6 (8.5 mg).
Step 6: (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide (7)
tert-Butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-2-carboxylate (8.5 mg, 0.015 mmol) was treated with trifluoroacetic acid (1 mL) in dichloromethane (1 mL) at room temperature for 90 minutes. Solvent was removed under reduced pressure and the residue was coevaporated with toluene to afford (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide 7 as TFA salt for next step.
Step 7: (1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide (338)
Into a mixture of (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt 7 (0.015 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid 8 (4.6 mg, 0.015 mmol) in N,N-dimethylformamide (1 mL), 0-(benzotriazol-1-yl)-N,N,N,N-tetramethyluronium tetrafluoroborate (0.007 g, 0.023 mmol) followed by N,N-diisopropylethylamine (0.019 g, 0.026 mL, 0.15 mmol) was added with stirring. After the reaction was complete, NaHCO3 aqueous solution was added and the mixture was extracted with EtOAc. Solvent was removed under reduced pressure and the residue was purified by column chromatography on silica gel (MeOH in DCM 0-10%) to afford (1R,3S,5R)-2-{2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-5-[(4-tert-butyl-1,3-thiazol-2-yl)methyl]-2-azabicyclo[3.1.0]hexane-3-carboxamide (338) (8.2 mg). 1H 1H NMR (400 MHz, Chloroform-d) δ 8.91 (s, 2H), 8.65 (s, 1H), 8.58 (dd, J=0.9, 1.7 Hz, 1H), 7.71-7.55 (m, 2H), 7.39-7.30 (m, 1H), 7.23 (d, J=7.9 Hz, 1H), 6.78 (s, 1H), 5.50 (s, 2H), 4.88 (d, J=8.4 Hz, 1H), 3.64 (d, J=15.2 Hz, 1H), 3.46 (dd, J=2.6, 5.6 Hz, 1H), 3.14 (d, J=15.3 Hz, 1H), 2.88 (d, J=13.7 Hz, 1H), 2.81 (s, 3H), 2.71 (s, 3H), 2.40 (t, J=11.4 Hz, 1H), 1.33 (s, 10H), 1.00 (dd, J=2.6, 5.8 Hz, 1H), 0.92-0.79 (m, 1H). LC (method A): tR=2.40 min. LC/MS (EI) m/z: [M+H]+ 741.
Figure US11708351-20230725-C01212
Figure US11708351-20230725-C01213
Step 1. tert-Butyl 5-bromo-7-methyl-1H-indazole-1-carboxylate (2)
A solution of 5-bromo-7-methyl-1H-indazole (45 g), Boc2O (55.8 g), potassium carbonate (5.9 g) and DMAP (0.26 g) in dichloromethane (900 mL) and water (90 mL) was stirred overnight at room temperature. The layers were separated, the organic layer was dried and concentrated. The residue was purified by silica gel column chromatography to afford the title compound.
Step 2. tert-Butyl 5-bromo-7-(bromomethyl)-1H-indazole-1-carboxylate (3)
A heterogeneous mixture of tert-butyl 5-bromo-7-methylindazole-1-carboxylate (0.2 g, 0.643 mmol, 1 equiv.), NBS (0.114 g, 0.641 mmol, 0.997 equiv.) and AIBN (0.017 g, 0.104 mmol, 0.161 equiv.) in carbon tetrachloride was refluxed for 4 hours. Starting material (15% of S2) remained and therefore 0.1 equiv of NBS and a crystal of AIBN was added and the reaction was refluxed for 1 hour. The reaction mixture was cooled and diluted with water and extracted with EtOAc. The organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (eluent: 0-5% EtOAc in hexanes) to afford the desired product as white solid. 1H-NMR (CDCl3): δ 1.72 (s, 9H), 4.88 (s, 2H), 7.48 (s, 1H), 7.77 (d, J=1.2 Hz, 1H), 8.56 (s, 1H).
Step 3. tert-Butyl 7-(acetoxymethyl)-5-bromo-1H-indazole-1-carboxylate (4)
To a solution of tert-butyl 5-bromo-7-(bromomethyl)indazole-1-carboxylate (41.43 g, 106.21 mmol, 1 equiv.) in DMF (410 mL) at room temperature was added potassium acetate (31.27 g) and the reaction stirred at room temperature for 15 minutes. Then the reaction mixture was placed in a 40° C. bath and stirred for 1.5 hours. The reaction was cooled to room temperature, diluted with EtOAc and washed with water. The organic layer was dried, and concentrated. The residue was purified by silica gel column chromatography (eluent: 0-1% EtOAc in dichloromethane) to afford the title compound as yellow solid.
Step 4. tert-Butyl 7-(acetoxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazole-1-carboxylate (5)
A heterogeneous mixture of 5-bromo-2-methylpyrimidine (23.91 g, 138.198 mmol, 1.501 equiv.), bis(pinacolato)diboron (38.47 g, 152.031 mmol, 1.651 equiv.), potassium acetate (27.13 g, 276.414 mmol, 3.002 equiv.), and dichloro 1,1′-bis(diphenylphosphino) palladium (II) dichloromethane adduct (5.64 g, 6.906 mmol, 0.075 equiv.) in dioxane was degassed with argon and heated at 100° C. overnight. The reaction mixture was cooled to room temperature and charged with tert-butyl 7-[(acetyloxy)methyl]-5-bromoindazole-1-carboxylate (34 g, 92.087 mmol, 1 equiv.), potassium carbonate (38.2 g, 276.391 mmol, 3.001 equiv.) and water. The reaction mixture was again degassed and heated at 100° C. for 1.5 hours. Then the solvent was removed under reduced pressure and the residue was partitioned between dichloromethane and water. The organic layer was separated and washed with water. The combined aqueous layer was extracted with dichloromethane. The combined organic layer was dried and concentrated. The residue was purified by silica gel column chromatography (eluent: 0-5% MeOH in dichloromethane) to afford the title compound as a cream colored solid.
Step 5. (5-(2-Methylpyrimidin-5-yl)-1H-indazol-7-yl)methyl acetate (6)
A finely powdered tert-Butyl 7-[(acetyloxy)methyl]-5-(2-methylpyrimidin-5-yl)indazole-1-carboxylate (20.8 g, 54.39 mmol, 1 equiv.) was suspended in 4N HCl in dioxane (210 mL, 54.39 mmol, 1 equiv.) and stirred at room temperature for 1 hour with frequent sonication. After the reaction was complete, the solid was isolated by filtration. The solid was partitioned between chloroform (1 L) and saturated aqueous sodium bicarbonate. The organic layer was separated, dried and concentrated to afford the title compound as cream colored solid.
Step 6. (3-Bromo-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl)methyl acetate (7)
[5-(2-Methylpyrimidin-5-yl)-1H-indazol-7-yl]methyl acetate (20 g, 70.846 mmol, 1 equiv.) was suspended in DMF (200 mL) and the mixture was warmed till the solution was homogeneous. This solution was then allowed to come to room temperature with stirring. Once the solution was cooled to room temperature, NBS (13.88 g) was added portion-wise at room temperature. The reaction mixture was stirred at room temperature for 30 minutes and then poured into 2 L of water with stirring. The solid was isolated by filtration, washed with 100 mL of saturated aqueous sodium bicarbonate solution and water and dried to afford the title compound as cream colored solid. 1H-NMR (DMSO-d6): δ 2.10 (s, 3H), 2.68 (s, 3H), 5.38 (s, 2H), 7.89 (s, 1H), 7.95 (s, 1H), 9.09 (s, 2H), 13.75 (s, 1H).
Step 7. (3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl)methyl acetate (8)
A solution of [3-bromo-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl]methyl acetate (10 g, 27.686 mmol, 1 equiv.) and trans-dichlorobis(triphenylphosphine)palladium (II) (1.94 g, 2.764 mmol, 0.1 equiv.) in DMF (200 mL) was purged with argon, and tributyl(1-ethoxyvinyl)tin (14.99 g, 14.03 mL, 41.506 mmol, 1.499 equiv.) was added while continuing to purge with argon for 5 additional minutes. Then the reaction mixture was heated at 80° C. overnight. The solvent was removed under reduced pressure. Chloroform (200 mL) and cold 2N aqeuous HCl (50 mL) was added to the reaction mixture and the mixture was stirred for 10 minutes in an ice bath. Then the reaction mixture was made basic by the careful addition of saturated aqueous NaHCO3 solution. The organic layer was separated and the aqueous layer was extracted with chloroform. The combined organic layer was taken to dryness. The residue was used as such for the next step.
Step 8. tert-Butyl 2-(7-(acetoxymethyl)-3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetate (9)
[3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl]methyl acetate (from above) was taken in DMF (150 mL) and potassium carbonate (7.65 g, 55.351 mmol, 2 equiv.) was added followed by tert-butyl bromoacetate (6.5 g, 4.921 mL, 33.325 mmol, 1.204 equiv.). The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was filtered through a fritted funnel and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0-5% MeOH in dichloromethane) to afford title compound as cream colored solid.
Step 9. (1R,3S,5R)-2-(2-(3-Acetyl-7-(hydroxymethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (526)
A solution of {3-acetyl-1-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methylpyrimidin-5-yl}indazol-7-yl)methyl acetate (S9, 0.05 g, 0.115 mmol, 1 equiv.) in dichloromethane (1 mL) and TFA (1 mL) was stirred at room temperature for 3 hours and the volatiles were removed under reduced pressure. Separately, tert-butyl (1R,3S,5R)-3-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.047 g, 0.115 mmol, 1 equiv.) S10, 1 mL of TFA, and 1 mL of dichloromethane in DCM (1 mL) was stirred at room temperature for 30 minutes. Upon evaporation of the solvents, the S10 mixture was mixed with the S9 reside. The reaction mixture was cooled in an ice-bath and DIPEA (0.1 mL) and HATU (0.048 g, 0.126 mmol, 1.102 equiv.) were added successively before the reaction mixture was stirred at room temperature for 30 minutes. The reaction mixture was then poured into 10 mL of 1% aqueous LiOH and extracted with chloroform. The organic layer was dried, concentrated and the residue was purified by silica gel column chromatography (eluent: 0-4% MeOH in dichloromethane) to afford Compound 526 as a white solid. 1H-NMR (Chloroform-d) δ 0.97 (d, J=5.2 Hz, 1H), 1.17 (t, J=5.5 Hz, 1H), 1.39 (s, 3H), 2.08-2.15 (m, 1H), 2.15 (s, 3H), 2.72-2.75 (m, 1H), 2.75 (s, 3H), 2.81 (s, 3H), 3.18 (d, J=3.7 Hz, 1H), 4.86 (d, J=8.1 Hz, 1H), 5.14-5.24 (m, 2H), 5.51 (d, J=16.9 Hz, 1H), 6.07 (d, J=17.0 Hz, 1H), 7.29 (d, J=8 Hz, 1H), 7.43 (d, J=8.0 Hz, 1H), 7.49 (s, 1H), 8.59 (s, 1H), 8.91 (s, 2H), 9.19 (s, 1H).
(3-Acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-7-yl)methyl Acetate (529)
Compound 529 was prepared in a similar manner to Compound 526 with the exception of Step 8: A solution of {3-acetyl-1-[2-(tert-butoxy)-2-oxoethyl]-5-(2-methylpyrimidin-5-yl)indazol-7-yl}methyl acetate (S9, 0.05 g, 0.114 mmol, 1 equiv.) in TFA (1 mL) and dichloromethane (1 mL) was stirred at room temperature for 3 hours. Then the volatiles were removed under reduced pressure. To the residue was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (0.035 g, 0.114 mmol, 1 equiv.) and DMF (1 mL). The solution was cooled in an ice-bath. DIPEA (0.1 mL) was added to this cooled solution, followed by TBTU (0.04 g). The reaction mixture was stirred at room temperature for 30 minutes. Then the solvent was removed under reduced pressure and the residue was partitioned between chloroform and saturated aqueous sodium bicarbonate solution. The organic layer was separated and washed with water. The organic layer was dried, concentrated and the residue was purified by silica gel column chromatography (0-2.5% MeOH in dichloromethane) to afford compound 529 as white solid. 1H NMR (400 MHz, Chloroform-d) δ 0.99 (dd, J=2.3, 5.4 Hz, 1H), 1.19 (t, J=5.2 Hz, 1H), 1.44 (s, 3H), 2.08 (s, 3H), 2.10 (s, 3H), 2.34 (t, J=11.4 Hz, 1H), 2.70-2.72 (m, 1H), 2.72 (s, 3H), 2.81 (s, 3H), 3.21 (d, J=3.6 Hz, 1H), 4.83 (d, J=8.3 Hz, 1H), 5.46-5.60 (m, 2H), 5.70 (d, J=17.4 Hz, 1H), 5.87 (d, J=17.4 Hz, 1H), 7.23 (d, J=8 Hz, 1H), 7.35 (d, J=7.9 Hz, 1H), 7.69 (s, 1H), 8.63 (s, 1H), 8.69 (s, 1H), 8.91 (s, 2H).
Figure US11708351-20230725-C01214
Figure US11708351-20230725-C01215
Step 1: 5-Bromo-7-methyl-1H-pyrrolo[2,3-c]pyridine (2)
A stirred solution of compound 1 (1.5 g 6.91 mmol) in THF (30 mL) under N2 atmosphere at −78° C. was treated with bromo(ethenyl)magnesium (20.7 mL, 20.7 mmol, 1M) and the mixture was stirred at −40° C. for 2 hours. The reaction mixture was quenched with saturated aqueous NH4Cl solution and diluted with EtOAc. The layers were separated and the organic phase was dried over Na2SO4 and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with PE:EtOAc=1:0 to 1:1) to afford compound 2 (0.45 g, yield 30.85%) as orange oil. LC/MS (ESI) m/z: 211/213 (M+H)+.
Step 2: 1-(5-Bromo-7-methyl-1H-pyrrolo[2,3-c]pyridin-3-yl)ethanone (3)
To a solution of compound 2 (464 mg, 2.2 mmol) in DCM (20 mL) was added acetyl chloride (0.345 g, 4.4 mmol) and AlCl3 (0.59 g, 4.4 mmol) and the reaction mixture was stirred at ambient temperature for 3 hours. The mixture was poured into ice-water and extracted with DCM twice. The combined organic layers were dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure to dryness. The residue was purified by silica gel chromatography (eluted with PE:EtOAc=4:1) to give compound 3 (0.22 g, yield 39.5%) as yellow oil. LC/MS (ESI) m/z: 253/255 (M+H)+.
Step 3: tert-Butyl 2-(3-acetyl-5-bromo-7-methyl-1H-pyrrolo[2,3-c]pyridin-1-yl)acetate (4)
To a solution of compound 3 (220 mg, 0.869 mmol) in DMF (5 mL) was added K2CO3 (0.24 g, 1.74 mmol) followed by tert-butyl 2-bromoacetate (0.203 g, 1.04 mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated under vacuum to afford compound 4 (0.21 g, yield 65.8%) as white solid. LC/MS (ESI) m/z: 367/369 (M+H)+.
Step 4: tert-Butyl 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetate (5)
To the stirred solution of compound 4 (210 mg, 0.57 mmol) in 1,4-dioxane (2 mL) and water (0.5 mL) was added 2-methylpyrimidin-5-ylboronic acid (95 mg, 0.69 mmol) and K2CO3 (0.158 g, 1.144 mmol). The mixture was degassed under N2 atmosphere for three times, Pd(dppf)Cl2 (0.042 g, 0.057 mmol) was added, and the reaction was stirred at 100° C. under N2 atmosphere for 16 hours. The reaction mixture was diluted with water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The obtained residue was purified by silica gel chromatography (eluted with PE:EtOAc=1:0 to 1:1) to afford compound 5 (0.15 g, yield 68.9%) as white solid. LC/MS (ESI) m/z: 381/383 (M+H)+.
Step 5: 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetic Acid (6)
To a solution of compound 5 (150 mg, 0.39 mmol) in THF (3 mL) and water (1 mL) was added lithium hydroxide (0.019 g, 0.79 mmol) and the reaction mixture was stirred at 25° C. for 2 hours. The mixture was diluted with water and washed with ether twice. The aqueous layer was acidified with 1N aqueous HCl to pH of approximately 3 and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness to afford compound 6 (75 mg, yield 58.6%) as white solid. LC/MS (ESI) m/z: 325 (M+H)+.
Step 6: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-pyrrolo[2,3-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (472)
To a stirred solution of compound 6 (20 mg, 0.062 mmol) and (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (25.6 mg, 0.062 mmol) in DMF (3 mL) was added HATU (23 mg, 0.062 mmol) and DIPEA (23.2 mg, 0.18 mmol) and the reaction mixture was stirred at ambient temperature for 4 hours. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to afford 472 (4.5 mg, yield 11.8%) as an off-white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.33 (s, 1H), 9.26 (s, 2H), 8.48 (t, J=11.9 Hz, 2H), 7.61 (d, J=8.0 Hz, 1H), 7.43 (d, J=7.9 Hz, 1H), 5.80 (d, J=17.9 Hz, 1H), 5.48 (d, J=17.8 Hz, 1H), 4.41 (m, 1H), 3.58-3.55 (m, 1H), 2.55 (m, 1H), 2.49 (s, 3H), 2.09-1.96 (m, 4H), 1.33 (s, 3H), 1.02 (m, 1H), 0.91 (m, 1H). LC/MS (ESI) m/z: 616/618 (M+H)+.
Figure US11708351-20230725-C01216
Figure US11708351-20230725-C01217
Step 1: 2-Bromo-6-fluoroisonicotinic Acid (2)
To a stirred solution of compound 1 (400 mg, 2.105 mmol) in sulfuric acid (3 mL) was added chromium trioxide (0.631 g, 6.315 mmol) portion-wise in a water bath while the temperature was maintained between 20-50° C. and the mixture was stirred at room temperature for 16 hours. The reaction mixture was poured slowly into ice-water and the mixture was stirred at room temperature for 1 hour. The mixture was filtered and the filter cake was washed with water, dried under vacuum to afford compound 2 (400 mg, yield 86.4%) as white solid. LC/MS (ESI) m/z: 220/222 (M+H)+.
Step 2: Methyl 2-bromo-6-fluoropyridine-4-carboxylate (3)
To a solution of compound 2 (400 mg, 1.82 mmol) in methanol (10 mL) was added sulfuric acid (0.5 mL) at 0° C. and the mixture was heated to 60° C. overnight. The mixture was then concentrated to dryness and the residue was partitioned between water and EtOAc. The layers were separated and the organic layer was dried over Na2SO4, filtered and concentrated under vacuum to afford compound 3 (380 mg, yield 89.2%) as white solid. LC/MS (ESI) m/z: 234/236 (M+H)+.
Step 3: Methyl 2-bromo-6-(tert-butylamino)pyridine-4-carboxylate (4)
Compound 3 (200 mg, 0.855 mmol) and erbumine (0.63 g, 8.55 mmol) were dissolved in NMP (3 mL) and the reaction mixture was stirred at 100° C. for 4 hours in a sealed tube. The mixture was diluted with EtOAc and washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE:EtOAc=5:1) to afford compound 4 (150 mg, yield 61.8%) as white solid. LC/MS (ESI) m/z: 287/289 (M+H)+.
Step 4: Methyl 2-amino-6-bromopyridine-4-carboxylate (5)
A solution of compound 4 (150 mg, 0.522 mmol) in TFA (3 mL) was stirred at 70° C. under N2 atmosphere for 16 hours. The mixture was concentrated to dryness and the residue was poured into saturated aqueous NaHCO3 solution and extracted with EtOAc twice. The combined organic layers were washed with brine, dried and concentrated to dryness. The residue was purified by silica gel column chromatography (eluted with PE:EtOAc=9:1 to 5:1) to afford compound 5 (81 mg, yield 67.1%) as white solid. LC/MS (ESI) m/z: 231/233 (M+H)+.
Step 5: tert-Butyl (1R,3S,5R)-3-{[6-bromo-4-(methoxycarbonyl)pyridin-2-yl]carbamoyl}-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (6)
To a mixture of compound 5 (71 mg, 0.307 mmol), pyridine (0.146 g, 1.844 mmol) and (2S,4S)-1-(tert-butoxycarbonyl)-4-methylpyrrolidine-2-carboxylic acid (74 mg, 0.307 mmol) in DCM (5 mL) was added POCl3 (0.061 g, 0.399 mmol) drop-wise at 0° C. and the mixture was stirred at 20° C. for 5 hours under N2 atmosphere. The mixture was diluted with DCM and washed with 0.5 N aqueous HCl and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (eluted with PE:EtOAc=9:1 to 5:1) to afford compound 6 (100 mg, yield 71.6%) as white solid. LC/MS (ESI) m/z: 454/456 (M+H)+.
Step 6: Methyl 2-bromo-6-[(1R,3S,5R)-5-methyl-2-azabicyclo[3.1.0]hexane-3-amido]pyridine-4-carboxylate (7)
To a solution of compound 6 (100 mg, 0.22 mmol) in DCM (2 mL) was added TFA (1 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness and the residue was washed with ether and dried under vacuum to afford compound 7 (95 mg, yield 100/a) as a yellow oil. LC/MS (ESI) m/z: 354/356 (M+H)+.
Step 7: Methyl 2-[(1R,3S,5R)-2-{2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-amido]-6-bromopyridine-4-carboxylate (8)
To a mixture of compound 7 (95 mg, 0.22 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (75 mg, 0.242 mmol) in DMF (4 mL) was added HATU (0.167 g 0.44 mmol) and DIPEA (0.114 g, 0.881 mmol). The reaction mixture was stirred at ambient temperature for 4 hours. The mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl solution and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column chromatography (eluted with PE:EtOAc=10:1 to 5:1) to afford compound 8 (110 mg, yield 77.3%) as white solid. LC/MS (ESI) m/z: 646/648 (M+H)+.
Step 8: 2-[(1R,3S,5R)-2-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-amido]-6-bromopyridine-4-carboxylic Acid (493)
A solution of compound 8 (110 mg, 0.17 mmol) in THF (2 mL) and water (1 mL) was added lithiumol (16 mg, 0.68 mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was acidified by adding 1N aqueous HCl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by prep-HPLC to afford Compound 493 (80 mg, yield 74.34%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 11.00 (s, 1H), 9.03 (s, 2H), 8.49 (s, 1H), 8.42 (s, 1H), 7.87 (m, 2H), 7.61 (m, 1H), 5.97 (d, J=17.3 Hz, 1H), 5.57 (d, J=17.2 Hz, 1H), 4.42 (m, 1H), 3.66-3.62 (m, 1H), 2.68 (s, 3H), 2.65 (s, 3H), 2.48 (m, 1H), 2.01 (m, 1H), 1.30 (s, 3H), 0.98 (m, 2H). LC/MS (ESI) m/z: 632/634 (M+H)+.
Figure US11708351-20230725-C01218
Step 1: 2-(2-Bromo-&-fluoropyridin-4-yl)acetic Acid (2)
To a solution of compound 1 (200 mg, 0.91 mmol) in DCM (5 mL) was added oxalyl chloride (0.231 g, 1.82 mmol) followed by DMF (0.1 mL) at 0° C. The mixture was stirred at room temperature for 2 hours and concentrated to dryness. The residue was dissolved in THF (5 mL) and TMSCHN2 (0.114 g, 1 mmol) was added at 0° C. The mixture was stirred at 0° C. for 3 hours and allowed to warm to room temperature. The reaction was quenched with acetic acid at 0° C., diluted with EtOAc, washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was dissolved in 1,4-dioxane (3 mL) and water (3 mL), and AgOAc (0.015 g, 0.091 mmol) was added. The reaction mixture was stirred at 100° C. for 12 hours. The mixture was diluted with EtOAc, washed with water and brine, dried over anhydrous Na2SO4 and concentrated dryness to afford compound 2 (150 mg, yield 70.5%) as a white solid. LC/MS (ESI) m/z: 234/236 (M+H)+.
Step 2: methyl 2-(2-Bromo-6-fluoropyridin-4-yl)acetate (3)
To a solution of compound 2 (150 mg, 0.64 mmol) in MeOH (4 mL) was added H2SO4 (1 mL) at 0° C. and the mixture was stirred at 60° C. overnight. The mixture was diluted with EtOAc, washed with saturated aqueous NaHCO3 solution and brine, dried over Na2SO4, filtered, and concentrated under vacuum to afford compound 3 (130 mg, yield 81.8%) as a white solid. LC/MS (ESI) m/z: 248/250 (M+H)+.
Step 3: methyl 2-(2-bromo-6-(tert-butylamino)pyridin-4-yl)acetate (4)
Compound 3 (130 mg, 0.524 mmol) and erbumine (0.46 g, 6.29 mmol) was dissolved in NMP (4 mL) and the reaction mixture was stirred at 100° C. for 24 hours in a sealed tube. The mixture was diluted with EtOAc, washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE:EtOAc=5:1) to afford compound 4 (48 mg, yield 30.4%) as yellow solid. LC/MS (ESI) m/z: 301/303 (M+H)+.
Step 4: methyl 2-(2-amino-6-bromopyridin-4-yl)acetate (5)
A solution of compound 4 (48 mg, 0.159 mmol) in TFA (3 mL) was heated to 70° C. under N2 for 2 hours. The mixture was concentrated to dryness, saturated aqueous NaHCO3 solution was added, and the oranganic layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried and concentrated to dryness. The residue was purified by silica gel column chromatography (eluted with: PE:EtOAc=9:1-5:1) to afford compound 5 (30 mg, yield 76.7%) as white solid. LC/MS (ESI) m/z: 245/247 (M+H)+.
Step 5: (1R,3S,5R)-tert-Butyl 3-((6-bromo-4-(2-methoxy-2-oxoethyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (6)
To a solution of compound 5 (40 mg, 0.163 mmol), pyridine (77 mg, 0.979 mmol) and (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (39 mg, 0.163 mmol) in DCM (5 mL) was added POCl3 (38 mg, 0.245 mmol) drop-wise at 0° C. The mixture was stirred at 20° C. for 5 hours. The mixture was diluted with EtOAc and washed with water and brine, dried, and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE:EtOAc=3:1) to afford compound 6 (26 mg, yield 34.0%) as white solid. LC/MS (ESI) m/z: 468/470 (M+H)+.
Step 6: Methyl 2-(2-bromo-6-((1R,3S,5R)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)pyridin-4-yl)acetate (7)
To a solution of compound 6 (26 mg, 0.055 mmol) in DCM (1 mL) was added TFA (0.5 mL) and the mixture was stirred at room temperature for 2 hours. The mixture was concentrated to dryness and the residue was washed with ether and dried under vacuum to afford compound 7 (25 mg, yield 100%) as a yellow solid. LC/MS (ESI) m/z: 368/370 (M+H)+.
Step 7: methyl 2-(2-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-6-bromopyridin-4-yl)acetate (8)
To a solution of compound 7 (25 mg, 0.055 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (21 mg, 0.068 mmol) in DMF (4 mL) was added HATU (0.043 g, 0.114 mmol) and DIPEA (0.029 g, 0.228 mmol) and the reaction mixture was stirred at ambient temperature for 4 hours. The mixture was diluted with EtOAc, washed with water and brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with PE:EtOAc=3:1 to 1:1) to afford compound 8 (25 mg, yield 66.4%) as white solid. LC/MS (ESI) m/z: 660/662 (M+H)+.
Step 8: 2-(2-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamido)-6-bromopyridin-4-yl)acetic Acid (514)
To a solution of compound 8 (25 mg, 0.038 mmol) in THF (1 mL) and water (0.5 mL) was added lithiumol (3 mg, 0.114 mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was acidified by adding 1N aqueous HCl and the organic layer was extracted with EtOAc twice. The combined organic layers were washed with brine, dried and concentrated to dryness. The residue was purified by prep-HPLC to afford Compound 514 (20 mg, yield 81.7%) as a white solid. 1H-NMR (400 MHz, CD3OD) δ 8.99 (s, 2H), 8.52 (s, 1H), 8.02 (s, 1H), 7.78 (m, 2H), 7.22 (m, 1H), 5.81 (d, J=18.0 Hz, 1H), 5.63 (d, J=16.9 Hz, 1H), 5.33 (m, 1H), 4.47 (m, 1H), 3.54 (m, 1H), 3.47 (m, 2H), 2.74 (s, 3H), 2.69 (s, 3H), 2.55 (m, 1H), 2.17-2.12 (m, 1H), 1.37 (s, 3H), 1.07 (m, 1H), 0.98 (m, 1H). LC/MS (ESI) m/z: 646/648 (M+H)+.
Figure US11708351-20230725-C01219
Figure US11708351-20230725-C01220
Step 1: Benzyl N-(2-hydroxypyridin-3-yl)carbamate (2)
To a solution of 3-amino-1,2-dihydropyridin-2-ol (4.97 g, 44.32 mmol) in THF (125 mL) was added a solution of sodium carbonate (5.16 g, 48.75 mmol) in water (60 mL) followed by the drop-wise addition of CbzCl (8.31 g, 48.75 mmol) at 0° C. The mixture was stirred at room temperature for 16 hours. The mixture was poured into ice-water and the resulting slurry was filtered. The filter cake was washed with water and dried under vacuum to afford benzyl N-(2-hydroxypyridin-3-yl)carbamate (6.51 g, yield 60.13%) as white solid. LC/MS (ESI) m/z: 245 (M+H)+.
Step 2: Benzyl N-{2-oxo-[1,2′-bipyridine]-3-yl}carbamate (3)
To a solution of benzyl N-(2-hydroxypyridin-3-yl)carbamate (0.51 g, 2.08 mmol) in 1,4-Dioxane (10 mL) was added 2-bromopyridine (0.42 g, 2.71 mmol), 1,2-dimethylethylenediamine (0.074 g, 0.83 mmol), copper iodide (0.08 g, 0.41 mmol) and K2CO3 (0.57 g, 4.17 mmol), and the mixture was degassed under N2 three times. The reaction was stirred at 115° C. for 16 hours in a sealed tube. The mixture was diluted with EtOAc and filtered. The filtrate was washed with water and brine, dried over anhydrous Na2SO4, and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with PE:EtOAc=3:1) to afford benzyl N-{2-oxo-[1,2′-bipyridine]-3-yl}carbamate (0.19 g, yield 28.3%) as white solid. LC/MS (ESI) m/z: 322 (M+H)+.
Step 3: 3-Amino-[1,2′-bipyridine]-2-one (4)
To a solution of benzyl N-{2-oxo-[1,2′-bipyridine]-3-yl} carbamate (0.19 g, 0.59 mmol) in methanol (6 mL) and THF (2 mL) was added Pd/C (20 mg, 10% wt), and the mixture was degassed under N2 three times. The reaction was stirred under a H2 balloon at room temperature for 2 hours. The mixture was filtered and the filtrate was concentrated to dryness to afford 3-amino-[1,2′-bipyridine]-2-one (0.11 g, yield 99.4%) as a yellow solid. LC/MS (ESI) m/z: 188 (M+H)+.
Step 4: tert-Butyl (1R,3S,5R)-5-methyl-3-({2-oxo-[1,2′-bipyridine]-3-yl}carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (5)
To a mixture of 3-amino-[1,2′-bipyridine]-2-one (0.051 g, 0.27 mmol) and (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (0.066 g, 0.27 mmol) in DCM (3 mL) was added pyridine (0.11 g, 1.36 mmol) followed by POCl3 (0.063 g, 0.41 mmol) at 0° C. The mixture was stirred at room temperature for 30 minutes and then diluted with DCM and washed with 0.5 N aqueous HCl and brine, dried over Na2SO4, filtered, and concentrated to afford tert-butyl (1R,3S,5R)-5-methyl-3-({2-oxo-[1,2′-bipyridine]-3-yl}carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.11 g, yield 98.4%) as a light yellow solid that was used directly in the next step. LC/MS (ESI) m/z: 411 (M+H)+.
Step 5: (1R,3S,5R)-5-Methyl-N-{2-oxo-[1,2′-bipyridine]-3-yl}-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (6)
To a solution of tert-butyl (1R,3S,5R)-5-methyl-3-({2-oxo-[1,2′-bipyridine]-3-yl} carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.11 g, 0.25 mmol) in DCM (3 mL) was added TFA (1.5 mL) at 0° C. and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated to dryness and co-evaporated with DCM twice and dried under vacuum to afford (1R,3S,5R)-5-methyl-N-{2-oxo-[1,2′-bipyridine]-3-yl}-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA salt (105 mg, yield 100%) as yellow oil that was used directly in the next step. LC/MS (ESI) m/z: 311 (M+H)+.
Step 6: (1R,3S,5R)-2-{2-[3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-5-methyl-N-{2-oxo-[1,2′-bipyridine]-3-yl}-2-azabicyclo[3.1.0]hexane-3-carboxamide (460)
To a mixture of (1R,3S,5R)-5-methyl-N-{2-oxo-[1,2′-bipyridine]-3-yl}-2-azabicyclo [3.1.0]hexane-3-carboxamide (40 mg, 0.12 mmol) and [3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (42 mg, 0.12 mmol) in DMF (3 mL) was added HATU (74 mg, 0.19 mmol) and DIPEA (84 mg, 0.64 mmol) and the mixture was stirred at room temperature for 1 hour. The reaction mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered, and concentrated to dryness. The residue was purified by prep.HPLC to afford 460 (31 mg, yield 38.8%) as white solid. 1H-NMR (400 MHz, CD3OD) δ 8.95 (s, 2H), 8.59-8.54 (m, 1H), 8.42-8.35 (m, 2H), 7.98-7.93 (m, 1H), 7.72 (d, J=8.1 Hz, 1H), 7.57-7.53 (m, 1H), 7.51-7.44 (m, 2H), 6.47-6.42 (m, 1H), 5.98 (d, J=17.8 Hz, 1H), 5.77 (d, J=17.7 Hz, 1H), 4.68-4.53 (m, 2H), 3.55-3.51 (m, 1H), 2.73 (d, J=4.9 Hz, 6H), 2.66 (s, 3H), 2.57-2.51 (m, 1H), 2.30-2.25 (m, 1H), 1.39 (s, 3H), 1.14-1.08 (m, 1H), 1.00-0.96 (m, 1H). LC/MS (ESI) m/z: 617 (M+H)+.
Figure US11708351-20230725-C01221
Figure US11708351-20230725-C01222
Step 1: 2-Bromo-4-(prop-2-en-1-yl)pyridine (2)
To a mixture of compound 1 (2.0 g, 7.05 mmol) and tributyl(prop-2-en-1-yl)stannane (2.33 g, 7.05 mmol) in toluene (20 mL) was added Pd(PPh3)4 (814 mg, 0.70 mmol) and the mixture was stirred at 100° C. under N2 atmosphere for 20 hours. The mixture was concentrated to dryness and the residue was purified by silica gel chromatography (PE:EtOAc=75:1) to afford compound 2 (1.0 g, yield 71.7%) as a yellow oil. LC/MS (ESI) m/z: 198/200 (M+H)+.
Step 2: 2-Bromo-4-propylpyridine (3)
To a solution of compound 2 (1.0 g, 5.05 mmol) in EtOAc (8 mL) was added PtO2 (120 mg) at 0° C. and the mixture was degassed under N2 atmosphere three times and stirred at room temperature under a H2 balloon for 10 minutes. The mixture was filtered and the filtrate was concentrated to dryness to afford compound 3 (990 mg, yield 98.0%) as white solid that was used directly in the next step. LC/MS (ESI) m/z: 200/202 (M+H)+.
Step 3: 2-Bromo-4-propylpyridine 1-oxide (4)
To a solution of compound 3 (990 mg, 4.9 mmol) in chloroform (10 mL) was added m-CPBA (1.37 g, 7.9 mmol) and the mixture was stirred at room temperature overnight under N2 atmosphere. The mixture was washed with saturated aqueous NaHCO3 solution and extracted with DCM twice. The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by column chromatography on silica gel (DCM:MeOH=20:1) to afford compound 4 (800 mg, yield 74.1%) as yellow oil. LC/MS (ESI) m/z: 216/218 (M+H)+.
Step 4: 6-Bromo-N-tert-butyl-4-propylpyridin-2-amine (5)
To a solution of compound 4 (800 mg, 3.7 mmol) in DCM (10 mL) was added 2-methylpropan-2-amine (1.34 g, 18.3 mmoL) followed by the drop-wise addition of trifluoromethanesulfonic anhydride (1.55 g, 5.5 mmol) at 0° C. The mixture was stirred at 0° C. for 30 minutes under a N2 atmosphere. The mixture was washed with aqueous NaHCO3 solution and brine, dried, and concentrated to dryness. The residue was purified by column chromatography on silica gel (PE:EtOAc=20:1) to afford compound 5 (800 mg, yield 80.4%) as yellow oil. LC/MS (ESI) m/z: 271/273 (M+H)+.
Step 5: 6-Bromo-4-propylpyridin-2-amine (6)
A solution of compound 5 (800 mg, 2.95 mmol) in TFA (8 mL) was stirred at 70° C. for 16 hours. The mixture was concentrated to dryness and the residue was poured into an ice-cooled saturated aqueous NaHCO3 solution and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with PE:EtOAc=10:1) to afford compound 6 (144 mg, yield 22.7%) as a light yellow oil. LC/MS (ESI) m/z: 215/217 (M+H)+.
Step 6: tert-Butyl (1R,3S,5R)-3-[(6-Bromo-4-propylpyridin-2-yl)carbamoyl]-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (7)
To a solution of compound 6 (68 mg, 0.32 mmol) and (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (76 mg, 0.32 mmol) in DCM (5 mL) was added pyridine (125 mg, 1.6 mmol) followed by the drop-wise addition of POCl3 (53 mg, 0.35 mmol) at 0° C. The mixture was stirred at room temperature for 1 hour. The mixture was diluted with DCM and washed with 0.5 N aqueous HCl and brine, dried over Na2SO4, filtered, and concentrated to dryness to afford compound 7 (139 mg, yield 100.0%) as a yellow solid that was used directly in the next step. LC/MS (ESI) m/z: 438/440 (M+H)+.
Step 7: (1R,3S,5R)—N-(6-Bromo-4-propylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (8)
To a solution of compound 7 (139 mg, 0.32 mmol) in DCM (4 mL) was added TFA (2 mL) at 0° C. and the reaction was stirred at room temperature for 2 hours. The mixture was concentrated to dryness and washed with ether and dried under vacuum to afford compound 8 (130 mg, yield 100%) as a brown syrup that was directly used to the next reaction without purification. LC/MS (ESI) m/z: 338/340 (M+H)+.
Step 8: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-4-propylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (516)
To a mixture of compound 8 (65 mg, 0.15 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (46 mg, 0.15 mmol) in DMF (5 mL) was added DIPEA (96 mg, 0.74 mmol) and HATU (84 mg, 0.22 mmol) at 0° C. and the mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over Na2SO4 and concentrated to dryness. The residue was purified by prep-HPLC to afford Compound 516 (12 mg, yield 12.9%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.73 (s, 1H), 9.04 (t, J=2.6 Hz, 2H), 8.43 (d, J=3.2 Hz, 1H), 7.91 (d, J=3.6 Hz, 1H), 7.88 (t, J=2.4 Hz, 2H), 7.21 (t, J=2.4 Hz, 1H), 5.96 (d, J=17.6 Hz, 1H), 5.57 (d, J=17.6 Hz, 1H), 4.40 (d, J=8.8 Hz, 1H), 3.63 (d, J=4.4 Hz, 1H), 2.69 (s, 3H), 2.66 (s, 3H), 2.63-2.52 (m, 2H), 2.46 (d, J=14.4 Hz, 1H), 2.02-1.95 (m, 1H), 1.57 (q, J=8.4 Hz, 2H), 1.30 (t, J=2.7 Hz, 3H), 0.98 (d, J=4.4 Hz, 2H), 0.90-0.84 (m, 3H). LC/MS (ESI) m/z: 630/632 (M+H)+.
Figure US11708351-20230725-C01223
Figure US11708351-20230725-C01224
Step 1: 2-Benzyl 1-tert-butyl (2S,4R)-4-fluoro-4-{[(4-fluorophenoxymethanethioyl)oxy] methyl}pyrrolidine-1,2-dicarboxylate (2)
To a mixture of compound 1 (0.41 g, 1.15 mmol) and 4-fluorophenyl chloromethanethioate (0.33 g, 1.73 mmol) in DCM (10 mL) was added DMAP (0.42 g, 3.39 mmol) and the mixture was stirred at 25° C. for 1 day. The mixture was diluted with DCM and washed with 0.5 N HCl and brine, dried and concentrated to dryness. The residue was purified by chromatography on silica gel (eluted with PE:EtOAc=30:1 to 20:1) to afford compound 2 (0.19 g yield 32%) as yellow oil. LC/MS (ESI) m/z: 452 (M+H)+.
Step 2: 2-Benzyl 1-tert-butyl (2S,4R)-4-fluoro-4-methylpyrrolidine-1,2-dicarboxylate (3)
To a solution of compound 2 (0.19 g, 0.37 mmol) in 1,4-dioxane (5 mL) was added tris(trimethylsilyl)silane (0.14 g 0.55 mmol) and VAZO (0.03 g, 0.18 mmol), and the mixture was stirred at 105° C. for 1.5 hours. The reaction mixture was concentrated to dryness and the residue was purified by column chromatographed on silica gel (PE:EtOAc=100:1) to afford compound 3 (84 mg, yield 94.60%) as light yellow oil that was used directly in the next step. LC/MS (ESI) m/z: 338 (M+H)+.
Step 3: (2S,4R)-1-(tert-Butoxycarbonyl)-4-fluoro-4-methylpyrrolidine-2-carboxylic Acid (4)
To a solution of compound 3 (84 mg, 0.25 mmol) in MeOH (3 mL) was added Pd/C (17 mg, 10% wt), and the mixture was degassed under N2 three times and stirred under a H2 balloon at room temperature for 2 hours. The mixture was filtered and the filtrate was concentrated to dryness to afford compound 4 (60 mg, yield 97.46%) as light oil. LC/MS (ESI) m/z: 248 (M+H)+.
Step 4: tert-Butyl (2S,4R)-2-[(6-bromo-3-methylpyridin-2-yl)carbamoyl]-4-fluoro-4-methylpyrrolidine-1-carboxylate (5)
To a mixture of compound 4 (60 mg, 0.24 mmol) and 6-bromo-3-methylpyridin-2-amine (0.045 g, 0.24 mmol) in DCM (3 mL) was added pyridine (0.096 g, 1.21 mmol) followed by POCl3 (0.041 g, 0.27 mmol) at 0° C. The mixture was stirred at room temperature for 30 minutes. The mixture was quenched by ice water and extracted with DCM. The combined organic layers were washed with 0.5 N HCl and brine, dried with anhydrous Na2SO4 and concentrated to dryness to afford compound 5 (87 mg, yield 86.13%) as a yellow solid. LC/MS (ESI) m/z: 416 (M+H)+.
Step 5: (2S,4R)—N-(6-Bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide TFA Salt (6)
To a solution of compound 5 (87 mg, 0.21 mmol) in DCM (2 mL) was added TFA (1 mL) at 0° C., and the mixture was stirred at 25° C. for 2 hours. The mixture was concentrated to dryness and washed with ether to afford compound 6 (90 mg, yield 100%) as a yellow solid that was used directly in the next step. LC/MS (ESI) m/z: 316 (M+H)+.
Step 6: (2S,4R)-1-{2-[3-Acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-methylpyrrolidine-2-carboxamide (430)
To a mixture of compound 6 (30 mg, 0.07 mmol) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl] acetic acid (25 mg, 0.079 mmol) in DMF (3 mL) was added HATU (45 mg, 0.12 mmol) and DIPEA (0.031 g, 0.24 mmol) at 0° C., and the mixture was stirred at room temperature for 1 hour. The reaction mixture diluted with EtOAc and washed with saturated aqueous NH4Cl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to afford 430 (8 mg, yield 17.04%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.46 (s, 1H), 9.04 (d, J=2.2 Hz, 2H), 8.43 (s, 1H), 7.87-7.78 (m, 2H), 7.60 (d, J=8.1 Hz, 1H), 7.42 (d, J=7.9 Hz, 1H), 5.82 (d, J=17.2 Hz, 1H), 5.57 (d, J=17.2 Hz, 1H), 4.64-4.59 (m, 1H), 4.27-4.20 (m, 1H), 3.94-3.86 (m, 1H), 2.68 (s, 3H), 2.64 (s, 3H), 2.20-2.04 (m, 2H), 2.00 (s, 3H), 1.64 (d, J=21.0 Hz, 3H). LC/MS (ESI) m/z: 607 (M+H)+.
Figure US11708351-20230725-C01225
Step 1: 1,3-Diphenylpropan-2-amine (2)
To a solution of dibenzyl ketone (500 mg, 2.38 mmol) in MeOH (10 mL) was added ammonium acetate (1.83 g, 23.78 mmol) and NaBH3CN (300 mg, 4.76 mmol) at 0° C. and the mixture was stirred at 25° C. for 3 hours. The reaction mixture was quenched with 1N aqueous NaOH solution and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography via silica gel (eluted with DCM:MeOH=200:1 to 20:1) to afford compound 2 (340 mg, yield 67.7%) as colorless oil. LC/MS (ESI) m/z: 212 (M+H)+.
Step 2: tert-Butyl(1R,3S,5R)-3-((1,3-diphenylpropan-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (3)
To a mixture of 2 (70 mg, 0.33 mmol) and (1R,3S,5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (88 mg, 0.36 mmol) in DMF (3 mL) was added DIPEA (86 mg, 0.66 mmol) and HATU (252 mg, 0.66 mmol) at 0° C. and the mixture was stirred at 25° C. for 2 hours. The mixture was diluted with ethyl acetate, washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography via silica gel (eluted with petroleum ether:EtOAc=50:1 to 1:1) to afford compound 3 (110 mg, yield 76.4%) as colorless oil. LC/MS (ESI) m/z: 435 (M+H)+.
Step 3: (1R,3S,5R)—N-(1,3-Diphenylpropan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (4)
To a solution of compound 3 (50 mg, 0.115 mmol) in DCM (3 mL) was added TFA (1 mL) at 0° C., and the mixture was stirred at 25° C. for 4 hours. The mixture was concentrated to dryness and the residue was co-evaporated with DCM twice and dried under vacuum to afford 4 (55 mg, yield 100%) as a brown oil that was directly used in the next step without further purification. LC/MS (ESI) m/z: 335 (M+H)+.
Step 4: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(1,3-diphenylpropan-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (505)
To a mixture of compound 4 (20 mg, 0.06 mmol) and 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (16.5 mg, 0.05 mmol) in DMF (1 mL) was added DIPEA (23 mg, 0.18 mmol) and HATU (45 mg, 0.12 mmol) at 0° C. and the mixture was stirred at room temperature for 2 hrs. The mixture was diluted with ethyl acetate, washed with water and brine, dried over Na2SO4, filtered and concentrated to dryness. The residue was purified by prep-HPLC to afford 505 (1.9 mg, yield 6.44%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 9.04 (s, 2H), 8.34 (s, 1H), 7.58-7.73 (m, 2H), 7.13-7.30 (m, 10H), 5.92-5.96 (d, J=17.9 Hz, 1H), 5.63-5.67 (d, J=17.8 Hz, 1H), 4.10-4.17 (m, 2H), 3.10-3.11 (m, 1H), 2.63-2.72 (m, 13H), 21.3-2.23 (m, 1H), 1.08 (s, 3H), 0.93-0.95 (m, 1H), 0.76-0.78 (m, 1H). LC/MS (ESI) m/z: 641 (M+H)+.
Figure US11708351-20230725-C01226
Figure US11708351-20230725-C01227
Step 1: (2S,4S)-2-Benzyl 1-tert-butyl 4-(((tert-butyldimethylsilyl)oxy)methyl)-4-fluoropyrrolidine-1,2-dicarboxylate (2)
To a solution of compound 1 (1.8 g, 3.87 mmol) in anhydrous DCM (30 mL) was added DAST (0.78 mL, 5.81 mmol) at −65° C. under N2 atmosphere and the reaction mixture was stirred at room temperature for 2 hours. Then the mixture was poured into ice-cooled saturated NaHCO3 solution and extracted with DCM twice. The combined organic layers was washed with brine, dried over anhydrous Na2SO4 and concentrated to dryness to afford compound 2 (1.6 g, crude) as yellow oil that was directly used to the next reaction without further purification. LC/MS (ESI) m/z: 468 (M+H)+.
Step 2: (2S,4S)-2-Benzyl 1-tert-butyl 4-fluoro-4-(hydroxymethyl)pyrrolidine-1,2-dicarboxylate (3)
To a solution of compound 2 (1.6 g, 34.2 mmol) in THF (15 mL) was added TBAF (4.3 mL, 4.28 mmol, 1M in THF) at 0° C. and the reaction mixture was stirred at room temperature for 30 minutes. Then the mixture was poured into ice water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=6:1 to 2:1) to afford compound 3 (700 mg, yield 57.9%) as light yellow oil. LC-MS: m/z 354 (M+H)+.
Step 3: (2S,4S)-2-Benzyl 1-tert-butyl 4-fluoro-4-(methoxymethyl)pyrrolidine-1,2-dicarboxylate (4)
To a solution of compound 3 (100 mg, 0.283 mmol) in anhydrous DCM (4 mL) was added AgOTf (116.4 mg, 0.453 mmol) followed by 2, 6-di-tert-butylpyridine (0.13 mL, 0.566 mmol). Then the reaction mixture was cooled to 0° C. (external temperature, ice bath) and MeI (0.04 mL, 0.567 mmol) was added drop wise. The resulting slurry was stirred at 0° C. for 1.5 hours at room temperature overnight. The mixture was filtered and the filtrate was evaporated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=15:1 to 5:1) to afford compound 4 (30 mg, yield 28.9%) as a light oil. LC-MS: m/z 368 (M+H)+.
Step 5: (2S,4S)-1-(tert-Butoxycarbonyl)-4-fluoro-4-(methoxymethyl)pyrrolidine-2-carboxylic Acid (5)
To a solution of compound 4 (30 mg, 0.082 mmol) in methanol (2 mL) was added Pd/C (5 mg, 10% wt) and the reaction mixture was stirred at room temperature under a H2 balloon for 1 hour. The mixture was filtered and the filtrate was concentrated to dryness to afford compound 5 (22 mg, yield 97.2%) as a light oil. LC-MS: m/z 278 (M+H)+.
Step 6: (2S,4S)-tert-Butyl 2-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-4-fluoro-4-(methoxymethyl)pyrrolidine-1-carboxylate (7)
To a mixture of compound 5 (22 mg, 0.079 mmol) and compound 6 (14.7 mg, 0.079 mmol) in anhydrous DCM (3 mL) was added pyridine (31.2 mg, 0.395 mmol) followed by POCl3 (13.3 mg, 0.087 mmol) at 0° C. under N2 atmosphere and the reaction mixture was stirred at room temperature for 30 minutes. The mixture was poured into ice water and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated to dryness to afford compound 7 (30 mg, crude) as a light yellow solid that was directly used to the next reaction without further purification. LC/MS (ESI) m/z: 446 (M+H)+.
Step 7: (2S,4S)—N-(6-Bromo-3-methylpyridin-2-yl)-4-fluoro-4-(methoxymethyl)pyrrolidine-2-carboxamide (8)
To a solution of compound 7 (30 mg) in DCM (2 mL) was added TFA (1 mL) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was evaporated to dryness to afford compound 8 (30 mg, crude) as a yellow oil that was directly used to the next reaction without further purification. LC/MS (ESI) m/z: 346 (M+H)+.
Step 8: (2S,4R)-1-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-4-fluoro-4-(methoxymethyl)pyrrolidine-2-carboxamide (421)
To a mixture of compound 8 (30 mg, 0.09 mmol) and compound 9 (28 mg, 0.09 mmol) in DMF (2 mL) was added DIPEA (35 mg, 0.27 mmol) followed by HATU (32 mg, 0.135 mmol) and the reaction mixture was stirred at room temperature for 1 hour. The mixture was poured into ice water and extracted with EtOAc twice. The organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by prep-HPLC to afford Compound 421 (8 mg, yield 14.48%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1H), 9.05 (s, 2H), 8.44 (s, 1H), 7.91-7.86 (m, 2H), 7.63 (d, J=8.3 Hz, 1H), 7.46 (d, J=7.9 Hz, 1H), 5.73 (d, J=17.3 Hz, 1H), 5.62 (d, J=17.2 Hz, 1H), 4.72 (d, J=10.3 Hz, 1H), 4.15 (d, J=27.8 Hz, 2H), 3.75-3.64 (m, 3H), 3.41 (s, 3H), 2.69 (s, 3H), 2.65 (s, 3H), 2.36-2.31 (m, 1H), 2.02 (s, 3H). LC/MS (ESI) m/z: 638 (M+H)+.
Figure US11708351-20230725-C01228
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a —CH2-oxadiazole in the R201 position. The skilled artisan will recognize that formohydrazide can be replaced with other hydrazide reagents to afford additional compounds of the present invention. For example, acetohydrazine could be utilized instead of formohydrazide to generate a substituted —CH2-oxadiazole in the R201 position.
Step 1: (1R,3S,5R)-3-Benzyl 2-tert-butyl 5-(2-(2-formylhydrazinyl)-2-oxoethyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (2)
To a mixture of compound 1 (0.2 g, 0.53 mmol) and N-formylhydrazine (0.064 g, 1.06 mmol) in 1,4-dioxane (4 mL) was added EDCI (0.124 g, 0.8 mmol) and HOBt (0.108 g, 0.8 mmol) followed by DIPEA (0.37 mL, 2.13 mmol) at 0° C., and the mixture was stirred at 25° C. for 16 hours. The mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl solution three times. The organic layer was dried over Na2SO4, filtered, and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with DCM:MeOH=20:1 to 10:1) to afford compound 2 (0.12 g, yield 53.9%) as light yellow solid. LC/MS (ESI) m/z: 440 (M+Na)+.
Step 2: (1R,3S,5R)-3-Benzyl 2-tert-butyl 5-((1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (3)
To a solution of compound 2 (0.12 g, 0.29 mmol) in tetrahydrofuran (5 mL) was added (A1) Burgess reagent (0.082 g, 0.34 mmol) in one portion under N2 atmosphere and the reaction was stirred at 75° C. under N2 atmosphere for 4 hours at which TLC (DCM:MeOH=20:1) showed about 30% conversion. Additional Burgess reagent (0.089 g, 0.37 mmol) was added and the reaction mixture was stirred under N2 atmosphere for 16 hours. The mixture was diluted with EtOAc, washed with water and brine, dried and concentrated to dryness. The residue was purified by silica gel chromatography (eluted with DCM:MeOH=30:1 to 15:1) to afford compound 3 (0.089 g, yield 62%) as a light yellow oil. LC/MS (ESI) m/z: 422 (M+Na)+.
Step 3: (1R,3S,5R)-5-((1,3,4-Oxadiazol-2-yl)methyl)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (4)
To a solution of compound 3 (0.08 g, 0.16 mmol) in THF (2 mL), MeOH (2 mL) and water (1 mL) was added lithiumol (0.012 g, 0.481 mmol) at 0° C. and the reaction mixture was stirred at 0° C. for 3 hours. The mixture was concentrated to dryness and diluted with water. The mixture was washed with EtOAc twice and the aqueous layer was acidified by adding 0.5 N HCl to pH of approximately 3. The mixture was extracted with DCM twice and the combined organic layers were dried over anhydrous Na2SO4, filtered, and concentrated to afford compound 4 (0.035 g, Yield 70.6%) as a yellow solid. LC/MS (ESI) m/z: 332 (M+Na)+.
Step 4: (1R,3S,5R)-tert-Butyl 5-((1,3,4-oxadiazol-2-yl)methyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (5)
To a mixture of compound 4 (0.035 g, 0.113 mmol) and 6-bromo-3-methylpyridin-2-amine (0.021 g, 0.113 mmol) in DCM (2 mL) was added pyridine (0.054 g, 0.679 mmol) and the mixture was cooled to 0° C. POCl3 (0.035 g, 0.226 mmol) was added to the mixture drop-wise at 0° C. and the reaction mixture was stirred at 0° C. for 3 hours. The mixture was diluted with DCM and washed with ice-cool 0.5 N aqueous HCl and brine, dried over Na2SO4, filtered, and concentrated to dryness to afford compound 5 (0.033 g, Yield 61%) as a light yellow solid that was directly used to the next reaction without purification. LC/MS (ESI) m/z: 480 (M+H)+.
Step 5: (1R,3S,5R)-5-((1,3,4-Oxadiazol-2-yl)methyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (6)
To a solution of compound 5 (0.033 g, 0.069 mmol) in DCM (1 mL) was added TFA (0.4 mL) at 0° C. and the mixture was stirred at 0° C. for 2 hours. The mixture was concentrated to dryness to afford compound 6 (0.04 g, yield 95.6%) as a yellow syrup that was directly used in the next reaction without purification. LC/MS (ESI) m/z: 380 (M+H)+.
Step 6: (1R,3S,5R)-5-((1,3,4-Oxadiazol-2-yl)methyl)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (359)
To a mixture of compound 6 (0.04 g, 0.081 mmol) and [3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (0.029 g, 0.089 mmol) in DMF (2 mL) was added DIPEA (0.053 g, 0.41 mmol) at 0° C. followed by HATU (0.046 g, 0.12 mmol) and the mixture was stirred at 25° C. for 4 hours. The mixture was diluted with EtOAc and washed with saturated aqueous NH4Cl solution and brine successively, dried over Na2SO4, filtered and concentrated to afford crude product that was purified by preparatory TLC (eluted with DCM:MeOH=15:1) to afford Compound 359 (6 mg, yield 10.8%) as white solid. 1H-NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.93 (s, 1H), 8.39 (s, 1H), 7.51-7.53 (d, J=8.0 Hz, 1H), 7.51 (s, 1H), 7.35-7.37 (d, J=8.0 Hz, 1H), 5.95-6.00 (d, J=18.0 Hz, 1H), 5.78-5.82 (d, J=18.0 Hz, 1H), 4.59-4.63 (m, 1H), 3.84-3.86 (m, 1H), 3.37-3.41 (d, J=16.0 Hz, 1H), 3.18-3.22 (d, J=16.0 Hz, 1H), 2.73 (s, 3H), 2.74 (s, 3H), 2.69-2.72 (m, 1H), 2.67 (s, 3H), 2.44-2.49 (m, 1H), 2.08 (s, 3H), 1.28-1.30 (m, 1H), 1.18-1.20 (m, 1H). LC/MS (ESI) m/z: 684/686 (M+H)+.
(1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((5-methyl-1,3,4-oxadiazol-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide
1H-NMR (400 MHz, CD3OD) δ 8.97 (s, 2H), 8.99 (s, 1H), 8.41 (s, 1H), 7.52-7.54 (d, J=8.0 Hz, 1H), 7.53 (s, 1H), 5.97-6.01 (d, J=17.6 Hz, 1H), 5.79-5.84 (d, J=17.6 Hz, 1H), 4.60-4.62 (m, 1H), 3.83-3.85 (m, 1H), 3.23-3.27 (d, J=15.6 Hz, 1H), 3.14-3.18 (d, J=15.6 Hz, 1H), 2.76 (s, 3H), 2.74 (s, 3H), 2.70-2.72 (m, 1H), 2.71 (s, 3H), 2.51 (s, 3H), 2.43-2.48 (m, 1H), 2.08 (s, 3H), 1.28-1.30 (m, 1H), 1.17-1.19 (m, 1H). LC/MS (ESI) m/z: 698/700 (M+H)+.
Figure US11708351-20230725-C01229
Step 1: 6-Bromo-2-fluoronicotinic Acid (2)
To a solution of compound 1 (5 g, 28.41 mmol) in tetrahydrofuran (80 mL) was added LDA (15.6 mL, 31.2 mmol, 2M in THF) drop-wise at −78° C. under N2 atmosphere and the mixture was stirred at −78° C. for 3 hours. A steam of dry CO2 was passed through the solution and the mixture was stirred at −78° C. for an additional 30 minutes. The reaction was quenched with water and washed with EtOAc. The aqueous layer was acidified with 1 N aqueous HCl and extracted with EtOAc twice. The combined organic layers were washed with brine, dried with anhydrous Na2SO4 and concentrated to afford compound 2 (2.85 g, yield 45.60%) as a yellow solid that was used directly in the next step. LC/MS (ESI) m/z: 221 (M+H)+.
Step 2: (6-Bromo-2-fluoropyridin-3-yl) methanol (3)
To a solution of compound 2 (2.85 g, 12.96 mmol) in tetrahydrofuran (20 mL) was added borane-tetrahydrofuran complex (32.3 mL, 32.3 mmol, 1M in THF) drop-wise at 0° C. and the mixture was stirred at room temperature under N2 atmosphere overnight. After cooling to 0° C., the reaction mixture was basified with saturated aqueous K2CO3 solution and the solvent was removed. The residue was extracted with EtOAc twice and the combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated. The residue was purified by column chromatography on silica gel (eluted with PE:EtOAc=30:1 to 10:1) to afford compound 3 (1 g, yield 37.47%) as a white solid. LC/MS (ESI) m/z: 206 (M+H)+.
Step 3: 6-Bromo-3-(chloromethyl)-2-fluoropyridine (4)
To a solution of compound 3 (53 mg, 0.26 mmol) in thionyl chloride (8 mL) was added DMF (0.02 mL) at 0° C. under a N2 atmosphere and the mixture was stirred at room temperature for 5 hours under N2 atmosphere. The mixture was concentrated to dryness and the residue was dissolved in DCM. The mixture was basified by adding saturated aqueous NaHCO3 solution and the layers were separated. The organic layers were washed with brine, dried with anhydrous Na2SO4, filtered and concentrated to dryness to afford compound 4 (52 mg, yield 90.07%) as a yellow oil that was used directly in the next step. LC/MS (ESI) m/z: 224 (M+H)+.
Step 4: 2-(6-Bromo-2-fluoropyridin-3-yl) acetonitrile (5)
Powered sodium cyanide (0.22 g, 4.46 mmol) was added to DMSO (5 mL) and the mixture was stirred at room temperature for 20 minutes. A solution of compound 4 (0.5 g, 2.23 mmol) in DMSO (5 mL) was added to the above mixture drop-wise for 10 minutes. The resulting mixture was stirred at room temperature for 1 hour. The mixture was cooled to 0° C. and water was added slowly to the mixture. The resulting mixture was extracted with DCM twice and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by column chromatography on silica gel (eluted with PE:EtOAc=50:1 to 40:1) to afford compound 5 (0.17 g, yield 34.66%) as a light yellow solid. LC/MS (ESI) m/z: 216 (M+H)+.
Step 5: 2-(6-Bromo-2-(tert-butylamino) pyridin-3-yl) acetonitrile (6)
To a mixture of compound 5 (0.17 g, 0.77 mmol) and DIPEA (0.3 g, 2.32 mmol) in DMSO (4 mL) was added erbumine (0.28 g, 3.86 mmol) and the mixture was stirred at 40° C. in a sealed tube overnight. The mixture was diluted with H2O and extracted with EtOAc twice. The combined organic layers were washed with brine, dried with anhydrous Na2SO4 and concentrated to dryness. The residue was purified by chromatography on silica gel (PE:EtOAc=100:1 to 60:1) to afford compound 6 (0.11 g, yield 53.13%) as a yellow oil. LC/MS (ESI) m/z: 268 (M+H)+.
Step 6: 2-(2-Amino-6-bromopyridin-3-yl) acetonitrile (7)
A round-bottom flask was charged with compound 6 (0.11 g, 0.41 mmol) and trifluoroacetic acid (2 mL) and the mixture was stirred at 70° C. for 0.5 hour. The reaction mixture was concentrated to dryness and the residue was basified with saturated aqueous NaHCO3 solution and extracted with EtOAc twice. The combined organic layers were washed with brine, dried with anhydrous Na2SO4 and concentrated to dryness. The residue was purified by chromatography on silica gel (PE:EtOAc=50:1 to 8:1) to afford compound 7 (69 mg, yield 79.31%) as white solid. LC/MS (ESI) m/z: 214 (M+H)+.
Step 7: (1R, 3S, 5R)-tert-Butyl 3-(6-bromo-3-(cyanomethyl) pyridin-2-ylcarbamoyl)-5-methyl-2-azabicyclo 13.1.01 hexane-2-carboxylate (8)
To a mixture of compound 7 (65 mg, 0.31 mmol) and (1R, 3S, 5R)-2-(tert-butoxycarbonyl)-5-methyl-2-azabicyclo [3.1.0] hexane-3-carboxylic acid (81 mg, 0.34 mmol) in dichloromethane (5 mL) was added pyridine (121 mg 1.53 mmol) followed by phosphoryl chloride (52 mg, 0.34 mmol) at 0° C. and the mixture was stirred at room temperature for 0.5 hour under N2 atmosphere. The mixture was poured into iced-water and extracted with DCM twice. The combined organic layers were washed with brine, dried with anhydrous Na2SO4 and concentrated to dryness. The residue was purified by chromatography on silica gel (PE:EtOAc=30:1 to 8:1) to afford compound 8 (45 mg, yield 33.72%) as a yellow solid. LC/MS (ESI) m/z: 436 (M+H)+.
Step 8: (1R, 3S, 5R)—N-(6-Bromo-3-(cyanomethyl) pyridin-2-yl)-5-methyl-2-azabicyclo [3.1.0] hexane-3-carboxamide (9)
To a solution of compound 8 (45 mg, 0.10 mmol) in dichloromethane (3 mL) was added trifluoroacetic acid (1 mL) at 0° C., and the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to dryness and the residue was washed with ether and dried under vacuum to afford compound 9 (30 mg, yield 86.58%) as a yellow solid that was used directly in the next step. LC/MS (ESI) m/z: 336 (M+H)+.
Step 9: (1R, 3S, 5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo [3, 4-c]pyridin-1-yl) acetyl)-N-(6-bromo-3-(cyanomethyl) pyridin-2-yl)-5-methyl-2-azabicyclo [3.1.0] hexane-3-carboxamide (11)
To a mixture of compound 9 (30 mg, 0.089 mmol) and compound 10 (28 mg, 0.089 mmol) in DMF (1.5 mL) was added DIPEA (58 mg, 0.45 mmol) followed by HATU (68 mg, 0.18 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with H2O and extracted with EtOAc twice. The combined organic layers were washed with 10% aqueous LiCl solution and brine, dried with anhydrous Na2SO4, and concentrated. The residue was purified by chromatography on silica gel (DCM:MeOH=100:1 to 50:1) to afford compound 11 (38 mg, yield 67.56%) as a dark green solid. LC/MS (ESI) m/z: 628 (M+H)+.
Step 10: (1R, 3S, 5R)—N-(3-((2H-Tetrazol-5-yl) methyl)-6-bromopyridin-2-yl)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo [3, 4-c] pyridin-1-yl) acetyl)-5-methyl-2-azabicyclo [3.1.0] hexane-3-carboxamide (397)
A sealed tube was charged with compound 11 (34 mg, 0.054 mmol), TBAF (0.1 mL, 1 M in THF) and azidotrimethylsilane (1 mL), and the reaction mixture was stirred at 85° C. overnight. The mixture was concentrated to dryness and the residue was purified by pre-HPLC to afford Compound 397 (5 mg, yield 27.5%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 11.21 (s, 1H), 9.33 (s, 2H), 9.26 (d, J=1.2 Hz, 1H), 8.60 (d, J=1.2 Hz, 1H), 7.63 (d, J=8.0 Hz, 1H), 7.45 (d, J=8.0 Hz, 1H), 6.23 (d, J=17.2 Hz, 1H), 5.74 (d, J=16.8 Hz, 1H), 4.44 (dd, J=9.6, 4.8 Hz, 1H), 4.05 (d, J=15.6 Hz, 2H), 3.53-3.50 (m, 1H), 2.68 (d, J=5.6 Hz, 6H), 2.16-1.96 (m, 2H), 1.28 (s, 3H), 1.10-1.05 (m, 1H), 1.05-1.00 (m, 1H). LC/MS (ESI) m/z: 671 (M+H)+.
Figure US11708351-20230725-C01230
Step 1: (E)-Ethyl 3-(6-bromo-2-fluoropyridin-3-yl)acrylate (2)
To a solution of compound 1 (500 mg, 2.45 mmol) in toluene (6 mL) was added ethyl 2-(triphenylphosphoranylidene)acetate (937.9 mg, 2.70 mmol) at 0° C. and the reaction mixture was stirred at 50° C. overnight. The mixture was evaporated under reduced pressure and the residue was purified by chromatography on silica gel (petroleum ether:ethyl acetate=20:1 to 10:1) to afford compound 2 (523 mg, yield 78.4%) as white solid. LC/MS (ESI) m/z: 274 (M+H)+.
Step 2: Ethyl 3-(6-bromo-2-fluoropyridin-3-yl)propanoate (3)
To a solution of compound 2 (523 mg, 1.92 mmol) in EtOAc (6 mL) was added PtO2 (53 mg) and the mixture was degassed under N2 atmosphere three times and stirred under a H2 balloon at room temperature for 2 hours. The mixture was filtered and the filtrate was evaporated under reduced pressure to afford compound 3 (500 mg, yield 94.7%) as white solid. LC/MS (ESI) m/z: 276 (M+H)+.
Step 3: Ethyl 3-(6-bromo-2-(tert-butylamino)pyridin-3-yl)propanoate (4)
To a mixture of compound 3 (500 mg, 1.82 mmol) and 2-methylpropan-2-amine (664 mg, 9.09 mmol) in DMSO (5 mL) was added DIPEA (704 mg, 5.45 mmol) and the reaction mixture was stirred at 75° C. in a sealed tube for 48 hours. The mixture was poured into ice water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=1:0 to 100:1) to afford compound 4 (104 mg, yield 17.4%) as a light oil. LC/MS (ESI) m/z: 329 (M+H)+.
Step 4: 3-(6-Bromo-2-(tert-butylamino)pyridin-3-yl)propan-1-ol (5)
To a solution of compound 4 (104 mg, 0.32 mmol) in anhydrous THF (3 mL) was added 1 M LiBH4 THF solution (0.64 mL, 0.64 mmol) at 0° C. under N2 atmosphere and the reaction mixture was stirred at 40° C. for 2 hours. The mixture was poured into ice water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford compound 5 (70 mg, yield 76.5%) as a yellow oil that was used in the next reaction without further purification. LC/MS (ESI) m/z: 287 (M+H)+.
Step 5: 3-(6-Bromo-2-(tert-butylamino)pyridin-3-yl)propyl methanesulfonate (6)
To a solution of compound 5 (69 mg, 0.24 mmol) in anhydrous DCM (3 mL) was added TEA (0.07 mL, 0.48 mmol) followed by a solution of MsCl (41.5 mg, 0.36 mmol) in DCM (0.5 mL) at 0° C. under N2 atmosphere. The reaction mixture was stirred at 0° C. for 1 hour. The mixture was poured into ice water and extracted with DCM twice. The combined organic layers were dried over anhydrous Na2SO4 and concentrated under reduced pressure to afford compound 6 (85 mg, yield 97.2%) as a yellow oil that was directly used in the next reaction without further purification. LC/MS (ESI) m/z: 365 (M+H)+.
Step 6: 6-Bromo-N-(tert-butyl)-3-(3-morpholinopropyl)pyridin-2-amine (7)
To a mixture of compound 6 (85 mg, 0.24 mmol) and 2-methylpropan-2-amine (0.1 mL, 1.21 mmol) in MeCN (2 mL) was added DIPEA (0.12 mL, 0.72 mmol) followed by NaI (26.4 mg, 0.24 mmol) and the reaction mixture was stirred at 50° C. overnight. The mixture was poured into ice water and extracted with EtOAc twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced pressure to afford compound 7 (75 mg, crude) as a yellow oil that was directly used to the next reaction without further purification. LC/MS (ESI) m/z: 329 (M+H)+.
Step 7: 6-Bromo-3-(3-morpholinopropyl)pyridin-2-amine (8)
A solution of compound 7 (75 mg, 0.24 mmol) in TFA (2 mL) was stirred at 70° C. for 30 minutes. The mixture was evaporated under reduced pressure and the residue was portioned with EtOAc and saturated aqueous NaHCO3 solution. The organic layer was washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=1:1 to 0:1) to afford compound 8 (44 mg, yield 61.3%) as a light brown solid. LC/MS (ESI) m/z: 300 (M+H)+.
Step 8: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-(3-morpholinopropyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (10)
To a mixture of compound 8 (44 mg, 0.15 mmol) and compound 9 (35.5 mg, 0.147 mmol) in anhydrous DCM (3 mL) was added pyridine (0.06 mL, 0.735 mmol) followed by POCl3 (0.02 mL, 0.162 mmol) at 0° C., and the reaction mixture was stirred at room temperature for 30 minutes. The mixture was poured into ice water and extracted with DCM twice. The organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (eluted with petroleum ether:ethyl acetate=1:1 to 0:1) to afford compound 10 (27 mg, yield 34.6%) as light yellow solid. LC/MS (ESI) m/z: 523 (M+H)+.
Step 9: (1R,3S,5R)-tert-Butyl 3-((6-bromo-3-(3-morpholinopropyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (11)
A solution of 4 N HCl/dioxane solution (2 mL) was added to compound 10 (27 mg, 0.05 mmol) at 0° C. under N2 atmosphere and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford compound 11 (20 mg, yield 100%) as a brown solid that was directly used in the next reaction without further purification. LC/MS (ESI) m/z: 423 (M+H)+.
Step 10: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-(3-morpholinopropyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (400)
To a mixture of compound 11 (20 mg, 0.052 mmol) and compound 12 (17.7 mg, 0.057 mmol) in DMF (2 mL) was added HATU (29.6 mg, 0.078 mmol) followed by DIPEA (0.04 mL, 0.156 mmol) at 0° C. and the reaction mixture was stirred at room temperature for 1.5 hours. The mixture was poured into ice water and extracted with EtOAc twice. The organic layers were washed with brine, dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was purified by prep-HPLC to afford 400 (7 mg, yield 18.9%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.22 (s, 1H), 9.35 (s, 2H), 9.31 (d, J=1.2 Hz, 1H), 8.62 (d, J=1.2 Hz, 1H), 7.65 (d, J=8.0 Hz, 1H), 7.47 (d, J=8.0 Hz, 1H), 6.07 (d, J=17.4 Hz, 1H), 5.72 (d, J=17.2 Hz, 1H), 4.40 (dd, J=9.2, 5.4 Hz, 1H), 3.61 (dd, J=5.5, 2.3 Hz, 1H), 3.40-3.37 (m, 4H), 2.69 (d, J=3.8 Hz, 6H), 2.60-2.52 (m, 2H), 2.41-2.33 (m, 2H), 2.03 (d, J=12.5 Hz, 4H), 1.94 (t, J=7.1 Hz, 2H), 1.54-1.46 (m, 2H), 1.34 (s, 3H), 1.09 (dd, J=5.3, 2.2 Hz, 1H), 1.01 (t, J=5.4 Hz, 1H). LC/MS (ESI) m/z: 716 (M+H)+.
Figure US11708351-20230725-C01231
Step 1: (1R,3S,5S)-2-tert-Butyl 3-ethyl 5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2,3-dicarboxylate (2)
To a mixture of compound 1 (500 mg, 1.44 mmol) and CuI (55 mg, 0.288 mmol) in anhydrous MeCN (25 mL) was added 2,2-difluoro-2-(fluorosulfonyl)acetic acid (513 mg, 2.88 mmol) at room temperature under N2 atmosphere and the resulting mixture was stirred at 45° C. under N2 atmosphere for 1 hour. The mixture was diluted with EtOAc and filtered, and the filtrate was washed with saturated aqueous NaHCO3 solution and brine, dried over anhydrous Na2SO4, filtered, and concentrated to afford crude product. The residue was purified by silica gel column (eluted with PE:EtOAc=15:1) to afford compound 2 (350 mg, yield 61.4%) as colorless oil. LC/MS (ESI) m/z: 420 (M+Na)+.
Step 2: (1R,3S,5S)-2-(tert-Butoxycarbonyl)-5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic Acid (3)
To a solution of compound 2 (350 mg, 0.88 mmol) in MeOH (12 mL) was added 4 mL of aqueous LiOH solution (4 mmol, 1 M) and the mixture was stirred at room temperature for 4 hours. The mixture was diluted with water (20 mL) and extracted with ether and the aqueous layer was collected and acidified with aqueous HCl solution (1 N) to pH of 5. The mixture was extracted with DCM/MeOH (20 mL×2, 15:1, v/v) and the combined organic layers were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 3 (240 mg, yield 88.9%) as a colorless oil. LC/MS (ESI) m/z: 330 (M+Na)+.
Step 3: (1R,3S,5S)-tert-Butyl 3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-2-carboxylate (4)
To a solution of compound 3 (138 mg, 0.45 mmol) and 6-bromo-3-methylpyridin-2-amine (85 mg, 0.45 mmol) in anhydrous DCM (10 mL) was added pyridine (178 mg, 2.25 mmol) followed by the drop-wise addition of POCl3 (77 mg, 0.5 mmol) at 0° C. The reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was quenched with ice-cool water and extracted with DCM twice. The combined organic phases were washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified by silica gel column (eluted with PE:EtOAc=6:1) to afford compound 4 (131 mg, yield 61.2%) as colorless oil. LC/MS (ESI) m/z: 476/478 (M+H)+.
Step 4: (1R,3S,5S)—N-(6-Bromo-3-methylpyridin-2-yl)-5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide TFA Salt (5)
To a solution of compound 4 (55 mg, 0.116 mmol) in DCM (2 mL) was added TFA (1 mL) drop-wise at 0° C. under a N2 atmosphere and the mixture was stirred at room temperature for 1 hour. The mixture was concentrated to dryness to afford compound 5 (60 mg, yield 95.9%) as a dark-brown oil that was directly used in the next reaction without further purification. LC/MS (ESI) m/z: 376/378 (M+H)+.
Step 5: (1R,3S,5S)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((difluoromethoxy)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (384)
To a mixture of compound 5 (60 mg, 0.116 mmol), compound 6 (36 mg, 0.116 mmol) and HATU (80 mg, 0.21 mmol) in DMF (3 mL) was added DIPEA (76 mg, 0.58 mmol) at 0° C. and the reaction mixture was stirred at room temperature for 1 hour. The mixture was diluted with EtOAc and washed with 10% aqueous LiCl solution and brine, dried over anhydrous Na2SO4, filtered and concentrated to dryness. The residue was purified via pre-HPLC to afford Compound 384 (25 mg, yield 32.3%) as white solid. 1H-NMR (400 MHz, DMSO-d6) δ 10.30 (s, 1H), 9.25-9.42 (m, 3H), 8.62 (d, J=1.1 Hz, 1H), 7.63 (d, J=8.1 Hz, 1H), 7.45 (d, J=7.9 Hz, 1H), 6.94 (s, 1H), 6.75 (s, 1H), 6.56 (s, 1H), 6.07 (d, J=17.3 Hz, 1H), 5.76 (d, J=17.2 Hz, 1H), 4.51 (dd, J=9.4, 4.7 Hz, 1H), 3.98 (dd, J=25.7, 10.9 Hz, 2H), 3.85 (dd, J=5.7, 2.7 Hz, 1H), 2.70 (s, 3H), 2.69 (s, 3H), 2.53-2.60 (m, 1H), 2.25-2.32 (m, 1H), 2.04 (s, 3H), 1.31-1.37 (m, 1H), 1.28 (t, J=5.6 Hz, 1H). LC/MS (ESI) m/z: 669/671 (M+H)+.
Figure US11708351-20230725-C01232
Figure US11708351-20230725-C01233
Step 1: 5-Bromo-1-(tert-butoxycarbonyl)-1H-indazole-3-carboxylic Acid (2)
To a solution of 5-bromo-1H-indazole-3-carboxylic acid (1 equiv) in THF (10 vol) at 0° C. under nitrogen atmosphere was added DMAP (0.1 equiv) and triethylamine (3 equiv). Boc anhydride (1 equiv) was added and the reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, water was added and the resulting mixture was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 2 that was used as such for the next step.
Step 2: 5-(2-Methylpyrimidin-5-yl)-1H-indazole-3-carboxylic Acid (3)
To a solution of compound 2 (1 equiv) in 1,4-dioxane (20 vol) and water (2 vol) at 0° C. under nitrogen atmosphere was added 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine (1.5 equiv), potassium carbonate (3 equiv). After degassing with nitrogen, PdCl2(dppf) (0.1 equiv) was added to the reaction mixture. The reaction mixture was sealed and kept in microwave at 100° C. for 1 hour. After completion of the reaction, the reaction mixture was concentrated to afford compound 3 and the resulting residue was used as such for the next step.
Step 3: N-Methoxy-N-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxamide (4)
To a solution of compound 3 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added N,O-dimethylhydroxylamine hydrochloride (1.5 equiv), EDCI-HCl (1.5 equiv) and DMAP (1.2 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 4 and the resulting residue was used as such for the next step.
Step 4: (5-(2-Methylpyrimidin-5-yl)-1H-indazol-3-yl)(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-2-yl)methanone (5)
To a solution of compound 4 (1 equiv) in THF (10 vol) at −40° C. under nitrogen atmosphere was added n-BuLi (5 equiv). The reaction mixture was stirred at −40° C. for 1 hour. 1-((2-(Trimethylsilyl)ethoxy)methyl)-1H-imidazole (5 equiv) was added to the reaction mixture and stirred at −40° C. for 3 hours. After completion of the reaction, the reaction mixture was quenched with ice water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative purification to afford compound 5.
Step 5: Methyl 2-(5-(2-methylpyrimidin-5-yl)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carbonyl)-1H-indazol-1-yl)acetate (6)
To a solution of compound 5 (1 equiv) in DMF (10 vol) was added potassium carbonate (1.5 equiv) and methyl 2-bromoacetate (1.1 equiv). The reaction mixture was stirred at 50° C. for 3 hours and then quenched with water. The resulting solid was filtered, taken in MTBE, stirred for 30 minutes, filtered, and dried to afford compound 6.
Step 6: 2-(5-(2-Methylpyrimidin-5-yl)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carbonyl)-1H-indazol-1-yl)acetic Acid (7)
To a solution of compound 6 (1 equiv) in THF/water (10 vol/2 vol) was added LiOH (3 equiv). The reaction mixture was stirred at room temperature for 4 hours and concentrated. Water was added to the residue and washed with ethyl acetate (3 times). The aqueous layer was acidified with 1.5 N HCl and then extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated to afford compound 7.
Step 7: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(5-(2-methylpyrimidin-5-yl)-3-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-2-carbonyl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (8)
To a solution of compound 7 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by preparative purification to afford compound 8.
Step 8: (1R,3S,5R)-2-(2-(3-(1H-Imidazole-2-carbonyl)-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (389)
A solution of compound 8 (1 equiv) in TFA (5 vol) was stirred at room temperature for 4 hours and concentrated. The residue was purified by preparative purification to afford Compound 389. 1H NMR (400 MHz, CD3OD) δ 9.08 (s, 2H), 8.68 (s, 1H), 7.97 (s, 2H), 7.85 (s, 2H), 7.55 (d, J=8.0 Hz, 1H), 7.40 (d, J=8.0 Hz, 1H), 6.01 (d, J=18.0 Hz, 1H), 5.96 (d, J=18.0 Hz, 1H), 3.75-3.69 (m, 2H), 3.61-3.59 (m, 2H), 3.80 (s, 3H), 2.13 (s, 3H), 1.45 (s, 3H), 1.21-1.28 (m, 1H), 1.11-1.10 (m, 1H).
Figure US11708351-20230725-C01234
Step 1: 7-Methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carbonitrile (2)
To a solution of 3-iodo-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole (1 equiv) in DMF (10 vol) and water (1 vol) at room temperature was added Zn(CN)2 (1.1 equiv). After degassing with nitrogen, Pd(dppf)Cl2 (0.1 equiv) and Pd2(dba)3 (0.1 equiv) were added and the mixture was stirred at 90° C. for 5 hours. The reaction mixture was cooled to room temperature. Water was added and the mixture was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated. The residue was purified by column chromatography on silica gel using hexane/EtOAc to afford compound 2.
Step 2: 7-Methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxylic Acid (3)
To a solution of compound 2 (1 equiv) in dioxane (5 vol) at 0° C. was added 6N HCl (20 vol). The reaction mixture was stirred at 90° C. for 3 hours in a sealed tube and then concentrated. 10% NaHCO3 was added and the resulting mixture was extracted with EtOAc. The organic layer was separated, dried over anhydrous Na2SO4, filtered, and concentrated to afford compound 3.
Step 3: 1-(tert-Butoxycarbonyl)-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazole-3-carboxylic Acid (4)
To a solution of compound 3 (1 equiv) in dioxane (10 vol) and water (3 vol) at 0° C. was added 2M NaOH (3 equiv). Boc anhydride (1.5 equiv) was added and the mixture was stirred at room temperature for 16 hours. After completion of the reaction, water was added and the resulting mixture was acidified with 1M citric acid solution before being extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 4.
Step 4: tert-Butyl 7-methyl-5-(2-methylpyrimidin-5-yl)-3-(2-azaspiro[3.3]heptane-2-carbonyl)-1H-indazole-1-carboxylate (5)
To a solution of compound 4 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added 2-azaspiro[3.3]heptane (1 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 5.
Step 5: tert-Butyl 2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(2-azaspiro[3.3]heptane-2-carbonyl)-1H-indazol-1-yl)acetate (6)
To a solution of compound 5 (1 equiv) in 1,4-dioxane (3 vol) at 0° C. under nitrogen atmosphere was added 4 N HCl in 1,4-dioxane (10 vol) and the mixture was stirred at room temperature for 3 hours. The volatiles were removed under reduced pressure and the resulting residue was used as such for the next step.
To a solution of above residue in DMF (10 vol) was added potassium carbonate (3 equiv) and tert-butyl 2-bromoacetate (1.5 equiv). The reaction mixture was stirred at 50° C. for 3 hours. After completion of the reaction, the mixture was quenched with water. The resulting mixture was extracted with EtOAc. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 6.
Step 6: 2-(7-Methyl-5-(2-methylpyrimidin-5-yl)-3-(2-azaspiro[3.3]heptane-2-carbonyl)-1H-indazol-1-yl)acetic Acid (7)
To a solution of compound 6 (1 equiv) in DCM (10 vol) at 0° C. was added TFA (5 vol). The reaction mixture was stirred at 50° C. for 2 hours. The volatiles were removed under reduced pressure to afford compound 7 and the resulting residue was used as such for the next step.
Step 7: (1R,3S,5R)—N-(6-Bromo-3-methylpyridin-2-yl)-5-methyl-2-(2-(7-methyl-5-(2-methylpyrimidin-5-yl)-3-(2-azaspiro[3.3]heptane-2-carbonyl)-1H-indazol-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (390)
To a solution of compound 7 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1.2 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative purification to afford Compound 390. 1H NMR (400 MHz, CD3OD) δ 9.01 (s, 2H), 8.41 (s, 1H), 7.57-7.54 (m, 2H), 7.40 (d, J=8.0 Hz, 1H), 5.92 (d, J=18.0 Hz, 1H), 5.78 (d, J=18.0 Hz, 1H), 4.65-4.64 (m, 1H), 4.19-4.17 (m, 2H), 3.65-3.64 (m, 1H), 3.56-3.55 (m, 1H), 2.76 (s, 3H), 2.33 (s, 3H), 2.27-2.13 (m, 2H), 1.92-1.91 (m, 2H), 1.43-1.42 (m, 2H), 1.30 (s, 3H), 1.29 (s, 3H), 0.97-0.91 (m, 2H).
Figure US11708351-20230725-C01235
Step 1: N-(6-Bromo-5-fluoropyridin-2-yl)-1,1-dimethyl-14-sulfanimine (2)
6-Bromo-5-fluoropyridin-2-amine (0.97 g, 5.078 mmol, 1 equiv.) in dichloromethane (5 mL, 1.016 M, 5.155 Vols) was cooled to −60° C. N-Chlorosuccinimide (0.712 g, 0.432 mL, 5.332 mmol, 1.05 equiv.) in dichloromethane (10 mL) was slowly added at −60° C. The reaction mixture was stirred for 30 minutes before methyl sulfide (0.947 g, 1.119 mL, 15.235 mmol, 3 equiv.) was slowly added and the reaction was stirred for 1 hour. Sodium methoxide (0.329 g, 12.188 mL, 6.094 mmol, 1.2 equiv.) was slowly at −60° C. and the reaction was stirred for 1 hour at −60° C. before the reaction was allowed to warm to room temperature. Upon evaporation of the solvent, crude material was purified by SiO2 chromatography to afford N-(6-bromo-5-fluoropyridin-2-yl)-S,S-dimethyl-λ4-sulfanimine (0.98 g, 3.903 mmol, yield 76.845%).
Step 2: 6-Bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-amine (3)
To N-(6-bromo-5-fluoropyridin-2-yl)-S,S-dimethyl-λ4-sulfanimine (0.98 g, 3.903 mmol), potassium tert-butoxide (4 mmol) in tert-butyl alcohol (10 mL) was added and the reaction was refluxed for 16 hours. Solvent was removed and the residue was purified by SiO2 chromatography to afford 6-bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-amine (0.5 g, 1.99 mmol, yield 51%).
Step 3: tert-Butyl (1R,3S,5R)-3-((6-bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (4)
(1R,3S,5R)-2-(tert-Butoxycarbonyl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxylic acid (0.05 g, 0.209 mmol, 1.05 equiv.) and 6-bromo-5-fluoro-3-[(methylsulfanyl)methyl]pyridin-2-amine (0.05 g, 0.199 mmol, 1 equiv.) were dissolved in dichloromethane (5 ml) and pyridine (0.079 g, 0.08 mL, 0.996 mmol, 5 equiv.) was added followed by phosphoryl chloride (0.031 g, 0.019 mL, 0.199 mmol, 1 equiv.) at 0° C. The reaction mixture was stirred for 1 hour at 0° C. and water was added followed by K2CO3 to basify the reaction. The organic layer was separated and solvent was removed. The crude material was purified by SiO2 chromatography to afford tert-butyl (1R,3S,5R)-3-({6-bromo-5-fluoro-3-[(methylsulfanyl)methyl]pyridin-2-yl}carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.09 g, 0.19 mmol, yield 95.284%)
Step 4: (1R,3S,5R)—N-(6-Bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide Hydrochloride (5)
To tert-butyl (1R,3S,5R)-3-({6-bromo-5-fluoro-3-[(methylsulfanyl)methyl]pyridin-2-yl}carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexane-2-carboxylate (0.09 g, 0.19 mmol, 1 equiv.), 4N hydrochloric acid in dioxane (5 mL) was added and the reaction was stirred for 1 hour at room temperature. Solvent was removed and the residue was used in the next step.
Step 5: (1R,3S,5R)-2-(2-(3-Acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-5-fluoro-3-((methylthio)methyl)pyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (438)
To a solution of (1R,3S,5R)—N-{6-bromo-5-fluoro-3-[(methylsulfanyl)methyl]pyridin-2-yl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (0.078 g, 0.19 mmol, 1 equiv.) and [3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetic acid (0.062 g, 0.199 mmol, 1.05 equiv.) in N,N-dimethylformamide (1.56 mL, 0.122 M, 20 Vols), was added Hunig's Base (0.123 g, 0.165 mL, 0.95 mmol, 5 equiv.) and the reaction was cooled to 0° C. N,N,N′,N′-Tetramethyl-O-(benzotriazol-1-yl)uronium tetrafluoroborate (0.067 g, 0.209 mmol, 1.1 equiv.) was added and the reaction was stirred for 1 hour. Excess solvent was removed and the residue was purified by SiO2 chromatography to afford (1R,3S,5R)-2-{2-[3-acetyl-5-(2-methylpyrimidin-5-yl)indazol-1-yl]acetyl}-N-{6-bromo-5-fluoro-3-[(methylsulfanyl)methyl]pyridin-2-yl}-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide 438 (0.05 g, 0.064 mmol, yield 33.729%) 1H NMR (400 MHz, DMSO-d6) δ 0.97-1.08 (m, 2H), 1.34 (s, 3H), 1.77 (s, 3H), 2.06 (m, 1H), 2.56 (m, 1H), 2.66 (s, 3H), 2.70 (s, 3H), 3.60 (m, 1H), 4.00-4.80 (m, 2H), 4.40 (m, 1H), 5.59 (m, 1H), 5.92 (m, 1H), 7.85-7.96 (m, 3H), 8.45 (s, 1H), 9.05 (s, 2H), 10.35 (s, 1H).
Figure US11708351-20230725-C01236
Figure US11708351-20230725-C01237
Figure US11708351-20230725-C01238
Figure US11708351-20230725-C01239
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a fatty acid in the R32 position via the formation of an amide bond utilizing the coupling reagent HATU. The skilled artisan will recognize that the A-ring shown above can be replaced with other A-rings to afford additional compounds of the present invention. The skilled artisan will also recognize that the fatty acid in the R32 shown above can be replaced with other fatty acids.
Step 1: Methyl 2-(3-acetyl-5-bromo-1H-indazol-1-yl)acetate (233-S2)
To a solution of 1-(5-bromo-1H-indazol-3-yl)ethan-1-one (1 equiv) in DMF (10 vol) was added potassium carbonate (2.5 equiv) and methyl bromoacetate (1.1 equiv). The reaction mixture was stirred at room temperature for 3 hours and quenched with water. The resulting solid was filtered, taken up in MTBE, stirred for 30 minutes, filtered, and dried to afford compound 233-S2.
Step-2: Methyl 2-(3-acetyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazol-1-yl)acetate (233-S3)
To a solution of compound 233-S32 (1 equiv) in 1,4-dioxane (10 vol) at 0° C. under nitrogen atmosphere was added 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane (1.5 equiv), potassium acetate (3 equiv) and PdCl2(dppf) (0.1 equiv). The reaction mixture was stirred at 90° C. for 12 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM and the organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using hexane/EtOAc to afford compound 233-S3.
Step-3: Methyl 2-(3-acetyl-5-(2-(((tert-butoxycarbonyl)amino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetate (233-S4)
To a solution of compound 233-S3 (1.2 equiv) in 1,4-dioxane (10 vol) at 0° C. under nitrogen atmosphere was added tert-butyl ((5-bromopyrimidin-2-yl)methyl)carbamate (1 equiv), potassium acetate (3 equiv) and PdCl2(dppf) (0.1 equiv). The reaction mixture was stirred at 90° C. for 12 hours and concentrated. The residue was purified by column chromatography on silica gel using hexane/EtOAc to afford compound 233-S4.
Step 4: 2-(3-Acetyl-5-(2-(((tert-butoxycarbonyl)amino)methyl)pyrimidin-5-yl)-1H-indazol-1-yl)acetic Acid (233-S5)
To a solution of compound 233-S4 (1 equiv) in THF/MeOH/water (2:1:1) was added LiOH (1.5 equiv). The reaction mixture was stirred at room temperature for 12 hours and concentrated. Water was added to the residue and the solution was washed with ethyl acetate (3 times). The aqueous layer was acidified with 1.5 N HCl and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated to afford compound 233-S5.
Step 5: tert-Butyl ((5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)methyl)carbamate (6)
To a solution of compound 233-S5 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (1 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 233-S6.
Step 6: (9H-Fluoren-9-yl)methyl (2-(2-(2-(((5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)methyl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamate (233-S7)
To a solution of compound 233-S6 (1 equiv) in 1,4-dioxane (2 vol) at 0° C. under nitrogen atmosphere was added 4 N HCl in 1,4-dioxane (10 vol) and the reaction was stirred at room temperature for 3 hours. The reaction mixture was concentrated and dissolved in DMF (10 vol). 1-(9H-Fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acid (1.2 equiv), EDCI-HCl (1.5 equiv), HOBt (1.2 equiv) and DIPEA (5 equiv) were added at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 233-S7.
Step 7: (9H-Fluoren-9-yl)methyl (1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)-3,12-dioxo-5,8,14,17-tetraoxa-2,11-diazanonadecan-19-yl)carbamate (233-S8)
A solution of compound 233-S7 (1 equiv) in 20% piperidine in DMF (20 vol) was stirred at room temperature for 16 hours. The reaction mixture was concentrated and dissolved in DMF (10 vol). 1-(9H-Fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oic acid (1.2 equiv), EDCI-HCl (1.5 equiv), HOBt (1.2 equiv) and DIPEA (5 equiv) were added at 0° C. under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 233-S8.
Step 8: Methyl (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)-24-((tert-butoxycarbonyl)amino)-3,12,21-trioxo-5,8,14,17-tetraoxa-2,11,20-triazapentacosan-25-oate (233-S9)
A solution of compound 233-S8 (1 equiv) in 20% piperidine in DMF (20 vol) was stirred at room temperature for 16 hours. The reaction mixture was concentrated and dissolved in DMF (10 vol) at 0° C. (S)-4-((tert-Butoxycarbonyl)amino)-5-methoxy-5-oxopentanoic acid (6 equiv), EDCI-HCl (6 equiv), HOBt (1.2 equiv) and DIPEA (7.5 equiv) were added under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 233-S9.
Step 9: (9H-Fluoren-9-yl)methyl (2-(2-(2-(((5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)methyl)amino)-2-oxoethoxy)ethoxy)ethyl)carbamate (233-S7)
To a solution of compound 233-S9 (1 equiv) in 1,4-dioxane (2 vol) at 0° C. under a nitrogen atmosphere 4 N HCl in 1,4-dioxane (10 vol) was added and the reaction stirred at room temperature for 3 hours. The reaction mixture was concentrated and dissolved in DMF (10 vol) at 0° C. 18-Methoxy-18-oxooctadecanoic acid (1.2 equiv), EDCI-HCl (1.5 equiv), HOBt (1.2 equiv) and DIPEA (5 equiv) were added under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 233-S10.
Step 10: (S)-1-(5-(3-Acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic Acid (233)
To a solution of compound 233-S10 (1 equiv) in THF/water (8:2) was added LiOH (4 equiv). The reaction mixture was stirred at room temperature for 4 hours and then quenched with 1 M citric acid. The resulting mixture was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated to afford 233. 1H NMR (400 MHz, CD3OD) δ 9.10 (s, 1H), 8.07-8.05 (m, 1H), 7.99 (s, 1H), 7.83-7.81 (m, 1H), 7.65-7.56 (m, 1H), 7.52-7.45 (m, 1H), 7.42-7.35 (m, 1H), 5.83 (d, J=17.2 Hz, 1H), 5.68 (d, J=17.2 Hz, 1H), 5.37-5.35 (m, 1H), 4.78-4.77 (m, 1H), 4.60-4.48 (m, 1H), 4.38-4.25 (m, 1H), 4.15-4.11 (m, 2H), 4.00-3.89 (m, 1H), 3.82-3.75 (m, 1H), 3.73-3.71 (m, 1H), 3.67-3.53 (m, 4H), 3.52-3.48 (m, 2H), 3.01-2.95 (m, 4H), 2.88 (s, 3H), 2.82-2.78 (m, 1H), 2.65-2.62 (m, 2H), 2.35-2.20 (m, 4H), 2.15-2.13 (m, 1H), 2.11-2.09 (m, 1H), 2.00-1.96 (m, 1H), 1.94 (s, 3H), 1.70-1.58 (m, 3H), 1.50-1.48 (m, 4H), 1.40 (s, 3H), 1.39-1.24 (m, 23H), 0.93-0.92 (m, 2H), 0.90-0.87 (m, 3H), 0.85-0.81 (m, 1H).
Methyl (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate
1H NMR (400 MHz, CD3OD) δ 9.08 (s, 2H), 8.44 (s, 1H), 7.56-7.55 (m, 2H), 7.51 (d, J=8.0 Hz, 1H), 5.95 (d, J=18.0 Hz, 1H), 5.87 (d, J=18.0 Hz, 1H), 4.75-4.74 (m, 1H), 4.55-4.54 (m, 1H), 4.34-4.33 (m, 2H), 4.19 (s, 2H), 3.95 (s, 2H), 3.85-3.43 (m, 25H), 2.82-2.79 (m, 2H), 2.32-1.85 (m, 15H), 1.55-1.53 (m, 4H), 1.42 (s, 3H), 1.28-1.19 (m, 28H), 1.11-0.98 (m, 2H).
(S)-1-(5-(3-Acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H-indazol-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic Acid
1H NMR (400 MHz, CD3OD) δ 9.08 (s, 2H), 8.45 (s, 1H), 7.57-7.55 (m, 2H), 7.39 (d, J=7.2 Hz, 1H), 5.97 (d, J=18.0 Hz, 1H), 5.87 (d, J=18.0 Hz, 1H), 4.75 (m, 2H), 4.57-4.55 (m, 1H), 4.32-4.31 (m, 1H), 4.17 (s, 2H), 3.98 (s, 2H), 3.82-3.41 (m, 13H), 2.81-2.80 (m, 2H), 2.75-2.73 (m, 4H), 2.41-1.99 (m, 10H), 1.61-1.60 (m, 4H), 1.42 (s, 3H), 1.35-1.31 (m, 29H), 1.11-1.10 (m, 2H).
Methyl (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate
1H NMR (400 MHz, CD3OD) δ 9.41 (s, 2H), 9.23 (s, 1H), 8.72 (s, 1H), 7.55 (d, J=7.2 Hz, 1H), 7.39 (d, J=7.2 Hz, 1H), 5.97 (d, J=18.0 Hz, 1H), 5.85 (d, J=18.0 Hz, 1H), 4.77-4.75 (m, 2H), 4.56-4.55 (m, 1H), 4.35-4.34 (m, 1H), 4.13 (s, 2H), 3.98 (s, 2H), 3.82-3.41 (m, 25H), 2.71 (s, 3H), 2.33-2.22 (m, 7H), 2.15 (s, 3H), 2.13-2.11 (m, 2H), 1.51-1.49 (m, 4H), 1.26-1.23 (m, 26H), 1.11-1.10 (m, 2H).
(S)-1-(5-(3-Acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic Acid
1H NMR (400 MHz, CD3OD) δ 9.44 (s, 2H), 9.26 (s, 1H), 8.74 (s, 1H), 7.56 (d, J=7.2 Hz, 1H), 7.41 (d, J=7.2 Hz, 1H), 6.00 (d, J=18.0 Hz, 1H), 5.85 (d, J=18.0 Hz, 1H), 4.85 (s, 2H), 4.55-4.54 (m, 1H), 4.31-4.30 (m, 1H), 4.18 (s, 2H), 3.98 (s, 2H), 3.82-3.21 (m, 18H), 2.74 (s, 3H), 2.73-2.72 (m, 1H), 2.33-2.12 (m, 10H), 2.02-1.98 (m, 1H), 1.61-1.60 (m, 8H), 1.42-1.28 (m, 22H), 1.11-1.10 (m, 1H), 0.98-0.97 (m, 1H).
Figure US11708351-20230725-C01240
The above scheme and following detailed description depicts one non-limiting method for synthesizing compounds with a fatty acid in the R301 position via the formation of an amide bond utilizing HATU. The skilled artisan will recognize that the A-ring shown above can be replaced with other A-rings to afford additional compounds of the present invention.
Step 1: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2-yl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (2)
To a solution of (1R,3S,5R)—N-(6-bromo-3-methylpyridin-2-yl)-5-((1,3-dioxoisoindolin-2-yl)methyl)-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (1.2 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added 2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetic acid (1 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by column chromatography on silica gel using DCM/MeOH to afford compound 2.
Step 2: (1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(aminomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (3)
To a solution of compound 2 (1 equiv) in MeOH (10 vol) at −30° C. was added saturated methanolic ammonia solution (50 vol). The reaction mixture was stirred at room temperature for 48 hours. After completion of the reaction, solvent was removed under reduced pressure and the residue was purified by preparative purification to afford compound 3.
Step 3: Methyl (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate (391)
To a solution of compound 3 (1 equiv) in DMF (10 vol) at 0° C. under nitrogen atmosphere was added (S)-22-(methoxycarbonyl)-3,20,25,34-tetraoxo-2,29,32,38,41-pentaoxa-21,26,35-triazatritetracontan-43-oic acid (1.1 equiv), HATU (1.5 equiv) and DIPEA (5 equiv). The reaction mixture was stirred at room temperature for 16 hours. After completion of the reaction, the reaction mixture was quenched with water. The resulting mixture was extracted with DCM. The organic layer was washed with brine, dried over anhydrous Na2SO4, filtered and concentrated. The residue was purified by preparative purification to afford Compound 391: 1H NMR (400 MHz, CD3OD) δ 9.00 (s, 2H), 8.42 (s, 1H), 7.54-7.51 (m, 2H), 7.39 (d, J=7.2 Hz, 1H), 5.97 (d, J=18.0 Hz, 1H), 5.85 (d, J=18.0 Hz, 1H), 4.63-4.62 (m, 1H), 4.44-4.43 (m, 1H), 4.08-4.01 (m, 4H), 3.89-3.45 (m, 17H), 3.31-3.29 (m, 4H), 2.85 (s, 3H), 2.83 (s, 3H), 2.56-2.55 (m, 3H), 2.32-2.12 (m, 8H), 2.55-2.53 (m, 4H), 1.32-1.21 (m, 33H), 1.11-1.10 (m, 2H).
Step 4: (S)-1-((1R,3S,5R)-2-(2-(3-Acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oic Acid (392)
To a solution of Compound 391 (1 equiv) in THF/water (8:2) was added CsOH (2 equiv). The reaction mixture was stirred at room temperature for 2 hours and then quenched with 1 M citric acid. The resulting mixture was extracted with ethyl acetate. The organic layer was separated, dried over anhydrous Na2SO4, filtered and concentrated. The residue is purified by preparative purification to afford Compound 392: 1H NMR (400 MHz, CD3OD) δ 9.03 (s, 2H), 8.45 (s, 1H), 7.57-7.56 (m, 2H), 7.40 (d, J=8.0 Hz, 1H), 5.99 (d, J=17.0 Hz, 1H), 5.85 (d, J=17.0 Hz, 1H), 4.65-4.63 (m, 3H), 4.12-4.00 (m, 4H), 3.81-3.53 (m, 13H), 2.81 (s, 3H), 2.79 (s, 3H), 2.56-2.55 (m, 3H), 2.32-2.29 (m, 6H), 2.12 (s, 3H), 1.61-1.59 (m, 4H), 1.42-1.39 (m, 33H), 0.89-0.85 (m, 2H).
Methyl (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate
1H NMR (400 MHz, CD3OD) δ 9.36 (s, 2H), 9.25 (s, 1H), 8.71 (s, 1H), 7.55 (d, J=7.2 Hz, 1H), 7.43 (d, J=7.2 Hz, 1H), 6.00 (d, J=18.0 Hz, 1H), 5.82 (d, J=18.0 Hz, 1H), 4.65-4.64 (m, 1H), 4.45-4.44 (m, 1H), 4.12-4.11 (m, 4H), 3.85-3.41 (m, 19H), 2.85 (s, 3H), 2.82 (s, 3H), 2.55-2.54 (m, 2H), 2.32-2.22 (m, 6H), 2.12 (s, 3H), 1.61-1.59 (m, 5H), 1.29-1.27 (m, 31H), 1.11-0.98 (m, 2H).
Figure US11708351-20230725-C01241
Step-1: Loading 2-chlorotrityl Chloride
A solution of 2-chlorotrityl chloride (1 equiv) in DCM (10 vol) was swelled in a closed syringe filter for 15 minutes and then filtered. A mixture of FmocGluOAll (1.5 equiv) in DCM (10 vol) and DIPEA (4 equiv) was added to the resin. The resulting mixture was shook for 16 hours and filtered. The resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes.
Capping: Capping solution (DCM, MeOH and DIPEA; 17:2:1) was added to the above resin and the mixture was shook for 1 hour at room temperature. The capping solution was pushed out=with nitrogen and the resin with washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes to afford compound 2.
Step-2: Deprotection of Fmoc
Resin (2) was treated with 20% piperidine solution in DMF (5 vol) and shook for 15 minutes. The piperidine solution was pushed out with nitrogen and the process was repeated once again. The resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes.
Manual coupling of amino acids: To a mixture of FmocTyr(OtBu)OH (3 equiv), DMF (10 vol), HATU (3 equiv) and DIPEA (5 equiv) was added to the above resin and shook for 6 hours at room temperature. The reaction mixture was pushed out with nitrogen and the resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes. The same process was repeated for all Fmoc-deprotections and amino acid couplings (FmocGlu(OtBu)OH, FmocLys(ivDde)OH, FmocGlu(OtBu)OH, FmocTyr(OtBu)OH and Ac-Glu(OtBu)-OH) to afford compound 3.
Step-3: Deprotection of ivDde
Resin was treated with 5% hydrazine in DMF (5 vol) and shook for 15 minutes. The hydrazine solution was pushed out with nitrogen and the process was repeated once again. The resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes.
Palmitic acid coupling: A mixture of palmitic acid (3 equiv), DMF (10 vol), HATU (3 equiv) and DIPEA (5 equiv) was added to the above resin and shook for 6 hours at room temperature. The reaction mixture was pushed out with nitrogen and the resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes to afford compound 4.
Step-4: Deprotection of Alloc
To a solution of resin compound 4 in DCM (10 vol), tetrakis (0.5 equiv) and phenylsilane (20 equiv) were added and the mixture was shook for 15 minutes and degassed with nitrogen. The reaction mixture was pushed out with nitrogen and the process was repeated once again. The resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes.
API coupling: To a mixture of (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(aminomethyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide (3 equiv), DMF (10 vol), DIPC (3 equiv) and HOBt (3 equiv) were added and the resin was shook for 6 hours at room temperature. The reaction mixture was pushed out with nitrogen and the resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times) again. The resulting resin was dried for 15 minutes to afford compound 5.
Step-5: Cleavage of Resin
Resin (compound 5) was treated with scavenger solution (TFA:TIPS:H2O; 9.5:0.25:0.25, 10 vol) and shook for 4 hours. the scavenger solution was filtered and the resin was washed with TFA (2 vol) and concentrated. The crude product was purified by preparative purification to afford Compound 443. 1H NMR (400 MHz, DMSO-d6) δ 12.08 (s, 2H), 10.31 (s, 1H), 9.21-9.20 (m, 1H), 9.00 (s, 2H), 8.12-8.00 (m, 4H), 7.98-7.96 (m, 2H), 7.56-7.55 (m, 2H), 7.42-7.41 (m, 2H), 7.00-6.98 (m, 3H), 6.55-6.54 (m, 3H), 6.00 (d, J=18.0 Hz, 1H), 5.65 (d, J=18.0 Hz, 1H), 4.44-4.43 (m, 2H), 4.21-4.20 (m, 4H), 3.63-3.62 (m, 1H), 3.00-2.98 (m, 4H), 2.81-2.80 (m, 10H), 2.32-2.31 (m, 10H), 1.98-1.97 (m, 10H), 1.56-1.55 (m, 12H), 1.21-1.10 (m, 37H), 1.11-1.10 (m, 1H), 0.98-0.97 (m, 1H).
Figure US11708351-20230725-C01242
Step-1: Perfluorophenyl 2,2,2-trifluoroacetate Coupling
To a mixture of compound 1 (1 equiv), DMF (10 vol), pyridine (5 equiv), and perfluorophenyl 2,2,2-trifluoroacetate (1.2 equiv) were added and the resin was shook for 16 hours at room temperature. The reaction mixture was pushed out with nitrogen and the resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times). The resulting resin was dried for 15 minutes to afford compound 2.
Step-2: API Coupling
A mixture of (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-(77-amino-3-oxo-6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75-tetracosaoxa-2-azaheptaheptacontyl)-N-(6-bromo-3-methylpyridin-2-yl)-2-azabicyclo[3.1.0]hexane-3-carboxamide hydrochloride (1.2 equiv), DMF (10 vol) and DIPEA (5 equiv) were added to the above resin (compound 2) and the resin was shook for 16 hours at room temperature. The reaction mixture was pushed out with nitrogen and the resin was washed with DMF (5 times), DCM (5 times) and DMF (5 times). The resulting resin was dried for 15 minutes to afford compound 3.
Step-3: Cleavage of Resin
Resin (compound 3) was treated with scavenger solution (TFA:TIPS:H2O; 9.5:0.25:0.25, 10 vol) and shook for 4 hours. The scavenger solution was filtered and the resin was washed with TFA (2 vol) and concentrated. The crude product was purified by preparative purification to afford Compound 535.
Example 9. Non-Limiting Examples of Compounds of the Present Invention I
Table 6, Table 7, and Table 8 show illustrative Factor D inhibitors with characterizing data. The assay of Example 10 was used to determine the IC50's of the compounds. Other standard factor D inhibition assays are also available. Three ***s are used to denote compounds with an IC50 less than 1 micromolar; two **s indicate compound with an IC50 between 1 micromolar and 10 micromolar, and one * denotes compounds with an IC50 greater than 10 micromolar.
TABLE 6
Non-limiting Examples of Compounds of the Present Invention
RT min
(Method
Cmp A, B, C MS
No. Structure Name IC50 or D) (M + 1)
1
Figure US11708351-20230725-C01243
 		*** 12.55 (D) 580 (M − 1)
2
Figure US11708351-20230725-C01244
 		(1S,3aS,6aR)-2- (2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)octahydro- cyclo- penta[c]pyrrole- 1-carboxamide **  3.52 (B) 602
3
Figure US11708351-20230725-C01245
 		(1s,4s)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[2.2.2] octane-3- carboxamide ***  3.07 (B) 616
4
Figure US11708351-20230725-C01246
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(piperidin- 1-ylmethyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.66 (B) 685
5
Figure US11708351-20230725-C01247
 		(3S)-5-(6- azaspiro[2.5]octan- 6-ylmethyl)-2- (2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.82 (B) 711
6
Figure US11708351-20230725-C01248
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- (azetidin-1- ylmethyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.57 (B) 657
7
Figure US11708351-20230725-C01249
 		(2S,4R)-1- ((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-4- fluoropyrrolidine- 2-carbonyl)-N- (6- bromopyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide **  1.68 (A) 695
8
Figure US11708351-20230725-C01250
 		*** 13.19 (C) 570
9
Figure US11708351-20230725-C01251
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethyl- amino)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.17 (B) 645
10
Figure US11708351-20230725-C01252
 		(1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethyl- amino)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide **  2.35 (B) 645
11
Figure US11708351-20230725-C01253
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((hexahydro- cyclopenta[c]pyrrol- 2(1H)- yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  0.36 (B) 711
12
Figure US11708351-20230725-C01254
 		(3S)-5-(3- azabicyclo[3.1.1] heptan-3- ylmethyl)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.63 (B) 697
13
Figure US11708351-20230725-C01255
 		(3S)-5-(2- azaspiro[3.3]heptan- 2-ylmethyl)- 2-(2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.58 (B) 697
14
Figure US11708351-20230725-C01256
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- isopropylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.06 (A) 630
15
Figure US11708351-20230725-C01257
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.71 (A) 605
16
Figure US11708351-20230725-C01258
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N- (cuban-1- ylmethyl)-4- fluoropyrrolidine- 2-carboxamide ** 10.52 (D) 541
17
Figure US11708351-20230725-C01259
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N- ((E)-2-fluoro-3- phenylbut-2-en- 1-yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.08 (A) 581
18
Figure US11708351-20230725-C01260
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 12.76 (C) 605 (M + 2)
19
Figure US11708351-20230725-C01261
 		(2S,4R)-1-(2-(3- acetyl-7- ((dimethyl- amino)methyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide ***  2.31 (B) 637
20
Figure US11708351-20230725-C01262
 		(2S,4R)-1-(2-(3- acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide ***  3.29 (B) 612
21
Figure US11708351-20230725-C01263
 		(2S,4R)-1-(2-(3- acetyl-7-((5- methylpyrimidin- 2-yl)methyl)-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide ***  3.18 (B) 686
22
Figure US11708351-20230725-C01264
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(piperazin- l-ylmethyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.77 (B) 686
23
Figure US11708351-20230725-C01265
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (cyanomethyl)- pyridin-2-yl)-4- fluoropyrrolidine- 2-carboxamide ***  1.50 (A) 619
24
Figure US11708351-20230725-C01266
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((4- methylpiperazin- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.70 (B) 700
25
Figure US11708351-20230725-C01267
 		methyl 3-acetyl- 1-(2-((2S,4R)-2- ((6- bromopyridin-2- yl)carbamoyl)-4- fluoropyrrolidin- 1-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazole-7- carboxylate ***  1.94 (A) 638
26
Figure US11708351-20230725-C01268
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- (aminomethyl)- N-(6-bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide **  2.49 (B) 617
27
Figure US11708351-20230725-C01269
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.01 (A) 634
28
Figure US11708351-20230725-C01270
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(3- chloro-2- fluorobenzyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 11.61 (C) 590
29
Figure US11708351-20230725-C01271
 		(1S,3S,5R)-2-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((allyloxy)- methyl)-N-(3- ((allyloxy)- methyl)-6- bromopyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.28 (A) 714
30
Figure US11708351-20230725-C01272
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide  3.69 (B) 620
31
Figure US11708351-20230725-C01273
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.48 (B) 634
32
Figure US11708351-20230725-C01274
 		(3S)-2-(2-(3- acetyl-7- (methoxymethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5- (methoxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.47 (B) 662
33
Figure US11708351-20230725-C01275
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(2- fluoro-3- (trifluoro- methoxy)phenyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 13.96 (C) 625
34
Figure US11708351-20230725-C01276
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N- ((S)-3-fluoro-4- methylpent-3-en- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide *** 10.92 (D) 547
35
Figure US11708351-20230725-C01277
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-N-(1- (2,2,2- trifluoroethyl)- 1H-pyrazol-3- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 10.92 (D) 595
36
Figure US11708351-20230725-C01278
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-N-(6- (trifluoromethyl) pyridin-2-yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 12.55 (D) 592
37
Figure US11708351-20230725-C01279
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-N-(6- (trifluoro- methoxy)pyridin- 2-yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 14.96 (C) 608
38
Figure US11708351-20230725-C01280
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(2′- chloro-2-fluoro- [1,1′-biphenyl]- 3-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide *** 15.94 (C) 652
39
Figure US11708351-20230725-C01281
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(2'- chloro-2-fluoro- [1,1'-biphenyl]- 3-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide *** 12.84 (D) 636 (M − 1)
40
Figure US11708351-20230725-C01282
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxylic acid *  1.31 (A) 434
41
Figure US11708351-20230725-C01283
 		3-acetyl-1-(2- ((2S,4R)-2-((6- bromopyridin-2- yl)carbamoyl)-4- fluoropyrrolidin- 1-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazole-7- carboxylic acid *** 624
42
Figure US11708351-20230725-C01284
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((methylamino) methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  4.42 (B) 631
43
Figure US11708351-20230725-C01285
 		(1S,3S,5S)-5- (acetamidomethyl)- 2-(2-(3-acetyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide **  3.00 (B) 645
44
Figure US11708351-20230725-C01286
 		(1R,3S,5R)-5- (acetamidomethyl)- 2-(2-(3-acetyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.08 (B) 645
45
Figure US11708351-20230725-C01287
 		methyl ((2S)-1- ((((3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3-((6- bromopyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0] hexan-5- yl)methyl)amino)- 3-methyl-1- oxobutan-2- yl)carbamate ***  3.32 (B) 760
46
Figure US11708351-20230725-C01288
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-5- fluoropyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.77 (B) 620
47
Figure US11708351-20230725-C01289
 		(1R,3S,5R)-2-(2- (3-acetyl-7- ethyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.59 (B) 630
48
Figure US11708351-20230725-C01290
 		methyl ((2S)-1- ((((3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3-((3- bromo-6- (methoxymethyl) pyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0] hexan-5- yl)methyl)amino)- 3-methyl-1- oxobutan-2- yl)carbamate *  3.20 (B) 804
49
Figure US11708351-20230725-C01291
 		(3S)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(3- bromo-6- (methoxymethyl) pyridin-2-yl)-5- (methoxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.07 (B) 662
50
Figure US11708351-20230725-C01292
 		5-(3-acetyl-1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-7- methyl-1H- indazol-5-yl)-2- methylpyrimidine- 1-oxide ***  3.15 (B) 632
51
Figure US11708351-20230725-C01293
 		(3S)-2-(2-(3- acetyl-7-methyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethyl- amino)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide  2.08 (B) 659
52
Figure US11708351-20230725-C01294
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N- ((R)-1-((R)-2,2- dichlorocyclo- propyl)ethyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 11.25 (D) 584
53
Figure US11708351-20230725-C01295
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyrazin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide 11.10 (C) 604
54
Figure US11708351-20230725-C01296
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-5- methylpyrazin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 14.12 (C) 615 (M − 2)
55
Figure US11708351-20230725-C01297
 		1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazole-3- carboxamide ***  8.30 (C) 601 (M − 2)
56
Figure US11708351-20230725-C01298
 		1-(2- ((1R,2S,5S)-2- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-3- azabicyclo[3.1.0] hexan-3-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazole-3- carboxamide ***  8.30 (D) 591 (M + 2)
57
Figure US11708351-20230725-C01299
 		1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazole-3- carboxamide ***  8.84 (C) 619 (M + 2)
58
Figure US11708351-20230725-C01300
 		1-(2- ((1R,3S,5R)-3- ((6- bromopyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazole-3- carboxamide *** 12.45 (C) 605 (M + 2)
59
Figure US11708351-20230725-C01301
 		(2S,4R)-1-(2-(3- acetyl-5-(2- hydroxypyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide  7.92 (D) 597
60
Figure US11708351-20230725-C01302
 		(1R,2S,5S)-3-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3- azabicyclo[3.1.0] hexane-2- carboxylic acid  1.10 (A) 420
61
Figure US11708351-20230725-C01303
 		methyl 2-(2- ((2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-4- fluoropyrrolidine- 2- carboxamido)-6- bromopyridin-3- yl)acetate ***  1.50 (A) 651
62
Figure US11708351-20230725-C01304
 		2-(2-((2S,4R)-1- (2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-4- fluoropyrrolidine- 2- carboxamido)-6- bromopyridin-3- yl)acetic acid ***  1.27 (A) 638
63
Figure US11708351-20230725-C01305
 		3-acetyl-1-(2- ((3S)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-5- ((dimethyl- amino)methyl)-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazole-7- carboxylic acid  2.07 (B) 689
64
Figure US11708351-20230725-C01306
 		5-(3-acetyl-1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-1H- indazol-5-yl)-2- methylpyrimidine- 1-oxide ***  3.06 (B) 618
65
Figure US11708351-20230725-C01307
 		(1R,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (hydroxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.46 (B) 618
66
Figure US11708351-20230725-C01308
 		(2S,4R)-1-(2-(3- acetyl-7-methyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-4-fluoro-4- (fluoromethyl)- pyrrolidine-2- carboxamide ***  2.88 (B) 640
67
Figure US11708351-20230725-C01309
 		(1R,3S,5R)-5-(2- azaspiro[3.3]heptan- 2-ylmethyl)- 2-(2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.78 (B) 697
68
Figure US11708351-20230725-C01310
 		(1S,3S,5S)-5-(2- azaspiro[3.3]heptan- 2-ylmethyl)- 2-(2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.71 (B) 697
69
Figure US11708351-20230725-C01311
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((4- methylpiperazin- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.56 (B) 714
70
Figure US11708351-20230725-C01312
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((allyl(methyl)- amino)methyl)-N- (3- ((allyloxy)- methyl)-6- bromopyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.35 (A) 727
71
Figure US11708351-20230725-C01313
 		(1R,2S,5S)-N- (6-bromo-3- methylpyridin-2- yl)-3-(2-(3-(1- hydroxyethyl)-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3- azabicyclo[3.1.0] hexane-2- carboxamide **  1.33 (A) 592
72
Figure US11708351-20230725-C01314
 		(1R,3S,5R)-N- (6-bromo-3- methylpyridin-2- yl)-2-(2-(3-(1- hydroxyethyl)-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide **  1.52 (A) 604
73
Figure US11708351-20230725-C01315
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(3- bromoisoquinolin- 1-yl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.04 (A) 638
74
Figure US11708351-20230725-C01316
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.19 (B) 677
75
Figure US11708351-20230725-C01317
 		(1S,3S,5S)-2-(2- (3-acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.28 (B) 677
76
Figure US11708351-20230725-C01318
 		(2S,4R)-1-(2-(3- acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-4-fluoro-4- (fluoromethyl)- pyrrolidine-2- carboxamide ***  3.22 (B) 658
77
Figure US11708351-20230725-C01319
 		(1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-7- (trifluoromethyl)- 1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *  3.66 (B) 670
78
Figure US11708351-20230725-C01320
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5-((4- acetylpiperazin- 1-yl)methyl)-N- (6-bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.69 (B) 728
79
Figure US11708351-20230725-C01321
 		(1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5-((4- acetylpiperazin- 1-yl)methyl)-N- (6-bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide **  3.74 (B) 728
80
Figure US11708351-20230725-C01322
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N- (3,3- dimethylbutyl)- 5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 11.05 (D) 531
81
Figure US11708351-20230725-C01323
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-N-(2- (trifluoro- methoxy)ethyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 10.79 (D) 559
82
Figure US11708351-20230725-C01324
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- methoxypyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide *** 11.79 (D) 554
83
Figure US11708351-20230725-C01325
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-4- fluoro-N-(6- hydroxypyridin- 2-yl)pyrrolidine- 2-carboxamide **  6.71 (C) 518
84
Figure US11708351-20230725-C01326
 		(2S,4R)-1-(2-(3- acetyl-5-(2-((1,1- dioxidothietan-3- yl)oxy)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-4- fluoropyrrolidine- 2-carboxamide ***  8.16 (C) 698 (M − 2)
86
Figure US11708351-20230725-C01327
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (methoxymethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(3- bromo-6- (methoxymethyl) pyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *  3.24 (B) 676
88
Figure US11708351-20230725-C01328
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(piperazin- 1-ylmethyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.03 (B) 700
89
Figure US11708351-20230725-C01329
 		(1R,3S,5R)-5-(2- azaspiro[3.3]heptan- 2-ylmethyl)- 2-(2-(3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.55 (B) 711
90
Figure US11708351-20230725-C01330
 		(1S,3S,5S)-2-(2- (3-acetyl-7- cyclopropyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.81 (B) 642
91
Figure US11708351-20230725-C01331
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- ((dimethylamino)- methyl)pyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.15 (A) 645
92
Figure US11708351-20230725-C01332
 		(1R,2S,5S)-3- ((1R,2S,5S)-3- (2-(3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3- azabicyclo[3.1.0] hexane-2- carbonyl)-N-(6- bromo-3- methylpyridin-2- yl)-3- azabicyclo[3.1.0] hexane-2- carboxamide **  1.77 (A) 713
93
Figure US11708351-20230725-C01333
 		(1R,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((allyloxy)- methyl)- N-(6-bromo-3- vinylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.01 (A) 670
94
Figure US11708351-20230725-C01334
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((methylamino) methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.06 (B) 645
95
Figure US11708351-20230725-C01335
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2- fluorocyclopent- 1-ene-1- carboxamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.47 (B) 743
96
Figure US11708351-20230725-C01336
 		(1R,3S,5R)-5- (acetamidomethyl)- 2-(2-(3-acetyl- 7-methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.96 (B) 673
97
Figure US11708351-20230725-C01337
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2- fluorobenzamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.52 (B) 753
98
Figure US11708351-20230725-C01338
 		(1R,3S,5S)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (methoxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.26 (B) 646
99
Figure US11708351-20230725-C01339
 		methyl ((S)-1- ((((1R,3S,5R)-2- (2-(3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0] hexan-5- yl)methyl)amino)- 3-methyl-1- oxobutan-2- yl)carbamate ***  3.36 (B) 788
100
Figure US11708351-20230725-C01340
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.55 (B) 659
101
Figure US11708351-20230725-C01341
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (methylsulfon- amidomethyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.47 (B) 709
102
Figure US11708351-20230725-C01342
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((3,3,3- trifluoro- propanamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.45 (B) 741
103
Figure US11708351-20230725-C01343
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- ((dimethylamino)- methyl)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.28 (A) 645
104
Figure US11708351-20230725-C01344
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.76 (A) 621
105
Figure US11708351-20230725-C01345
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- hydroxypyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  8.61 (D) 540
106
Figure US11708351-20230725-C01346
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- hydroxypyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  8.16 (C) 603 (M − 1)
107
Figure US11708351-20230725-C01347
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- ((1,1- dioxidothietan-3- yl)oxy)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  9.30 (C) 706 (M − 2)
108
Figure US11708351-20230725-C01348
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methoxypyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 12.23 (D) 606 (M + 2)
109
Figure US11708351-20230725-C01349
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- hydroxypyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  9.82 (D) 588 (M − 2)
110
Figure US11708351-20230725-C01350
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- ((1,1- dioxidothietan-3- yl)oxy)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *** 10.49 (C) 692 (M − 2)
111
Figure US11708351-20230725-C01351
 		(1R,2S,5S)-3-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3- azabicyclo[3.1.0] hexane-2- carboxylic acid *  1.23 (A) 434
112
Figure US11708351-20230725-C01352
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- cyclopropyl- pyridin-2-yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide hexane-3- carboxamide ***  2.37 (B) 671
113
Figure US11708351-20230725-C01353
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(((2- fluoroethyl)- amino)methyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.21 (B) 677
114
Figure US11708351-20230725-C01354
 		(1R,3S,5S)-2-(2- (3-acetyl-7- (methoxymethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (methoxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.36 (B) 676
115
Figure US11708351-20230725-C01355
 		(1R,2S,5S)-N- (6-bromo-3- methylpyridin-2- yl)-3-(2-(3-(1- hydroxyethyl)-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3- azabicyclo[3.1.0] hexane-2- carboxamide **  1.47 (A) 604
116
Figure US11708351-20230725-C01356
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-4- fluoropyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.31 (A) 620
117
Figure US11708351-20230725-C01357
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3-(2- (dimethylamino)- 2- oxoethyl)- pyridin-2-yl)-4- fluoropyrrolidine- 2-carboxamide ***  1.33 (A) 665
118
Figure US11708351-20230725-C01358
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((diethylamino) methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.76 (B) 687
119
Figure US11708351-20230725-C01359
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (((3aR,6aS)- hexahydrocyclo- penta[c]pyrrol- 2(1H)- yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.82 (B) 711
120
Figure US11708351-20230725-C01360
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- (methylamino)- pyrimidin-5-yl)- 1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.77(A) 617
121
Figure US11708351-20230725-C01361
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- hydroxypyrimidin- 5-yl)-7- methyl-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.52 (A) 617
122
Figure US11708351-20230725-C01362
 		(1S,3S,5S)-2-(2- (3-acetyl-7- (fluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide  2.06 (A) 633
123
Figure US11708351-20230725-C01363
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- vinylpyridin-2- yl)-5-((hex-5-en- 1- yl(methyl)amino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.47 (A) 725
124
Figure US11708351-20230725-C01364
 		(1R,3S,5R)-2-(2- (3-acetyl-7- cyano-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.94 (A) 629
125
Figure US11708351-20230725-C01365
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- (dimethylamino) pyrimidin-5-yl)- 1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.13 (A) 631
126
Figure US11708351-20230725-C01366
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxylic acid *  1.42 (A) 448
127
Figure US11708351-20230725-C01367
 		(1R,3S,5R)-5-(2- oxa-6- azaspiro[3.3]- heptan-6- ylmethyl)- 2-(2-(3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.35 (B) 713
128
Figure US11708351-20230725-C01368
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (((3aR,6aS)- hexahydro- cyclopenta[c]pyrrol- 2(1H)- yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.90 (B) 725
129
Figure US11708351-20230725-C01369
 		(1R,3S,5R)-5-(2- azaspiro[3.4]- octan-2-ylmethyl)- 2- (2-(3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.78 (B) 725
130
Figure US11708351-20230725-C01370
 		(1R,3S,5R)-2-(2- (3-acetyl-4- fluoro-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.41 (B) 620
131
Figure US11708351-20230725-C01371
 		(1R,5R)-2-(2-(3- acetyl-7- cyclopropyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.66 (B) 642
132
Figure US11708351-20230725-C01372
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((ethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.31 (B) 659
133
Figure US11708351-20230725-C01373
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-7- (trifluoromethyl)- 1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.72 (B) 670
134
Figure US11708351-20230725-C01374
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(3- ((allyloxy)- methyl)-6- bromopyridin-2- yl)-5-vinyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.15 (A) 670
135
Figure US11708351-20230725-C01375
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- chloro-3- ((dimethylamino)- methyl)pyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.12 (A) 601
136
Figure US11708351-20230725-C01376
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- ((dimethylamino)- methyl)pyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.24 (A) 659
137
Figure US11708351-20230725-C01377
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- chloro-3- ((dimethylamino)- methyl)pyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.21 (A) 615
138
Figure US11708351-20230725-C01378
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (morpholino- methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.21 (A) 687
139
Figure US11708351-20230725-C01379
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- chloro-3- (morpholino- methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.19 (A) 643
140
Figure US11708351-20230725-C01380
 		(1R,3S,5R)-N- (6-bromo-3- methylpyridin-2- yl)-2-(2-(3-(1- hydroxyethyl)-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.63 (A) 618
141
Figure US11708351-20230725-C01381
 		(1R,2S,5S)-3-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-3- azabicyclo[3.1.0] hexane-2- carboxamide ***  1.46 (A) 589
142
Figure US11708351-20230725-C01382
 		(1R,3S,5R)-5-(2- azaspiro[3.4]octan- 2-ylmethyl)-2- (2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.49 (B) 711
143
Figure US11708351-20230725-C01383
 		(1R,3S,5R)-2-(2- (3-acetyl-7- cyano-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.59 (B) 670
144
Figure US11708351-20230725-C01384
 		(1S,3S,5S)-2-(2- (3-acetyl-7- cyano-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide **  2.65 (B) 670
145
Figure US11708351-20230725-C01385
 		1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-4- fluoro-5-(2- methylpyrimidin- 5-yl)-1H- indazole-3- carboxamide ***  2.40 (B) 621
146
Figure US11708351-20230725-C01386
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (difluoromethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.72 (B) 652
147
Figure US11708351-20230725-C01387
 		(1R,3S,5R)-2-(2- (3-acetyl-7- fluoro-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.92 (A) 620
148
Figure US11708351-20230725-C01388
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- (2- (dimethylamino)- 2- oxoethyl)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.66 (A) 673
149
Figure US11708351-20230725-C01389
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- (azetidin-1- ylmethyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.34 (B) 671
150
Figure US11708351-20230725-C01390
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((3,3- difluoroazetidin- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.46 (B) 707
151
Figure US11708351-20230725-C01391
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((cyclopropyl- amino)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.82 (B) 657
152
Figure US11708351-20230725-C01392
 		(1R,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (methoxymethyl) pyridin-2-yl)-5- (methoxymethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.33 (B) 662
153
Figure US11708351-20230725-C01393
 		methyl ((S)-1- ((((1R,3S,5R)-2- (2-(3-acetyl-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-3-((6- bromo-3- (methoxymethyl) pyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0] hexan-5- yl)methyl)amino)- 3-methyl-1- oxobutan-2- yl)carbamate ***  2.95 (B) 804
154
Figure US11708351-20230725-C01394
 		(1R,3S,5S)-2-(2- (3-acetyl-7-allyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((allyloxy)methyl)- N-(6-bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  3.71 (B) 698
155
Figure US11708351-20230725-C01395
 		(1R,3S,5R)-2-(2- (3-acetyl-4- fluoro-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.33 (B) 663
156
Figure US11708351-20230725-C01396
 		(1S,3S,5S)-2-(2- (3-acetyl-4- fluoro-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide *  2.51 (B) 663
157
Figure US11708351-20230725-C01397
 		(1R,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2- (dimethylamino) ethoxy)methyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.08 (A) 688
158
Figure US11708351-20230725-C01398
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2,2- difluorocyclo- pentane-1- carboxamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.87 (A) 762
159
Figure US11708351-20230725-C01399
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2,2- difluorocyclo- pentane-1- carboxamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.79 (A) 748
160
Figure US11708351-20230725-C01400
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2,2,2- trifluoroethyl)- amino)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.70 (A) 712
161
Figure US11708351-20230725-C01401
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((benzylamino)- methyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.36 (A) 720
162
Figure US11708351-20230725-C01402
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (cyanomethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.65 (A) 640
163
Figure US11708351-20230725-C01403
 		(1R,3S,5S)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (fluoromethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.77 (A) 633
164
Figure US11708351-20230725-C01404
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((3- hydroxyazetidin- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.05 (A) 686
165
Figure US11708351-20230725-C01405
 		(1R,3S,5R)-5- (acetamidomethyl)- 2-(2-(3-acetyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (methoxymethyl) pyridin-2-yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.36 (A) 688
166
Figure US11708351-20230725-C01406
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (methoxymethyl) pyridin-2-yl)-5- ((dimethylamino)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.02 (A) 674
167
Figure US11708351-20230725-C01407
 		(1R,3S,5R)-2-(2- (3-acetyl-7- ((dimethylamino)- methyl)-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.27 (A) 658
168
Figure US11708351-20230725-C01408
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((2,2,2- trifluoro- acetamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.89 (A) 726
169
Figure US11708351-20230725-C01409
 		(1R,3S,5R)-2-(2- (3-acetyl-7- (methoxymethyl)- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (methoxymethyl) pyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.01 (A) 675
170
Figure US11708351-20230725-C01410
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(((2- fluorobenzyl)- amino)methyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.35 (A) 738
171
Figure US11708351-20230725-C01411
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- vinylpyridin-2- yl)-5-((but-3-en- 1- ylsulfonamido)- methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.85 (A) 748
172
Figure US11708351-20230725-C01412
 		(1R,2S,5S)-3-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-3- azabicyclo[3.1.0] hexane-2- carboxamide ***  1.55 (A) 607
173
Figure US11708351-20230725-C01413
 		(1R,3S,5S)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N3-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3,5- dicarboxamide *  3.02 (B) 645
174
Figure US11708351-20230725-C01414
 		(1R,3S,5S)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-cyano-2- azabicyclo[3.1.0] hexane-3- carboxamide *  3.35 (B) 627
175
Figure US11708351-20230725-C01415
 		(2S,4S)-1-(2-(3- acetyl-7-methyl- 5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-4- (trifluoromethyl) pyrrolidine-2- carboxamide ***  3.36 (B) 658
176
Figure US11708351-20230725-C01416
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((bis(2- fluoroethyl)- amino)methyl)- N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.48 (B) 723
177
Figure US11708351-20230725-C01417
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3-((3,3- difluoroazetidin- 1- yl)methyl)pyridin- 2-yl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.83 (A) 693
178
Figure US11708351-20230725-C01418
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.87 (A) 620
179
Figure US11708351-20230725-C01419
 		(1R,3S,5R)-2-(2- (3-acetyl-7-(2- fluoro-1- hydroxyethyl)-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.70 (B) 604
180
Figure US11708351-20230725-C01420
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrazolo[1, 5-a]pyrimidin- 6-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.04 (A) 641
181
Figure US11708351-20230725-C01421
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- b]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide  1.70 (A) 603
182
Figure US11708351-20230725-C01422
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- b]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.79 (A) 621
183
Figure US11708351-20230725-C01423
 		(1R,2S,5S)-3-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- b]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-3- azabicyclo[3.1.0] hexane-2- carboxamide ***  1.47 (A) 589
184
Figure US11708351-20230725-C01424
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[4,3- b]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide **  1.55 (A) 603
185
Figure US11708351-20230725-C01425
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[4,3- b]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide **  1.64 (A) 621
187
Figure US11708351-20230725-C01426
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- (difluoromethyl)- 4- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.04 (A) 652
188
Figure US11708351-20230725-C01427
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- vinylpyridin-2- yl)-5-(((N- methylbut-3-en- 1- yl)sulfonamido) methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.01 (A) 761
189
Figure US11708351-20230725-C01428
 		(1R,3S,5S)-2-(2- (3-acetyl-7-(but- 3-en-1-yl)-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- ((allyloxy)methyl)- N-(6-bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.36 (A) 711
190
Figure US11708351-20230725-C01429
 		(1R,3S,5R)-2-(2- (3-acetyl-7-(1- fluoroethyl)-5- (2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.05 (A) 647
191
Figure US11708351-20230725-C01430
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-7-(oxetan- 3-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide
192
Figure US11708351-20230725-C01431
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- (morpholino- methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.10 (A) 688
193
Figure US11708351-20230725-C01432
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methoxypyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.84 (A) 619
194
Figure US11708351-20230725-C01433
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- aminopyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.49 (A) 604
195
Figure US11708351-20230725-C01434
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- aminopyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.58 (A) 622
196
Figure US11708351-20230725-C01435
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-N-(3- methyl-6- (trifluoromethoxy)- pyridin-2-yl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.04 (A) 608
197
Figure US11708351-20230725-C01436
 		(1R,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-(oxazol-5- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.55 (A) 655
198
Figure US11708351-20230725-C01437
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methoxypyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.92 (A) 637
199
Figure US11708351-20230725-C01438
 		1-(2- ((1R,3S,5R)-3- ((6-bromo-5- fluoro-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridine-3- carboxamide ***  1.39 (A) 623
200
Figure US11708351-20230725-C01439
 		5-(3-acetyl-1-(2- ((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0] hexan-2-yl)-2- oxoethyl)-1H- pyrazolo[3,4- c]pyridin-5-yl)- 2- methylpyrimidin e 1-oxide ***  2.97 (B) 619
201
Figure US11708351-20230725-C01440
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((4- cyclopropyl-1H- 1,2,3-triazol-1- yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.65 (A) 709
202
Figure US11708351-20230725-C01441
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((4- (trimethylsilyl)- 1H-1,2,3-triazol- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.99 (A) 741
203
Figure US11708351-20230725-C01442
 		(1R,3S,5R)-5- ((1H-1,2,3- triazol-1- yl)methyl)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.41 (A) 669
204
Figure US11708351-20230725-C01443
 		(1R,3S,5R)-N- (3-(2-oxa-6- azaspiro[3.3]heptan- 6-ylmethyl)- 6-bromopyridin- 2-yl)-2-(2-(3- acetyl-5-(2- methylpyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.16 (A) 699
205
Figure US11708351-20230725-C01444
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] ***  1.78 (A) 617
206
Figure US11708351-20230725-C01445
 		(1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (((3aR,6aS)- hexahydrocyclo- penta[c]pyrrol- 2(1H)- yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.15 (B) 712
207
Figure US11708351-20230725-C01446
 		(1S,3S,5S)-5- ((2- azaspiro[3.4]- octan-2- yl)methyl)- 2-(2-(3-acetyl-5- (2- met-hylpyrimidin 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  2.16 (B) 712
208
Figure US11708351-20230725-C01447
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- (oxetan-3- yloxy)pyrimidin- 5-yl)-1H- indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  9.30 (D) 676 (M + 2)
209
Figure US11708351-20230725-C01448
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-5-fluoro- 3-methylpyridin- 2-yl)-5-methyl- 2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.86 (A) 635
210
Figure US11708351-20230725-C01449
 		(1R,3S,5R)-2-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[4,3- b]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *  1.80 (A) 617
211
Figure US11708351-20230725-C01450
 		1-(2-((2S,4R)-2- ((6- bromopyridin-2- yl)carbamoyl)-4- fluoropyrrolidin- 1-yl)-2- oxoethyl)-5- (pyridin-3-yl)- 1H-pyrazole-3- carboxamide ***  0.97 (A) 516
212
Figure US11708351-20230725-C01451
 		(1R,3S,5R)-N- (6-bromo-3- methylpyridin-2- yl)-2-(2-(3- carbamoyl-5- (furan-2-yl)-1H- pyrazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.56 (A) 527
213
Figure US11708351-20230725-C01452
 		(1R,3S,5R)-N- (6-bromo-3- methylpyridin-2- yl)-2-(2-(5- carbamoyl-3- (furan-2-yl)-1H- pyrazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide **  1.67(A) 527
214
Figure US11708351-20230725-C01453
 		(1R,3S,5R)-N- (6-bromo-3- methylpyridin-2- yl)-2-(2-(3- carbamoyl-5- (thiophen-2-yl)- 1H-pyrazol-1- yl)acetyl)-5- methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.65 (A) 543
215
Figure US11708351-20230725-C01454
 		1-(2-((2S,4R)-2- ((6- broyl)carbamoyl)-4-mopyridin-2- fluoropyrrolidin- 1-yl)-2- oxoethyl)-5-(2- methylpyrimidin- 5-yl)-1H- pyrazole-3- carboxamide *  1.15 (A) 531
216
Figure US11708351-20230725-C01455
 		1-(2-((2S,4R)-2- ((6- bromopyridin-2- yl)carbamoyl)-4- fluoropyrrolidin- 1-yl)-2- oxoethyl)-3-(2- methylpyrimidin- 5-yl)-1H- pyrazole-5- carboxamide **  1.04 (A) 531
217
Figure US11708351-20230725-C01456
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-7- (trifluoromethyl)- 2H-indazol-2- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide *  3.62 (B) 670
218
Figure US11708351-20230725-C01457
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-((3,3- difluoroazetidin- 1-yl)methyl)-2- azabicyclo[3.1.0] hexane-3- carboxamide
219
Figure US11708351-20230725-C01458
 		(1R,3S,5R)-2-(2- (3-acetyl-5-(2- methyl- pyrazolo[1,5- a]pyrimidin- 6-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0] hexane-3- carboxamide ***  1.94 (A) 642
231
Figure US11708351-20230725-C01459
 		(1S,3S,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (cyanomethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide  2.45 (B) 628
232
Figure US11708351-20230725-C01460
 		(1S,3R,5S)-2-(2- (3-acetyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-5- (cyanomethyl)- 2- azabicyclo[3.1.0] hexane-3- carboxamide  2.34 (B) 628
233
Figure US11708351-20230725-C01461
 		(1R,2S,5S)-3-(2- (3-acetyl-7- methyl-5-(2- methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2- yl)-3- azabicyclo[3.1.0] hexane-2- carboxamide  1.58 (A) 603
TABLE 7
Additional Non-limiting Examples of Compounds of the Present Invention
RT
Cmp IC5 min MS
No. Structure Name (Stars) (A, B, C or D) (M + 1)
234
Figure US11708351-20230725-C01462
 		(1S,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((3,3-difluoroazetidin- 1-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide
235
Figure US11708351-20230725-C01463
 		(1S,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (fluoromethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.06 (B) 621
237
Figure US11708351-20230725-C01464
 		(1R,3S,5R)-2-(2-(3- acetyl-7-(1,2- difluoroethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.12 (B) 666
238
Figure US11708351-20230725-C01465
 		(1R,3S,5R)-2-(2-(3- acetyl-7-(2-fluoro-1- hydroxyethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.70 (B) 664
239
Figure US11708351-20230725-C01466
 		(1S,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (cyanomethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 2.45 (B) 628
240
Figure US11708351-20230725-C01467
 		(1S,3R,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (cyanomethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 2.34 (B) 628
241
Figure US11708351-20230725-C01468
 		(1R,2S,5S)-3-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 1.58 (A) 603
245
Figure US11708351-20230725-C01469
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (((3aR,6aS)- hexahydrocyclo- penta[c]pyrrol-2(1H)- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.44 (B) 712
246
Figure US11708351-20230725-C01470
 		(1R,3S,5R)-5-(2- azaspiro[3.4]octan-2- ylmethyl)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.49 (B) 712
247
Figure US11708351-20230725-C01471
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((4-cyclopropyl-1H- 1,2,3-triazol-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.56 (A) 710
248
Figure US11708351-20230725-C01472
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-((bis(2-hydroxy- ethyl)amino)methyl)- N-(6-bromo-5-fluoro-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.11 (B) 724
249
Figure US11708351-20230725-C01473
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-(cyanomethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.04 (B) 646
250
Figure US11708351-20230725-C01474
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-((3,3- difluoroazetidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.07 (B) 712
251
Figure US11708351-20230725-C01475
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-(fluoromethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.88 (B) 639
252
Figure US11708351-20230725-C01476
 		(1R,3S,5R)-5-(2- azaspiro[3.4]octan-2- ylmethyl)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.32 (B) 730
253
Figure US11708351-20230725-C01477
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-(((3aR,6aS)- hexahydrocyclo- penta[c]pyrrol-2(1H)- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.26 (B) 730
254
Figure US11708351-20230725-C01478
 		5-(3-acetyl-1-(2- ((1R,3S,5R)-3-((6- bromo-5-fluoro-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)- 1H-pyrazolo[3,4- c]pyridin-5-yl)-2- methylpyrimidine 1- oxide *** 2.50 (B) 637
255
Figure US11708351-20230725-C01479
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-((2- fluoroethoxy)meth- yl)pyridin-2-yl)-5-methyl- 2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.77 (A) 666
256
Figure US11708351-20230725-C01480
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-N-(3- methyl-6- (trifluoromethoxy)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.93 (A) 609
257
Figure US11708351-20230725-C01481
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-((S)-3-fluoro-4- methylpent-3-en-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.16 (A) 533
258
Figure US11708351-20230725-C01482
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- isobutylpyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.05 (A) 645
259
Figure US11708351-20230725-C01483
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-((R)-1-((R)-2,2- dichlorocyclo- propyl)ethyl)-5-methyl- 2-azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.11 (A) 569
260
Figure US11708351-20230725-C01484
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (fluoromethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.95 (B) 621
261
Figure US11708351-20230725-C01485
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((3,3-difluoroazetidin- 1-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.47 (B) 694
262
Figure US11708351-20230725-C01486
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-((bis(2-hydroxy- ethyl)amino)methyl)- N-(6-bromo- 3-methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.34 (B) 706
263
Figure US11708351-20230725-C01487
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-5-fluoro-3- methylpyridin-2-yl)-5- ((dimethylamino)meth- yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.56 (B) 677
264
Figure US11708351-20230725-C01488
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5- ((dimethylamino)meth- yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.33 (B) 664
265
Figure US11708351-20230725-C01489
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-((3,4- dihydroisoquinolin- 2(1H)- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.46 (A) 734
269
Figure US11708351-20230725-C01490
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-7- (trifluoromethyl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.54 (B) 671
270
Figure US11708351-20230725-C01491
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((3-hydroxyazetidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.84 (B) 674
271
Figure US11708351-20230725-C01492
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-7- (trifluoromethyl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.68 (B) 689
272
Figure US11708351-20230725-C01493
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((E)- (hydroxyimino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.37 (B) 632
273
Figure US11708351-20230725-C01494
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- cyano-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.87 (B) 614
274
Figure US11708351-20230725-C01495
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (cyanomethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.43 (B) 628
275
Figure US11708351-20230725-C01496
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methoxypyrimidin-5- yl)-7-methyl-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.96 (A) 633
277
Figure US11708351-20230725-C01497
 		(1R,3S,5R)-N-(3-(2- oxa-5- azabicyclo[2.2.1]heptan- 5-ylmethyl)-6- bromopyridin-2-yl)-2- (2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.14 (A) 700
278
Figure US11708351-20230725-C01498
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- (methoxymethyl)py- rimidin-5-yl)-1H- indazol-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.77 (A) 632
279
Figure US11708351-20230725-C01499
 		(1R,3R,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 2.23 (A) 601
280
Figure US11708351-20230725-C01500
 		(1S,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.22 (A) 601
281
Figure US11708351-20230725-C01501
 		(1S,3R,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 2.14 (A) 601
282
Figure US11708351-20230725-C01502
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((S)-1,2- dihydroxyethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.77 (B) 649
283
Figure US11708351-20230725-C01503
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((S)-2-oxo-1,3- dioxolan-4-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide 2.45 (B) 675
284
Figure US11708351-20230725-C01504
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ethyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.28 (B) 617
285
Figure US11708351-20230725-C01505
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((S)-2,2-dimethyl-1,3- dioxolan-4-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.38 (B) 689
286
Figure US11708351-20230725-C01506
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ethyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.22 (B) 616
287
Figure US11708351-20230725-C01507
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (2-(S-methyl- sulfonimidoyl)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.56 (B) 707
288
Figure US11708351-20230725-C01508
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5-(2- (methylsulfonyl)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.96 (B) 708
289
Figure US11708351-20230725-C01509
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- ((3,3,5,5- tetramethylmorpho- lino)methyl)pyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.91 (A) 744
290
Figure US11708351-20230725-C01510
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2-(3- hydroxyoxetan-3- yl)pyrimidin-5-yl)-7- methyl-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.15 (A) 673
291
Figure US11708351-20230725-C01511
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2-(3- fluorooxetan-3- yl)pyrimidin-5-yl)-7- methyl-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.41 (A) 675
292
Figure US11708351-20230725-C01512
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(7- methyl-5-(2- methylpyrimidin-5- yl)-3-(oxetan-3-yl)- 1H-indazol-1- yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.07 (A) 629
293
Figure US11708351-20230725-C01513
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2-fluoro-6- methylpyridin-3-yl)- 1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.09 (A) 620
294
Figure US11708351-20230725-C01514
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2-(methoxy- methyl)pyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.66 (A) 633
295
Figure US11708351-20230725-C01515
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (methoxymethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.04 (B) 633
296
Figure US11708351-20230725-C01516
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (pyrrolidin-1- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.23 (B) 685
297
Figure US11708351-20230725-C01517
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((isopropyl- amino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.91 (B) 673
298
Figure US11708351-20230725-C01518
 		methyl (((1R,3S,5R)- 2-(2-(3-acetyl-7- methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0]hexan- 5-yl)methyl)-L- prolinate *** 2.92 (B) 743
299
Figure US11708351-20230725-C01519
 		(((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-2- azabicyclo[3.1.0]hexan- 5-yl)methyl)-L- proline *** 2.85 (B) 729
300
Figure US11708351-20230725-C01520
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((tert- butylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.16 (B) 687
301
Figure US11708351-20230725-C01521
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((2-fluoro- ethoxy)methyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.89 (A) 664
302
Figure US11708351-20230725-C01522
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((2,2,6,6- tetramethylpiperidin- 1-yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
303
Figure US11708351-20230725-C01523
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(5- methylpyrazin-2-yl)- 1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.91 (A) 603
304
Figure US11708351-20230725-C01524
 		(2S,4R)-4-((1H-1,2,3- triazol-1-yl)methyl)-1- (2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoropyrrolidine-2- carboxamide *** 3.03 (B) 675
305
Figure US11708351-20230725-C01525
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (morpholinomethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.03 (B) 703
306
Figure US11708351-20230725-C01526
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (4,4- difluoropiperidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.95 (B) 737
307
Figure US11708351-20230725-C01527
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((tert- butylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.26 (B) 675
308
Figure US11708351-20230725-C01528
 		(1R,3S,5R)-N-(3-(2- azabicyclo[2.2.1]heptan- 2-ylmethyl)-6- bromopyridin-2-yl)-2- (2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
309
Figure US11708351-20230725-C01529
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (1-isopropyl-1H-1,2,3- triazol-4-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.71 (A) 699
310
Figure US11708351-20230725-C01530
 		(1R,3S,5R)-5-((1H- pyrazol-1-yl)methyl)- 2-(2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.62 (A) 670
311
Figure US11708351-20230725-C01531
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((3-(tert-butyl)-1H- pyrazol-1-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.22 (A) 726
312
Figure US11708351-20230725-C01532
 		(1R,3S,5R)-5-((1H- 1,2,4-triazol-1- yl)methyl)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.36 (A) 671
313
Figure US11708351-20230725-C01533
 		(1R,3S,5R)-5-((1H- 1,2,4-triazol-1- yl)methyl)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.27 (A) 672
314
Figure US11708351-20230725-C01534
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((4-methyl-1H- imidazol-1-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.12 (A) 684
315
Figure US11708351-20230725-C01535
 		(1R,3R,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((4-methyl-1H- imidazol-1-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.19 (A) 684
316
Figure US11708351-20230725-C01536
 		(1R,3S,5R)-2-(2-(3- acetyl-7-ethyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((dimethylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.17 (B) 675
319
Figure US11708351-20230725-C01537
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (3-fluoropropyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.05 (B) 651
320
Figure US11708351-20230725-C01538
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((dimethylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.23 (B) 648
321
Figure US11708351-20230725-C01539
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-((4- fluoro-4- methylpiperidin-1- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.26 (A) 718
322
Figure US11708351-20230725-C01540
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((4-fluoro-4- methylpiperidin-1- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
323
Figure US11708351-20230725-C01541
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-(3- fluoropropyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
324
Figure US11708351-20230725-C01542
 		(1R,3S,5R)-2-(2-(3- acetyl-7-cyclopropyl- 5-(2-methylpyrimidin- 5-yl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.07 (A) 643
325
Figure US11708351-20230725-C01543
 		(1R,3S,5R)-2-(2-(3- acetyl-7-(1,2- difluoroethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((dimethylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.09 (B) 709
326
Figure US11708351-20230725-C01544
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (2-fluoroethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.31 (B) 635
327
Figure US11708351-20230725-C01545
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (3,3-difluoropropyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.56 (B) 667
328
Figure US11708351-20230725-C01546
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (2,2-difluoroethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.37 (B) 653
330
Figure US11708351-20230725-C01547
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2-((3,3- difluoropiperidin-1- yl)methyl)pyrimidin- 5-yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.65 (A) 722
331
Figure US11708351-20230725-C01548
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2,4- dimethylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.81 (A) 618
332
Figure US11708351-20230725-C01549
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-N-(3- methyl-6- (trifluoromethoxy)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.03 (A) 623
333
Figure US11708351-20230725-C01550
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (3-isopropylisoxazol- 5-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.13 (A) 699
334
Figure US11708351-20230725-C01551
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.91 (A) 589
335
Figure US11708351-20230725-C01552
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromopyrazin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.71 (A) 592
336
Figure US11708351-20230725-C01553
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromopyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.02 (A) 603
337
Figure US11708351-20230725-C01554
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromopyrazin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.82 (A) 604
338
Figure US11708351-20230725-C01555
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((4-(tert-butyl)thiazol- 2-yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.40 (A) 741
339
Figure US11708351-20230725-C01556
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((4-ethylthiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.99 (A) 713
340
Figure US11708351-20230725-C01557
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-N-(3- methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.82 (A) 593
341
Figure US11708351-20230725-C01558
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-N-(3- methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.92 (A) 607
342
Figure US11708351-20230725-C01559
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (((3-fluoro- propyl)amino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.62 (B) 691
344
Figure US11708351-20230725-C01560
 		(1R,3S,5R)-5-(2- azaspiro[3.3]heptan-2- ylmethyl)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.71 (B) 712
345
Figure US11708351-20230725-C01561
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5-(3- (dimethylamino)propyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.61 (B) 705
346
Figure US11708351-20230725-C01562
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-(azetidin-1- ylmethyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.31 (B) 672
347
Figure US11708351-20230725-C01563
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (pyrrolidin-1- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.29 (B) 686
348
Figure US11708351-20230725-C01564
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((dimethylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.56 (B) 660
349
Figure US11708351-20230725-C01565
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((5-isopropylthiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.20 (A) 729
350
Figure US11708351-20230725-C01566
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((3,3- dimethylazetidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.47 (B) 699
351
Figure US11708351-20230725-C01567
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (pyrrolidin-1- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.28 (B) 703
352
Figure US11708351-20230725-C01568
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((3,3- dimethylazetidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.25 (B) 700
353
Figure US11708351-20230725-C01569
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-(azetidin- 1-ylmethyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.46 (B) 689
354
Figure US11708351-20230725-C01570
 		(1R,3S,5R)-5-(2- azaspiro[3.3]heptan-2- ylmethyl)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.26 (B) 729
355
Figure US11708351-20230725-C01571
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((3,3- dimethylazetidin-1- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.95 (B) 717
356
Figure US11708351-20230725-C01572
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-((3- (trifluoromethyl)-5,6- dihydro- [1,2,4]triazolo[4,3- a]pyrazin-7(8H)- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
357
Figure US11708351-20230725-C01573
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((3- (trifluoromethyl)-5,6- dihydro- [1,2,4]triazolo[4,3- a]pyrazin-7(8H)- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
359
Figure US11708351-20230725-C01574
 		(1R,3S,5R)-5-((1,3,4- oxadiazol-2- yl)methyl)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.87 (B) 684
360
Figure US11708351-20230725-C01575
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((5-methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.98 (B) 698
361
Figure US11708351-20230725-C01576
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridine-3- carboxamide *** 2.50 (B) 604
362
Figure US11708351-20230725-C01577
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-(5-isopropyl- 1,3,4-oxadiazol-2- yl)pyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.93 (A) 700
363
Figure US11708351-20230725-C01578
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methoxypyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.80 (A) 620
364
Figure US11708351-20230725-C01579
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((3- fluoroazetidin-1- yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.74 (B) 675
365
Figure US11708351-20230725-C01580
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- (cyanomethyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.39 (B) 641
366
Figure US11708351-20230725-C01581
 		(1R,3S,5R)-5-(5- azaspiro[2.3]hexan-5- ylmethyl)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.74 (B) 697
367
Figure US11708351-20230725-C01582
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-2- (2-(3-(cyanomethyl)- 5-(2-methylpyrimidin- 5-yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 3.05 (B) 599
368
Figure US11708351-20230725-C01583
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-2- (2-(3-(2-cyanopropan- 2-yl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 3.74 (B) 627
369
Figure US11708351-20230725-C01584
 		(1R,3S,5R)-5-(5- azaspiro[2.3]hexan-5- ylmethyl)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.65 (B) 715
370
Figure US11708351-20230725-C01585
 		(1R,3S,5R)-5-(5- azaspiro[2.3]hexan-5- ylmethyl)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.67 (B) 698
371
Figure US11708351-20230725-C01586
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (((4,5-dihydrooxazol- 2-yl)amino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.53 (B) 687
372
Figure US11708351-20230725-C01587
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.00 (B) 698
373
Figure US11708351-20230725-C01588
 		(1R,3S,5R)-2-(2-(3- acetyl-6-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.89 (A) 616
374
Figure US11708351-20230725-C01589
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-((5- butyl-1,3,4-oxadiazol- 2-yl)methyl)pyridin-2- yl)-5-vinyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.04 (A) 741
375
Figure US11708351-20230725-C01590
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-(1,2- dihydroxyethyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.19 (B) 649
376
Figure US11708351-20230725-C01591
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (2,3- dihydroxypropyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.44 (B) 663
377
Figure US11708351-20230725-C01592
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5-(2- (dimethylamino)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.42 (B) 691
378
Figure US11708351-20230725-C01593
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (4-(dimethyl- amino)butyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.24 (B) 719
380
Figure US11708351-20230725-C01594
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-(3- (dimethylamino)propyl)- N-(3-methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.95 (B) 695
381
Figure US11708351-20230725-C01595
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-(2,2- dimethyl-1,3- dioxolan-4-yl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.29 (B) 689
382
Figure US11708351-20230725-C01596
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- propyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.40 (B) 631
383
Figure US11708351-20230725-C01597
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-(2-oxo- 1,3-dioxolan-4- yl)pyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.70 (B) 675
384
Figure US11708351-20230725-C01598
 		(1R,3S,5S)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- ((difluoro- methoxy)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.86 (B) 669
385
Figure US11708351-20230725-C01599
 		(1R,3R,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- isobutyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 3.55 (B) 645
386
Figure US11708351-20230725-C01600
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- chloropyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.35 (B) 622
387
Figure US11708351-20230725-C01601
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(5-(2- methylpyrimidin-5- yl)-3-vinyl-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.78 (A) 586
388
Figure US11708351-20230725-C01602
 		(1R,2S,5S)-3-(2-(3- acetyl-7-isopropyl-5- (2-methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 2.01 (A) 633
389
Figure US11708351-20230725-C01603
 		(1R,3S,5R)-2-(2-(3- (1H-imidazole-2- carbonyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 8.79 (D) 656 (M + 2)
390
Figure US11708351-20230725-C01604
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(7- methyl-5-(2- methylpyrimidin-5- yl)-3-(2- azaspiro[3.3]heptane- 2-carbonyl)-1H- indazol-1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 11.51  (D) 695 (M − 2)
393
Figure US11708351-20230725-C01605
 		(1R,2S,5S)-3-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 1.73 (A) 623
394
Figure US11708351-20230725-C01606
 		(1R,3S,5R)-2-(2-(3- acetyl-6-methoxy-5- (2-methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.88 (A) 632
395
Figure US11708351-20230725-C01607
 		methyl 3-acetyl-1-(2- ((1R,3S,5R)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-indazole-6- carboxylate *** 1.87 (A) 660
396
Figure US11708351-20230725-C01608
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(3-((bis(3,3,3-trifluoro- propyl)amino)methyl)-6- bromopyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.62 (A) 810
397
Figure US11708351-20230725-C01609
 		(1R,3S,5R)-N-(3- ((2H-tetrazol-5- yl)methyl)-6- bromopyridin-2-yl)-2- (2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.94 (B) 671
398
Figure US11708351-20230725-C01610
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- (2-oxopropyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.77 (B) 645
399
Figure US11708351-20230725-C01611
 		(1R,3S,5R)-2-(2-(3- acetyl-6-chloro-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((dimethyl- amino)methyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.77 (B) 679
400
Figure US11708351-20230725-C01612
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3-(3- morpholinopropyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.48 (B) 716
401
Figure US11708351-20230725-C01613
 		(1R,3S,5R)-N-(6- bromo-5-fluoro-3- methylpyridin-2-yl)-2- (2-(3-(1- hydroxyethyl)-7- methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.62 (A) 636
402
Figure US11708351-20230725-C01614
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-2- (2-(3-(1- hydroxyethyl)-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.42 (A) 607
407
Figure US11708351-20230725-C01615
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-2- (2-(3-cyano-7-methyl- 5-(2-methylpyrimidin- 5-yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 11.21  (D) 601 (M + 2)
408
Figure US11708351-20230725-C01616
 		(1R,3S,5R)-2-(2-(3- acetyl-7-chloro-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((dimethyl- amino)methyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.00 (B) 679
409
Figure US11708351-20230725-C01617
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.92 (B) 716
410
Figure US11708351-20230725-C01618
 		(2S,4R)-1-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-4- fluoro-4-(fluoro- methyl)pyrrolidine- 2-carboxamide *** 3.02 (B) 641
411
Figure US11708351-20230725-C01619
 		(1R,2S,5S)-3-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(3-chloro-2- fluorobenzyl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 3.29 (B) 576
412
Figure US11708351-20230725-C01620
 		(1R,2S,5S)-3-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- chloro-2- fluorobenzyl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 3.28 (B) 561
413
Figure US11708351-20230725-C01621
 		(1R,2S,5S)-3-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- chloro-2- fluorobenzyl)-3- azabicyclo[3.1.0]hexane- 2-carboxamide *** 3.41 (B) 575
415
Figure US11708351-20230725-C01622
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5-((di- isopropylamino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.81 (B) 715
416
Figure US11708351-20230725-C01623
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.70 (A) 603
417
Figure US11708351-20230725-C01624
 		(2S,4R)-1-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 4-fluoro-4- (fluoromethyl)pyrrolidine- 2-carboxamide *** 3.11 (B) 659
418
Figure US11708351-20230725-C01625
 		(2S,4R)-1-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromopyrazin-2- yl)-4-fluoro-4- (fluoromethyl)pyrrolidine- 2-carboxamide *** 3.13 (B) 628
419
Figure US11708351-20230725-C01626
 		(2S,4S)-4-((1H-1,2,3- triazol-1-yl)methyl)-1- (2-(3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoropyrrolidine-2- carboxamide *** 2.97 (B) 675
420
Figure US11708351-20230725-C01627
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- ((dimethylamino)methyl)-4- fluoropyrrolidine-2- carboxamide ** 2.16 (B) 651
421
Figure US11708351-20230725-C01628
 		(2S,4S)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoro-4-(methoxy- methyl)pyrrolidine- 2-carboxamide *** 3.22 (B) 638
422
Figure US11708351-20230725-C01629
 		(2S,4S)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoro-4-(fluoro- methyl)pyrrolidine- 2-carboxamide *** 2.67 (B) 626
423
Figure US11708351-20230725-C01630
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.44 (B) 717
424
Figure US11708351-20230725-C01631
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-5-fluoro-3- methylpyridin-2-yl)-5- ((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.54 (B) 716
425
Figure US11708351-20230725-C01632
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-((3- methyl-1,2,4- oxadiazol-5- yl)methyl)-N-(3- methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.66 (B) 688
426
Figure US11708351-20230725-C01633
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.78 (A) 615
427
Figure US11708351-20230725-C01634
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- chloro-2- fluorobenzyl)-5-((3- methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.62 (B) 671
428
Figure US11708351-20230725-C01635
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- chloropyridin-2-yl)-5- ((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.35 (B) 720
429
Figure US11708351-20230725-C01636
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (fluoromethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- ((5-methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.22 (B) 716
430
Figure US11708351-20230725-C01637
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoro-4- methylpyrrolidine-2- carboxamide *** 3.18 (B) 608
431
Figure US11708351-20230725-C01638
 		1-(2-((1R,3S,5R)-3- ((6-bromo-5-fluoro-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-7- methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridine-3- carboxamide *** 1.55 (A) 636
432
Figure US11708351-20230725-C01639
 		(2S,4R)-1-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-4- fluoro-4- methylpyrrolidine-2- carboxamide *** 2.84 (B) 623
433
Figure US11708351-20230725-C01640
 		(2S,4R)-1-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-4- fluoro-4- methylpyrrolidine-2- carboxamide *** 2.96 (B) 622
434
Figure US11708351-20230725-C01641
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- chloro-2- fluorobenzyl)-5-((5- methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.15 (B) 671
435
Figure US11708351-20230725-C01642
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-((5- methyl-1,3,4- oxadiazol-2- yl)methyl)-N-(3- methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.27 (B) 688
436
Figure US11708351-20230725-C01643
 		1-(2-((1R,2S,5S)-2- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-3- azabicyclo[3.1.0]hexan- 3-yl)-2-oxoethyl)-7- methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridine-3- carboxamide *** 1.30 (A) 604
437
Figure US11708351-20230725-C01644
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrrolo[2,3- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.46 (A) 602
438
Figure US11708351-20230725-C01645
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6-bromo- 5-fluoro-3-((methyl- thio)methyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
439
Figure US11708351-20230725-C01646
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-4-fluoro-N- (6-iodopyridin-2- yl)pyrrolidine-2- carboxamide *** 2.93 (B) 628
440
Figure US11708351-20230725-C01647
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-4-fluoro-N- (pyridin-2- yl)pyrrolidine-2- carboxamide *** 1.63 (B) 502
441
Figure US11708351-20230725-C01648
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- (((1-(2,2,2- trifluoroethyl)-1H- pyrazol-3- yl)amino)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.23 (B) 779
444
Figure US11708351-20230725-C01649
 		(2S,4R)-N-(6- bromopyridin-2-yl)-4- fluoro-1-(2-(5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)pyrrolidine- 2-carboxamide ** 2.68 (B) 538
445
Figure US11708351-20230725-C01650
 		(2S,4R)-N-(6- bromopyridin-2-yl)-1- (2-(3-ethyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-4- fluoropyrrolidine-2- carboxamide ** 3.18 (B) 566
446
Figure US11708351-20230725-C01651
 		(2S,4R)-1-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromopyridin-2-yl)-4- fluoro-N- methylpyrrolidine-2- carboxamide * 3.05 (B) 594
447
Figure US11708351-20230725-C01652
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromopyrazin-2-yl)-5- ((3-methyl-1,2,4- oxadiazol-5- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.33 (B) 685
448
Figure US11708351-20230725-C01653
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-5-methyl-N- (3-methyl-6-(trifluoro- methoxy)pyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.04 (A) 621
449
Figure US11708351-20230725-C01654
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (6-(pyridin-2- yloxy)pyridin-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.16 (B) 617
450
Figure US11708351-20230725-C01655
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (5-methyl-[2,2′- bipyridin]-6-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 2.31 (B) 601
451
Figure US11708351-20230725-C01656
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-oxo-2H-[1,2′- bipyridin]-6′-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.00 (B) 617
452
Figure US11708351-20230725-C01657
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(pyridin-4- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.26 (B) 587
453
Figure US11708351-20230725-C01658
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(5- methylpyridin-2-yl)- 1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.20 (B) 601
454
Figure US11708351-20230725-C01659
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-4- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide 3.36 (B) 603
455
Figure US11708351-20230725-C01660
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-4- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.48 (B) 617
456
Figure US11708351-20230725-C01661
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.50 (B) 616
457
Figure US11708351-20230725-C01662
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-N-(6- bromo-5-fluoro-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.89 (B) 619
458
Figure US11708351-20230725-C01663
 		((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-L- leucine *** 2.98 (B) 561
459
Figure US11708351-20230725-C01664
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-5-methyl-N- (3-methyl-6- (trifluoromethyl)pyridin- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.92 (A) 605
460
Figure US11708351-20230725-C01665
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-oxo-2H-[1,2′- bipyridin]-3-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.35 (B) 617
461
Figure US11708351-20230725-C01666
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(2-bromo-5- fluoropyridin-4-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 3.48 (B) 607
462
Figure US11708351-20230725-C01667
 		((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-D- phenylalanine ** 3.50 (B) 595
463
Figure US11708351-20230725-C01668
 		((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-L- phenylalanine 3.48 (B) 595
464
Figure US11708351-20230725-C01669
 		((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-D- leucine ** 3.30 (B) 561
465
Figure US11708351-20230725-C01670
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(5-(2- methylpyrimidin-5- yl)-3-(2,2,2- trifluoroacetyl)-1H- indol-1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.51 (B) 655
466
Figure US11708351-20230725-C01671
 		(1R,3S,5R)-2-(2-(3- acetyl-6-fluoro-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.28 (B) 620
467
Figure US11708351-20230725-C01672
 		methyl 1-(2- ((1R,3S,5R)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-indazole-3- carboxylate ***
468
Figure US11708351-20230725-C01673
 		(1R,3S,5R)-2- ((1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
469
Figure US11708351-20230725-C01674
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-indazole-3- carboxylic acid * 1.52 (A) 604
470
Figure US11708351-20230725-C01675
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(5-(2- methylpyrimidin-5- yl)-3-(2,2,2- trifluoroacetyl)-1H- pyrrolo[2,3-c]pyridin- 1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.67 (B) 656
471
Figure US11708351-20230725-C01676
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrrolo[2,3- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.95 (B) 634
472
Figure US11708351-20230725-C01677
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrrolo[2,3- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.88 (B) 616
473
Figure US11708351-20230725-C01678
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-4- fluoropyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.68 (B) 621
474
Figure US11708351-20230725-C01679
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- ethyl-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide *** 1.71 (A) 631
481
Figure US11708351-20230725-C01680
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- fluoropyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.03 (B) 607
482
Figure US11708351-20230725-C01681
 		(1R,3S,5R)-2-(2-(3- acetyl-6-fluoro-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.34 (B) 619
483
Figure US11708351-20230725-C01682
 		(1R,3S,5R)-2-(2-(3- acetyl-2-methyl-5-(2- methylpyrimidin-5- yl)-1H-indol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.29 (B) 615
484
Figure US11708351-20230725-C01683
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-5-fluoro-3- methylpyridin-2-yl)-5- ((5-methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.04 (B) 716
485
Figure US11708351-20230725-C01684
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-5-fluoro- 3-methylpyridin-2-yl)- 5-((5-methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.97 (B) 717
486
Figure US11708351-20230725-C01685
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- chloropyridin-2-yl)-5- ((5-methyl-1,3,4- oxadiazol-2- yl)methyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.92 (B) 720
487
Figure US11708351-20230725-C01686
 		1-(2-((1R,3S,5R)-5- methyl-3- (propylcarbamoyl)-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-N-propyl-1H- indazole-3- carboxamide ** 1.57 (A) 518
488
Figure US11708351-20230725-C01687
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-butyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.67 (A) 489
492
Figure US11708351-20230725-C01688
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.49 (B) 602
493
Figure US11708351-20230725-C01689
 		2-((1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamido)-6- bromoisonicotinic acid *** 3.37 (B) 632
494
Figure US11708351-20230725-C01690
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methoxy-5- (2-methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.39 (B) 632
495
Figure US11708351-20230725-C01691
 		((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)glycine ** 2.88 (B) 505
496
Figure US11708351-20230725-C01692
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- methyl-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide *** 1.31 (A) 461
497
Figure US11708351-20230725-C01693
 		3-((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane-3- carboxamido)propanoic acid *** 2.92 (B) 519
498
Figure US11708351-20230725-C01694
 		4-((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane-3- carboxamido)butanoic acid *** 3.09 (B) 533
501
Figure US11708351-20230725-C01695
 		(1R,3S,5R)-2- ((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carbonyl)-N- (3,6-dimethylpyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
502
Figure US11708351-20230725-C01696
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2-(3- chloro-2- fluorophenyl)propan- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.31 (A) 617
503
Figure US11708351-20230725-C01697
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- carbamoylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.80 (B) 631
504
Figure US11708351-20230725-C01698
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4- (benzyloxy)-6- bromopyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.42 (B) 694
505
Figure US11708351-20230725-C01699
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(1,3- diphenylpropan-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 3.87 (B) 641
506
Figure US11708351-20230725-C01700
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-ethyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.42 (A) 474
507
Figure US11708351-20230725-C01701
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- propyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.58 (A) 488
508
Figure US11708351-20230725-C01702
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-butyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.77 (A) 502
509
Figure US11708351-20230725-C01703
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- pentyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.94 (A) 516
510
Figure US11708351-20230725-C01704
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N- (cyclopropylmethyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.64 (A) 500
511
Figure US11708351-20230725-C01705
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- neopentyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide 1.92 (A) 516
512
Figure US11708351-20230725-C01706
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-isobutyl- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.75 (A) 502
513
Figure US11708351-20230725-C01707
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N,5- dimethyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
514
Figure US11708351-20230725-C01708
 		2-(2-((1R,3S,5R)-2-(2- (3-acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamido)-6- bromopyridin-4- yl)acetic acid *** 3.23 (B) 646
516
Figure US11708351-20230725-C01709
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- propylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 4.10 (B) 630
517
Figure US11708351-20230725-C01710
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2,6- dimethylheptan-4-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.30 (B) 573
518
Figure US11708351-20230725-C01711
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- aminopropyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 0.89 (A) 489
519
Figure US11708351-20230725-C01712
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N-(3- (methylamino)propyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 0.91 (A) 503
520
Figure US11708351-20230725-C01713
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- (dimethylamino)propyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 0.93 (A) 517
521
Figure US11708351-20230725-C01714
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- propyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.48 (A) 474
522
Figure US11708351-20230725-C01715
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- pentyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.86 (A) 502
523
Figure US11708351-20230725-C01716
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- neopentyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.81 (A) 502
524
Figure US11708351-20230725-C01717
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-benzyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.74 (A) 522
525
Figure US11708351-20230725-C01718
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-hexyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.12 (A) 530
526
Figure US11708351-20230725-C01719
 		(1R,3S,5R)-2-(2-(3- acetyl-7- (hydroxymethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.68 (A) 632
529
Figure US11708351-20230725-C01720
 		(3-acetyl-1-(2- ((1R,3S,5R)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-indazol-7- yl)methyl acetate *** 1.95 (A) 674
532
Figure US11708351-20230725-C01721
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4-ethylpyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.71 (B) 616
533
Figure US11708351-20230725-C01722
 		2-((1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamido)-2- phenethyl-4- phenylbutanoic acid * 3.96 (B) 713
534
Figure US11708351-20230725-C01723
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4-(2- amino-2-oxoethyl)-6- bromopyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.81 (B) 645
536
Figure US11708351-20230725-C01724
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- phenethyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.94 (A) 550
537
Figure US11708351-20230725-C01725
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (3-phenylpropyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.03 (A) 564
541
Figure US11708351-20230725-C01726
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- isopropylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.93 (B) 630
542
Figure US11708351-20230725-C01727
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- isobutylpyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.45 (B) 644
543
Figure US11708351-20230725-C01728
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- cyanopyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.95 (B) 613
544
Figure US11708351-20230725-C01729
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4-(1H-tetrazol- 5-yl)pyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.65 (B) 656
545
Figure US11708351-20230725-C01730
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- isopentylpyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.65 (B) 658
546
Figure US11708351-20230725-C01731
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- (methoxymethyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 3.68 (B) 632
547
Figure US11708351-20230725-C01732
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- phenylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.45 (B) 664
548
Figure US11708351-20230725-C01733
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- phenethylpyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.45 (B) 692
549
Figure US11708351-20230725-C01734
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4-butylpyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 4.53 (B) 644
550
Figure US11708351-20230725-C01735
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4- (trifluoromethyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
551
Figure US11708351-20230725-C01736
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- cyclopropyl-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide *** 1.73 (A) 642
552
Figure US11708351-20230725-C01737
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3,3- dimethylbutyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
553
Figure US11708351-20230725-C01738
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-1-phenylethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
554
Figure US11708351-20230725-C01739
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-1- (trifluoromethoxy)propan- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
555
Figure US11708351-20230725-C01740
 		(1R,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4- benzyl-6- bromopyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
556
Figure US11708351-20230725-C01741
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4-(2- hydroxyphenyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
557
Figure US11708351-20230725-C01742
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4- ((benzyloxy)methyl)- 6-bromopyridin-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
558
Figure US11708351-20230725-C01743
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((R)-1-phenylethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
559
Figure US11708351-20230725-C01744
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((E)-2- fluoro-3-phenylbut-2- en-1-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.14 (A) 581
560
Figure US11708351-20230725-C01745
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-pyrrolo[2,3- c]pyridin-1-yl)acetyl)- N-((E)-2-fluoro-3- phenylbut-2-en-1-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.85 (A) 581
561
Figure US11708351-20230725-C01746
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((E)-2- fluoro-3-phenylbut-2- en-1-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.23 (A) 595
562
Figure US11708351-20230725-C01747
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- isopropyl-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide ** 1.87 (A) 644
563
Figure US11708351-20230725-C01748
 		N-allyl-1-(2- ((1R,3S,5R)-3-((6- bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-1H-indazole-3- carboxamide *** 1.80 (A) 642
564
Figure US11708351-20230725-C01749
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-5- (2-methylpyrimidin-5- yl)-N-(prop-2-yn-1- yl)-1H-indazole-3- carboxamide *** 1.73 (A) 640
565
Figure US11708351-20230725-C01750
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-2- (2-(3-iodo-7-methyl-5- (2-methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.15 (A) 699
566
Figure US11708351-20230725-C01751
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- (1-cyclopropylethyl)- 5-(2-methylpyrimidin- 5-yl)-1H-indazole-3- carboxamide *** 2.07 (A) 670
567
Figure US11708351-20230725-C01752
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- (2-methylbut-3-yn-2- yl)-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide * 1.99 (A) 668
568
Figure US11708351-20230725-C01753
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- (2-cyclopropylpropan- 2-yl)-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide * 2.30 (A) 684
570
Figure US11708351-20230725-C01754
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- (tert-butyl)-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide * 2.14 (A) 658
571
Figure US11708351-20230725-C01755
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-3-((4- (methylsulfonyl)piperidin- 1-yl)methyl)pyridin-2- yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.28 (A) 776
572
Figure US11708351-20230725-C01756
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(6- bromo-4-(2,2,2- trifluoroethyl)pyridin- 2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
573
Figure US11708351-20230725-C01757
 		1-(2-((1R,3S,5R)-3- ((6-bromo-3- methylpyridin-2- yl)carbamoyl)-5- methyl-2- azabicyclo[3.1.0]hexan- 2-yl)-2-oxoethyl)-N- (but-3-yn-2-yl)-5-(2- methylpyrimidin-5- yl)-1H-indazole-3- carboxamide *** 1.87 (A) 654
574
Figure US11708351-20230725-C01758
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-benzyl-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.88 (A) 536
575
Figure US11708351-20230725-C01759
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2- methoxybenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.94 (A) 566
576
Figure US11708351-20230725-C01760
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- methoxybenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.86 (A) 566
577
Figure US11708351-20230725-C01761
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4- methoxybenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.90 (A) 566
578
Figure US11708351-20230725-C01762
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((R)-1- (trifluoromethoxy)propan- 2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide
579
Figure US11708351-20230725-C01763
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl- N-(2-(trifluoro- methoxy)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
580
Figure US11708351-20230725-C01764
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-1-phenylethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.93 (A) 550
581
Figure US11708351-20230725-C01765
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((R)-1-phenylethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.92 (A) 550
582
Figure US11708351-20230725-C01766
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2- fluorobenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.87 (A) 554
583
Figure US11708351-20230725-C01767
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(3- fluorobenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.86 (A) 554
584
Figure US11708351-20230725-C01768
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(4- fluorobenzyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.88 (A) 554
585
Figure US11708351-20230725-C01769
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-methylbenzyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.95 (A) 550
586
Figure US11708351-20230725-C01770
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (3-methylbenzyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.96 (A) 550
587
Figure US11708351-20230725-C01771
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (4-methylbenzyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.96 (A) 550
588
Figure US11708351-20230725-C01772
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-4,4- dimethylpentan-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide **
589
Figure US11708351-20230725-C01773
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((R)-4,4- dimethylpentan-2-yl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
590
Figure US11708351-20230725-C01774
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-1-(3- chloro-2- fluorophenyl)ethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
591
Figure US11708351-20230725-C01775
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyrimidin-2- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.37 (A) 538
592
Figure US11708351-20230725-C01776
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyrimidin-4- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.32 (A) 538
593
Figure US11708351-20230725-C01777
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyrimidin-5- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.31 (A) 538
594
Figure US11708351-20230725-C01778
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyridin-2-ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.24 (A) 537
595
Figure US11708351-20230725-C01779
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyridin-3-ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.15 (A) 537
596
Figure US11708351-20230725-C01780
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyridin-4-ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.13 (A) 537
597
Figure US11708351-20230725-C01781
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (pyridazin-3- ylmethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.26 (A) 538
598
Figure US11708351-20230725-C01782
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-1-(p-tolyl)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide **
599
Figure US11708351-20230725-C01783
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-1-(3- chlorophenyl)ethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
600
Figure US11708351-20230725-C01784
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-1-(2- fluorophenyl)ethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
601
Figure US11708351-20230725-C01785
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((R)-1-(3- chloro-2- fluorophenyl)ethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide ***
602
Figure US11708351-20230725-C01786
 		(1R,3S,5R)-N-(6- bromo-3- methylpyridin-2-yl)-5- methyl-2-(2-(5-(2- methylpyrimidin-5- yl)-3- (methylsulfonyl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide 1.53 (A) 640
603
Figure US11708351-20230725-C01787
 		2-((1R,3S,5R)-2-(2-(3- acetyl-7- (aminomethyl)-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamido)-6- bromoisonicotinic acid *** 1.39 (A) 660
604
Figure US11708351-20230725-C01788
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2- cyclohexylethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 2.29 (A) 556
605
Figure US11708351-20230725-C01789
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-(piperidin-1- yl)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide * 1.23 (A) 557
606
Figure US11708351-20230725-C01790
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-(tetrahydro-2H- pyran-4-yl)ethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.55 (A) 558
607
Figure US11708351-20230725-C01791
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- (2-morpholinoethyl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide ** 1.14 (A) 559
608
Figure US11708351-20230725-C01792
 		(1R,3S,5R)-2-(2-(3- acetyl-7-methyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-(2- cyclopentylethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide 2.14 (A) 542
609
Figure US11708351-20230725-C01793
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-isopentyl- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
610
Figure US11708351-20230725-C01794
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-3-methylbutan-2- yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide
611
Figure US11708351-20230725-C01795
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-3,3- dimethylbutan-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
612
Figure US11708351-20230725-C01796
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-5-methyl-N- ((S)-pentan-2-yl)-2- azabicyclo[3.1.0]hexane- 3-carboxamide
613
Figure US11708351-20230725-C01797
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)- hexan-2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
614
Figure US11708351-20230725-C01798
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)- heptan-2-yl)-5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
615
Figure US11708351-20230725-C01799
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-1-(4- fluorophenyl)ethyl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
616
Figure US11708351-20230725-C01800
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrimidin-5- yl)-1H-indazol-1- yl)acetyl)-N-((S)-1- (2,3-dimethyl- phenyl)ethyl)- 5-methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide
617
Figure US11708351-20230725-C01801
 		(1R,3S,5R)-2-(2-(3- acetyl-5-(2- methylpyrazolo[1,5- a]pyrimidin-6-yl)-1H- pyrazolo[3,4- c]pyridin-1-yl)acetyl)- N-(6-bromo-3- methylpyridin-2-yl)-5- methyl-2- azabicyclo[3.1.0]hexane- 3-carboxamide *** 1.94 (A) 642
TABLE 8
Additional Non-limiting Examples of Compounds of the Present Invention
RT min
Cmp (A, B, C MS
No. Structure and Name IC50 or D) (M + 1)
236
Figure US11708351-20230725-C01802
 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7- (2H-tetrazol-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3- methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane- 3-carboxamide		 ***  3.34 (B)  670
242
Figure US11708351-20230725-C01803
 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3- methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5- yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26-tetraoxo- 5,8,14,17-tetraoxa-2,11,20,25-tetraazatritetracontan-43- oic acid		 *** 15.30 (C) 1334
243
Figure US11708351-20230725-C01804
 (5S,8S)-7-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5- yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin- 2-yl)-3-phenyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-8- carboxamide		 **  3.73 (B)  721
244
Figure US11708351-20230725-C01805
 (8S)-7-(2-(3-acetyl-7-methyl-5-(2-methylpyrimidin-5-yl)- 1H-indazol-1-yl)acetyl)-N-(6-bromo-3-methylpyridin-2- yl)-3-cyclohexyl-1-oxa-2,7-diazaspiro[4.4]non-2-ene-8- carboxamide		 ***  3.82 (B)  727
266
Figure US11708351-20230725-C01806
 (1R,3S,5R)-2-(2-(3-acetyl-7-(but-3-en-1-yl)-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6- bromo-3-methylpyridin-2-yl)-5-(hex-5-enamidomethyl)- 2-azabicyclo[3.1.0]hexane-3-carboxamide		 ***  3.73 (B)  767
317
Figure US11708351-20230725-C01807
 (1R,3S,5R)-2-(2-(3-acetyl-7-cyclopropyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6- bromo-3-methylpyridin-2-yl)-5-((dimethylamino)methyl)- 2-azabicyclo[3.1.0]hexane-3-carboxamide		 ***  2.18 (B)  687
318
Figure US11708351-20230725-C01808
 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7- (trifluoromethyl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3- methylpyridin-2-yl)-5-((dimethylamino)methyl)-2- azabicyclo[3.1.0]hexane-3-carboxamide		 ***  2.39 (B)  715
329
Figure US11708351-20230725-C01809
 (S)-methyl 1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo- 3-methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H-indazol-5- yl)pyrimidin-2-yl)-24-(methoxycarbonyl)-3,12,21,26- tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oate		 *** 14.33 (D) 1363 (M + 2)
343
Figure US11708351-20230725-C01810
 (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-7- (oct-7-en-1-yl)-1H-indazol-1-yl)acetyl)-N-(3-allyl-6- bromopyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane- 3-carboxamide		 ***  4.43 (B)  738
358
Figure US11708351-20230725-C01811
 (S)-methyl 1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6- bromo-3-methylpyridin-2-yl)carbamoyl)-2- azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)- 3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oate		 * 14.18 (D) 1363 (M + 2)
379
Figure US11708351-20230725-C01812
 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5- yl)-1H-indazol-1-yl)acetyl)-3-((6-bromo-3-methylpyridin- 2-yl)carbamoyl)-2-azabicyclo[3.1.0]hexan-5-yl)-24- carboxy-3,12,21,26-tetraoxo-5,8,14,17-tetraoxa- 2,11,20,25-tetraazatritetracontan-43-oic acid		 ***  2.41 (A) 1332
391
Figure US11708351-20230725-C01813
 (S)-methyl 1-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6- bromo-3-methylpyridin-2-yl)carbamoyl)-2- azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)- 3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oate		 *** 13.74 (D) 1377 (M + 2)
392
Figure US11708351-20230725-C01814
 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6- bromo-3-methylpyridin-2-yl)carbamoyl)-2- azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26- tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oic acid		 *** 12.83 (C) 1345 (M − 2)
403
Figure US11708351-20230725-C01815
 (S)-methyl 1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo- 3-methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H- indazol-5-yl)pyrimidin-2-yl)-24-(methoxycarbonyl)- 3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oate		 *** 13.95 (D) 1377 (M + 2)
404
Figure US11708351-20230725-C01816
 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3- methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-7-methyl-1H- indazol-5-yl)pyrimidin-2-yl)-24-carboxy-3,12,21,26- tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oic acid		 *** 13.32 (C) 1349 (M + 2)
405
Figure US11708351-20230725-C01817
 (S)-methyl 1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo- 3-methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24- (methoxycarbonyl)-3,12,21,26-tetraoxo-5,8,14,17- tetraoxa-2,11,20,25-tetraazatritetracontan-43-oate		 *** 14.41 (D) 1364 (M + 2)
406
Figure US11708351-20230725-C01818
 (S)-methyl 1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2- methylpyrimidin-5-yl)-1H-pyrazolo[3,4-c]pyridin-1- yl)acetyl)-3-((6-bromo-3-methylpyridin-2-yl)carbamoyl)- 2-azabicyclo[3.1.0]hexan-5-yl)-24-(methoxycarbonyl)- 3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oate		 *** 13.42 (D) 1364 (M + 2)
414
Figure US11708351-20230725-C01819
 (S)-1-(5-(3-acetyl-1-(2-((1R,3S,5R)-3-((6-bromo-3- methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1H- pyrazolo[3,4-c]pyridin-5-yl)pyrimidin-2-yl)-24-carboxy- 3,12,21,26-tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oic acid		 ***  9.04 (D) 1336 (M + 2)
442
Figure US11708351-20230725-C01820
 (S)-1-((1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5- yl)-1H-pyrazolo[3,4-c]pyridin-1-yl)acetyl)-3-((6-bromo- 3-methylpyridin-2-yl)carbamoyl)-2- azabicyclo[3.1.0]hexan-5-yl)-24-carboxy-3,12,21,26- tetraoxo-5,8,14,17-tetraoxa-2,11,20,25- tetraazatritetracontan-43-oic acid		 ***  4.92 (D) 1336 (M + 2)
443 (Structure is shown below) ** 14.70 1884
(4S,7S,10S,13S,16S,19S,22S)-22-acetamido-4- (C) (M + 2)
((((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-
methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-
bromo-3-methylpyridin-2-yl)carbamoyl)-2-
azabicyclo[3.1.0]hexan-5-yl)methyl)carbamoyl)-10,16-
bis(2-carboxyethyl)-7,19-bis(4-hydroxybenzyl)-
6,9,12,15,18,21-hexaoxo-13-(4-palmitamidobutyl)-
5,8,11,14,17,20-hexaazapentacosanedioic acid
475
Figure US11708351-20230725-C01821
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-propyl-1H- indazole-3-carboxamide		 ***  1.89 (A)  645
476
Figure US11708351-20230725-C01822
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-butyl-5-(2-methylpyrimidin-5-yl)-1H- indazole-3-carboxamide		 ***
477
Figure US11708351-20230725-C01823
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-pentyl-1H- indazole-3-carboxamide		 *  2.26 (A)  673
478
Figure US11708351-20230725-C01824
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-(cyclopropylmethyl)-5-(2- methylpyrimidin-5-yl)-1H-indazole-3-carboxamide		 ***  1.95 (A)  657
479
Figure US11708351-20230725-C01825
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-(cyclobutylmethyl)-5-(2-methylpyrimidin- 5-yl)-1H-indazole-3-carboxamide		 **  2.14 (A)  671
480
Figure US11708351-20230725-C01826
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-neopentyl-1H- indazole-3-carboxamide		 *  2.21 (A)  673
489
Figure US11708351-20230725-C01827
 N-(2-aminoethyl)-1-(2-((1R,3S,5R)-3-((6-bromo-3- methylpyridin-2-yl)carbamoyl)-5-methyl-2- azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-5-(2- methylpyrimidin-5-yl)-1H-indazole-3-carboxamide		 **  1.29 (A)  646
490
Figure US11708351-20230725-C01828
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-(2-(methylamino)ethyl)-5-(2- methylpyrimidin-5-yl)-1H-indazole-3-carboxamide		 **  1.31 (A)  660
491
Figure US11708351-20230725-C01829
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-(2-(dimethylamino)ethyl)-5-(2- methylpyrimidin-5-yl)-1H-indazole-3-carboxamide		 *  1.33 (A)  674
499
Figure US11708351-20230725-C01830
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-5-(2-methylpyrimidin-5-yl)-N-(2,2,2- trifluoroethyl)-1H-indazole-3-carboxamide		 ***
500
Figure US11708351-20230725-C01831
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-isobutyl-5-(2-methylpyrimidin-5-yl)-1H- indazole-3-carboxamide		 ***
515
Figure US11708351-20230725-C01832
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-7-cyano-5-(2-methylpyrimidin-5-yl)-1H- indazole-3-carboxamide		 ***  3.15 (B)  628
527
Figure US11708351-20230725-C01833
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-heptyl- 5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		 ***
528
Figure US11708351-20230725-C01834
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl- N-octyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		 **  2.50 (A)  558
530
Figure US11708351-20230725-C01835
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl- N-nonyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		 **  2.68 (A)  572
531
Figure US11708351-20230725-C01836
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-decyl- 5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide		 *  2.87 (A)  586
535 (Structure is shown below) **   1.51 ( ) 1506
(4S,7S,10S,13S,16S,19S,22S)-22-acetamido-4-((1- ((M + 2)/2)
((1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2-
methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-3-((6-
bromo-3-methylpyridin-2-yl)carbamoyl)-2-
azabicyclo[3.1.0]hexan-5-yl)-3-oxo-
6,9,12,15,18,21,24,27,30,33,36,39,42,45,48,51,54,57,60,63,66,69,72,75-
tetracosaoxa-2-azaheptaheptacontan-77-
yl)carbamoyl)-10,16-bis(2-carboxyethyl)-7,19-bis(4-
hydroxybenzyl)-6,9,12,15,18,21-hexaoxo-13-(4-
palmitamidobutyl)-5,8,11,14,17,20-
hexaazapentacosanedioic acid
538
Figure US11708351-20230725-C01837
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl- N-(4-phenylbutyl)-2-azabicyclo[3.1.0]hexane-3- carboxamide		 ***  2.18 (A)  578
539
Figure US11708351-20230725-C01838
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl- N-(5-phenylpentyl)-2-azabicyclo[3.1.0]hexane-3- carboxamide		 ***  2.34 (A)  592
540
Figure US11708351-20230725-C01839
 (1R,3S,5R)-2-(2-(3-acetyl-7-methyl-5-(2- methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-5-methyl- N-(6-phenylhexyl)-2-azabicyclo[3.1.0]hexane-3- carboxamide		 **  2.49 (A)  606
569
Figure US11708351-20230725-C01840
 1-(2-((1R,3S,5R)-3-((6-bromo-3-methylpyridin-2- yl)carbamoyl)-5-methyl-2-azabicyclo[3.1.0]hexan-2-yl)- 2-oxoethyl)-N-(sec-butyl)-5-(2-methylpyrimidin-5-yl)- 1H-indazole-3-carboxamide		 **  2.05 (A)  658
Figure US11708351-20230725-C01841
Example 10. Human Factor D Assay
Human Factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various concentrations for 5 min at room temperature in 50 mM Tris, 1M NaCl, pH 7.5. A synthetic substrate Z-L-Lys-SBzl and DTNB (Ellman's reagent) are added to final concentrations of 100 μM each. Absorbance at 405 nm (A405) is recorded at 30 second intervals for 30 min using a microplate spectrophotometer. IC50 values are calculated by nonlinear regression of complement Factor D reaction rates as a function of test compound concentration.
Example 11. Hemolysis Assay
The hemolysis assay was previously described by G. Ruiz-Gomez, et al., J. Med. Chem. (2009) 52: 6042-6052. Prior to the assay, the optimum concentration of Normal Human Serum (NHS) needed to achieve 100% lysis of rabbit erythrocytes (RE) is determined by titration. In the assay, NHS (Complement Technology) is diluted in GVB0 Buffer (0.1% gelatin, 5 mM Veronal, 145 mM NaCl, 0.025% NaN3, pH 7.3, Complement Technology) plus 10 mM Mg-EGTA and incubated with test compound at various concentrations for 15 min at 37° C. RE (Complement Technology) freshly suspended in GVB0 plus 10 mM Mg-EGTA are added to a final concentration of 1×108 cells/mL and reactions are incubated for 30 min at 37° C. Positive control reactions (100% lysis) consist of GVB0 plus 10 mM Mg-EGTA with NHS and RE but without test compound; negative control reactions (0% lysis) consist of GVB0 plus 10 mM Mg-EGTA with RE only. Samples are centrifuged at 2000 g for 3 min and supernatants collected. Absorbance at 405 nm (A405) is recorded using a microplate spectrophotometer. IC50 values are calculated by nonlinear regression from the percentage of hemolysis as a function of test compound concentration.
This specification has been described with reference to embodiments of the invention. However, one of ordinary skill in the art appreciates that various modifications and changes can be made without departing from the scope of the invention as set forth in the claims below. Accordingly, the specification is to be regarded in an illustrative rather than a restrictive sense, and all such modifications are intended to be included within the scope of invention.

Claims (17)

What is claimed is:
1. A method of treating a disorder mediated by complement cascade Factor D, the method comprising administering to a subject ion need thereof an effective amount of a compound selected from:
Figure US11708351-20230725-C01842
Figure US11708351-20230725-C01843
Figure US11708351-20230725-C01844
or a pharmaceutically acceptable salt thereof.
2. The method of claim 1, wherein the compound is
Figure US11708351-20230725-C01845
or a pharmaceutically acceptable salt thereof.
3. The method of claim 1, wherein the compound is
Figure US11708351-20230725-C01846
or a pharmaceutically acceptable salt thereof.
4. The method of claim 1, wherein the compound is
Figure US11708351-20230725-C01847
or a pharmaceutically acceptable salt thereof.
5. The method of claim 1, wherein the compound is
Figure US11708351-20230725-C01848
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1, wherein the compound is
Figure US11708351-20230725-C01849
or a pharmaceutically acceptable salt thereof.
7. The method of claim 1, wherein the subject is a human.
8. The method of claim 1, wherein the disorder is selected from acute respiratory distress syndrome, age-related macular degeneration, arthritis, asthma, Alzheimer's dementia, amyotrophic lateral sclerosis, antibody-mediated transplant rejection, antineutrophil cytoplasm antibody-associated vasculitis, antiphospholipid syndrome, atypical or typical hemolytic uremic syndrome, a cardiovascular disease, cold agglutinin disease, chronic obstructive pulmonary disease, cirrhosis, Crohn's disease, C3 glomerulonephritis, diabetic retinopathy, dense deposit disease, dermatomyositis, dermatitis, epidermolysis bullosa acquisita, fatty liver, focal segmental glomerulosclerosis, geographic atrophy, glomerulonephritis, graft versus host disease, Guillain Barre syndrome, hemolytic anemia, hidradenitis suppurativa, IgA nephropathy, ischemia/reperfusion injury, liver failure, liver inflammation, lupus nephritis, membrane proliferative glomerulonephritis, multifocal motor neuropathy, multiple sclerosis, myasthenia gravis, neuromyelitis optica, nonalcoholic steatohepatitis (NASH), an ophthalmic disease, pancreatitis, paroxysmal nocturnal hemoglobinuria, pemphigoid, pemphigus vulgaris, pre-eclampsia, reduced glomerular filtration rate, a renovascular disorder, a respiratory disease, retinal detachment, rheumatoid arthritis, scleroderma, sepsis, shiga toxin E. coli-related hemolytic uremic syndrome, spinal cord injury, sickle cell disease, traumatic brain injury, and ulcerative colitis.
9. The method of claim 8, wherein the disorder is IgA nephropathy.
10. The method of claim 8, wherein the disorder is geographic atrophy.
11. The method of claim 8, wherein the disorder is lupus nephritis.
12. The method of claim 8, wherein the disorder is myasthenia gravis.
13. The method of claim 8, wherein the disorder is reduced glomerular filtration rate.
14. The method of claim 8, wherein the disorder is renovascular disorder.
15. The method of claim 8, wherein the disorder is sickle cell disease.
16. The method of claim 8, wherein the disorder is C3 glomerulonephritis.
17. The method of claim 8, wherein the disorder is dense deposit disease.
US17/366,670 2017-03-01 2021-07-02 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders Active 2038-04-16 US11708351B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17/366,670 US11708351B2 (en) 2017-03-01 2021-07-02 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US18/196,128 US20230357199A1 (en) 2017-03-01 2023-05-11 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762465782P 2017-03-01 2017-03-01
US201762466301P 2017-03-02 2017-03-02
PCT/US2018/020528 WO2018160889A1 (en) 2017-03-01 2018-03-01 Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US16/555,914 US11084800B2 (en) 2017-03-01 2019-08-29 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US17/366,670 US11708351B2 (en) 2017-03-01 2021-07-02 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/555,914 Continuation US11084800B2 (en) 2017-03-01 2019-08-29 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US18/196,128 Continuation US20230357199A1 (en) 2017-03-01 2023-05-11 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Publications (2)

Publication Number Publication Date
US20220396563A1 US20220396563A1 (en) 2022-12-15
US11708351B2 true US11708351B2 (en) 2023-07-25

Family

ID=63370540

Family Applications (3)

Application Number Title Priority Date Filing Date
US16/555,914 Active US11084800B2 (en) 2017-03-01 2019-08-29 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US17/366,670 Active 2038-04-16 US11708351B2 (en) 2017-03-01 2021-07-02 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US18/196,128 Pending US20230357199A1 (en) 2017-03-01 2023-05-11 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/555,914 Active US11084800B2 (en) 2017-03-01 2019-08-29 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
US18/196,128 Pending US20230357199A1 (en) 2017-03-01 2023-05-11 Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Country Status (10)

Country Link
US (3) US11084800B2 (en)
EP (2) EP3985002A1 (en)
JP (3) JP7133561B2 (en)
KR (2) KR20240019857A (en)
CN (1) CN110603252A (en)
AU (2) AU2018227849B2 (en)
CA (1) CA3053818A1 (en)
IL (3) IL294069B2 (en)
MX (2) MX2019010381A (en)
WO (1) WO2018160889A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
IL294069B2 (en) 2017-03-01 2023-11-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
CN112119072A (en) * 2018-03-20 2020-12-22 普莱希科公司 Compounds and methods for IDO and TDO modulation, and indications thereof
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for the treatment of complement factor d medical disorders
US20210330676A1 (en) * 2018-08-22 2021-10-28 Merck Sharp & Dohme Corp. Novel aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
WO2020051532A2 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
BR112021004263A2 (en) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. morphic forms of danicopane
KR20210093855A (en) 2018-09-25 2021-07-28 아칠리온 파르마세우티칼스 인코포레이티드 Conformational forms of complement factor D inhibitors
CN111487398B (en) * 2019-01-25 2022-11-11 四川大学华西医院 Biomarkers for hemangioma treatment
KR20220041121A (en) * 2019-07-31 2022-03-31 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Dihydropyrimidine derivatives and their use in the treatment of HBV infection or HBV-induced disease
CN111592557A (en) * 2020-05-09 2020-08-28 河北合佳医药科技集团股份有限公司 One-step environment-friendly preparation method of 7-amino-3-vinyl cephalosporanic acid
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2024008121A1 (en) * 2022-07-06 2024-01-11 南京明德新药研发有限公司 Difluoro-substituted azabicyclo compounds and uses thereof

Citations (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020099A2 (en) 1992-03-27 1993-10-14 Ferring B.V. Cck and/or gastrin receptor ligands
WO1995029697A1 (en) 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
WO1999048492A1 (en) 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US20020133004A1 (en) 1999-09-03 2002-09-19 Ajinomoto Co. Inc Process for producing new oxazepine derivatives
US6489476B1 (en) 1998-09-09 2002-12-03 Metabasis Therapeutics, Inc. Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
US6492402B1 (en) 1998-12-29 2002-12-10 Lg Life Sciences, Ltd. Thrombin inhibitors
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
WO2004007501A1 (en) 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004111041A1 (en) 2003-06-12 2004-12-23 Fujisawa Pharmaceutical Co., Ltd. Pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-iv (dpp)
US20050228000A1 (en) 2004-04-13 2005-10-13 Smallheer Joanne M Bicyclic heterocycles useful as serine protease inhibitors
US20050245497A1 (en) 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
US20050267108A1 (en) 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
US20060004000A1 (en) 2002-10-02 2006-01-05 Sanofi-Aventis Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
US20070155712A1 (en) 2004-03-24 2007-07-05 Jerini Ag Compounds for the inhibition of angiogenesis and use thereof
US20080075720A1 (en) 2004-02-10 2008-03-27 Holers Vernon M Inhibition of factor B, the alternative complement pathway and methods related thereto
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
WO2008047831A1 (en) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US7629340B2 (en) 2005-12-12 2009-12-08 Smithkline Beecham Corporation N-(6-membered aromatic ring)-amido anti-viral compounds
US20100041628A1 (en) 2007-01-15 2010-02-18 Hiroshi Enomoto Novel indole derivative having ikappab kinase beta inhibitory activity
US7888323B2 (en) 2005-11-28 2011-02-15 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
US7999081B2 (en) 2002-07-11 2011-08-16 Adienne Srl Anti-C5 alpha antibodies
US20110280808A1 (en) 2010-04-16 2011-11-17 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US8241628B2 (en) 2008-08-05 2012-08-14 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
US20120231471A1 (en) 2009-10-16 2012-09-13 Ayumi Sato Marker associated with non-alcoholic steatohepatitis
US20120237515A1 (en) 2006-03-15 2012-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2012177782A1 (en) 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
US8524716B2 (en) 2007-12-24 2013-09-03 Janssen R&D Ireland Macrocyclic indoles as hepatitis C virus inhibitors
US20130296377A1 (en) 2012-05-04 2013-11-07 Christopher Michael ADAMS Complement pathway modulators and uses thereof
WO2013166436A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
US20130344073A1 (en) 2012-06-18 2013-12-26 University Of Leicester Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
WO2013192345A1 (en) 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002067A2 (en) 2012-06-29 2014-01-03 Consiglio Nazionale Delle Ricerche Method of processing optical coherence tomography images
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002057A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014116880A1 (en) 2013-01-23 2014-07-31 Baerbel Rohrer Targeting constructs based on natural antibodies and uses thereof
US20140323407A1 (en) 2011-05-11 2014-10-30 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US20140371133A1 (en) 2011-06-22 2014-12-18 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
WO2015008861A1 (en) 2013-07-19 2015-01-22 大日本住友製薬株式会社 Novel imidazopyridine compound
US8946145B2 (en) 2009-05-01 2015-02-03 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and C-terminal modifications
WO2015021166A2 (en) 2013-08-07 2015-02-12 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome biomarker proteins
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
US20150158915A1 (en) 2011-09-07 2015-06-11 The Trustees Of The University Of Pennsylvania Compstatin Analogs with Improved Pharmacokinetic Properties
US20150239921A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Phosphonate Compounds for Treatment of Complement Mediated Disorders
US20150269868A1 (en) 2012-12-11 2015-09-24 Fluidity Software, Inc. Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
US20150368271A1 (en) 2009-12-31 2015-12-24 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
US20160024079A1 (en) 2013-03-14 2016-01-28 Novartis Ag Complement Factor B inhibitors and uses there of
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US20160215020A1 (en) 2012-11-15 2016-07-28 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US20160215022A1 (en) 2013-03-15 2016-07-28 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
US20170057950A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide Compounds for Treatment of Medical Disorders
WO2017035353A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
US20170056428A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for the Treatment of Medical Disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017098328A2 (en) 2015-12-11 2017-06-15 Lifesci Phamaceuticals, Inc. Therapeutic inhibitory compounds
US20170202935A1 (en) 2012-06-20 2017-07-20 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2017136395A1 (en) 2016-02-01 2017-08-10 Biocryst Pharmaceuticals, Inc. Benzopyrazole compounds and analogues thereof
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018026722A1 (en) 2016-08-01 2018-02-08 Omeros Corporation Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US10092547B2 (en) 2011-05-27 2018-10-09 Achillion Pharmaceuticals, Inc. Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero- heteraphanes and metallocenes useful for treating HCV infections
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019070714A1 (en) 2017-10-04 2019-04-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2021021909A1 (en) 2019-07-31 2021-02-04 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral complement factor d inhibitors
US20220079943A1 (en) 2018-12-17 2022-03-17 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150003903A (en) 2012-05-04 2015-01-09 노파르티스 아게 Complement pathway modulators and uses thereof
JO3425B1 (en) 2013-07-15 2019-10-20 Novartis Ag Piperidinyl indole derivatives and their use as complement factor b inhibitors
MX2016000675A (en) 2013-07-18 2016-05-10 Novartis Ag Aminomethyl-biaryl derivatives as complement factor d inhibitors and uses thereof.
US9676728B2 (en) 2013-10-30 2017-06-13 Novartis Ag 2-benzyl-benzimidazole complement factor B inhibitors and uses thereof
US20190292155A1 (en) 2016-07-15 2019-09-26 Lifesci Pharmaceuticals, Inc. Therapeutic inhibitory compounds

Patent Citations (234)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020099A2 (en) 1992-03-27 1993-10-14 Ferring B.V. Cck and/or gastrin receptor ligands
WO1995029697A1 (en) 1994-05-02 1995-11-09 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases
US5628984A (en) 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6319897B1 (en) 1996-03-13 2001-11-20 John D. Lambris Peptides which inhibit complement activation
US6653340B1 (en) 1997-06-03 2003-11-25 Biocryst Pharmaceuticals, Inc. Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation
WO1999048492A1 (en) 1998-03-26 1999-09-30 Japan Tobacco Inc. Amide derivatives and nociceptin antagonists
RU2202344C2 (en) 1998-03-26 2003-04-20 Джапан Тобакко Инк. Nociceptine antagonists, amide derivatives, analgetic agent, method of initiation of antagonistic effect to nociceptine, method of pain treatment, pharmaceutical compositions
US6489476B1 (en) 1998-09-09 2002-12-03 Metabasis Therapeutics, Inc. Heteroaromatic compounds containing a phosphonate group that are inhibitors of fructose-1,6-bisphosphatase
US6492402B1 (en) 1998-12-29 2002-12-10 Lg Life Sciences, Ltd. Thrombin inhibitors
US20020133004A1 (en) 1999-09-03 2002-09-19 Ajinomoto Co. Inc Process for producing new oxazepine derivatives
US20050267108A1 (en) 2001-12-13 2005-12-01 Hsing-Pang Hsieh Indole compounds
US7999081B2 (en) 2002-07-11 2011-08-16 Adienne Srl Anti-C5 alpha antibodies
WO2004007501A1 (en) 2002-07-16 2004-01-22 Amura Therapeutics Limited Biologically active compounds
US7989589B2 (en) 2002-09-20 2011-08-02 The Trustees Of The University Of Pennsylvania Compstatin analogs with improved activity
US20060004000A1 (en) 2002-10-02 2006-01-05 Sanofi-Aventis Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors
WO2004045518A2 (en) 2002-11-15 2004-06-03 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US20080108691A1 (en) 2002-11-15 2008-05-08 Bristol-Myers Squibb Company Open-chain prolyl urea-related modulators of androgen receptor function
WO2004111041A1 (en) 2003-06-12 2004-12-23 Fujisawa Pharmaceutical Co., Ltd. Pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-iv (dpp)
US20080075720A1 (en) 2004-02-10 2008-03-27 Holers Vernon M Inhibition of factor B, the alternative complement pathway and methods related thereto
US20070155712A1 (en) 2004-03-24 2007-07-05 Jerini Ag Compounds for the inhibition of angiogenesis and use thereof
US20050245497A1 (en) 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
US20050228000A1 (en) 2004-04-13 2005-10-13 Smallheer Joanne M Bicyclic heterocycles useful as serine protease inhibitors
US20080075728A1 (en) 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
US20160060297A1 (en) 2005-10-08 2016-03-03 Potentia Pharmaceuticals, Inc. Compstatin and analogs thereof for eye disorders
US9056076B2 (en) 2005-10-08 2015-06-16 Potentia Pharmaceuticals, Inc. Method of treating age-related macular degeneration comprising administering a compstatin analog
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US7888323B2 (en) 2005-11-28 2011-02-15 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US9169307B2 (en) 2005-11-28 2015-10-27 The Trustees Of The University Of Pennsylvania Potent compstatin analogs
US7629340B2 (en) 2005-12-12 2009-12-08 Smithkline Beecham Corporation N-(6-membered aromatic ring)-amido anti-viral compounds
US20160015810A1 (en) 2006-01-19 2016-01-21 Potentia Pharmaceuticals, Inc. Injectable combination therapy for eye disorders
US20120237515A1 (en) 2006-03-15 2012-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
WO2008047831A1 (en) 2006-10-17 2008-04-24 Kyowa Hakko Kirin Co., Ltd. Jak inhibitor
US20100041628A1 (en) 2007-01-15 2010-02-18 Hiroshi Enomoto Novel indole derivative having ikappab kinase beta inhibitory activity
RU2470918C2 (en) 2007-01-15 2012-12-27 Сантен Фармасьютикал Ко., Лтд. NOVEL INDOLE DERIVATIVES HAVING IκB KINASE β INHIBITING ACTIVITY
US8580735B2 (en) 2007-02-05 2013-11-12 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US20140050739A1 (en) 2007-02-05 2014-02-20 Apellis Pharmaceuticals, Inc. Local complement inhibition for treatment of complement-mediated disorders
US8524716B2 (en) 2007-12-24 2013-09-03 Janssen R&D Ireland Macrocyclic indoles as hepatitis C virus inhibitors
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
US8241628B2 (en) 2008-08-05 2012-08-14 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
US8883158B2 (en) 2008-08-05 2014-11-11 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
US8946145B2 (en) 2009-05-01 2015-02-03 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and C-terminal modifications
US9371365B2 (en) 2009-05-01 2016-06-21 The Trustees Of The University Of Pennsylvania Modified compstatin with peptide backbone and C-terminal modifications
US9291622B2 (en) 2009-05-21 2016-03-22 Apellis Pharmaceuticals, Inc. Complement assays and uses thereof
US20120231471A1 (en) 2009-10-16 2012-09-13 Ayumi Sato Marker associated with non-alcoholic steatohepatitis
US20130029912A1 (en) 2009-11-05 2013-01-31 Holers V Michael Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
WO2011057158A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
US20150368271A1 (en) 2009-12-31 2015-12-24 Hutchison Medipharma Limited Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
US20110280808A1 (en) 2010-04-16 2011-11-17 Ac Immune, S.A. Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
US20130324482A1 (en) 2010-07-09 2013-12-05 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of rhinosinusitis and nasal polyposis
CN103402996A (en) 2011-01-04 2013-11-20 诺瓦提斯公司 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (AMD)
US9085555B2 (en) 2011-01-04 2015-07-21 Novartis Ag Complement pathway modulators and uses thereof
US20120295884A1 (en) 2011-01-04 2012-11-22 Novartis Ag Complement pathway modulators and uses thereof
WO2012093101A1 (en) 2011-01-04 2012-07-12 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
JP2014506877A (en) 2011-01-04 2014-03-20 ノバルティス アーゲー Indole compounds or analogs useful for the treatment of age-related macular degeneration (AMD)
US20140323407A1 (en) 2011-05-11 2014-10-30 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and uses thereof
US10092547B2 (en) 2011-05-27 2018-10-09 Achillion Pharmaceuticals, Inc. Substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero- heteraphanes and metallocenes useful for treating HCV infections
WO2012177782A1 (en) 2011-06-20 2012-12-27 Myrexis, Inc. Compounds and therapeutic uses thereof
US20140371133A1 (en) 2011-06-22 2014-12-18 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US20130035392A1 (en) 2011-08-01 2013-02-07 Mcgeer Patrick L Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex
US20150158915A1 (en) 2011-09-07 2015-06-11 The Trustees Of The University Of Pennsylvania Compstatin Analogs with Improved Pharmacokinetic Properties
WO2013166436A1 (en) 2012-05-03 2013-11-07 Kala Pharmaceuticals, Inc. Pharmaceutical nanoparticles showing improved mucosal transport
US20130296377A1 (en) 2012-05-04 2013-11-07 Christopher Michael ADAMS Complement pathway modulators and uses thereof
US20130344073A1 (en) 2012-06-18 2013-12-26 University Of Leicester Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
US20170202935A1 (en) 2012-06-20 2017-07-20 The Trustees Of The University Of Pennsylvania Methods of treating or preventing periodontitis and diseases associated with periodontitis
WO2013192345A1 (en) 2012-06-20 2013-12-27 Novartis Ag Complement pathway modulators and uses thereof
JP2015522007A (en) 2012-06-28 2015-08-03 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002057A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US20150322060A1 (en) 2012-06-28 2015-11-12 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US20150141455A1 (en) 2012-06-28 2015-05-21 Novartis Ag Complement pathway modulators and uses thereof
WO2014002052A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US9468661B2 (en) 2012-06-28 2016-10-18 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002053A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
US20150191462A1 (en) 2012-06-28 2015-07-09 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
WO2014002054A1 (en) 2012-06-28 2014-01-03 Novartis Ag Pyrrolidine derivatives and their use as complement pathway modulators
JP2015522005A (en) 2012-06-28 2015-08-03 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
JP2015522008A (en) 2012-06-28 2015-08-03 ノバルティス アーゲー Complement pathway modulators and uses thereof
WO2014002051A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
JP2015522006A (en) 2012-06-28 2015-08-03 ノバルティス アーゲー Pyrrolidine derivatives and their use as complement pathway regulators
WO2014002058A2 (en) 2012-06-28 2014-01-03 Novartis Ag Complement pathway modulators and uses thereof
WO2014002067A2 (en) 2012-06-29 2014-01-03 Consiglio Nazionale Delle Ricerche Method of processing optical coherence tomography images
WO2014002059A1 (en) 2012-06-29 2014-01-03 Novartis Ag CRYSTALLINE FORMS OF 1-(2-((1R,3S,5R)-3-(((R)-1-(3-chloro-2-fluorophenyl)ethyl)carbamoyl)-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)-1Hpyrazolo[3,4-c]pyridine-3-carboxamide
WO2014005150A1 (en) 2012-06-29 2014-01-03 Novartis Ag Crystalline forms of l-(2-((lr,3s,5r)-3-( (2 -fluoro-3 - (trifluoromethoxy) phenyl) carbamoyl) - 2 -azabicycl o [3.1.0] hexan- 2 -yl) - 2 -oxoethyl) - 5 -methyl - 1h - pyrazolo [3, 4 -c] pyridine - 3 - carboxami de and salts thereof
WO2014009833A2 (en) 2012-07-12 2014-01-16 Novartis Ag Complement pathway modulators and uses thereof
JP2015522062A (en) 2012-07-12 2015-08-03 ノバルティス アーゲー Complement pathway modulators and uses thereof
US20150148374A1 (en) 2012-07-12 2015-05-28 Novartis Ag Complement pathway modulators and uses thereof
WO2014037480A1 (en) 2012-09-10 2014-03-13 F. Hoffmann-La Roche Ag 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
US20160215020A1 (en) 2012-11-15 2016-07-28 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US20160194359A1 (en) 2012-11-15 2016-07-07 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
US20150269868A1 (en) 2012-12-11 2015-09-24 Fluidity Software, Inc. Computerized system and method for teaching, learning, and assessing step by step solutions to stem problems
WO2014116880A1 (en) 2013-01-23 2014-07-31 Baerbel Rohrer Targeting constructs based on natural antibodies and uses thereof
US20160024079A1 (en) 2013-03-14 2016-01-28 Novartis Ag Complement Factor B inhibitors and uses there of
US20160215022A1 (en) 2013-03-15 2016-07-28 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2015008861A1 (en) 2013-07-19 2015-01-22 大日本住友製薬株式会社 Novel imidazopyridine compound
WO2015021166A2 (en) 2013-08-07 2015-02-12 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome biomarker proteins
WO2015054569A1 (en) 2013-10-10 2015-04-16 Viropharma Holdings Limited Methods of inhibiting the alternative pathway of complement immune system activation and compositions used therein
US20150239921A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Phosphonate Compounds for Treatment of Complement Mediated Disorders
WO2015130854A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
WO2015130842A2 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
WO2015130806A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
WO2015130784A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
WO2015130845A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
WO2015130795A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
WO2015130838A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
WO2015130830A1 (en) 2014-02-25 2015-09-03 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
US20150239919A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Carbamate, Ester, and Ketone Compounds for Treatment of Complement Mediated Disorders
US20150239920A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Ether Compounds for Treatment of Complement Mediated Disorders
US20150239895A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders
US20150239894A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Amino Compounds for Treatment of Complement Mediated Disorders
US20150239837A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Factor D Inhibitors Useful for Treating Inflammatory Disorders
US20150239868A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Alkyne Compounds for Treatment of Complement Mediated Disorders
US20160362432A1 (en) 2014-02-25 2016-12-15 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US20160362398A1 (en) 2014-02-25 2016-12-15 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US20160361329A1 (en) 2014-02-25 2016-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
US20160362399A1 (en) 2014-02-25 2016-12-15 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US20160362433A1 (en) 2014-02-25 2016-12-15 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US20150239838A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Compounds for Treatment of Complement Mediated Disorders
JP6688352B2 (en) 2014-02-25 2020-04-28 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders
US20200062790A1 (en) 2014-02-25 2020-02-27 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US10550140B2 (en) 2014-02-25 2020-02-04 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US10464956B2 (en) 2014-02-25 2019-11-05 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US10428095B2 (en) 2014-02-25 2019-10-01 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
US10428094B2 (en) 2014-02-25 2019-10-01 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US10370394B2 (en) 2014-02-25 2019-08-06 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
JP6537532B2 (en) 2014-02-25 2019-07-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Compounds for the treatment of complement mediated disorders
US10301336B2 (en) 2014-02-25 2019-05-28 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US20190144473A1 (en) 2014-02-25 2019-05-16 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
US10253053B2 (en) 2014-02-25 2019-04-09 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US20190085005A1 (en) 2014-02-25 2019-03-21 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US20190048033A1 (en) 2014-02-25 2019-02-14 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US20190031692A1 (en) 2014-02-25 2019-01-31 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
US10189869B2 (en) 2014-02-25 2019-01-29 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
US20190023729A1 (en) 2014-02-25 2019-01-24 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
JP2018199714A (en) 2014-02-25 2018-12-20 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic compounds for treatment of complement mediated disorders
US10106563B2 (en) 2014-02-25 2018-10-23 Achillion Pharmaecuticals, Inc. Ether compounds for treatment of complement mediated disorders
US10100072B2 (en) 2014-02-25 2018-10-16 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US20150239893A1 (en) 2014-02-25 2015-08-27 Achillion Pharmaceuticals, Inc. Amide Compounds for Treatment of Complement Mediated Disorders
JP6400738B2 (en) 2014-02-25 2018-10-03 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders
US10087203B2 (en) 2014-02-25 2018-10-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of complement mediated disorders
US10081645B2 (en) 2014-02-25 2018-09-25 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US9598446B2 (en) 2014-02-25 2017-03-21 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of complement mediated disorders
JP2017511815A (en) 2014-02-25 2017-04-27 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic compounds for the treatment of complement-mediated disorders
US9643986B2 (en) 2014-02-25 2017-05-09 Achillion Pharmaceuticals, Inc. Factor D inhibitors useful for treating inflammatory disorders
US9663543B2 (en) 2014-02-25 2017-05-30 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US10005802B2 (en) 2014-02-25 2018-06-26 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US9695205B2 (en) 2014-02-25 2017-07-04 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US20170189410A1 (en) 2014-02-25 2017-07-06 Achillion Pharmaceuticals, Inc. Amino Compounds for Treatment of Complement Mediated Disorders
US20180022766A1 (en) 2014-02-25 2018-01-25 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US20180072762A1 (en) 2014-02-25 2018-03-15 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
US20180030075A1 (en) 2014-02-25 2018-02-01 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US20170226142A1 (en) 2014-02-25 2017-08-10 Achillion Pharmaceuticals, Inc. Factor D Inhibitors Useful for Treating Inflammatory Disorders
US20180022767A1 (en) 2014-02-25 2018-01-25 Achillion Pharmaceuticals, Inc. Compounds for Treatment of Complement Mediated Disorders
US9732103B2 (en) 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
US9732104B2 (en) 2014-02-25 2017-08-15 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of complement mediated disorders
US9758537B2 (en) 2014-02-25 2017-09-12 Achillion Pharmaceuticals Compounds for treatment of complement mediated disorders
US20170260219A1 (en) 2014-02-25 2017-09-14 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of complement mediated disorders
US20170298085A1 (en) 2014-02-25 2017-10-19 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of complement mediated disorders
US20170298084A1 (en) 2014-02-25 2017-10-19 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of complement mediated disorders
US9796741B2 (en) 2014-02-25 2017-10-24 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
US9828396B2 (en) 2014-02-25 2017-11-28 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of complement mediated disorders
WO2017035408A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
US10287301B2 (en) 2015-08-26 2019-05-14 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US11407738B2 (en) 2015-08-26 2022-08-09 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
JP6877406B2 (en) 2015-08-26 2021-05-26 アキリオン ファーマシューティカルズ，インコーポレーテッド Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders
US11001600B2 (en) 2015-08-26 2021-05-11 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of medical disorders
US10919884B2 (en) 2015-08-26 2021-02-16 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
US10906887B2 (en) 2015-08-26 2021-02-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US20180179236A1 (en) 2015-08-26 2018-06-28 Achillion Pharmaceutical, Inc. Disubstituted compounds for treatment of medical disorders
US20180179185A1 (en) 2015-08-26 2018-06-28 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US20180177761A1 (en) 2015-08-26 2018-06-28 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
US20180179186A1 (en) 2015-08-26 2018-06-28 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US10011612B2 (en) 2015-08-26 2018-07-03 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US20180186782A1 (en) 2015-08-26 2018-07-05 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
US20180201580A1 (en) 2015-08-26 2018-07-19 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune inflammatory disorders
EA201890594A1 (en) 2015-08-26 2018-08-31 Ачиллион Фармасьютикалс, Инк. Aryl, Heteroaryl, and Heterocyclic Compounds for the Treatment of Disorders
US10822352B2 (en) 2015-08-26 2020-11-03 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US10807952B2 (en) 2015-08-26 2020-10-20 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune inflammatory disorders
US20200262818A1 (en) 2015-08-26 2020-08-20 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US20170066783A1 (en) 2015-08-26 2017-03-09 Achillion Pharmaceuticals, Inc. Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Medical Disorders
WO2017035349A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of medical disorders
WO2017035411A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US10092584B2 (en) 2015-08-26 2018-10-09 Achillion Pharmaceuticals, Inc. Compounds for the treatment of medical disorders
WO2017035413A2 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of immune and inflammatory disorders
WO2017035360A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for the treatment of medical disorders
US20180305375A1 (en) 2015-08-26 2018-10-25 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US10138225B2 (en) 2015-08-26 2018-11-27 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of medical disorders
WO2017035417A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of immune and inflammatory disorders
WO2017035418A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for treatment of immune and inflammatory disorders
US20170056428A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Compounds for the Treatment of Medical Disorders
WO2017035415A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of immune and inflammatory disorders
US10660876B2 (en) 2015-08-26 2020-05-26 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
US10662175B2 (en) 2015-08-26 2020-05-26 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US20170057983A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate Compounds for Treatment of Medical Disorders
WO2017035353A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US20170057950A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide Compounds for Treatment of Medical Disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035362A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035357A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
US20190211033A1 (en) 2015-08-26 2019-07-11 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders
US20170057993A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether Compounds for Treatment of Medical Disorders
US10385097B2 (en) 2015-08-26 2019-08-20 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035348A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Alkyne compounds for treatment of medical disorders
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
WO2017035352A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Carbamate, ester, and ketone compounds for treatment of medical disorders
WO2017098328A2 (en) 2015-12-11 2017-06-15 Lifesci Phamaceuticals, Inc. Therapeutic inhibitory compounds
US20170202821A1 (en) 2016-01-14 2017-07-20 Chemocentryx, Inc. Method of treating c3 glomerulopathy
WO2017127761A1 (en) 2016-01-20 2017-07-27 Vitrisa Therapeutics, Inc. Compositions and methods for inhibiting factor d
WO2017136395A1 (en) 2016-02-01 2017-08-10 Biocryst Pharmaceuticals, Inc. Benzopyrazole compounds and analogues thereof
WO2018005552A1 (en) 2016-06-27 2018-01-04 Achillion Pharmaceuticals, Inc. Quinazoline and indole compounds to treat medical disorders
WO2018026722A1 (en) 2016-08-01 2018-02-08 Omeros Corporation Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
US11053253B2 (en) 2017-03-01 2021-07-06 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11447465B2 (en) 2017-03-01 2022-09-20 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for treatment of medical disorders
US20200002347A1 (en) 2017-03-01 2020-01-02 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11084800B2 (en) 2017-03-01 2021-08-10 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US20190382376A1 (en) 2017-03-01 2019-12-19 Achillion Pharmaceuticals, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160889A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroary, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US20200071301A1 (en) 2017-03-01 2020-03-05 Achillion Pharmaceuticals, Inc. Aryi, Heteroaryl, and Heterocyclic Pharmaceutical Compounds for Treatment of Medical Disorders
US20200101071A1 (en) 2017-08-02 2020-04-02 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
WO2019070714A1 (en) 2017-10-04 2019-04-11 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of patients with membranoproliferative glomerulonephritis
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
US20210332026A1 (en) 2018-09-25 2021-10-28 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
WO2020109343A1 (en) 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
US20220079943A1 (en) 2018-12-17 2022-03-17 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
WO2021021909A1 (en) 2019-07-31 2021-02-04 Biocryst Pharmaceuticals, Inc. Dosing regimens for oral complement factor d inhibitors

Non-Patent Citations (167)

* Cited by examiner, † Cited by third party
Title
"Are There Any Treatments for ALS?" WebMD, <https://www.webmd.com/brain/understanding-als-treatment#1>, retrieved on May 3, 2019 (8 pages).
"Arteriosclerosis/atherosclerosis," Mayo Clinic, <https://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/diagnosis-treatment/drc-20350575>, retrieved on Apr. 24, 2018 (10 pages).
"Cancer," MedLine Plus, <http://www.nlm.nih.gov/medlineplus/cancer.html>, retrieved Jul. 6, 2007 (10 pages).
"Dermatomyositis," Mayo Clinic, <https://www.mayoclinic.org/diseases-conditions/dermatomyositis/diagnosis-treatment/drc-20353192>, retrieved on Aug. 1, 2017 (7 pages).
"History of Changes for Study: NCT03053102—A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)," U.S. National Library of Medicine, available at: <https://clinicaltrials.gov/ct2/history/NCT03053102?V_4=View#StudyPageTop>, submitted Jun. 6, 2017, retrieved Mar. 9, 2021 (3 pages).
"NCT03472885—A Treatment Study of ACH-0144471 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) With Inadequate Response to Eculizumab (PNH)," U.S. National Library of Medicine, available at: <https://clinicaltrials.gov/ct2/show/NCT03472885>, first posted Mar. 21, 2018, last update posted Dec. 3, 2019, retrieved Mar. 27, 2020 (7 pages).
"Patient Information for Tarpeyo (tar-PAY-oh) (budesonide) delayed release capsules," Calliditas Therapeutics AB, 2021 (2 pages).
"Reperfusion injury," Wikipedia, <https://en.wikipedia.org/wiki/Reperfusion_injury>, retrieved Apr. 30, 2020 (8 pages).
"Treatment for Multiple Sclerosis," WebMD, <https://www.webmd.com/multiple-sclerosis/ms-treatment#1>, retrieved on May 3, 2019 (24 pages).
"What are the Treatments for Cirrhosis?," WebMD, <https://www.webmd.com/digestive-disorders/understanding-cirrhosis-treatment#1>, retrieved May 3, 2019 (15 pages).
"What is Cardiovascular Disease?" American Heart Association, <https://www.heart.org/en/health-topics/consumer-healthcare/what-is-cardiovascular-disease>, last reviewed May 31, 2017 (4 pages).
"What is Dementia?" Alzheimer's Association, <https://www.alz.org/alzheimers-dementia/what-is-dementia>, retrieved on Nov. 17, 2020 (6 pages).
Airey et al., "A Convenient Preparation of Thieno[3,2-c]pyrazole," Synthesis. 46: 96-100 (2014).
Andrighetto et al., "Complement and Complement Targeting Therapies in Glomerular Diseases," Int J Mol Sci. 20(24):6336 (Dec. 2019), available <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940904/>, retrieved on May 26, 2022 (21 pages).
Armand, "Fatty liver disease: What it is and what to do about it," Harvard Health Publishing, <https://www.health.harvard.edu/blog/fatty-liver-disease-what-it-is-and-what-to-do-about-it-2019011015746>, dated Jan. 10, 2019, retrieved May 2, 2019 (3 pages).
Babiker et al., "Transfer of prostasomal CD59 to CD59-deficient red blood cells results in protection against complement-mediated hemolysis," Am J Reprod Immunol. 47(3): 183-92 (2002) (Abstract Only).
Barraclough et al., "Synthesis of (2S,3R)- and (2S,3S)-[3-2H1]-proline via highly selective hydrolysis of a silyl enol ether," Tetrahedron Letters. 46(1): 4653-4655 (2005).
Barraclough et al., "Two separate and distinct syntheses of stereospecifically deuteriated samples of (2S)-proline," Org Biomol Chem. 4(8):1483-1491 (2006).
Borowitz et al., "Guidelines for the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria and Related Disorders by Flow Cytometry," Cytometry B Clin Cytom. 78B(4): 211-230 (2010).
Brodsky, "Eculizumab: another breakthrough," Blood. 129(8):922-3 (2017).
Carter, "Complement Activation: An Emerging Player in the Pathogenesis of Cardiovascular Disease," Scientifica. 2012:402783 (2012) (14 pages).
CAS RN 1236228-05-9, dated Aug. 16, 2010 (1 page).
CAS RN 1236251-51-6, dated Aug. 17, 2010 (2 pages).
CAS RN 1270608-88-2, dated 2019 (1 page).
CAS RN 1277041-86-7, dated Apr. 8, 2011 (2 pages).
Cofiell et al., "Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS," Blood. 125(21):3253-62 (2015).
Cole et al. "Structure of 3,4-Dichloroisocoumarin-Inhibited Factor D," Acta Crystallogr D Biol Crystallogr. 54(Pt 5): 711-717 (1998).
Compound Summary for CID 1129904, PubChem. <https://pubchem.ncbi.nlm.nih.gov/compound/1129904> retrieved Jul. 14, 2020, created Jul. 10, 2005 (10 pages).
Compound Summary for CID 118324207, PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/118324207>, created Feb. 23, 2016, retrieved on Jul. 14, 2020 (8 pages).
Compound Summary for CID 123543544, PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/123543544>, created on Jan. 25, 2017, retrieved on Jul. 13, 2020 (8 pages).
Compound Summary for CID 134222466, PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/134222466>, created on Jun. 23, 2018, retrieved on Jul. 14, 2020 (11 pages).
Compound Summary for CID 59912842, PubChem, <https://pubchem.ncbi.nlm.nih.gov/compound/59912842>, created Aug. 20, 2012, retrieved Jul. 14, 2020 (9 pages).
Damasio, "Alzheimer's disease and related dementias," Cecil Textbook of Medicine, 20th Edition, vol. 2. Bennet and Plum, 1992-6 (1996).
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN1236248-20-6, Entered STN: Aug. 16, 2010 (1 page).
Database Registry Chemical Abstracts Service, Columbus, Ohio, Accession No. RN1380849-41-1, Entered STN: Jul. 3, 2012 (2 pages).
De Luca et al., "HIV-1 integrase strand-transfer inhibitors: Design, synthesis and molecular modeling investigation," Eur J Med Chem. 46(2): 756-764 (2011).
DeZern et al., "Paroxysmal nocturnal hemoglobinuria: a complement-mediated hemolytic anemia," available in PMC Dec. 30, 2015, published in final edited form as: Hematol Oncol Clin North Am. 29(3):479-94 (2015) (18 pages).
Donthiri et al., "Copper-Catalyzed C—H Functionalization of Pyridines and Isoquinolines with Vinyl Azides: Synthesis of Imidazo Heterocycles," J Org Chem. 79(22): 11277-11284 (2014).
Dormoy et al., "Synthesis of N-t-Butoxycarbonyl-4,4-dideuterio-L-proline," Synthesis. 1: 81-82 (1986).
Ellis-Pegler et al., "An Orally Administered Small Molecule Factor D Inhibitor (ACH-4471) for Treatment of PNH and Complement Diseases: Preliminary Phase 1 Results In Healthy Volunteers," European Hematology Association. Abstract LB2250, available <https://library.ehaweb.org/eha/2016/21st/135361/roderick.b.ellis-pegler.an.orally.administered.small.molecule.factor.d.html> (2016) (2 pages).
Ellis-Pegler et al., "An Orally Administered Small Molecule Factor D Inhibitor (ACH-4471) for Treatment of PNH, C3G and Complement—Mediated Diseases: Interim Phase 1 Results In Healthy Volunteers," European Hematology Association, Copenhagen 21st Congress, Jun. 9-12, Abstract ID: EHA-4145 (2016).
Extended European Search Report for European Application No. 18761960.6, dated Mar. 1, 2021 (10 pages).
Extended European Search Report for European Application No. 18840849.6, dated Mar. 17, 2021 (11 pages).
Gadhachanda et al., CAplus Database Summary Sheet for Document No. 164:507515, Accession No. 2016:627420, CAplus on STN. (2016) (6 pages).
Gavrillaki et al., "275 Small Molecule Factor D Inhibitors Block Complement Activation in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome," ASH 57th Annual Meeting & Exposition, Session: 101. Dec. 6, 2015 (2 pages).
Gilkeson, "Complement-Targeted Therapies in Lupus," Curr Treat Options in Rheum. 1:10-18 (Jan. 22, 2015).
Golub et al., "Molecular classification of cancer: class discovery and class prediction by gene expression monitoring," Science. 286(5439):531-537 (1999) (8 pages).
Gura, "Systems for identifying new drugs are often faulty," Science. 278(5340):1041-2 (1997).
Haddrill, "Stargardt's Disease (Fundus Flavimaculatus)," All About Vision, <https://www.allaboutvision.com/conditions/stargardts.htm#article-section-2>, retrieved May 3, 2019 (5 pages).
Harder et al., "Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation," Blood.129(8):970-80 (2017).
Harris et al., "Developments in anti-complement therapy; from disease to clinical trial," Mol Immunol. 102:89-119 (Oct. 2018).
Hartmann et al., "Diagnostic Specificity of Sucrose Hemolysis Test for Paroxysmal Nocturnal Hemoglobinuria," Blood. 35(4):462-475 (1970).
Hecker et al., "Liver-Targeted Prodrugs of 2′-C-Methyladenosine for Therapy of Hepatitis C Virus Infection," J Med Chem. 50(16): 3891-3896 (2007).
Hom et al., "Complement Inhibitors for Treatment of Geographic Atrophy and Advanced Nonexudative AMD," Retinal Physician. 16:28-31 (Mar. 1, 2019) (7 pages).
Hruby et al., "13C Nuclear Magnetic Resonance Studies of the Peptide Hormones Oxytocin, Arginine Vasopressin, Isotocin, Mesotocin, Glumitocin, Aspartocin, Related Analogues, and Diastereoisomers. Use of Specifically Deuterated Hormone Derivatives for Assignments and Effects of Structural Changes on 13C NMR Chemical Shifts in Peptides," J Am Chem Soc. 101(1): 202-212(1979).
Hu et al., "Evidence of complement dysregulation in outer retina of Stargardt disease donor eyes," Redox Biol. 37:101787 (2020) (10 pages).
Iatropoulos et al., "Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN," J Am Soc Nephrol. 29(1):283-94 (with supplemental material) (Jan. 2018) (36 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017523, dated May 14, 2015 (7 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017538, dated May 14, 2015 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017554, dated May 14, 2015 (7 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017583, dated May 27, 2015 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017593, dated Jun. 16, 2015 (6 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017597, dated Jan. 29, 2016 (10 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017600, dated May 27, 2015 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US2015/017609, dated May 29, 2015 (6 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048688, dated Dec. 28, 2016 (11 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048690, dated Dec. 28, 2016 (11 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048693, dated Jan. 13, 2017 (11 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048695, dated Dec. 30, 2016 (10 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048696, dated Jan. 5, 2017 (10 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048701, dated Jan. 10, 2017 (10 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048704, dated Dec. 27, 2016 (7 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048707, dated Jan. 5, 2017 (10 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048709, dated Jan. 17, 2017 (9 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048710, dated Jan. 5, 2017 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048779, dated Dec. 27, 2016 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048783, dated Feb. 3, 2017 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048787, dated Jan. 5, 2017 (13 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048788, dated Jan. 5, 2017 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048793, dated Dec. 28, 2016 (8 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048795, dated Feb. 17, 2017 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048797, dated Jan. 5, 2017 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048799, dated Nov. 15, 2016 (7 pages).
International Search Report and Written Opinion for International Application No. PCT/US2016/048800, dated Jan. 5, 2017 (12 pages).
International Search Report and Written Opinion for International Application No. PCT/US21/18871, dated May 24, 2021 (24 pages).
International Search Report and Written Opinion for International Application No. PCT/US21/21563, dated May 18, 2021 (15 pages).
International Search Report for International Application No. PCT/US18/20530, dated Jun. 25, 2018 (3 pages).
International Search Report for International Application No. PCT/US20/24017, dated Jun. 26, 2020 (3 pages).
International Search Report for International Application No. PCT/US2018/020528, dated Apr. 24, 2018 (3 pages).
International Search Report for International Application No. PCT/US2018/045057, dated Nov. 15, 2018 (5 pages).
International Search Report for International Application No. PCT/US2018/20531, dated May 15, 2018 (3 pages).
International Search Report for International Application No. PCT/US2019/034210, dated Sep. 13, 2019 (4 pages).
International Search Report for International Application No. PCT/US2019/047252, dated Dec. 17, 2019 (4 pages).
International Search Report for International Application No. PCT/US2019/050065, dated Feb. 25, 2020 (4 pages).
International Search Report for International Application No. PCT/US2019/050073, dated Nov. 21, 2019 (3 pages).
International Search Report for International Application No. PCT/US2019/053012, dated Jan. 28, 2020 (4 pages).
International Search Report for International Application No. PCT/US2019/066999, dated Feb. 12, 2020 (3 pages).
Ishibashi et al., "Four-year outcomes of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a treat-and-extend regimen in Japanese patients," Ther Adv Ophthalmol. 13:1-5 (2021).
Jensen et al., "Associations between the Complement System and Choroidal Neovascularization in Wet Age-Related Macular Degeneration," Int J Mol Sci. 21(24):9752 (2020) (28 pages).
Johnson et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," Br J Cancer. 84(10):1424-31 (2001).
Józsi, "Anti-Complement Autoantibodies in Membranoproliferative Glomerulonephritis and Dense Deposit Disease", An Update on Glomerulopathies—Etiology and Pathogenesis. Prof. Sharma Prabhakar, 31-46 (2011) (18 pages).
Kathuria, "Membranoproliferative Glomerulonephritis Medication," Medscape, <https://emedicine.medscape.com/article/240056-medication>, updated Jun. 23, 2016, retrieved May 3, 2019, (1 page).
Kinman, "COPD Drugs: A List of Medications to Help Relieve Your Symptoms," Healthline, <https://www.healthline.com/health/copd/drugs>, retrieved on May 3, 2019 (12 pages).
Kocinsky et al., "Abstract SaO018: Factor D inhibition with ACH-4471 to reduce complement alternative pathway hyperactivity and proteinuria in C3 glomerulopathy: preliminary proof of concept data," Nephrology Dialysis Transplantation. 33(Supplement 1):i322-3 (May 2018) (1 page).
Komiya et al., CAplus Database Summary Sheet for Document No. 162:229476, Accession No. 2015:126147, CAplus on STN. (2015) (2 pages).
Krauss, "Laboratory Diagnosis of Paroxysmal Nocturnal Hemoglobinuria," Annals of Clinical & Laboratory Science. 33(4): 401-406 (2003).
Kuang et al., "Synthesis of (Z)-1-bromo-1-alkenes and terminal alkynes from anti-2,3-dibromoalkanoic acids by microwave-induced reaction," Tetrahedron. 61(16):4043-4052 (2005).
Lala et al., "Role of nitric oxide in tumor progression: lessons from experimental tumors," Cancer Metastasis Rev. 17(1):91-106 (1998).
Lassmann, "What drives disease in multiple sclerosis: Inflammation or neurodegeneration?" Clinical and Experimental Neuroimmunology. 1:2-11 (2010).
Layzer, "Degenerative Diseases of the Nervous System," Cecil Textbook of Medicine, 20th Edition, vol. 2. J. Claude Bennett and Fred Plum, p. 2050-2057 (1996).
Le et al., "A mechanistic pharmacokinetic/pharmacodynamic model of factor D inhibition in cynomolgus monkeys by lampalizumab for the treatment of geographic atrophy," J Pharmacol Exp Ther. 355(2):288-96 (2015).
MacKay et al., "Rapid Synthesis of the N-Methylwelwitindolinone Skeleton," Org Lett. 7(16):3421-4 (2005).
Mantegazza et al., "Complement Inhibition for the Treatment of Myasthenia Gravis," Immunotargets Ther. 9:317-31 (2020), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751298/>, retrieved on May 26, 2022 (24 pages).
Marinozzi et al., "C5 nephritic factors drive the biological phenotype of C3 glomerulopathies," Kidney Int. 92(5):1232-41 (Nov. 2017).
Mastellos et al., "Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape," available in PMC Apr. 2, 2015, published in final edited form as: Expert Rev Hematol. 7(5):583-98 (2014) (26 pages).
Michels et al., "Long-term follow-up including extensive complement analysis of a pediatric C3 glomerulopathy cohort," Pediatr Nephrol. 37(3):601-12 (Mar. 2022).
Noris et al., "Overview of Complement Activation and Regulation," Semin Nephrol. 33:479-492 (2013).
Office Action issued for Eurasian Patent Application No. 201992005, dated Oct. 23, 2020 (6 pages).
Okutani et al., "Conversion of Bromoalkenes into Alkynes by Wet Tetra-n-butylammonium Fluoride," J Org Chem. 74(1):442-444 (2009).
Oseini et al., "Therapies in Non-Alcoholic Steatohepatitis (NASH)," available in PMC Jan. 1, 2018, published in final edited form as: Liver Int. 37(Suppl 1):97-103 (2017) (15 pages).
Oshima et al., "Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study," BMC Ophthalmol. 21(1):58 (2021) (11 pages).
Pandya et al., "Complement System in Lung Disease," Am J Respir Cell Mol Biol. 51(4):467-473 (2014).
Parker, "Update on the diagnosis and management of paroxysmal nocturnal hemoglobinuria," Hematology Am Soc Hemtol Educ Program. 2016(1):208-16 (2016).
Partial Supplementary European Search Report for European Application No. 18761960.6, dated Nov. 27, 2020 (12 pages).
Patel et al., "In Vitro Combination Studies of ACH-4471 with Eculizumab to Assess a Potential ‘Switch’ Treatment Approach for Paroxysmal Nocturnal Hemoglobinuria" 59th American Society of Hematology Annual Meeting and Exposition, Dec. 9-12, Atlanta, Georgia, Poster Abstract 2198 (2017).
Pearce et al., "Failure modes in anticancer drug discovery and development," Cancer Drug Design and Discovery Edited by Stephen Neidle, Chapter 18, pp. 424-435 (2008).
Peifer et al., "Design, Synthesis, and Biological Evaluation of Novel 3-Aryl-4-(1H-indole-3yl)-1,5-dihydro-2H-pyrrole-2-ones as Vascular Endothelial Growth Factor Receptor (VEGF-R) Inhibitors," J Med Chem. 51(13):3814-3824 (2008).
Pugsley et al., "Inhibitors of the complement system currently in development for cardiovascular disease," Cardiovasc Toxicol. 3(1):43-69 (2003).
Qu et al., "Recent Developments in Low Molecular Weight Complement Inhibitors," available in PMC, Dec. 1, 2010, published in final edited form as: Mol Immunol. 47(2-3):185-195 (2009) (25 pages).
Quesada et al., "One-pot conversion of activated alcohols into terminal alkynes using manganese dioxide in combination with the Bestmann--Ohira reagent," Tetrahedron Letters. 46:6473-6476 (2005).
Ricklin et al., "Complement in immune and inflammatory disorders: pathophysiological mechanisms," J Immunol. 190(8):3831-3838 (2013).
Risitano et al., "Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab," Blood. 113(17):4094-4100 (2009) (25 pages).
Risitano et al., "Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria," Haematologica. 106(12):3188-97 (2021).
Risitano et al., "Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria," Blood. 123(13):2094-101 (2014).
Risitano et al., "Safety and Pharmacokinetics of the Complement Inhibitor TT30 in a Phase I Trial for Untreated PNH Patients" Blood. 126(23): 2137 (2015) (Abstract Only) (7 pages).
Risitano et al., "Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria," Am J Hematol. 93(4):564-77 (2018).
Risitano, "Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going," Transl Med UniSa. 8:43-52 (2014).
Risitano, "Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition," Am J Hematol. 91(4):359-60 (2016).
Rohrer et al., "Eliminating complement factor D reduces photoreceptor susceptibility to light-induced damage," Invest Ophthalmol Vis Sci. 48(11):5282-9 (2007).
Roth et al., "Further Improvements of the Synthesis of Alkynes from Aldehydes," Synthesis. 1:59-62 (2004).
Ruiz-Gómez et al., "Structure--Activity Relationships for Substrate-Based Inhibitors of Human Complement Factor B," J Med Chem. 52(19):6042-6052 (2009).
Salifu, "Chronic Glomerulonephritis Medication," Medscape, <https://emedicine.medscape.com/article/239392-medication>, updated Feb. 1, 2017, retrieved on May 2, 2019 (1 page).
Segers et al., "Complement Alternative Pathway Activation in Human Nonalcoholic Steatohepatitis," PLOS ONE. 9(10):e110053 (2014) (9 pages).
Sica et al., "Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes," J Hematol Oncol. 10(1):126 (2017) (10 pages).
Simone, "Oncology: Introduction," Cecil Textbook of Medicine, 20th Edition, vol. 1, pp. 1004-1010, (1996).
Stanton et al., "Complement Factor D in Age-Related Macular Degeneration," Invest Ophthalmol Vis Sci. 52(12):8828-8834 (2011) (15 pages).
Steinle et al., "Impact of Baseline Characteristics on Geographic Atrophy Progression in the FILLY Trial Evaluating the Complement C3 Inhibitor Pegcetacoplan," Am J Ophthalmol. DOI: https://doi.org/10.1016/j.ajo.2021.02.031 (Journal Pre-proof version) (2021) (19 pages).
Strobel et al., "Anti-factor B autoantibody in dense deposit disease," Mol Immunol. 47:1476-1483 (2010).
Tandon et al., "Substrate specificity of human prolyl-4-hydroxylase," Bioorg Med Chem Lett. 8(10):1139-1144 (1998).
Tang et al. "Palladium-Catalyzed Carbonylative Sonogashira Coupling of Aryl Bromides via tert-Butyl Isocyanide Insertion," J Org Chem. 78(7):3170-3175 (2013).
Varelas et al., "Complement in Sickle Cell Disease: Are We Ready for Prime Time?," J Blood Med. 12:177-87 (2021), <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001680/>, dated Mar. 23, 2021, retrieved on May 26, 2022 (19 pages).
Wehling et al., "Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders," Clin Exp Immunol. 187(2):304-15 (2017).
Willows et al., "The role of complement in kidney disease," Clin Med (Lond). 20(2):156-60 (2020) (9 pages).
Written Opinion for International Application No. PCT/US18/20528, dated Apr. 24, 2018 (6 pages).
Written Opinion for International Application No. PCT/US18/20530, dated Jun. 25, 2018 (6 pages).
Written Opinion for International Application No. PCT/US18/20531, dated May 15, 2018 (7 pages).
Written Opinion for International Application No. PCT/US19/47252, dated Dec. 17, 2019 (6 pages).
Written Opinion for International Application No. PCT/US19/50065, dated Feb. 25, 2020 (7 pages).
Written Opinion for International Application No. PCT/US19/53012, dated Jan. 28, 2020 (5 pages).
Written Opinion for International Application No. PCT/US19/66999, dated Feb. 12, 2020 (7 pages).
Written Opinion for International Application No. PCT/US20/24017, dated Jun. 26, 2020 (6 pages).
Written Opinion for International Application No. PCT/US2018/045057, dated Nov. 15, 2018 (7 pages).
Written Opinion for International Application No. PCT/US2019/034210, dated Sep. 13, 2019 (17 pages).
Written Opinion for International Application No. PCT/US2019/050073, dated Nov. 21, 2019 (4 pages).
Yonemoto-Kobayashi et al., "Carboxylation of alkynylsilanes with carbon dioxide mediated by cesium fluoride in DMSO," Org Biomol Chem. 11(23):3773-5 (2013).
Yuan et al., "Small-molecule Factor D Inhibitors Selectively Block the Alternative Pathway of Complement in Paroxysmal Nocturnal Hemoglobinuria and Atypical Hemolytic Uremic Syndrome," Haematologica. 102(3):466-75 (2017).
Zhang et al., "Defining the complement biomarker profile of C3 glomerulopathy," Clin J Am Soc Nephrol. 9(11):1876-82 (supplemental materials) (Nov. 7, 2014) (10 pages).

Also Published As

Publication number Publication date
EP3589628A4 (en) 2021-03-31
US20230357199A1 (en) 2023-11-09
CA3053818A1 (en) 2018-09-07
IL294069A (en) 2022-08-01
JP2024023337A (en) 2024-02-21
RU2019130019A3 (en) 2021-04-01
US11084800B2 (en) 2021-08-10
WO2018160889A1 (en) 2018-09-07
EP3589628A1 (en) 2020-01-08
IL294069B2 (en) 2023-11-01
EP3985002A1 (en) 2022-04-20
IL268738A (en) 2019-10-31
KR102632860B1 (en) 2024-02-02
JP2022174122A (en) 2022-11-22
IL303696A (en) 2023-08-01
MX2019010381A (en) 2020-01-21
KR20240019857A (en) 2024-02-14
US20220396563A1 (en) 2022-12-15
MX2023002688A (en) 2023-04-03
JP7133561B2 (en) 2022-09-08
US20200071301A1 (en) 2020-03-05
RU2019130019A (en) 2021-04-01
AU2018227849B2 (en) 2022-04-28
IL294069B1 (en) 2023-07-01
JP7390449B2 (en) 2023-12-01
KR20190126831A (en) 2019-11-12
AU2018227849A1 (en) 2019-09-19
AU2022202403B2 (en) 2024-02-01
CN110603252A (en) 2019-12-20
IL268738B (en) 2022-07-01
JP2020514331A (en) 2020-05-21

Similar Documents

Publication Publication Date Title
US11708351B2 (en) Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US11407738B2 (en) Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11447465B2 (en) Pharmaceutical compounds for treatment of medical disorders
US11718626B2 (en) Macrocyclic compounds for treatment of medical disorders
US20230085372A1 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
EP4216946A1 (en) Pharmaceutical compounds for the treatment of complement mediated disorders
US20230022157A1 (en) Pharmaceutical compounds for the treatment of complement factor d medical disorders
US11814391B2 (en) Macrocyclic compounds for the treatment of medical disorders
RU2773030C2 (en) Aryl, heteroaryl and heterocyclic pharmaceutical compounds for treatment of medical disorders
EA041794B1 (en) ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
AU2024201826A1 (en) Aryl, Heteroary, And Heterocyclic Pharmaceutical Compounds For Treatment Of Medical Disorders

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: ACHILLION PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WANG, XIANGZHU;REEL/FRAME:058507/0958

Effective date: 20021211

Owner name: ACHILLION PHARMACEUTICALS, INC., MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:WILES, JASON ALLAN;PHADKE, AVINASH S.;DESHPANDE, MILIND;AND OTHERS;SIGNING DATES FROM 20180228 TO 20180301;REEL/FRAME:058507/0927

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE